Israel drug index search

1	ABBOSYNAGIS	ABBOSYNAGIS 100 MG/ML	PALIVIZUMAB	PALIVIZUMAB 100MG/ML	SOLUTION	RECIEPT	Abbosynagis is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease: • Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season. • Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months. • Children less than 2 years of age and with haemodynamically significant congenital heart disease.
3	ABILIFY MAINTENA	ABILIFY MAINTENA 300 MG	ARIPIPRAZOLE AS MONOHYDRATE	ARIPIPRAZOLE AS MONOHYDRATE 300MG/VIAL 200 mg/ml after reconstitution	POWDER	RECIEPT	Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
7	ABILIFY MAINTENA	ABILIFY MAINTENA 400 MG	ARIPIPRAZOLE AS MONOHYDRATE	ARIPIPRAZOLE AS MONOHYDRATE 400MG/VIAL 200 mg/ml after reconstitution	POWDER	RECIEPT	Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
11	ABIPLATIN	ABIPLATIN TEVA	CISPLATIN	CISPLATIN 1MG/ML	CONCENTRATE	RECIEPT	Palliative therapy to be employed either alone, or more commonly in established combination therapy with orher approved chemotherapeutic agents and in patients with metastatic testicular tumor and metastatic ovarian tumor who have alreasy received appropriate surgical and/or radiotherapeutic procedures and in patients with advanced bladder cancer.
12	ABIRATERONE	ABIRATERONE TEVA 250 MG	ABIRATERONE ACETATE	ABIRATERONE ACETATE 250MG	TABLETS	RECIEPT	Abiraterone Acetate is CYP 17 inhibitor and it is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. The treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
14	ABITREN	ABITREN 100	DICLOFENAC SODIUM	DICLOFENAC SODIUM 100MG	TABLETS	RECIEPT	Rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout. Control of pain and inflammation in orthopedic, dental, and other minor surgery.
16	ABITREN	ABITREN SUPPOSITORIES 50 MG	DICLOFENAC SODIUM	DICLOFENAC SODIUM 50MG	SUPPOSITORIES	RECIEPT	Rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal . Disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout. Control of pain and inflammation in orthopedic, dental, and other monor surgery.
17	ABITREN	ABITREN TEVA 75MG/3ML	DICLOFENAC SODIUM	DICLOFENAC SODIUM 75MG/3ML	SOLUTION	RECIEPT	Treatment of: - Exacerbations of inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondylarthritis, non-articular rheumatism. - Treatment of painful conditions due to inflammation of non rheumatic origin. - Renal colic and biliary colic - Post-traumatic and post-operative pain, inflammation and swelling
18	ABITREXATE	ABITREXATE TEVA	METHOTREXATE	METHOTREXATE 25MG/ML	SOLUTION	RECIEPT	Antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. Palliation of acute lymphocytic leukemia. Abitrexate is also indicated in the treatment and prophylaxis of meningeal leukemia. Greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. In combination with other anticancer agents, Abitrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. Abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. Abitrexate is effective in the treatment of the advanced stages (III and IV Peter's Staging System) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. Psoriasis: because of the high risk attending its use, Abitrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. Rheumatoid Arthritis: Abitrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose NSAIDs and usually a trial of at least one or more disease-modifying antirheumatic drugs.
20	ABRAXANE	ABRAXANE	PACLITAXEL	PACLITAXEL 100MG/VIAL	POWDER	RECIEPT	Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
22	ABROL	ABROL 500MG 20TAB	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Analgesic, anti-pyretic relief of cough associated with pain and fever.
23	ABROL	ABROL TABLETS	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Analgesic, antipyretic.
28	ABROLET	ABROLET SYRUP	PARACETAMOL	PARACETAMOL 125MG/5ML	SYRUP		Analgesic and antipyretic.
29	ABROLET	ABROLET SYRUP SF 115ML	PARACETAMOL	PARACETAMOL 125MG/5ML	SYRUP		Analgesic and antipyretic.
24	ABROLET	ABROLET 150MG 12SUPP	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		Analgesic and antipyretic.
27	ABROLET	ABROLET SUPPOSITORIES	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		Analgesic, antipyretic pediatric suppositories.
25	ABROLET	ABROLET FORTE SUPPOSITORIES	PARACETAMOL	PARACETAMOL 250MG	SUPPOSITORIES		Analgesic and antipyretic.
26	ABROLET	ABROLET FTE 250MG 12 SUP	PARACETAMOL	PARACETAMOL 250MG	SUPPOSITORIES		Analgesic and antipyretic.
30	ABSTRAL	ABSTRAL 100 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 100MCG	TABLETS	RECIEPT	Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
31	ABSTRAL	ABSTRAL 200 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 200MCG	TABLETS	RECIEPT	Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
32	ABSTRAL	ABSTRAL 300 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 300MCG	TABLETS	RECIEPT	Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
33	ABSTRAL	ABSTRAL 400 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 400MCG	TABLETS	RECIEPT	Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
34	ABSTRAL	ABSTRAL 600 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 600MCG	TABLETS	RECIEPT	Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
35	ABSTRAL	ABSTRAL 800 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 800MCG	TABLETS	RECIEPT	Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
45	ACAMOL	ACAMOL FOCUS	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 250MG;PARACETAMOL 250MG;CAFFEINE 65MG ANHYDROUS	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
46	ACAMOL	ACAMOL FOCUS 30CAPLIOTS	ASPIRIN	ASPIRIN 250MG;PARACETAMOL 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
47	ACAMOL	ACAMOL FOCUS 50CAPLIOTS	ASPIRIN	ASPIRIN 250MG;PARACETAMOL 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
50	ACAMOL	ACAMOL TSIN.LIQUI.GEL 30D+10N CAPSULE	PARACETAMOL	PARACETAMOL 250MG;PEUDOEPHEDRINE 30MG	CAPSULES	RECIEPT	For the relief of common cold and nasal congestion associated with fever and pain. Day care medicine.
51	ACAMOL	ACAMOL TSIN.LIQUI.GEL 30DAY CAPSULE	PARACETAMOL	PARACETAMOL 250MG;PEUDOEPHEDRINE 30MG	GEL	RECIEPT	For the relief of common cold and nasal congestion associated with fever and pain. Day care medicine.
52	ACAMOL	ACAMOL TSIN.LIQUI.GEL.10NIGHT CAPSULE	PARACETAMOL	PARACETAMOL 250MG;PEUDOEPHEDRINE 30MG	CAPSULES	RECIEPT	For the relief of common cold and nasal congestion associated with fever and pain. Day care medicine.
78	ACAMOL	ACAMOL TSINUN LIQUIGEL DAY	PARACETAMOL	PARACETAMOL 250MG;PSEUDOEPHEDRINE AS HYDROCHLORIDE 30MG	CAPSULES	RECIEPT	For the relief of common cold and nasal congestion associated with fever and pain. Day care medicine.
83	ACAMOL	ACAMOL TSINUN LIQUIGEL DAY + NIGHT ( 30 + 10 )	PARACETAMOL	PARACETAMOL 250MG;PSEUDOEPHEDRINE AS HYDROCHLORIDE 30MG	CAPSULES	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה
84	ACAMOL	ACAMOL TSINUN LIQUIGEL NIGHT	PARACETAMOL	PARACETAMOL 250MG;PSEUDOEPHEDRINE AS HYDROCHLORIDE 30MG;CHLORPHENIRAMINE MALEATE 2MG	CAPSULES	RECIEPT	For the relief of common cold and nasal congestion associated with fever and pain. Night care medicine.
36	ACAMOL	ACAMOL	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
42	ACAMOL	ACAMOL 21 CAPLETS	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Relief of mild to moderate pain. Relief of fever and cough associated with fever.
43	ACAMOL	ACAMOL 500MG 20TAB	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Relief of mild to moderate pain. Relief of fever and cough associated with fever.
44	ACAMOL	ACAMOL 500MG 50CAP	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Relief of mild to moderate pain. Relief of fever and cough associated with fever.
74	ACAMOL	ACAMOL TSINUN CLASSIC NIGHT	PARACETAMOL	PARACETAMOL 500MG;CHLORPHENIRAMINE MALEATE 2MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	For the relief of common cold associated with symptoms such as , nasal congestion and runny nose accompanied by pain and fever. Night care medicine.
59	ACAMOL	ACAMOL TSINUN & SHAPA'AT NIGHT	PARACETAMOL	PARACETAMOL 500MG;CHLORPHENIRAMINE MALEATE 2MG;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG;DEXTROMETHORPHAN HYDROBROMIDE 15MG	TABLETS	RECIEPT	For the relief of cold, cough and nasal congestion associated with fever and pain, for night care.
49	ACAMOL	ACAMOL NIGHT 20 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;DIPHENHYDRAMINE HCL 25MG	TABLETS		Antipyretic and analgesic for the temporary relief of occasional headache and minor pains with accompanying sleeplessness.
48	ACAMOL	ACAMOL NIGHT	PARACETAMOL	PARACETAMOL 500MG;DIPHENHYDRAMINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Antipyretic and analgesic for the temporary relief of occasional headache and minor pains with accompanying sleeplessness.
63	ACAMOL	ACAMOL TSINUN & SHAPA'AT NIGHT 14 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE 30MG;CHLORPHENIRAMIN MALEATE 2MG;DEXTROMETHORFAN 15MG	TABLETS	RECIEPT	For the relief of cold, cough and nasal congestion associated with fever and pain, for night care.
89	ACAMOL	ACAMOL TSINUN& SHAAPAT 35D+14N CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE 30MG;CHLORPHENIRAMIN MALEATE 2MG;DEXTROMETHORFAN 15MG	TABLETS	RECIEPT	For the relief of cold, cough and nasal congestion associated with fever and pain, for night care.
64	ACAMOL	ACAMOL TSINUN CLASSIC 21D+14N CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG	TABLETS	RECIEPT	For the relief of common cold associated with symptoms such as , nasal congestion and runny nose accompanied by pain and fever. Night care medicine.
65	ACAMOL	ACAMOL TSINUN CLASSIC 35D+14N CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG	TABLETS	RECIEPT	For the relief of common cold associated with symptoms such as , nasal congestion and runny nose accompanied by pain and fever. Night care medicine.
72	ACAMOL	ACAMOL TSINUN CLASSIC DAY 21 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה
73	ACAMOL	ACAMOL TSINUN CLASSIC DAY 35 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה
58	ACAMOL	ACAMOL TSINUN & SHAPA'AT DAY 35 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 30MG;DEXTROMETHORPHAN HYDROBROMIDE 15MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה
66	ACAMOL	ACAMOL TSINUN CLASSIC DAY	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	For the relief of common cold associated with symptoms such as fever or pains accompanied with nasal congestion, day care medicine.
70	ACAMOL	ACAMOL TSINUN CLASSIC DAY + NIGHT (21 + 14)	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה
71	ACAMOL	ACAMOL TSINUN CLASSIC DAY + NIGHT (35 + 14)	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה
53	ACAMOL	ACAMOL TSINUN & SHAPA'AT DAY	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG;DEXTROMETHORPHAN HYDROBROMIDE 15MG	TABLETS	RECIEPT	For the relief of cold, cough and nasal congestion associated with fever and pain, for day care.
57	ACAMOL	ACAMOL TSINUN & SHAPA'AT DAY + NIGHT ( 35 + 14 )	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG;DEXTROMETHORPHAN HYDROBROMIDE 15MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה
90	ACAMOLI	ACAMOLI 125 MG/5 ML SYRUP FRUIT FLAVOUR	PARACETAMOL	PARACETAMOL 125MG/5ML	SYRUP		Analgesic, antipyretic.
91	ACAMOLI	ACAMOLI 125 MG/5 ML SYRUP RASPBERRY FLAVOUR	PARACETAMOL	PARACETAMOL 125MG/5ML	SYRUP		Analgesic, antipyretic.
92	ACAMOLI	ACAMOLI 125 MG/5 ML SYRUP STRAWBERRY FLAVOUR	PARACETAMOL	PARACETAMOL 125MG/5ML	SYRUP		Analgesic, antipyretic.
103	ACAMOLI	ACAMOLI FRUIT SYR 100ML	PARACETAMOL	PARACETAMOL 125MG/5ML	SYRUP		Analgesic and antipyretic.
104	ACAMOLI	ACAMOLI RASPERRY SYR 100ML	PARACETAMOL	PARACETAMOL 125MG/5ML	SYRUP		Analgesic and antipyretic.
105	ACAMOLI	ACAMOLI STRAW SYR 100ML	PARACETAMOL	PARACETAMOL 125MG/5ML	SYRUP		Analgesic and antipyretic.
93	ACAMOLI	ACAMOLI 150 MG SUPPOSITORIES	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		Analgesic and antipyretic.
94	ACAMOLI	ACAMOLI 150MG 12SUPP	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		For the relief of cold symptoms such as nasal congestion and runny nose, accompanied with pains and fever.
95	ACAMOLI	ACAMOLI 150MG 18SUPP	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		For the relief of cold symptoms such as nasal congestion and runny nose, accompanied with pains and fever.
108	ACAMOLI	ACAMOLI TSINUN STRAWBERRY FLAVOR	PARACETAMOL	PARACETAMOL 160MG/5ML;CHLORPHENIRAMINE MALEATE 1MG/5ML;PSEUDOEPHEDRINE HYDROCHLORIDE 15MG/5ML	SYRUP	RECIEPT	For the relief of cold symptoms such as nasal congestion and runny nose, accompanied with pains and fever.
98	ACAMOLI	ACAMOLI COLD SYRUP STRW100ML	PARACETAMOL	PARACETAMOL 160MG;CHLORPHENIRAMINE MALEATE 1MG;PSEUDOEPHEDRINE HCL 15MG/5ML	SYRUP	RECIEPT	Analgesic and antipyretic.
99	ACAMOLI	ACAMOLI FORTE 250MG 12 SUPP	PARACETAMOL	PARACETAMOL 250MG	SUPPOSITORIES		Analgesic, antipyretic.
100	ACAMOLI	ACAMOLI FORTE 250 MG SUPPOSITORIES	PARACETAMOL	PARACETAMOL 250MG	SUPPOSITORIES		Relief of pain and fever.
101	ACAMOLI	ACAMOLI FORTE 250 MG/5 ML SYRUP STRAWBERRY FLAVOUR	PARACETAMOL	PARACETAMOL 250MG/5ML	SYRUP		Analgesic, antipyretic.
102	ACAMOLI	ACAMOLI FORTE 250 MG/5 ML SYRUP TUTTI-FRUTTI FLAVOUR	PARACETAMOL	PARACETAMOL 250MG/5ML	SYRUP		Analgesic, antipyretic.
106	ACAMOLI	ACAMOLI SYR FOR BIG KIDS TUTTI FRUTTI 100ML	PARACETAMOL	PARACETAMOL 250MG/5ML	SYRUP		Analgesic and antipyretic.
107	ACAMOLI	ACAMOLI SYR FOR BIG KIDS STRAB 100ML	PARACETAMOL	PARACETAMOL 250MG/5ML	SYRUP		Analgesic and antipyretic.
96	ACAMOLI	ACAMOLI BABY 80 MG SUPPOSITORIES	PARACETAMOL	PARACETAMOL 80MG	SUPPOSITORIES		Analgesic and antipyretic.
97	ACAMOLI	ACAMOLI BABY 80MG 12 SUPP	PARACETAMOL	PARACETAMOL 80MG	SUPPOSITORIES		Analgesic and antipyretic.
109	ACCOFIL	ACCOFIL 300 MCG/0.5 ML	FILGRASTIM	FILGRASTIM 300MCG/0.5ML	SOLUTION	RECIEPT	ACCOFIL is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of ACCOFIL are similar in adults and children receiving cytotoxic chemotherapy. ACCOFIL is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs). In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of less or equal to 0.5 x 109 /L, and a history of severe or recurrent infections, long term administration of ACCOFIL is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. ACCOFIL is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109 /L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
110	ACCOFIL	ACCOFIL 480 MCG/0.5 ML	FILGRASTIM	FILGRASTIM 480MCG/0.5ML	SOLUTION	RECIEPT	ACCOFIL is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of ACCOFIL are similar in adults and children receiving cytotoxic chemotherapy. ACCOFIL is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs). In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of less or equal to 0.5 x 109 /L, and a history of severe or recurrent infections, long term administration of ACCOFIL is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. ACCOFIL is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109 /L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
112	ACERIL	ACERIL 12.5	CAPTOPRIL	CAPTOPRIL 12.5MG	TABLETS	RECIEPT	Hypertension, Congestive Heart Failure, insulin dependent diabetic nephropathey in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.
113	ACERIL	ACERIL 25	CAPTOPRIL	CAPTOPRIL 25MG	TABLETS	RECIEPT	Hypertension, Congestive Heart Failure, insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.
114	ACERIL	ACERIL 50	CAPTOPRIL	CAPTOPRIL 50MG	TABLETS	RECIEPT	Hypertension, Congestive Heart Failure, insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.
115	ACETOSAL	ACETOSAL 300	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 300MG	TABLETS		Analgesic, antipyretic, treatment of non-infective inflammatory conditions.
116	ACETOSAL	ACETOSAL 300MG 30TAB	ASPIRIN	ASPIRIN 300MG	TABLETS		Analgesic, antipyretic, treatment of non-infective inflammatory conditions.
117	ACID BORIC	ACID BORIC 1.9% 10ML	BORIC ACID	BORIC ACID 1.9%	DROPS		Mild antiseptic for the eyes and for the relief of mild irritation of the eyes caused by various irritants e.g. smoke, dust etc.
118	ACLASTA	ACLASTA	ZOLEDRONIC ACID	ZOLEDRONIC ACID 5MG/100ML	SOLUTION	RECIEPT	Treatment of Paget's disease of the bone. Treatment of osteoporosis : - in post-menopausal women - in men at increased risk of fracture including those with a recent low-trauma hip fracture. Treatment and prevention of glucocorticoid-induced osteoporosis. Prevention of postmenopausal osteoporosis in women for whom bisphosphonate therapy is indicated.
120	ACNETRIM	ACNETRIM	ERYTHROMYCIN	ERYTHROMYCIN 2%W/V	SOLUTION	RECIEPT	As a topical antibiotic treatment for all forms of acne, particularly inflamatory acne with papules and pustules.
121	ACROSE	ACROSE 100	ACARBOSE	ACARBOSE 100MG	TABLETS	RECIEPT	Treatment of non-insulin dependent diabetes mellitus (NIDDM) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.
122	ACROSE	ACROSE 50	ACARBOSE	ACARBOSE 50MG	TABLETS	RECIEPT	Treatment of non-insulin dependent diabetes mellitus (NIDDM) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.
123	ACTEMRA	ACTEMRA 162 MG S.C.	TOCILIZUMAB	TOCILIZUMAB 162MG/0.9ML	SOLUTION	RECIEPT	• Actemra in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. In these patients, Actemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. • Actemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate. • Actemra in combination with methotrexate (MTX) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX • Actemra (tocilizumab) is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
124	ACTEMRA	ACTEMRA 20MG/ML I.V.	TOCILIZUMAB	TOCILIZUMAB 20MG/ML	CONCENTRATE	RECIEPT	Actemra (tocilizumab), is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more DMARDs(Disease Modifying Anti-Rheumatic Drugs) or TNF antagonists or in whom DMARDs cannot be used. Actemra can be used alone or in combination with methotrexate or other DMARDs. Actemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate. Actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. Actemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Actemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. Actemra in combination with methotrexate (MTX) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.
125	ACT-HIB	ACT-HIB	HAEMOPHILUS B	HAEMOPHILUS B 10MCG/0.5ML	POWDER	RECIEPT	Prevention in infants of invasive diseases caused by Haemophilus influenzae type B ( meningitis septicemia cellulitis arthritis epiglotitis).
127	ACTILYSE	ACTILYSE 50 MG	ALTEPLASE	ALTEPLASE 50MG/VIAL	POWDER	RECIEPT	Acute myocardial infarction : Actilyse is indicated for use in the management of acute myocardial infraction (AMI) in adults for the lysis of thrombi obstructing coronary arteries, the reduction of infract size, improvement of ventricular function, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms. Acute massive pulmonary embolism with hemodynamic deprivation: Actylise is indicated in the management of acute massive pulmonary embolism (PE) in adults: - for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lung, and - for the lysis of pulmonary emboli accompanied by unstable hemodynamics e.g. failure to maintain blood pressure without supportive measures. The diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning. For fibrinolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). The treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome. This treatment is restricted to a prescription by a specialist in neurology.
126	ACTILYSE	ACTILYSE 20 MG	RECOMBINANT HUMAN TPA	RECOMBINANT HUMAN TPA 20MG/DOSE	POWDER	RECIEPT	Acute myocardial infarction : Actilyse is indicated for use in the management of acute myocardial infraction (AMI) in adults for the lysis of thrombi obstructing coronary arteries, the reduction of infract size, improvement of ventricular function, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms. Acute massive pulmonary embolism with hemodynamic deprivation: Actylise is indicated in the management of acute massive pulmonary embolism (PE) in adults: - for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lung, and - for the lysis of pulmonary emboli accompanied by unstable hemodynamics e.g. failure to maintain blood pressure without supportive measures. The diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning. For fibrinolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). The treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome. This treatment is restricted to a prescription by a specialist in neurology.
129	ACTIQ	ACTIQ 1200 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 1200MCG/DOSE	TABLETS	RECIEPT	Actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
130	ACTIQ	ACTIQ 1600 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 1600MCG/DOSE	TABLETS	RECIEPT	Actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
131	ACTIQ	ACTIQ 200 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 200MCG/DOSE	TABLETS	RECIEPT	Actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
132	ACTIQ	ACTIQ 400 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 400MCG/DOSE	TABLETS	RECIEPT	Actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
133	ACTIQ	ACTIQ 600 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 600MCG/DOSE	TABLETS	RECIEPT	Actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
134	ACTIQ	ACTIQ 800 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 800MCG/DOSE	TABLETS	RECIEPT	Actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
135	ACTIVELLE	ACTIVELLE	ESTRADIOL AS HEMIHYDRATE	ESTRADIOL AS HEMIHYDRATE 1MG;NORETHISTERONE AS ACETATE 0.5MG	TABLETS	RECIEPT	Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in women more than one year after menopause. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of , or contraindicated for, other medicinal products approved for the prevention of osteoporosis. The experience treating women older than 65 years is limited.
136	ACTONEL ONCE A MONTH	ACTONEL ONCE A MONTH 150 MG	RISEDRONIC ACID AS SODIUM	RISEDRONIC ACID AS SODIUM 150MG	TABLETS	RECIEPT	Treatment of postmenopausal osteoporosis. Prevention of postmenopausal osteoporosis.
138	ACTOS	ACTOS 15 MG	PIOGLITAZONE AS HYDROCHLORIDE	PIOGLITAZONE AS HYDROCHLORIDE 15MG	TABLETS	RECIEPT	Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. - Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance . After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained .
139	ACTOS	ACTOS 30 MG	PIOGLITAZONE AS HYDROCHLORIDE	PIOGLITAZONE AS HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. - Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance . After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained .
140	ACTOS	ACTOS 45 MG	PIOGLITAZONE AS HYDROCHLORIDE	PIOGLITAZONE AS HYDROCHLORIDE 45MG	TABLETS	RECIEPT	Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. - Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance . After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained .
142	ACTRAPID	ACTRAPID VIAL	INSULIN (HUMAN)	INSULIN (HUMAN) 100IU/ML	SOLUTION	RECIEPT	Therapeutic indications Actrapid is indicated for treatment of diabetes mellitus.
141	ACTRAPID	ACTRAPID PENFILL	INSULIN (HUMAN)	INSULIN (HUMAN) 100U/ML	SOLUTION	RECIEPT	Therapeutic indications Actrapid is indicated for treatment of diabetes mellitus.
143	ACYCLO-V	ACYCLO-V 200	ACYCLOVIR	ACICLOVIR 200MG	TABLETS	RECIEPT	For the treatment of herpes simplex virus infections of skin and mucous membranes including initial and recurrent genital herpes. For the suppression ( prevention of recurrent) or recurrent herpes simplex infections in immunecompetent patients. For the prophylaxis of herpes simplex infections in immune-compromised patients. For the treatment of herpes zoster infections. For the treatment of chickenpox .
144	ACYCLO-V	ACYCLO-V 400	ACYCLOVIR	ACICLOVIR 400MG	TABLETS	RECIEPT	For the treatment of herpes simplex virus infections of skin and mucous membranes including initial and recurrent genital herpes. For the suppression ( prevention of recurrent) or recurrent herpes simplex infections in immunecompetent patients. For the prophylaxis of herpes simplex infections in immune-compromised patients. For the treatment of herpes zoster infections. For the treatment of chickenpox .
145	ACYCLOVENIR	ACYCLOVENIR	ACYCLOVIR	ACICLOVIR 250MG	POWDER	RECIEPT	For the treatment of Herpes Simplex infections and severe intial genital herpes in the non immunocompromised. For the prophylaxis of Herpes Simplex infections in immune-compromised patients. In the treatment of Varicella zoster infections. For Herpes Simplex Encephalitis. For the treatment of herpes simplex infection in the neonate and infant up to 3 months of age.
146	ADACEL	ADACEL	PERTUSSIS TOXOID VACCINE	PERTUSSIS TOXOID VACCINE 2.5MCG/DOSE;FILAMENTOUS HAEMAGGLUTININ (FHA) 5MCG/DOSE;FIMBRAE TUPES 2 + 3 (FIM) 5MCG/DOSE;PERTACTIN (PRN) 3MCG/DOSE;DIPHTHERIA TOXOID 2LF/1 DOSES;TETANUS TOXOID 5LF/1 DOSES	SUSPENSION	RECIEPT	Active booster immunization against diphtheria, tetanus and pertussis in children, adolescents and adults aged 4 to 64 years. Adacel is not indicated for treating diseases caused by B.pertussis, C.diphtheriae or C. tetani infections.
147	ADACEL POLIO	ADACEL POLIO	FIMBRAE TUPES	FIMBRAE TUPES 2 + 3 (FIM) 5MCG/DOSE;PERTUSSIS TOXOID VACCINE 2.5MCG/DOSE;FILAMENTOUS HAEMAGGLUTININ (FHA) 5MCG/DOSE;PERTACTIN (PRN) 3MCG/DOSE;DIPHTHERIA TOXOID 2LF/1 DOSES;TETANUS TOXOID 5LF/1 DOSES;INACTIVATED POLIO VIRUS (IPV) TYPE 1 40DU/DOSE;INACTIVATED POLIO VIRUS (IPV) TYPE 2 8DU/DOSE;INACTIVATED POLIO VIRUS (IPV) TYPE 3 32DU/DOSE	SUSPENSION		Active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 4 years and over as a booster following primary immunisation. Adacel polio is not indicated for primary immunisation. Adacel polio is not indicated for treating diseases caused by B.pertussis, C.Diphtheriae or C.tetani or by poliomyelitis infections
148	ADAFERIN	ADAFERIN CREAM	ADAPALENE	ADAPALENE 0.1%W/W	CREAM	RECIEPT	For the cutaneous treatment of acne vulgaris, where comedones, papules and postules predominate. Acne of the face, chest or back is appropriate for treatment. The treatment is limited up to six months in adolescents over 12 years.
149	ADAFERIN	ADAFERIN GEL	ADAPALENE	ADAPALENE 0.1%W/W	GEL	RECIEPT	Continuous treatment of acne vulgaris where papules and postules predominate. Acne of the chest, face or back is appropriate for treatment.
3786	ADALAT	OSMO - ADALAT 20 MG	NIFEDIPINE	NIFEDIPINE 20MG	TABLETS	RECIEPT	Chronic stable angina, hypertension.
3787	ADALAT	OSMO - ADALAT 30 MG	NIFEDIPINE	NIFEDIPINE 30MG	TABLETS	RECIEPT	Chronic stable angina, hypertension.
3788	ADALAT	OSMO - ADALAT 60 MG	NIFEDIPINE	NIFEDIPINE 60MG	TABLETS	RECIEPT	Chronic stable angina, hypertension.
150	ADCETRIS	ADCETRIS 50 MG	BRENTUXIMAB VEDOTIN	BRENTUXIMAB VEDOTIN 50MG/VIAL	POWDER	RECIEPT	ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following ASCT. ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy . ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
151	ADDAMEL-N	ADDAMEL-N	COPPER CHLORIDE	COPPER CHLORIDE 0.34MG/ML;POTASSIUM IODIDE 16.6MCG/ML;SODIUM MOLYBDATE 4.85MCG/ML;SODIUM SELENITE 6.9MCG/ML;ZINC CHLORIDE 1.36MG/ML;CHROMIUM CHLORIDE 5.33MCG/ML;FERRIC CHLORIDE 0.54MG/ML;SODIUM FLUORIDE 0.21MG/ML;MANGANESE CHLORIDE 99MCG/ML	CONCENTRATE	RECIEPT	Supplement in IV nutrition for adults to meet the requirements of trace elements.
152	ADDAVEN	ADDAVEN	SODIUM FLUORIDE	SODIUM FLUORIDE 210MCG/1ML;CHROMIC CHLORIDE HEXAHYDRATE 5.330MCG/1ML;POTASSIUM IODIDE 16.60MCG/1ML;SODIUM MOLYBDATE DIHYDRATE 4.850MCG/1ML;SODIUM SELENITE ANHYDROUS 17.29MCG/1ML;COPPER CHLORIDE DIHYDRATE 102.3MCG/1ML;MANGANESE CHLORIDE TETRAHYDRATE 19.79MCG/1ML;ZINC CHLORIDE 1050MCG/1ML;FERRIC CHLORIDE HEXAHYDRATE 540MCG/1ML	CONCENTRATE	RECIEPT	To meet basal to moderately increased requirements of trace elements in intravenous nutrition.
153	ADEMPAS	ADEMPAS 0.5 MG	RIOCIGUAT	RIOCIGUAT 0.5MG	TABLETS	RECIEPT	Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.
154	ADEMPAS	ADEMPAS 0.5MG	RIOCIGUAT	RIOCIGUAT 0.5MG	TABLETS	RECIEPT	Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.
157	ADEMPAS	ADEMPAS 1.5 MG	RIOCIGUAT	RIOCIGUAT 1.5MG	TABLETS	RECIEPT	Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.
155	ADEMPAS	ADEMPAS 1 MG	RIOCIGUAT	RIOCIGUAT 1MG	TABLETS	RECIEPT	Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.
161	ADEMPAS	ADEMPAS 2.5 MG	RIOCIGUAT	RIOCIGUAT 2.5MG	TABLETS	RECIEPT	Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.
159	ADEMPAS	ADEMPAS 2 MG	RIOCIGUAT	RIOCIGUAT 2MG	TABLETS	RECIEPT	Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.
163	ADENO	ADENO-AVENIR	ADENOSINE	ADENOSINE 3MG/ML	SOLUTION	RECIEPT	Rapid conversion to a normal sinus rhythm of paroxymal supraventicular tachycardias including those associated with accessory bypass tracts (wolf parkinson-white syndrome).
164	ADENOCOR	ADENOCOR	ADENOSINE	ADENOSINE 6MG/2ML	SOLUTION	RECIEPT	Rapid conversion to a normal sinus rhythm of paroxysmal supraventicular tachycardias including those associated with accessory bypass tracts (wolf parkinson-white syndrome).
165	ADENOHARDT	ADENOHARDT	ADENOSINE	ADENOSINE 3MG/1ML	SOLUTION	RECIEPT	Rapid conversion to a normal sinus rhythm of paroxymal supraventicular tachycardias including those associated with accessory bypass tracts (wolf parkinson-white syndrome).
166	ADEX	ADEX 200	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	For the relief of mild to moderate pain such as headache, toothache, primary dysmenorrhea, backache, muscular pain. Anti - inflammatory and relieves pain in reumatoid arthritis and osteo arthritis. For the reduction of fever. For the treatment of pain associated with migraine.
167	ADEX	ADEX 200MG 40CAPLETS	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	For the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. For the relief of mild to moderate pain and treatment of primary dysmenorrhea. For the treatment of pain associated with migraine.
170	ADEX	ADEX LIQUIGEL 200MG 30CAPS	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	For the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. For the relief of mild to moderate pain and treatment of primary dysmenorrhea. For the treatment of pain associated with migraine.
172	ADEX	ADEX LIQUI-GELS 200	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.
168	ADEX	ADEX FORTE 400	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	For the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. For the relief of mild to moderate pain and treatment of primary dysmenorrhea. For the treatment of pain associated with migraine.
169	ADEX	ADEX FORTE 400MG 40CAPLETS	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	For the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. For the relief of mild to moderate pain and treatment of primary dysmenorrhea. For the treatment of pain associated with migraine.
171	ADEX	ADEX LIQUIGEL 400MG 20CAPS	IBUPROFEN	IBUPROFEN 400MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.
173	ADEX	ADEX LIQUI-GELS 400	IBUPROFEN	IBUPROFEN 400MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.
174	ADIZEM CD	ADIZEM CD 120	DILTIAZEM HYDROCHLORIDE	DILTIAZEM HYDROCHLORIDE 120MG	CAPSULES	RECIEPT	Calcium channel blocker that is indicated for the treatment of hypertension and angina.
175	ADIZEM CD	ADIZEM CD 180	DILTIAZEM HYDROCHLORIDE	DILTIAZEM HYDROCHLORIDE 180MG	CAPSULES	RECIEPT	Calcium channel blocker that is indicated for the treatment of hypertension and angina.
176	ADIZEM CD	ADIZEM CD 240	DILTIAZEM HYDROCHLORIDE	DILTIAZEM HYDROCHLORIDE 240MG	CAPSULES	RECIEPT	Calcium channel blocker that is indicated for the treatment of hypertension and angina.
177	ADOLAN	ADOLAN 0.04 %	METHADONE HYDROCHLORIDE	METHADONE HYDROCHLORIDE 0.4MG/ML	SOLUTION	RECIEPT	Relief of moderate to severe pain.
178	ADRENALINE	ADRENALINE S.A.L.F 1 MG/ML	EPINEPHRINE	EPINEPHRINE 1MG/ML	SOLUTION	RECIEPT	Adrenaline S.A.L.F. 1 mg/ml is indicated for: - Relief of respiratory distress due to bronchospasm. - Rapid relief of hypersensitivity reaction to drugs and other allergens. - Prolongation of the action of infiltration anesthetics. - Adrenaline may be of value in restoring cardiac rhythm in cardiac arrest. However, it is not used in cardiac failure or in hemorrhagic, traumatic or cardiogenic shock. - Treatment of mucosal congestion of hay fever rhinitis and acute sinusitis. - Relief of bronchial asthmatic paroxysms. - Symptomatic relief of serum sickness urticarial and angioneurotic edema. - Relaxation of uterine musculature and inhibition of uterine contractions. - Hemostatic agent in syncope due to complete heart block or carotid sinus hypersensitivity and for resuscitation in cardiac arrest following anesthetic accidents.
179	ADRENALINE	ADRENALINE TEVA	EPINEPHRINE	EPINEPHRINE 1MG/ML	SOLUTION	RECIEPT	Relief of respiratory distress due to bronchospasm. Rapid relief of hypersensitivity reaction to drugs and other allergens. Prolongation of the action of infiltration anesthetics. Adrenaline may be of value in restoring cardiac rhythm in cardiac arrest. However it is not used in cardiac failure or in hemorrhagic traumatic or cardiogenic shock. Treatment of mucosal congestion of hay fever rhinitis and acute sinusitis. Relief of bronchial asthmatic paroxysms. Symptomatic relief of serum sickness urticaria and angioneurotic edema. Open-angle glaucoma. Relaxation of uterine musculature and inhibition of uterine contractions. Hemostatic agent in syncope due to complete heart block or carotid sinus hypersensitivity and for resuscitation in cardiac arrest following anesthetic accidents.
180	ADVAGRAF	ADVAGRAF 0.5 MG	TACROLIMUS AS MONOHYDRATE	TACROLIMUS AS MONOHYDRATE 0.5MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult kidney or liver allograft recipient patients.
181	ADVAGRAF	ADVAGRAF 1 MG	TACROLIMUS AS MONOHYDRATE	TACROLIMUS AS MONOHYDRATE 1MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult kidney or liver allograft recipient patients.
182	ADVAGRAF	ADVAGRAF 3 MG	TACROLIMUS AS MONOHYDRATE	TACROLIMUS AS MONOHYDRATE 3MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult kidney or liver allograft recipient patients.
183	ADVAGRAF	ADVAGRAF 5 MG	TACROLIMUS AS MONOHYDRATE	TACROLIMUS AS MONOHYDRATE 5MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult kidney or liver allograft recipient patients.
184	ADVATE	ADVATE 1000 IU	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT)	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT) 1000IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
185	ADVATE	ADVATE 1500 IU	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT)	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT) 1500IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
186	ADVATE	ADVATE 2000 IU	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT)	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT) 2000IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
187	ADVATE	ADVATE 250 IU	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT)	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT) 250IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
188	ADVATE	ADVATE 3000 IU	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT)	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT) 3000IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
189	ADVATE	ADVATE 500 IU	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT)	OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT) 500IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
193	ADVIL	ADVIL CHILDREN'S FRUIT FLAVOR	IBUPROFEN	IBUPROFEN 100MG/5ML	SUSPENSION	RECIEPT	For the reduction of fever and relief of mild to moderate pain. For infants and children aged 3 months to 12 years .
194	ADVIL	ADVIL CHILDREN'S GRAPE FLAVOR	IBUPROFEN	IBUPROFEN 100MG/5ML	SUSPENSION	RECIEPT	For the reduction of fever and relief of mild to moderate pain. For infants and children aged 3 months to 12 years .
199	ADVIL	ADVIL FRUIT SYR CHILD 120ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
200	ADVIL	ADVIL GRAP SYR CHILD 120ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
190	ADVIL	ADVIL 200MG 20LIQUI-GELS	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	For the relief of pain associated with headache, toothache, backache, muscular and menstrual pains. Antipyretic. Antiinflammatory for rheumatic diseases. For the treatment of pain assosiated with migraine.
191	ADVIL	ADVIL 200MG 40LIQUI-GELS	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	For the relief of pain associated with headache, toothache, backache, muscular and menstrual pains. Antipyretic. Antiinflammatory for rheumatic diseases. For the treatment of pain assosiated with migraine.
192	ADVIL	ADVIL 200MG 80LIQUI-GELS	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	For the relief of pain associated with headache, toothache, backache, muscular and menstrual pains. Antipyretic. Antiinflammatory for rheumatic diseases. For the treatment of pain assosiated with migraine.
201	ADVIL	ADVIL LIQUI-GELS 200	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	For the relief of pain associated with headache, toothache, backache, muscular and menstrual pains. Antipyretic. Antiinflammatory for rheumatic diseases. For the treatment of pain assosiated with migraine.
196	ADVIL	ADVIL COLD & SINUS 16 CAPS	IBUPROFEN	IBUPROFEN 200MG;PSEUDOEPHEDRINE HCL 30MG	CAPSULES	RECIEPT	Temporarily relieves symptoms associated with the common cold, or flu: in the presence of fever or pain with associated congestion.
195	ADVIL	ADVIL COLD & SINUS	IBUPROFEN	IBUPROFEN 200MG;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG	CAPSULES	RECIEPT	Temporarily relieves symptoms associated with the common cold, or flu: in the presence of fever or pain with associated congestion.
197	ADVIL	ADVIL FORTE 400	IBUPROFEN	IBUPROFEN 400MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, treatment of pain associated with migraine toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever.
198	ADVIL	ADVIL FORTE 400MG 20CAPS	IBUPROFEN	IBUPROFEN 400MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, treatment of pain associated with migraine toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever.
206	AERIUS	AERIUS TABLETS	DESLORATADINE	DESLORATADINE 5MG	TABLETS	RECIEPT	Aerius tablet is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with: - allergic rhinitis - urticaria
207	AEROVENT	AEROVENT	IPRATROPIUM BROMIDE	IPRATROPIUM BROMIDE 0.25MG/ML	SOLUTION	RECIEPT	For the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema . Aerovent respirator solution is of particular benefit in relieving acute bronchospasm when used concomitantly with inhaled beta agonists.
209	AERRANE	AERRANE	ISOFLURANE	ISOFLURANE 100ML/100ML	LIQUID	RECIEPT	Aerrane is a volatile halogenated anesthetic for general inhalation anesthesia.
210	AF KID	AF KID	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%	SOLUTION	RECIEPT	Relief of nasal congestion especially for babies.
211	AF KID	AF KID NASAL SOL 10ML	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%	DROPS		Relief of nasal congestion, especially for babies.
212	AF TIPA	AF TIPA	OXYMETAZOLINE HYDROCHLORIDE	OXYMETAZOLINE HYDROCHLORIDE 0.05%	SPRAY		Relief of nasal congestion, which is a result of common colds, sinusitis, hay fever or allergies of the upper respiratory system.
214	AFALPI	AFALPI SYRUP	PSEUDOEPHEDRINE HYDROCHLORIDE	PSEUDOEPHEDRINE HYDROCHLORIDE 30MG/5ML	SYRUP	RECIEPT	Sympthomatic treatment of nasal congestion, for relief of Eustachian tube congestion.
215	AF-CARE	AF-CARE	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 0.1%	DROPS		Rapid relief of nasal congestion for up to 10 hours.
216	AF-CARE	AF-CARE CHILDREN	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 0.05%	DROPS		Rapid relief of nasal congestion for up to 10 hours.
217	AFINITOR	AFINITOR 10 MG	EVEROLIMUS	EVEROLIMUS 10MG	TABLETS	RECIEPT	- For the treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEG
218	AFINITOR	AFINITOR 2.5 MG	EVEROLIMUS	EVEROLIMUS 2.5MG	TABLETS	RECIEPT	- For the treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEG
219	AFINITOR	AFINITOR 5 MG	EVEROLIMUS	EVEROLIMUS 5MG	TABLETS	RECIEPT	- For the treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEG
220	AFLUMYCIN	AFLUMYCIN	PREDNISOLONE	PREDNISOLONE 0.5%;GENTAMICIN SULFATE 0.16%	CREAM	RECIEPT	For the treatment of skin inflammation associated with bacterial infection.
221	AGGRASTAT	AGGRASTAT	TIROFIBAN AS HYDROCHLORIDE MONOHYDRATE	TIROFIBAN AS HYDROCHLORIDE MONOHYDRATE 0.05MG/ML	SOLUTION	RECIEPT	Aggrastat in combination with heparin, is indicated for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.
223	AGIOCUR	AGIOCUR	ISPAGHULA HUSKS	ISPAGHULA HUSKS 2.2G/100 G;ISPAGHULA SEED 65G/100 G	GRANULES		Managemant of bowel function.
224	AGIOCUR	AGIOCUR GRANULES 200GR	SEEDS PLANTAGO OVATA	SEEDS PLANTAGO OVATA 65G/100GR;ISPAGHULA 2.2G/100GR	GRANULES		Aid in treatment of constipation
225	AGIOLAX	AGIOLAX	ISPAGHULA HUSKS	ISPAGHULA HUSKS 2.2 G/100 G;SENNA 6.74G/100 G;ISPAGHULA SEED 52G/100 G	GRANULES	RECIEPT	For short - term treatment of constipation.
226	AGISERC	AGISERC 16	BETAHISTINE DIHYDROCHLORIDE	BETAHISTINE DIHYDROCHLORIDE 16MG	TABLETS	RECIEPT	Meniere's syndrom. Symptomatic treatment of peripheral vertigo.
227	AGISPOR	AGISPOR CREAM 15GR	BIFONAZOLE	BIFONAZOLE 1%	CREAM		Broad spectrum antimycotic agent.
228	AGISPOR	AGISPOR GEL	BIFONAZOLE	BIFONAZOLE 1%	GEL		Broad spectrum antimycotic agent.
229	AGISPOR	AGISPOR GEL 15GR	BIFONAZOLE	BIFONAZOLE 1%	GEL		Broad spectrum antimycotic agent.
231	AGISPOR	AGISPOR SHAMPOO	BIFONAZOLE	BIFONAZOLE 1%	SHAMPOO	RECIEPT	Pityriorisis versicolor and sebarrrhoeic dermatitis of the scalp caused by pityrosporum.
232	AGISPOR	AGISPOR SOL 15ML	BIFONAZOLE	BIFONAZOLE 1%	SOLUTION		Broad spectrum antimycotic agent.
230	AGISPOR	AGISPOR ONYCHOSET	BIFONAZOLE	BIFONAZOLE 1%;UREA 40%	OINTMENT	RECIEPT	For nail stripping and antifungal treatment of fungal infections of the finger nails and toe nails.
233	AGISPOR	AGISPOR SOLUTION	BIFONAZOLE	BIFONAZOLE 1G/100ML	SOLUTION		Broad spectrum antimycotic agent.
234	AGISTEN	AGISTEN 1 VAGINAL TAB 0.5GR	CLOTRIMAZOLE	CLOTRIMAZOLE 0.5GR	TABLETS	RECIEPT	Skin inflammation involving fungal infection
236	AGISTEN	AGISTEN BABY	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	PASTE	RECIEPT	For treatment of fungal nappy rash in children, that lasts over 72 hours.
237	AGISTEN	AGISTEN BABY PASTE 30GR	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	For treatment of fungal nappy rash in children, that lasts over 72 hours.
240	AGISTEN	AGISTEN CREAM	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	Skin infections caused by dermatophytes or candida species.
241	AGISTEN	AGISTEN CREAM 1%+ALOE VERA 20G	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	Skin inflammation involving fungal infection
242	AGISTEN	AGISTEN CREAM 30GR	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	Skin inflammation involving fungal infection
244	AGISTEN	AGISTEN PASTE	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	PASTE	RECIEPT	For treatment of abrasions and skin infections caused by species of fungi sensitive to clotrimazole .
245	AGISTEN	AGISTEN SOL 1% 20ML	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	SOLUTION	RECIEPT	Skin infection caused by dermatophytes or candida species.
246	AGISTEN	AGISTEN SOLUTION	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	SOLUTION	RECIEPT	Skin infection caused by dermatophytes or candida species.
243	AGISTEN	AGISTEN LOZENGES	CLOTRIMAZOLE	CLOTRIMAZOLE 10MG	TABLETS	RECIEPT	For local treatment of oropharyngeal candidiasis. Prophylactic treatment to reduce incidence of oropharyngeal candidiasis in patients immunocompromised by: - chemotherapy, - radiotherapy, - steroid therapy in Leukemia, - solid tumors, - renal transplantation.
235	AGISTEN	AGISTEN ALOEVERA CREAM	CLOTRIMAZOLE	CLOTRIMAZOLE 1G/100 G	CREAM	RECIEPT	Skin infections caused by dermatophytes or candida species.
250	AGISTEN	AGISTEN V 2 % VAGINAL CREAM	CLOTRIMAZOLE	CLOTRIMAZOLE 2%	CREAM	RECIEPT	Broad spectrum antimycotic with fungicidal action
247	AGISTEN	AGISTEN V 0.2 G. VAGINAL TABLETS	CLOTRIMAZOLE	CLOTRIMAZOLE 200MG	TABLETS	RECIEPT	Vaginal fungal infections caused mainly by candida species. Vaginal infections caused by trichomonas and microorganisms sensitive to clotrimazole.
251	AGISTEN	AGISTEN V 200MG 3 TAB	CLOTRIMAZOLE	CLOTRIMAZOLE 200MG	TABLETS	RECIEPT	Broad spectrum antimycotic with fungicidal action
238	AGISTEN	AGISTEN COMBI	CLOTRIMAZOLE	CLOTRIMAZOLE 200MG(TAB);CLOTRIMAZOLE 1%(CREAM)	TABLETS	RECIEPT	Cream: Skin infections caused by dermatophytes or candida species. Vag Tablets: Vaginal fungal infections caused mainly by candida species. Vaginal infections caused by trichomonas and microorganisms sensitive to Clotrimazole.
249	AGISTEN	AGISTEN V 0.5 G. VAGINAL TABLET	CLOTRIMAZOLE	CLOTRIMAZOLE 500MG	TABLETS	RECIEPT	Broad spectrum antimycotic with fungicidal and trichomonacidal action (for single dose treatment).
252	AGNUCASTON	AGNUCASTON	AGNI CASTI FRUCTUS DRY EXTRACT:	AGNI CASTI FRUCTUS DRY EXTRACT: 20% (7-11:1) EXTRACTION SOLVENT ETHANOL 70% V/V) 4MG	TABLETS	RECIEPT	Premenstrual syndrome, mastodynia.
253	AGRIPPAL S1	AGRIPPAL S1	B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE)	B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE) 15MCG/0.5ML;B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) 15MCG/0.5ML;A/KANSAS/14/2017 (H3N2) LIKE VIRUS 15MCG/0.5ML;A/BRISBANE/02/2018(H1N1)PDM09-LIKE VIRUS 15MCG/0.5ML	SUSPENSION	RECIEPT	Prophylaxis of influenza.
254	AHISTON	AHISTON	CHLORPHENIRAMINE MALEATE	CHLORPHENIRAMINE MALEATE 2MG	TABLETS	RECIEPT	Symptomatic relief of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild uncomplicated urticaria and angioedema, amelioration of allergic reactions to blood or plasma, dermatographism, adjunctive therapy in anaplylactic reactions.
256	AIMOVIG	AIMOVIG 70 MG	ERENUMAB	ERENUMAB 70MG/1ML	SOLUTION	RECIEPT	Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig
257	AIR	AIR - MEDICAL GAS	OXYGEN	OXYGEN 20.4%	GAS		Gas for inhalation.
258	AIR	AIR SYNTHETIC MEDICINAL	OXYGEN	OXYGEN 21.0%V/V	GAS	RECIEPT	Gas for inhalation
259	AJOVY	AJOVY	FREMANEZUMAB	FREMANEZUMAB 225MG/1.5ML	SOLUTION	RECIEPT	AJOVY is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
260	AKNEMYCIN	AKNEMYCIN	ERYTHROMYCIN	ERYTHROMYCIN 2%	SOLUTION	RECIEPT	All forms of acne, particularly inflammatory forms with papules and pustules.
261	AKNEMYCIN	AKNEMYCIN PLUS	ERYTHROMYCIN	ERYTHROMYCIN 4G/100 G;TRETINOIN 0.025G/100 G	SOLUTION	RECIEPT	All forms of acne, both non-inflammatory forms with comedones and inflammatory forms with papules and pustules, particularly in the case of fat-rich skin.
262	AKYNZEO	AKYNZEO	NETUPITANT	NETUPITANT 300MG;PALONOSETRON AS HYDROCHLORIDE 0.50MG	CAPSULES	RECIEPT	Prevention of Acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
265	ALBIOMIN	ALBIOMIN 20 %	PLASMA PROTEIN FRACTION	PLASMA PROTEIN FRACTION 200G/L	SOLUTION	RECIEPT	Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendation.
2414	ALBUMIN	HUMAN ALBUMIN 20% BEHRING	ALBUMIN HUMAN	ALBUMIN HUMAN 200MG/ML	SOLUTION	RECIEPT	Hypoalbuminemia (liver cirrhosis nephrosis) toxic processes ( pregnancy toxicosis, hyperbilirubinemia ) ,volume substitution therapy.
5518	ALBUMIN	HUMAN ALBUMIN	ALBUMIN HUMAN	ALBUMIN HUMAN 200MG/ML	SOLUTION		For restoration and maintenance of circulating blood volume where volume deficiency has been demontrated and use of a colloid such as albumin is appropriate. The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient based on official recommendations. שינוי משטר מינון: 19/2//2019 שינוי משטר מינון.
266	ALBUNORM	ALBUNORM 20 %	ALBUMIN HUMAN	ALBUMIN HUMAN 200G/1000ML;PLASMA PROTEIN FRACTION 96%	SOLUTION	RECIEPT	Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate. The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on the official recommendations
267	ALBUNORM	ALBUNORM 5 %	ALBUMIN HUMAN	ALBUMIN HUMAN 50G/1000ML;PLASMA PROTEIN FRACTION 96%	SOLUTION	RECIEPT	Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate. The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on the official recommendations
268	ALCINAL	ALCINAL NEW SYRUP 115CC	DEXTROMETHORPHAN HYDROBROMIDE	DEXTROMETHORP HBR 7.5MG;GUIAPHENESIN 150MG;CHLORPHENIRAMINE MALEATE 1MG	SYRUP		For relief of cough and expecctorant.
269	ALCINAL	ALCINAL SYRUP	GUAIFENESIN	GUAIFENESIN 105MG/5ML;DEXTROMETHORPHAN HYDROBROMIDE 7.88MG/5ML;CHLORPHENIRAMINE MALEATE 1MG/5ML	SYRUP	RECIEPT	For the symptomatic relief of cough and nasal congestion associated with colds.
270	ALCOHOL	ALCOHOL 70 % VITAMED	ALCOHOL	ALCOHOL 70%	SOLUTION		Skin disinfection.
271	ALCOHOL	ALCOHOL 70 % VITAMED 1 L	ALCOHOL	ALCOHOL 70%	LIQUID		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
272	ALCOHOL	ALCOHOL 70% FLORIS	ALCOHOL	ALCOHOL 70%	SOLUTION		Antiseptic.
273	ALCOHOL	ALCOHOL 70% 100ML	ALCOHOL	ALCOHOL 70%	LIQUID		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
275	ALCOHOL	ALCOHOL 70% 1L	ALCOHOL	ALCOHOL 70%	LIQUID		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
276	ALCOHOL	ALCOHOL 70% 200ML	ALCOHOL	ALCOHOL 70%	LIQUID		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
278	ALCOHOL	ALCOHOL 70% 5L	ALCOHOL	ALCOHOL 70%	LIQUID		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
282	ALCOSEPT	ALCOSEPT	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION	RECIEPT	Skin antiseptic.
283	ALCOSEPT	ALCOSEPT 1 LITER	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Skin antiseptic.
284	ALCOSEPT	ALCOSEPT 100ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Skin antiseptic.
285	ALCOSEPT	ALCOSEPT 300ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Skin antiseptic.
286	ALCOSEPT	ALCOSEPT 500ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Skin antiseptic.
287	ALCOTINT	ALCOTINT 70	ALCOHOL	ALCOHOL 95% 59.7G/100ML	SOLUTION		For cleaning and disinfection of the skin.
288	ALCOTINT	ALCOTINT 70% 100ML	ETHANOL	ETHANOL 95%	LIQUID		For cleaning and disinfection of the skin.
289	ALCOXIDINE	ALCOXIDINE	ALCOHOL	ALCOHOL 70%V/V;CHLORHEXIDINE GLUCONATE 0.5%V/V	SOLUTION		Disinfection of skin.
290	ALCOXIDINE	ALCOXIDINE 100ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Disinfection of skin.
291	ALCOXIDINE	ALCOXIDINE 500ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Disinfection of skin.
292	ALCOXIDINE	ALCOXIDINE SOL 1 L	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Disinfection of skin.
293	ALDACTONE	ALDACTONE 25 MG	SPIRONOLACTONE	SPIRONOLACTONE 25MG	TABLETS	RECIEPT	Congestive heart failure, cirrhotic ascites.
294	ALDARA	ALDARA 5 %	IMIQUIMOD	IMIQUIMOD 5%	CREAM	RECIEPT	Indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients. For the treatment of actinic keratoses in adults with normal immune systems. For the treatment of superficial basal cell carcinoma in adults with normal immune systems when surgical methods are less appropriate.
296	ALDURAZYME	ALDURAZYME	LARONIDASE	LARONIDASE 500UNITS/5ML	CONCENTRATE	RECIEPT	Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I alfa-l-iduronidase deficiency) to treat the non-neurological manifestations of the disease.
297	ALECENSA	ALECENSA	ALECTINIB AS HYDROCHLORIDE	ALECTINIB AS HYDROCHLORIDE 150MG	CAPSULES	RECIEPT	Alectinib is indicated for the treatment of patients with ALK positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who progressed on or are intolerant to crizotinib Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
298	ALENDRONATE	ALENDRONATE TEVA 10 MG	ALENDRONIC ACID AS MONOHYDRATE	ALENDRONIC ACID AS MONOHYDRATE 10MG	TABLETS	RECIEPT	For the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures). For the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. For the treatment to increase bone mass in men with osteoporosis.
300	ALENDRONATE	ALENDRONATE TEVA 70 MG	ALENDRONIC ACID AS SODIUM	ALENDRONIC ACID AS SODIUM 70MG MONOHYDRATE	TABLETS	RECIEPT	For the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures). Treatment to increase bone mass in men with osteoporosis.
302	ALERGIT	ALERGIT	LORATADINE	LORATADINE 0.1G/100ML	SYRUP		Antihistamine preparation for treatment of allergic rhinitis and urticaria.
303	ALERGIT	ALERGIT SYR 120 ML	LORATADINE	LORATADINE 5MG/5ML	SYRUP		Seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
304	ALEXAN	ALEXAN	CYTARABINE	CYTARABINE 50MG/1ML	SOLUTION	RECIEPT	For induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas ( non-Hodgkin's lymphomas of high malignancy).
305	ALFU-KAL XL	ALFU-KAL XL	ALFUZOSIN HYDROCHLORIDE	ALFUZOSIN HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. Adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.
306	ALFUZOSIN	ALFUZOSIN ER TEVA 10 MG	ALFUZOSIN HYDROCHLORIDE	ALFUZOSIN HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. Adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.
307	ALIMTA	ALIMTA 100 MG	PEMETREXED	PEMETREXED 100MG/VIAL	POWDER	RECIEPT	Alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
308	ALIMTA	ALIMTA 500 MG	PEMETREXED	PEMETREXED 500MG/VIAL	POWDER	RECIEPT	Alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
310	ALKASOLVE	ALKASOLVE 180TAB	POTASSIUM CITRATE	POTASSIUM CITRATE 330MG;SODIUM CITRATE 300MG	TABLETS		Urinary alkalizer.
311	ALKASOLVE	ALKASOLVE TABLETS	POTASSIUM CITRATE	POTASSIUM CITRATE 330MG;SODIUM CITRATE 300MG	TABLETS	RECIEPT	Urinary alkalizer.
313	ALKERAN	ALKERAN TABLETS 2 MG	MELPHALAN	MELPHALAN 2MG	TABLETS	RECIEPT	For the treatment of : Multiple myeloma and Advanced ovarian adenocarcinoma
312	ALKERAN	ALKERAN INJECTION	MELPHALAN	MELPHALAN 50MG/VIAL	POWDER	RECIEPT	For the palliative treatment of multiple myeloma and for the palliation of non resectable epithelial cancer of the ovary.
315	ALLEGRO SPRAY	ALLEGRO NASAL SPRAY 15ML (120DOSES)	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.05% W/W	SPRAY	RECIEPT	Prophylaxis and treatment of seasonal allergic rhinitis including hay fever and perennial rhinitis, in adults and children of the age of 4 years and above.
314	ALLEGRO SPRAY	ALLEGRO NASAL SPRAY	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.05%W/W	SUSPENSION	RECIEPT	Prophylaxis and treatment of seasonal allergic rhinitis including hay fever and perennial rhinitis, in adults and children of the age of 4 years and above.
316	ALLERGY-CARE	ALLERGY-CARE	CETIRIZINE DIHYDROCHLORIDE	CETIRIZINE DIHYDROCHLORIDE 10MG	TABLETS		Antihistaminic drug for the treatment of allergies. For the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in children aged 6 years and over and adults.
317	ALLERGY-CARE	ALLERGY-CARE 20 tab	CETIRIZINE DIHYDROCHLORIDE	CETIRIZINE DIHYDROCHLORIDE 10MG	TABLETS		Antihistaminic drug for the treatment of allergies. For the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in children aged 6 years and over and adults.
318	ALLERGYX	ALLERGYX	LORATADINE	LORATADINE 10MG	TABLETS	RECIEPT	Relief of symptoms of allergy in seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
319	ALLERGYX	ALLERGYX 10MG 10TAB	LORATADINE	LORATADINE 10MG	TABLETS		Relief of symptoms of allergy in seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
320	ALLERGYX	ALLERGYX 10MG 20TAB	LORATADINE	LORATADINE 10MG	TABLETS		Relief of symptoms of allergy in seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
321	ALLORIL	ALLORIL 100	ALLOPURINOL	ALLOPURINOL 100MG	TABLETS	RECIEPT	Management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). Management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
322	ALLORIL	ALLORIL 300	ALLOPURINOL	ALLOPURINOL 300MG	TABLETS	RECIEPT	Management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). Management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
323	ALNASE	ALNASE DROPS 10ML	PHENYLEPHRINE HCL	PHENYLEPHRINE HCL 0.25%;NAPHAZOLINE HCL 0.05%;MEPYRAMINE MALEATE 0.50%	DROPS		Nasal congestion.
326	ALNASE	ALNASE SPRAY 10ML	PHENYLEPHRINE HCL	PHENYLEPHRINE HCL 0.25%;NAPHAZOLINE HCL 0.05%;MEPYRAMINE MALEATE 0.50%	SPRAY		Nasal congestion.
325	ALNASE NOSE	ALNASE NOSE DROPS	MEPYRAMINE MALEATE	MEPYRAMINE MALEATE 0.5%;PHENYLEPHRINE HYDROCHLORIDE 0.25%;NAPHAZOLINE HYDROCHLORIDE 0.05%	DROPS	RECIEPT	For the relief of nasal congestion due to the common cold, rhinitis, sinusitis, hay fever and other upper respiratory allergies.
324	ALNASE SPRAY	ALNASE NASAL SPRAY	MEPYRAMINE MALEATE	MEPYRAMINE MALEATE 0.5%;PHENYLEPHRINE HYDROCHLORIDE 0.25%;NAPHAZOLINE HYDROCHLORIDE 0.05%	SOLUTION	RECIEPT	For the relief of nasal congestion due to the common cold, rhinitis, sinusitis, hay fever and other upper respiratory allergies.
327	ALOFISEL	ALOFISEL	DARVADSTROCEL	DARVADSTROCEL 5000000CELLS/ML	SUSPENSION	RECIEPT	Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used only after conditioning of the fistulas.
328	ALPHA D3	ALPHA D3 0.25 MCG	ALFACALCIDOL	ALFACALCIDOL 0.25MCG	CAPSULES	RECIEPT	- Renal bone disease (renal osteodystrophy). - Hypoparathyroidism. - Hyperparathyroidism (with bone disease) - primary and tertiary. - Rickets and osteomalacia. - Osteoporosis.
336	ALPHA D3	ALPHA D3 DROPS	ALFACALCIDOL	ALFACALCIDOL 0.25MCG	DROPS	RECIEPT	Renal bone disease. Hypoparathyroidism. Rickets and osteomalacia. Osteoporosis. Primary and tertiary hyperparathyroidism. Neonatal hypocalcemia.
331	ALPHA D3	ALPHA D3 0.5 MCG	ALFACALCIDOL	ALFACALCIDOL 0.5MCG	CAPSULES	RECIEPT	- Renal bone disease (renal osteodystrophy). - Hypoparathyroidism. - Hyperparathyroidism (with bone disease)- primary and tertiary. - Rickets and osteomalacia. - Osteoporosis.
333	ALPHA D3	ALPHA D3 1.0 MCG	ALFACALCIDOL	ALFACALCIDOL 1MCG	CAPSULES	RECIEPT	- Renal bone disease (renal osteodystrophy). - Hypoparathyroidism. - Hyperparathyroidism (with bone disease) - primary and tertiary. - Rickets and osteomalacia. - Osteoporosis.
337	ALPHAGAN	ALPHAGAN P	BRIMONIDINE TARTRATE	BRIMONIDINE TARTRATE 0.15%W/V	SOLUTION	RECIEPT	Alphagan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
339	ALPHOSYL	ALPHOSYL 2 IN 1 250MG	ALCOHOLIC EXTR. OF COAL TAR	ALCOHOLIC EXTR. OF COAL TAR 5%	SHAMPOO		Treatment of scalp disorders such as psoriasis seborrhoeic dermatitis scalping and itching (often associated with eczema) and dandruff.
338	ALPHOSYL	ALPHOSYL "2 IN 1" MEDICAL SHAMPOO WITH CONDITIONER	COAL TAR ALCOHOLIC EXTRACT	COAL TAR ALCOHOLIC EXTRACT 5%W/W	SHAMPOO		Treatment of scalp disorders such as psoriasis seborrhoeic dermatitis scalping and itching (often associated with eczema) and dandruff.
340	ALPRALID	ALPRALID 0.25	ALPRAZOLAM	ALPRAZOLAM 0.25MG	TABLETS	RECIEPT	Treatment of symptoms of tension and anxiety, anxiety accompanied by depression and in panic states with or without phobia.
341	ALPRALID	ALPRALID 0.5	ALPRAZOLAM	ALPRAZOLAM 0.5MG	TABLETS	RECIEPT	Treatment of symptoms of tension and anxiety, anxiety accompanied by depression and in panic states with or without phobia.
342	ALPRALID	ALPRALID 1	ALPRAZOLAM	ALPRAZOLAM 1MG	TABLETS	RECIEPT	Treatment of symptoms of tension and anxiety, anxiety accompanied by depression and in panic states with or without phobia.
343	ALPROLIX	ALPROLIX 1000	COAGULATION FACTOR IX (RECOMBINANT FC FUSION PROTEIN –RFIXFC)	COAGULATION FACTOR IX (RECOMBINANT FC FUSION PROTEIN –RFIXFC) 1000 IU	POWDER	RECIEPT	ALPROLIX™, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children 12 years of age and older with hemophilia B for: • Control and prevention of bleeding episodes, • Perioperative management, • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ALPROLIX™ is not indicated for induction of immune tolerance in patients with Hemophilia B.
344	ALPROLIX	ALPROLIX 2000	COAGULATION FACTOR IX (RECOMBINANT FC FUSION PROTEIN –RFIXFC)	COAGULATION FACTOR IX (RECOMBINANT FC FUSION PROTEIN –RFIXFC) 2000 IU	POWDER	RECIEPT	ALPROLIX™, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children 12 years of age and older with hemophilia B for: • Control and prevention of bleeding episodes, • Perioperative management, • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ALPROLIX™ is not indicated for induction of immune tolerance in patients with Hemophilia B..
345	ALPROLIX	ALPROLIX 3000	COAGULATION FACTOR IX (RECOMBINANT FC FUSION PROTEIN –RFIXFC)	COAGULATION FACTOR IX (RECOMBINANT FC FUSION PROTEIN –RFIXFC) 3000 IU	POWDER	RECIEPT	ALPROLIX™, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children 12 years of age and older with hemophilia B for: • Control and prevention of bleeding episodes, • Perioperative management, • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ALPROLIX™ is not indicated for induction of immune tolerance in patients with Hemophilia B.
346	ALPROLIX	ALPROLIX 500	COAGULATION FACTOR IX (RECOMBINANT FC FUSION PROTEIN –RFIXFC)	COAGULATION FACTOR IX (RECOMBINANT FC FUSION PROTEIN –RFIXFC) 500 IU	POWDER	RECIEPT	ALPROLIX™, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children 12 years of age and older with hemophilia B for: • Control and prevention of bleeding episodes, • Perioperative management, • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ALPROLIX™ is not indicated for induction of immune tolerance in patients with Hemophilia B..
357	ALRIN	ALRIN KIDS 0.025% MDS 10ML	OXYMETAZOLINE HCL	OXYMETAZOLINE HCL 0.025%	SPRAY		For temporary relief of nasal congestion due to cold or sinusitis or allergies of the upper respiratory tract.
349	ALRIN	ALRIN 0.05% M.D. 15ML	OXYMETAZOLINE HCL	OXYMETAZOLINE HCL 0.05%	SPRAY		For temporary relief of nasal congestion due to cold or sinusitis or allergies of the upper respiratory tract.
350	ALRIN	ALRIN 0.05% SPRAY 15CC	OXYMETAZOLINE HCL	OXYMETAZOLINE HCL 0.05%	SPRAY		For temporary relief of nasal congestion due to cold or sinusitis or allergies of the upper respiratory tract.
353	ALRIN	ALRIN DROPS 0.05% 10ML	OXYMETAZOLINE HCL	OXYMETAZOLINE HCL 0.05%	DROPS		For temporary relief of nasal congestion due to cold or sinusitis or allergies of the upper respiratory tract.
356	ALRIN	ALRIN FOR KIDS	OXYMETAZOLINE HYDROCHLORIDE	OXYMETAZOLINE HYDROCHLORIDE 0.025%	SOLUTION		For temporary relief of nasal congestion due to cold or sinusitis or allergies of the upper respiratory tract.
347	ALRIN	ALRIN	OXYMETAZOLINE HYDROCHLORIDE	OXYMETAZOLINE HYDROCHLORIDE 0.05%	SOLUTION		Relief of nasal congestion due to allergic and infectious disorders of the upper respiratory tract.
354	ALRIN	ALRIN FOR BABIES 0.74% DROPS 10ML	SODIUM CHLORIDE	SODIUM CHLORIDE 0.74%	DROPS		Relief of nasal congestion, especially for babies.
355	ALRIN	ALRIN FOR BABIES 0.74% MD 10ML	SODIUM CHLORIDE	SODIUM CHLORIDE 0.74%	SPRAY		Relief of nasal congestion, especially for babies.
352	ALRIN	ALRIN BABY SALT SOLUTION	SODIUM CHLORIDE	SODIUM CHLORIDE 0.74%W/V	SOLUTION	RECIEPT	Relief of nasal congestion, especially for babies.
351	ALRIN	ALRIN AF TEVA	OXYMETAZOLINE HYDROCHLORIDE	OXYMETAZOLINE HYDROCHLORIDE 0.05%	SOLUTION		Relief of nasal congestion, which is a result of common colds, sinusitis, hay fever or allergies of the upper respiratory system.
358	ALUNBRIG	ALUNBRIG 30 MG	BRIGATINIB	BRIGATINIB 30MG	TABLETS	RECIEPT	ALUNBRIG is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK) - positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
360	ALUNBRIG	ALUNBRIG 90 MG	BRIGATINIB	BRIGATINIB 90MG	TABLETS	RECIEPT	ALUNBRIG is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK) - positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
362	ALZIGMINE	ALZIGMINE 1.5	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 1.5MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the Alzheimer type, also termed probable Alzheimer's disease or Alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease..
363	ALZIGMINE	ALZIGMINE 3	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 3MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the Alzheimer type, also termed probable Alzheimer's disease or Alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease..
364	ALZIGMINE	ALZIGMINE 4.5	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 4.5MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the Alzheimer type, also termed probable Alzheimer's disease or Alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease..
365	ALZIGMINE	ALZIGMINE 6	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 6MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the Alzheimer type, also termed probable Alzheimer's disease or Alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease..
366	AMANDIN	AMANDIN 100	AMANTADINE SULFATE	AMANTADINE SULFATE 100MG	TABLETS	RECIEPT	Parkinsonian syndromes: Treatment of symptoms of Parkinson’s disease such as rigor, tremor, hypokinesia and akinesia.
368	AMARYL	AMARYL 1 MG	GLIMEPIRIDE	GLIMEPIRIDE 1MG	TABLETS	RECIEPT	Non-insulin-dependent diabetes melitus ( adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.
369	AMARYL	AMARYL 2 MG	GLIMEPIRIDE	GLIMEPIRIDE 2MG	TABLETS	RECIEPT	Non-insulin-dependent diabetes melitus ( adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.
370	AMARYL	AMARYL 3 MG	GLIMEPIRIDE	GLIMEPIRIDE 3MG	TABLETS	RECIEPT	Non-insulin-dependent diabetes melitus ( adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.
371	AMARYL	AMARYL 4 MG	GLIMEPIRIDE	GLIMEPIRIDE 4MG	TABLETS	RECIEPT	Non-insulin-dependent diabetes melitus ( adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.
372	AMBIEN	AMBIEN CR 12.5 MG	ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE 12.5MG	TABLETS	RECIEPT	For the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset).
373	AMBIEN	AMBIEN CR 6.25 MG	ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE 6.25MG	TABLETS	RECIEPT	For the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset).
374	AMBISOME	AMBISOME	AMPHOTERICIN B	AMPHOTERICIN B 50MG/VIAL	POWDER	RECIEPT	Antifungal antibiotic for the treatment of severe systemic and/or deep mycoses where toxicity precludes the use of conventional systemic amphotericin B in effective dosages. This drug should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests. Ambisome is also indicated for the treatment of systemic fungal infections in immunocompromised patients (e.g. patients with AIDS or cancer). Ambisome is also indicated for the primary therapy of visceral leishmaniasis in immunocompetent patients and immunocompromised patients (e.g. HIV positive). Empirical treatment of presumed fungal infection in febrile neutropenic patients.
377	AMELUZ	AMELUZ 78 MG/G GEL	5-AMINOLEVULINIC ACID AS HYDROCHLORIDE	5-AMINOLEVULINIC ACID AS HYDROCHLORIDE 78MG/G	GEL	RECIEPT	Treatment of actinic keratosis of mild to moderate intensity on the face and scalp (Olsen grade 1 to 2).
378	AMIKACIN	AMIKACIN - MEDO	AMIKACIN AS SULFATE	AMIKACIN AS SULFATE 250MG/1ML	SOLUTION	RECIEPT	AMIKACIN - MEDO is indicated in the short-term treatment of Gram-negative organisms, including pseudomonas and some Gram-positive organisms. Sensitive Gram-negative organisms include; Pseudomonas aeruginosa, Escherichia coli., indole-positive and indole-negative Proteus spp., Klebsiella, Enterobacter and Serratia spp., Minea-Herralae, Citrobacter freundii, Salmonella, Shigella, Acinetobacter and Providencia spp. The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including some methicillin-resistant strains. AMIKACIN - MEDO has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.
379	AMIKAN	AMIKAN	AMIKACIN AS SULFATE	AMIKACIN AS SULFATE 250MG/1ML	SOLUTION	RECIEPT	Amikan is indicated in the short-term treatment of Gram-negative organisms, including pseudomonas and some Gram-positive organisms. Sensitive Gram-negative organisms include; Pseudomonas aeruginosa, Escherichia coli., indole-positive and indole-negative Proteus spp., Klebsiella, Enterobacter and Serratia spp., Minea-Herralae, Citrobacter freundii, Salmonella, Shigella, Acinetobacter and Providencia spp. The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including some methicillin-resistant strains. Amikan has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.
380	AMINOPHYLLINE	AMINOPHYLLINE 250 MG/10 ML	AMINOPHYLLINE	AMINOPHYLLINE 250MG/10ML	SOLUTION	RECIEPT	For symptomatic relief or prevention of bronchial asthma and for treatment of reversible bronchospasm associated with chronic bronchitis and emphysema.
381	AMINOPHYLLINE	AMINOPHYLLINE S.A.L.F 240 MG/10 ML	THEOPHYLLINE ETHYLENEDIAMINE DEHYDRATE	THEOPHYLLINE ETHYLENEDIAMINE DEHYDRATE 240MG/10ML	CONCENTRATE	RECIEPT	- Bronchial asthma; - Pulmonary affections with bronchial spastic component.
382	AMINOPLASMAL	AMINOPLASMAL B. BRAUN 10% E	ISOLEUCINE	ISOLEUCINE 5.00G/L;LEUCINE 8.9G/L;METHIONINE 4.40G/L;PHENYLALANINE 4.70G/L;THREONINE 4.20G/L;TRYPTOPHAN 1.60G/L;VALINE 6.20G/L;ARGININE 11.50G/L;HISTIDINE 3.00G/L;GLYCINE 12.00G/L;L- ALANINE 10.50G/L;PROLINE 5.50G/L;ASPARTIC ACID 5.60G/L;GLUTAMINE 7.20G/L;SERINE 2.30G/L;TYROSINE 0.40G/L;POTASSIUM ACETATE 2.453G/L;SODIUM ACETATE TRIHYDRATE 2.858G/L;MAGNESIUM CHLORIDE HEXAHYDRATE 0.508G/L;LYSINE AS ACETATE 8.56G/L;DISODIUM PHOSPHATE DODECAHYDRATE 3.581G/L	SOLUTION	RECIEPT	Supply of amino acids as a substrate for protein synthesis in parenteral nutrition, when oral or enteral nutrition is impossible, insufficient or contra-indicated
383	AMINOPLASMAL	AMINOPLASMAL B.BRAUN 10%	ISOLEUCINE	ISOLEUCINE 5.00G/L;LEUCINE 8.9G/L;METHIONINE 4.40G/L;PHENYLALANINE 4.70G/L;THREONINE 4.20G/L;TRYPTOPHAN 1.60G/L;VALINE 6.20G/L;ARGININE 11.50G/L;HISTIDINE 3.00G/L;L- ALANINE 10.50G/L;GLYCINE 12.00G/L;ASPARTIC ACID 5.60G/L;GLUTAMINE 7.20G/L;PROLINE 5.50G/L;SERINE 2.30G/L;TYROSINE 0.40G/L;LYSINE AS ACETATE 5.74G/L;LYSINE AS MONOHYDRATE 3.12G/L	SOLUTION	RECIEPT	Supply of amino acids as a substrate for protein synthesis in parenteral nutrition, when oral or enteral nutrition is impossible, insufficient or contra-indicated.
384	AMIOCARD	AMIOCARD	AMIODARONE HYDROCHLORIDE	AMIODARONE HYDROCHLORIDE 200MG	TABLETS	RECIEPT	Coronary insufficiency arrhythmias resistant to other treatments.
385	AMIODACORE	AMIODACORE INJECTION	AMIODARONE HYDROCHLORIDE	AMIODARONE HYDROCHLORIDE 150MG/3ML	SOLUTION	RECIEPT	Treatment should be initiated and normally monitored only under hospital or specialist supervision. Amiodacore injection is indicated for Corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome. Amiodacore intravenous can be used where a rapid response is required or where oral administration is not possible.
386	AMLODIPINE	AMLODIPINE TEVA 10 MG	AMLODIPINE AS BESYLATE	AMLODIPINE AS BESYLATE 10MG	TABLETS	RECIEPT	Mild to moderate hypertension. Vasospastic angina (Prinzmetal's or variant angina ). Chronic stable angina.
388	AMLODIPINE	AMLODIPINE TEVA 5 MG	AMLODIPINE AS BESYLATE	AMLODIPINE AS BESYLATE 5MG	TABLETS	RECIEPT	Mild to moderate hypertension. Vasospastic angina (Prinzmetal's or variant angina ). Chronic stable angina.
390	AMLOW	AMLOW 10	AMLODIPINE AS MALEATE	AMLODIPINE AS MALEATE 10MG	TABLETS	RECIEPT	Mild to moderate hypertension. Vasospastic angina (Prinzmetal's or variant angina). Chronic stable angina.
392	AMLOW	AMLOW 5	AMLODIPINE AS MALEATE	AMLODIPINE AS MALEATE 5MG	TABLETS	RECIEPT	Mild to moderate hypertension. Vasospastic angina (Prinzmetal's or variant angina). Chronic stable angina.
394	AMOXICLAV	AMOXICLAV TEVA 875 MG	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 875MG;CLAVULANIC ACID AS POTASSIUM SALT 125MG	TABLETS	RECIEPT	Amoxiclav teva is indicated for the treatment of the following infections in adults and children : • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. • Bone and joint infections, in particular osteomyelitis.
395	AMOXY FORTE	AMOXY CARE FORTE 250 SUSPENSION	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 250MG/5ML	SUSPENSION	RECIEPT	Antibiotic for the treatment of infections caused by bacteria sensitive to Amoxycillin.
396	AMOXY FORTE	AMOXY CARE FORTE 500	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 500MG	CAPSULES	RECIEPT	Infections caused by amoxicillin susceptible organisms.
402	AMPISULVENIR	AMPISULVENIR 1.5 G	AMPICILLIN AS SODIUM SALT	AMPICILLIN AS SODIUM SALT 1000MG;SULBACTAM AS SODIUM SALT 500MG	POWDER	RECIEPT	Antibiotic for the treatment of bacterial infections caused by susceptible beta-lactamase producing strains of microorganisms, in the following conditions: 1. Skin and Skin Structure Infections ; 2. Intra- Abdominal Infections ; 3. Gynecological Infections .
403	AMPISULVENIR	AMPISULVENIR 3 G	AMPICILLIN AS SODIUM SALT	AMPICILLIN AS SODIUM SALT 2000MG;SULBACTAM AS SODIUM SALT 1000MG	POWDER	RECIEPT	Antibiotic for the treatment of bacterial infections caused by susceptible beta-lactamase producing strains of microorganisms, in the following conditions: 1. Skin and Skin Structure Infections ; 2. Intra- Abdominal Infections ; 3. Gynecological Infections .
410	ANAESTHETIC	ANAESTHETIC EAR DRPS10ML	AMETHOCAINE HCL	AMETHOCAINE HCL.5%;PHENAZONE 5%	DROPS	RECIEPT	fFor symptomatic relief of otic pain, ear pain.
409	ANAESTHETIC	ANAESTHETIC	TETRACAINE HYDROCHLORIDE	TETRACAINE HYDROCHLORIDE 0.5%W/W;PHENAZONE 5%W/W	DROPS	RECIEPT	For the relief of pain in acute otitis media and the external, auditory canal.
411	ANAFRANIL	ANAFRANIL 25 MG	CLOMIPRAMINE HYDROCHLORIDE	CLOMIPRAMINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Depression of varying origin: In children and adolescents there is not sufficient evidence of safety and efficacy of Anafranil in the treatment of depressive states of varying aetiology and symptomatology. The use of Anafranil in children and odolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. Obsessive compulcive syndromes: No experience is available in children younger than 5 years of age.
412	ANAFRANIL	ANAFRANIL SR 75 MG TABLETS	CLOMIPRAMINE HYDROCHLORIDE	CLOMIPRAMINE HYDROCHLORIDE 75MG	TABLETS	RECIEPT	Depression of varying origin: In children and adolescents there is not sufficient evidence of safety and efficacy of Anafranil in the treatment of depressive states of varying aetiology and symptomatology. The use of Anafranil in children and odolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. Obsessive compulcive syndromes: No experience is available in children younger than 5 years of age.
413	ANAGRID	ANAGRID 0.5	ANAGRELIDE AS HYDROCHLORIDE	ANAGRELIDE AS HYDROCHLORIDE 0.5MG	CAPSULES	RECIEPT	Anagrid 0.5 is indicated for the reduction of an increased platelet number and associated clinical symptoms in high risk patients with Essential Thrombocythemia. High risk patient with essential thrombocythemia show one or more following symptoms: Age >= 60, Platelet count >= 1.000.000/ μl, Increase of platelet count >= 300.000/ μl within 3 month, Severe thrombohaemorrhagic or ischaemic symptoms in anamnesis, Vascular risk factors.
414	ANASTROZOLE	ANASTROZOLE INOVAMED 1 MG	ANASTROZOLE	ANASTROZOLE 1MG	TABLETS	RECIEPT	Treatment of advanced breast cancer in post menopausal women. Efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
415	ANASTROZOLE	ANASTROZOLE TEVA	ANASTROZOLE	ANASTROZOLE 1MG	TABLETS	RECIEPT	Treatment of advanced breast cancer in post menopausal women. Efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
417	ANDROCUR	ANDROCUR 10	CYPROTERONE ACETATE	CYPROTERONE ACETATE 10MG	TABLETS	RECIEPT	Anti androgen for moderate and severe signs of androgenization in the women.
418	ANDROCUR	ANDROCUR 50	CYPROTERONE ACETATE	CYPROTERONE ACETATE 50MG	TABLETS	RECIEPT	For antiandrogen therapy in men: sexual disorders, inoperable prostatic carcinoma.
421	ANDROGEL	ANDROGEL 50 MG	TESTOSTERONE	TESTOSTERONE 0.05G/DOSE	GEL	RECIEPT	Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
424	ANGELIQ	ANGELIQ	DROSPIRENONE	DROSPIRENONE 2MG;ESTRADIOL AS HEMIHYDRATE 1MG	TABLETS	RECIEPT	Angeliq is indicated for hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women more than 1 year post menopause. Prevention of postmenopausal osteoporosis in women with an increased risk of future osteoporosis fractures.
426	ANHYDROL FORTE	ANHYDROL FORTE 60ML	ALUMINIUM CHLORIDE	ALUMINIUM CHLORIDE 20%	SOLUTION		For the topical treatment of hyperhydrosis specifically involving axillae, hands or feet.
425	ANHYDROL FORTE	ANHYDROL FORTE	ALUMINIUM CHLORIDE HEXAHYDRATE	ALUMINIUM CHLORIDE HEXAHYDRATE 20%W/V	SOLUTION		For the topical treatment of hyperhydrosis specifically involving axillae, hands or feet.
427	ANORO ELLIPTA	ANORO ELLIPTA 55/22 MCG	VILANTEROL AS TRIFENATATE	VILANTEROL AS TRIFENATATE 22MCG;UMECLIDINIUM AS BROMIDE 55MCG	POWDER	RECIEPT	ANORO is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.
428	ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD) FORMULA A	ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD) FORMULA A	CITRIC ACID ANHYDROUS	CITRIC ACID ANHYDROUS 730MG/100ML;SODIUM CITRATE 2.2G/100ML DIHYDRATE;GLUCOSE AS MONOHYDRATE 2.45G/100ML	SOLUTION	RECIEPT	For use with Cytapheresis Device only.
429	ANTIHEMOPHILLIC FACTOR (HUMAN) HEMOFIL M METHOD M MONOCLONAL PURIFIED	ANTIHEMOPHILLIC FACTOR (HUMAN) HEMOFIL M METHOD M MONOCLONAL PURIFIED	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 220 IU	POWDER	RECIEPT	Hemophilia A - for the prevention and control of hemorrhagic episodes
431	ANTROLIN	ANTROLIN	LIDOCAINE HYDROCHLORIDE	LIDOCAINE HYDROCHLORIDE 1.5%;NIFEDIPINE 0.3%	CREAM	RECIEPT	Treatment of anal fissures and proctologies generally associated with anal sphincter hypertonia.
432	APIDRA	APIDRA	INSULIN GLULISINE	INSULIN GLULISINE 100U/ML	SOLUTION	RECIEPT	Treatment of adults, adolescents and children, 6 years or older with diabetes mellitus, where treatment with insulin is required.
433	APO-GO	APO GO PEN 10 MG/ML	APOMORPHINE HYDROCHLORIDE	APOMORPHINE HYDROCHLORIDE 10MG/ML	SOLUTION	RECIEPT	Treatment of motor fluctuations (“on-off” phenomena) in patients with Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medication.
434	APO-GO	APO-GO	APOMORPHINE HYDROCHLORIDE	APOMORPHINE HYDROCHLORIDE 10MG/ML	SOLUTION	RECIEPT	Treatment of motor fluctuations (“on-off” phenomena) in patients with Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medication.
438	APOTEL	APOTEL	PARACETAMOL	PARACETAMOL 150MG/1ML	SOLUTION	RECIEPT	Apotel is indicated for the short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by and urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.
439	AQUIMOD	AQUIMOD CREAM 5 %	IMIQUIMOD	IMIQUIMOD 5%	CREAM	RECIEPT	Indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients. For the treatment of actinic keratoses in adults with normal immune systems. For the treatment of superficial basal cell carcinoma in adults with normal immune systems when surgical methods are less appropriate.
440	ARA-CELL	ARA-CELL 4 G	CYTARABINE	CYTARABINE 4000MG/80ML	SOLUTION	RECIEPT	ARA-cell 4000 mg is indicated for induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas (non-Hodgkin's lymphomas of high malignancy).
442	ARA-CELL	ARA-CELL 5 G	CYTARABINE	CYTARABINE 5G/50ML	CONCENTRATE	RECIEPT	ARA-cell 100 mg/ml is used in combination with other cytostatic agents in high-dose therapy for: • refractory non-Hodgkin’s lymphoma • refractory acute non-lymphocytic leukaemia • refractory acute lymphoblastic leukaemia • recurrent cases of acute leukaemia • types of leukaemia with special risk: – secondary leukaemia following previous chemotherapy and/or radiation treatment – manifest leukaemia following transformation of pre-leukaemia • consolidation of the remission of acute non-lymphocytic leukaemia in patients under 60 years of age.
445	ARANESP	ARANESP 100 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 100MCG/0.5ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age
444	ARANESP	ARANESP 10 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 10MCG/0.4ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age
446	ARANESP	ARANESP 150 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 150MCG/0.3ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age. Aranesp is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
447	ARANESP	ARANESP 20 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 20MCG/0.5ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age
449	ARANESP	ARANESP 300 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 300MCG/0.6ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age. Aranesp is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
448	ARANESP	ARANESP 30 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 30MCG/0.3ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age
450	ARANESP	ARANESP 40 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 40MCG/0.4ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age
452	ARANESP	ARANESP 500 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 500MCG/ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age. Aranesp is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
451	ARANESP	ARANESP 50 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 50MCG/0.5ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age
453	ARANESP	ARANESP 60 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 60MCG/0.3ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age
454	ARANESP	ARANESP 80 MCG	DARBEPOETIN ALFA	DARBEPOETIN ALFA 80MCG/0.4ML	SOLUTION	RECIEPT	Aranesp is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients ≥ 1 year of age
455	ARAVA	ARAVA 10 MG	LEFLUNOMIDE	LEFLUNOMIDE 10MG	TABLETS	RECIEPT	Arava is indicated in adults for the treatment of active rheumatoid arthritis (RA) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by X-ray erosions and joint space narrowing 3. to imptove physical function. Arava is indicated for the treatment of adult patients with active psoriatic arthritis.
456	ARAVA	ARAVA 20 MG	LEFLUNOMIDE	LEFLUNOMIDE 20MG	TABLETS	RECIEPT	Arava is indicated in adults for the treatment of active rheumatoid arthritis (RA) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by X-ray erosions and joint space narrowing 3. to imptove physical function. Arava is indicated for the treatment of adult patients with active psoriatic arthritis.
457	ARCALYST	ARCALYST	RILONACEPT	RILONACEPT 80MG/ML	POWDER	RECIEPT	Arcalyst (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.
459	ARCO	ARCO - TEVA 120 MG	ETORICOXIB	ETORICOXIB 120MG	TABLETS	RECIEPT	Arco - Teva 120 mg is indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.
461	ARCO	ARCO - TEVA 30 MG	ETORICOXIB	ETORICOXIB 30MG	TABLETS	RECIEPT	Arco - Teva 30mg is indicated for the symptomatic relief of osteoarthritis (OA).
463	ARCO	ARCO - TEVA 60 MG	ETORICOXIB	ETORICOXIB 60MG	TABLETS	RECIEPT	Arco - Teva 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis.
465	ARCO	ARCO - TEVA 90 MG	ETORICOXIB	ETORICOXIB 90MG	TABLETS	RECIEPT	Arco - Teva 90 mg is indicated for the symptomatic relief of rheumatoid arthritis (RA) and ankylosing spondylitis. For the short-term treatment of moderate pain associated with dental surgery.
467	ARCOXIA	ARCOXIA 120 MG TABLETS	ETORICOXIB	ETORICOXIB 120MG	TABLETS	RECIEPT	Arcoxia 120 mg tablets are indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.
470	ARCOXIA	ARCOXIA 30 MG TABLETS	ETORICOXIB	ETORICOXIB 30MG	TABLETS	RECIEPT	Arcoxia tablets are indicated for the symptomatic relief of osteoarthritis (OA).
471	ARCOXIA	ARCOXIA 60 MG TABLETS	ETORICOXIB	ETORICOXIB 60MG	TABLETS	RECIEPT	Arcoxia 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis.
474	ARCOXIA	ARCOXIA 90 MG TABLETS	ETORICOXIB	ETORICOXIB 90MG	TABLETS	RECIEPT	Arcoxia 90 mg tablets are indicated for the symptomatic relief of rheumatoid arthritis (RA) and ankylosing spondylitis. For the short-term treatment of moderate pain associated with dental surgery.
477	ARESTIN	ARESTIN	MINOCYCLINE AS HYDROCHLORIDE	MINOCYCLINE AS HYDROCHLORIDE 1MG	POWDER	RECIEPT	Arestin is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. Arestin may be used as part of a periodontal maintenance program which includes good oral hygiene, and scaling and root planing.
478	ARIMIDEX	ARIMIDEX	ANASTROZOLE	ANASTROZOLE 1.0MG	TABLETS	RECIEPT	Treatment of advanced breast cancer in post menopausal women. Efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
479	ARIPIPRAZOLE	ARIPIPRAZOLE SANDOZ 10	ARIPIPRAZOLE	ARIPIPRAZOLE 10MG	TABLETS	RECIEPT	Aripiprazole Sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode. Aripiprazole Sandoz is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
481	ARIPIPRAZOLE	ARIPIPRAZOLE SANDOZ 15	ARIPIPRAZOLE	ARIPIPRAZOLE 15MG	TABLETS	RECIEPT	Aripiprazole Sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode. Aripiprazole Sandoz is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
483	ARIPIPRAZOLE	ARIPIPRAZOLE SANDOZ 20	ARIPIPRAZOLE	ARIPIPRAZOLE 20MG	TABLETS	RECIEPT	Aripiprazole Sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode. Aripiprazole Sandoz is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
485	ARIPIPRAZOLE	ARIPIPRAZOLE SANDOZ 30	ARIPIPRAZOLE	ARIPIPRAZOLE 30MG	TABLETS	RECIEPT	Aripiprazole Sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode. Aripiprazole Sandoz is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
487	ARIPIPRAZOLE	ARIPIPRAZOLE SANDOZ 5	ARIPIPRAZOLE	ARIPIPRAZOLE 5MG	TABLETS	RECIEPT	Aripiprazole Sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode. Aripiprazole Sandoz is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
489	ARIPLY	ARIPLY 10	ARIPIPRAZOLE	ARIPIPRAZOLE 10MG	TABLETS	RECIEPT	Ariply is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Ariply is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode. Ariply is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
491	ARIPLY	ARIPLY 15	ARIPIPRAZOLE	ARIPIPRAZOLE 15MG	TABLETS	RECIEPT	Ariply is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Ariply is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode. Ariply is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
493	ARIPLY	ARIPLY 30	ARIPIPRAZOLE	ARIPIPRAZOLE 30MG	TABLETS	RECIEPT	Ariply is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment
495	ARIPLY	ARIPLY 5	ARIPIPRAZOLE	ARIPIPRAZOLE 5MG	TABLETS	RECIEPT	Ariply is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Ariply is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode. Ariply is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
497	ARIXTRA	ARIXTRA 2.5 MG/0.5 ML	FONDAPARINUX SODIUM	FONDAPARINUX SODIUM 2.5MG/0.5ML	SOLUTION	RECIEPT	Prevention of Venous Thromboembolic Events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture major knee surgery or hip replacement surgery. Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications such as patients undergoing abdominal cancer surgery. Prevention of Venous Thromboembolic Events (VTE) in adults medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders and/or acute infectious or inflammatory disease. Treatment of unstable angina or non-ST segment elevation myocardial infarcton (UA/NSTEMI) in adults for whom urgent ( < 120 mins) invasive management (PCI) is not indicated . Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
498	ARIXTRA	ARIXTRA 7.5 MG/0.6 ML	FONDAPARINUX SODIUM	FONDAPARINUX SODIUM 7.5MG/0.6ML	SOLUTION	RECIEPT	Treatment of adults with acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.
499	ARMONIA	ARMONIA	DUTASTERIDE	DUTASTERIDE 0.5MG	CAPSULES	RECIEPT	Armonia is indicated for: Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
502	AROMASIN	AROMASIN	EXEMESTANE	EXEMESTANE 25MG	TABLETS	RECIEPT	Aromasin is indicated for the treatment of advanced breast cancer (ABC) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. Aromasin is also indicated for the treatment of postmenopausal women with ABC whose disease has progressed following multiple hormonal therapies. Aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
503	ARTHRYL	ARTHRYL	GLUCOSAMINE SULFATE (CRYSTALLINE)	GLUCOSAMINE SULFATE (CRYSTALLINE) 1500MG	POWDER		Treatment of osteoarthritis symptoms ( i.e. pain and function limitation).
505	ARTHRYL	ARTHRYL GO	GLUCOSAMINE SULFATE (CRYSTALLINE)	GLUCOSAMINE SULFATE (CRYSTALLINE) 1500MG	POWDER		Relief of symptoms in mild to moderate osteoarthritis of the knee.
504	ARTHRYL	ARTHRYL 1500MG 30 SACHETS	GLUCOSAMINE SULPHATE (CRISTALINE)	GLUCOSAMINE SULPHATE (CRISTALINE) 1500MG	POWDER		Relief of symptoms in mild to moderate osteoarthritis of the knee.
507	ARTICAINE HCL	ARTICAINE HCL 4 % AND EPINEPHRINE 1 : 200,000	EPINEPHRINE BITARTRATE	EPINEPHRINE BITARTRATE 0.015MG/1.7ML;ARTICAINE HYDROCHLORIDE 68MG/1.7ML	SOLUTION	RECIEPT	For infiltration anaesthesia and nerve block anaesthesia in clinical dentistry.
506	ARTICAINE HCL	ARTICAINE HCL 4 % AND EPINEPHRINE 1 : 100,000	EPINEPHRINE BITARTRATE	EPINEPHRINE BITARTRATE 0.031MG/1.7ML;ARTICAINE HYDROCHLORIDE 68MG/1.7ML	SOLUTION	RECIEPT	For infiltration anaesthesia and nerve block anaesthesia in clinical dentistry.
508	ARTOFEN	ARTOFEN 200 MG	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	For the relief of pain such as: headache, toothache, menstrual pain backache muscle ache anti-inflammatory for rheumatic diseases reduction of fever.
510	ARTOFEN	ARTOFEN 200MG 20TAB	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	For the treatment of rheumatoid arthritis and osteoarthritis, it is indicated both in the treatment of acute flares and in the longterm management of these diseases. For the relief of mild to moderate pain and for the treatment of primary dysmenorrhea.
511	ARTOFEN	ARTOFEN 400 MG	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	For the treatment of rheumatoid arthritis and osteoarthritis, it is indicated both in the treatment of acute flares and in the longterm management of these diseases. For the relief of mild to moderate pain and for the treatment of primary dysmenorrhea.
513	ARTOFEN	ARTOFEN 400MG 50TAB	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	For the treatment of rheumatoid arthritis and osteoarthritis, it is indicated both in the treatment of acute flares and in the longterm management of these diseases. For the relief of mild to moderate pain and for the treatment of primary dysmenorrhea.
514	ASACOL	ASACOL 400	MESALAZINE	MESALAZINE 400MG	TABLETS	RECIEPT	Maintenance of remission in ulcerative colitis and for treatment of acute episodes in crohn's disease.
516	ASACOL	ASACOL 800	MESALAZINE	MESALAZINE 800MG	TABLETS	RECIEPT	Maintenance of remission in ulcerative colitis and for treatment of acute episodes in crohn's disease.
518	ASENTA	ASENTA 10	DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE 10MG	TABLETS	RECIEPT	For the treatment of mild to moderately severe Alzheimer's dementia
519	ASENTA	ASENTA 5	DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE 5MG	TABLETS	RECIEPT	For the treatment of mild to moderately severe Alzheimer's dementia
524	ASPIRIN	ASPIRIN CARDIO	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
522	ASPIRIN	ASPIRIN C	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 400MG;ASCORBIC ACID 240MG	TABLETS		Pain relief, fever reduction, antirheumatic treatment.
521	ASPIRIN	ASPIRIN 500	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 500MG	TABLETS		Pain relief, fever reduction .
520	ASPIRIN	ASPIRIN 0.5GR 20TAB	ASPIRIN	ASPIRIN 0.5GR	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
525	ASPIRIN	ASPIRIN CARDIO 100MG 30TAB	ASPIRIN	ASPIRIN 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
526	ASPIRIN	ASPIRIN CARDIO 90 TAB	ASPIRIN	ASPIRIN 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
523	ASPIRIN	ASPIRIN C 20 TAB EFF.	ASPIRIN	ASPIRIN 400MG;ASCORBIC ACID 240MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
527	ASSIVAL	ASSIVAL 10 MG	DIAZEPAM	DIAZEPAM 10MG	TABLETS	RECIEPT	Tension, anxiety, agitation due to acute alcohol withdrawal, adjunct for the relief of skeletal muscle spasm, convulsive disorders.
530	ASSIVAL	ASSIVAL 10 MG/2 ML	DIAZEPAM	DIAZEPAM 10MG/2ML	SOLUTION	RECIEPT	Symptomatic relief of tension and anxiety either alone or when associated with stressful situations. Psychoneurotic states manifested by tension, anxiety, apprehension, fatigue and depressive symptoms. In acute alcohol withdrawal, Assival may be useful in the symptomatic relief of tremor, impending or acute delirium tremens and hallucinosis. Assival is a useful adjunct in the relief of skeletal muscle spasm, spasticity, stiffman syndrome and tetanus. When used intravenously, Assival injection is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. As premedication in patients undergoing surgical procedures (the intramuscular route is preferred) or in patients undergoing cardioversion (when the intravenous route is preferred).
537	ASSIVAL	ASSIVAL TEVA 10 MG/2 ML	DIAZEPAM	DIAZEPAM 10MG/2ML	SOLUTION	RECIEPT	Symptomatic relief of tension and anxiety either alone or when associated with stressful situations. Psychoneurotic states manifested by tension, anxiety, apprehension, fatique and depressive symptoms. In acute alcohol withdrawal, Assival Teva may be useful in the symptomatic relief of tremor, impending or acure delirium tremens and hallucinosis. Assival Teva is a useful adjunct in the relief of skeletal muscle spasms, spasticity, stiffman syndrome and tetanus. When used intravenously, Assival Teva injection is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. As premedication in patients undergoing surgical procedures (the intramuscular route is preferred) or in patients undergoing cardioversion(when the intravenous route is preferred).
531	ASSIVAL	ASSIVAL 2 MG	DIAZEPAM	DIAZEPAM 2MG	TABLETS	RECIEPT	Tension, anxiety, agitation due to acute alcohol withdrawal, adjunct for the relief of skeletal muscle spasm, convulsive disorders.
534	ASSIVAL	ASSIVAL 5 MG	DIAZEPAM	DIAZEPAM 5MG	TABLETS	RECIEPT	Tension, anxiety, agitation due to acute alcohol withdrawal, adjunct for the relief of skeletal muscle spasm, convulsive disorders.
538	ATACAND	ATACAND 16 MG	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL 16MG	TABLETS	RECIEPT	Hypertension. Treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated.
541	ATACAND	ATACAND PLUS	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL 16MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	Essential hypertension, where monotherapy with candesartan cilexetil or hydrochlorothiazide is not sufficient.
539	ATACAND	ATACAND 4 MG	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL 4MG	TABLETS	RECIEPT	Hypertension. Treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated.
540	ATACAND	ATACAND 8 MG	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL 8MG	TABLETS	RECIEPT	Hypertension. Treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated.
542	ATAZANAVIR	ATAZANAVIR TEVA 150 MG	ATAZANAVIR AS SULFATE	ATAZANAVIR AS SULFATE 150MG	CAPSULES	RECIEPT	Atazanavir Teva is indicated in combination with other antiretroviral agents for for the treatment of HIV-1 infection.
543	ATAZANAVIR	ATAZANAVIR TEVA 200 MG	ATAZANAVIR AS SULFATE	ATAZANAVIR AS SULFATE 200MG	CAPSULES	RECIEPT	Atazanavir Teva is indicated in combination with other antiretroviral agents for for the treatment of HIV-1 infection.
544	ATAZANAVIR	ATAZANAVIR TEVA 300 MG	ATAZANAVIR AS SULFATE	ATAZANAVIR AS SULFATE 300MG	CAPSULES	RECIEPT	Atazanavir Teva is indicated in combination with other antiretroviral agents for for the treatment of HIV-1 infection.
546	ATOMIC	ATOMIC 25	ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Atomic is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Atomic should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
548	ATOMIC	ATOMIC 40	ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HYDROCHLORIDE 40MG	TABLETS	RECIEPT	Atomic is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Atomic should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
550	ATOMIC	ATOMIC 60	ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Atomic is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Atomic should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
552	ATORVA	ATORVA - DEX 10	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Atorva - dex is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva - dex is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva - dex is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease, Litorva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
555	ATORVA	ATORVA TEVA 10 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Atorva Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva Teva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorva Teva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
553	ATORVA	ATORVA - DEX 20	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Atorva - dex is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva - dex is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva - dex is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease, Litorva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
557	ATORVA	ATORVA TEVA 20 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Atorva Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva Teva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorva Teva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
554	ATORVA	ATORVA - DEX 40	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Atorva - dex is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva - dex is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva - dex is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease, Litorva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
559	ATORVA	ATORVA TEVA 40 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Atorva Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva Teva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorva Teva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
561	ATORVA	ATORVA TEVA 80 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 80MG	TABLETS	RECIEPT	Atorva Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva Teva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorva Teva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
563	ATORVASTATIN	ATORVASTATIN TEVA 10 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Atorvastatin Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorvastatin is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
565	ATORVASTATIN	ATORVASTATIN TEVA 20 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Atorvastatin Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorvastatin is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
567	ATORVASTATIN	ATORVASTATIN TEVA 40 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Atorvastatin Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorvastatin is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
569	ATORVASTATIN	ATORVASTATIN TEVA 80 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 80MG	TABLETS	RECIEPT	Atorvastatin Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorvastatin is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
573	ATOSIBAN	ATOSIBAN GENFARMA	ATOSIBAN	ATOSIBAN 7.5MG/1ML	SOLUTION	RECIEPT	Atosiban Genfarma is indicated to delay imminent pre-term birth in pregnant women with: - regular uterine contractions of at least 30 seconds duration at a rate of 4 or more per 30 minutes - a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of 50 % or more - age: 18 years and above - a gestational age from 24 until 33 completed weeks - a normal foetal heart rate
571	ATOSIBAN FERRING	ATOSIBAN - FERRING	ATOSIBAN	ATOSIBAN 7.5MG/ML	SOLUTION	RECIEPT	Atosiban is indicated to delay imminent pre-term birth in pregnant women with: - regular uterine contractions of at least 30 seconds duration at a rate of 4 or more per 30 minutes - a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of 50 % or more - age: 18 years and above - a gestational age from 24 until 33 completed weeks - a normal foetal heart rate.
574	ATOZET	ATOZET10 MG/10 MG	ATORVASTATIN AS CALCIUM TRIHYDRATE	ATORVASTATIN AS CALCIUM TRIHYDRATE 10MG;EZETIMIBE 10MG	TABLETS	RECIEPT	- Prevention of Cardiovascular Events Atozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not. - Hyperch
575	ATOZET	ATOZET10 MG/20 MG	ATORVASTATIN AS CALCIUM TRIHYDRATE	ATORVASTATIN AS CALCIUM TRIHYDRATE 20MG;EZETIMIBE 10MG	TABLETS	RECIEPT	- Prevention of Cardiovascular Events Atozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not. - Hyperch
576	ATOZET	ATOZET10 MG/40 MG	ATORVASTATIN AS CALCIUM TRIHYDRATE	ATORVASTATIN AS CALCIUM TRIHYDRATE 40MG;EZETIMIBE 10MG	TABLETS	RECIEPT	- Prevention of Cardiovascular Events Atozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not. - Hyperch
577	ATOZET	ATOZET10 MG/80 MG	ATORVASTATIN AS CALCIUM TRIHYDRATE	ATORVASTATIN AS CALCIUM TRIHYDRATE 80MG;EZETIMIBE 10MG	TABLETS	RECIEPT	- Prevention of Cardiovascular Events Atozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not. - Hyperch
578	ATRIANCE	ATRIANCE 5 MG/ML	NELARABINE	NELARABINE 5MG/ML	SOLUTION	RECIEPT	Atriance 5 mg/ml is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
579	ATRIPLA	ATRIPLA	TENOFOVIR DISOPROXIL AS	TENOFOVIR DISOPROXIL AS 245MG;EMTRICITABINE 200MG;EFAVIRENZ 600MG	TABLETS	RECIEPT	Atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
581	ATROPINE	ATROPINE CARTRIDGE FOR AUTOMATIC INJECTION 0.5 MG	ATROPINE AS SULFATE	ATROPINE AS SULFATE 0.5MG	SOLUTION	RECIEPT	For the treatment of organophosphate cholinesterase inhibitors, chemical warfare and nerve gas.
582	ATROPINE	ATROPINE CARTRIDGE FOR AUTOMATIC INJECTION 1 MG	ATROPINE AS SULFATE	ATROPINE AS SULFATE 1MG	SOLUTION	RECIEPT	For the treatment of organophosphate cholinesterase inhibitors, chemical warfare and nerve gas.
583	ATROPINE	ATROPINE CARTRIDGE FOR AUTOMATIC INJECTION 2 MG	ATROPINE AS SULFATE	ATROPINE AS SULFATE 2MG	SOLUTION	RECIEPT	For the treatment of organophosphate cholinesterase inhibitors, chemical warfare and nerve gas.
584	ATROPINE	ATROPINE SULPHATE S.A.L.F. 1 MG/ML	ATROPINE SULFATE	ATROPINE SULFATE 1MG/1ML	SOLUTION	RECIEPT	Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension. Antidote in poisoning by organophosphorus.
585	ATROPINE	ATROPINE TEVA 1 MG/ML	ATROPINE SULFATE	ATROPINE SULFATE 1MG/ML	SOLUTION	RECIEPT	Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension. Antidote in poisoning by organophosphorus.
586	ATROPINE	ATROPINE TEVA 20 MG/10 ML	ATROPINE SULFATE	ATROPINE SULFATE 20MG/10ML	SOLUTION	RECIEPT	Preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. Treatment of sinus bradycardia, particularly if complicated by hypotension. Antidote in poisoning by organophosphorus.
587	ATROSPAN	ATROSPAN EYE DROPS	ATROPINE SULFATE	ATROPINE SULFATE 1%	DROPS	RECIEPT	Mydriatic.
588	ATROVENT	ATROVENT	IPRATROPIUM BROMIDE	IPRATROPIUM BROMIDE 0.02MG	INHALATION	RECIEPT	For the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema.
592	ATTENT	ATTENT 5 MG	AMPHETAMINE SULFATE	AMPHETAMINE SULFATE 1.250MG;DEXTROAMPHETAMINE SULFATE 1.250MG;AMPHETAMINE ASPARTATE MONOHYDRATE 1.250MG;DEXTROAMPHETAMINE SACCHARATE 1.250MG	TABLETS	RECIEPT	Treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.
589	ATTENT	ATTENT 10 MG	AMPHETAMINE SULFATE	AMPHETAMINE SULFATE 2.500MG;DEXTROAMPHETAMINE SULFATE 2.500MG;AMPHETAMINE ASPARTATE MONOHYDRATE 2.500MG;DEXTROAMPHETAMINE SACCHARATE 2.500MG	TABLETS	RECIEPT	Treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.
590	ATTENT	ATTENT 20 MG	AMPHETAMINE SULFATE	AMPHETAMINE SULFATE 5.000MG;DEXTROAMPHETAMINE SULFATE 5.000MG;AMPHETAMINE ASPARTATE MONOHYDRATE 5.000MG;DEXTROAMPHETAMINE SACCHARATE 5.000MG	TABLETS	RECIEPT	Treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.
591	ATTENT	ATTENT 30 MG	AMPHETAMINE SULFATE	AMPHETAMINE SULFATE 7.500MG;DEXTROAMPHETAMINE SULFATE 7.500MG;AMPHETAMINE ASPARTATE MONOHYDRATE 7.500MG;DEXTROAMPHETAMINE SACCHARATE 7.500MG	TABLETS	RECIEPT	Treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.
593	ATZIRUT	ATZIRUT X	BISACODYL	BISACODYL 5MG	TABLETS	RECIEPT	All types of constipation in ambulatory and bedridden patients over the age of 6 years. Preparation of patients for abdominal radiography and proctoscopy.
594	AUBAGIO	AUBAGIO	TERIFLUNOMIDE	TERIFLUNOMIDE 14MG	TABLETS	RECIEPT	Aubagio is indicated for the treatment of adult patients with relapsing remitting forms of Multiple Sclerosis (MS) ) to reduce the frequency of clinical relapses and to delay the progression of physical disability.
595	AUGMENTIN	AUGMENTIN 1G INJECTION	AMOXICILLIN AS SODIUM	AMOXICILLIN AS SODIUM 1000MG;CLAVULANIC ACID AS POTASSIUM CLAVULANATE 200MG	POWDER	RECIEPT	Augmentin is indicated for the treatment of the following infections in adults and children: severe infections of the ear, nose and throat (such as mastoiditis, peritonsillar infections, epiglottitis, and sinusitis when accompanied by severe systemic signs and symptoms), acute exacerbations of chronic bronchitis (adequately diagnosed), community acquired pneumonia. cystitis, pyelonephritis, Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis, bone and joint infections, in particular osteomyelitis, intra-abdominal infections, female genital infections. Prophylaxis against infections associated with major surgical procedures in adults, such as those involving the: gastrointestinal tract, pelvic cavity, head and neck, biliary tract surgery.
598	AUGMENTIN	AUGMENTIN 500 MG INJECTON	AMOXICILLIN AS SODIUM	AMOXICILLIN AS SODIUM 500MG;CLAVULANIC ACID AS POTASSIUM CLAVULANATE 100MG	POWDER	RECIEPT	Augmentin is indicated for the treatment of the following infections in adults and children: severe infections of the ear, nose and throat (such as mastoiditis, peritonsillar infections, epiglottitis, and sinusitis when accompanied by severe systemic signs and symptoms), acute exacerbations of chronic bronchitis (adequately diagnosed), community acquired pneumonia. cystitis, pyelonephritis, Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis, bone and joint infections, in particular osteomyelitis, intra-abdominal infections, female genital infections. Prophylaxis against infections associated with major surgical procedures in adults, such as those involving the: gastrointestinal tract, pelvic cavity, head and neck, biliary tract surgery. .
610	AUGMENTIN	AUGMENTIN SUSPENTION 250 MG/5 ML	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 250MG/5ML;CLAVULANIC ACID AS POTASSIUM SALT 62.5MG/5ML	POWDER	RECIEPT	Augmentin is indicated for the treatment of the following infections in adults and children: • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. • Bone and joint infections, in particular osteomyelitis.
597	AUGMENTIN	AUGMENTIN 250 MG TABLETS	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 250MG;CLAVULANIC ACID AS POTASSIUM SALT 125MG	TABLETS	RECIEPT	Augmentin is indicated for the treatment of the following infections in adults and children : • Acute bacterial sinusitis (adequately diagnosed) • Otitis media infection • Acute pharyngitis • Cystitis • Pyelonephritis • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.
600	AUGMENTIN	AUGMENTIN 500 MG TABLETS	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 500MG;CLAVULANIC ACID AS POTASSIUM SALT 125MG	TABLETS	RECIEPT	Augmentin is indicated for the treatment of the following infections in adults and children : • Acute bacterial sinusitis (adequately diagnosed) • Acute Otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. • Bone and joint infections, in particular osteomyelitis.
604	AUGMENTIN	AUGMENTIN ES 600 MG/5 ML	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 600MG/5ML;CLAVULANIC ACID AS POTASSIUM 42.9MG/5ML	POWDER	RECIEPT	Augmentin ES is indicated for the treatment of acute otitis media in children aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-resistant Streptococcus pneumoniae: Consideration should be given to official guidance on the appropriate use of antibacterial agents.
602	AUGMENTIN	AUGMENTIN 875 MG TABLETS	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 875MG;CLAVULANIC ACID AS POTASSIUM SALT 125MG	TABLETS	RECIEPT	Augmentin is indicated for the treatment of the following infections in adults and children : • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. • Bone and joint infections, in particular osteomyelitis.
608	AUGMENTIN	AUGMENTIN SUSPENSION 400 MG/5 ML	CLAVULANIC ACID AS POTASSIUM SALT	CLAVULANIC ACID AS POTASSIUM SALT 57MG/5ML;AMOXICILLIN AS TRIHYDRATE 400MG/5ML	POWDER	RECIEPT	Augmentin is indicated for the treatment of the following infections in adults and children: • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. • Bone and joint infections, in particular osteomyelitis. • Recurrent tonsillitis
613	AVAMYS	AVAMYS	FLUTICASONE FUROATE	FLUTICASONE FUROATE 27.5MCG/DOSE	SPRAY	RECIEPT	AVAMYS (fluticasone furoate) Nasal Spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.
614	AVASTIN	AVASTIN	BEVACIZUMAB	BEVACIZUMAB 25MG/ML	CONCENTRATE	RECIEPT	- Avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum. - Avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of
617	AVAXIM	AVAXIM 160 U	HEPATITIS A VACCINES	HEPATITIS A VACCINES 160AU/0.5ML	SUSPENSION	RECIEPT	For active immunisation against infection caused by Hepatitis A virus in adults and adolescents over the age of 15
618	AVAXIM	AVAXIM 80 U PEDIATRIC	HEPATITIS A VACCINES	HEPATITIS A VACCINES 80UNITS/0.5ML	SUSPENSION	RECIEPT	Avaxim 80 u pediatric is indicated for active immunisation against infection caused by Hepatitis a virus in children aged from 12 months to 15 years inclusive, who are at risk either of contaminating or spreading infection or of a life threatening disease if infected.
624	AVCAMOL	AVCAMOL FOR BIG KIDS 250 MG STRAW/VANI 10 SACHETS	PARACETAMOL	PARACETAMOL 250MG	GRANULES		Analgesic and antipyretic.
620	AVCAMOL	AVCAMOL 250 MG	PARACETAMOL	PARACETAMOL 250MG/STICK PACK	GRANULES		Analgesic, Antipyretic .
623	AVCAMOL	AVCAMOL 500 MG STRAW/VANILLA 10 SACHETS	PARACETAMOL	PARACETAMOL 500MG	GRANULES		Relief of pain and fever of different etiologies such as headache, toothache, cold, influenza, rheumatic pain and dysmenorrhea
619	AVCAMOL	AVCAMOL	PARACETAMOL	PARACETAMOL 500MG/STICK PACK	GRANULES		Relief of pain and fever of different etiologies such as headache, toothache, cold, influenza, rheumatic pain and dysmenorrhea
622	AVCAMOL	AVCAMOL 500 MG	PARACETAMOL	PARACETAMOL 500MG/STICK PACK	GRANULES		Relief of pain and fever of different etiologies such as headache, toothache, cold, influenza, rheumatic pain and dysmenorrhea
625	AVILAC	AVILAC 300ML	LACTULOSE	LACTULOSE 0.67G/ML (66.7%;66.7G/100ML)	SYRUP		Constipation. Acute and chronic hepatic encephalopathy.
626	AVILAC	AVILAC SYRUP	LACTULOSE	LACTULOSE 66.7G/100ML	SYRUP		Constipation. Acute and chronic hepatic encephalopathy.
627	AVODART	AVODART	DUTASTERIDE	DUTASTERIDE 0.5MG	CAPSULES	RECIEPT	Avodart is indicated for : Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
628	AVONEX	AVONEX SOLUTION FOR INJECTION	INTERFERON BETA	INTERFERON BETA 1A 30MCG/0.5ML	SOLUTION	RECIEPT	Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. Treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of MRI abnormalities characteristic of MS and if they are determined to be at high risk of developing clinically definite multiple sclerosis. Safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.
629	AZACITIDINE	AZACITIDINE TEVA	AZACITIDINE	AZACITIDINE 100MG/VIAL	POWDER	RECIEPT	Azacitidine Teva is indicated for treatment of patients with the following French-American- British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
630	AZADINE	AZADINE	AZACITIDINE	AZACITIDINE 100MG/VIAL	POWDER	RECIEPT	Azadine is indicated for treatment of patients with the following French-American- British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
631	AZARGA	AZARGA	BRINZOLAMIDE	BRINZOLAMIDE 10MG/ML;TIMOLOL AS MALEATE 5MG/ML	SUSPENSION	RECIEPT	Decrease of intra-ocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
632	AZENIL	AZENIL 200 MG/5 ML SUSPENSION	AZITHROMYCIN AS DIHYDRATE	AZITHROMYCIN AS DIHYDRATE 200MG/5ML	POWDER	RECIEPT	Infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.
633	AZENIL	AZENIL CAPSULES	AZITHROMYCIN AS DIHYDRATE	AZITHROMYCIN AS DIHYDRATE 250MG	CAPSULES	RECIEPT	Infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.
634	AZILECT	AZILECT	RASAGILINE AS MESYLATE	RASAGILINE AS MESYLATE 1MG	TABLETS	RECIEPT	Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
638	AZITHRO	AZITHRO TEVA	AZITHROMYCIN AS DIHYDRATE	AZITHROMYCIN AS DIHYDRATE 200MG/5ML	POWDER	RECIEPT	For the treatment of infections caused by susceptible organisms: in lower respiratory tract Including bronchitis and pneumonia, skin and soft tissue infections, otitis media upper respiratory tract infections including sinusitis pharyngitis and tonsillitis. Azithro Teva is also indicated in the treatment of uncomplicated genital infections due to Chlamydia trachomatis.
641	AZITHROMYCIN	AZITHROMYCIN TEVA	AZITHROMYCIN	AZITHROMYCIN 200MG/5ML	POWDER	RECIEPT	For infections caused by susceptible organisms : in lower respiratory tract infections including bronchitis and pneumonia, in skin and soft tissue infections, in otitis media and in upper respiratory tract infections including sinusitis and pharyngitis tonsillitis. Azithromycin Teva is also indicated in the treatment of uncomplicated genital infections due to Chlamydia trachomatis.
639	AZITHROMYCIN	AZITHROMYCIN INOVAMED 250 MG	AZITHROMYCIN AS DIHYDRATE	AZITHROMYCIN AS DIHYDRATE 250MG	CAPSULES	RECIEPT	Infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.
640	AZITHROMYCIN	AZITHROMYCIN MBI 500 MG/VIAL	AZITHROMYCIN AS DIHYDRATE	AZITHROMYCIN AS DIHYDRATE 500MG	POWDER	RECIEPT	Treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.
644	AZITHROVENIR	AZITHROVENIR	AZITHROMYCIN AS DIHYDRATE	AZITHROMYCIN AS DIHYDRATE 500MG/VIAL	POWDER	RECIEPT	Treatment of infections caused by susceptible strains of the designated microorganism in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.
645	AZOLIN	AZOLIN	TETRAHYDROZOLINE HYDROCHLORIDE	TETRAHYDROZOLINE HYDROCHLORIDE 0.05%	DROPS		For the relief of mild ocular irritation caused by various factors such as smoke, dust, pollen, etc.
646	AZOLINE	AZOLINE DROPS 15CC	TETRAHYDROZOLINE HCL	TETRAHYDROZOLINE HCL 0.05%	DROPS		For relief in cases of redness in the eye as a result of irritation, caused by various materials such as dust, smoke, plants, etc.
281	AZOPT	ALCON AZOPT 1%	BRINZOLAMIDE	BRINZOLAMIDE 1%	SUSPENSION	RECIEPT	Alcon Azopt is indicated to decrease elevated intraocular pressure in: ocular hypertension open-angle glaucoma as monotherapy in patients unresponsive to beta-blockers or in patients in whom beta-blockers are contra-indicated or as adjunctive therapy to beta-blockers.
866	B SIX	B-SIX 300 TABLETS	PYRIDOXINE (VIT B6) HYDROCHLORIDE	PYRIDOXINE (VIT B6) HYDROCHLORIDE 300MG	TABLETS		Vitamin B6 supplement.
647	B SIX	B SIX 300 30TAB	PYRIDOXINE HCL	PYRIDOXINE HCL 300MG	TABLETS		Vitamin B6 supplement.
648	BABY AF	BABY AF DROPS 10ML	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%	DROPS		Relief of nasal congestion, especially for babies.
650	BABY AF	BABYAF SALINE NASAL DROPS	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%W/V	DROPS	RECIEPT	Relief of nasal congestion in infants and small children.
649	BABY GUM	BABY GUM	CETALKONIUM CHLORIDE	CETALKONIUM CHLORIDE 0.01%;CHOLINE SALICYLATE 8.7%	GEL		As an antiseptic and local pain reliever for mouth ulcers, teething pain, denture irritation, and cold sores.
652	BABYZIM	BABYZIM DROPS 40ML	PEPSIN	PEPSIN 0.6%;SODIUM GLYCEROPHOSPHATE 0.8%;NICOTINIC ACID 0.2%	DROPS	RECIEPT	Treatment of constipation and flatulence.
651	BABYZIM	BABYZIM DROPS	PEPSIN	PEPSIN 0.6%W/V;NICOTINIC ACID 0.2%W/V;SODIUM GLYCEROPHOSPHATE 0.8%W/V	DROPS	RECIEPT	Treatment of constipation and flatulence.
654	BACLOFEN	BACLOFENE BIOINDUSTRIA L.I.M 10 MG/5 ML	BACLOFEN	BACLOFEN 10MG/5ML	SOLUTION	RECIEPT	Baclofene Bioindustria L.I.M. 10mg/5ml is indicated in patients with severe chronic spasticity resulting from trauma, multiple sclerosis or other spinal cord disorders, who are unresponsive to oral baclofen or other orally administered antispastic agents and/or those patients who experience unacceptable side effects at effective oral doses. Baclofene Bioindustria L.I.M. 10mg/5ml is effective in adult patients with severe chronic spasticity of cerebral origin, resulting e.g. from cerebral palsy, brain trauma or cerebrovascular accident; however, clinical experience is limited. Pediatric population: Baclofene Bioindustria L.I.M. 10mg/5ml is indicated in patients aged 4 to <18 years with severe chronic spasticity of cerebral origin or of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.
653	BACLOFEN	BACLOFEN SINTETICA 2 MG/ ML	BACLOFEN	BACLOFEN 2MG/ML	SOLUTION	RECIEPT	Baclofen Sintetica is indicated in patients with severe chronic spasticity resulting from trauma, multiple sclerosis or other spinal cord disorders, who are unresponsive to oral baclofen or other orally administered antispastic agents and/or those patients who experience unacceptable side effects at effective oral doses. Baclofen Sintetica is effective in adult patients with severe chronic spasticity of cerebral origin, resulting e.g. from cerebral palsy, brain trauma or cerebrovascular accident; however, clinical experience is limited. Paediatric population: Baclofen Sintetica indicated in patients aged 4 to <18 years with severe chronic spasticity of cerebral origin or of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.
655	BACLOSAL	BACLOSAL 10	BACLOFEN	BACLOFEN 10MG	TABLETS	RECIEPT	Muscle spasticity of various origins.
657	BACLOSAL	BACLOSAL 25	BACLOFEN	BACLOFEN 25MG	TABLETS	RECIEPT	Muscle spasticity of various origins.
660	BACTROBAN	BACTROBAN DERMAL	MUPIROCIN	MUPIROCIN 2%W/W	OINTMENT	RECIEPT	Bactroban is a topical antibacterial agent, active against those organisms responsible for the majority of skin infections. Bactroban Dermal is used for skin infections, e.g. impetigo, folliculitis, furunculosis.
661	BACTROBAN	BACTROBAN NASAL	MUPIROCIN AS CALCIUM	MUPIROCIN AS CALCIUM 2%W/W	OINTMENT	RECIEPT	The elimination of nasal carriage of staphylococci, including methycillin-resistant staphylococus aureus (MRSA).
663	BALNEUM PLUS	BALNEUM PLUS SOL 200ML	LAURETH	LAURETH 9 15%;SOYA OIL 82.95%	SOLUTION		Skin care
662	BALNEUM PLUS	BALNEUM PLUS	SOYA OIL	SOYA OIL 82.95G/100 G;POLIDOCANOL 15G/100 G	SOLUTION	RECIEPT	Refatting medical oil bath with antipruritic effect.
664	BAMYXIN OINTMENT	BAMYXIN EYE OINTMENT	BACITRACIN	BACITRACIN 400U/G;POLYMYXIN B SULFATE 5000U/G;NEOMYCIN AS SULFATE 5MG/G	OINTMENT	RECIEPT	Short term treatment of superficial external ocular infections caused by organisms susceptible to one or more of the antibiotics contained therein.
665	BASAGLAR	BASAGLAR	INSULIN GLARGINE	INSULIN GLARGINE 100U/ML	SOLUTION	RECIEPT	Treatment of adult patients 18 years and over with type 1 or type 2 diabetes mellitus who require basal (long acting) insulin for the control of hyperglycaemia.
667	BATRAFEN	BATRAFEN NAIL LAQUER 3ML	CICLOPIROX	CICLOPIROX 8%(80MG/G)	LACQUE		Treatment of fungal infections of the nails.
666	BATRAFEN	BATRAFEN NAIL LACQUER	CICLOPIROX	CICLOPIROX 80MG/G	LACQUE		For the treatment of fungal infections of the nails.
668	BAVENCIO	BAVENCIO	AVELUMAB	AVELUMAB 20MG/1ML	CONCENTRATE	RECIEPT	Bavencio is indicated for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who: - Have disease progression during or following platinum-containing chemotherapy - disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Bavencio in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) .
671	BEDODEKA	BEDODEKA	CYANOCOBALAMIN	CYANOCOBALAMIN 1MG/ML	SOLUTION	RECIEPT	Pernicious anemia and its neurological complications, subacute combined degeneration of the spinal cord. Treatment of vitamin B12 deficiency states and macrocytic anemias associated with nutritional deficiencies, gastrectomy and abnormalities of , or malabsorption from, the gastrointestinal tract such as celiac disease, sprue and accompanying folic acid deficiency. Bedodeka is also suitable for use as the flushing dose in the schilling test for pernicious anemia.
672	BEKUNIS	BEKUNIS	SENNA	SENNA 150-220MG	DRAGEE	RECIEPT	Laxative.
673	BELARA	BELARA	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.03MG;CHLORMADINONE ACETATE 2MG	TABLETS	RECIEPT	Oral hormonal contraceptive.
674	BELVIQ	BELVIQ 10 MG	LORCASERIN HYDROCHLORIDE HEMIHYDRATE	LORCASERIN HYDROCHLORIDE HEMIHYDRATE 10.4MG	TABLETS	RECIEPT	Belviq is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obese), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)
675	BEMFOLA	BEMFOLA	FOLLITROPIN ALFA	FOLLITROPIN ALFA 600IU/ML	SOLUTION	RECIEPT	In adult women • Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate. • Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT). • Follitropin alfa in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. Inclinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/l. In adult men • Follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy
677	BEN GAY	BEN GAY ULTRA STR 2OZ	METHYL SALICYL	METHYL SALICYL 30%;MENTHOL 10%;CAMPHO 4%	CREAM		This medicine is indicated for the temporary relief of minor aches and pains of muscles and joints, such as simple backache, lumbago, arthritis, strains, bruises and sprains.
678	BEN GAY	BEN GAY ULTRA STR 4OZ	METHYL SALICYL	METHYL SALICYL 30%;MENTHOL 10%;CAMPHO 4%	CREAM		This medicine is indicated for the temporary relief of minor aches and pains of muscles and joints, such as simple backache, lumbago, arthritis, strains, bruises and sprains.
676	BEN GAY	BEN GAY OINT 2OZ	METHYL SALICYLATE	METHYL SALICYLATE 15%;MENTHOL 10%	OINTMENT		This medicine is indicated for the temporary relief of minor aches and pains of muscles and joints, such as simple backache, lumbago, arthritis, strains, bruises and sprains.
685	BEN GAY	BENGAY GREASELESS PAIN RELIEVING CREAM	METHYL SALICYLATE	METHYL SALICYLATE 15%;MENTHOL 10%	CREAM		This medicine is indicated for the temporary relief of minor aches and pains of muscles and joints, such as simple backache, lumbago, arthritis, strains, bruises and sprains.
686	BEN GAY	BENGAY ULTRA STRENGTH	METHYL SALICYLATE	METHYL SALICYLATE 30%;MENTHOL 10%;CAMPHOR 4%	CREAM		This medicine is indicated for the temporary relief of minor aches and pains of muscles and joints, such as simple backache, lumbago, arthritis, strains, bruises and sprains.
679	BENDAMUSTINE S.K.	BENDAMUSTINE S.K. 100 MG	BENDAMUSTINE AS HYDROCHLORIDE MONOHYDRATE	BENDAMUSTINE AS HYDROCHLORIDE MONOHYDRATE 100MG/VIAL	POWDER	RECIEPT	First-line of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotheraphy is not appropiate. Indolent non-Hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. Follicular non-Hodgkin’s lymphoma as first line treatment in combination with rituximab.
680	BENDAMUSTINE S.K.	BENDAMUSTINE S.K. 25 MG	BENDAMUSTINE AS HYDROCHLORIDE MONOHYDRATE	BENDAMUSTINE AS HYDROCHLORIDE MONOHYDRATE 25MG/VIAL	POWDER	RECIEPT	First-line of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotheraphy is not appropiate. Indolent non-Hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. Follicular non-Hodgkin’s lymphoma as first line treatment in combination with rituximab.
681	BENEFIX	BENEFIX 1000 IU/VIAL	COAGULATION FACTOR IX RECOMBINANT-RFIX	COAGULATION FACTOR IX RECOMBINANT-RFIX 1000IU/VIAL	POWDER	RECIEPT	Benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (PTP) and previously untreated patients (PUP). Benefix is not indicated for the treatment of other factor deficiencies (e.g. factors II,VII, and X)' nor for the treatment of hemophilia A patients with inhibitors to factor VIII, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.
682	BENEFIX	BENEFIX 2000 IU/VIAL	COAGULATION FACTOR IX RECOMBINANT-RFIX	COAGULATION FACTOR IX RECOMBINANT-RFIX 2000 IU	POWDER	RECIEPT	Benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (PTP) and previously untreated patients (PUP). Benefix is not indicated for the treatment of other factor deficiencies (e.g. factors II,VII, and X)' nor for the treatment of hemophilia A patients with inhibitors to factor VIII, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.
683	BENEFIX	BENEFIX 250 IU/VIAL	COAGULATION FACTOR IX RECOMBINANT-RFIX	COAGULATION FACTOR IX RECOMBINANT-RFIX 250IU/VIAL	POWDER	RECIEPT	Benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (PTP) and previously untreated patients (PUP). Benefix is not indicated for the treatment of other factor deficiencies (e.g. factors II,VII, and X)' nor for the treatment of hemophilia A patients with inhibitors to factor VIII, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.
684	BENEFIX	BENEFIX 500 IU/VIAL	COAGULATION FACTOR IX RECOMBINANT-RFIX	COAGULATION FACTOR IX RECOMBINANT-RFIX 500IU/VIAL	POWDER	RECIEPT	Benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (PTP) and previously untreated patients (PUP). Benefix is not indicated for the treatment of other factor deficiencies (e.g. factors II,VII, and X)' nor for the treatment of hemophilia A patients with inhibitors to factor VIII, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.
687	BENLYSTA	BENLYSTA 120 MG	BELIMUMAB	BELIMUMAB 120MG 80 mg/ml after reconstitution	POWDER	RECIEPT	Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g positive anti dsDNA and low complement) despite standard therapy.
688	BENLYSTA	BENLYSTA 200 MG	BELIMUMAB	BELIMUMAB 200MG/1ML	SOLUTION	RECIEPT	Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.
689	BENLYSTA	BENLYSTA 400 MG	BELIMUMAB	BELIMUMAB 400MG 80 mg/ml after reconstitution	POWDER	RECIEPT	Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g positive anti dsDNA and low complement) despite standard therapy.
693	BENZ	BENZAC AC 10% 60GR	BENZOYL PEROXIDE	BENZOYL PEROXIDE 10%	GEL	RECIEPT	For topical treatment of acne vulgaris.
694	BENZ	BENZAC AC 2.5% 60GR	BENZOYL PEROXIDE	BENZOYL PEROXIDE 2.5%	GEL	RECIEPT	For topical treatment of acne vulgaris.
695	BENZ	BENZAC AC 5% 60GR	BENZOYL PEROXIDE	BENZOYL PEROXIDE 5%	GEL	RECIEPT	For topical treatment of acne vulgaris.
690	BENZAC	BENZAC 10 %	BENZOYL PEROXIDE	BENZOYL PEROXIDE 10%W/W	GEL	RECIEPT	For topical treatment of acne vulgaris.
691	BENZAC	BENZAC 2.5 %	BENZOYL PEROXIDE	BENZOYL PEROXIDE 2.5%W/W	GEL	RECIEPT	For the topical treatment of acne vulgaris.
692	BENZAC	BENZAC 5 %	BENZOYL PEROXIDE	BENZOYL PEROXIDE 5%W/W	GEL	RECIEPT	For the topical treatment of acne vulgaris.
696	BEPANTHEN	BEPANTHEN	DEXPANTHENOL	DEXPANTHENOL 5%	OINTMENT		For the treatment of light skin wounds. Prevention and treatment of chafed, cracked or split skin. Dry skin. Regular breast care in nursing mothers and treatment of sore or cracked nipples. Infant care: prevention and treatment of nappy (diaper) rash.
697	BEPANTHEN	BEPANTHEN OINT 5% 100G	DEXPANTHENOL	DEXPANTHENOL 5%	OINTMENT		For the treatment of light skin wounds. Prevention and treatment of chafed, cracked or split skin. Dry skin. Regular breast care in nursing mothers and treatment of sore or cracked nipples. Infant care: prevention and treatment of nappy (diaper) rash.
698	BEPANTHEN	BEPANTHEN OINT 5% 30G	DEXPANTHENOL	DEXPANTHENOL 5%	OINTMENT		For the treatment of light skin wounds. Prevention and treatment of chafed, cracked or split skin. Dry skin. Regular breast care in nursing mothers and treatment of sore or cracked nipples. Infant care: prevention and treatment of nappy (diaper) rash.
699	BEPANTHEN	BEPANTHEN OINT 5% 50 GR	DEXPANTHENOL	DEXPANTHENOL 5%	OINTMENT		For the treatment of light skin wounds. Prevention and treatment of chafed, cracked or split skin. Dry skin. Regular breast care in nursing mothers and treatment of sore or cracked nipples. Infant care: prevention and treatment of nappy (diaper) rash.
700	BEPANTHEN	BEPANTHEN OINT5% 3.5G	DEXPANTHENOL	DEXPANTHENOL 5%	OINTMENT		For the treatment of light skin wounds. Prevention and treatment of chafed, cracked or split skin. Dry skin. Regular breast care in nursing mothers and treatment of sore or cracked nipples. Infant care: prevention and treatment of nappy (diaper) rash.
701	BEPANTHEN	BEPANTHEN PLUS	DEXPANTHENOL	DEXPANTHENOL 5%;CHLORHEXIDINE HYDROCHLORIDE 0.5%	CREAM		Antiseptic healing treatment of wounds of any kind with an infection risk : such as slight skin irritations, wounds, cuts, burns and skin inflammation.
702	BEPANTHEN	BEPANTHEN PLUS CR 5% 3.5G	DEXPANTHENOL	DEXPANTHENOL 50MG;CHLORHEXIDINE HCL 5MG/1G	CREAM		Antiseptic healing treatment of wounds of any kind with an infection risk : such as slight skin irritations, wounds, cuts, burns and skin inflammation.
703	BEPANTHEN	BEPANTHEN PLUS CR 5% 30G	DEXPANTHENOL	DEXPANTHENOL 50MG;CHLORHEXIDINE HCL 5MG/1G	CREAM		Antiseptic healing treatment of wounds of any kind with an infection risk : such as slight skin irritations, wounds, cuts, burns and skin inflammation.
704	BERIGLOBIN	BERIGLOBIN P	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 160MG/ML	SOLUTION	RECIEPT	Substitution in - Primary antibody deficiency syndromes resulting from defective antibody synthesis. - Protracted transitory hypogammaglobulinaemia especially in premature infants . Prophylaxis of hepatitis A - Before exposure - Within 2 weeks after exposure
705	BERINERT	BERINERT	C -	C - 1 ESTERASE INHIBITOR HUMAN 500IU/VIAL	POWDER	RECIEPT	Hereditary angioedema type I and II (HAE). Treatment and pre-procedure (prior to oral, dental, and upper respiratory tract procedures) prevention of acute episodes
706	BERIPLEX P/N	BERIPLEX P/N 250	COAGULATION FACTOR II (HUMAN)	COAGULATION FACTOR II (HUMAN) 200 IU;COAGULATION FACTOR VII (HUMAN) 100 IU;COAGULATION FACTOR IX (HUMAN) 200 IU;COAGULATION FACTOR X (HUMAN) 220 IU;PROTEIN C 150 IU;PROTEIN S ANTIGEN 120 IU	POWDER	RECIEPT	Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.
707	BERIPLEX P/N	BERIPLEX P/N 500	COAGULATION FACTOR II (HUMAN)	COAGULATION FACTOR II (HUMAN) 400 IU;COAGULATION FACTOR VII (HUMAN) 200 IU;COAGULATION FACTOR IX (HUMAN) 400 IU;COAGULATION FACTOR X (HUMAN) 440 IU;PROTEIN C 300 IU;PROTEIN S ANTIGEN 240 IU	POWDER	RECIEPT	Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.
708	BERIRAB	BERIRAB	HUMAN-RABIES IMMUNOGLOBULIN	HUMAN-RABIES IMMUNOGLOBULIN 150IU/ML	SOLUTION	RECIEPT	Prophylaxis of rabies.
709	BESPONSA	BESPONSA	INOTUZUMAB OZOGAMICIN	INOTUZUMAB OZOGAMICIN 1MG/VIAL	POWDER	RECIEPT	BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).
710	BETACAP	BETACAP	BETAMETHASONE VALERATE	BETAMETHASONE VALERATE 0.12%W/W	SOLUTION	RECIEPT	Topical treatment of dermatoses of the scalp such as psoriasis which are unresponsive to less potent corticosteroids.
711	BETACORTEN	BETACORTEN CREAM	BETAMETHASONE AS VALERATE	BETAMETHASONE AS VALERATE 0.1%W/W	CREAM	RECIEPT	Betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.
714	BETACORTEN	BETACORTEN OINTMENT	BETAMETHASONE AS VALERATE	BETAMETHASONE AS VALERATE 0.1%W/W	OINTMENT	RECIEPT	Betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.
715	BETACORTEN	BETACORTEN SCALP SOLUTION	BETAMETHASONE AS VALERATE	BETAMETHASONE AS VALERATE 0.1%W/W	SOLUTION	RECIEPT	Steroid responsive dermatoses of the scalp, such as psoriasis, seborrheic capitis and inflammation associated with severe dandruff.
712	BETACORTEN	BETACORTEN G CREAM	BETAMETHASONE AS VALERATE	BETAMETHASONE AS VALERATE 0.1%W/W;GENTAMICIN AS SULFATE 0.1%W/W	CREAM	RECIEPT	For local treatment of inflammatory dermatoses and allergic skin conditions complicated by infections.
713	BETACORTEN	BETACORTEN G OINTMENT	BETAMETHASONE AS VALERATE	BETAMETHASONE AS VALERATE 0.1%W/W;GENTAMICIN AS SULFATE 0.1%W/W	OINTMENT	RECIEPT	For local treatment of inflammatory dermatoses and allergic skin conditions complicated by infections.
717	BETADINE	BETADINE TOPICAL SPRAY	POVIDONE-IODINE	POVIDONE-IODINE 2.5%	POWDER		As antiseptic for prevention and treatment of infections associated with burns, cuts and scrapes, and for preventive treatment of wounds at risk of infection, e.g. after placement of a suture for wound treatment or after surgery.
716	BETADINE	BETADINE GARGLE	POVIDONE-IODINE	POVIDONE-IODINE 7.5%	SOLUTION		For the treatment of infectious/inflammatory diseases of oropharyngeal mucosa and gingiva caused by fungi, viruses and bacteria (oral thrush, aphthae, superinfected and herpetic ulcers, gingivitis, stomatitis, pharyngitis, supportive treatment of tonsillitis) ; treatment oral or pharyngeal injuries ; antiseptic treatment of the oral mucosa (e.g. prior to surgery), in particular in immunocompromised patients with a risk of endocarditis (prevention of bacteremia) ; prevention of radiation-induced mucositis in patients undergoing radiotherapy or radiochemotherapy.
718	BETAFERON	BETAFERON	INTERFERON BETA	INTERFERON BETA 1B 0.3MG/VIAL	POWDER	RECIEPT	Use in ambulatory patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing progressive M.S. to reduce the frequency of clinical exacerbations. Treatment of secondary progressive (SP) form of multiple sclerosis. Treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of MRI abnormalities characteristic of M.S. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
719	BETAHISTINE	BETAHISTINE TEVA 16 MG	BETAHISTINE DIHYDROCHLORIDE	BETAHISTINE DIHYDROCHLORIDE 16MG	TABLETS	RECIEPT	Meniere's syndrom. Symptomatic treatment of peripheral vertigo.
720	BETAREN	BETAREN 100 S.R.	DICLOFENAC SODIUM	DICLOFENAC SODIUM 100MG	TABLETS	RECIEPT	Analgesic, anti-inflammatory
721	BETEN CARE	BETEN CARE	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 262MG	TABLETS		For relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.
723	BETEN CARE	BETEN CARE 262MG 30 CHEW TAB	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG	TABLETS		For relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.
724	BETISTINE	BETISTINE 16 MG	BETAHISTINE HYDROCHLORIDE	BETAHISTINE HYDROCHLORIDE 16MG	TABLETS	RECIEPT	Meniere`s syndrome. Symptomatic treatment of peripheral vertigo.
725	BETMIGA	BETMIGA 25 MG	MIRABEGRON	MIRABEGRON 25MG	TABLETS	RECIEPT	Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome
727	BETMIGA	BETMIGA 50 MG	MIRABEGRON	MIRABEGRON 50MG	TABLETS	RECIEPT	Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome
729	BETNESOL	BETNESOL TABLETS	BETAMETHASONE	BETAMETHASONE 0.5MG	TABLETS	RECIEPT	Diseases responsive to oral glucocorticosteroid therapy.
730	BETNOVATE	BETNOVATE CREAM	BETAMETHASONE AS VALERATE	BETAMETHASONE AS VALERATE 0.1%W/W	CREAM	RECIEPT	Betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.
731	BETNOVATE	BETNOVATE OINTMENT	BETAMETHASONE AS VALERATE	BETAMETHASONE AS VALERATE 0.1%W/W	OINTMENT	RECIEPT	Betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.
732	BETNOVATE	BETNOVATE SCALP APPLICATION	BETAMETHASONE AS VALERATE	BETAMETHASONE AS VALERATE 0.1%W/W	SOLUTION	RECIEPT	Steroid responsive dermatoses of the scalp, such as psoriasis, seborrheic capitis and inflammation associated with severe dandruff.
733	BEXSERO	BEXSERO	NEISSERIA MENINGITIDES GROUP B STRAIN NZ98/254	NEISSERIA MENINGITIDES GROUP B STRAIN NZ98/254 25MCG OUTER MEMBRANE VESICLES (OMV);NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN 50MCG;NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN 50MCG;NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN 50MCG	SUSPENSION	RECIEPT	Bexsero is indicated for active immunization of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
734	BEZAFIBRATE	BEZAFIBRATE 400	BEZAFIBRATE	BEZAFIBRATE 400MG	TABLETS	RECIEPT	Hyperlipidemia of types IIa, IIb, III, IV, V in patients where diet alone is insufficient.
735	BIAFINE	BIAFINE	TRIETHANOLAMINE	TRIETHANOLAMINE 0.67 G/100 G	CREAM		Soothes burns, sunburns, sores and wounds.
736	BIAFINE	BIAFINE 186GR	TRIETHANOLAMINE	TRIETHANOLAMINE 0.67G/100G	CREAM		Soothes burns, sunburns, sores and wounds.
737	BIAFINE	BIAFINE 93GR	TRIETHANOLAMINE	TRIETHANOLAMINE 0.67G/100G	CREAM		Soothes burns, sunburns, sores and wounds.
740	BICA VERA	BICA VERA 4.25 % GLUCOSE, 1.75 MMOL/L CALCIUM	SODIUM CHLORIDE	SODIUM CHLORIDE 11.57G/L solution A;CALCIUM CHLORIDE DIHYDRATE 0.5145G/L solution A;MAGNESIUM CHLORIDE HEXAHYDRATE 0.2033G/L solution A;GLUCOSE AS MONOHYDRATE 93.50G/L =anydrous glucose 85.0 g solution A;GLUCOSE MONOHYDRATE 46.75G/L =anydrous glucose 42.5 g mixed solution;MAGNESIUM CHLORIDE HEXAHYDRATE 0.1017G/L mixed solution;CALCIUM CHLORIDE DIHYDRATE 0.2573G/L mixed solution;SODIUM HYDROGEN CARBONATE 2.940G/L mixed solution;SODIUM CHLORIDE 5.786G/L mixed solution;SODIUM HYDROGEN CARBONATE 5.880G/L solution B	SOLUTION	RECIEPT	End-stage (decompensated ) chronic renal failure of any origin treated with peritoneal dialysis.
739	BICA VERA	BICA VERA 2.3 % GLUCOSE, 1.75 MMOL/L CALCIUM	SODIUM CHLORIDE	SODIUM CHLORIDE 11.57G/L solution A;CALCIUM CHLORIDE DIHYDRATE 0.5145G/L solution A;MAGNESIUM CHLORIDE HEXAHYDRATE 0.2033G/L solution A;GLUCOSE MONOHYDRATE 25.0G/L = anydrus glucose 22.73 g mixed solution;MAGNESIUM CHLORIDE HEXAHYDRATE 0.1017G/L mixed solution;CALCIUM CHLORIDE DIHYDRATE 0.2573G/L mixed solution;SODIUM HYDROGEN CARBONATE 2.940G/L mixed solution;SODIUM CHLORIDE 5.786G/L mixed solution;SODIUM HYDROGEN CARBONATE 5.880G/L solution B;GLUCOSE MONOHYDRATE 50.00G/L = anydrus glucose 45.46 g solution A	SOLUTION	RECIEPT	End-stage (decompensated ) chronic renal failure of any origin treated with peritoneal dialysis.
738	BICA VERA	BICA VERA 1.5 % GLUCOSE 1.75 MMOL/L CALCIUM	SODIUM CHLORIDE	SODIUM CHLORIDE 11.57G/L solution A;CALCIUM CHLORIDE DIHYDRATE 0.5145G/L solution A;MAGNESIUM CHLORIDE HEXAHYDRATE 0.2033G/L solution A;SODIUM CHLORIDE 5.786G/L mixed solution;GLUCOSE MONOHYDRATE 33.0G/L = anhydrous glucose 30.0 g solution A;GLUCOSE MONOHYDRATE 16.5G/L = anhydrous glucose 15 g mixed solution;MAGNESIUM CHLORIDE HEXAHYDRATE 0.1017G/L mixed solution;CALCIUM CHLORIDE DIHYDRATE 0.2573G/L mixed solution;SODIUM HYDROGEN CARBONATE 2.940G/L mixed solution;SODIUM HYDROGEN CARBONATE 5.880G/L solution b	SOLUTION	RECIEPT	End-stage (decompensated ) chronic renal failure of any origin treated with peritoneal dialysis.
741	BICALUTAMIDE	BICALUTAMIDE INOVAMED 150 MG	BICALUTAMIDE	BICALUTAMIDE 150MG	TABLETS	RECIEPT	In patients with locally advanced prostate cancer (T3 - T4 any N M0 T1 -T2 N+ M0), Bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. The management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable
743	BICALUTAMIDE	BICALUTAMIDE TEVA 150 MG	BICALUTAMIDE	BICALUTAMIDE 150MG	TABLETS	RECIEPT	In patients with locally advanced prostate cancer (T3-T4 any N M0 T1-T2 N+ M0) Bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. The management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.
742	BICALUTAMIDE	BICALUTAMIDE INOVAMED 50 MG	BICALUTAMIDE	BICALUTAMIDE 50MG	TABLETS	RECIEPT	For the treatment of advanced prostate cancer in combination with luteinising hormone-releasing hormone (LHRH) analog therapy or surgical castration.
744	BICALUTAMIDE	BICALUTAMIDE TEVA 50 MG	BICALUTAMIDE	BICALUTAMIDE 50MG	TABLETS	RECIEPT	For the treatment of advanced prostate cancer in combination with LHRH analog therapy or surgical castration.
745	BIFOVIT	BIFOVIT	BIFONAZOLE	BIFONAZOLE 1%	CREAM		Broad spectrum product for the treatment of fungal infections.
746	BIFOVIT	BIFOVIT CREAM 1% 15GR	BIFONAZOLE	BIFONAZOLE 1%	CREAM		Broad spectrum product for the treatment of fungal infections.
747	BIKTARVY	BIKTARVY	TENOFOVIR ALAFENAMIDE AS FUMARATE	TENOFOVIR ALAFENAMIDE AS FUMARATE 25MG;EMTRICITABINE 200MG;BICTEGRAVIR AS SODIUM 50MG	TABLETS	RECIEPT	Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus 1 (HIV 1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.
749	BILAXTEN	BILAXTEN	BILASTINE	BILASTINE 20MG	TABLETS	RECIEPT	Bilaxten is indicated for the symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticariai in adults and adolescents (12 years of age and over).
750	BIMATILOL	BIMATILOL TEVA	TIMOLOL AS MALEATE	TIMOLOL AS MALEATE 5MG/1ML;BIMATOPROST 0.3MG/1ML	DROPS	RECIEPT	Reduction of intraocular pressure in patients with open- angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues
752	BIMATOPROST	BIMATOPROST TEVA	BIMATOPROST	BIMATOPROST 0.3MG/1ML	SOLUTION	RECIEPT	Reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
751	BIMATOPROST S.K.	BIMATOPROST S.K.	BIMATOPROST	BIMATOPROST 0.3MG/1ML	SOLUTION	RECIEPT	Reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
754	BINOCRIT	BINOCRIT 1000 IU/ 0.5 ML	EPOETIN ALFA	EPOETIN ALFA 1000 IU/0.5ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
755	BINOCRIT	BINOCRIT 10000 I.U / 1 ML	EPOETIN ALFA	EPOETIN ALFA 10000 IU/1ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
756	BINOCRIT	BINOCRIT 2000 I.U/ 1 ML	EPOETIN ALFA	EPOETIN ALFA 2000 IU/1ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
757	BINOCRIT	BINOCRIT 20000 I.U / 0.5 ML	EPOETIN ALFA	EPOETIN ALFA 20000 IU/0.5ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
758	BINOCRIT	BINOCRIT 3000 I.U / 0.3 ML	EPOETIN ALFA	EPOETIN ALFA 3000 IU/0.3ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
759	BINOCRIT	BINOCRIT 30000 I.U/ 0.75 ML	EPOETIN ALFA	EPOETIN ALFA 30000 IU/0.75ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
760	BINOCRIT	BINOCRIT 4000 I.U/ 0.4 ML	EPOETIN ALFA	EPOETIN ALFA 4000 IU/0.4ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
761	BINOCRIT	BINOCRIT 40000 I.U / 1 ML	EPOETIN ALFA	EPOETIN ALFA 40000 IU/1ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
762	BINOCRIT	BINOCRIT 5000 I.U/ 0.5 ML	EPOETIN ALFA	EPOETIN ALFA 5000 IU/0.5ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
763	BINOCRIT	BINOCRIT 6000 I.U / 0.6 ML	EPOETIN ALFA	EPOETIN ALFA 6000 IU/0.6ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
764	BINOCRIT	BINOCRIT 8000 I.U / 0.8 ML	EPOETIN ALFA	EPOETIN ALFA 8000 IU/0.8ML	SOLUTION	RECIEPT	Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): - in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis . - in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. Binocrit is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. Hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).
765	BINOSTO	BINOSTO	ALENDRONIC ACID AS TRIHYDRATE	ALENDRONIC ACID AS TRIHYDRATE 70MG	TABLETS	RECIEPT	For the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures). Treatment to increase bone mass in men with osteoporosis
766	BIODROXIL	BIODROXIL 250 MG/5 ML	CEFADROXIL AS MONOHYDRATE	CEFADROXIL AS MONOHYDRATE 250MG/5ML	SUSPENSION	RECIEPT	Treatment of the following infections caused by cefadroxil-susceptible organisms when an oral therapy is indicated: - Streptococal pharyngitis and tonsillitis - Bronchopneumonia, bacterial pneumonia - Uncomplicated urinary tract infections: pyelonephritis, cystitis - Skin and soft tissue infections: abscesses, furunculosis, impetigo, erysipelas, pyoderma, lymphadenitis
767	BIODROXIL	BIODROXIL 500 MG	CEFADROXIL AS MONOHYDRATE	CEFADROXIL AS MONOHYDRATE 500MG	CAPSULES	RECIEPT	Treatment of the following infections caused by cefadroxil-susceptible organisms when an oral therapy is indicated: - Streptococal pharyngitis and tonsillitis - Bronchopneumonia, bacterial pneumonia - Uncomplicated urinary tract infections: pyelonephritis, cystitis - Skin and soft tissue infections: abscesses, furunculosis, impetigo, erysipelas, pyoderma, lymphadenitis
768	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE INOVAMED 10 MG	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE 10MG	TABLETS	RECIEPT	- Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides. - Hype
770	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE INOVAMED 2.5 MG	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE 2.5MG	TABLETS	RECIEPT	Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides.
772	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE INOVAMED 5 MG	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE 5MG	TABLETS	RECIEPT	- Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides. - Hype
777	BITNI	BITNI X TABLETS	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 262MG	TABLETS		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
775	BITNI	BITNI X SUSPENSION	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 262MG/15ML	SUSPENSION		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
774	BITNI	BITNI X 20 TAB	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG	TABLETS		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
776	BITNI	BITNI X SUSPENSION 100 ML	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG/15ML( 1.75% )	SUPPOSITORIES		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
778	BLASTOVIN	BLASTOVIN TEVA	VINBLASTINE SULFATE	VINBLASTINE SULFATE 1MG/1ML	SOLUTION	RECIEPT	Vinblastine has proved effective in the treatment of the following neoplasms, either alone or in conjunction with other oncolytic drugs: Frequently Responsive Malignancies : • Generalized Hodgkin's disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Non-Hodgkin's lymphoma: - Reticulum-cell sarcoma - Lymphosarcoma • Mycosis fungoides. • Neuroblastoma. • Histiocytosis X. Less Frequently Responsive Malignancies : • Choriocarcinoma resistant to other chemotherapeutic agents. • Embryonal carcinoma of the testis. • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.
779	BLEOMYCIN	BLEOMYCIN PFI	BLEOMYCIN SULFATE	BLEOMYCIN SULFATE 15000IU/VIAL	POWDER	RECIEPT	Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) . Malignant effusions of serous cavities (intrapleural and intraperitoneal). Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.
780	BLINCYTO	BLINCYTO ™	BLINATUMOMAB	BLINATUMOMAB 35MCG/1 VIAL	POWDER	RECIEPT	BLINCYTO is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). BLINCYTO is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. Limitations of use: After failure of two previous treatments and with no CNS involvement.
782	BONDORMIN	BONDORMIN	BROTIZOLAM	BROTIZOLAM 0.25MG	TABLETS	RECIEPT	Treatment of Insomnia.
784	BONSERIN	BONSERIN	MIANSERIN HYDROCHLORIDE	MIANSERIN HYDROCHLORIDE 30MG	TABLETS	RECIEPT	For the treatment of depression.
785	BOOSTRIX	BOOSTRIX	DIPHTHERIA TOXOID	DIPHTHERIA TOXOID 2 IU/0.5ML;TETANUS TOXOID 20 IU/0.5ML;FILAMENTOUS HAEMAGGLUTININ (FHA) 8MCG/0.5ML;PERTUSSIS TOXOID (PT) 8MCG/0.5ML;PERTACTIN (PRN OR 69 KDA OMP) 2.5MCG/0.5ML	SUSPENSION	RECIEPT	For Booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards. The administration of Boostrix should be based on official recommendations
786	BOOSTRIX	BOOSTRIX POLIO	PERTACTIN (PRN OR	PERTACTIN (PRN OR 69 KDA OMP) 2.5MCG/0.5ML;DIPHTHERIA TOXOID 2 IU/0.5ML;TETANUS TOXOID 20 IU/0.5ML;FILAMENTOUS HAEMAGGLUTININ (FHA) 8MCG/0.5ML;PERTUSSIS TOXOID VACCINE 8MCG/0.5ML;INACTIVATED POLIO VIRUS (IPV) TYPE 3 32DU/0.5ML;INACTIVATED POLIO VIRUS (IPV) TYPE 1 40DU/0.5ML;INACTIVATED POLIO VIRUS (IPV) TYPE 2 8DU/0.5ML	SUSPENSION	RECIEPT	For booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of three years onwards. The administration of Boostrix Polio should be based on official recommendations.
787	BORIC	BORIC ACID VITAMED	BORIC ACID	BORIC ACID 1.9%W/V	DROPS	RECIEPT	Mild antiseptic for the eyes and for the relief of mild irritation of the eyes caused by various irritants e.g. smoke, dust etc.
788	BORTEZ	BORTEZ TEVA 3.5 MG	BORTEZOMIB	BORTEZOMIB 3.5MG	POWDER	RECIEPT	Bortezo Teva is indicated for the treatment of patients with multiple myeloma. Bortezo Teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezo Teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
792	BORTEZOMIB	BORTEZOMIB TEVA 1 MG	BORTEZOMIB	BORTEZOMIB 1MG	POWDER	RECIEPT	Bortezomib Teva is indicated for the treatment of patients with multiple myeloma. Bortezomib Teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib Teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
793	BORTEZOMIB	BORTEZOMIB TEVA 2.5 MG	BORTEZOMIB	BORTEZOMIB 2.5MG	POWDER	RECIEPT	Bortezomib Teva is indicated for the treatment of patients with multiple myeloma. Bortezomib Teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib Teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
789	BORTEZOMIB	BORTEZOMIB INOVAMED 3.5 MG	BORTEZOMIB	BORTEZOMIB 3.5MG	POWDER	RECIEPT	Bortezomib is indicated for the treatment of patients with multiple myeloma. Bortezomib is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
794	BORTEZOMIB	BORTEZOMIB TEVA 3.5 MG	BORTEZOMIB	BORTEZOMIB 3.5MG	POWDER	RECIEPT	Bortezomib Teva is indicated for the treatment of patients with multiple myeloma. Bortezomib Teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib Teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
791	BORTEZOMIB	BORTEZOMIB TARO 3.5 MG	BORTEZOMIB	BORTEZOMIB 3.5MG/VIAL	POWDER	RECIEPT	Bortezomib is indicated for the treatment of patients with multiple myeloma. Bortezomib is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
790	BORTEZOMIB	BORTEZOMIB S.K. 3.5 MG	BORTEZOMIB AS MANNITOL BORONIC ESTER	BORTEZOMIB AS MANNITOL BORONIC ESTER 3.5MG	POWDER	RECIEPT	Multiple Myeloma BORTEZOMIB S.K is indicated for the treatment of patients with multiple myeloma. Mantle Cell Lymphoma BORTEZOMIB S.K is indicated for the treatment of patients with mantle cell Lymphoma who have received at least one prior therapy. BORTEZOMIB S.K in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
795	BOSENTAN	BOSENTAN TEVA 125 MG	BOSENTAN AS MONOHYDRATE	BOSENTAN AS MONOHYDRATE 125MG	TABLETS	RECIEPT	Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV. Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease.
796	BOSENTAN	BOSENTAN TEVA 62.5 MG	BOSENTAN AS MONOHYDRATE	BOSENTAN AS MONOHYDRATE 62.5MG	TABLETS	RECIEPT	Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV. Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease.
797	BOSULIF	BOSULIF 100 MG	BOSUTINIB	BOSUTINIB 100MG	TABLETS	RECIEPT	Bosulif is indicated for the treatment of adult patients with: • newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML). • chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
798	BOSULIF	BOSULIF 500 MG	BOSUTINIB	BOSUTINIB 500MG	TABLETS	RECIEPT	Bosulif is indicated for the treatment of adult patients with: • newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML). • chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
799	BOTOX	BOTOX 100	BOTULINUM A TOXIN	BOTULINUM A TOXIN 100UNITS	POWDER	RECIEPT	Neurologic disorders: • Focal spasticity associated with dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients two years of age or older. • Focal spasticity of the wrist and hand in adult post stroke patients Focal spasticity of the ankle in adult post stroke patients, 6 months post stroke • Blepharospasm or VII nerve disorders in patients over 12 years, hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. • Reduction of the signs and symptoms of Cervical dystonia (spasmodic torticollis) in adults. • Symptom relief in adults fulfilling criteria for chronic migraine (headaches on ≥15 days per month of which at least 8 days with migraine) in patients who have responded inadequately or are intolerant of prophylactic migraine medications . Bladder disorders: • Management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medication. • Urinary incontinence in adults with neurogenic detrusor overactivity resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis. Skin and skin appendage disorder: • Management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment. • In adult patients aged 65 years or less, BOTOX is indicated for the temporary improvement in the appearance of: moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines).
800	BOTOX	BOTOX 200	BOTULINUM A TOXIN	BOTULINUM A TOXIN 200U/VIAL	POWDER	RECIEPT	Neurologic disorders: • Focal spasticity associated with dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients two years of age or older. • Focal spasticity of the wrist and hand in adult post stroke patients Focal spasticity of the ankle in adult post stroke patients, 6 months post stroke • Blepharospasm or VII nerve disorders in patients over 12 years, hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. • Reduction of the signs and symptoms of Cervical dystonia (spasmodic torticollis) in adults. • Symptom relief in adults fulfilling criteria for chronic migraine (headaches on ≥15 days per month of which at least 8 days with migraine) in patients who have responded inadequately or are intolerant of prophylactic migraine medications . Bladder disorders: • Management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medication. • Urinary incontinence in adults with neurogenic detrusor overactivity resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis. Skin and skin appendage disorder: • Management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment. • In adult patients aged 65 years or less, BOTOX is indicated for the temporary improvement in the appearance of: moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines).
801	BOTOX	BOTOX 50	BOTULINUM A TOXIN	BOTULINUM A TOXIN 50UNITS	POWDER	RECIEPT	Neurologic disorders: • Focal spasticity associated with dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients two years of age or older. • Focal spasticity of the wrist and hand in adult post stroke patients Focal spasticity of the ankle in adult post stroke patients, 6 months post stroke . • Blepharospasm or VII nerve disorders in patients over 12 years, hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. • Reduction of the signs and symptoms of Cervical dystonia (spasmodic torticollis) in adults. • Symptom relief in adults fulfilling criteria for chronic migraine (headaches on ≥15 days per month of which at least 8 days with migraine) in patients who have responded inadequately or are intolerant of prophylactic migraine medications . Bladder disorders • Management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medication. • Urinary incontinence in adults with neurogenic detrusor overactivity resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis. Skin and skin appendage disorder: • Management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment. •In adult patients aged 65 years or less, BOTOX is indicated for the temporary improvement in the appearance of: • moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) • moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile, when the severity of these lines has an important psychological impact for the patient, • moderate to severe crow’s feet lines seen at maximum smile, when the severity of these lines has an important psychological impact for the patient, and glabellar lines seen at maximum frown when treated simultaneously.
803	BRAMITOB	BRAMITOB	TOBRAMYCIN	TOBRAMYCIN 300MG/4ML	SOLUTION	RECIEPT	Management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients with cystic fibrosis aged 6 years and older.
820	BREAKYL	BREAKYL 1200 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 1200MCG	BUCCAL FILM	RECIEPT	Breakyl is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.
821	BREAKYL	BREAKYL 200 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 200MCG	BUCCAL FILM	RECIEPT	Breakyl is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.
822	BREAKYL	BREAKYL 400 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 400MCG	BUCCAL FILM	RECIEPT	Breakyl is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.
823	BREAKYL	BREAKYL 600 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 600MCG	BUCCAL FILM	RECIEPT	Breakyl is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.
824	BREAKYL	BREAKYL 800 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 800MCG	BUCCAL FILM	RECIEPT	Breakyl is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.
825	BRENZYS	BRENZYS 50 MG/ML	ETANERCEPT	ETANERCEPT 50MG/ML	SOLUTION	RECIEPT	Rheumatoid arthritis Treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate. Brenzys can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Brenzys, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Brenzys has not been studied in children aged less than 2 years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis (AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Non-radiographic axial spondyloarthritis Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). Plaque psoriasis Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Paediatric plaque psoriasis Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
826	BREXIN	BREXIN SACHETS	PIROXICAM AS BETA-CYCLODEXTRIN	PIROXICAM AS BETA-CYCLODEXTRIN 20MG	POWDER	RECIEPT	Piroxicam is indicated for symptomatic relief of osteoarthritis rheumatoid arthritis or ankylosing spondylitis. When an NSAID is indicated piroxicam should be considered as a second line option. The desicion to prescribe piroxocam should be based on an assesment of the individual's patient overall risk
827	BREXIN	BREXIN TABLETS	PIROXICAM AS BETA-CYCLODEXTRIN	PIROXICAM AS BETA-CYCLODEXTRIN 20MG	TABLETS	RECIEPT	Piroxicam is indicated for symptomatic relief of osteoarthritis rheumatoid arthritis or ankylosing spondylitis. When an NSAID is indicated piroxicam should be considered as a second line option. The desicion to prescribe piroxocam should be based on an assesment of the individual's patient overall risk.
828	BRICALIN	BRICALIN TURBUHALER	TERBUTALINE SULFATE	TERBUTALINE SULFATE 0.5MG/DOSE	POWDER	RECIEPT	For the relief of bronchospasm in patients with reversible onbstructive airway disease, including asthma, chronic bronchitis and emphysema.
830	BRIDION	BRIDION	SUGAMMADEX	SUGAMMADEX 100MG/ML	SOLUTION	RECIEPT	Reversal of neuromuscular blockade induced by rocuronium or vecuronium.
832	BRILINTA	BRILINTA 60 MG	TICAGRELOR	TICAGRELOR 60MG	TABLETS	RECIEPT	Brilinta, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (ACS) or - a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1). Limitations of use: 90 mg twice daily during the first year after an ACS event followed by 60 mg twice daily for additional 2 years.
833	BRILINTA	BRILINTA 90 MG	TICAGRELOR	TICAGRELOR 90MG	TABLETS	RECIEPT	Brilinta, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (ACS) or - a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1). Limitations of use: 90 mg twice daily during the first year after an ACS event followed by 60 mg twice daily for additional 2 years.
834	BRIMONIDINE	BRIMONIDINE TEVA	BRIMONIDINE TARTRATE	BRIMONIDINE TARTRATE 0.15%W/V	SOLUTION	RECIEPT	For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
835	BRINAVESS	BRINAVESS 20 MG/ML	VERNAKALANT HYDROCHLORIDE	VERNAKALANT HYDROCHLORIDE 20MG/ML	CONCENTRATE	RECIEPT	Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults who are hemodynamically stable. - For non-surgery patients: atrial fibrillation ≤ 7 days duration - For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration
836	BRINTELLIX	BRINTELLIX 10 MG	VORTIOXETINE AS HYDROBROMIDE	VORTIOXETINE AS HYDROBROMIDE 10MG	TABLETS	RECIEPT	Brintellix is indicated for the treatment of major depressive episodes in adults.
838	BRINTELLIX	BRINTELLIX 15 MG	VORTIOXETINE AS HYDROBROMIDE	VORTIOXETINE AS HYDROBROMIDE 15MG	TABLETS	RECIEPT	Brintellix is indicated for the treatment of major depressive episodes in adults.
840	BRINTELLIX	BRINTELLIX 20 MG	VORTIOXETINE AS HYDROBROMIDE	VORTIOXETINE AS HYDROBROMIDE 20MG	TABLETS	RECIEPT	Brintellix is indicated for the treatment of major depressive episodes in adults.
842	BRINTELLIX	BRINTELLIX 5 MG	VORTIOXETINE AS HYDROBROMIDE	VORTIOXETINE AS HYDROBROMIDE 5MG	TABLETS	RECIEPT	Brintellix is indicated for the treatment of major depressive episodes in adults.
844	BRINZOLAMIDE	BRINZOLAMIDE SK	BRINZOLAMIDE	BRINZOLAMIDE 10MG/ML	SUSPENSION	RECIEPT	Brinzolamide S.K. is indicated to decrease elevated intraocular pressure in: ocular hypertension open-angle glaucoma as monotherapy in patients unresponsive to beta-blockers or in patients in whom beta-blockers are contra-indicated or as adjunctive therapy to beta-blockers.
847	BRIVIACT	BRIVIACT 100 MG FILM COATED TABLETS	BRIVARACETAM	BRIVARACETAM 100MG	TABLETS	RECIEPT	Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
845	BRIVIACT	BRIVIACT 10 MG FILM COATED TABLETS	BRIVARACETAM	BRIVARACETAM 10MG	TABLETS	RECIEPT	Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
846	BRIVIACT	BRIVIACT 10 MG/ML SOLUTION FOR INJECTION/INFUSION	BRIVARACETAM	BRIVARACETAM 10MG/1ML	SOLUTION	RECIEPT	Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
851	BRIVIACT	BRIVIACT ORAL SOLUTION	BRIVARACETAM	BRIVARACETAM 10MG/1ML	SOLUTION	RECIEPT	Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
848	BRIVIACT	BRIVIACT 25 MG FILM COATED TABLETS	BRIVARACETAM	BRIVARACETAM 25MG	TABLETS	RECIEPT	Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.mg/kg/day.
849	BRIVIACT	BRIVIACT 50 MG FILM COATED TABLETS	BRIVARACETAM	BRIVARACETAM 50MG	TABLETS	RECIEPT	Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
850	BRIVIACT	BRIVIACT 75 MG FILM COATED TABLETS	BRIVARACETAM	BRIVARACETAM 75MG	TABLETS	RECIEPT	Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
854	BRONCHICLEAR	BRONCHICLEAR 20 TAB	PRIMULA ROOT	PRIMULA ROOT (6;7:1);ETHANOL 47.4% (V/V) 60MG;THYME HERB (6;10:1);ETHANOL 70.0% (V/V) 160MG	TABLETS		For the relief of symptoms in acute bronchitis with coughs and colds associated with viscous mucus in children from 12 years of age, adolescents and adults.
853	BRONCHICLEAR	BRONCHICLEAR	PRIMULA ROOT	PRIMULA ROOT DRY EXTRACT (6-7:1);EXTRACTING AGENT : ETHANOL 47.4% (V/V) 60MG;THYME HERB DRY EXTRACT (6-10:1);EXTRACTING AGENT: ETHANOL 70.0% (V/V) 160MG	TABLETS		For the relief of symptoms in acute bronchitis with coughs and colds associated with viscous mucus in children from 12 years of age, adolescents and adults.
855	BRONCHITOL	BRONCHITOL	MANNITOL	MANNITOL 40MG	POWDER	RECIEPT	Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.
857	BRONCHO	BRONCHO D SYROP 120ML	DIPHENHYDRAMINE HCL	DIPHENHYDRAMINE HCL 10MG/5ML;AMMONIUM CHLORIDE 136MG/5ML	SYRUP		Symptomatic relief of nasal congestion. Symptomatic relief of eustachian tube congestion in ear inflammation. Symptomatic relief of cough.
858	BRONCHO	BRONCHO KID SYROP 120ML	DIPHENHYDRAMINE HCL	DIPHENHYDRAMINE HCL 10MG/5ML;PSEUDOEPHEDRINE HCL 20MG/5ML	SYRUP	RECIEPT	Symptomatic relief of nasal congestion. Symptomatic relief of eustachian tube congestion in ear inflammation. Symptomatic relief of cough.
856	BRONCHO	BRONCHO D	DIPHENHYDRAMINE HYDROCHLORIDE	DIPHENHYDRAMINE HYDROCHLORIDE 10MG/5ML;AMMONIUM CHLORIDE 136MG/5ML	SYRUP		For the relief of coughs and congestion in the respiratory tract.
859	BRONCHO	BRONCHO-KID SYRUP	PSEUDOEPHEDRINE HYDROCHLORIDE	PSEUDOEPHEDRINE HYDROCHLORIDE 20MG/5ML;DIPHENHYDRAMINE HYDROCHLORIDE 10MG/5ML	SYRUP	RECIEPT	Symptomatic relief of nasal congestion or auditory canal congestion in ear infections. Symptomatic relief of cough.
860	BRONCHOLATE	BRONCHOLATE FORTE	CODEINE PHOSPHATE	CODEINE PHOSPHATE 5MG/5ML;PSEUDOEPHEDRINE HYDROCHLORIDE 20MG/5ML;DIPHENHYDRAMINE HYDROCHLORIDE 10MG/5ML	SYRUP	RECIEPT	Symptomatic relief of cough accompanied by nasal congestion or auditory canal congestion in ear infections.
864	BRONCHOLATE	BRONCHOLATE SYRUP 120ML	DIPHENHYDRAMINE HCL	DIPHENHYDRAMINE HCL 10MG/5ML;PSEUDOEPHEDRINE HCL 20MG/5ML	SYRUP	RECIEPT	Symptomatic relief of nasal congestion. Symptomatic relief of eustachian tube congestion in ear inflammation. Symptomatic relief of cough.
863	BRONCHOLATE	BRONCHOLATE SYRUP	DIPHENHYDRAMINE HYDROCHLORIDE	DIPHENHYDRAMINE HYDROCHLORIDE 0.2%W/V;PSEUDOEPHEDRINE HYDROCHLORIDE 0.4%W/V	SYRUP	RECIEPT	Symptomatic relief of nasal congestion. Symptomatic relief of eustachian tube congestion in ear inflammation. Symptomatic relief of cough.
862	BRONCHOLATE	BRONCHOLATE PLUS 20TAB	PARACETAMOL	PARACETAMOL 400MG;DIPHENHYDRAMINE HCL 30MG;PSEUDOEPHEDRINE HCL 20MG	TABLETS	RECIEPT	Symptomatic relief of cold, cough, nasal congestion and auditory canal congestion accompanied by fever and pain.
861	BRONCHOLATE	BRONCHOLATE PLUS	PARACETAMOL	PARACETAMOL 400MG;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG;DIPHENHYDRAMINE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Symptomatic relief of cold, cough, nasal congestion and auditory canal congestion accompanied by fever and pain.
865	BROTIZOLAM	BROTIZOLAM TEVA 0.25 MG	BROTIZOLAM	BROTIZOLAM 0.25MG	TABLETS	RECIEPT	For the treatment of insomnia.
867	BUCCOLAM	BUCCOLAM 10 MG	MIDAZOLAM AS HYDROCHLORIDE	MIDAZOLAM AS HYDROCHLORIDE 10MG	SOLUTION	RECIEPT	Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). Buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available
868	BUCCOLAM	BUCCOLAM 2.5 MG	MIDAZOLAM AS HYDROCHLORIDE	MIDAZOLAM AS HYDROCHLORIDE 2.5MG	SOLUTION	RECIEPT	Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). Buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.
869	BUCCOLAM	BUCCOLAM 5 MG	MIDAZOLAM AS HYDROCHLORIDE	MIDAZOLAM AS HYDROCHLORIDE 5MG	SOLUTION	RECIEPT	Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). Buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.
870	BUCCOLAM	BUCCOLAM 7.5 MG	MIDAZOLAM AS HYDROCHLORIDE	MIDAZOLAM AS HYDROCHLORIDE 7.5MG	SOLUTION	RECIEPT	Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). Buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.
871	BUDESON	BUDESON 3 MG CAPSULES	BUDESONIDE	BUDESONIDE 3MG	CAPSULES	RECIEPT	Acute mild to moderate Crohn’s disease with involvement of the ileum (twisted intestine) and/or ascending colon (part of large bowel). Collagenous colitis. Autoimmune hepatitis.
873	BUDESON	BUDESON 9 MG GRANULES	BUDESONIDE	BUDESONIDE 9MG	GRANULES	RECIEPT	Acute mild to moderate Crohn’s disease with involvement of the ileium (twisted intestine) and/or ascending colon (part of large bowel). Collagenous colitis.
876	BUDESONIDE	BUDESONIDE STERINEBS TEVA 0.5 MG/2 ML	BUDESONIDE	BUDESONIDE 0.25MG/1ML	SUSPENSION	RECIEPT	Bronchial asthma especially in cases where other therapy is insufficient or insuitable.
877	BUDESONIDE	BUDESONIDE STERINEBS TEVA 1 MG/2 ML	BUDESONIDE	BUDESONIDE 0.5MG/1ML	SUSPENSION	RECIEPT	Bronchial asthma especially in cases where other therapy is insufficient of unsuitable.
878	BUDICORT	BUDICORT RESPULES 0.5 MG/2 ML	BUDESONIDE	BUDESONIDE 0.5MG	SUSPENSION	RECIEPT	Bronchial asthma, especially in cases where other therapy is insufficient or unsuitable.
880	BUDICORT	BUDICORT TURBUHALER 100 MCG/DOSE	BUDESONIDE	BUDESONIDE 100MCG/DOSE	POWDER	RECIEPT	Bronchial asthma.
879	BUDICORT	BUDICORT RESPULES 1 MG/2ML	BUDESONIDE	BUDESONIDE 1MG	SUSPENSION	RECIEPT	Bronchial asthma, especially in cases where other therapy is insufficient or unsuitable.
881	BUDICORT	BUDICORT TURBUHALER 200 MCG/DOSE	BUDESONIDE	BUDESONIDE 200MCG/DOSE	POWDER	RECIEPT	Bronchial asthma.
883	BUPIVACAINE	BUPIVACAINE BAXTER 5 MG/ML	BUPIVACAINE AS HYDROCHLORIDE ANHYDROUS	BUPIVACAINE AS HYDROCHLORIDE ANHYDROUS 5MG/1ML	SOLUTION	RECIEPT	Long acting local anaesthetic.
884	BUSULFEX	BUSULFEX	BUSULFAN	BUSULFAN 60MG/10ML	SOLUTION	RECIEPT	For use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.
886	BUTAMINE	BUTAMINE 12.5 MG/ML	DOBUTAMINE AS HYDROCHLORIDE	DOBUTAMINE AS HYDROCHLORIDE 250MG/20ML	SOLUTION	RECIEPT	Dobutamine is indicated for patients who require a positive inotropic support in the short term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures, especially when a low cardiac output is associated with raised pulmonary pressure
888	BUTRANS	BUTRANS 10	BUPRENORPHINE	BUPRENORPHINE 10MG	PATCHES	RECIEPT	Treatment of moderate to severe opioid responsive chronic pain conditions which are not adequately responding to non-opioid analgesics.
889	BUTRANS	BUTRANS 15	BUPRENORPHINE	BUPRENORPHINE 15MG	PATCHES	RECIEPT	Treatment of moderate to severe opioid responsive chronic pain conditions which are not adequately responding to non-opioid analgesics.
890	BUTRANS	BUTRANS 20	BUPRENORPHINE	BUPRENORPHINE 20MG	PATCHES	RECIEPT	Treatment of moderate to severe opioid responsive chronic pain conditions which are not adequately responding to non-opioid analgesics.
891	BUTRANS	BUTRANS 5	BUPRENORPHINE	BUPRENORPHINE 5MG	PATCHES	RECIEPT	Treatment of moderate to severe opioid responsive chronic pain conditions which are not adequately responding to non-opioid analgesics.
892	BYDUREON	BYDUREON 2 MG	EXENATIDE	EXENATIDE 2MG	POWDER	RECIEPT	Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with : • Metformin • Sulphonylurea • Metformin and sulphonylurea in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control .
894	C13 UREA	C13 - UREA	UREA	UREA- C 13 75MG	TABLETS	RECIEPT	Intended for use in the qualitative detection of urease associated with H. Pylory in the human stomach and as an aid in the initial diagnosis and post treatment monitoring of H. Pylory infection in adult patients.
895	CABOMETYX	CABOMETYX 20 MG	CABOZANTINIB (S) MALATE	CABOZANTINIB (S) MALATE 20MG	TABLETS	RECIEPT	Renal Cell Carcinoma (RCC) CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC): - in treatment-naïve adults with intermediate or poor risk, per IMDC criteria. - in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Hepatocellular Carcinoma (HCC) CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC), in adults with Child-Pugh Class A hepatic impairment who have previously been treated with sorafenib.
896	CABOMETYX	CABOMETYX 40 MG	CABOZANTINIB (S) MALATE	CABOZANTINIB (S) MALATE 40MG	TABLETS	RECIEPT	Renal Cell Carcinoma (RCC) CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC): - in treatment-naïve adults with intermediate or poor risk, per IMDC criteria. - in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Hepatocellular Carcinoma (HCC) CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC), in adults with Child-Pugh Class A hepatic impairment who have previously been treated with sorafenib.
897	CABOMETYX	CABOMETYX 60 MG	CABOZANTINIB (S) MALATE	CABOZANTINIB (S) MALATE 60MG	TABLETS	RECIEPT	Renal Cell Carcinoma (RCC) CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC): - in treatment-naïve adults with intermediate or poor risk, per IMDC criteria. - in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Hepatocellular Carcinoma (HCC) CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC), in adults with Child-Pugh Class A hepatic impairment who have previously been treated with sorafenib.
898	CABOTRIM	CABOTRIM 0.5	CABERGOLINE	CABERGOLINE 0.5MG	TABLETS	RECIEPT	Treatment of hyperprolactinemic disorders. Cabotrim is indicated for the treatment of dysfunctions associated with hyperprolactinemia, including amenorrhea, oligomenorrhea, anovulation and galactorrhea. Cabotrim is indicated in patients with prolactin-secreting pituitary adenomas (micro-and macroprolactinomas), idiopathic hyperprolactinemia, or empty sella syndrome with associated hyperprolactinemia. Inhibition and supression of lactation .
899	CABOTRIM	CABOTRIM 2	CABERGOLINE	CABERGOLINE 2MG	TABLETS	RECIEPT	Parkinson's disease. Combination therapy with L-dopa and as monotherapy for newly diagnosed illness.
900	CADEX	CADEX 1 MG	DOXAZOSIN AS MESYLATE	DOXAZOSIN AS MESYLATE 1MG	TABLETS	RECIEPT	Antihypertensive agent. For the treatment of benign prostatic hyperthropy.
901	CADEX	CADEX 2 MG	DOXAZOSIN AS MESYLATE	DOXAZOSIN AS MESYLATE 2MG	TABLETS	RECIEPT	Antihypertensive agent. For the treatment of benign prostatic hyperthropy.
902	CADEX	CADEX 4 MG	DOXAZOSIN AS MESYLATE	DOXAZOSIN AS MESYLATE 4MG	TABLETS	RECIEPT	Antihypertensive agent. For the treatment of benign prostatic hyperthropy.
903	CAELYX	CAELYX	DOXORUBICIN HYDROCHLORIDE	DOXORUBICIN HYDROCHLORIDE 2.0MG/ML	CONCENTRATE	RECIEPT	First or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease The treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. Refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. As monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. In combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
906	CALAMINE	CALAMINE LOT 100ML	CALAMINE	CALAMINE 15%;ZINC OXIDE 5%	LOTION		Relief of skin irritation.
907	CALAMINE	CALAMINE LOTION 100ML	CALAMINE	CALAMINE 15%;ZINC OXIDE 5%	LOTION		Relief of skin irritation.
908	CALAMINE	CALAMINE LOTION FLORIS	CALAMINE	CALAMINE 15%;ZINC OXIDE 5%	LOTION		For relief of skin irritations.
909	CALAMINE	CALAMINE LOTION VITAMED	CALAMINE	CALAMINE 15%;ZINC OXIDE 5%	LOTION		Relief of skin irritation.
912	CALCILESS	CALCILESS TABLETS	SODIUM PHOSPHATE DIBASIC	SODIUM PHOSPHATE DIBASIC 285MG;POTASSIUM PHOSPHATE MONOBASIC 602MG	TABLETS	RECIEPT	Prevention and treatment of calcium oxalate stones.
914	CALCIMORE	CALCIMORE	CALCIUM CARBONATE	CALCIUM CARBONATE 600MG	TABLETS		Antacid, calcium deficiency.
915	CALCIMORE	CALCIMORE 60TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 600MG	TABLETS		Antacid, calcium deficiency.
921	CALCIUM	CALCIUM SOURCE 500 MG	CALCIUM (AS LACTATE GLUCONATE)	CALCIUM (AS LACTATE GLUCONATE) 149.7MG;CALCIUM (AS CARBONATE) 350.3MG	TABLETS		Oral calcium therapy.
920	CALCIUM	CALCIUM SANDOZ 500MG 20T EFF	CALCIUM CARBONATE	CALCIUM CARBONATE 500MG	TABLETS		Antacid.
919	CALCIUM	CALCIUM GLUCONATE 10 % INJECTION B.P.	CALCIUM GLUCONATE	CALCIUM GLUCONATE 0.94G/10ML	SOLUTION	RECIEPT	Treatment of acute symptomatic hypocalcaemia.
918	CALCIUM	CALCIUM GLUCONATE - FRESENIUS	CALCIUM GLUCONATE	CALCIUM GLUCONATE 902.5MG/10ML	SOLUTION	RECIEPT	All conditions where injectable calcium supplement is indicated.
916	CALCIUM	CALCIUM - D - SOURCE	CALCIUM LACTATE GLUCONATE	CALCIUM LACTATE GLUCONATE 1358MG;CALCIUM CARBONATE 1050MG;COLECALCIFEROL 4MG	TABLETS		Calcium and Vitamin D supplement. Calcium helps in the maintenance of bones and teeth. Vitamin D helps in the absorption and use of calcium.
917	CALCIUM	CALCIUM D SANDOZ 60 TAB EFF	CHOLECALCIFEROL	CHOLECALCIFEROL 4MG;CALCIUM GLUCONATE 1358MG;CALCIUM CARBONATE 1050MG	TABLETS		Vitamin D deficiency. Calcium deficiency.
926	CALMANERVIN	CALMANERVIN ELIXIR 120 ML	PASSIFLORA LIQ. EXTR.	PASSIFLORA LIQ. EXTR. 50MG/ML (5%);VALERIAN LIQUID 12MG/ML (1.2%)	LIQUID		Sedative in states of tension, nervousness and insomnia.
927	CALMANERVIN	CALMANERVIN S ELIXIR	PASSIFLORA LIQ. EXTR.	PASSIFLORA LIQ. EXTR. 50MG/ML;VALERIAN LIQUID EXTRACT 12MG/ML	LIQUID		Sedative in states of tension, nervousness and insomnia.
928	CALMANERVIN	CALMANERVIN TABLETS	THIAMINE (VIT B1)	THIAMINE (VIT B1) 10MG MONONITRATE;PASSIFLORA 250MG;VALERIAN DRY EXTRACT 60MG;PYRIDOXINE (VIT B6) HYDROCHLORIDE 10MG	TABLETS		Sedative in states of tension, nervousness and insomnia.
923	CALMANERVIN	CALMANERVIN 10TAB	THIAMINE (VIT B1)	THIAMINE (VIT B1) 10MG;VALERIAN 60MG;PASSIFLORA 250MG;PYRIDOXINE (VIT B6) 10MG	TABLETS		Sedative in states of tension, nervousness and insomnia.
924	CALMANERVIN	CALMANERVIN 20TAB	THIAMINE (VIT B1)	THIAMINE (VIT B1) 10MG;VALERIAN 60MG;PASSIFLORA 250MG;PYRIDOXINE (VIT B6) 10MG	TABLETS		Sedative in states of tension, nervousness and insomnia.
925	CALMANERVIN	CALMANERVIN 30TAB	THIAMINE (VIT B1)	THIAMINE (VIT B1) 10MG;VALERIAN 60MG;PASSIFLORA 250MG;PYRIDOXINE (VIT B6) 10MG	TABLETS		Sedative in states of tension, nervousness and insomnia.
929	CALQUENCE	CALQUENCE	ACALABRUTINIB	ACALABRUTINIB 100MG	CAPSULES	RECIEPT	CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
930	CAMBRIDGE LIDOCAINE WITH EPINEPHRINE	CAMBRIDGE LIDOCAINE WITH EPINEPHRINE 100	LIDOCAINE HYDROCHLORIDE ( AS MONOHYDRATE)	LIDOCAINE HYDROCHLORIDE ( AS MONOHYDRATE) 20MG/ML;EPINEPHRINE AS BITARTRATE 0.01MG/ML	SOLUTION	RECIEPT	Production of local anesthesia by nerve block or infiltration technique.
932	CAMPTO	CAMPTO	IRINOTECAN HYDROCHLORIDE	IRINOTECAN HYDROCHLORIDE 20MG/ML	SOLUTION	RECIEPT	Campto is indicated for the treatment of patients with metastatic colorectal cancer: In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. For the treatment of patients with small cell lung cancer. For the treatment of patients with gastric cancer. Irinotecan in combination with leucovorin, Oxaliplatin and 5-fluorouracil for the first-line treatment of patients with metastatic pancreatic adenocarcinoma.
934	CANCIDAS	CANCIDAS 50 MG	CASPOFUNGIN AS ACETATE	CASPOFUNGIN AS ACETATE 50MG/VIAL	POWDER	RECIEPT	Cancidas is indicated in adults and pediatric patients (3 months and older) for: - Empirical therapy for presumed fungal infections in febrile, neutropenic patients. - Treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. Cancidas has not been studied in endocarditis, ostemyelitis, and meningitis due to Candida. - Treatment of esophageal candidiasis. - Treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). Cancidas has not been studied as initial therapy for invasive aspergillosis.
935	CANCIDAS	CANCIDAS 70 MG	CASPOFUNGIN AS ACETATE	CASPOFUNGIN AS ACETATE 70MG/VIAL	POWDER	RECIEPT	Cancidas is indicated in adults and pediatric patients (3 months and older) for: - Empirical therapy for presumed fungal infections in febrile, neutropenic patients. - Treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. Cancidas has not been studied in endocarditis, ostemyelitis, and meningitis due to Candida. - Treatment of esophageal candidiasis. - Treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). Cancidas has not been studied as initial therapy for invasive aspergillosis.
936	CANDOR	CANDOR 16	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL 16MG	TABLETS	RECIEPT	Hypertension. Treatment of patients with heart failure and impaired left ventricle systolic function (left ventricular ejection fraction < or = 40 % ) as add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated
937	CANDOR	CANDOR 8	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL 8MG	TABLETS	RECIEPT	Hypertension. Treatment of patients with heart failure and impaired left ventricle systolic function (left ventricular ejection fraction < or = 40 % ) as add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated
938	CANDOR	CANDOR PLUS	HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE 12.5MG;CANDESARTAN CILEXETIL 16MG	TABLETS	RECIEPT	Essential hypertension, where monotherapy with candesartan cilexetil or hydrochlorothiazide is not sufficient
939	CANESTEN	CANESTEN CREAM	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	For the treatment of fungal infections of the skin and mucosa caused by dermatophytes, yeasts, moulds and other fungi such as Malassezia furfur as well as skin infections caused by Corynebacterium minutissimum. Indicated also for Candida vulvitis and Candida balanitis.
940	CANESTEN	CANESTEN CREAM 1% 20GR	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	For the treatment of fungal infections of the skin and mucosa caused by dermatophytes, yeasts, moulds and other fungi such as Malassezia furfur as well as skin infections caused by Corynebacterium minutissimum. Indicated also for Candida vulvitis and Candida balanitis.
941	CANESTEN	CANESTEN V	CLOTRIMAZOLE	CLOTRIMAZOLE 200MG	TABLETS	RECIEPT	Infections in external female genital organs and vagina caused by clotrimazole-sensitive microorganisms such as fungi (Candida albicans) and Trichomonas. During treatment of vaginitis caused by Trichomonas, Canesten V must be combined with an oral trichomonacide (e.g metronidazole).
944	CANESTEN	CANESTEN V 200MG 3 VAG. TAB	CLOTRIMAZOLE	CLOTRIMAZOLE 200MG	TABLETS	RECIEPT	Infections in external female genital organs and vagina caused by clotrimazole-sensitive microorganisms such as fungi (Candida albicans) and Trichomonas. During treatment of vaginitis caused by Trichomonas, Canesten V must be combined with an oral trichomonacide (e.g metronidazole).
948	CAPASAL	CAPASAL SHAMPOO 250 ML	SALICYLIC ACID	SALICYLIC ACID 0.5%;COCONUT OIL 1%;COAL TAR DISTILLED 1%	LIQUID		Treatment of dry scaly scalp conditions such as seborrheic eczema, seborrheic dermatitis, psoriasis, dandruff and cradle cap in children.
949	CAPASAL	CAPASAL THERAPEUTIC SHAMPOO	SALICYLIC ACID	SALICYLIC ACID 0.5%;COCONUT OIL 1%;COAL TAR DISTILLED 1%	SHAMPOO	RECIEPT	Treatment of dry scaly scalp conditions such as seborrheic eczema, seborrheic dermatitis, psoriasis, dandruff and cradle cap in children.
955	CAPD	CAPD 4 PERITONEAL DIALYSIS SOLUTION	CALCIUM CHLORIDE	CALCIUM CHLORIDE 0.2573G/L;SODIUM CHLORIDE 5.786G/L;GLUCOSE AS MONOHYDRATE 25G/L;LACTIC ACID AS SODIUM 3.925G/L;MAGNESIUM CHLORIDE 0.1017G/L	SOLUTION	RECIEPT	For use in patients with end-stage (decompensated) chronic renal failure of any origin being maintained on peritoneal dialysis.
954	CAPD	CAPD 3 PERITONEAL DIALYSIS SOLUTION	LACTIC ACID AS SODIUM	LACTIC ACID AS SODIUM 3.925G/L;CALCIUM CHLORIDE 0.2573G/L;GLUCOSE AS MONOHYDRATE 46.75G/L;MAGNESIUM CHLORIDE 0.1017G/L;SODIUM CHLORIDE 5.786G/L	SOLUTION	RECIEPT	For use in patients with end-stage (decompensated) chronic renal failure of any origin being maintained on peritoneal dialysis.
953	CAPD	CAPD 2 PERITONEAL DIALYSIS SOLUTION	MAGNESIUM CHLORIDE	MAGNESIUM CHLORIDE 0.1017G/L;SODIUM CHLORIDE 5.786G/L;CALCIUM CHLORIDE 0.2573G/L;GLUCOSE AS MONOHYDRATE 16.5G/L;LACTIC ACID AS SODIUM 3.925G/L	SOLUTION	RECIEPT	For use in patients with end-stage (decompensated) chronic renal failure of any origin being maintained on peritoneal dialysis.
950	CAPD	CAPD 17 SOLUTION FOR PERITONEAL DIALYSIS	MAGNESIUM CHLORIDE	MAGNESIUM CHLORIDE 0.1017G;CALCIUM CHLORIDE 0.1838G;GLUCOSE AS MONOHYDRATE 16.5G;LACTIC ACID AS SODIUM 3.925G;SODIUM CHLORIDE 5.786G	SOLUTION	RECIEPT	For use in patients with end-stage (decompensated) chronic renal failure of any origin which can be treated with peritoneal dialysis.
952	CAPD	CAPD 19 SOLUTION FOR PERITONEAL DIALYSIS	MAGNESIUM CHLORIDE	MAGNESIUM CHLORIDE 0.1017G;GLUCOSE AS MONOHYDRATE 25G;CALCIUM CHLORIDE 0.1838G;SODIUM CHLORIDE 5.786G;LACTIC ACID AS SODIUM 3.925G	SOLUTION	RECIEPT	For use in patients with end-stage (decompensated) chronic renal failure of any origin which can be treated with peritoneal dialysis.
951	CAPD	CAPD 18 SOLUTION FOR PERITONEAL DIALYSIS	SODIUM CHLORIDE	SODIUM CHLORIDE 5.786G;LACTIC ACID AS SODIUM 3.925G;GLUCOSE AS MONOHYDRATE 46.75G;CALCIUM CHLORIDE 0.1838G;MAGNESIUM CHLORIDE 0.1017G	SOLUTION	RECIEPT	For use in patients with end-stage (decompensated) chronic renal failure of any origin which can be treated with peritoneal dialysis.
959	CAPECITABINE	CAPECITABINE TEVA 150 MG	CAPECITABINE	CAPECITABINE 150MG	TABLETS	RECIEPT	Adjuvant Colon Cancer: Capecitabine Teva is indicated for the adjuvant treatment of patients following surgery of stage III (Dukesע stage C) colon cancer. Colorectal Cancer: Capecitabine Teva is indicated for the treatment of patients with advanced or metastatic colorectal cancer. Advanced gastric cancer: Capecitabine Teva is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. Breast Cancer Combination Therapy: Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Breast Cancer Monotherapy: Capecitabine Teva is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.
956	CAPECITABINE	CAPECITABINE TARO 500 MG	CAPECITABINE	CAPECITABINE 500MG	TABLETS	RECIEPT	Adjuvant Colon Cancer: Capecitabine Taro 500mg is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes stage C) colon cancer. Colorectal Cancer: Capecitabine Taro 500mg is indicated for the treatment of patients with advanced or metastatic colorectal cancer. Advanced gastric cancer: Capecitabine Taro 500mg is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. Breast Cancer Combination Therapy: Capecitabine Taro 500mg in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Breast Cancer Monotherapy: Capecitabine Taro 500mg is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.
957	CAPECITABINE	CAPECITABINE INOVAMED 500 MG	CAPECITABINE	CAPECITABINE 500MG	TABLETS	RECIEPT	Adjuvant Colon Cancer: Capecitabine is indicated for the adjuvant treatment of patients following surgery of stage III (Dukesע stage C) colon cancer. Colorectal Cancer: Capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer. Advanced gastric cancer: Capecitabine is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. Breast Cancer Combination Therapy: Capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Breast Cancer Monotherapy: Capecitabine is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.
960	CAPECITABINE	CAPECITABINE TEVA 500 MG	CAPECITABINE	CAPECITABINE 500MG	TABLETS	RECIEPT	Adjuvant Colon Cancer: Capecitabine Teva is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes stage C) colon cancer. Colorectal Cancer: Capecitabine Teva is indicated for the treatment of patients with advanced or metastatic colorectal cancer. Advanced gastric cancer: Capecitabine Teva is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. Breast Cancer Combination Therapy: Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Breast Cancer Monotherapy: Capecitabine Teva is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.
961	CAPRELSA	CAPRELSA 100 MG	VANDETANIB	VANDETANIB 100MG	TABLETS	RECIEPT	Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
962	CARBAGLU	CARBAGLU	CARGLUMIC ACID	CARGLUMIC ACID 200MG	TABLETS	RECIEPT	Carbaglu is indicated in treatment of : - hyperammonaemia due to N - acetylglutamate synthase primary deficiency. - hyperammonaemia due to isovaleric acidaemia. - hyperammonaemia due to methymalonic acidaemia. - hyperammonaemia due to propionic acidaemia.
3134	CARBON DIOXIDE	MEDICAL CARBON DIOXIDE	CARBON DIOXIDE	CARBON DIOXIDE 99%	GAS	RECIEPT	-Carbon Dioxide may be insufflated into the abdominal cavity to distend it to allow the investigation and treatment of intra-abdominal disease -Carbon Dioxide may be administered through a metered supply, fed into the oxygenator of an extracorporeal circ
970	CARBOPLATIN	CARBOPLATIN TEVA	CARBOPLATIN	CARBOPLATIN 10MG/ML	CONCENTRATE	RECIEPT	Advanced ovarian carcinoma in initial treatment and secondary treatment. Metastatic small cell carcinoma of the lung.
972	CARBOSYLANE	CARBOSYLANE 48CAPS(24 blue+24pink)	SIMETHICONE	SIMETHICONE 45MG;CHARCOAL 140MG	CAPSULES		Anti-flatulent, for symptomatic treatment of stomach ache resulting from accumulation of gas, relief of sensation of fullness, meteorism, bloating and flatulence.
971	CARBOSYLANE	CARBOSYLANE	SIMETHICONE	SIMETHICONE 45MG;CHARCOAL ACTIVATED 140MG	CAPSULES		Anti-flatulent, for symptomatic treatment of stomach ache resulting from accumulation of gas, relief of sensation of fullness, meteorism, bloating and flatulence.
975	CARDILOC	CARDILOC 10	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE 10MG	TABLETS	RECIEPT	Management of angina pectoris, hypertention. Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides.
980	CARDILOC	CARDILOC 5	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE 5MG	TABLETS	RECIEPT	Management of angina pectoris, hypertention. Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides.
973	CARDILOC	CARDILOC 1.25	BISOPROLOL HEMIFUMARATE	BISOPROLOL HEMIFUMARATE 1.25MG	TABLETS	RECIEPT	Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function (ejection fraction < 35%, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides
977	CARDILOC	CARDILOC 2.5	BISOPROLOL HEMIFUMARATE	BISOPROLOL HEMIFUMARATE 2.5MG	TABLETS	RECIEPT	Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides.
982	CARDIOLITE	CARDIOLITE	TETRAKIS COPPER - TETRAFLUOROBORATE	TETRAKIS COPPER - TETRAFLUOROBORATE 1MG/VIAL	POWDER	RECIEPT	Myocardial imaging. Prognostication. Pharmacologic stress. Breast imaging.
983	CARDIOPIRIN	CARDIOPIRIN	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
984	CARDIOPIRIN	CARDIOPIRIN 100 MG 28 TAB	ASPIRIN	ASPIRIN 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
985	CARDIOXANE	CARDIOXANE	DEXRAZOXANE AS HYDROCHLORIDE	DEXRAZOXANE AS HYDROCHLORIDE 500MG/VIAL	POWDER	RECIEPT	Prevention of cardiotoxicity in adult women with advanced and/or metastatic breast cancer at high risk of heart failure who have received a prior cumulative dose of 300 mg/m2 of doxorubicin or a prior cumulative dose of 540 mg/m2 of epirubicin when further anthracycline treatment is required.
986	CARDOXIN	CARDOXIN FORTE	DIPYRIDAMOLE	DIPYRIDAMOLE 75MG	TABLETS	RECIEPT	As an adjunct to oral anticoagulants for prophylaxis of thromboembolism associated with prosthetic heart valves. Reduction of proteinuria in the nephrotis syndrome. Treatment of membranoproliferative glomerulonephritis. Prevention of pre-eclampsia in the final trimester of pregnancy. Prevention of transplant artery stenosis. Prevention of post-operative thromboembolic complications of coronary artery surgery. In combination with acetylsalicylic acid in cases of recurrent deep vein thrombosis resistant to oral anticoagulants. Prevention of thrombogenic manifestations. As an alternative to exercise stress in thallium myocardial imaging particularly in patients unable to exercise or in those for whom exercise may be contraindicated.
987	CARMUSTINE RAZ	CARMUSTINE RAZ 100 MG	CARMUSTINE	CARMUSTINE 100MG	POWDER	RECIEPT	Carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved agents in the following: • Brain tumors - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors. • Multiple myeloma - in combination with glucocorticoid such as prednisone. • Hodgkin’s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. • Non-Hodgkin’s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
988	CARNATION	CARNATION CALLOUS CAPS	SALICYLIC ACID	SALICYLIC ACID 40%	PATCHES	RECIEPT	For the treatment of hard skin on the sole of the foot.
989	CARNATION	CARNATION CORN CAPS	SALICYLIC ACID	SALICYLIC ACID 40%	PATCHES	RECIEPT	Keratolytic for the removal of corn.
990	CARNITINE	CARNITINE SOLUTION 30%	LEVOCARNITINE	LEVOCARNITINE 30%	SOLUTION	RECIEPT	Systemic and myopathic carnitine deficiency.
995	CARTIA	CARTIA	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
996	CARTIA	CARTIA 100MG 28TAB	ASPIRIN	ASPIRIN 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
997	CARVEDEXXON	CARVEDEXXON 12.5	CARVEDILOL	CARVEDILOL 12.5MG	TABLETS	RECIEPT	Treatment of symptomatic congestive heart failure. Carvedexxon may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ACE inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.
998	CARVEDEXXON	CARVEDEXXON 6.25	CARVEDILOL	CARVEDILOL 6.25MG	TABLETS	RECIEPT	Treatment of symptomatic congestive heart failure. Carvedexxon may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ACE inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.
999	CARVEDILOL	CARVEDILOL TEVA 12.5 MG	CARVEDILOL	CARVEDILOL 12.5MG	TABLETS	RECIEPT	Treatment of symptomatic congestive heart failure. Carvedilol Teva may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ACE inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.
1000	CARVEDILOL	CARVEDILOL TEVA 6.25 MG	CARVEDILOL	CARVEDILOL 6.25MG	TABLETS	RECIEPT	Treatment of symptomatic congestive heart failure. Carvedilol Teva may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ACE inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.
1001	CASODEX	CASODEX 150 MG	BICALUTAMIDE	BICALUTAMIDE 150MG	TABLETS	RECIEPT	In patients with locally advanced prostate cancer (T3 - T4 any N M0 T1 -T2 N+ M0) Casodex 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. The management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.
1002	CASODEX	CASODEX 50 MG	BICALUTAMIDE	BICALUTAMIDE 50MG	TABLETS	RECIEPT	For the treatment of advanced prostate cancer in combination with LHRH analog therapy or surgical castration.
1003	CASPOVIDAE	CASPOVIDAE 50 MG	CASPOFUNGIN AS ACETATE	CASPOFUNGIN AS ACETATE 50MG/VIAL	POWDER	RECIEPT	Indicated in adults and pediatric patients (3 months and older) for: - Empirical therapy for presumed fungal infections in febrile, neutropenic patients. - Treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. Has not been studied in endocarditis, ostemyelitis, and meningitis due to Candida. - Treatment of esophageal candidiasis. - Treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). Has not been studied as initial therapy for invasive aspergillosis.
1004	CASPOVIDAE	CASPOVIDAE 70 MG	CASPOFUNGIN AS ACETATE	CASPOFUNGIN AS ACETATE 70MG/VIAL	POWDER	RECIEPT	Indicated in adults and pediatric patients (3 months and older) for: - Empirical therapy for presumed fungal infections in febrile, neutropenic patients. - Treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. Has not been studied in endocarditis, ostemyelitis, and meningitis due to Candida. - Treatment of esophageal candidiasis. - Treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). Has not been studied as initial therapy for invasive aspergillosis.
1005	CATAFLAM	CATAFLAM 50 MG	DICLOFENAC AS POTASSIUM	DICLOFENAC AS POTASSIUM 50MG	TABLETS	RECIEPT	Management of pain and primary dysmenorrhea, when prompt pain relief is desired.
1006	CATHEJELL	CATHEJELL WITH LIDOCAINE	LIDOCAINE HYDROCHLORIDE	LIDOCAINE HYDROCHLORIDE 2%W/W;CHLORHEXIDINE DIHYDROCHLORIDE 0.05%W/W	GEL	RECIEPT	Instillation into the urethra prior to the instillation of catheters or other instruments and manipulations which require the use of a local anesthetic.
1007	CAVERJECT	CAVERJECT 10 MCG	ALPROSTADIL	ALPROSTADIL 10MCG	POWDER	RECIEPT	For the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic or mixed etiology. Useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
1009	CAVERJECT	CAVERJECT 20 MCG	ALPROSTADIL	ALPROSTADIL 20MCG/VIAL	POWDER	RECIEPT	Treatment of erectile dysfunction. Useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
1011	CAYSTON	CAYSTON	AZTREONAM	AZTREONAM 75MG/VIAL	POWDER	RECIEPT	Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
1014	CEFAZOL	CEFAZOL 1g	CEFAZOLIN AS SODIUM	CEFAZOLIN AS SODIUM 1G/VIAL	POWDER		Treatment of serious infections caused by susceptible organisms and also perioperatively for prophylaxis. Treatment Respiratory tract: Respiratory tract infections due to streptococcus pneumoniae (formerly diplococcus pneumoniae) klebsiella species haemophilus influenzae staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A B - hemolytic streptococci. Cefazolin is effective in the eradication of streptococci from the nasopharynx. However data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. Urinary tract: Infections due to escherichia coli klebsiella species proteus mirabilis and some strains of Enterobacter and enterococci. Skin and skin structure: -hemolytic beta Infections due to Staphylococcus aureus (penicillin-sensitive and penicillin-resistant) group A streptococci and other strains of streptococci. Biliary tract: Infections due to escherichia coli various strains of streptococci proteus mirabilis klebsiella species and staphylococcus aureus. Bone and joint : Infections due to staphylococcus aureus. Genital infections (i.e. prostatitis epididymitis) due to escherichia coli proteus mirabilis klebsiella species and some strains of enterococci. Septicemia due to streptococcus pneumoniae (formerly diplococcus pneumoniae) staphylococcus aureus (penicillin-sensitive and penicillin-resistant) proteus mirabilis escherichia coli and klebsiella species. Endocarditis caused by staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organism to cefazolin. Perioperative prophylaxis: The prophylactic administraton of cefazolin perioperatively (preoperatively intraoperatively and postoperatively) may reduce the incidence of certain postoperative infectons in patients undergoing surgical procedures (e.g. hysterectomy gastrointestinal surgery and transurethral prostatectomy) that are classified as contaminated or potentially contaminated. The perioperative use of cefazolin may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g. open-heart surgery and prosthetic arthroplasty).
1015	CEFAZOLIN	CEFAZOLIN - FRESENIUS	CEFAZOLIN AS SODIUM	CEFAZOLIN AS SODIUM 1000MG	POWDER	RECIEPT	Cefazolin - Fresenius is indicated in the treatment of serious infections due to susceptible micro-organisms.
1018	CEFAZOLIN	CEFAZOLIN -VIT	CEFAZOLIN AS SODIUM	CEFAZOLIN AS SODIUM 1000MG/VIAL	POWDER	RECIEPT	Treatment of serious infections caused by susceptible organisms and also perioperatively for prophylaxis. Treatment Respiratory tract: Respiratory tract infections due to streptococcus pneumoniae (formerly diplococcus pneumoniae) klebsiella species haemophilus influenzae staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A B - hemolytic streptococci. Cefazolin is effective in the eradication of streptococci from the nasopharynx. However data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. Urinary tract: Infections due to escherichia coli klebsiella species proteus mirabilis and some strains of Enterobacter and enterococci. Skin and skin structure: -hemolytic beta Infections due to Staphylococcus aureus (penicillin-sensitive and penicillin-resistant) group A streptococci and other strains of streptococci. Biliary tract: Infections due to escherichia coli various strains of streptococci proteus mirabilis klebsiella species and staphylococcus aureus. Bone and joint : Infections due to staphylococcus aureus. Genital infections (i.e. prostatitis epididymitis) due to escherichia coli proteus mirabilis klebsiella species and some strains of enterococci. Septicemia due to streptococcus pneumoniae (formerly diplococcus pneumoniae) staphylococcus aureus (penicillin-sensitive and penicillin-resistant) proteus mirabilis escherichia coli and klebsiella species. Endocarditis caused by staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organism to cefazolin. Perioperative prophylaxis: The prophylactic administraton of cefazolin perioperatively (preoperatively intraoperatively and postoperatively) may reduce the incidence of certain postoperative infectons in patients undergoing surgical procedures (e.g. hysterectomy gastrointestinal surgery and transurethral prostatectomy) that are classified as contaminated or potentially contaminated. The perioperative use of cefazolin may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g. open-heart surgery and prosthetic arthroplasty).
1016	CEFAZOLIN	CEFAZOLIN PANPHARMA 1 G	CEFAZOLIN AS SODIUM	CEFAZOLIN AS SODIUM 1G	POWDER	RECIEPT	Cefazolin is indicated for the treatment of infections due to susceptible organisms and also perioperatively for prophylaxis.
1019	CEFONICID	CEFONICID TEVA	CEFONICIDE AS SODIUM	CEFONICIDE AS SODIUM 1000MG/VIAL	POWDER	RECIEPT	Treatment of serious bacterial infections caused by microorganisms susceptible to cefonicid. Studies on specimens obtained prior to therapy should be used to determine the susceptibility or the causative organisms to Cefonicid. Therapy with Cefonicid may be initiated pending results of the studies however. Treatment should be adjusted according to study findings. Cefonicid-teva is indicated in the treatment of the infections of the lower respiratory tract urinary tract skin and skin structure bone and joints. In the treatment of the above-mentioned infections the product is particularly used in weak and/or immuno-depressed patients. Surgical prophylaxis: The administration of a single 1 g. dose of Cefonicid-teva before surgery may reduce the incidence of post-operative infections caused by susceptible microorganisms in patients undergoing surgical procedures classified as contaminated or potentially contaminated or in patients in whom infection at the operative site would present a serious risk providing protection during all the surgery period and for about 24 hours following administration. Supplementary doses of Cefonicid-teva may be administered for two additional days to patients undergoing prosthetic arthroplasty. In cesarean section the intra-operative administration of Cefonicid-teva (after the umbilical cord has been clamped) reduces the incidence of post-operative sepsis.
1023	CEFOVIT	CEFOVIT SUSPENSION	CEFALEXIN AS MONOHYDRATE	CEFALEXIN AS MONOHYDRATE 125MG/5ML	SUSPENSION	RECIEPT	Antibiotic for the treatment of infections caused by micro-organisms sensitive to Cephalexin.
1020	CEFOVIT	CEFOVIT 250	CEFALEXIN AS MONOHYDRATE	CEFALEXIN AS MONOHYDRATE 250MG	CAPSULES	RECIEPT	Antibiotic for the treatment of infections caused by micro-organisms sensitive to Cephalexin.
1022	CEFOVIT	CEFOVIT FORTE SUSPENSION	CEFALEXIN AS MONOHYDRATE	CEFALEXIN AS MONOHYDRATE 250MG/5ML	SUSPENSION	RECIEPT	Antibiotic for the treatment of infections caused by micro-organisms sensitive to Cephalexin.
1021	CEFOVIT	CEFOVIT FORTE 500	CEFALEXIN AS MONOHYDRATE	CEFALEXIN AS MONOHYDRATE 500MG	CAPSULES	RECIEPT	Treatment of infections caused by cephalexin susceptible microorganisms.
1024	CEFTAZIDIME	CEFTAZIDIME - VIT	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 1.000G/VIAL	POWDER	RECIEPT	Ceftazidime-VIT is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). • Nosocomial pneumonia • Broncho-pulmonary infections in cystic fibrosis • Bacterial meningitis • Chronic suppurative otitis media • Malignant otitis externa • Complicated urinary tract infections • Complicated skin and soft tissue infections • Complicated intra-abdominal infections • Bone and joint infections • Peritonitis associated with dialysis in patient on CAPD. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP). The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria. Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity. Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
1025	CEFTAZIDIME	CEFTAZIDIME FRESENIUS 1 G	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 1000MG/VIAL	POWDER	RECIEPT	Ceftazidime is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). • Nosocomial pneumonia • Broncho-pulmonary infections in cystic fibrosis • Bacterial meningitis • Chronic suppurative otitis media • Malignant otitis externa • Complicated urinary tract infections • Complicated skin and soft tissue infections • Complicated intra-abdominal infections • Bone and joint infections • Peritonitis associated with dialysis in patients on CAPD. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP). The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria (see sections 4.4 and 5.1). Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum of activity. Consideration should be given to official guidelines regarding the appropriate use of antibacterial agents
1027	CEFTAZIDIME	CEFTAZIDIME PANPHARMA 1 G	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 1G	POWDER	RECIEPT	Ceftazidime Panpharma is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). - Nosocomial pneumonia - Broncho-pulmonary infections in cystic fibrosis - Bacterial meningitis - Chronic supportive otitis media - Malignant otitis externa - Complicated urinary tract infections - Complicated skin and soft issues infections - Complicated intra-abdominal infections - Bone and joint infections - Peritonitis associated with dialysis in patients with CAPD Treatment of patients with bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (TURP).
1029	CEFTAZIDIME	CEFTAZIDIME TEVA 1 G	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 1G/VIAL	POWDER	RECIEPT	Treatment of single or multiple infections caused by susceptible microorganisms.
1026	CEFTAZIDIME	CEFTAZIDIME FRESENIUS 2 G	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 2000MG/VIAL	POWDER	RECIEPT	Ceftazidime is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). • Nosocomial pneumonia • Broncho-pulmonary infections in cystic fibrosis • Bacterial meningitis • Chronic suppurative otitis media • Malignant otitis externa • Complicated urinary tract infections • Complicated skin and soft tissue infections • Complicated intra-abdominal infections • Bone and joint infections • Peritonitis associated with dialysis in patients on CAPD. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP). The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria (see sections 4.4 and 5.1). Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum of activity. Consideration should be given to official guidelines regarding the appropriate use of antibacterial agents
1028	CEFTAZIDIME	CEFTAZIDIME PANPHARMA 2 G	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 2G	POWDER	RECIEPT	Ceftazidime Panpharma is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). - Nosocomial pneumonia - Broncho-pulmonary infections in cystic fibrosis - Bacterial meningitis - Chronic supportive otitis media - Malignant otitis externa - Complicated urinary tract infections - Complicated skin and soft issues infections - Complicated intra-abdominal infections - Bone and joint infections - Peritonitis associated with dialysis in patients with CAPD Treatment of patients with bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (TURP).
1033	CEFTRIAXONE	CEFTRIAXONE-VIT	CEFTRIAXONE AS DISODIUM HEMIHEPTAHYDRATE	CEFTRIAXONE AS DISODIUM HEMIHEPTAHYDRATE 1.0G/VIAL	POWDER	RECIEPT	Ceftriaxone VIT is indicated for the treatment of the following infections in adults and children including term neonates (from birth): -Bacterial Meningitis - Community acquired pneumonia -Hospital acquired pneumonia -Acute otitis media -Intra-abdominal infections -Complicated urinary tract infections (including pyelonephritis) -Infections of bones and joints -Complicated skin and soft tissue infections -Gonorrhoea -Syphilis -Bacterial endocarditis Ceftriaxone VIT may be used: - For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults - For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III) in adults and children including neonates from 15 days of age. - For pre-operative prophylaxis of surgical site infections -In the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone – susceptible bacterial infection - In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above Ceftriaxone VIT should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.
1030	CEFTRIAXONE	CEFTRIAXONE - FRESENIUS	CEFTRIAXONE AS SODIUM	CEFTRIAXONE AS SODIUM 1000MG/VIAL	POWDER	RECIEPT	* Ceftriaxone-Fresenius is indicated for the treatment of the following infections in adults and children including term neonates (from birth) : - Bacterial Meningitis - Community acquired pneumonia - Hospital acquired pneumonia - Acute otitis media - Intra-abdominal infections - Complicated urinary tract infections (including pyelonephritis) - Infections of bones and joints - Complicated skin and soft tissue infections - Gonorrhoea - Syphilis - Bacterial endocarditis * Ceftriaxone-Fresenius may be used: - For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults - For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age. - For Pre-operative prophylaxis of surgical site infections In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above * Ceftriaxone-Fresenius should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum. * Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
1032	CEFTRIAXONE	CEFTRIAXONE S.K.	CEFTRIAXONE AS SODIUM	CEFTRIAXONE AS SODIUM 1000MG/VIAL	POWDER	RECIEPT	Ceftriaxone S.K. is indicated for the treatment of the following infections in adults and children including term neonates (from birth): - Bacterial Meningitis - Community acquired pneumonia - Hospital acquired pneumonia - Acute otitis media - Intra-abdominal infections - Complicated urinary tract infections (including pyelonephritis) - Infections of bones and joints - Complicated skin and soft tissue infections - Gonorrhoea - Syphilis - Bacterial endocarditis Ceftriaxone S.K. may be used: - For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults - For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III) in adults and children including neonates from 15 days of age. - For pre-operative prophylaxis of surgical site infections - In the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone – susceptible bacterial infection - In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above
1031	CEFTRIAXONE	CEFTRIAXONE PANPHARMA 1 G	CEFTRIAXONE AS SODIUM	CEFTRIAXONE AS SODIUM 1G/VIAL	POWDER	RECIEPT	Treatment of infections caused by pathogens sensitive to ceftriaxone, e.g.: sepsis, meningitis, abdominal infections (peritonitis, infection of the biliary and gastrointestinal tract), infections of the bones, loints, soft tissue, skin and of wounds, infections in patients with impaired defense mechanisms, renal and urinary tract infections, respiratory tract infections, particularly pneumonia, and ear, nose and throat infections, genital infections including gonorrhea. Perioperative prophylaxis of infections.
1036	CEFUROXIME	CEFUROXIME - VIT	CEFUROXIME AS SODIUM	CEFUROXIME AS SODIUM 750MG	POWDER	RECIEPT	Infections caused by susceptible microorganisms, prophylaxis against post operative infections in a variety of operations.
1037	CEFUROXIME	CEFUROXIME PANPHARMA 750 MG	CEFUROXIME AS SODIUM	CEFUROXIME AS SODIUM 750MG/VIAL	POWDER	RECIEPT	Infections caused by susceptible microorganisms, prophylaxis against post operative infections in a variety of operations.
1034	CEFUROXIME	CEFUROXIME - FRESENIUS 1500 MG POWDER FOR SOLUTION FOR INJECTION	CEFUROXIME AS SODIUM SALT	CEFUROXIME AS SODIUM SALT 1500MG	POWDER	RECIEPT	Treatment of infections due to Cefuroxime susceptible micro-organisms
1035	CEFUROXIME	CEFUROXIME - FRESENIUS 750 MG POWDER FOR SOLUTION FOR INJECTION	CEFUROXIME AS SODIUM SALT	CEFUROXIME AS SODIUM SALT 750MG	POWDER	RECIEPT	Treatment of infections due to Cefuroxime susceptible micro-organisms
1038	CELCOX	CELCOX 100 MG	CELECOXIB	CELECOXIB 100MG	CAPSULES	RECIEPT	Symptomatic treatment of inflammation and pain in osteoarthritis (OA) and rheumatoid arthritis (RA).
1039	CELCOX	CELCOX 200 MG	CELECOXIB	CELECOXIB 200MG	CAPSULES	RECIEPT	Symptomatic treatment of inflammation and pain in osteoarthritis (OA) and rheumatoid arthritis (RA).
1040	CELESTONE	CELESTONE CHRONODOSE	BETAMETHASONE ACETATE	BETAMETHASONE ACETATE 3MG/ML;BETAMETHASONE SODIUM PHOSPHATE 3.945MG/ML	SUSPENSION	RECIEPT	Indicated in the management of conditions known to be responsive to corticosteroid therapy.
1041	CELLCEPT	CELLCEPT 250 MG	MYCOPHENOLATE MOFETIL	MYCOPHENOLATE MOFETIL 250MG	CAPSULES	RECIEPT	Prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. Cellcept should be used concomitantly with cyclosporin and corticosteroids. Allogenic hepatic transplant.
1042	CELLCEPT	CELLCEPT 500 MG	MYCOPHENOLATE MOFETIL	MYCOPHENOLATE MOFETIL 500MG	TABLETS	RECIEPT	Prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. Cellcept should be used concomitantly with cyclosporin and corticosteroids. Allogenic hepatic transplant.
1044	CELLUSPAN	CELLUSPAN	HYDROXYETHYLCELLULOSE	HYDROXYETHYLCELLULOSE 1.4%	DROPS		Diagnostic agent.
1045	CELSENTRI	CELSENTRI 150 MG	MARAVIROC	MARAVIROC 150MG	TABLETS	RECIEPT	Celsentri is a CCR5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only CCR5-tropic HIV-1. • In treatment-naïve subjects, more subjects treated with Celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz. • Tropism testing with a highly sensitive tropism assay is required for the appropriate use of Celsentri.
1046	CELSENTRI	CELSENTRI 300 MG	MARAVIROC	MARAVIROC 300MG	TABLETS	RECIEPT	Celsentri is a CCR5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only CCR5-tropic HIV-1. • In treatment-naïve subjects, more subjects treated with Celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz. • Tropism testing with a highly sensitive tropism assay is required for the appropriate use of Celsentri.
1048	CERAZETTE	CERAZETTE	DESOGESTREL	DESOGESTREL 0.075MG	TABLETS	RECIEPT	Contraceptive.
1049	CERDELGA	CERDELGA	ELIGLUSTAT	ELIGLUSTAT 84.4MG	CAPSULES		Cerdelga is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1), who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (IMs) or extensive metabolisers (EMs).
1050	CEREBONIN	CEREBONIN 120 MG	DRY EXTRACT FROM GINKGO BILOBA LEAVES (35-67:1)	DRY EXTRACT FROM GINKGO BILOBA LEAVES (35-67:1) 120MG	TABLETS	RECIEPT	- For the symptomatic treatment of mental losses due to organic brain syndrome within the framework of a general therapeutic concept for dementia syndromes having as major symptoms: Deficient memory, disturbances of concentration, depressive mood, dizzine
1052	CERETEC	CERETEC	EXAMETAZIME	EXAMETAZIME 0.5MG/VIAL	POWDER	RECIEPT	Regional cerebral blood flow scintigraphy- leucocytes labelling.
1054	CEREZYME	CEREZYME 400 UNITS	IMIGLUCERASE	IMIGLUCERASE 400U/VIAL	POWDER	RECIEPT	For the long term enzyme replacement therapy for patients with a confirmed diagnosis of Type 1 gaucher disease that results in one or more of the following conditions: - Anemia - Thrombocytopenia - Bone disease - Hepatomegaly or splenomegaly.
1055	CERNEVIT	CERNEVIT	RETINOL PALMITATE	RETINOL PALMITATE 3500 IU/VIAL;COLECALCIFEROL 220 IU/VIAL;TOCOPHEROL 10.2MG/VIAL;ASCORBIC ACID 125MG/VIAL;RIBOFLAVINE 5.67MG/VIAL;PYRIDOXINE (VIT B6) HYDROCHLORIDE 5.5MG/VIAL;CYANOCOBALAMIN 0.006MG/VIAL;FOLIC ACID 0.414MG/VIAL;DEXPANTHENOL 16.15MG/VIAL;BIOTIN 0.069MG/VIAL;NICOTINAMIDE 46MG/VIAL;COCARBOXYLASE TETRAHYDRATE 5.8MG/VIAL	POWDER	RECIEPT	Vitamin supplementation in patients receiving parenteral nutrition. Only for adults and children over 11 years of age.
1057	CERTICAN	CERTICAN 0.25 MG TABLETS	EVEROLIMUS	EVEROLIMUS 0.25MG	TABLETS	RECIEPT	Kidney and heart transplantation Certican is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. In kidney and heart transplantation, Certican should be used in combination with ciclosporin for microemulsion and corticosteroids. Liver transplantation Certican is indicated for the prophylaxis of organ rejection in adult patients receiving a hepatic transplant. In liver transplantation, Certican should be used in combination with tacrolimus and corticosteroids.
1058	CERTICAN	CERTICAN 0.5 MG TABLETS	EVEROLIMUS	EVEROLIMUS 0.5MG	TABLETS	RECIEPT	Kidney and heart transplantation Certican is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. In kidney and heart transplantation, Certican should be used in combination with ciclosporin for microemulsion and corticosteroids. Liver transplantation Certican is indicated for the prophylaxis of organ rejection in adult patients receiving a hepatic transplant. In liver transplantation, Certican should be used in combination with tacrolimus and corticosteroids.
1059	CERTICAN	CERTICAN 0.75 MG TABLETS	EVEROLIMUS	EVEROLIMUS 0.75MG	TABLETS	RECIEPT	Kidney and heart transplantation Certican is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. In kidney and heart transplantation, Certican should be used in combination with ciclosporin for microemulsion and corticosteroids. Liver transplantation Certican is indicated for the prophylaxis of organ rejection in adult patients receiving a hepatic transplant. In liver transplantation, Certican should be used in combination with tacrolimus and corticosteroids.
1060	CERVARIX	CERVARIX	HPV-18 L1	HPV-18 L1 20MCG/0.5ML;HPV-16 L1 20MCG/0.5ML	SUSPENSION	RECIEPT	Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant genital (cervical, vulvar and vaginal) lesions and cervical cancer causally related to certain oncogenic Human Papillomavirus (HPV) types.
1061	CETRAXAL	CETRAXAL	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 3MG/1ML;FLUOCINOLONE ACETONIDE 0.25MG/1ML	DROPS	RECIEPT	Cetraxal is indicated for the local treatment of acute diffuse otitis externa of bacterial origin without tympanic membrane perforation in adults and in children aged 7 years and older caused by ciprofloxacin susceptible microorganisms
1062	CETRIMIDE	CETRIMIDE SHAMP 100ML	CETRIMIDE	CETRIMIDE 10%	LIQUID		For the treatment of dandruff.
1063	CETRIMIDE	CETRIMIDE SHAMPOO VITAMED	CETRIMIDE	CETRIMIDE 10%	SHAMPOO		For the treatment of dandruff.
1064	CETRIN	CETRIN CONCENTRATED SOL 1L	CETRIMIDE	CETRIMIDE 15%;CHLORHEXIDINE GLUCONATE 1.5%	SOLUTION		As an antiseptic for external use, for cleansing and sterilizing of instruments, hands and skin.
1065	CETRIN	CETRIN CONCENTRATED SOLUTION	CETRIMIDE	CETRIMIDE 15%;CHLORHEXIDINE GLUCONATE 1.5%	SOLUTION		As an antiseptic for external use, for cleansing and sterilizing of instruments, hands and skin.
1066	CETROTIDE	CETROTIDE 0.25	CETRORELIX AS ACETATE	CETRORELIX AS ACETATE 0.25MG/VIAL	POWDER	RECIEPT	Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques.
1072	CHAMPIX	CHAMPIX 0.5 MG	VARENICLINE AS TARTRATE	VARENICLINE AS TARTRATE 0.5MG	TABLETS	RECIEPT	Champix is indicated as an aid to smoking cessation treatment adults over 18 years of age. 11.06.2017 בקשה לשינוי משטר מינון For patients who are sure that they are not able or willing to quit abruptly, consider a gradual approach to quitting smoking with CHAMPIX. Patients should begin CHAMPIX dosing and reduce smoking by 50% from baseline within the first four weeks, by an additional 50% in the next four weeks, and continue reducing with the goal of reaching complete abstinence by 12 weeks. Continue CHAMPIX treatment for an additional 12 weeks, for a total of 24 weeks of treatment. Encourage patients to attempt quitting sooner if they feel ready.
1073	CHAMPIX	CHAMPIX 1.0 MG	VARENICLINE AS TARTRATE	VARENICLINE AS TARTRATE 1MG	TABLETS	RECIEPT	Champix is indicated as an aid to smoking cessation treatment adults over 18 years of age. 11.06.2017 בקשה לשינוי משטר מינון For patients who are sure that they are not able or willing to quit abruptly, consider a gradual approach to quitting smoking with CHAMPIX. Patients should begin CHAMPIX dosing and reduce smoking by 50% from baseline within the first four weeks, by an additional 50% in the next four weeks, and continue reducing with the goal of reaching complete abstinence by 12 weeks. Continue CHAMPIX treatment for an additional 12 weeks, for a total of 24 weeks of treatment. Encourage patients to attempt quitting sooner if they feel ready.
1074	CHENODEOXYCHOLIC ACID LEADIANT	CHENODEOXYCHOLIC ACID LEADIANT	CHENODEOXYCHOLIC ACID	CHENODEOXYCHOLIC ACID 250MG	CAPSULES	RECIEPT	The treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults.
1075	CHINA OEL	CHINA OEL	PEPPERMINT OIL	PEPPERMINT OIL 100%	OIL		Per os: For the treatment of symptoms of discomfort abdominal colic and distension following irritable bowel syndrome. Inhalation: As an aid in the relief of the common cold.
1076	CHLORAMPHENICOL	CHLORAMPHENICOL VUAB 1 G.	CHLORAMPHENICOL AS SODIUM SUCCINATE	CHLORAMPHENICOL AS SODIUM SUCCINATE 1G	POWDER	RECIEPT	Typhus and parathyphus, salmonellosis with septic development, meningitis, epiglottis, pertussis and parapertussis, serious infections with aerobe and anaerobe flora (pulmonary, abdominal, gynecologic) and other infections caused by bacteria susceptible to chloramphenicol.
1078	CHLORHEXIDINE	CHLORHEXIDINE LACER MOUTHWASH	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 0.12%W/V	SOLUTION		1. As an aid to maintaining oral hygiene. 2. As an aid in the treatment and prevention of gingivitis. 3. Inhibition of formation of dental plaque. 4. For use in aphtous ulceration and oral candidal infections (e.g. denture stomatitis and thrush). 5. For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
1077	CHLORHEXIDINE	CHLORHEXIDINE LACER GEL	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 0.2%W/W	GEL		1. As an aid to maintaining oral hygiene. 2. As an aid in the treatment and prevention of gingivitis. 3. Inhibition of formation of dental plaque. 4. For use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush). 5. For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
280	CHLORHEXIDINE	ALCOHOL CHLORHEXIDINE TEVA 100ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Skin disinfectant especially for pre-invasive procedures. Disinfection of the newly born umbilical cord. disinfection of thermometers.
279	CHLORHEXIDINE	ALCOHOL CHLORHEXIDINE TEVA	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%W/V;ISOPROPANOL 70%V/V	SOLUTION	RECIEPT	Skin disinfectant especially for pre-invasive procedures. Disinfection of the newly born umbilical cord. disinfection of thermometers.
1079	CHLORPHENICOL	CHLORPHENICOL SKIN OINTMENT	CHLORAMPHENICOL	CHLORAMPHENICOL 3%	OINTMENT	RECIEPT	For treating superficial skin infections caused by microorganisms sensitive to chloramphenicol.
1080	CHOLBAM	CHOLBAM 250 MG	CHOLIC ACID	CHOLIC ACID 250MG	CAPSULES	RECIEPT	• Cholbam is indicated for the treatment of inborn errors in primary bile acid synthesis due to Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency, • 2- (or alfa - ) methylacyl-CoA racemase (AMACR) deficiency in infants, children and adolescents aged 1 month to 18 years and adults • Cholesterol 7 alfa - hydroxylase (CYP7A1) deficiency in infants, children and adolescents aged 1 month to 18 years and adults • 3β-hydroxy-5-C27-steroid oxidoreductase deficiency (also known as 3β-hydroxy-5-C27-steroid dehydrogenase/isomerase or 3β-HSD or HSD3β7.
1081	CHOLBAM	CHOLBAM 50 MG	CHOLIC ACID	CHOLIC ACID 50MG	CAPSULES	RECIEPT	•Cholbam is indicated for the treatment of inborn errors in primary bile acid synthesis due to Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency, • 2- (or alfa - ) methylacyl-CoA racemase (AMACR) deficiency in infants, children and adolescents aged 1 month to 18 years and adults • Cholesterol 7 alfa - hydroxylase (CYP7A1) deficiency in infants, children and adolescents aged 1 month to 18 years and adults • 3β-hydroxy-5-C27-steroid oxidoreductase deficiency (also known as 3β-hydroxy-5-C27-steroid dehydrogenase/isomerase or 3β-HSD or HSD3β7.
1088	CIALIS	CIALIS TABLETS 10 MG	TADALAFIL	TADALAFIL 10MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men.
1089	CIALIS	CIALIS TABLETS 2.5 MG	TADALAFIL	TADALAFIL 2.5MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men.
1090	CIALIS	CIALIS TABLETS 20 MG	TADALAFIL	TADALAFIL 20MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men.
1091	CIALIS	CIALIS TABLETS 5 MG	TADALAFIL	TADALAFIL 5MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men. Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) Treatment of ED and the signs and symptoms of BPH (ED/BPH)
1092	CICLODERM	CICLODERM	CICLOPIROX OLAMINE	CICLOPIROX OLAMINE 1%	CREAM	RECIEPT	Topical treatment of localized fungal infections of the body and fungal infections of the feet.
1094	CICLODERM	CICLODERM SOLUTION	CICLOPIROX OLAMINE	CICLOPIROX OLAMINE 1%	SOLUTION	RECIEPT	Broad spectrum antimycotic preparation for topical treatment of fungal infections of the skin.
1095	CICLOPOLI	CICLOPOLI 8%	CICLOPIROX	CICLOPIROX 80MG/G	LACQUE		Fungal infections of the nails caused by ciclopirox-sensitive fungi.
1096	CILARIL	CILARIL 1	CILAZAPRIL	CILAZAPRIL 1MG	TABLETS	RECIEPT	A blood pressure lowering agent. Chronic heart failure.
1098	CILARIL	CILARIL 2.5	CILAZAPRIL	CILAZAPRIL 2.5MG	TABLETS	RECIEPT	A blood pressure lowering agent. Chronic heart failure.
1100	CILARIL	CILARIL 5	CILAZAPRIL	CILAZAPRIL 5MG	TABLETS	RECIEPT	A blood pressure lowering agent. Chronic heart failure.
1102	CILARIL	CILARIL PLUS	CILAZAPRIL	CILAZAPRIL 5MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	Treatment of essential hypertension in patients who have been stabilized on the individual components given in the same proportions.
1106	CILAZAPRIL	CILAZAPRIL TEVA 2.5 MG	CILAZAPRIL	CILAZAPRIL 2.5MG	TABLETS	RECIEPT	Treatment of essential hypertension, renal hypertension and chronic heart failure.
1108	CILAZAPRIL	CILAZAPRIL TEVA 5 MG	CILAZAPRIL	CILAZAPRIL 5MG	TABLETS	RECIEPT	Treatment of essential hypertension, renal hypertension and chronic heart failure.
1104	CILAZAPRIL PLUS	CILAZAPRIL PLUS TEVA	CILAZAPRIL AS MONOHYDRATE	CILAZAPRIL AS MONOHYDRATE 5MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	Treatment of essential hypertension in patients who have been stabilized on the individual components given in the same proportions.
1110	CILOXAN	CILOXAN	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 3MG/ML	SOLUTION	RECIEPT	Corneal ulcers and conjunctivitis caused by susceptible gram positive and gram negative microorganisms for adults and pediatric patients above the age of 1 year. For localized or diffuse otitis externa accompanied by a strong inflammatory reaction and of which the strains are susceptible to ciprofloxacin, and for the acute flare-up of a chronic otitis media. In this case, a mucopurulent secretion comes through the perforated eardrum. Pseudomonas aeruginosa is one of the organisms most likely to be found in this case. Also in other infections of the ear in which Pseudomonas aeruginosa and/or other susceptible strains may be demonstrated or suspected (for example with suppurating tympanic tubes), Ciloxan can be used under the strict supervision of an ear specialist. It must be understood that this is not a routine treatment and that improper use must be avoided.
1111	CIMIDONA	CIMIDONA 6.5mg	DRY EXTRACT FROM CIMICIFUGAE RHIZOMA (BLACK COHOSH)	DRY EXTRACT FROM CIMICIFUGAE RHIZOMA (BLACK COHOSH) 6.5MG	TABLETS		Alleviation of menopausal complaints.(hot flashes, excessive perspiration, sleep disorders, nervousness and depressive moods).
1112	CIMZIA	CIMZIA	CERTOLIZUMAB PEGOL	CERTOLIZUMAB PEGOL 200MG/ML	SOLUTION	RECIEPT	Rheumatoid arthritis: Cimzia, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Axial spondyloarthritis: Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising: Ankylosing spondylitis (AS): Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Axial spondyloarthritis without radiographic evidence of AS Adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs. Crohn's Disease : CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Plaque psoriasis: Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
1113	CINACALCET	CINACALCET TARO 30 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet Taro may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1119	CINACALCET	CINACALCET TEVA 30 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyrodism (HPT) in patients with end-dtage renal disease (ESRD) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1122	CINACALCET	CINACALCET TRIMA 30 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet -Trima may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1115	CINACALCET	CINACALCET TARO 60 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet Taro may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1120	CINACALCET	CINACALCET TEVA 60 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyrodism (HPT) in patients with end-dtage renal disease (ESRD) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1123	CINACALCET	CINACALCET TRIMA 60 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet -Trima may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1117	CINACALCET	CINACALCET TARO 90 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 90MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet Taro may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1121	CINACALCET	CINACALCET TEVA 90 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 90MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyrodism (HPT) in patients with end-dtage renal disease (ESRD) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1124	CINACALCET	CINACALCET TRIMA 90 MG	CINACALCET AS HYDROCHLORIDE	CINACALCET AS HYDROCHLORIDE 90MG	TABLETS	RECIEPT	Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet -Trima may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
1125	CINQAIR	CINQAIR	RESLIZUMAB	RESLIZUMAB 10MG/1ML	CONCENTRATE	RECIEPT	CINQAIR is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies (14)]. Limitation of Use: • CINQAIR is not indicated for treatment of other eosinophilic conditions. • CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus
1126	CIPRALEX	CIPRALEX 10 MG	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 10MG	TABLETS	RECIEPT	Treatment of depression and panic disorder. Treatment of generalized anxiety disorder (GAD) treatment of social anxiety disorder (social phobia). Treatment of obsessive - compulsive disorder.
1128	CIPRALEX	CIPRALEX 15 MG	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 15MG	TABLETS	RECIEPT	Treatment of depression and panic disorder. Treatment of generalized anxiety disorder (GAD) treatment of social anxiety disorder (social phobia). Treatment of obsessive - compulsive disorder.
1129	CIPRALEX	CIPRALEX 20 MG	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 20MG	TABLETS	RECIEPT	Treatment of depression and panic disorder. Treatment of generalized anxiety disorder (GAD) treatment of social anxiety disorder (social phobia). Treatment of obsessive - compulsive disorder.
1130	CIPRALEX	CIPRALEX 5 MG	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 5MG	TABLETS	RECIEPT	Treatment of depression and panic disorder. Treatment of generalized anxiety disorder (GAD) treatment of social anxiety disorder (social phobia). Treatment of obsessive - compulsive disorder.
1131	CIPRAMIL	CIPRAMIL 20 MG TABLETS	CITALOPRAM AS HYDROBROMIDE	CITALOPRAM AS HYDROBROMIDE 20MG	TABLETS	RECIEPT	For the treatment of states of depression and panic disorder.
1132	CIPRAMIL	CIPRAMIL 40 MG TABLETS	CITALOPRAM AS HYDROBROMIDE	CITALOPRAM AS HYDROBROMIDE 40MG	TABLETS	RECIEPT	For the treatment of states of depresion and panic disorder.
1133	CIPRODEX	CIPRODEX 250	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 250MG	TABLETS	RECIEPT	* Adults : Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens. * Children and adolescents: • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa • Complicated urinary tract infections and pyelonephritis • Inhalation anthrax (post-exposure prophylaxis and curative treatment) Ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no other alternative . Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents
1134	CIPRODEX	CIPRODEX 500	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 500MG	TABLETS	RECIEPT	* Adults : Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens. * Children and adolescents: • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa • Complicated urinary tract infections and pyelonephritis • Inhalation anthrax (post-exposure prophylaxis and curative treatment) Ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no other alternative . Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents
1135	CIPRODEX	CIPRODEX 750	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 750MG	TABLETS	RECIEPT	* Adults : Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens. * Children and adolescents: • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa • Complicated urinary tract infections and pyelonephritis • Inhalation anthrax (post-exposure prophylaxis and curative treatment) Ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no other alternative . Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents
1136	CIPROFLOXACIN	CIPROFLOXACIN I.V G.E.S. 2 MG/ML	CIPROFLOXACIN	CIPROFLOXACIN 2MG/1ML	SOLUTION	RECIEPT	Adults: Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens. Children and adolescents: • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa • Complicated urinary tract infections and pyelonephritis • Inhalation anthrax (post-exposure prophylaxis and curative treatment) Ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no other alternative. Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.
1137	CIPROFLOXACIN	CIPROFLOXACIN TEVA 250 MG	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 250MG	TABLETS	RECIEPT	Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. Treatment of acute pulmonary exacerbation of cystic fibrosis associated with P. aeruginosa infections in pediatric patients aged 5-17 years.
1138	CIPROFLOXACIN	CIPROFLOXACIN TEVA 500 MG	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 500MG	TABLETS	RECIEPT	Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. Treatment of acute pulmonary exacerbation of cystic fibrosis associated with P. aeruginosa infections in pediatric patients aged 5-17 years.
1139	CIPROFLOXACIN	CIPROFLOXACIN TEVA 750 MG	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 750MG	TABLETS	RECIEPT	Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. Treatment of acute pulmonary exacerbation of cystic fibrosis associated with P. aeruginosa infections in pediatric patients aged 5-17 years.
1141	CIPROFLOXACIN	CIPRO-TEVA 2 MG/ML	CIPROFLOXACIN AS LACTATE	CIPROFLOXACIN AS LACTATE 2MG/1ML	SOLUTION	RECIEPT	* Adults : Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens. * Children and adolescents: • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa • Complicated urinary tract infections and pyelonephritis • Inhalation anthrax (post-exposure prophylaxis and curative treatment) Ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no other alternative . Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents
1142	CIRCADIN	CIRCADIN	MELATONIN	MELATONIN 2MG	TABLETS	RECIEPT	Short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
1144	CITALOPRAM	CITALOPRAM TEVA 20 MG	CITALOPRAM AS HYDROBROMIDE	CITALOPRAM AS HYDROBROMIDE 20MG	TABLETS	RECIEPT	For the treatment of states of depression and panic disorder.
1146	CITRAFLEET	CITRAFLEET	CITRIC ACID ANHYDROUS	CITRIC ACID ANHYDROUS 10.97G;LIGHT MAGNESIUM OXIDE 3.5G;SODIUM PICOSULFATE 10MG	POWDER	RECIEPT	For bowel cleansing prior to any diagnostic procedures requiring a clean bowel e.g. colonoscopy or x-ray examination.
1147	CLARINASE	CLARINASE REPETABS	LORATADINE	LORATADINE 5MG;PSEUDOEPHEDRINE SULFATE 120MG	TABLETS	RECIEPT	Relief of symptoms of seasonal allergic rhinitis when both the antihistaminic properties and the nasal decongestant activity are desired.
1149	CLARITONE	CLARITONE RINSE15 ML	BENZALKONIUM CHLORIDE	BENZALKONIUM CHLORIDE 0.01%	DROPS		For rinsing and soothing the eyes against irritation due to various causes such as: dust, smoke, plants etc. For first aid use in helping remove a foreign body from the eye.
1148	CLARITONE	CLARITONE	BENZALKONIUM CHLORIDE	BENZALKONIUM CHLORIDE 0.01%	DROPS		For rinsing and soothing the eyes against irritation due to various causes such as: dust, smoke, plants etc. For first aid use in helping remove a foreign body from the eye.
1150	CLASTEON	CLASTEON 800 MG	CLODRONIC ACID AS DISODIUM TETRATHYDRATE	CLODRONIC ACID AS DISODIUM TETRATHYDRATE 800MG	TABLETS	RECIEPT	Treatment of hypercalcemia due to malignancy. Palliative treatment of osteolysis due to malignancy.
1151	CLAVENIR	CLAVENIR 1 G.	AMOXICILLIN AS SODIUM	AMOXICILLIN AS SODIUM 1000MG/VIAL;CLAVULANIC ACID AS POTASSIUM 200MG/VIAL	POWDER	RECIEPT	Short - term treatment of bacterial infections caused by susceptible microorganisms which are resistant to other beta - lactamase inhibitors.
1152	CLAVENTIN	CLAVENTIN 250	CLAVULANIC ACID AS POTASSIUM	CLAVULANIC ACID AS POTASSIUM 62.5MG/5ML;AMOXICILLIN AS TRIHYDRATE 250MG/5ML	SUSPENSION	RECIEPT	Lower respiratory infections, otitis media, sinusitis, acute pharyngitis, urinary tract infections, skin and soft tissue infections caused by beta-lactamase producing organisms susceptible to Amoxycillin and Clavulanic acid.
1154	CLEAN-AF	CLEAN-AF SOL 20ML	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%	DROPS		Relief of nasal congestion, especially for babies.
1153	CLEAN-AF	CLEAN-AF	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%W/V	SOLUTION	RECIEPT	For the relief of nasal congestion in children and infants.
1155	CLEAROCIN	CLEAROCIN CHERRY	LIDOCAINE	LIDOCAINE 1MG;TYROTHRICIN 4MG;CETRIMONIUM BROMIDE 2MG	TABLETS	RECIEPT	For the relief of pain associated with severe sore throat and mouth infections.
1156	CLEAROCIN	CLEAROCIN LEMON	LIDOCAINE	LIDOCAINE 1MG;TYROTHRICIN 4MG;CETRIMONIUM BROMIDE 2MG	TABLETS	RECIEPT	For the relief of pain associated with severe sore throat and mouth infections.
1159	CLEXANE	CLEXANE FORTE	ENOXAPARIN SODIUM	ENOXAPARIN SODIUM 150MG/ML	SOLUTION	RECIEPT	Clexane Forte is indicated in adults for: • Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery. • Prevention of thrombus formation in extra corporeal circulation during haemodialysis. • Acute coronary syndrome: - Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid. - Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).
1157	CLEXANE	CLEXANE	ENOXAPARIN SODIUM	ENOXAPARIN SODIUM 20MG/0.2ML	SOLUTION	RECIEPT	Enoxaparin sodium is an anti-coagulant. At dosesof 20 mg and 40 mg it is indicated for: - Prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - Prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. At dosege of 40 mg the indications are: - Prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - Heart failure (HYHA class III or IV) - Acute respiratory failure - Episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. At high doses of 60, 80 ,100 mg Clexan is indicated for: -Treatment of deep vein thrombosis (DVT). - Treatment of unstable angina and non-Q-wave myocardial infaction administered concurrently with aspirin. - Treatment of pulmonary embolism. Treatment of acute ST- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible or not for subsequent coronary angioplasty.
1163	CLINDAMYCIN	CLINDAMYCIN INJECTIONS	CLINDAMYCIN AS PHOSPHATE	CLINDAMYCIN AS PHOSPHATE 150MG/ML	SOLUTION	RECIEPT	The treatment of infections caused by susceptible strains of microorganisms.
1164	CLINOLEIC	CLINOLEIC 20 %	OLIVE OIL	OLIVE OIL 80%;SOYA OIL 20%	EMULSION	RECIEPT	Source of lipids during parenteral nutrition in situations where oral or enteral feeding is impossible, insufficient or contra-indicated.
1165	CLOBETASOL PROPIONATE	CLOBETASOL PROPIONATE - TRIMA CREAM	CLOBETASOL PROPIONATE	CLOBETASOL PROPIONATE 0.05%W/W	CREAM	RECIEPT	Resistant dermatoses responsive to potent corticosteroid therapy.
1166	CLOBETASOL PROPIONATE	CLOBETASOL PROPIONATE TRIMA SCALP SOLUTION	CLOBETASOL PROPIONATE	CLOBETASOL PROPIONATE 0.05%W/W	SOLUTION	RECIEPT	For the topical treatment of inflammatory conditions of the scalp responsive only to corticosteroids.
1193	CLODERM	CLOTRIMADERM 1% 15GR	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	For the treatment of fungal infections of the skin and mucosa caused by dermatophytes, yeasts, moulds and other fungi such as Malassezia furfur as well as skin infections caused by Corynebacterium minutissimum. Indicated also for Candida vulvitis and Candida balanitis.
1167	CLONEX	CLONEX 0.5 MG	CLONAZEPAM	CLONAZEPAM 0.5MG	TABLETS	RECIEPT	Typical or atypical petit mal, Lennox - Gastaut syndrome (petit mal variant), generalized primary or secondary tonic-clonic seizures including grand mal and focal seizures. Panic disorder.
1169	CLONEX	CLONEX 2 MG	CLONAZEPAM	CLONAZEPAM 2MG	TABLETS	RECIEPT	Typical or atypical petit mal, Lennox - Gastaut syndrome (petit mal variant), generalized primary or secondary tonic-clonic seizures including grand mal and focal seizures. Panic disorder.
1171	CLONNIRIT	CLONNIRIT	CLONIDINE HYDROCHLORIDE	CLONIDINE HYDROCHLORIDE 25MCG	TABLETS	RECIEPT	Prophylaxis of migraine and recurrent vascular headache, but not acute attacks. Treatment of menopausal flushing.
1172	CLOOD	CLOOD	CLOPIDOGREL AS HYDROGEN SULFATE	CLOPIDOGREL AS HYDROGEN SULFATE 75MG	TABLETS	RECIEPT	Prevention of atherotrobmotic events Clopidogrel is indicated in : • Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. • Adult Patients suffering from Acute Coronary Syndrome - Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy Prevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
1174	CLOPIDEXCEL	CLOPIDEXCEL 75	CLOPIDOGREL AS BESYLATE	CLOPIDOGREL AS BESYLATE 75MG	TABLETS	RECIEPT	Prevention of atherotrobmotic events. Clopidogrel is indicated in: • Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. • Adult Patients suffering from Acute Coronary Syndrome - Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. Prevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
1175	CLOPIDOGREL	CLOPIDOGREL TEVA	CLOPIDOGREL AS BISULFATE	CLOPIDOGREL AS BISULFATE 75MG	TABLETS	RECIEPT	Prevention of atherotrobmotic events Clopidogrel is indicated in : • Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. • Adult Patients suffering from Acute Coronary Syndrome - Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy Prevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
1182	CLOPIXOL	CLOPIXOL ACUPHASE 50 MG/ML	ZUCLOPENTHIXOL ACETATE	ZUCLOPENTHIXOL ACETATE 50MG/ML	SOLUTION	RECIEPT	Acute psychoses.
1186	CLOPIXOL	CLOPIXOL TABLETS 10 MG	ZUCLOPENTHIXOL AS DIHYDROCHLORIDE	ZUCLOPENTHIXOL AS DIHYDROCHLORIDE 10MG	TABLETS	RECIEPT	Acute schizophrenia .Other acute psychoses.
1185	CLOPIXOL	CLOPIXOL DROPS	ZUCLOPENTHIXOL AS DIHYDROCHLORIDE	ZUCLOPENTHIXOL AS DIHYDROCHLORIDE 20MG/ML	SOLUTION	RECIEPT	Acute schizophrenia and other acute psychoses.
1181	CLOPIXOL	CLOPIXOL 25 MG TABLETS	ZUCLOPENTHIXOL AS DIHYDROCHLORIDE	ZUCLOPENTHIXOL AS DIHYDROCHLORIDE 25MG	TABLETS	RECIEPT	Acute Schizophrenia. Other acute psychoses.
1180	CLOPIXOL	CLOPIXOL 2 MG TABLETS	ZUCLOPENTHIXOL AS DIHYDROCHLORIDE	ZUCLOPENTHIXOL AS DIHYDROCHLORIDE 2MG	TABLETS	RECIEPT	Acute schizophrenia, other acute psycoses.
1183	CLOPIXOL	CLOPIXOL DEPOT 200	ZUCLOPENTHIXOL DECANOATE	ZUCLOPENTHIXOL DECANOATE 200MG/ML	SOLUTION	RECIEPT	Clopixol Depot injection is a depot neuroleptic preparation designed for the maintenance treatment of acute and chronic schizophrenia and other paranoid psychoses, especially where compliance with oral medication is a problem.
1184	CLOPIXOL	CLOPIXOL DEPOT 500	ZUCLOPENTHIXOL DECANOATE	ZUCLOPENTHIXOL DECANOATE 500MG/ML	SOLUTION	RECIEPT	Acute schizophrenia, other acute psychoses.
1189	CLOTHREE	CLOTHREE	CLOTRIMAZOLE	CLOTRIMAZOLE 200MG	TABLETS	RECIEPT	Vaginal fungal infections caused mainly by candida species. Vaginal infections caused by trichomonas and microorganisms sensitive to clotrimazole.
1192	CLOTHREE-	CLOTHREE-TEVA 200MG 3 VAG+APPLICA	CLOTRIMAZOLE	CLOTRIMAZOLE 200MG	TABLETS	RECIEPT	Vaginal fungal infections caused mainly by candida species. Vaginal infections caused by trichomonas and microorganisms sensitive to clotrimazole.
1194	CLOTRISONE	CLOTRISONE	CLOTRIMAZOLE	CLOTRIMAZOLE 1%W/W;BETAMETHASONE DIPROPIONATE 0.064%W/W	CREAM	RECIEPT	Clotrimazole and Betamethasone Dipropionate cream, are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosusm.
1195	CLOTRIVIT	CLOTRIVIT	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	Antifungal agent for the local treatment of skin infections caused by candida species or dermatophytes.
1196	CLOTRIVIT	CLOTRIVIT CREAM 1% 20GR	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	Antifungal agent for the local treatment of skin infections caused by candida species or dermatophytes.
1197	CLOXACILLIN	CLOXACILLIN - MEDO 500 MG	CLOXACILLIN AS SODIUM	CLOXACILLIN AS SODIUM 500MG/VIAL	POWDER	RECIEPT	Cloxacillin-Medo is indicated principally in the treatment of infections caused by penicillinase-producing staphylococci. Because of the high incidence of staphylococcal isolates resistant to penicillin G, both within and outside the hospital environment, Cloxacillin-Medo is recommended as initial therapy in patients with suspected staphylococcal infections. Cloxacillin-Medo is also effective in the treatment of other commonly encountered Gram-positive coccal infections. Typical indications include: Respiratory tract infections, such as pneumonia, sinusitis. Infected wounds and burns. Osteomyelitis and septic arthritis. Other infections due to staphylococci (including penicillin-resistant strains) such as staphylococcal septicemia, staphylococcal endocarditis, staphylococcal enterocolitis and staphylococcal urinary tract infections.
1201	CODABROL	CODABROL	PARACETAMOL	PARACETAMOL 325MG;CODEINE PHOSPHATE 15MG	TABLETS	RECIEPT	Analgesic, anti-pyretic relief of cough associated with pain and fever.
1202	COD-ACAMOL	COD-ACAMOL 15/325	PARACETAMOL	PARACETAMOL 325MG;CODEINE PHOSPHATE 15.0MG	TABLETS	RECIEPT	Relief of mild to moderate pain. Relief of fever and cough associated with fever.
1203	CODICAL	CODICAL TABLETS	CODEINE PHOSPHATE	CODEINE PHOSPHATE 20MG	TABLETS	RECIEPT	Indicated as an analgesic for the relief of mild to moderate pain. For the symptomatic relief of unproductive cough
1204	CO-DIOVAN	CO-DIOVAN 160/12.5 MG FILM-COATED TABLETS	VALSARTAN	VALSARTAN 160MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	Co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. This fixed combination should be used as second-line therapy.
1205	CO-DIOVAN	CO-DIOVAN 160/25 MG FILM-COATED TABLETS	VALSARTAN	VALSARTAN 160MG;HYDROCHLOROTHIAZIDE 25MG	TABLETS	RECIEPT	Co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. This fixed combination should be used as second-line therapy.
1206	CO-DIOVAN	CO-DIOVAN 80/12.5 MG FILM COATED TABLETS	VALSARTAN	VALSARTAN 80MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	Co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.
1207	CODIVIS	CODIVIS CAPSULES	CODEINE	CODEINE 30MG;PHENYLTOLOXAMINE AS RESINATE 10MG	CAPSULES	RECIEPT	For the relief of cough.
1208	CODIVIS	CODIVIS SYRUP	PHENYLTOLOXAMINE AS RESINATE	PHENYLTOLOXAMINE AS RESINATE 3.3MG/4.5ML;CODEINE AS RESINATE 10MG/4.5ML	SYRUP	RECIEPT	For the relief of cough.
1209	COLCHICINE	COLCHICINE	COLCHICINE	COLCHICINE 500MCG	TABLETS	RECIEPT	Prevention and treatment of gout and FMF (familial mediterranean fever).
1210	COLD-CARE	COLD-CARE	GUAIFENESIN	GUAIFENESIN 100MG/5ML;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG/5ML;TRIPROLIDINE HYDROCHLRIDE 1.25MG/5ML	SYRUP	RECIEPT	Cold-care is a proven combination for providing an effective antiallergic action, decongestion with an added expectorant effect.
1211	COLDEX	COLDEX 20 CAPLETS	PARACETAMOL	PARACETAMOL 300MG;CHLORPHENIRAMINE MALEATE 2MG;CAFFEINE 30MG;PHELYLEPHRINE 10MG	TABLETS		Symptomatic relief of common cold, congestion associated with sinusitis, allergic rhinitis accompanied by fever and pain.
1212	COLDEX	COLDEX 20 TAB	PARACETAMOL	PARACETAMOL 300MG;CHLORPHENIRAMINE MALEATE 2MG;CAFFEINE 30MG;PHELYLEPHRINE 10MG	TABLETS		Symptomatic relief of common cold, congestion associated with sinusitis, allergic rhinitis accompanied by fever and pain.
1213	COLDEX	COLDEX 30 CAPLIOTS	PARACETAMOL	PARACETAMOL 300MG;CHLORPHENIRAMINE MALEATE 2MG;CAFFEINE 30MG;PHELYLEPHRINE 10MG	TABLETS		Symptomatic relief of common cold, congestion associated with sinusitis, allergic rhinitis accompanied by fever and pain.
1214	COLESTID	COLESTID	COLESTIPOL HYDROCHLORIDE	COLESTIPOL HYDROCHLORIDE 5G/SACHET	GRANULES	RECIEPT	Adjunctive therapy to diet in the managnent of elevated cholesterol levels.
1218	COLIRACIN	COLIRACIN	COLISTIMETHATE SODIUM	COLISTIMETHATE SODIUM 1000000U/VIAL	POWDER	RECIEPT	Antibiotic for treatment of infections caused by micro-organisms sensitive to colistin.
1222	COLOTAL	COLOTAL 135MG 50TAB	MEBEVERINE HCL	MEBEVERINE HCL 135MG	TABLETS		Irritable bowel syndrome and conditions included in this group such as: Chronic irritable colon, Gastro- intestinal spasm secondary to organic diseases
1223	COLOTAL	COLOTAL TABLETS 135 MG	MEBEVERINE HYDROCHLORIDE	MEBEVERINE HYDROCHLORIDE 135MG	TABLETS	RECIEPT	Irritable bowel syndrome and conditions included in this group such as: Chronic irritable colon, Gastro- intestinal spasm secondary to organic diseases
1224	COLPERMIN	COLPERMIN	PEPPERMINT OIL	PEPPERMINT OIL 187MG	CAPSULES		For the treatment of symptoms of discomfort abdominal colic and distension following irritable bowel syndrome
1225	COLPERMIN	COLPERMIN 20 CAPS	PEPPERMINT OIL	PEPPERMINT OIL 187MG	CAPSULES		For the treatment of symptoms of discomfort abdominal colic and distension following irritable bowel syndrome
1227	COMAGIS	COMAGIS CREAM	FLUOCINONIDE	FLUOCINONIDE 0.05 G;BIFONAZOLE 1.00 G	CREAM	RECIEPT	Broad-spectrum drug for relief of inflammatory conditions accompanied by fungal infection, which respond to corticoid therapy.
1228	COMBIGAN	COMBIGAN	TIMOLOL	TIMOLOL 5MG/ML;BRIMONIDINE TARTRATE 2MG/ML	SOLUTION	RECIEPT	Combigan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
1229	COMBIVIR	COMBIVIR	LAMIVUDINE	LAMIVUDINE 150MG;ZIDOVUDINE 300MG	TABLETS	RECIEPT	Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.
1231	COMBODEX	COMBODEX	IBUPROFEN	IBUPROFEN 150MG;PARACETAMOL 500MG	TABLETS	RECIEPT	Temporary relief of pain associated with: headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. Reduces fever.
1232	COMBODEX	COMBODEX 24 CAPLETS	IBUPROFEN	IBUPROFEN 150MG;PARACETAMOL 500MG	TABLETS	RECIEPT	Temporary relief of pain associated with: headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. Reduces fever.
1233	COMPETACT	COMPETACT 15 MG / 850 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 850MG;PIOGLITAZONE AS HYDROCHLORIDE 15MG	TABLETS	RECIEPT	Competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone. After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
1235	COMPOUND SODIUM LACTATE	COMPOUND SODIUM LACTATE	SODIUM CHLORIDE	SODIUM CHLORIDE 6G/L;POTASSIUM CHLORIDE 0.4G/L;CALCIUM CHLORIDE 0.27G/L;SODIUM LACTATE 3.12G/L	SOLUTION	RECIEPT	Fluid and electrolytes replacement.
1236	COMPOUND SODIUM LACTATE HARTMANN'S SOLUTION	COMPOUND SODIUM LACTATE BP ( HARTMANN'S SOLUTION)	SODIUM LACTATE	SODIUM LACTATE 0.32%W/V;CALCIUM CHLORIDE DIHYDRATE 0.027%W/V;POTASSIUM CHLORIDE 0.04%W/V;SODIUM CHLORIDE 0.6%W/V	SOLUTION	RECIEPT	Source of water and electrolytes. Regulation or maintenance of metabolic acidosis ( except lactic acidosis).
1237	COMTAN	COMTAN	ENTACAPONE	ENTACAPONE 200MG	TABLETS	RECIEPT	Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with Parkinson`s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
1238	CONCERTA	CONCERTA 18 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 18MG	TABLETS	RECIEPT	Concerta is indicated for the treatment of Attention deficit hyperactivity disorder (ADHD).
1239	CONCERTA	CONCERTA 27 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 27MG	TABLETS	RECIEPT	Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
1240	CONCERTA	CONCERTA 36 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 36MG	TABLETS	RECIEPT	Concerta is indicated for the treatment of Attention deficit hyperactivity disorder (ADHD).
1241	CONCERTA	CONCERTA 54 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 54MG	TABLETS	RECIEPT	Concerta is indicated for the treatment of Attention deficit hyperactivity disorder (ADHD).
1242	CONCOR	CONCOR 10 MG	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE 10MG	TABLETS	RECIEPT	- Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides. - Hype
1243	CONCOR	CONCOR 5 MG	BISOPROLOL FUMARATE	BISOPROLOL FUMARATE 5MG	TABLETS	RECIEPT	- Treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ACE inhibitors and diuretics, and optionally cardiac glycosides. - Hype
1244	CONDYLOX	CONDYLOX	PODOPHYLLOTOXIN	PODOPHYLLOTOXIN 5MG/ML	SOLUTION	RECIEPT	Treatment of external genital warts (Condyloma Acuminatum).
1245	CONTALAX	CONTALAX	BISACODYL	BISACODYL 0.566%	SUPPOSITORIES	RECIEPT	Laxative for the relief of constipation.
1246	CONTROLOC	CONTROLOC 20 MG	PANTOPRAZOLE	PANTOPRAZOLE 20MG	TABLETS	RECIEPT	For the treatment of reflux oesophagitis and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing). For long-term management and prevention of relapse in reflux oesophagitis. Prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in patients at risk with a need for continuous NSAIDs treatment.
1247	CONTROLOC	CONTROLOC 40	PANTOPRAZOLE	PANTOPRAZOLE 40MG	TABLETS	RECIEPT	Short term treatment of acute duodenal ulcer. Acute gastric ulcer. Moderate and severe reflux oesophagitis. Eradication of the Helicobacter pylori in combination with clarithromycin and amoxycillin or clarithromycin and metronidazole/tinidazole or amoxycillin and metronidazole/tinidazole in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism. Zollinger-Ellison-Syndrome.
1248	CONTROLOC	CONTROLOC I.V.	PANTOPRAZOLE AS SODIUM	PANTOPRAZOLE AS SODIUM 40MG/VIAL	POWDER	RECIEPT	For the treatment of duodenal ulcer, gastric ulcer, moderate and severe forms of reflux oesophagitis. Zollinger Ellison Syndrome.
1250	COPAXONE	COPAXONE 20 MG/ML	GLATIRAMER ACETATE	GLATIRAMER ACETATE 20MG/DOSE	SOLUTION	RECIEPT	For reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. Copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (CDMS). These patients should have MRI findings which are compatible with the diagnosis of multiple sclerosis.
1252	COPAXONE	COPAXONE 40 MG/ML	GLATIRAMER ACETATE	GLATIRAMER ACETATE 40MG	SOLUTION	RECIEPT	Copaxone 40 mg/ml is indicated for reducing the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
1254	CORALAN	CORALAN 5 MG	IVABRADINE AS HYDROCHLORIDE	IVABRADINE AS HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
1255	CORALAN	CORALAN 7.5 MG	IVABRADINE AS HYDROCHLORIDE	IVABRADINE AS HYDROCHLORIDE 7.5MG	TABLETS	RECIEPT	Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
1259	CORSODYL	CORSODYL MOUTHWASH	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 0.2%W/V	SOLUTION		Antibacterial solution for the disinfection of the mouth. 1. As an aid to maintaining oral hygiene. 2. As an aid in the treatment and prevention of gingivitis. 3. Inhibition of formation of dental plaque. 4. For use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush). 5. For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
1256	CORSODYL	CORSODYL DENTAL GEL	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 1%W/W	GEL		1. As an aid to maintaining oral hygiene. 2. As an aid in the treatment and prevention of gingivitis. 3. Inhibition of formation of dental plaque. 4. For use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush). 5. For use in a post- periodontal surgery or treatment regimen to promote gingival healing. 6. As an adjunct to fluoride in the prevention of dental caries in high risk patients.
1258	CORSODYL	CORSODYL MINT 0.2% SOL 300ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.2%	SOLUTION		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
1257	CORSODYL	CORSODYL DENTAL GEL 1% 50GR	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 1% W/W	GEL		1. As an aid to maintaining oral hygiene. 2. As an aid in the treatment and prevention of gingivitis. 3. Inhibition of formation of dental plaque. 4. For use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush). 5. For use in a post- periodontal surgery or treatment regimen to promote gingival healing. 6. As an adjunct to fluoride in the prevention of dental caries in high risk patients.
4879	CORTEF	SOLU CORTEF 100 MG	HYDROCORTISONE AS SODIUM SUCCINATE	HYDROCORTISONE AS SODIUM SUCCINATE 100MG	POWDER	RECIEPT	Solu-Cortef is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: - allergic states, - dermatologic diseases, - endocrine disorders, - gastrointestinal diseases, - hematologic disorders, - neoplastic diseases, - nervous system disorders, - ophthalmic diseases, - renal diseases, - respiratory diseases, - rheumatic disorders, - certain medical emergencies.
4880	CORTEF	SOLU CORTEF 500	HYDROCORTISONE AS SODIUM SUCCINATE	HYDROCORTISONE AS SODIUM SUCCINATE 125MG/ML	POWDER	RECIEPT	Solu-Cortef is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: - allergic states, - dermatologic diseases, - endocrine disorders, - gastrointestinal diseases, - hematologic disorders, - neoplastic diseases, - nervous system disorders, - ophthalmic diseases, - renal diseases, - respiratory diseases, - rheumatic disorders, - certain medical emergencies.
1260	CORTIFOAM	CORTIFOAM	HYDROCORTISONE ACETATE	HYDROCORTISONE ACETATE 10%W/W	FOAM	RECIEPT	Anti-inflammatory corticosteroid as adjunctive therapy in the topical treatment of ulcerative proctitis of the rectum.
1261	CORTIMENT	CORTIMENT	BUDESONIDE	BUDESONIDE 9MG	TABLETS	RECIEPT	For induction of remission in patients with mild to moderate active ulcerative colitis (UC).
1262	CORTISONE ACETATE	CORTISONE ACETATE 25 MG TABLETS	CORTISONE ACETATE	CORTISONE ACETATE 25MG	TABLETS	RECIEPT	Anti- inflammatory.
1264	COSENTYX	COSENTYX 150 MG SOLUTION FOR INJECTION	SECUKINUMAB	SECUKINUMAB 150MG	SOLUTION	RECIEPT	- Plaque psoriasis: Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - Psoriatic arthritis: Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the
1263	COSENTYX	COSENTYX 150 MG POWDER FOR SOLUTION FOR INJECTION	SECUKINUMAB	SECUKINUMAB 150MG/DOSE	POWDER	RECIEPT	- Plaque psoriasis: Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - Psoriatic arthritis: Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the
1265	COSOPT	COSOPT	DORZOLAMIDE AS HYDROCHLORIDE	DORZOLAMIDE AS HYDROCHLORIDE 20MG/ML;TIMOLOL AS MALEATE 5MG/ML	SOLUTION	RECIEPT	For the treatment of elevated intraocular pressure (IOP ) in patients with ocular hypertension, open-angle glaucoma, or other secondary open-angle glaucoma when concomitant therapy is appropriate.
1266	COTELLIC	COTELLIC	COBIMETINIB AS HEMIFUMARATE	COBIMETINIB AS HEMIFUMARATE 20MG	TABLETS	RECIEPT	Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
1268	COUMADIN	COUMADIN 10 MG	WARFARIN SODIUM	WARFARIN SODIUM 10MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1267	COUMADIN	COUMADIN 1 MG	WARFARIN SODIUM	WARFARIN SODIUM 1MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1270	COUMADIN	COUMADIN 2.5 MG	WARFARIN SODIUM	WARFARIN SODIUM 2.5MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1269	COUMADIN	COUMADIN 2 MG	WARFARIN SODIUM	WARFARIN SODIUM 2MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. Coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1271	COUMADIN	COUMADIN 3 MG	WARFARIN SODIUM	WARFARIN SODIUM 3MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1272	COUMADIN	COUMADIN 4 MG	WARFARIN SODIUM	WARFARIN SODIUM 4MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1273	COUMADIN	COUMADIN 5 MG	WARFARIN SODIUM	WARFARIN SODIUM 5MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolis. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1274	COUMADIN	COUMADIN 6 MG	WARFARIN SODIUM	WARFARIN SODIUM 6MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolis. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1275	COUMADIN	COUMADIN 7.5 MG	WARFARIN SODIUM	WARFARIN SODIUM 7.5MG	TABLETS	RECIEPT	Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
1279	CREON	CREON 10.000	PANCREATIN	PANCREATIN 150MG	CAPSULES	RECIEPT	Pancreatic exocrine insufficiency.
1280	CREON	CREON 10000 U(150MG) 100CAPS	PANCREATIN	PANCREATIN 150MG	CAPSULES	RECIEPT	For the treatment of pancreatic exocrine insufficiency.
1281	CREON	CREON 25000	PANCREATIN	PANCREATIN 300MG	CAPSULES	RECIEPT	For the treatment of pancreatic exocrine insufficiency.
1282	CRESEMBA	CRESEMBA 100 MG CAPSULES	ISAVUCONAZOLE AS SULFATE	ISAVUCONAZOLE AS SULFATE 100MG	CAPSULES	RECIEPT	Cresemba is indicated in adults for the treatment of: Invasive aspergillosis Mucormycosis in patients for whom amphotericin B is inappropriate Consideration should be given to official guidance on the appropriate use of antifungal agents.
1283	CRESEMBA	CRESEMBA 200 MG IV	ISAVUCONAZOLE AS SULFATE	ISAVUCONAZOLE AS SULFATE 200MG	POWDER	RECIEPT	Cresemba is indicated in adults for the treatment of: Invasive aspergillosis Mucormycosis in patients for whom amphotericin B is inappropriate
1284	CRESTOR	CRESTOR 10 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
1285	CRESTOR	CRESTOR 20 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
1286	CRESTOR	CRESTOR 40 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
1287	CRESTOR	CRESTOR 5 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 5MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
1288	CRINONE	CRINONE 8 %	PROGESTERONE	PROGESTERONE 8%W/W	GEL	RECIEPT	Treatment of infertility due to inadequete luteal phase. For use during in-vitro fertilisation, where infertility is mainly due to tubal idiopathic or endometriosis linked sterility associated with normal obulatory.
1289	CROMO-COMOD	CROMO-COMOD EYE DROPS	CROMOGLICIC ACID AS SODIUM	CROMOGLICIC ACID AS SODIUM 20MG/ML	DROPS		Preventative treatment for all types of allergic conjunctivitis.
1291	CROMO-COMOD	CROMO-COMOD NASAL SPRAY	CROMOGLICIC ACID AS SODIUM	CROMOGLICIC ACID AS SODIUM 20MG/ML	SPRAY		Prophylactic treatment for allergic rhinitis, seasonal and perrenial.
1292	CROMO-COMOD	CROMO-COMOD NASAL SPRAY 15ML	SOD.CROMOGLYCATE	SOD.CROMOGLYCATE 2%(20MG/ML)	SPRAY		Prophylactic treatment for allergic rhinitis, seasonal and perrenial.
1290	CROMO-COMOD	CROMO-COMOD EYE DROPS 10ML	SODIUM CROMOGLYCATE	SODIUM CROMOGLYCATE 20MG/ML	DROPS	RECIEPT	Preventative treatment for all types of allergic conjunctivitis.
1293	CROMOPTIC	CROMOPTIC	CROMOGLICIC ACID SODIUM	CROMOGLICIC ACID SODIUM 2%W/V	DROPS		Preventative treatment of all forms of allergic conjunctivitis.
1294	CROMOPTIC	CROMOPTIC 2% EYE DROPS 13.5ML	SODIUM CROMOGLYCATE	SODIUM CROMOGLYCATE 20MG/ML	DROPS	RECIEPT	Preventative treatment of all forms of allergic conjunctivitis.
1295	CRUSIA	CRUSIA	ENOXAPARIN	ENOXAPARIN 100MG/1ML	SOLUTION	RECIEPT	Crusia is indicated in adults for: •Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. •Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. •Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE ikely to require thrombolytic therapy or surgery. Prevention of thrombus formation in extra corporeal circulation during haemodialysis. •Acute coronary syndrome: -Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid. -Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).
1299	CUBICIN	CUBICIN 500 MG	DAPTOMYCIN	DAPTOMYCIN 500MG/VIAL	POWDER	RECIEPT	Cubicin is indicated for the treatment of the infections listed below. * Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). * Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. * Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram negative or anaerobic organisms
1300	CURATANE	CURATANE 10 MG	ISOTRETINOIN	ISOTRETINOIN 10MG	CAPSULES	RECIEPT	For the treatment of severe cystic acne that does not respond to other treatment.
1302	CURATANE	CURATANE 20 MG	ISOTRETINOIN	ISOTRETINOIN 20MG	CAPSULES	RECIEPT	For the treatment of severe cystic acne that does not respond to other treatment.
1304	CURATANE	CURATANE 40 MG	ISOTRETINOIN	ISOTRETINOIN 40MG	CAPSULES	RECIEPT	For the treatment of severe cystic acne that does not respond to other treatment.
1306	CURATANE	CURATANE 5 MG	ISOTRETINOIN	ISOTRETINOIN 5MG	CAPSULES	RECIEPT	For the treatment of severe cystic acne that does not respond to other treatment
1308	CUROSURF	CUROSURF	PHOSPHOLIPIDS FRACTION FROM PORCINE LUNG	PHOSPHOLIPIDS FRACTION FROM PORCINE LUNG 80MG/ML	SUSPENSION	RECIEPT	Treatment of preterm babies with respiratory distress syndrome (RDS). Prophylactic use in premature infants at high risk of RDS.
1309	CYCLOLUX	CYCLOLUX 0.5 MMOL/ML	GADOTERIC ACID	GADOTERIC ACID 279.32MG/1ML	SOLUTION	RECIEPT	Enhancement of contrast in magnetic resonance imaging. Aencephalic and spinal pathologies: brain tumours tumours of the spine and the surrounding tissue intervertebral disk prolapse infectious diseases. Abdominal pathologies: primary and secondary liver tumours. Osteo-articular pathology: bone and soft tissue tumours synovial diseases. Magnetic resonance imaging for angiography.
1310	CYCLOVIR	CYCLOVIR	ACYCLOVIR	ACICLOVIR 5%W/W	CREAM	RECIEPT	For the treatment of cold sores (herpes labialis).
1313	CYMBALTA	CYMBALTA 30 MG	DULOXETINE AS HYDROCHLORIDE	DULOXETINE AS HYDROCHLORIDE 30MG	CAPSULES	RECIEPT	Cymbalta is indicated for the treatment of major depressive episodes. - Cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). - Cymbalta is indicated for the management of fibromyalgia. - Cymbalta is indicated for the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. This has been established in studies in patients with chronic low back pain (CLBP) and chronic pain due to osteoarthritis.
1315	CYMBALTA	CYMBALTA 60 MG	DULOXETINE AS HYDROCHLORIDE	DULOXETINE AS HYDROCHLORIDE 60MG	CAPSULES	RECIEPT	Cymbalta is indicated for the treatment of major depressive episodes. - Cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). - Cymbalta is indicated for the management of fibromyalgia. - Cymbalta is indicated for the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. This has been established in studies in patients with chronic low back pain (CLBP) and chronic pain due to osteoarthritis.
1317	CYMEVENE	CYMEVENE 500 MG	GANCICLOVIR SODIUM	GANCICLOVIR SODIUM 500MG	SOLUTION	RECIEPT	Cymevene IV is indicated for the treatment of CMV retinitis in immunocompromised patiens, including patients with acquired immunodeficiency syndrome (AIDS). Cymevene IV is also indicated for the prevention of CMV disease in transplant recipients at risk for CMV disease.
1319	CYRAMZA	CYRAMZA 10 MG/ML	RAMUCIRUMAB	RAMUCIRUMAB 10MG/ML	CONCENTRATE	RECIEPT	Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.
1320	CYSTADANE	CYSTADANE	BETAINE ANHYDROUS	BETAINE ANHYDROUS 1G/G	POWDER	RECIEPT	Treatment of homocystinuria.
1324	CYSTAGON	CYSTAGON 150 MG	CYSTEAMINE AS BITARTRATE	CYSTEAMINE AS BITARTRATE 150MG	CAPSULES	RECIEPT	CYSTAGON is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
1328	CYSTAGON	CYSTAGON 50 MG	CYSTEAMINE AS BITARTRATE	CYSTEAMINE AS BITARTRATE 50MG	CAPSULES	RECIEPT	CYSTAGON is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
1330	CYTOSAR	CYTOSAR 1 G.	CYTARABINE	CYTARABINE 1G/VIAL	POWDER	RECIEPT	Induction and maintenance of remission in acute myelocytic leukemia of adults and children. Treatment of other leukemias.
1331	CYTOTEC	CYTOTEC 200 MCG TABLETS	MISOPROSTOL	MISOPROSTOL 200MCG	TABLETS	RECIEPT	For the treatment of duodenal and gastric ulcer. Treatment and prevention NSAID induced ulcers lesions, erosions, while NSAID therapy continues. Use in conjunction with Mifepristone subject to the approval of a committee for the termination of pregnancy according to the Israeli penal law 1977. First-trimester pregnancy failure: Use is intended for emptying the uterus in states of first trimester pregnancy failure, including: presentation of a pregnancy sac in the uterus with no fetal echo, missed abortion (until week 11+6 and a fetus 40 mm in length) or incomplete abortion. The preparation is to be used after location of the sac in the uterus has been proved and the diagnosis of pregnancy failure is certain. The preparation can be used for this purpose in an ambulatory setting. The dosage and route of administration will be similar to the use of Cytotec in pregnancy termination after using Mifegyne. Informed consent and medical surveillance are required. Softening and dilation of the cervix for performing intrauterine procedures, such as: curettage, hysteroscopy, IUD insertion and others, according to clinical judgment. The preparation can be used for this purpose in an ambulatory setting. The route of administration (vaginal, sublingual, buccal, oral or rectal) and the dosage are according to the decision of the attending doctor.
1334	DABIGATRAN	DABIGATRAN TEVA 150 MG	DABIGATRAN ETEXILATE AS MESYLATE	DABIGATRAN ETEXILATE AS MESYLATE 150MG	CAPSULES	RECIEPT	Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
1335	DACARBAZINE	DACARBAZINE - DACIN 200 MG	DACARBAZINE	DACARBAZINE 200MG/VIAL	POWDER	RECIEPT	For the treatment of metastatic malignant melanoma, Hodgkin's disease as a second line therapy when used in combination with other agents.
1336	DACARBAZINE	DACARBAZINE MEDAC 1000 MG	DACARBAZINE AS CITRATE	DACARBAZINE AS CITRATE 1000MG/VIAL	POWDER	RECIEPT	Decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of a combination chemotherapy in advanced Hodgkin's disease as a second line.
1338	DACARBAZINE	DACARBAZINE MEDAC 200 MG	DACARBAZINE AS CITRATE	DACARBAZINE AS CITRATE 200MG/VIAL	POWDER	RECIEPT	Decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of a combination chemotherapy in advanced Hodgkin's disease as a second line.
1340	DACARBAZINE	DACARBAZINE MEDAC 500 MG	DACARBAZINE AS CITRATE	DACARBAZINE AS CITRATE 500MG/VIAL	POWDER	RECIEPT	Decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. Further indications for dacarbazine as part of a combination chemotherapy in advanced Hodgkin's disease as a second line.
1342	DACOGEN	DACOGEN	DECITABINE	DECITABINE 50MG/VIAL	POWDER	RECIEPT	Dacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2 and High-Risk International Prognostic Scoring System groups. Dacogen is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.
1344	DAIVOBET	DAIVOBET	BETAMETHASONE AS DIPROPIONATE	BETAMETHASONE AS DIPROPIONATE 0.5MG/G;CALCIPOTRIOL AS HYDRATE 50MCG/G	OINTMENT	RECIEPT	Topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy.
1345	DAKTACORT	DAKTACORT CREAM	HYDROCORTISONE	HYDROCORTISONE 10MG/G;MICONAZOLE NITRATE 20MG/G	CREAM	RECIEPT	Infections of the skin caused by dermatophytes or candida species in which inflammatory symptoms are prominent.
1348	DAKTARIN	DAKTARIN ORAL GEL	MICONAZOLE	MICONAZOLE 20MG/G	GEL	RECIEPT	Oral mycosis (thrush) and fungal infections of the upper gastrointestinal tract. Daktarin oral gel can be used for the prevention of oral thrush in patient receiving long-term treatment with antibiotics, steroids, cytotoxic and radiation therapy.
1347	DAKTARIN	DAKTARIN CREAM 15GR	MICONAZOLE NITRATE	MICONAZOLE NITRATE 2%	CREAM	RECIEPT	Broad spectrum antimycotic
1349	DAKTARIN	DAKTARIN ORAL GEL40G	MICONAZOLE NITRATE	MICONAZOLE NITRATE 2%	GEL	RECIEPT	Oral mycosis (thrush) and fungal infections of the upper gastrointestinal tract. Daktarin oral gel can be used for the prevention of oral thrush in patient receiving long-term treatment with antibiotics, steroids, cytotoxic and radiation therapy.
1346	DAKTARIN	DAKTARIN CREAM	MICONAZOLE NITRATE	MICONAZOLE NITRATE 20MG/G	CREAM	RECIEPT	Broad spectrum antimycotic
1354	DALACIN	DALACIN VAGINAL OVULES	CLINDAMYCIN AS PHOSPHATE	CLINDAMYCIN AS PHOSPHATE 100MG	TABLETS	RECIEPT	Dalacin vaginal ovules are indicated for 3-day treatment of bacterial vaginosis .
1352	DALACIN	DALACIN C CAPSULES 150 MG	CLINDAMYCIN HYDROCHLORIDE	CLINDAMYCIN HYDROCHLORIDE 150MG	CAPSULES	RECIEPT	Treatment of infections caused by susceptible strains of anaerobic microorganisms.
1353	DALACIN	DALACIN C CAPSULES 300 MG	CLINDAMYCIN HYDROCHLORIDE	CLINDAMYCIN HYDROCHLORIDE 300MG	CAPSULES	RECIEPT	Treatment of infections caused by susceptible anaerobic bacteria.
1351	DALACIN	DALACIN C 150 MG/ML	CLINDAMYCIN PHOSPHATE	CLINDAMYCIN PHOSPHATE 150MG/ML	SOLUTION	RECIEPT	For the treatment of infections caused by susceptible anaerobic bacteria.
1350	DALACIN	DALACIN 2 % VAGINAL CREAM	CLINDAMYCIN PHOSPHATE	CLINDAMYCIN PHOSPHATE 2%	CREAM	RECIEPT	Treatment of bacterial vaginosis only if bacteria susceptible to clindamycin were found.
1355	DALAGIS	DALAGIS FOAM	CLINDAMYCIN PHOSPHATE	CLINDAMYCIN PHOSPHATE 1%	FOAM	RECIEPT	Dalagis Foam is indicated for the topical treatment of mild to moderate acne vulgaris in adults and children 12 years and older.
1356	DALIRESP	DALIRESP 500 MCG	ROFLUMILAST	ROFLUMILAST 500MCG	TABLETS	RECIEPT	Maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment..
1359	DANALONE	DANALONE	PREDNISOLONE	PREDNISOLONE 15MG/5ML	SYRUP	RECIEPT	For glucocorticoid respousive inflamination as: Endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states and gastrointestinal diseases.
1360	DANOL	DANOL 200	DANAZOL	DANAZOL 200MG	CAPSULES	RECIEPT	Treatment of endometriosis amenable to hormonal management, hereditary angioedema.
1361	DARUNAVIR	DARUNAVIR TEVA 800 MG	DARUNAVIR	DARUNAVIR 800MG	TABLETS	RECIEPT	Darunavir Teva co-administered with 100 mg ritonavir and with other antiretroviral agents,is indicated for the treatment of human immunodeficiency virus (HIV-1) infection for patients over 18 years of age.
1362	DARZALEX	DARZALEX	DARATUMUMAB	DARATUMUMAB 20MG/1ML	CONCENTRATE	RECIEPT	DARZALEX is indicated: • in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. • in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. • as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
1363	DATSCAN	DATSCAN 74 MBQ/ML	IOFLUPANE	IOFLUPANE 74MBQ/ML	SOLUTION	RECIEPT	Datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum: - In adult patients with clinically uncertain Parkinsonian Syndromes, for example those with early symptoms, in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson's Disease Multiple System Atrophy and Progressive Supranuclear Palsy. - Datscan is unable to discriminate between Parkinson's Disease Multiple System Atrophy and Progressive Supranuclear Palsy. - In adult patients to help differentiate probable dementia with Lewy bodies from Alzheimer's disease. Datscan is unable to discriminate between dementia with Lewy bodies and Parkinson's disease dementia
1364	DECAPEPTYL	DECAPEPTYL 0.1	TRIPTORELIN ACETATE	TRIPTORELIN ACETATE 0.1MG/ML	SOLUTION	RECIEPT	Precocius puberty, prostatic cancer, endomethriosis, uterus myomatoses and IVF.
1366	DECAPEPTYL	DECAPEPTYL C.R.	TRIPTORELIN AS ACETATE	TRIPTORELIN AS ACETATE 3.75MG/VIAL	POWDER	RECIEPT	Lowering sexual hormones, prostate cancer, endomedtriosis, uterus myomatosus, fertility treatment IVF. Central precocious puberty.
1367	DECAPEPTYL	DECAPEPTYL DEPOT 11.25 MG	TRIPTORELIN AS EMBONATE	TRIPTORELIN AS EMBONATE 11.25MG	POWDER	RECIEPT	- Lowering of sexual hormones and - treatment of advanced hormone-dependent prostate cancer.
1368	DECAPEPTYL	DECAPEPTYL DEPOT 22.5 MG	TRIPTORELIN AS EMBONATE	TRIPTORELIN AS EMBONATE 22.5MG	POWDER	RECIEPT	Symptomatic treatment of advanced hormone-dependent prostate cancer. As an alternative treatment, if orchiectomy or the administration of oestrogens are not indicated or are unacceptable to the patient. Treatment of central precocious puberty (CPP) in children 2 years and older with an onset of CPP before 8 years in girls and 10 years in boys.
1369	DECAPEPTYL	DECAPEPTYL DEPOT 3.75 MG	TRIPTORELIN AS EMBONATE	TRIPTORELIN AS EMBONATE 3.75MGML	POWDER	RECIEPT	- Lowering of sexual hormones and - treatment of advanced hormone-dependent prostate cancer. - Central precocious puberty.
1372	DEFERASIROX	DEFERASIROX TEVA 125 MG	DEFERASIROX	DEFERASIROX 125MG	TABLETS	RECIEPT	Deferasirox Teva is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). Deferasirox Teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg /l). LIC is the preferred method of iron overload determination and should be used wherever available.
1373	DEFERASIROX	DEFERASIROX TEVA 250 MG	DEFERASIROX	DEFERASIROX 250MG	TABLETS	RECIEPT	Deferasirox Teva is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). Deferasirox Teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg /l).LIC is the preferred method of iron overload determination and should be used wherever available.
1374	DEFERASIROX	DEFERASIROX TEVA 500 MG	DEFERASIROX	DEFERASIROX 500MG	TABLETS	RECIEPT	Deferasirox Teva is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). Deferasirox Teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg /l). LIC is the preferred method of iron overload determination and should be used wherever available.
1375	DEFINITY	DEFINITY	PEFLURTEN	PEFLURTEN 1.1MG/ML	SUSPENSION	RECIEPT	Echocardiography: Definity (perflutren injectable suspension) is indicated for contrast-enhanced ultrasound imaging of cardiac structures (ventricular chambers and endocardial borders) and function (regional wall motion) in adult patients with suboptimal echocardiograms. Abdominal ultrasound : Definity is also indicated for contrast-enhanced ultrasound imaging of the liver and kidneys in adult patients to improve the evaluation of pathology.
1376	DEFITELIO	DEFITELIO	DEFIBROTIDE	DEFIBROTIDE 200MG/2.5ML	CONCENTRATE	RECIEPT	Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age .
1377	DEKINET	DEKINET	BIPERIDEN HYDROCHLORIDE	BIPERIDEN HYDROCHLORIDE 2MG	TABLETS	RECIEPT	All types of Parkinson's disease.
1378	DEMUSTIN	DEMUSTIN 100 MG	BENDAMUSTINE HYDROCHLORIDE	BENDAMUSTINE HYDROCHLORIDE 100MG/VIAL	POWDER	RECIEPT	First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate. Indolent non-Hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. Follicular non-Hodgkin’s lymphoma as first line treatment in combination with rituximab.
1380	DEMUSTIN	DEMUSTIN 25 MG	BENDAMUSTINE HYDROCHLORIDE	BENDAMUSTINE HYDROCHLORIDE 25MG/VIAL	POWDER	RECIEPT	First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate. Indolent non-Hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. Follicular non-Hodgkin’s lymphoma as first line treatment in combination with rituximab.
1382	DENTIN	DENTIN SOLUTION	EUGENOL	EUGENOL 9%;BENZOCAINE 8%;CHLORBUTOL 2%	SOLUTION	RECIEPT	Dental analgesic.
1385	DEPALEPT	DEPALEPT CHRONO 500 MG	VALPROIC ACID	VALPROIC ACID 145MG;VALPROIC ACID AS SODIUM 333MG	TABLETS	RECIEPT	Treatment of generalized or partial epilepsy secondary epilepsy and mixed forms of epilepsy. Bipolar disorders: Treatment and/or prevention of acute manic episodes in the context of bipolar disorders.
1383	DEPALEPT	DEPALEPT 200 MG	VALPROIC ACID AS SODIUM	VALPROIC ACID AS SODIUM 200MG	TABLETS	RECIEPT	Anti-epileptic.
1388	DEPALEPT	DEPALEPT SYRUP	VALPROIC ACID AS SODIUM	VALPROIC ACID AS SODIUM 200MG/5ML	SYRUP	RECIEPT	Generalized or partial epilepsy secondary generalized epilepsy and mixed forms of epilepsy.
1387	DEPALEPT	DEPALEPT ORAL SOLUTION	VALPROIC ACID AS SODIUM	VALPROIC ACID AS SODIUM 200MG/ML	SOLUTION	RECIEPT	Treatment of generalized or partial epilepsy secondary generalized epilepsy and mixed forms of epilepsy.
1384	DEPALEPT	DEPALEPT 500 ENTERIC COATED TABLETS	VALPROIC ACID AS SODIUM	VALPROIC ACID AS SODIUM 500MG	TABLETS	RECIEPT	Generalized or partial epilepsy, secondary generalized epilepsy, mixed forms of epilepsy.
1389	DEPO MEDROL	DEPO MEDROL + LIDOCAINE	LIDOCAINE AS HYDROCHLORIDE	LIDOCAINE AS HYDROCHLORIDE 10MG/ML;METHYLPREDNISOLONE ACETATE 40MG/ML	SUSPENSION	RECIEPT	Depo-Medrol with Lidocaine is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - synovitis of osteoarthritis - rheumatoid arthritis - acute and subacute bursitis - acute gouty arthritis - epicondylitis - acute nonspecific tenosynovitis - post-traumatic osteoarthritis.
1390	DEPO MEDROL	DEPO MEDROL 40 MG/ML	METHYLPREDNISOLONE ACETATE	METHYLPREDNISOLONE ACETATE 40MG/ML	SUSPENSION	RECIEPT	For the treatment of conditions responsive to steroid injection therapy.
1391	DEPO-PROVERA	DEPO-PROVERA 150 MG/ML	MEDROXYPROGESTERONE ACETATE	MEDROXYPROGESTERONE ACETATE 150MG/ML	SUSPENSION	RECIEPT	For contraception where medically indicated and oral administration is inapplicable.
1392	DEPO-PROVERA	DEPO-PROVERA 500	MEDROXYPROGESTERONE ACETATE	MEDROXYPROGESTERONE ACETATE 150MG/ML	SUSPENSION	RECIEPT	Palliation of inoperable recurrent or metastatic carcinoma of endometrium, breast, ovary and kidney.
1393	DEPREXAN	DEPREXAN	DESIPRAMINE HYDROCHLORIDE	DESIPRAMINE HYDROCHLORIDE 25MG	DRAGEE	RECIEPT	Treatment of depression.
1394	DERALIN	DERALIN 10 MG	PROPRANOLOL HYDROCHLORIDE	PROPRANOLOL HYDROCHLORIDE 10MG	TABLETS	RECIEPT	1. Management of angina pectoris. 2. Control of essential and renal hypertension essential tremor most forms of cardiac dysrhythmias. 3. As an adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises hypertrophic obstructive cardiomyopathy pheochromocytoma (with an alpha-blocker). 4. Deralin Tablets are also indicated for long-term prophylaxis following recovery from acute myocardial infarction (treatment to be initiated by a hospital physician). 5. Migraine prophylaxis.
4833	DERALIN	SLOW DERALIN 160 MG	PROPRANOLOL HYDROCHLORIDE	PROPRANOLOL HYDROCHLORIDE 160MG	CAPSULES	RECIEPT	Management of angina pectoris. Control of essential and renal hypertension and essential tremor. As an adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises. Migraine prophylaxis.
1395	DERALIN	DERALIN 40 MG	PROPRANOLOL HYDROCHLORIDE	PROPRANOLOL HYDROCHLORIDE 40MG	TABLETS	RECIEPT	1. Management of angina pectoris. 2. Control of essential and renal hypertension essential tremor most forms of cardiac dysrhythmias. 3. As and adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises hypertrophic obstructive cardiomyopathy pheochromocytoma (with an alpha blocker). 4. Deralin is also indicated for long term prophylaxis following recovery from acute myocardial infarction (treatment to be initiated by a hospital physician) . 5. Migraine prophylaxis.
4835	DERALIN	SLOW DERALIN 80 MG	PROPRANOLOL HYDROCHLORIDE	PROPRANOLOL HYDROCHLORIDE 80MG	CAPSULES	RECIEPT	Management of angina pectoris. Control of essential and renal hypertension and essential tremor. As an adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises. Migraine prophylaxis.
1396	DERMACOMBIN	DERMACOMBIN CREAM	NYSTATIN	NYSTATIN 100000IU/G;GRAMICIDIN 0.25MG/G;NEOMYCIN AS SULFATE 2.5MG/G;TRIAMCINOLONE ACETONIDE 1MG/G	CREAM	RECIEPT	For local treatment of skin inflammations accompanied with mycotic and/or bacterial infection.
1397	DERMACOMBIN	DERMACOMBIN OINTMENT	TRIAMCINOLONE ACETONIDE	TRIAMCINOLONE ACETONIDE 1MG/G;NEOMYCIN AS SULFATE 2.5MG/G;GRAMICIDIN 0.25MG/G;NYSTATIN 100000IU/G	OINTMENT	RECIEPT	Antifungal, Antibacterial
1398	DERMASIL	DERMASIL	TERBINAFINE HYDROCHLORIDE	TERBINAFINE HYDROCHLORIDE 1%	CREAM	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidemophyton floccosum. Yeast infections of the skin, principally those caused by the genus Candida (e.g. candida albicans). Pityriasis (tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).
1399	DERMAX	DERMAX	TRICLOSAN	TRICLOSAN 1%	SOLUTION		For treatment and disinfection of skin infections .
1400	DERMAX	DERMAX 200ML	TRICLOSAN	TRICLOSAN 1%	LIQUID		For treatment and disinfection of skin infections .
1401	DERMAX	DERMAX 500ML	TRICLOSAN	TRICLOSAN 1%	LIQUID		For treatment and disinfection of skin infections .
1402	DERMOVATE	DERMOVATE CREAM	CLOBETASOL	CLOBETASOL 17- PROPIONATE 0.05%W/W	CREAM	RECIEPT	Clobetasol is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the short term treatment only of more resistant inflammatory and pruritic manifestations of steroid responsive dermatoses unresponsive to less potent corticosteroids. These include the following: • Psoriasis (excluding widespread plaque psoriasis) • Recalcitrant dermatoses • Lichen planus • Discoid lupus erythematosus • Other skin conditions which do not respond satisfactorily to less potent steroids.
1403	DERMOVATE	DERMOVATE OINTMENT	CLOBETASOL	CLOBETASOL 17- PROPIONATE 0.05%W/W	OINTMENT	RECIEPT	Clobetasol is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the short term treatment only of more resistant inflammatory and pruritic manifestations of steroid responsive dermatoses unresponsive to less potent corticosteroids. These include the following: • Psoriasis (excluding widespread plaque psoriasis) • Recalcitrant dermatoses •Lichen planus • Discoid lupus erythematosus • Other skin conditions which do not respond satisfactorily to less potent steroids.
1404	DERMOVATE	DERMOVATE SCALP APPLICATION	CLOBETASOL PROPIONATE	CLOBETASOL PROPIONATE 0.05%W/W	SOLUTION	RECIEPT	For the topical treatment of inflammatory conditions of the scalp responsive only to corticosteroids.
1405	DESCOVY	DESCOVY 200 MG/10 MG	TENOFOVIR ALAFENAMIDE FUMARATE	TENOFOVIR ALAFENAMIDE FUMARATE 10MG;EMTRICITABINE 200MG	TABLETS	RECIEPT	Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV 1).
1407	DESCOVY	DESCOVY 200 MG/25 MG	TENOFOVIR ALAFENAMIDE FUMARATE	TENOFOVIR ALAFENAMIDE FUMARATE 25MG;EMTRICITABINE 200MG	TABLETS	RECIEPT	Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV 1).
1409	DESFERAL	DESFERAL 0.5 G.	DEFEROXAMINE MESYLATE	DEFEROXAMINE MESYLATE 0.5G/VIAL	POWDER	RECIEPT	Treatment of chronic iron overload e.g.: Transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias Idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy Iron overload associated with porphyria cutanea tarda. Treatment of acute iron poisoning. Treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. Diagnosis of iron overload.
1413	DESLORATADINE	DESLORATADINE - TRIMA SYRUP 0.5 MG/ML	DESLORATADINE	DESLORATADINE 0.5MG/ML	SYRUP	RECIEPT	For the relief of symptoms associated with allergic rhinitis and/or chronic idiopathic urticaria in adults and children 1 year of age and above.
1412	DESLORATADINE	DES-LORATADIM	DESLORATADINE	DESLORATADINE 5MG	TABLETS	RECIEPT	Des-Loratadim is indicated for the relief of symptoms associated with allergic rhinitis, urticaria.
1414	DESLORATADINE	DESLORATADINE - TRIMA TABLETS	DESLORATADINE	DESLORATADINE 5MG	TABLETS	RECIEPT	Desloratadine - Trima tablets are indicated in adults and adolescents aged 12 yars and older for the relief of symptoms associated with: - allergic rhinitis, - urticaria
1415	DESMOPRESSIN	DESMOPRESSIN TEVA 0.1 MG	DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE 0.1MG	TABLETS	RECIEPT	Desmopressin teva tablets are indicated for central diabetes insipidus, nocturnal enuresis ( in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. The treatment must be started befor the age of 65.
1416	DESMOPRESSIN	DESMOPRESSIN TEVA 0.2 MG	DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE 0.2MG	TABLETS	RECIEPT	Desmopressin teva tablets are indicated for central diabetes insipidus, nocturnal enuresis ( in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. The treatment must be started befor the age of 65.
1417	DESO CARE	DESO CARE	POLYMYXIN B SULFATE	POLYMYXIN B SULFATE 10000 IU;DEXAMETHASONE AS SODIUM PHOSPHATE 1MG;NEOMYCIN AS SULFATE 5MG	DROPS	RECIEPT	For the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics
1418	DESOREN	DESOREN EAR DROPS	POLYMYXIN B SULFATE	POLYMYXIN B SULFATE 10000 IU;DEXAMETHASONE AS SODIUM PHOSPHATE 1MG;NEOMYCIN AS SULFATE 5MG	DROPS	RECIEPT	For the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics
1419	DETHAMYCIN	DETHAMYCIN	NEOMYCIN SULFATE	NEOMYCIN SULFATE 0.5%W/V;DEXAMETHASONE SODIUM PHOSPHATE 0.1%W/V	SOLUTION	RECIEPT	For the treatment of inflammations with probable secondary bacterial infections.
1420	DETRUSITOL	DETRUSITOL SR 2 MG	TOLTERODINE L-TARTRATE	TOLTERODINE L-TARTRATE 2MG	CAPSULES	RECIEPT	For the treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence.
1421	DETRUSITOL	DETRUSITOL SR 4 MG	TOLTERODINE L-TARTRATE	TOLTERODINE L-TARTRATE 4MG	CAPSULES	RECIEPT	For the treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence.
1422	DEXACORT	DEXACORT FORTE	DEXAMETHASONE SODIUM PHOSPHATE	DEXAMETHASONE SODIUM PHOSPHATE 20MG/ML	SOLUTION	RECIEPT	Intravenous use as adjunctive treatment of severe shock of hemorrhagic, traumatic, surgical or septic origin.
1425	DEXAMETHASONE	DEXAMETHASONE 0.5 MG	DEXAMETHASONE	DEXAMETHASONE 0.5MG	TABLETS	RECIEPT	Anti-inflammatory.
1426	DEXAMETHASONE	DEXAMETHASONE 2 MG	DEXAMETHASONE	DEXAMETHASONE 2MG	TABLETS	RECIEPT	Anti - inflammatory.
1427	DEXAMETHASONE	DEXAMETHASONE KERN PHARMA	DEXAMETHASONE AS SODIUM PHOSPHATE	DEXAMETHASONE AS SODIUM PHOSPHATE 4MG/ML	SOLUTION	RECIEPT	Dexamethasone Kern Pharma is indicated in the treatment of: • Endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia. • Allergy: Severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs. • Ophtalmic: Serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers. • Inflammatory Bowel dis.: Systemic treatment in exacerbations of ulcerative colitis and regional enteritis. • Dermatological diseases (pemphigus, Stevens Johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • Respiratory diseases (symptomatic sarcoidosis, berylliosis, Loeffler's syndrome) • Haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia • Nephrotic syndrome of the idioplathic type or that due to lupus erythematosus • Cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis • Collagen diseases: Active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, Juvenile idiopathic arthritis with severe systemic-onset form (Still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, SLE, temporal arteritis. • Infectious Diseases: Bacterial meningitis – adjunct to antibiotics in suspected Pneumococcal meningitis and TB meningitis. Severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. Only with simultaneous anti-infective therapy) • Fetal lung maturation • Chemotherapy – associated nausea and vomiting • Multiple Myeloma – part of chemotherapy protocols (eg VAD) • Prevention and treatment of acute mountain sickness/HACE
1436	DEXAMOL	DEXAMOL KID	PARACETAMOL	PARACETAMOL 250MG	TABLETS		Analgesic and antipyretic
1437	DEXAMOL	DEXAMOL KID 20TAB	PARACETAMOL	PARACETAMOL 250MG	TABLETS		Analgesic and antipyretic
1444	DEXAMOL	DEXAMOLCOLD DAY + NIGHT (30 + 20)	PARACETAMOL	PARACETAMOL 325MG;GUAIFENESIN 200MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG;DEXTROMETHORPHAN HYDROBROMIDE 10MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה.
1445	DEXAMOL	DEXAMOLCOLD DAY + NIGHT (48 + 16)	PARACETAMOL	PARACETAMOL 325MG;GUAIFENESIN 200MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG;DEXTROMETHORPHAN HYDROBROMIDE 10MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה.
1446	DEXAMOL	DEXAMOLCOLD DAY CARE	PARACETAMOL	PARACETAMOL 325MG;GUAIFENESIN 200MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG;DEXTROMETHORPHAN HYDROBROMIDE 10MG	TABLETS	RECIEPT	For the symptomatic relief of cold, cough and nasal congestion accompanied by fever and pain, for day care.
1434	DEXAMOL	DEXAMOL COLD DAY 30 CAPLIOTS	PARACETAMOL	PARACETAMOL 325MG;GUAIPHENESIN 200MG;DEXTROMETORPHAN 10MG;PSEUDOEPHEDRINE 25MG	TABLETS	RECIEPT	For the symptomatic relief of cold, cough and nasal congestion accompanied by fever and pain, for day care.
1430	DEXAMOL	DEXAMOL	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
1431	DEXAMOL	DEXAMOL 500MG 20CAP	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Symptomatic relief of cold and nasal congestion accompanied by fever and pain. night care medicine
1432	DEXAMOL	DEXAMOL 500MG 50CAP	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Symptomatic relief of cold and nasal congestion accompanied by fever and pain. night care medicine
1438	DEXAMOL	DEXAMOL PLUS	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE 50MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
1439	DEXAMOL	DEXAMOL PLUS 20 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE 50MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
1440	DEXAMOL	DEXAMOL PLUS 32 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE 50MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
1447	DEXAMOL	DEXAMOLCOLD NIGHT CARE	PARACETAMOL	PARACETAMOL 500MG;CHLORPHENIRAMINE MALEATE 2MG;DEXTROMETHORPHAN HYDROBROMIDE 10MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	For the symptomatic relief of cold, cough and nasal congestion accompanied by fever and pain, for treatment at night.
1451	DEXAMOL	DEXAMOLSINUS NIGHT CARE	PARACETAMOL	PARACETAMOL 500MG;CHLORPHENIRAMINE MALEATE 2MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain. night care medicine
1442	DEXAMOL	DEXAMOL SINUS DAY 30 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain.
1441	DEXAMOL	DEXAMOL SINUS D30&N20	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG;CHLORPHENIRAMINE MALEATE 2MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain.
1443	DEXAMOL	DEXAMOL SINUS NIGHT 20 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG;CHLORPHENIRAMINE MALEATE 2MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain.
1435	DEXAMOL	DEXAMOL COLD NIGHT 20 CAPLIOTS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG;DEXTROMETHORPHAN 10MG;CHLORPENIRAMINE MALEATE 2MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain.
1448	DEXAMOL	DEXAMOLSINUS DAY + NIGHT ( 30 + 20 )	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה
1449	DEXAMOL	DEXAMOLSINUS DAY + NIGHT ( 48 + 16 )	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	מארז התרופה מכיל שתי אריזות נפרדות: לטיפול ביום ולטיפול בלילה. למידע נוסף יש להקליד את שם התרופה המופיע על האריזה הנפרדת, או לסרוק את הברקוד שעליה.
1450	DEXAMOL	DEXAMOLSINUS DAY CARE	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain. day care medicine
1433	DEXAMOL	DEXAMOL COLD D30&N20	PARACETAMOL	PARACETAMOL;GUAIPHENESIN;DEXTR	TABLETS		Analgesic and antipyretic.
1452	DEXEFRIN	DEXEFRIN EYE DROPS	PHENYLEPHRINE HYDROCHLORIDE	PHENYLEPHRINE HYDROCHLORIDE 0.12%;DEXAMETHASONE AS SODIUM PHOSPHATE 0.1%;NEOMYCIN AS SULFATE 0.5%	DROPS	RECIEPT	Ocular inflammatory conditions associated with bacterial infection.
1453	DEXILANT	DEXILANT 30 MG	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE 30MG	CAPSULES	RECIEPT	Dexilant 30 is indicated in adults and in adolescents aged 12 to 17 years for the following: • Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn • Short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (GORD).
1455	DEXILANT	DEXILANT 60 MG	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE 60MG	CAPSULES	RECIEPT	Dexilant 60 is indicated in adults and in adolescents aged 12 to 17 years for the following: • Treatment of erosive reflux oesophagitis
1457	DEXIMUNE	DEXIMUNE 100	CICLOSPORIN	CICLOSPORIN 100MG	CAPSULES	RECIEPT	Prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that did not respond to other treatment. Atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis: Severe cases in which standard treatments are ineffective or inappropriate. Nephrotic syndrom type MCD (minimal change disease) in cases where conventional therapy has failed.
1458	DEXIMUNE	DEXIMUNE 25	CICLOSPORIN	CICLOSPORIN 25MG	CAPSULES	RECIEPT	Prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that did not respond to other treatment. Atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis: Severe cases in which standard treatments are ineffective or inappropriate. Nephrotic syndrom type MCD (minimal change disease) in cases where conventional therapy has failed.
1459	DEXIMUNE	DEXIMUNE 50	CICLOSPORIN	CICLOSPORIN 50MG	CAPSULES	RECIEPT	Prophylaxis of organ rejection in kidney, liver, heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejections in patients previously treated with other immunosuppresive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that does not respond to other treatment . Atopic dermatitis in adults only up to 8 weeks, for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis, severe cases when standard treatment is ineffective or inappropriate. Nephrotic syndrome type MCD (minimal change disease) in cases where conventional therapy has failed.
1460	DEX-OTIC	DEX-OTIC	DEXAMETHASONE SODIUM PHOSPHATE	DEXAMETHASONE SODIUM PHOSPHATE 1MG/ML;NEOMYCIN SULFATE 5MG/ML;POLYMYXIN B SULFATE 10000U/ML	DROPS	RECIEPT	Inflammatory conditions, superficial bacterial infections.
1469	DEXTROSE	DEXTROSE 5 % AND SODIUM CHLORIDE 0.33 %	GLUCOSE ANHYDROUS	GLUCOSE ANHYDROUS 5G/100ML;SODIUM CHLORIDE 0.33G/100ML	SOLUTION	RECIEPT	Supply of water for administration of electrolytes or calories. Vehicle for therapeutic regimen.
1470	DEXTROSE	DEXTROSE 5 % AND SODIUM CHLORIDE 0.45 % INJECTION	GLUCOSE ANHYDROUS	GLUCOSE ANHYDROUS 5G/100ML;SODIUM CHLORIDE 0.45G/100ML	SOLUTION	RECIEPT	Supply of water for administration of electrolytes or calories. Vehicle for therapeutic regimen.
1476	DEXTROSE	DEXTROSE INJECTION 10%	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 10%	SOLUTION	RECIEPT	As intravenous injection: Dextrose 10 % injection is indicated as a source of water and calories. As parenteral nutrient: Dextrose 10 % injection is indicated as a caloric component in parenteral nutrition regimen. It is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) The alimentary tract cannot should not be used. 2) Gastrointestinal absorption of protein is impaired, or 3) metabolic requirements for protein are substantially increased, as extensive burns.
1461	DEXTROSE	DEXTROSE 20 % INJECTION	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 20G/100ML	SOLUTION	RECIEPT	Dextrose injection is indicated as a caloric compnent in parenteral nutrition regimen. It is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot/should not be used 2) gastrointestinal absorption of protein is impaired or 3) metabolic requirement sfor protein are substantially increases as extensive burns.
1474	DEXTROSE	DEXTROSE 5% IN 0.9 % SODIUM CHLORIDE INJECTION	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 5%;SODIUM CHLORIDE 0.9%	SOLUTION	RECIEPT	Intravenous solutions are indicated as a source of water, electrolytes and/or calories.
1466	DEXTROSE	DEXTROSE 5 %	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 55G/1000ML	SOLUTION	RECIEPT	Vehicle solution for supplementary medication. Energy supply, hypertonic dehydration.
1477	DEXTROSE	DEXTROSE INJECTION 5 %	GLUCOSE HYDROUS	GLUCOSE HYDROUS 5G/100ML	SOLUTION	RECIEPT	A source of water supply and calories.
1475	DEXTROSE	DEXTROSE 50 % INJECTION	GLUCOSE MONOHYDRATE	GLUCOSE MONOHYDRATE 50%	SOLUTION	RECIEPT	Dextrose 50 % injection is indicated as a caloric component in a parenteral nutrition regimen. It is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot/should not be used 2) gastrointestinal absorption of protein is impaired or 3) metabolic requirements for protein are substantially increased , as with extensive burns.
1472	DEXTROSE	DEXTROSE 5% AND 0.33% SODIUM CHLORIDE INJECTION	GLUCOSE MONOHYDRATE	GLUCOSE MONOHYDRATE 5G/100ML;SODIUM CHLORIDE 0.33G/100ML	SOLUTION	RECIEPT	A source of water, electrolytes and calories.
1464	DEXTROSE	DEXTROSE 4.3 % AND 0.18 % SODIUM CHLORIDE INJECTION	SODIUM CHLORIDE	SODIUM CHLORIDE 0.18G/100ML;DEXTROSE MONOHYDRATE 4.68G/100ML	SOLUTION	RECIEPT	For replacing calories and electrolytes.
1465	DEXTROSE	DEXTROSE 4.3 % AND SODIUM CHLORIDE 0.18 % INJECTION	SODIUM CHLORIDE	SODIUM CHLORIDE 0.18G/100ML;GLUCOSE ANHYDROUS 4.3G/100ML	SOLUTION	RECIEPT	Supply of water for administration of electrolytes or calories. Vehicle for therapeutic regimen.
1462	DEXTROSE	DEXTROSE 3.3 % AND SODIUM CHLORIDE 0.3 % INJECTION	SODIUM CHLORIDE	SODIUM CHLORIDE 0.3G/100ML;GLUCOSE ANHYDROUS 3.3G/100ML	SOLUTION	RECIEPT	Supply of water for administration of electrolytes or calories. Vehicle for therapeutic regimen.
1463	DEXTROSE	DEXTROSE 3.3% AND 0.3 % SODIUM CHLORIDE INJECTION	SODIUM CHLORIDE	SODIUM CHLORIDE 0.3G/100ML;GLUCOSE MONOHYDRATE 3.3G/100ML	SOLUTION	RECIEPT	A source of water supply, electrolytes and calories.
1468	DEXTROSE	DEXTROSE 5 % AND SODIUM CHLORIDE 0.3 % AND POTASSIUM CHLORIDE 0.15% INJECTION	SODIUM CHLORIDE	SODIUM CHLORIDE 0.3G/100ML;POTASSIUM CHLORIDE 0.15G/100ML;GLUCOSE ANHYDROUS 5G/100ML	SOLUTION	RECIEPT	Supply of water for administration of electrolytes or calories. Vehicle for therapeutic regimen.
1471	DEXTROSE	DEXTROSE 5 % AND SODIUM CHLORIDE 0.9 % INJECTION	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9G/100ML;GLUCOSE ANHYDROUS 5G/100ML	SOLUTION	RECIEPT	Supply of water for administration of electrolytes or calories. Vehicle for therapeutic regimen.
1473	DEXTROSE	DEXTROSE 5% AND 0.45% SODIUM CHLORIDE INJECTION	SODIUM CHLORIDE	SODIUM CHLORIDE 4.5MG/ML;GLUCOSE AS MONOHYDRATE 50MG/ML	SOLUTION	RECIEPT	Provides electrolytes and calories and is a source of water for hydration.
1478	DIALINE CALCIUM PERITONEAL DIALYSIS	DIALINE LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH 1.5 % DEXTROSE	GLUCOSE HYDROUS	GLUCOSE HYDROUS 1.5G/100ML;CALCIUM CHLORIDE 18.3MG/100ML DIHYDRATE;SODIUM CHLORIDE 538MG/100ML;LACTIC ACID AS SODIUM 448MG/100ML;MAGNESIUM CHLORIDE 5.08MG/100ML	SOLUTION	RECIEPT	For use in chronic renal failure patients being maintained in peritoneal dialysis.
1479	DIALINE CALCIUM PERITONEAL DIALYSIS	DIALINE LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH 2.5 % DEXTROSE	GLUCOSE HYDROUS	GLUCOSE HYDROUS 2.5G/100ML;CALCIUM CHLORIDE 18.3MG/100ML DIHYDRATE;SODIUM CHLORIDE 538MG/100ML;LACTIC ACID AS SODIUM 448MG/100ML;MAGNESIUM CHLORIDE 5.08MG/100ML	SOLUTION	RECIEPT	For use in chronic renal failure patients being maintained in peritoneal dialysis.
1480	DIALINE CALCIUM PERITONEAL DIALYSIS	DIALINE LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH 4.25 % DEXSTROSE	GLUCOSE HYDROUS	GLUCOSE HYDROUS 4.25G/100ML;MAGNESIUM CHLORIDE 5.08MG/100ML;SODIUM CHLORIDE 538MG/100ML;LACTIC ACID AS SODIUM 448MG/100ML;CALCIUM CHLORIDE 18.3MG/100ML DIHYDRATE	SOLUTION	RECIEPT	For use in chronic renal failure patient being maintained in peritoneal dialysis.
1483	DIALINE DIALYSIS	DIALINE PERITONEAL DIALYSIS SOLUTION WITH 4.25 % DEXTROSE	CALCIUM CHLORIDE	CALCIUM CHLORIDE 25.7MG/100ML DIHYDRATE;LACTIC ACID AS SODIUM 448MG/100ML;MAGNESIUM CHLORIDE 5.08MG/100ML;GLUCOSE 3.86G/100ML ANHYDROUS;SODIUM CHLORIDE 538MG/100ML	SOLUTION	RECIEPT	Indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis.
1482	DIALINE DIALYSIS	DIALINE PERITONEAL DIALYSIS SOLUTION WITH 2.5% DEXTROSE	DEXTROSE MONOHYDRATE	DEXTROSE MONOHYDRATE 2.5G/100ML;SODIUM CHLORIDE 538MG/100ML;SODIUM LACTATE 448MG/100ML;CALCIUM CHLORIDE DIHYDRATE 25.7MG/100ML;MAGNESIUM CHLORIDE HEXAHYDRATE 5.08MG/100ML	SOLUTION	RECIEPT	Indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis
1481	DIALINE DIALYSIS	DIALINE PERITONEAL DIALYSIS SOLUTION WITH 1.5% DEXTROSE	LACTIC ACID AS SODIUM	LACTIC ACID AS SODIUM 448MG/100ML;MAGNESIUM CHLORIDE HEXAHYDRATE 5.08MG/100ML;CALCIUM CHLORIDE DIHYDRATE 25.7MG/100ML;SODIUM CHLORIDE 538MG/100ML;DEXTROSE HYDROUS 1.5G/100ML	SOLUTION	RECIEPT	Indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis.
1484	DIAMILLA	DIAMILLA	DESOGESTREL	DESOGESTREL 0.075MG	TABLETS	RECIEPT	Oral contraception .
1485	DIANE	DIANE 35	ETHINYLESTRADIOL	ETHINYLESTRADIOL 35MCG;CYPROTERONE ACETATE 2MG	TABLETS	RECIEPT	Treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. For the treatment of acne, Diane-35 should only be used after topical therapy or systemic antibiotic treatments have failed.
1488	DIANEAL	DIANEAL PD-4 PERITONEAL DIALYSIS SOLUTION WITH 3.86 % GLUCOSE	GLUCOSE	GLUCOSE 38.6G/L ANHYDROUS;LACTIC ACID AS SODIUM 4.5G/L;GLUCOSE AS MONOHYDRATE 42.5G/L;MAGNESIUM CHLORIDE 0.051G/L;SODIUM CHLORIDE 5.4G/L;CALCIUM CHLORIDE 0.184G/L	SOLUTION	RECIEPT	Indicated whenever peritoneal dialysis is employed including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.
1487	DIANEAL	DIANEAL PD-4 PERITONEAL DIALYSIS SOLUTION WITH 2.27 % GLUCOSE	SODIUM CHLORIDE	SODIUM CHLORIDE 5.4G/L;GLUCOSE 22.7G/L ANHYDROUS;CALCIUM CHLORIDE 0.184G/L;MAGNESIUM CHLORIDE 0.051G/L;GLUCOSE AS MONOHYDRATE 25G/L;LACTIC ACID AS SODIUM 4.5G/L	SOLUTION	RECIEPT	Indicated whenever peritoneal dialysis is employed including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.
1489	DIANEAL	DIANEAL PD-4 PERITONEAL SOLUTION WITH 1.36 % GLUCOSE	SODIUM CHLORIDE	SODIUM CHLORIDE 5.4G/L;MAGNESIUM CHLORIDE 0.051G/L;CALCIUM CHLORIDE 0.184G/L;GLUCOSE AS MONOHYDRATE 15G/L;GLUCOSE 13.6G/L ANHYDROUS;LACTIC ACID AS SODIUM 4.5G/L	SOLUTION	RECIEPT	For peritoneal dialysis including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.
1490	DIATRIM	DIATRIM	DIACEREIN	DIACEREIN 50MG	CAPSULES	RECIEPT	Symptomatic treatment of functional symptoms of osteoarthritis.
1494	DIBENYLINE	DIBENYLINE	PHENOXYBENZAMINE HYDROCHLORIDE	PHENOXYBENZAMINE HYDROCHLORIDE 10MG	CAPSULES	RECIEPT	Pheochromocytoma, benign prostatic hypertrophy.
1495	DICLECTIN	DICLECTIN	PYRIDOXINE (VIT B6) HYDROCHLORIDE	PYRIDOXINE (VIT B6) HYDROCHLORIDE 10MG;DOXYLAMINE SUCCINATE 10MG	TABLETS	RECIEPT	Diclectin is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
1497	DICLOFTIL	DICLOFTIL 0.1 %	DICLOFENAC SODIUM	DICLOFENAC SODIUM 0.1%	SOLUTION	RECIEPT	Post-operative inflammation following cataract extraction. Control of ocular pain and discomfort associated with corneal epithelial defects after laser excimer PRK or accidental trauma.
1500	DICLOPLAST	DICLOPLAST PACK 5	DICLOFENAC HYDROXYETHYL	DICLOFENAC HYDROXYETHYL	PLASTER		Local treatment of pain, inflammation and swelling in adults and adolescents aged 12 years and over due to: • Soft tissue injuries: Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. • By physician's order - Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers Should not be used for more than 14 days
1498	DICLOPLAST	DICLOPLAST	DICLOFENAC SODIUM	DICLOFENAC SODIUM 140MG	PATCHES	RECIEPT	Dicloplast is indicated for topical treatment of rheumatic diseases, pain and non-infectious inflammation.
1501	DICLOREN	DICLOREN GEL	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Self medication for the following indications: Local treatment of pain, inflammation and swelling due to: • Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. By Physicians order : • Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers
1502	DICLOREN	DICLOREN GEL 50GR	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Self medication for the following indications: Local treatment of pain, inflammation and swelling due to: • Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. By Physicians order : • Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers
1503	DICLOVIT	DICLOVIT	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of rheumatic diseases, non infected inflammations and pain.
1504	DICLOVIT	DICLOVIT 1% 50GR	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of rheumatic diseases, non infected inflammations and pain.
1505	DICLOVIT	DICLOVIT 1%100 GR	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of rheumatic diseases, non infected inflammations and pain.
1506	DIFICLIR	DIFICLIR	FIDAXOMICIN	FIDAXOMICIN 200MG	TABLETS	RECIEPT	Indicated in adults for the treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD)
1507	DIFLUCAN	DIFLUCAN 50 MG/5 ML	FLUCONAZOLE	FLUCONAZOLE 50MG/5ML	POWDER	RECIEPT	Fluconazole is indicated in the following fungal infections. Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis. • Coccidioidomycosis. • Invasive candidiasis. • Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. • Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate. • Candidal balanitis when local therapy is not appropriate. • Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated. • Tinea unguinium (onychomycosis) when other agents are not considered appropriate. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year). • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation). Fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
1508	DIFOLTA	DIFOLTA	PRALATREXATE	PRALATREXATE 20MG/ML	SOLUTION	RECIEPT	For the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
1509	DIGOXIN	DIGOXIN KERN PHARMA 0.25 MG	DIGOXIN	DIGOXIN 0.25MG	TABLETS	RECIEPT	Cardiac failure: Digoxin KERN PHARMA is indicated for the treatment of chronic cardiac failure where the principal cause is systolic dysfunction. The greatest therapeutic benefit is achieved in patients with ventricular dilatation. Digoxin KERN PHARMA is specifically indicated where cardiac failure is accompanied by atrial fibrilation. Supraventricular arrhythmias: Digoxin KERN PHARMA is indicated for the treatment of certain supraventricular arrhythmias, particularly atrial fibrillation and flutter, where its principal beneficial effect is to reduce the ventricular rate.
1510	DIGOXIN	DIGOXIN-ZORI	DIGOXIN	DIGOXIN 0.25MG	TABLETS	RECIEPT	Congestive heart failure (CHF), atrial fibrillation, atrial flutter, supraventricular tachycardia.
1511	DILANTIN	DILANTIN 125	PHENYTOIN	PHENYTOIN 125MG/5ML	SUSPENSION	RECIEPT	For the control of tonic clonic (Grand- mal) and psychomotor (Temporal lobe seizures).
1512	DILATAM	DILATAM 120 SR	DILTIAZEM HYDROCHLORIDE	DILTIAZEM HYDROCHLORIDE 120MG	TABLETS	RECIEPT	Hypertension: either as monotherapy or with other antihypertensive medications such as diuretics. Angina pectoris: chronic stable angina, angina due to coronary artery spasm.
1514	DILTIAZEM	DILTIAZEM TEVA 30 MG	DILTIAZEM HYDROCHLORIDE	DILTIAZEM HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Calcium channel blocker for the treatment of angina pectoris.
1515	DILTIAZEM	DILTIAZEM TEVA 60 MG	DILTIAZEM HYDROCHLORIDE	DILTIAZEM HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Calcium channel blocker for the treatment of angina pectoris.
6002	DIMENHYDRINATE	DIMENHYDRINATE 100MG	DIMENHYDRINATE	DIMENHYDRINATE 100MG	TABLETS		בחילות nausea
1517	DIOVAN	DIOVAN 160 MG FILM-COATED TABLETS	VALSARTAN	VALSARTAN 160MG	TABLETS	RECIEPT	For treatment of hypertension. Diovan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Diovan signicantly reduced hospitalisations for heart failure. There is no evidence that Diovan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.
1518	DIOVAN	DIOVAN 40 MG FILM-COATED TABLETS	VALSARTAN	VALSARTAN 40MG	TABLETS	RECIEPT	Diovan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Diovan significantly reduced hospitalisations for heart failure. There is no evidence that Diovan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.
1519	DIOVAN	DIOVAN 80 MG FILM-COATED TABLETS	VALSARTAN	VALSARTAN 80MG	TABLETS	RECIEPT	For treatment of hypertension. Diovan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Diovan signicantly reduced hospitalisations for heart failure. There is no evidence that Diovan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.
1520	DIPEPTIVEN	DIPEPTIVEN	L- ALANINE	L- ALANINE 8.2 G/100ML;L - GLUTAMINE 13.46G/100ML	CONCENTRATE	RECIEPT	Dipeptiven is indicated as part of an intravenous parenteral nutrition regimen as a supplement to amino acid solutions or an amino acid containing infusion regimen. In patients in extreme cases of hypercatabolic stage such as major abdominal surgery, BMT, diffuse injury of GI mucous.
1523	DIPHERELINE	DIPHERELINE 0.1 MG	TRIPTORELIN AS ACETATE	TRIPTORELIN AS ACETATE 0.1MG/VIAL	POWDER	RECIEPT	Female infertility: Management of ovarian stimulation in association with the gonadotrophins (hMG, FSH, hCG) in view of in vitro fertilisation and embrio transfer (I.V.F.E.T.) and other assisted conception techniques.
1524	DIPHERELINE	DIPHERELINE 3.75 MG	TRIPTORELIN AS ACETATE	TRIPTORELIN AS ACETATE 3.75MG/VIAL	POWDER	RECIEPT	Prostate cancer: Treatment of prostate cancer with metastases. Patients who have not previously received hormone therapy show a more marked response to the treatment and respond more frequently if the patient has not previously receieved another hormone treatment. Precocious puberty: (Before 8 years in girls and 10 years in boys). Genital and extragenital endometriosis (stage I to stage IV): Treatment should not be administered for more than 6 months. It is not recomended to start a second treatment course with triptorelin or another GnRH analogue. Treatment of uterine fibromyomas prior to surgery: associated with Anaemia ( haemoglobin less than, or equal to 8 g/dl). When a reduction in the size of the fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery. The treatment duration is restricted to 3 months. Female infertility: Supplementary treatment in combination with gonadotrophins (hMG, FSH, hCG) to induce ovulation with a view to in vitro fertilisation and embryo transfer (I.V.F.E.T.).
1525	DIPROFOL	DIPROFOL 1 %	PROPOFOL	PROPOFOL 10MG/ML	EMULSION	RECIEPT	Diprofol 1% is a short-acting intravenous general anaesthetic for: • Induction and maintenance of general anaesthesia in adults and children > 1 month. • Sedation of ventilated patients > 16 years of age in the intensive care unit. • Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > 1 month. .
1527	DIPROFOL	DIPROFOL 2 %	PROPOFOL	PROPOFOL 20MG/ML	EMULSION	RECIEPT	Propofol 2% is a short- acting intravenous general anaesthetic for: • Induction and maintenance of general anaethesia in adults and children > 3 years. • Sedation of ventilated patients >16 years of age in the intensive care unit. • Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > 3 years.
1529	DIPROGENTA	DIPROGENTA OINTMENT	BETAMETHASONE AS DIPROPIONATE	BETAMETHASONE AS DIPROPIONATE 0.5MG/1 G;GENTAMICIN AS SULFATE 1MG/1 G	OINTMENT	RECIEPT	Topical treatment of dermatosis complicated by secondary infection caused by organisms sensitive to Gentamicin
1528	DIPROGENTA	DIPROGENTA CREAM	GENTAMICIN (AS SULFATE)	GENTAMICIN (AS SULFATE) 1MG/G;BETAMETHASONE AS DIPROPIONATE 0.5MG/G	CREAM	RECIEPT	For the relief of the inflammatory manifestations of corticosteroid-responsive dermatoses when complicated by secondary infections caused by organisms susceptible to gentamycin.
1530	DIPROSALIC	DIPROSALIC LOTION	SALICYLIC ACID	SALICYLIC ACID 20MG/G;BETAMETHASONE AS DIPROPIONATE 0.5MG/G	LOTION	RECIEPT	Provides anti-inflammatory, antipruritic, anti-allergic and keratinolytic activity in the topical management of subacute and chronic hyperkeratotic and dry dermatoses responsive to corticosteroid therapy
1531	DIPROSALIC	DIPROSALIC OINTMENT	SALICYLIC ACID	SALICYLIC ACID 30MG/G;BETAMETHASONE AS DIPROPIONATE 0.5MG/G	OINTMENT	RECIEPT	Provides anti inflammatory, antipruritic, anti allergic and chronic hyperkeratotic and dry keratolytic activity in the topical management of subacute dermatoses responsive to corticosteroid therapy.
1532	DIPROSPAN	DIPROSPAN INJECTION	BETAMETHASONE SODIUM PHOSPHATE	BETAMETHASONE SODIUM PHOSPHATE 2MG/ML;BETAMETHASONE AS DIPROPIONATE 5MG/ML	SUSPENSION	RECIEPT	Produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.
1534	DIPYRAZ	DIPYRAZ ORAL DROPS 500MG/ML 20ML	DIPYRONE	DIPYRONE 500MG/1ML	LIQUID		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
1533	DIPYRAZ	DIPYRAZ ORAL DROPS	DIPYRONE	DIPYRONE 500MG/ML	DROPS		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
1535	DIPYRONE	DIPYRONE KALCEKS 500 MG/ML	METAMIZOLE SODIUM MONOHYDRATE	METAMIZOLE SODIUM MONOHYDRATE 500MG/1ML DIPYRONE	SOLUTION	RECIEPT	As an analgesic: Dypirone Kalceks, by intravenous administration, is indicated for the relief of severe and acute pain when oral treatment is not feasible or suitable, as in post-traumatic or post-surgical pain, biliary or renal colic, and pain associated with malignant diseases. As an antipyretic: Dypirone Kalceks by intramuscular administration is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision
1536	DISEPTYL	DISEPTYL	SULPHAMETHOXAZOLE	SULPHAMETHOXAZOLE 4%;TRIMETHOPRIM 0.8%	SUSPENSION	RECIEPT	Antibacterial for treatment of infections due to susceptible micro-organisms in the upper and lower respiratory tract infections, urinary tract infections, gastro-intestinal tract infections.
1537	DISEPTYL	DISEPTYL FORTE CAPLETS	TRIMETHOPRIM	TRIMETHOPRIM 160MG;SULPHAMETHOXAZOLE 800MG	TABLETS	RECIEPT	Antibacterial treatment in infections due to susceptible microorganisms in urinary, respiratory and gastro-intestinal tract .
1538	DISOTHIAZIDE	DISOTHIAZIDE 25	HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE 25MG	TABLETS	RECIEPT	Diuretic to treat hypertension, edema.
1539	DOBUTAMINE	DOBUTAMINE BAXTER 12.5 MG/ML	DOBUTAMINE AS HYDROCHLORIDE	DOBUTAMINE AS HYDROCHLORIDE 12.5MG/ML	CONCENTRATE	RECIEPT	Dobutamine is indicated for patients who require a positive inotropic support in the short term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures, especially when a low cardiac output is associated with raised pulmonary pressure.
1540	DOCETAXEL	DOCETAXEL EBEWE 10 MG/1 ML	DOCETAXEL	DOCETAXEL 10MG/1ML	CONCENTRATE	RECIEPT	Breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. docetaxel in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Non-small cell lung cancer : docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma. Ovarian Cancer: docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. Prostate cancer: docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Esophageal cancer: Docetaxel for the treatment of esophageal cancer. Gastric cancer : Docetaxel for the treatment of advanced gastric cancer. Head and neck (SCCHN) : docetaxel as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. Docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
1541	DOCETAXEL	DOCETAXEL HOSPIRA 10 MG/ML	DOCETAXEL	DOCETAXEL 10MG/1ML	SOLUTION	RECIEPT	Breast cancer: Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Doxorubicin and cyclophosphamide followed by Docetaxel in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Non-small cell lung cancer: Docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma. Ovarian Cancer: Docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. Prostate cancer: Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Esophageal cancer: Docetaxel for the treatment of esophageal cancer. Gastric cancer: Docetaxel for the treatment of advanced gastric cancer. Head and neck (SCCHN): Docetaxel as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. Docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck
1543	DOLESTINE	DOLESTINE	PETHIDINE HYDROCHLORIDE	PETHIDINE HYDROCHLORIDE 50MG/ML	SOLUTION	RECIEPT	Relief of severe pain pre-operative medication support of anesthesia obstetrical analgesia.
1547	DONEPEZIL	DONEPEZIL TEVA 10 MG	DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of mild to moderately severe Alzheimer's dementia.
1550	DONEPEZIL	DONEPEZIL TEVA 5 MG	DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Treatment of mild to moderately severe Alzheimer's dementia.
1553	DOPAMINE HCI	DOPAMINE HCI - FRESENIUS 200 MG/5 ML	DOPAMINE HYDROCHLORIDE	DOPAMINE HYDROCHLORIDE 200MG/5ML	SOLUTION	RECIEPT	To correct hemodynamic imbalances associated with myocardial infarction trauma septic shock and cardiac surgery. Dopamine Hydrochloride is used in the treatment of : 1. Shock unresponsive to replacement of fluid loss and especially where renal function is impaired. 2. To correct haemodynamic imbalances associated with myocardial infarction trauma septic shock and cardiac surgery. 3. It is also used in the management of chtonic refractory congestive heart failure.
1554	DOPICAR	DOPICAR	LEVODOPA	LEVODOPA 250MG;CARBIDOPA 25MG	TABLETS	RECIEPT	For the relief of symptoms associated with parkinson's disease.
1556	DORMINOL NIGHT	DORMINOL NIGHT	HOP CONES DRY EXTRACT	HOP CONES DRY EXTRACT 60MG;VALERIAN ROOT DRY EXTRACT 250MG	TABLETS		Herbal medicinal product for problems falling asleep and staying asleep, as well as restless sleep.
1557	DORMINOL NIGHT	DORMINOL NIGHT 20 tab	HOP CONES DRY EXTRACT	HOP CONES DRY EXTRACT 60MG;VALERIAN ROOT DRY EXTRACT 250MG	TABLETS		Herbal medicinal product for problems falling asleep and staying asleep, as well as restless sleep.
1558	DORZATOL	DORZATOL-AVENIR	TIMOLOL AS MALEATE	TIMOLOL AS MALEATE 5MG/ML;DORZOLAMIDE AS HYDROCHLORIDE 20MG/ML	DROPS	RECIEPT	For the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension, open-angle glaucoma, or other secondary open-angle glaucoma when concomitant therapy is appropriate.
1560	DORZOLAMIDE TIMOLOL	DORZOLAMIDE TIMOLOL TEVA PRESERVATIVE FRE	DORZOLAMIDE AS HCL	DORZOLAMIDE AS HCL 20MG/ML;TIMOLOL AS MALEATE 5MG/ML	SOLUTION	RECIEPT	For the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension, open-angle glaucoma or other secondary open-angle glaucomas when concomitant therapy is appropriate, and in patients who may be sensitive to a preservative, or for whom the use of a preservative-free formulation is otherwise advisable.
1559	DORZOLAMIDE TIMOLOL	DORZOLAMIDE TIMOLOL TARO	TIMOLOL AS MALEATE	TIMOLOL AS MALEATE 5MG/ML;DORZOLAMIDE AS HYDROCHLORIDE 20MG/ML	DROPS	RECIEPT	For the treatment of elevated intraocular pressure (IOP ) in patients with ocular hypertension, open-angle glaucoma, or other secondary open-angle glaucoma when concomitant therapy is appropriate
1561	DOSTINEX	DOSTINEX	CABERGOLINE	CABERGOLINE 0.5MG	TABLETS	RECIEPT	Treatment of hyperprolactinemic disorders. Dostinex is indicated for the treatment of dysfunctions associated with hyperprolactinemia, including amenorrhea, oligomenorrhea, anovulation and galactorrhea. Dostinex is indicated in patients with prolactin-secreting pituitary adenomas (micro-and macroprolactinomas), idiopathic hyperprolactinemia, or empty sella syndrome with associated hyperprolactinemia. Inhibition and supression of lactation .
1563	DOTAREM	DOTAREM PRE-FILLED SYRINGES	GADOTERIC ACID	GADOTERIC ACID 27.932 G/100ML	SOLUTION	RECIEPT	Enhancement of contrast in magnetic resonance imaging. Aencephalic and spinal pathologies: brain tumours tumours of the spine and the surrounding tissue intervertebral disk prolapse infectious diseases. Abdominal pathologies: primary and secondary liver tumours. Osteo-articular pathology: bone and soft tissue tumours synovial diseases. Magnetic resonance imaging for angiography.
1562	DOTAREM	DOTAREM	GADOTERIC ACID	GADOTERIC ACID 27.93G/100ML	SOLUTION	RECIEPT	Enhancement of contrast in magnetic resonance imaging. Aencephalic and spinal pathologies: brain tumours tumours of the spine and the surrounding tissue intervertebral disk prolapse infectious diseases. Abdominal pathologies: primary and secondary liver tumours. Osteo-articular pathology: bone and soft tissue tumours synovial diseases. Magnetic resonance imaging for angiography.
1566	DOXORUBICIN	DOXORUBICIN "EBEWE" 2 MG/ML	DOXORUBICIN HYDROCHLORIDE	DOXORUBICIN HYDROCHLORIDE 2MG/ML	SOLUTION	RECIEPT	Soft tissue and bone sarcomas, Hodgkin's and non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms` tumor, carcinomas of the thyroid, breast, ovary, bladder, small cell bronchogenic carcinoma and neuroblastoma.
1567	DOXORUBICIN	DOXORUBICIN TEVA	DOXORUBICIN HYDROCHLORIDE	DOXORUBICIN HYDROCHLORIDE 2MG/ML	CONCENTRATE	RECIEPT	To produce regression in disseminated neoplastic conditions such as: - acute lymphoblastic leukemia, - acute myeloblastic leukemia, - Wilms' tumor neuroblastoma, - soft tissue and bone sarcomas, - breast carcinoma, - lymphomas of both Hodgkin's and non-Hodgkin's types, - bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types, - gastric carcinoma.
1568	DOXY	DOXY 100 CAPSULES	DOXYCYCLINE AS HYCLATE	DOXYCYCLINE AS HYCLATE 100MG	CAPSULES	RECIEPT	Treatment of infections due to bacteria which are sensitive to the product. For the prevention of malaria when orher drugs are not suitable or when the malaria parasite is resistant to other drugs, especially to Mefloquine.
1571	DOXYLIN	DOXYLIN 100	DOXYCYCLINE AS HYCLATE	DOXYCYCLINE AS HYCLATE 100MG	TABLETS	RECIEPT	Doxycycline has been found clinically effective in the treatment of a variety of infections caused by susceptible strains of Gram-positive and Gram-negative bacteria and certain other microorganisms. -Respiratory tract infections: Pneumonia and other lower respiratory tract infections due to susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis and other organisms. Mycoplasma pneumonia. Treatment of chronic bronchitis, sinusitis. -Urinary tract infections: Infections caused by susceptible strains of Klebsiella species, Enterobacter species, Escherichia coli, Streptococcus faecalis and other organisms. -Sexually transmitted diseases: Infections due to Chlamdyia trachomatis including uncomplicated urethral, endocervical or rectal infections. Non-gonococcal urethritis caused by Ureaplasma urealiticum (T-mycoplasma). Doxylin 100 is also indicated in infections due to Calymmatobacterium granulomatis. Doxylin is an alternative drug in the treatment of gonorrhoea and syphilis. Since Doxycycline is a member of the tetracycline series of antibiotics, it may be expected to be useful in the treatment of infections which respond to other tetracyclines, such as: -Ophthalmic infections: Treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral Doxycycline alone or in combination with topical agents. -Rickettsial infections: Rocky Mountain spotted fever, typhus group, Q fever, Coxiella endocarditis. -Other infections: Psittocosis, brucellosis (in combination with streptomycin), cholera, bubonic plague, louse and tick-borne relapsing fever including stage 1 and stage 2 Lyme disease, leptospirosis, tularaemia glanders, chloroquine-resistant falciparum malaria and acute intestinal amoebiasis (as an adjunct to amoebicides). Infections due to susceptible strains of Bacteroides species, and Listeria species. -Doxylin is an alternative drug in the treatment of leptospirosis, gas gangrene and tetanus. -Doxylin is indicated for prophylaxis in the following conditions: Scrub typhus, traveller's diarrhoea (enterotoxigenic Escherichia coli), leptospirosis, malaria and cholera. -Anthrax due to Bacillus anthracis, including inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
1579	DUAC	DUAC	CLINDAMYCIN AS PHOSPHATE	CLINDAMYCIN AS PHOSPHATE 1%W/W;BENZOYL PEROXIDE AS HYDROUS 5%W/W	GEL	RECIEPT	Mild to moderate acne vulgaris, particulary inflammatory lesions.
1580	DUAKLIR GENUAIR	DUAKLIR GENUAIR 340/12 MCG	FORMOTEROL FUMARATE DIHYDRATE	FORMOTEROL FUMARATE DIHYDRATE 11.8MCG;ACLIDINIUM AS BROMIDE 340MCG	POWDER	RECIEPT	Maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD)
1581	DUAVIVE	DUAVIVE	BAZEDOXIFENE ACETATE	BAZEDOXIFENE ACETATE 20MG;ESTROGENS CONJUGATED 0.45MG	TABLETS	RECIEPT	Treatment of the following conditions in women with a uterus: • Treatment of moderate to severe vasomotor symptoms associated with menopause • Prevention of postmenopausal osteoporosis
1583	DULERGIN	DULERGIN 500MG/ML 20ML	DIPYRONE	DIPYRONE 500MG/1ML	LIQUID		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
1582	DULERGIN	DULERGIN	DIPYRONE	DIPYRONE 500MG/ML	DROPS		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
1584	DULOXETINE	DULOXETINE DR TEVA 30 MG	DULOXETINE AS HYDROCHLORIDE	DULOXETINE AS HYDROCHLORIDE 30MG	CAPSULES	RECIEPT	Indicated for the treatment of major depressive episodes. Indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. Indicated for the treatment of generalized anxiety disorder (GAD). Indicated for the management of fibromyalgia. Management of chronic muscoskeletal pain. This has been established in studies in patients with chronic low ‎back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated
1585	DULOXETINE	DULOXETINE DR TEVA 60 MG	DULOXETINE AS HYDROCHLORIDE	DULOXETINE AS HYDROCHLORIDE 60MG	CAPSULES	RECIEPT	Indicated for the treatment of major depressive episodes. Indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. Indicated for the treatment of generalized anxiety disorder (GAD). Indicated for the management of fibromyalgia. Management of chronic muscoskeletal pain. This has been established in studies in patients with chronic low ‎back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated
1586	DUO SCABIL	DUO SCABIL 20GR	CROTAMITON	CROTAMITON 10%;SULPHUR 8%	CREAM		Anti scabies treatment, symptomatic treatment of skin irritation.
1595	DUO SCABIL	DUO-SCABIL	CROTAMITON	CROTAMITON 10%;SULPHUR PRECIPITATED 8%	CREAM		Anti scabies treatment, symptomatic treatment of skin irritation.
1587	DUODART	DUODART	DUTASTERIDE	DUTASTERIDE 0.5MG;TAMSULOSIN HYDROCHLORIDE 0.4MG	CAPSULES	RECIEPT	Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
1591	DUODOPA	DUODOPA	LEVODOPA	LEVODOPA 20MG/ML;CARBIDOPA AS MONOHYDRATE 5MG/ML	GEL	RECIEPT	Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
1593	DUORESP SPIROMAX	DUORESP SPIROMAX 160 MCG/4.5 MCG	FORMOTEROL FUMARATE DIHYDRATE	FORMOTEROL FUMARATE DIHYDRATE 4.5MCG/DOSE;BUDESONIDE MICRONIZED 160MCG/DOSE	POWDER	RECIEPT	Asthma DuoResp Spiromax 160/4.5 mcg/dose is indicated in adults and adolescents (12 years and older), for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor agonist) is appropriate: Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor agonists. Or Patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptor-agonists. Chronic Obstructive Pulmonary Disease (COPD) DuoResp Spiromax 160/4.5 mcg/dose is indicated in adults, aged 18 years and older, for the Symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1)< 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy
1594	DUORESP SPIROMAX	DUORESP SPIROMAX 320 MCG/9 MCG	FORMOTEROL FUMARATE DIHYDRATE	FORMOTEROL FUMARATE DIHYDRATE 9MCG/DOSE;BUDESONIDE MICRONIZED 320MCG/DOSE	POWDER	RECIEPT	DuoResp Spiromax 320/9 mcg/dose is indicated in adults and adolescents, age 12 -17 for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor-agonist) is appropriate: -Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor-agonists. Or - Patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptoragonists. Chronic Obstructive Pulmonary Disease (COPD) DuoResp Spiromax 320/9 mcg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in I second (FEV1) < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy
1597	DUOTRAV	DUOTRAV	TRAVOPROST	TRAVOPROST 40MCG/ML;TIMOLOL AS MALEATE 5MG/ML	SOLUTION	RECIEPT	Decrease of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
1598	DUPHASTON	DUPHASTON	DYDROGESTERONE	DYDROGESTERONE 10MG	TABLETS	RECIEPT	Cases where progesterone supplement is needed.
1599	DUPIXENT	DUPIXENT	DUPILUMAB	DUPILUMAB 150MG/1ML	SOLUTION	RECIEPT	Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
1600	DUPLEX	DUPLEX 10/160	VALSARTAN	VALSARTAN 160MG;AMLODIPINE AS BESILATE 10MG	TABLETS	RECIEPT	Treatment of essential hypertension. Duplex is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
1602	DUPLEX	DUPLEX 5/160	VALSARTAN	VALSARTAN 160MG;AMLODIPINE AS BESILATE 5MG	TABLETS	RECIEPT	Treatment of essential hypertension. Duplex is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
1604	DUPLEX	DUPLEX 5/80	VALSARTAN	VALSARTAN 80MG;AMLODIPINE AS BESILATE 5MG	TABLETS	RECIEPT	Treatment of essential hypertension. Duplex is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
1607	DURATEARS	DURATEARS OINT 3.5GR	MINERAL OIL	MINERAL OIL 3%;LANOLIN OIL 3%	OINTMENT		Eye dryness.
1606	DURATEARS	DURATEARS	MINERAL OIL	MINERAL OIL 30MG/G;LANOLIN 30MG/G;PETROLATUM 1G/G	OINTMENT		Eye dryness.
1608	DUTASTERIDE	DUTASTERIDE TARO	DUTASTERIDE	DUTASTERIDE 0.5MG	CAPSULES	RECIEPT	Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
1609	DUTASTERIDE	DUTASTERIDE TEVA	DUTASTERIDE	DUTASTERIDE 0.5MG	CAPSULES	RECIEPT	Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
1610	DYSPORT	DYSPORT 300	BOTULINUM A TOXIN	BOTULINUM A TOXIN 300U/VIAL Clostridium Botulinum Type A toxin-haemagglutinin complex	POWDER	RECIEPT	Dysport is indicated for symptomatic treatment of focal spasticity of: - Upper limbs in adults due to stroke or traumatic brain injury - Dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older. Dysport is indicated in adults for symptomatic treatment of: - Spasmodic torticollis - Blepharospasm - Hemifacial spasm. Dysport is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at frown, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient. Dysport is indicated for symptomatic treatment of persistent severe primary hyperhidrosis of the axillae, which interferes with the activities of daily living and is resistant to topical treatment.
1611	DYSPORT	DYSPORT 500	BOTULINUM A TOXIN	BOTULINUM A TOXIN 500U/VIAL Clostridium Botulinum Type A toxin-haemagglutinin complex	POWDER	RECIEPT	Dysport is indicated for symptomatic treatment of focal spasticity of: - Upper limbs in adults due to stroke or traumatic brain injury - Dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older. Dysport is indicated in adults for symptomatic treatment of: - Spasmodic torticollis - Blepharospasm - Hemifacial spasm. Dysport is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at frown, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient. Dysport is indicated for symptomatic treatment of persistent severe primary hyperhidrosis of the axillae, which interferes with the activities of daily living and is resistant to topical treatment.
6001	EASY GO ENEMA	EASY GO ENEMA 180ML	WATER FOR INJECTIONS	WATER FOR INJECTIONS 180ML	ENEMA		CONSTIPATION
1613	EASYLAX	EASYLAX TABLETS	PHENOLPHTALEIN YELLOW	PHENOLPHTALEIN YELLOW 120MG	TABLETS	RECIEPT	Laxative.
1615	EBETAXEL	EBETAXEL 6 MG/ML	PACLITAXEL	PACLITAXEL 6MG/ML	CONCENTRATE	RECIEPT	Paclitaxel is indicated alone or in combination, for the treatment of advanced carcinoma of the ovary. For the treatment of metastatic breast cancer after failure of combination chemotherapy. Prior therapy should have included an anthracycline unless clinically containdicated. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. Advanced non small cell lung cancer: Paclitaxel associated with cisplatinum is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Kaposis's sarcoma: Paclitaxel is indicated in the second-line treatment of AIDS related Kaposi's sarcoma. For the treatment of advanced gastric carcinoma.
1617	EBIXA	EBIXA TABLETS 10 MG	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of patient with moderate to severe Alzheimer's disease.
1616	EBIXA	EBIXA 5 MG/PUMP ACTUATION ORAL SOLUTION	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 10MG/G	DROPS	RECIEPT	Treatment of patient with moderately to severe Alzheimer's disease.
1618	EBIXA	EBIXA TABLETS 20 MG	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Treatment of patient with moderate to severe Alzheimer's disease.
1620	EDRONAX	EDRONAX	REBOXETINE METHAN SULFONATE	REBOXETINE METHAN SULFONATE 4MG	TABLETS	RECIEPT	Reboxetine is indicated for the acute treatment of depressive illness/major depression and for maintaining the clinical improvement in patients initially responding to treatment.
1621	EDURANT	EDURANT	RILPIVIRINE AS HYDROCHLORIDE	RILPIVIRINE AS HYDROCHLORIDE 25MG	TABLETS	RECIEPT	EDURANT™, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy.
1622	EFEXOR XR	EFEXOR XR 150	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 150MG	CAPSULES	RECIEPT	For the treatment of depression. Maintenance of recurrent depression. Generalized anxiety disorder (GAD) - short term and long-term. Social anxiety Disorder (SAD).
1624	EFEXOR XR	EFEXOR XR 75	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 75MG	CAPSULES	RECIEPT	For the treatment of depression. Maintenance of recurrent depression. Generalized anxiety disorder (GAD) - short term and long-term. Social anxiety Disorder (SAD).
1626	EFFERAMOL	EFFERAMOL	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
1627	EFFIENT	EFFIENT 10 MG	PRASUGREL AS HYDROCHLORIDE	PRASUGREL AS HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Effient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI] undergoing primary or delayed percutaneous coronary intervention (PCI). The increased efficacy should be balanced with the increased risk in patients with bleeding tendency in those who had TIA/CVA in the past and in those above the age of 75 or weight below 60 kg.
1628	EFFIENT	EFFIENT 5 MG	PRASUGREL AS HYDROCHLORIDE	PRASUGREL AS HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Effient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI] undergoing primary or delayed percutaneous coronary intervention (PCI). The increased efficacy should be balanced with the increased risk in patients with bleeding tendency in those who had TIA/CVA in the past and in those above the age of 75 or weight below 60 kg.
1629	EFRIN	EFRIN 10	PHENYLEPHRINE HYDROCHLORIDE	PHENYLEPHRINE HYDROCHLORIDE 10%	DROPS	RECIEPT	Mydriasis and vasoconstriction.
1630	EFUDIX	EFUDIX CREAM 5%	FLUOROURACIL	FLUOROURACIL 50MG/1 G	CREAM	RECIEPT	Antineoplastic agent to treat actinic keratosis multiple and superfacial basel cell carcinoma.
1631	EKLIRA GENUAIR	EKLIRA GENUAIR 322 MCG	ACLIDINIUM BROMIDE	ACLIDINIUM BROMIDE 0.4MG	POWDER	RECIEPT	Maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD)
1633	ELAPRASE	ELAPRASE	IDURSULFASE	IDURSULFASE 2MG/ML	CONCENTRATE	RECIEPT	Long term treatment of patients with Hunter syndrome (MPS II).
1634	ELATROL	ELATROL	AMITRIPTYLINE HYDROCHLORIDE	AMITRIPTYLINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states. Enuresis nocturna.
1636	ELATROLET	ELATROLET	AMITRIPTYLINE HYDROCHLORIDE	AMITRIPTYLINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. Enuresis nocturna.
1638	ELELYSO	ELELYSO	TALIGLUCERASE ALFA	TALIGLUCERASE ALFA 200U/VIAL	POWDER	RECIEPT	ELELYSO™ (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease
1639	ELETRIPTAN	ELETRIPTAN - TRIMA 40 MG	ELETRIPTAN AS HYDROBROMIDE	ELETRIPTAN AS HYDROBROMIDE 40MG	TABLETS	RECIEPT	Acute treatment of the headache phase of migraine attacks, with or without aura
1640	ELETRIPTAN	ELETRIPTAN - TRIMA 80 MG	ELETRIPTAN AS HYDROBROMIDE	ELETRIPTAN AS HYDROBROMIDE 80MG	TABLETS	RECIEPT	Acute treatment of the headache phase of migraine attacks, with or without aura
1641	ELIDEL	ELIDEL CREAM 1 %	PIMECROLIMUS	PIMECROLIMUS 1%	CREAM	RECIEPT	Elidel 1 % cream is indicated for the short-term treatment of the signs and symptoms of atopic dermatitis (eczema) and intermittent long-term treatment to prevent progression to flares in patients 3 months of age and above. Treatment with Elidel is indicated in patients in whom the use of conventional topical corticosteroids therapy is deemed inadvisable because of potential risks or in patients who are not adequately responsive to or intolerant of conventional topical corticosteroids therapy.
1643	ELIGARD	ELIGARD 22.5 MG	LEUPRORELIN ACETATE	LEUPRORELIN ACETATE 22.5MG	POWDER	RECIEPT	ELIGARD is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
1645	ELIGARD	ELIGARD 45 MG	LEUPRORELIN ACETATE	LEUPRORELIN ACETATE 45MG	POWDER	RECIEPT	ELIGARD is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
1647	ELIGARD	ELIGARD 7.5 MG	LEUPRORELIN ACETATE	LEUPRORELIN ACETATE 7.5MG	POWDER	RECIEPT	ELIGARD is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
1649	ELIQUIS	ELIQUIS 2.5 MG	APIXABAN	APIXABAN 2.5MG	TABLETS	RECIEPT	Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
1650	ELIQUIS	ELIQUIS 5 MG	APIXABAN	APIXABAN 5MG	TABLETS	RECIEPT	Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.
1651	ELLA	ELLA	ULIPRISTAL ACETATE	ULIPRISTAL ACETATE 30MG	TABLETS		Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.
1654	ELLA	ELLA 30MG 1TAB	ULIPRISTAL ACETATE	ULIPRISTAL ACETATE 30MG	TABLETS		Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.
1655	ELOCOM	ELOCOM CREAM	MOMETASONE FUROATE	MOMETASONE FUROATE 0.1%	CREAM	RECIEPT	For the relief of the inflammatory and pruritic manifestations of corticosteroid - responsive dermatoses such as psoriasis and atopic dermatitis.
1658	ELOCOM	ELOCOM OINTMENT	MOMETASONE FUROATE	MOMETASONE FUROATE 0.1%	OINTMENT	RECIEPT	For the relief of the inflammatory and pruritic manifestations of corticosteroid - responsive dermatoses such as psoriasis and atopic dermatitis.
1656	ELOCOM	ELOCOM LOTION	MOMETASONE FUROATE	MOMETASONE FUROATE 1MG/G	LOTION	RECIEPT	The relief of the inflammatory and pruritic manifestations of corticosteroid - responsive dermatoses, such as psoriasis and atopic dermatitis.
1659	ELOCTATE	ELOCTATE 1000	COAGULATION FACTOR VIII	COAGULATION FACTOR VIII 1000 IU	POWDER	RECIEPT	ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for: • Control and prevention of bleeding episodes. • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. • Perioperative management (surgical prophylaxis). ELOCTATE is not indicated for the treatment of von Willebrand disease.
1660	ELOCTATE	ELOCTATE 1500	COAGULATION FACTOR VIII	COAGULATION FACTOR VIII 1500 IU	POWDER	RECIEPT	ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for: • Control and prevention of bleeding episodes. • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. • Perioperative management (surgical prophylaxis). ELOCTATE is not indicated for the treatment of von Willebrand disease.
1661	ELOCTATE	ELOCTATE 2000	COAGULATION FACTOR VIII	COAGULATION FACTOR VIII 2000 IU	POWDER	RECIEPT	ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for: • Control and prevention of bleeding episodes. • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. • Perioperative management (surgical prophylaxis). ELOCTATE is not indicated for the treatment of von Willebrand disease.
1662	ELOCTATE	ELOCTATE 250	COAGULATION FACTOR VIII	COAGULATION FACTOR VIII 250 IU	POWDER	RECIEPT	ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for: • Control and prevention of bleeding episodes. • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. • Perioperative management (surgical prophylaxis). ELOCTATE is not indicated for the treatment of von Willebrand disease.
1663	ELOCTATE	ELOCTATE 3000	COAGULATION FACTOR VIII	COAGULATION FACTOR VIII 3000 IU	POWDER	RECIEPT	ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for: • Control and prevention of bleeding episodes. • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. • Perioperative management (surgical prophylaxis). ELOCTATE is not indicated for the treatment of von Willebrand disease.
1664	ELOCTATE	ELOCTATE 500	COAGULATION FACTOR VIII	COAGULATION FACTOR VIII 500 IU	POWDER	RECIEPT	ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children 12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for: • Control and prevention of bleeding episodes. • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. • Perioperative management (surgical prophylaxis). ELOCTATE is not indicated for the treatment of von Willebrand disease.
1665	ELOCTATE	ELOCTATE 750	COAGULATION FACTOR VIII	COAGULATION FACTOR VIII 750 IU	POWDER	RECIEPT	ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for: • Control and prevention of bleeding episodes. • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. • Perioperative management (surgical prophylaxis). ELOCTATE is not indicated for the treatment of von Willebrand disease.
1666	ELONVA	ELONVA 100 MCG / 0.5 ML	CORIFOLLITROPIN ALFA	CORIFOLLITROPIN ALFA 100MCG/0.5ML	SOLUTION	RECIEPT	Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.
1667	ELONVA	ELONVA 150 MCG / 0.5 ML	CORIFOLLITROPIN ALFA	CORIFOLLITROPIN ALFA 150MCG/0.5ML	SOLUTION	RECIEPT	Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.
1669	ELTROXIN	ELTROXIN TABLETS 50 MCG	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM 0.05MG	TABLETS	RECIEPT	Treatment of hypothyroidism. Cretinism and juvenile myxoedema.
1668	ELTROXIN	ELTROXIN TABLETS 100 MCG	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM 100MCG	TABLETS	RECIEPT	Treatment of hypothyroidism, cretinism and juvenile myxoedema.
1671	EMEND	EMEND 125 MG CAPSULES	APREPITANT	APREPITANT 125MG	CAPSULES	RECIEPT	Emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
1674	EMEND	EMEND 80 MG CAPSULES	APREPITANT	APREPITANT 80MG	CAPSULES	RECIEPT	Emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
1677	EMERADE	EMERADE 150 MCG	EPINEPHRINE AS TARTRATE	EPINEPHRINE AS TARTRATE 1MG/1ML	SOLUTION	RECIEPT	Emerade is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Emerade is intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Emerade is intended for immediate administration as emergency supportive therapy only and is not a substitute for immediate medical care.
1678	EMERADE	EMERADE 300 MCG	EPINEPHRINE AS TARTRATE	EPINEPHRINE AS TARTRATE 1MG/1ML	SOLUTION	RECIEPT	Emerade is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Emerade is intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Emerade is intended for immediate administration as emergency supportive therapy only and is not a substitute for immediate medical care.
1679	EMERADE	EMERADE 500 MCG	EPINEPHRINE AS TARTRATE	EPINEPHRINE AS TARTRATE 1MG/1ML	SOLUTION	RECIEPT	Emerade is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Emerade is intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Emerade is intended for immediate administration as emergency supportive therapy only and is not a substitute for immediate medical care.
1680	EMGALITY	EMGALITY 120 MG	GALCANEZUMAB	GALCANEZUMAB 120MG/1ML	SOLUTION	RECIEPT	Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
1681	EMILY	EMILY	GESTODENE	GESTODENE 0.075MG;ETHINYLESTRADIOL 0.02MG	TABLETS	RECIEPT	Oral contraception.
1682	EMLA	EMLA 5%	LIDOCAINE	LIDOCAINE 2.5%;PRILOCAINE 2.5%	CREAM		Topical anaesthetic for superficial dermal analgesia in connection with insertion of IV catheters, blood sampling and superficial surgical procedures.
1683	EMLA	EMLA CREAM 5% 30GR	LIDOCAINE	LIDOCAINE 25MG/G (2.5%);PRILOCAINE 25MG/G (2.5%)	CREAM		Topical anaesthetic for superficial dermal analgesia in connection with insertion of IV catheters, blood sampling and superficial surgical procedures.
1684	EMPLICITI	EMPLICITI 300 MG	ELOTUZUMAB	ELOTUZUMAB 300MG/VIAL	POWDER	RECIEPT	Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy.
1685	EMPLICITI	EMPLICITI 400 MG	ELOTUZUMAB	ELOTUZUMAB 400MG/VIAL	POWDER	RECIEPT	Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy.
1686	EMTRICITABINE/TENOFOVIR	EMTRICITABINE/TENOFOVIR TEVA	TENOFOVIR DISOPROXIL AS PHOSPHATE	TENOFOVIR DISOPROXIL AS PHOSPHATE 245MG;EMTRICITABINE 200MG	TABLETS	RECIEPT	Treatment of HIV-1 infection: Emtricitabine/Tenofovir Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults over 18 years of age. Pre-exposure prophylaxis (PrEP): Emtricitabine/Tenofovir Teva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
1687	EMTRIVIR	EMTRIVIR TEVA	EMTRICITABINE	EMTRICITABINE 200MG;TENOFOVIR DISOPROXIL AS FUMARATE 245MG	TABLETS	RECIEPT	Emtrivir Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults over 18 years of age. Emtrivir Teva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
1688	ENALADEX	ENALADEX 10 MG	ENALAPRIL MALEATE	ENALAPRIL MALEATE 10MG	TABLETS	RECIEPT	Treatment of essntial hypertension, renovascular hypertension congestive heart failure and to reduce mortality in patients with all degrees of heart failure. To retard the development of symptomatic heart failure in asymptomatic patients with left ventricular dysfunction.
1689	ENALADEX	ENALADEX 20 MG	ENALAPRIL MALEATE	ENALAPRIL MALEATE 20MG	TABLETS	RECIEPT	Treatment of essential hypertension, renovascular hypertension congestive heart failure and to reduce mortality in patients with all degrees of heart failure. To retard the development of symptomatic heart failure in asymptomatic patients with left ventricular dysfunction.
1690	ENALADEX	ENALADEX 5 MG	ENALAPRIL MALEATE	ENALAPRIL MALEATE 5MG	TABLETS	RECIEPT	Treatment of essential hypertension, renovascular hypertension congestive heart failure and to reduce mortality in patients with all degrees of heart failure. To retard the development of symptomatic heart failure in asymptomatic patients with left ventricular dysfunction.
1691	ENALAPRIL	ENALAPRI 10	ENALAPRIL MALEATE	ENALAPRIL MALEATE 10MG	TABLETS	RECIEPT	Treatment of essential hypertension, renovascular hypertension congestive heart failure and to reduce mortality in patients with all degrees of heart failure. To retard the development of symptomatic heart failure in asymptomatic patients with left ventrcular dysfunction.
1692	ENALAPRIL	ENALAPRI 20	ENALAPRIL MALEATE	ENALAPRIL MALEATE 20MG	TABLETS	RECIEPT	Treatment of essential hypertension, renovascular hypertension congestive heart failure and to reduce mortality in patients with all degrees of heart failure. To retard the development of symptomatic heart failure in asymptomatic patients with left ventrcular dysfunction.
1693	ENALAPRIL	ENALAPRI 5	ENALAPRIL MALEATE	ENALAPRIL MALEATE 5MG	TABLETS	RECIEPT	Treatment of essential hypertension, renovascular hypertension congestive heart failure and to reduce mortality in patients with all degrees of heart failure. To retard the development of symptomatic heart failure in asymptomatic patients with left ventrcular dysfunction.
1695	ENBREL	ENBREL 25 MG PRE-FILLED SYRINGE	ETANERCEPT	ETANERCEPT 25MG/DOSE	SOLUTION	RECIEPT	* Rheumatoid arthritis: Enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate.. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. * Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease. * Plaque psoriasis Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. * Paediatric plaque psoriasis Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. * Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Enbrel has not been studied in children aged less than 2 years. * Axial spondyloarthritis * Ankylosing spondylitis(AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. * Non-radiographic axial spondyloarthritis Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs)
1694	ENBREL	ENBREL	ETANERCEPT	ETANERCEPT 25MG/VIAL	POWDER	RECIEPT	* Rheumatoid arthritis: Enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate.. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. * Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease. * Plaque psoriasis Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. * Paediatric plaque psoriasis Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. * Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Axial spondyloarthritis Ankylosing spondylitis(AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. *Non-radiographic axial spondyloarthritis Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs)
1696	ENBREL	ENBREL 50 MG SOLUTION FOR INJECTION	ETANERCEPT	ETANERCEPT 50MG/DOSE	SOLUTION	RECIEPT	* Rheumatoid arthritis: Enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate.. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. * Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease. * Plaque psoriasis Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. * Paediatric plaque psoriasis Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. * Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Enbrel has not been studied in children aged less than 2 years. * Axial spondyloarthritis * Ankylosing spondylitis(AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. * Non-radiographic axial spondyloarthritis Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs)
1698	ENCYPALMED	ENCYPALMED 40 DRAGEES	PANCREATIN	PANCREATIN 72MG;OX BILE EXTR 35MG;FRANGULA BARK 10MG;RHUARB PWD 10MG	DRAGEE	RECIEPT	Regulation of digestive disturbances, indigestion fermentative dyspepsia, gastroenteritis, meteorism, epigastric fullness and post prandial distress.
1699	ENCYPALMED	ENCYPALMED 60 DRAGEES	PANCREATIN	PANCREATIN 72MG;OX BILE EXTR 35MG;FRANGULA BARK 10MG;RHUARB PWD 10MG	DRAGEE	RECIEPT	Regulation of digestive disturbances, indigestion fermentative dyspepsia, gastroenteritis, meteorism, epigastric fullness and post prandial distress.
1697	ENCYPALMED	ENCYPALMED	PANCREATIN	PANCREATIN 72MG;OX BILE EXTRACT 35MG	DRAGEE	RECIEPT	Regulation of digestive disturbances, indigestion fermentative dyspepsia, gastroenteritis, meteorism, epigastric fullness and post prandial distress.
1701	ENDOMETRIN	ENDOMETRIN	PROGESTERONE	PROGESTERONE 100MG	TABLETS	RECIEPT	Progesterone supplementation or replacement in cases such as treatment of infertile women and IVF.
1702	ENDOXAN	ENDOXAN 1 G INJECTION	CYCLOPHOSPHAMIDE	CYCLOPHOSPHAMIDE 1G/VIAL	POWDER	RECIEPT	Malignant Diseases: Cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible. Cycophosphamide treatment: 1) Malignant lymphomas (Stages III and IV of the Ann Arbor staging system) Hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma Burkitt`s lymphoma. 2) Multiple myeloma. 3) Leukemias: Chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) Mycosis fungoides (advenced disease). 5) Neuroblastoma (disseminated disease). 6) Adenocarcinoma of the ovary. 7) Retinoblastoma. 8) Carcinoma of the breast. Nonmallgnant Disease Biopsy proven caretMinimal Changecaret nephrotic syndrome in children whose disease fails to respond adequately to another treatment. Severe cases of systemic lupus Erythematos as which did not respond to other treatment especially with nephritis
1703	ENDOXAN	ENDOXAN 500 MG INJECTION	CYCLOPHOSPHAMIDE	CYCLOPHOSPHAMIDE 500MG/VIAL	POWDER	RECIEPT	Malignant Diseases: Cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible. Cycophosphamide treatment: 1) Malignant lymphomas (Stages III and IV of the Ann Arbor staging system) Hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma Burkitt`s lymphoma. 2) Multiple myeloma. 3) Leukemias: Chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) Mycosis fungoides (advenced disease). 5) Neuroblastoma (disseminated disease). 6) Adenocarcinoma of the ovary. 7) Retinoblastoma. 8) Carcinoma of the breast. Nonmallgnant Disease Biopsy proven caretMinimal Changecaret nephrotic syndrome in children whose disease fails to respond adequately to another treatment. Severe cases of systemic lupus Erythematos as which did not respond to other treatment especially with nephritis
1706	ENGERIX	ENGERIX B 10 MCG	HEPATITIS B VACCINES	HEPATITIS B VACCINES 10MCG/0.5ML	SUSPENSION	RECIEPT	Engerix B is indicated for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes in non immune subjects . The 20 µg dose vaccine in 1.0 ml suspension is intended for use in subjects 16 years of age and above. The 10 µg dose vaccine in 0.5 ml suspension is intended for use in subjects up to and including 15 years of age, including neonates. The categories within the population to be immunised are determined on the basis of official recommendations. It can be expected that hepatitis D will also be prevented by immunisation with Engerix B as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
1707	ENGERIX	ENGERIX B 20 MCG	HEPATITIS B VACCINES	HEPATITIS B VACCINES 20MCG/ML	SUSPENSION	RECIEPT	Engerix B is indicated for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes in non immune subjects .. The 20 µg dose vaccine in 1.0 ml suspension is intended for use in subjects 16 years of age and above. The 10 µg dose vaccine in 0.5 ml suspension is intended for use in subjects up to and including 15 years of age, including neonates. The categories within the population to be immunised are determined on the basis of official recommendations. It can be expected that hepatitis D will also be prevented by immunisation with Engerix B as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
1712	ENTACAPONE	ENTACAPONE MEDOCHEMIE	ENTACAPONE	ENTACAPONE 200MG	TABLETS	RECIEPT	Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with Parkinson`s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
1713	ENTECAVIR	ENTECAVIR TEVA 0.5 MG	ENTECAVIR AS MONOHYDRATE	ENTECAVIR AS MONOHYDRATE 0.5MG	TABLETS	RECIEPT	Entecavir teva is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: - Compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (ALT) levels. - Decompensated liver disease.
1714	ENTECAVIR	ENTECAVIR TEVA 1 MG	ENTECAVIR AS MONOHYDRATE	ENTECAVIR AS MONOHYDRATE 1MG	TABLETS	RECIEPT	Entecavir teva is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: - Compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (ALT) levels. - Decompensated liver disease.
1721	ENTRESTO	ENTRESTO 50 MG	SACUBITRIL/VALSARTAN AS SODIUM SALT COMPLEX	SACUBITRIL/VALSARTAN AS SODIUM SALT COMPLEX 24/26MG	TABLETS	RECIEPT	EntrestoTM is indicated for the treatment of heart failure (NYHA class II-IV) in patients with systolic dysfunction. EntrestoTM has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ACE) inhibitor therapy
1715	ENTRESTO	ENTRESTO 100 MG	SACUBITRIL/VALSARTAN AS SODIUM SALT COMPLEX	SACUBITRIL/VALSARTAN AS SODIUM SALT COMPLEX 49/51MG	TABLETS	RECIEPT	EntrestoTM is indicated for the treatment of heart failure (NYHA class II-IV) in patients with systolic dysfunction. EntrestoTM has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ACE) inhibitor therapy
1718	ENTRESTO	ENTRESTO 200 MG	SACUBITRIL/VALSARTAN AS SODIUM SALT COMPLEX	SACUBITRIL/VALSARTAN AS SODIUM SALT COMPLEX 97/103MG	TABLETS	RECIEPT	EntrestoTM is indicated for the treatment of heart failure (NYHA class II-IV) in patients with systolic dysfunction. EntrestoTM has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ACE) inhibitor therapy
1724	ENTUMIN	ENTUMIN	CLOTIAPINE	CLOTIAPINE 40MG	TABLETS	RECIEPT	For the treatment of severe mental and emotional disorders (Neuroleptic).
1725	ENTYVIO	ENTYVIO	VEDOLIZUMAB	VEDOLIZUMAB 300MG/VIAL	POWDER	RECIEPT	Ulcerative Colitis: Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist. Crohn’s Disease: Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.
1726	EPANUTIN	EPANUTIN 100 MG	PHENYTOIN SODIUM	PHENYTOIN SODIUM 100MG	CAPSULES	RECIEPT	Treatment of epilepsy.
1727	EPCLUSA	EPCLUSA	VELPATASVIR	VELPATASVIR 100MG;SOFOSBUVIR 400MG	TABLETS	RECIEPT	Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults.
1729	EPHEDRIN	EPHEDRIN SINTETICA 50 MG/ML	EPHEDRINE HYDROCHLORIDE	EPHEDRINE HYDROCHLORIDE 50MG/ML	SOLUTION	RECIEPT	Ephedrine Hydrochloride is used in the prevention and treatment of hypotension from spinal or epidural anaesthesia and during general anaesthesia, with or without a reduction in the heart rate, administered for a surgical or obstetric procedure.
1730	EPHEDRINE HCL	EPHEDRINE HCL STEROP 50 MG/1 ML	EPHEDRINE HYDROCHLORIDE	EPHEDRINE HYDROCHLORIDE 50MG/1ML	SOLUTION	RECIEPT	Ephedrine Hydrochloride is used in the prevention and treatment of hypotension from spinal or epidural anesthesia and during general anesthesia, with or without a reduction in the heart rate, administered for a surgical or obstetric procedure.
1731	EPI-CELL	EPI-CELL 50 MG	EPIRUBICIN HYDROCHLORIDE	EPIRUBICIN HYDROCHLORIDE 50MG/25ML	SOLUTION	RECIEPT	For the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma (high doses), ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. Intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection. I.V. administration for the treatment of advanced bladder carcinoma.
1733	EPIDUO	EPIDUO	BENZOYL PEROXIDE	BENZOYL PEROXIDE 25MG;ADAPALENE 1MG	GEL	RECIEPT	Cutaneous treatment of Acne vulgaris when comedones, papules and pustules are present.
1734	EPIFOAM	EPIFOAM	PRAMOCAINE HYDROCHLORIDE	PRAMOCAINE HYDROCHLORIDE 0.9363%W/W;HYDROCORTISONE ACETATE 0.9363%W/W	FOAM	RECIEPT	Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
1735	EPINEPHRINE	EPINEPHRINE INJECTION MYLAN 0.3 MG	EPINEPHRINE	EPINEPHRINE 0.3MG/0.3ML	SOLUTION	RECIEPT	Epinephrine is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera which includes bees,wasps,hornets,yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs,diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise induced anaphylaxis. Epinephrine is intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Epinephrine is intended for immediate administration as emergency supportive therapy only, and is not a substitute for immediate medical care
1736	EPINEPHRINE JR	EPINEPHRINE INJECTION MYLAN JR 0.15 MG	EPINEPHRINE	EPINEPHRINE 0.15MG/0.3ML	SOLUTION	RECIEPT	Epinephrine is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera which includes bees,wasps,hornets,yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs,diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise induced anaphylaxis. Epinephrine is intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Epinephrine is intended for immediate administration as emergency supportive therapy only, and is not a substitute for immediate medical care
1738	EPIPEN	EPIPEN JR	EPINEPHRINE	EPINEPHRINE 0.15MG/0.3ML	SOLUTION	RECIEPT	EpiPen Jr is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EpiPen Jr is intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. EpiPen Jr is intended for immediate administration as emergency supportive therapy only and is not a substitute for immediate medical care.
1737	EPIPEN	EPIPEN	EPINEPHRINE	EPINEPHRINE 0.3MG/0.3ML	SOLUTION	RECIEPT	EpiPen is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EpiPen is intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. EpiPen is intended for immediate administration as emergency supportive therapy only and is not a substitute for immediate medical care.
1740	EPIRUBICIN	EPIRUBICIN INOVAMED	EPIRUBICIN HYDROCHLORIDE	EPIRUBICIN HYDROCHLORIDE 2MG/1ML	SOLUTION	RECIEPT	For the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma high doses, ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. Intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection. I.V. administration for the treatment of advanced bladder carcinoma.
1739	EPIRUBICIN	EPIRUBICIN caretEBEWEcaret 2 MG/ML	EPIRUBICIN HYDROCHLORIDE	EPIRUBICIN HYDROCHLORIDE 2MG/ML	CONCENTRATE	RECIEPT	For the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma (high doses), ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. Intravesical administration of farmorubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after stransurethral resection. I.V. administration for the treatment of advanced bladder carcinoma.
1745	EPIVIR	EPIVIR ORAL SOLUTION	LAMIVUDINE	LAMIVUDINE 10MG/ML	SOLUTION	RECIEPT	Epivir is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children. 28/10/2018 בקשה לשינוי משטר מינון.
1741	EPIVIR	EPIVIR 150 MG	LAMIVUDINE	LAMIVUDINE 150MG	TABLETS	RECIEPT	Epivir is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children. 25/10/2018 בקשה לשינוי משטר מינון
1743	EPIVIR	EPIVIR 300 MG	LAMIVUDINE	LAMIVUDINE 300MG	TABLETS	RECIEPT	Epivir is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.
1746	EPLERENONE	EPLERENONE INOVAMED 25 MG	EPLERENONE	EPLERENONE 25MG	TABLETS	RECIEPT	Eplerenone is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF < 40 % ) and clinical evidence of heart failure after recent myocardial infarction.
1747	EPLERENONE	EPLERENONE INOVAMED 50 MG	EPLERENONE	EPLERENONE 50MG	TABLETS	RECIEPT	Eplerenone is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF < 40 % ) and clinical evidence of heart failure after recent myocardial infarction.
1752	EPREX	EPREX 20000	ERYTHROPOIETIN HUMAN RECOMBINANT	ERYTHROPOIETIN HUMAN RECOMBINANT 20000 IU/0.5ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).
1754	EPREX	EPREX 30000	ERYTHROPOIETIN HUMAN RECOMBINANT	ERYTHROPOIETIN HUMAN RECOMBINANT 30000 IU/0.75ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).
1756	EPREX	EPREX 40000	ERYTHROPOIETIN HUMAN RECOMBINANT	ERYTHROPOIETIN HUMAN RECOMBINANT 40000 IU/ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).
1757	EPREX	EPREX 5000	ERYTHROPOIETIN HUMAN RECOMBINANT	ERYTHROPOIETIN HUMAN RECOMBINANT 5000 IU/0.5ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).
1758	EPREX	EPREX 6000	ERYTHROPOIETIN HUMAN RECOMBINANT	ERYTHROPOIETIN HUMAN RECOMBINANT 6000 IU/0.6ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).
1759	EPREX	EPREX 8000	ERYTHROPOIETIN HUMAN RECOMBINANT	ERYTHROPOIETIN HUMAN RECOMBINANT 8000 IU/0.8ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).
1749	EPREX	EPREX 1000	RECOMBINANT HUMAN ERYTHROPOIETIN	RECOMBINANT HUMAN ERYTHROPOIETIN 1000 IU/0.5ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).
1750	EPREX	EPREX 10000	RECOMBINANT HUMAN ERYTHROPOIETIN	RECOMBINANT HUMAN ERYTHROPOIETIN 10000IU/ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).
1751	EPREX	EPREX 2000	RECOMBINANT HUMAN ERYTHROPOIETIN	RECOMBINANT HUMAN ERYTHROPOIETIN 2000 IU/0.5ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).
1753	EPREX	EPREX 3000	RECOMBINANT HUMAN ERYTHROPOIETIN	RECOMBINANT HUMAN ERYTHROPOIETIN 3000 IU/0.3ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).
1755	EPREX	EPREX 4000	RECOMBINANT HUMAN ERYTHROPOIETIN	RECOMBINANT HUMAN ERYTHROPOIETIN 4000 IU/0.4ML	SOLUTION	RECIEPT	Treatment of severe anemia associated with chronic renal failure, anemia in Zidovudine treated HIV infected patients, anemia in cancer patients on chemotherapy. To increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. Treatment is indicated in patients with moderate anemia (packed cell volume (PCV) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. Perisurgery: Reduction of allogeneic blood transfusion in surgery patients : Eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. Eprex is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of Eprex has been studied only in patients who are receiving anticoagulant prophylaxis. Eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).
1762	ERAXIS	ERAXIS 100 MG	ANIDULAFUNGIN	ANIDULAFUNGIN 100MG	POWDER	RECIEPT	Treatment of invasive candidiasis in adult patients.
1763	ERBITUX	ERBITUX 5 MG/ML	CETUXIMAB	CETUXIMAB 5MG/ML	SOLUTION	RECIEPT	Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR) - expressing, RAS wild-type metastatic colorectal cancer • In combination with irinotecan-based chemotherapy • In first-line in combination with FOLFOX • as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (SCCHN) • in combination with radiation therapy for locally advanced disease • in combination with platinum-based chemotherapy for recurrent and/or metastatic disease • as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease
1764	ERDOTIN	ERDOTIN	ERDOSTEINE	ERDOSTEINE 300MG	CAPSULES	RECIEPT	Mucolytic agent in acute and chronic respiratory diseases.
1765	ERELZI	ERELZI 25	ETANERCEPT	ETANERCEPT 25MG/0.5ML	SOLUTION	RECIEPT	Rheumatoid arthritis Erelzi is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate. Erelzi can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis .Etanercept, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis (AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Non-radiographic axial spondyloarthritis Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs). Plaque psoriasis Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Paediatric plaque psoriasis Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
1766	ERELZI	ERELZI 50	ETANERCEPT	ETANERCEPT 50MG/1ML	SOLUTION	RECIEPT	Rheumatoid arthritis Erelzi is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate. Erelzi can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis .Etanercept, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis (AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Non-radiographic axial spondyloarthritis Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs). Plaque psoriasis Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Paediatric plaque psoriasis Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
1767	ERIVEDGE	ERIVEDGE	VISMODEGIB	VISMODEGIB 150MG	CAPSULES	RECIEPT	ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation
1768	ERLEADA	ERLEADA	APALUTAMIDE	APALUTAMIDE 60MG	TABLETS	RECIEPT	ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).
1770	ERYTHRO	ERYTHRO-TEVA 250 MG	ERYTHROMYCIN AS STEARATE	ERYTHROMYCIN AS STEARATE 250MG	TABLETS	RECIEPT	Treatment of the following infections when caused by susceptible organisms: Upper and lower respiratory tract infections. Skin and soft tissue infections. Conjunctivitis of the newborn caused by chlamydia trachomatis. Urogenital infections caused by chlamydia trachomatis. Venereal diseases (as an alternative regimen to penicillins and tetracyclines). Intestinal amebiasis. Legionnaires' disease. Long-term prophylaxis in rheumatic fever. Short-term prophlaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. Enteric infections caused by Campylobacter jejuni.
1772	ERYTHRO	ERYTHRO-TEVA 500 MG	ERYTHROMYCIN AS STEARATE	ERYTHROMYCIN AS STEARATE 500MG	TABLETS	RECIEPT	Treatment of the following infections when caused by susceptible organisms: Upper and lower respiratory tract infections. Skin and soft tissue infections. Conjunctivitis of the newborn caused by chlamydia trachomatis. Urogenital infections caused by chlamydia trachomatis. Venereal diseases (as an alternative regimen to penicillins and tetracyclines). Intestinal amebiasis. Legionnaires' disease. Long-term prophylaxis in rheumatic fever. Short-term prophylaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. Enteric infections caused by Campylobacter jejuni.
1769	ERYTHROCIN LACTOBIONATE	ERYTHROCIN LACTOBIONATE I.V.	ERYTHROMYCIN	ERYTHROMYCIN 1G/VIAL	POWDER	RECIEPT	For the treatment of bacterial infections susceptible to erythromycin and require RECIEPT. treatment .
1774	ESBRIET	ESBRIET 267 MG	PIRFENIDONE	PIRFENIDONE 267MG	CAPSULES	RECIEPT	Esbriet is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF). 27/01/2019 בקשה לתוספת התויה Renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. Esbriet should be used with caution in patients with moderate (CrCl 30-50 ml/min) renal impairment.
1776	ESBRIET	ESBRIET 267 MG TABLETS	PIRFENIDONE	PIRFENIDONE 267MG	TABLETS	RECIEPT	Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).
1777	ESBRIET	ESBRIET 801 MG TABLETS	PIRFENIDONE	PIRFENIDONE 801MG	TABLETS	RECIEPT	Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF)..
1778	ESCITALOPRAM	ESCITALOPRAM TEVA 10 MG	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 10MG	TABLETS	RECIEPT	Treatment of depression. Treatment of panic disorder. Treatment of generalized anxiety disorder (GAD). Treatment of social anxiety disorder ( social phobia). Treatment of obsessive - compulsive disorder.
1779	ESCITALOPRAM	ESCITALOPRAM TEVA 20 MG	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 20MG	TABLETS	RECIEPT	Treatment of depression. Treatment of panic disorder. Treatment of generalized anxiety disorder (GAD). Treatment of social anxiety disorder ( social phobia). Treatment of obsessive - compulsive disorder.
1780	ESKAZOLE	ESKAZOLE	ALBENDAZOLE	ALBENDAZOLE 400MG	TABLETS	RECIEPT	Albendazole is indicated for the treatment of the following systemic helminth diseases: * Echinococcosis (hydatid disease) Albendazole is indicated for the treatment of liver, lung and peritoneal cysts. Experience with bone cysts and those in the central nervous system and heart is limited. * Cystic echinococcosis (caused by Echinococcus granulosus) Albendazole is used in patients with cystic echinococcosis: 1. When surgical intervention is not feasible . 2. As a co-adjunct to surgical treatment. 3. Prior to surgical intervention. 4. If preoperative treatment was too short, if spillage has occurred or if viable cysts were found at surgery. 5. Following percutaneous drainage of cysts for diagnostic or therapeutic reasons. * Alveolar echinococcosis (caused by Echinococcus multilocularis) Although its efficacy has not been completely demonstrated in clinical trials, albendazole is used in patients with alveolar echinococcosis in the following situations: 1. In inoperable disease, particularly in cases of local or distant metastasis. 2. Following palliative surgery. 3. Following radical surgery or liver transplantation.
1781	ESMERON	ESMERON	ROCURONIUM BROMIDE	ROCURONIUM BROMIDE 10MG/ML	SOLUTION	RECIEPT	Adjunct to general anaesthesia to facilitate tracheal intubation, to provide skeletal muscle relaxation during surgery. Esmeron indicated as an adjunct in the intensive care unit (ICU) to facilitate tracheal intubation and mechanical ventilation.
1784	ESMOLOL	ESMOLOL AMOMED 100 MG/10 ML	ESMOLOL HYDROCHLORIDE	ESMOLOL HYDROCHLORIDE 100MG/10ML	SOLUTION	RECIEPT	Esmolol Amomed 100 mg/10 ml is indicated for supraventricular tachycardia (except for pre-excitation syndromes) and for the rapid control of the ventricular rate in adult patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable. Esmolol Amomed 100 mg/10 ml is also indicated for tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia in adult patients where, in the physician’s judgement the rapid heart rate requires specific intervention. Esmolol Amomed 100 mg/10 ml is not intended for use in chronic settings.
1786	ESMYA	ESMYA 5 MG TABLETS	ULIPRISTAL ACETATE	ULIPRISTAL ACETATE 5MG	TABLETS	RECIEPT	Pre operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
1787	ESOMED	ESOMED GEL	HYDROQUINONE	HYDROQUINONE 4%W/W	GEL	RECIEPT	Lightening skin spots.
1788	ESOMEPRAZOLE	ESOMEPRAZOLE INOVAMED 20 MG	ESOMEPRAZOLE AS MAGNESIUM AMORPHOUS	ESOMEPRAZOLE AS MAGNESIUM AMORPHOUS 20MG	TABLETS	RECIEPT	Esomeprazole Inovamed tablets are indicated in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with an appropriate antibacterial therapeutic regimen for the eradication of Helicobacter pylori and: - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers. Patients requiring NSAID therapy - healing of gastric ulcers associated with NSAID therapy. - prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk. Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Esomeprazole Inovamed 20 mg tablets are indicated in adolescents from the age of 12 years for Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophgeal reflux disease (GERD) In combination with antibiotics in treatment of duodenal ulcer caused by Helicobactor pylori
1789	ESOMEPRAZOLE	ESOMEPRAZOLE INOVAMED 40 MG	ESOMEPRAZOLE AS MAGNESIUM AMORPHOUS	ESOMEPRAZOLE AS MAGNESIUM AMORPHOUS 40MG	TABLETS	RECIEPT	Esomeprazole Inovamed tablets are indicated in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with an appropriate antibacterial therapeutic regimen for the eradication of Helicobacter pylori and: - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers. Patients requiring NSAID therapy - healing of gastric ulcers associated with NSAID therapy. - prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk. Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Esomeprazole Inovamed 40 mg tablets are indicated in adolescents from the age of 12 years for; Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis
1790	ESOPRIM S.K	ESOPRIM S.K 20 MG	ESOMEPRAZOLE AS SODIUM	ESOMEPRAZOLE AS SODIUM 20MG	CAPSULES	RECIEPT	Esoprim S.K. 20 mg indicated in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease. In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and - healing of Helicobacter pylori associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers - Patients requiring continued NSAID therapy Healing of gastric ulcers associated with NSAID therapy. - Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk. - Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Esoprim S.K 20 mg is indicated in adolescents from the age of 12 years for: Gastro-esophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis -long-term management of patients with healed esophagitis to prevent relapse -symptomatic treatment of gastro-esophageal reflux disease In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori.
1791	ESOPRIM S.K	ESOPRIM S.K 40 MG	ESOMEPRAZOLE AS SODIUM	ESOMEPRAZOLE AS SODIUM 40MG	CAPSULES	RECIEPT	Esoprim S.K. 40 mg is indicated in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and - healing of Helicobacter pylori associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers - Patients requiring continued NSAID therapy Healing of gastric ulcers associated with NSAID therapy. - Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk. - Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. EsoprIM S.K 40 mg IS indicated in adolescents from the age of 12 years for: Gastro-esophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis
1793	ESRACAIN	ESRACAIN CREAM 5 %	LIDOCAINE	LIDOCAINE 5%	CREAM	RECIEPT	Topical anesthetic.
1796	ESRACAIN	ESRACAIN INJECTION 1%	LIDOCAINE HYDROCHLORIDE	LIDOCAINE HYDROCHLORIDE 10MG/ML	SOLUTION	RECIEPT	Anesthesia, cardiac arrhythmias.
1794	ESRACAIN	ESRACAIN GEL	LIDOCAINE HYDROCHLORIDE	LIDOCAINE HYDROCHLORIDE 2%	GEL	RECIEPT	Local anesthetic, not to be used for procedures requiring sterile products
1797	ESRACAIN	ESRACAIN INJECTION 2 %	LIDOCAINE HYDROCHLORIDE	LIDOCAINE HYDROCHLORIDE 20MG/ML	SOLUTION	RECIEPT	Anaesthesia, cardiac arrhythmias.
1795	ESRACAIN	ESRACAIN GEL 30GR 2%	LIGNOCAINE HCL	LIGNOCAINE HCL 2%	GEL	RECIEPT	Local anesthetic, not to be used for procedures requiring sterile products
1792	ESRACAIN	ESRACAIN CREAM 20GR 5%	LIGNOCAINE HCL	LIGNOCAINE HCL 5%	CREAM	RECIEPT	Topical anesthetic.
1798	ESTELLE-35	ESTELLE-35	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.035MG;CYPROTERONE ACETATE 2MG	TABLETS	RECIEPT	For the treatment of signs of androgenization in women such as pronounced forms of acne, androgenic alopecia and mild forms of hirsutism.
1800	ESTO	ESTO 10	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 10MG	TABLETS	RECIEPT	Treatment of depression and panic disorder. Treatment of generalized anxiety disorder (GAD), treatment of social anxiety disorder (social phobia). Treatment of obsessive compulsive disorder.
1802	ESTO	ESTO 15	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 15MG	TABLETS	RECIEPT	Treatment of depression and panic disorder. Treatment of generalized anxiety disorder (GAD), treatment of social anxiety disorder (social phobia). Treatment of obsessive compulsive disorder.
1803	ESTO	ESTO 20	ESCITALOPRAM AS OXALATE	ESCITALOPRAM AS OXALATE 20MG	TABLETS	RECIEPT	Treatment of depression and panic disorder. Treatment of generalized anxiety disorder (GAD), treatment of social anxiety disorder (social phobia). Treatment of obsessive compulsive disorder.
1805	ESTROFEM	ESTROFEM 1 MG	ESTRADIOL AS HEMIHYDRATE	ESTRADIOL AS HEMIHYDRATE 1MG	TABLETS	RECIEPT	Hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women. Prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. Estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.
1806	ESTROFEM	ESTROFEM 2 MG	ESTRADIOL AS HEMIHYDRATE	ESTRADIOL AS HEMIHYDRATE 2MG	TABLETS	RECIEPT	Hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women. Prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. Estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy. The experience treating women older than 65 years is limited.
1811	ETODOLAC	ETODOLAC TEVA 400 MG	ETODOLAC	ETODOLAC 400MG	TABLETS	RECIEPT	For the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. For the management of pain.
1809	ETODOLAC	ETODOLAC ER TEVA 400 MG	ETODOLAC	ETODOLAC 400MG	TABLETS	RECIEPT	For the management of signs and symptoms of osteoarthritis and rehumatoid arthritis.
1810	ETODOLAC	ETODOLAC ER TEVA 600 MG	ETODOLAC	ETODOLAC 600MG	TABLETS	RECIEPT	For the management of signs and symptoms of osteoarthritis and rehumatoid arthritis.
1812	ETOMIDATE	ETOMIDATE-LIPURO	ETOMIDATE	ETOMIDATE 20MG/10ML	EMULSION	RECIEPT	Induction of general anaesthesia.
1813	ETOPAN	ETOPAN 200	ETODOLAC	ETODOLAC 200MG	CAPSULES	RECIEPT	For the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. For the management of pain.
1814	ETOPAN	ETOPAN 300	ETODOLAC	ETODOLAC 300MG	CAPSULES	RECIEPT	For the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. For the management of pain.
1815	ETOPAN	ETOPAN 400	ETODOLAC	ETODOLAC 400MG	TABLETS	RECIEPT	For the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. For the management of pain.
1817	ETOPAN	ETOPAN XL 400	ETODOLAC	ETODOLAC 400MG	TABLETS	RECIEPT	For the management of signs and symptoms of osteoarthrities and rheumatoid arthritis.
1816	ETOPAN	ETOPAN 500	ETODOLAC	ETODOLAC 500MG	TABLETS	RECIEPT	For the managament of signs and symptoms of osteoarthritis and rheumatoid arthritis. For the management of pain.
1818	ETOPAN	ETOPAN XL 500	ETODOLAC	ETODOLAC 500MG	TABLETS	RECIEPT	For the management of signs and symptoms of osteoarthrities and rheumatoid arthritis.
1819	ETOPAN	ETOPAN XL 600	ETODOLAC	ETODOLAC 600MG	TABLETS	RECIEPT	For the management of signs and symptoms of osteoarthritis and rheumatoid arthritis.
1820	ETOPOSID	ETOPOSID "EBEWE" 20 MG/ML	ETOPOSIDE	ETOPOSIDE 20MG/ML	CONCENTRATE	RECIEPT	Small cell lung cancer, resistant non-seminomatous testicular carcinoma, Hodgkin's and non-Hodgkin's lymphoma, acute myelocytic leukemia.
1821	ETOPOSIDE	ETOPOSIDE TEVA	ETOPOSIDE	ETOPOSIDE 20MG/ML	CONCENTRATE	RECIEPT	Hodgkin's disease. Malignant (non-Hodgkin's) Lymphomas, especially of the Histiocytic variety. Acute Non-Lymphocytic leukemia. Management of refractory testicular tumors and of small cell lung cancer.
1826	ETORICOXIB	ETORICOXIB DEXCEL 120 MG	ETORICOXIB	ETORICOXIB 120MG	TABLETS	RECIEPT	For the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.
1830	ETORICOXIB	ETORICOXIB TARO 120 MG	ETORICOXIB	ETORICOXIB 120MG	TABLETS	RECIEPT	Indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.
1827	ETORICOXIB	ETORICOXIB DEXCEL 30 MG	ETORICOXIB	ETORICOXIB 30MG	TABLETS	RECIEPT	For the symptomatic relief of osteoarthritis (OA).
1831	ETORICOXIB	ETORICOXIB TARO 30 MG	ETORICOXIB	ETORICOXIB 30MG	TABLETS	RECIEPT	Indicated for the symptomatic relief of osteoarthritis (OA).
1828	ETORICOXIB	ETORICOXIB DEXCEL 60 MG	ETORICOXIB	ETORICOXIB 60MG	TABLETS	RECIEPT	For the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis.
1832	ETORICOXIB	ETORICOXIB TARO 60 MG	ETORICOXIB	ETORICOXIB 60MG	TABLETS	RECIEPT	Indicated for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis.
1829	ETORICOXIB	ETORICOXIB DEXCEL 90 MG	ETORICOXIB	ETORICOXIB 90MG	TABLETS	RECIEPT	For the symptomatic relief of rheumatoid arthritis (RA) and ankylosing spondylitis. For the short-term treatment of moderate pain associated with dental surgery.
1833	ETORICOXIB	ETORICOXIB TARO 90 MG	ETORICOXIB	ETORICOXIB 90MG	TABLETS	RECIEPT	Indicated for the symptomatic relief of rheumatoid arthritis (RA) and ankylosing spondylitis. For the short-term treatment of moderate pain associated with dental surgery.
1822	ETORICOXIB	ETORICOXIB - TRIMA 120 MG	ETORICOXIB	ETORICOXIB 120MG	TABLETS	RECIEPT	Etoricoxib - Trima 120 mg tablets are indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.
1823	ETORICOXIB	ETORICOXIB - TRIMA 30 MG	ETORICOXIB	ETORICOXIB 30MG	TABLETS	RECIEPT	Etoricoxib - Trima 30 mg tablets are indicated for the symptomatic relief of osteoarthritis (OA).
1824	ETORICOXIB	ETORICOXIB - TRIMA 60 MG	ETORICOXIB	ETORICOXIB 60MG	TABLETS	RECIEPT	Etoricoxib - Trima 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis.
1825	ETORICOXIB	ETORICOXIB - TRIMA 90 MG	ETORICOXIB	ETORICOXIB 90MG	TABLETS	RECIEPT	Etoricoxib - Trima 90 mg tablets are indicated for the symptomatic relief of rheumatoid arthritis (RA) and ankylosing spondylitis. For the short-term treatment of moderate pain associated with dental surgery.
1834	EUCARBON	EUCARBON	SENNAE FOLIUM	SENNAE FOLIUM 105MG;RHUBARB 25MG;SULFUR PURIFIED 50MG;MEDICINAL CHARCOAL 180MG	TABLETS	RECIEPT	Mild laxative, anti-flatulant.
1835	EUCREAS	EUCREAS 50/1000 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 1000MG;VILDAGLIPTIN 50MG	TABLETS	RECIEPT	Eucreas is indicated in the treatment of type 2 diabetes mellitus: - Eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. - Eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea. - Eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
1836	EUCREAS	EUCREAS 50/500 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 500MG;VILDAGLIPTIN 50MG	TABLETS	RECIEPT	Eucreas is indicated in the treatment of type 2 diabetes mellitus: - Eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. - Eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea. - Eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
1837	EUCREAS	EUCREAS 50/850 MG	VILDAGLIPTIN	VILDAGLIPTIN 50MG;METFORMIN HYDROCHLORIDE 850MG	TABLETS	RECIEPT	Eucreas is indicated in the treatment of type 2 diabetes mellitus: - Eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. - Eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea. - Eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
1838	EUMOVATE	EUMOVATE CREAM	CLOBETASONE BUTYRATE	CLOBETASONE BUTYRATE 0.05%W/W	CREAM	RECIEPT	Eumovate Cream is a moderately potent topical corticosteroid indicated for adults, elderly, children and infants for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses. These include the following: - Atopic dermatitis - Irritant or allergic contact dermatitis - Seborrhoeic dermatitis - Nappy rash - Photodermatitis - Otitis externa - Prurigo nodularis - Insect bite reactions Eumovate may be used as maintenance therapy between courses of one of the more potent topical steroids.
1839	EUMOVATE	EUMOVATE OINTMENT	CLOBETASONE BUTYRATE	CLOBETASONE BUTYRATE 0.05%W/W	OINTMENT	RECIEPT	Eumovate ointment is a moderately potent topical corticosteroid indicated for adults, elderly, children and infants for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses. These include the following: - Atopic dermatitis - Irritant or allergic contact dermatitis - Seborrhoeic dermatitis - Nappy rash - Photodermatitis - Otitis externa - Prurigo nodularis - Insect bite reactions Eumovate may be used as maintenance therapy between courses of one of the more potent topical steroids.
1841	EURAX	EURAX CREAM 10% 20GR	CROTAMITON	CROTAMITON 10%	CREAM		Anti scabies treatment, symptomatic treatment of skin irritation.
1840	EURAX	EURAX	CROTAMITON	CROTAMITON 10%W/W	CREAM		Relief of pruritus and treatment of scabies.
1842	EUTHYROX	EUTHYROX 100 MCG	LEVOTHYROXINE AS SODIUM	LEVOTHYROXINE AS SODIUM 100MCG	TABLETS	RECIEPT	Euthyrox 25 - 200 microgram : - Treatment of benign euthyroid goitre. - Prophylaxis of relapse after surgery for euthyroid goitre, depending on the post - operative hormone status. - Substitution therapy in hypothyroidism. - Suppression therapy in thyroid cancer. Euthyrox 25 - 100 microgram : - Concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism. Euthyrox 100/150/200 microgram : - Diagnostic use for thyroid suppression testing.
1843	EUTHYROX	EUTHYROX 50 MCG	LEVOTHYROXINE AS SODIUM	LEVOTHYROXINE AS SODIUM 50MCG	TABLETS	RECIEPT	Euthyrox 25 - 200 microgram : - Treatment of benign euthyroid goitre. - Prophylaxis of relapse after surgery for euthyroid goitre, depending on the post - operative hormone status. - Substitution therapy in hypothyroidism. - Suppression therapy in thyroid cancer. Euthyrox 25 - 100 microgram : - Concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism. Euthyrox 100/150/200 microgram : - Diagnostic use for thyroid suppression testing.
1844	EVEROLIMUS	EVEROLIMUS TEVA 10 MG	EVEROLIMUS	EVEROLIMUS 10MG	TABLETS	RECIEPT	• For the treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. • Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of Everolimus in the treatment of patients with carcinoid tumors have not been established. • For the treatment of hormone receptor – positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression follwing a non – steroidal aromatase inhibitor. • Everolimus Teva is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of Everolimus in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. • Everolimus Teva is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. •Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease
1845	EVEROLIMUS	EVEROLIMUS TEVA 2.5 MG	EVEROLIMUS	EVEROLIMUS 2.5MG	TABLETS	RECIEPT	• For the treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. • Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of Everolimus in the treatment of patients with carcinoid tumors have not been established. • For the treatment of hormone receptor – positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression follwing a non – steroidal aromatase inhibitor. • Everolimus Teva is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of Everolimus in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. • Everolimus Teva is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. • Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease
1846	EVEROLIMUS	EVEROLIMUS TEVA 5 MG	EVEROLIMUS	EVEROLIMUS 5MG	TABLETS	RECIEPT	• For the treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. • Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of Everolimus in the treatment of patients with carcinoid tumors have not been established. • For the treatment of hormone receptor – positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression follwing a non – steroidal aromatase inhibitor. • Everolimus Teva is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of Everolimus in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. • Everolimus Teva is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. • Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease
1847	EVEROLIMUS	EVEROLIMUS TEVA 7.5 MG	EVEROLIMUS	EVEROLIMUS 7.5MG	TABLETS	RECIEPT	• For the treatment of patients with SEGA associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. • Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of Everolimus in the treatment of patients with carcinoid tumors have not been established. • For the treatment of hormone receptor – positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression follwing a non – steroidal aromatase inhibitor. • Everolimus Teva is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of Everolimus in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. • Everolimus Teva is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. • Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease
1848	EVIANA	EVIANA	ESTRADIOL AS HEMIHYDRATE	ESTRADIOL AS HEMIHYDRATE 0.5MG;NORETHISTERONE ACETATE 0.1MG	TABLETS	RECIEPT	Eviana is indicated for women who have a uterus for the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered . The experience treating women older than 65 years is limited .
1849	EVICEL SURGICAL	EVICEL HUMAN SURGICAL SEALANT	THROMBIN	THROMBIN 800 IU/1ML;CALCIUM CHLORIDE 5.6MG/1ML;PROTEIN CLOTTABLE 50MG/1ML	SOLUTION	RECIEPT	General haemostasis : Evicel is used as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. Efficacy has been demonstrated in liver surgery and orthopaedic surgery. Evicel is also indicated as suture support for haemostasis for suture line sealing in dura mater closure.
1850	EVIPLERA	EVIPLERA	TENOFOVIR DISOPROXIL AS FUMARATE	TENOFOVIR DISOPROXIL AS FUMARATE 245MG;RILPIVIRINE AS HYDROCHLORIDE 25MG;EMTRICITABINE 200MG	TABLETS	RECIEPT	EVIPLERA, a combination of two nucleoside analog HIV 1 reverse transcriptase inhibitors (emtricitabine and tenofovir disoproxil fumarate) and one non-nucleoside reverse transcriptase inhibitor (rilpivirine), is indicated for use as a complete regimen for the treatment of HIV-1 infection in adult patients with no antiretroviral treatment history and with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy, and in certain virologically-suppressed (HIV-1 RNA <50 copies/mL) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see below). The following points should be considered when initiating therapy with EVIPLERA in adult patients with no antiretroviral treatment history: • More rilpivirine-treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to rilpivirine-treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL [See Clinical Studies (14)]. • Regardless of HIV-1 RNA level at the start of therapy, more rilpivirine-treated subjects with CD4+ cell count less than 200 cells/mm3 experienced virologic failure compared to rilpivirine-treated subjects with CD4+ cell count greater than or equal to 200 cells/mm3 [See Clinical Studies (14)]. • The observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the NNRTI class compared to efavirenz [See Microbiology (12.4)] • More subjects treated with rilpivirine developed tenofovir and lamivudine/emtricitabine associated resistance compared to efavirenz [See Microbiology (12.4)].
1853	EVISTA	EVISTA	RALOXIFENE HYDROCHLORIDE	RALOXIFENE HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Evista is indicated for the treatment of osteoporosis in post menopausal women. Evista is indicated for the prevention of osteoporosis in post menopausal women . Evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. Evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.
1856	EVITOL	EVITOL 100MG 30TAB	ALPHA-TOCOPHEROL ACETATE (VIT E)	ALPHA;TOCOPHERO ACETATE (VIT E) 100MG	TABLETS		For the prevention and treatment of diseases caused by Vitamin E deficiency.
1859	EVITOL	EVITOL 200MG 30TAB	ALPHA-TOCOPHEROL ACETATE (VIT E)	ALPHA;TOCOPHEROL ACETATE (VIT E) 200MG	TABLETS		For the prevention and treatment of diseases caused by Vitamin E deficiency.
1854	EVITOL	EVITOL 100 MG	TOCOPHEROL (VIT E) (AS TOCOPHERYL ACETATE)	TOCOPHEROL (VIT E) (AS TOCOPHERYL ACETATE) 100MG	TABLETS		For the prevention and treatment of diseases caused by Vitamin E deficiency.
1857	EVITOL	EVITOL 200 MG	TOCOPHEROL (VIT E) (AS TOCOPHERYL ACETATE)	TOCOPHEROL (VIT E) (AS TOCOPHERYL ACETATE) 200MG	TABLETS		For the prevention and treatment of diseases caused by Vitamin E deficiency.
1860	EVOLTRA	EVOLTRA	CLOFARABINE	CLOFARABINE 1MG/ML	CONCENTRATE	RECIEPT	Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and who are about to undergo transplantation. Safety and efficacy have been assessed in studies of patients < or = 21 years old at initial diagnosis .
1861	EVOREL	EVOREL 50	ESTRADIOL AS HEMIHYDRATE	ESTRADIOL AS HEMIHYDRATE 3.2MG	PATCHES	RECIEPT	Deficiency symptoms by absence of Estrogen after the menopause or after surgical removal of the ovarians. They comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis. In women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.
1863	EVOREL	EVOREL SEQUI	ESTRADIOL AS HEMIHYDRATE	ESTRADIOL AS HEMIHYDRATE 3.2MG Evorel Conti;NORETHISTERONE ACETATE 11.2MG Evorel Conti;ESTRADIOL AS HEMIHYDRATE 3.2MG Evorel 50	PATCHES	RECIEPT	Hormone replacement therapy for the relief of menopausal symptoms.
1862	EVOREL	EVOREL CONTI	ESTRADIOL AS HEMIHYDRATE	ESTRADIOL AS HEMIHYDRATE 3.2MG;NORETHISTERONE ACETATE 11.2MG	PATCHES	RECIEPT	Hormone replacement therapy for the relief of menopausal symptoms.
1864	EVRA	EVRA	NORELGESTROMIN	NORELGESTROMIN 6MG;ETHINYLESTRADIOL 0.6MG	PATCHES	RECIEPT	Female contraception. Evra is intended for women of fertile age.
1868	EXCEDRIN	EXCEDRIN 32 CAPLETS	ASPIRIN	ASPIRIN 250MG;PARACETAMOL 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
1869	EXCEDRIN	EXCEDRIN 50 CAPLETS	ASPIRIN	ASPIRIN 250MG;PARACETAMOL 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
1866	EXCEDRIN	EXCEDRIN	PARACETAMOL	PARACETAMOL 250MG;ACETYLSALICYLIC ACID 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
1876	EXELON	EXELON PATCH 15	RIVASTIGMINE	RIVASTIGMINE 27MG	PATCHES	RECIEPT	Exelon Patch is indicated for the treatment of dementia of the Alzheimr’s type (AD). Efficacy has been demonstrated in patients with mild, moderate and severe Alzheimer’s disease.
1877	EXELON	EXELON PATCH 5	RIVASTIGMINE	RIVASTIGMINE 4.6MG/DAY	PATCHES	RECIEPT	Treatment of mild to moderate dementia of the Alzheimer's type.
1875	EXELON	EXELON PATCH 10	RIVASTIGMINE	RIVASTIGMINE 9.5MG/DAY	PATCHES	RECIEPT	Treatment of mild to moderate dementia of the Alzheimer's type.
1871	EXELON	EXELON 1.5 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 1.5MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
1872	EXELON	EXELON 3 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 3MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
1873	EXELON	EXELON 4.5 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 4.5MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe alzheimer's dementia Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
1874	EXELON	EXELON 6 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 6MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
1878	EXEMASIN	EXEMASIN - VIT	EXEMESTANE	EXEMESTANE 25MG	TABLETS	RECIEPT	Exemasin-VIT is indicated for the treatment of advanced breast cancer (ABC) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. Exemasin-VIT is also indicated for the treatment of postmenopausal women with ABC whose disease has progressed following multiple hormonal therapies. Exemasin-VIT is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
1879	EXEMESTAN	EXEMESTAN ACTAVIS 25 MG	EXEMESTANE	EXEMESTANE 25MG	TABLETS	RECIEPT	Treatment of advanced breast cancer (ABC) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. Treatment of postmenopausal women with ABC whose disease has progressed following multiple hormonal therapies. Adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy.
1880	EXEMESTANE	EXEMESTANE TEVA 25 MG	EXEMESTANE	EXEMESTANE 25MG	TABLETS	RECIEPT	Exemestane Teva is indicated for the treatment of advanced breast cancer (ABC) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. Exemestane Teva is also indicated for the treatment of postmenopausal women with ABC whose disease has progressed following multiple hormonal therapies. Exemestane Teva is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy
1883	EXEMESTANE	EXEMESTANE-TRIMA	EXEMESTANE	EXEMESTANE 25MG	TABLETS	RECIEPT	- Adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2-3 years of initial adjuvant tamoxifen therapy. - Treatment of advanced breast cancer (ABC) in women with natural or induced postmenop
1884	EXFORGE	EXFORGE 10 MG/160 MG	AMLODIPINE AS BESYLATE	AMLODIPINE AS BESYLATE 10MG;VALSARTAN 160MG	TABLETS	RECIEPT	Treatment of essential hypertension. Exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
1885	EXFORGE	EXFORGE 5 MG/160 MG	AMLODIPINE AS BESYLATE	AMLODIPINE AS BESYLATE 5MG;VALSARTAN 160MG	TABLETS	RECIEPT	Treatment of essential hypertension. Exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
1886	EXFORGE	EXFORGE 5 MG/80 MG	AMLODIPINE AS BESYLATE	AMLODIPINE AS BESYLATE 5MG;VALSARTAN 80MG	TABLETS	RECIEPT	Treatment of essential hypertension. Exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
1887	EXIDOL	EXIDOL	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 250MG;PARACETAMOL 250MG;CAFFEINE 65MG ANHYDROUS	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
1889	EXIDOL	EXIDOL 24 CAPLETS	ASPIRIN	ASPIRIN 250MG;PARACETAMOL 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
1890	EXIDOL	EXIDOL 50 CAPLETS	ASPIRIN	ASPIRIN 250MG;PARACETAMOL 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
1891	EXIMOL	EXIMOL CARE	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 250MG;PARACETAMOL 250MG;CAFFEINE ANHYDROUS 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
1893	EXIMOL	EXIMOL CARE 50 TAB	ASPIRIN	ASPIRIN 250MG;PARACETAMOL 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.
1894	EXIPAN	EXIPAN	PIROXICAM	PIROXICAM 0.5%	GEL	RECIEPT	For local treatment of inflammatory conditions accompanied by pain.
1895	EXIPAN	EXIPAN GEL ROLL ON 90GR	PIROXICAM	PIROXICAM 0.5%	GEL	RECIEPT	For local treatment of inflammatory conditions accompanied by pain.
1896	EXIPAN	EXIPAN GEL TUBE 50GR	PIROXICAM	PIROXICAM 0.5%	GEL	RECIEPT	For local treatment of inflammatory conditions accompanied by pain.
1897	EXJADE	EXJADE 125 MG	DEFERASIROX	DEFERASIROX 125MG	TABLETS	RECIEPT	Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). Exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). LIC is the preferred method of iron overload determination and should be used wherever available
1898	EXJADE	EXJADE 250 MG	DEFERASIROX	DEFERASIROX 250MG	TABLETS	RECIEPT	Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). Exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). LIC is the preferred method of iron overload determination and should be used wherever available
1899	EXJADE	EXJADE 500 MG	DEFERASIROX	DEFERASIROX 500MG	TABLETS	RECIEPT	Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). Exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). LIC is the preferred method of iron overload determination and should be used wherever available
1900	EXONDYS	EXONDYS 51	ETEPLIRSEN	ETEPLIRSEN 50MG/1ML	CONCENTRATE	RECIEPT	EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
1901	EXTEROL	EXTEROL EAR DROPS 12ML	UREA HYDROGEN PEROXIDE	UREA HYDROGEN PEROXIDE 5%	DROPS		An aid for the removal of hardened ear wax.
1902	EXTEROL	EXTEROL 5 % EAR DROPS	UREA HYDROGEN PEROXIDE	UREA HYDROGEN PEROXIDE 5%	DROPS		An aid for the removal of hardened ear wax.
1903	EXTRANEAL	EXTRANEAL	ICODEXTRIN	ICODEXTRIN 75G/L;MAGNESIUM CHLORIDE HEXAHYDRATE 0.051G/L;CALCIUM CHLORIDE DIHYDRATE 0.257G/L;SODIUM (S) - LACTATE 4.5G/L;SODIUM CHLORIDE 5.4G/L	SOLUTION	RECIEPT	Once daily replacement of a single glucose exchange as part of Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD) in the treatment of chronic renal failure.
1907	EYECON	EYECON	HYALURONIC ACID AS SODIUM	HYALURONIC ACID AS SODIUM 0.015%	DROPS		Symptomatic treatment of dry eye syndrome.
1908	EYLEA	EYLEA	AFLIBERCEPT	AFLIBERCEPT 40MG/ML	SOLUTION	RECIEPT	Eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch CRVO or central RVO) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV).
1909	E-Z-CAT	E-Z-CAT	BARIUM SULFATE	BARIUM SULFATE 4.9224%W/V	SUSPENSION	RECIEPT	For use in x-ray departments. Opacification of the gastro intestinal tract prior to computerized axial tomography.
1910	EZECOR	EZECOR	EZETIMIBE	EZETIMIBE 10MG	TABLETS	RECIEPT	Primary hypercholesterolemia: Ezecor administered with an HMG-CoA reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. Homozygous familial hypercholesterolemia (HoFH): Ezecor administered with a statin are indicated for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis). Homozygous sitosterolemia (Phytosterolemia): Ezecor are indicated for use in patients with homozygous familial sitosterolemia.
1912	EZETIMIBE	EZETIMIBE SANDOZ	EZETIMIBE	EZETIMIBE 10MG	TABLETS	RECIEPT	Primary hypercholesterolemia: Ezetimibe Sandoz administered with an HMG-CoA reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. Homozygous familial hypercholesterolemia (HoFH): Ezetimibe Sandoz administered with a statin are indicated for use in patients with HoFH.Patients may also receive adjunctive treatments (e.g. LDL apheresis). Homozygous sitosterolemia (Phytosterolemia): Ezetimibe Sandoz are indicated for use in patients with homozygous familial sitosterolemia.
1913	EZETIMIBE	EZETIMIBE TEVA	EZETIMIBE	EZETIMIBE 10MG	TABLETS	RECIEPT	- Primary hypercholesterolemia: Ezetimibe Teva administered with an HMG-CoA reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
1914	EZETROL	EZETROL 10 MG TABLETS	EZETIMIBE	EZETIMIBE 10MG	TABLETS	RECIEPT	Primary hypercholesterolemia: Ezetrol administered with an HMG-CoA reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. Homozygous familial hypercholesterolemia (HoFH): Ezetrol administered with a statin are indicated for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis). Homozygous sitosterolemia (Phytosterolemia): Ezetrol are indicated for use in patients with homozygous familial sitosterolemia.
1915	E-Z-GAS	E-Z-GAS II	CITRIC ACID ANHYDROUS	CITRIC ACID ANHYDROUS 38.21%W/W;SIMETHICONE 1%W/W;SODIUM BICARBONATE 55.14%W/W	GRANULES	RECIEPT	For the relief of heartburn sour stomach acid indigestion upset stomach and gas associated with these symptoms. For use only in X-ray departments: Endoscopic adjunct. Is indicated as an adjunct to contrast media utilized during a double - contrast upper gastro-intestinal (DCUGI) examination.
1916	E-Z-HD	E-Z-HD	BARIUM SULFATE	BARIUM SULFATE 98.3845%W/W	POWDER	RECIEPT	For double contrast radiography of the oesophagus, stomach and duodenum.
1917	E-Z-PAQUE	E-Z-PAQUE	BARIUM SULFATE	BARIUM SULFATE 96%W/W	POWDER	RECIEPT	Single - contrast radiography of the oesophagus stomach duodenum and small bowel. For use only in x-ray departments.
1918	FABRAZYME	FABRAZYME 35 MG	AGALSIDASE BETA	AGALSIDASE BETA 35MG/VIAL	POWDER	RECIEPT	Fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. (alfa - galactosidase A deficiency).
1919	FAMO	FAMO 20	FAMOTIDINE	FAMOTIDINE 20MG	TABLETS	RECIEPT	Treatment of duodenal ulcer. Prevention of relapses of duodenal ulceration. Treatment of benign gastric ulcer. Pathological hypersecretory conditions such as zollinger-syndrome. Gastroesophageal reflux disease.
1920	FAMO	FAMO 40	FAMOTIDINE	FAMOTIDINE 40MG	TABLETS	RECIEPT	Treatment of duodenal ulcer. Prevention of relapses of duodenal ulceration. Treatment of benign gastric ulcer. Pathological hypersecretory conditions such as zollinger-syndrome. Gastroesophageal reflux disease.
1921	FAMOTIDINE	FAMOTIDINE TEVA 20 MG	FAMOTIDINE	FAMOTIDINE 20MG	TABLETS	RECIEPT	Treatment and prevention of heartburn and hyperacidity in the upper gastrointestinal tract.
1924	FAMOTIDINE	FAMOTIDINE TEVA 20MG 30TAB	FAMOTIDINE	FAMOTIDINE 20MG	TABLETS	RECIEPT	Treatment of Duodenal Ulcer, Benign Gastric Ulcer, Pathological hypersecretory conditions such as Zollinger-ellison syndrome, Gastroesophageal reflux disease. Prevention of relapses of duodenal ulceration.
1925	FAMOTIDINE	FAMOTIDINE TEVA 40 MG	FAMOTIDINE	FAMOTIDINE 40MG	TABLETS	RECIEPT	Treatment of Duodenal Ulcer, Benign Gastric Ulcer, Pathological hypersecretory conditions such as Zollinger-ellison syndrome, Gastroesophageal reflux disease. Prevention of relapses of duodenal ulceration.
1928	FAMPYRA	FAMPYRA 10 MG	FAMPRIDINE	FAMPRIDINE 10MG	TABLETS	RECIEPT	FAMPYRA is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7)
1930	FANAPT	FANAPT TABLETS 10 MG	ILOPERIDONE	ILOPERIDONE 10MG	TABLETS	RECIEPT	Fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
1931	FANAPT	FANAPT TABLETS 12 MG	ILOPERIDONE	ILOPERIDONE 12MG	TABLETS	RECIEPT	Fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
1929	FANAPT	FANAPT TABLETS 1 MG	ILOPERIDONE	ILOPERIDONE 1MG	TABLETS	RECIEPT	FANAPT is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
1932	FANAPT	FANAPT TABLETS 2 MG	ILOPERIDONE	ILOPERIDONE 2MG	TABLETS	RECIEPT	FANAPT is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
1933	FANAPT	FANAPT TABLETS 4 MG	ILOPERIDONE	ILOPERIDONE 4MG	TABLETS	RECIEPT	FANAPT is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
1934	FANAPT	FANAPT TABLETS 6 MG	ILOPERIDONE	ILOPERIDONE 6MG	TABLETS	RECIEPT	FANAPT is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
1935	FANAPT	FANAPT TABLETS 8 MG	ILOPERIDONE	ILOPERIDONE 8MG	TABLETS	RECIEPT	Fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
1936	FANHDI	FANHDI 100 IU/ML (FACTOR VIII)	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 1000 IU	POWDER	RECIEPT	Is indicated for the prevention and control of bleeding in patients with moderate or severe factor VIII deficiency due to classical hemophilia A . Fanhdi is not effective in controlling the bleeding of patients with Von Willebrond's disease.
1937	FANHDI	FANHDI 100 IU/ML, 1500 IU (FACTOR VIII)	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 1500 IU/DOSE	POWDER	RECIEPT	Is indicated for the prevention and control of bleeding in patients with moderate or severe factor VIII deficiency due to classical hemophilia A . Fanhdi is not effective in controlling the bleeding of patients with Von Willebrond's disease.
1938	FANHDI	FANHDI 25 IU/ML (FACTOR VIII)	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 250 IU	POWDER	RECIEPT	Is indicated for the prevention and control of bleeding in patients with moderate or severe factor VIII deficiency due to classical hemophilia A . Fanhdi is not effective in controlling the bleeding of patients with Von Willebrond's disease.
1939	FANHDI	FANHDI 50 IU/ML (FACTOR VIII)	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 500 IU	POWDER	RECIEPT	Is indicated for the prevention and control of bleeding in patients with moderate or severe factor VIII deficiency due to classical hemophilia A . Fanhdi is not effective in controlling the bleeding of patients with Von Willebrond's disease.
1941	FASENRA	FASENRA	BENRALIZUMAB	BENRALIZUMAB 30MG/1ML	SOLUTION	RECIEPT	Fasenra is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
1942	FASLODEX	FASLODEX	FULVESTRANT	FULVESTRANT 250MG/5ML	SOLUTION	RECIEPT	Monotherapy : Faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or with disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy. Combination Therapy with Palbociclib: Faslodex is indicated for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy
1945	FASTUM	FASTUM GEL	KETOPROFEN	KETOPROFEN 2.5%W/W	GEL	RECIEPT	Local treatment of painful disorders of the osteo-articular and muscular system of rheumatic or traumatic origin: contusions, distortions, muscle strains, stiff neck, lumbago.
1949	FAVOXIL	FAVOXIL 100	FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE 100MG	TABLETS	RECIEPT	For the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. Treatment of obsessive compulsive disorders (OCD).
1950	FAVOXIL	FAVOXIL 50	FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE 50MG	TABLETS	RECIEPT	For the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. Treatment of obsessive compulsive disorders (OCD).
1951	FEBURIC	FEBURIC 80 MG	FEBUXOSTAT	FEBUXOSTAT 80MG	TABLETS	RECIEPT	Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Feburic is indicated in adults.
1952	FEIBA	FEIBA NF 1000 U	FACTOR VIII INHIBITOR BYPASSING FRACTION	FACTOR VIII INHIBITOR BYPASSING FRACTION 1000 U/VIAL	POWDER	RECIEPT	Control of bleeding episodes in haemophilia A patients with Factor VIII Inhibitors and also in patients with acquired Factor VIII Inhibitors . Control of bleeding in hemophilia B patients with inhibitors, if no other specific treatment is available.
1953	FEIBA	FEIBA NF 500 U	FACTOR VIII INHIBITOR BYPASSING FRACTION	FACTOR VIII INHIBITOR BYPASSING FRACTION 500 U/VIAL	POWDER	RECIEPT	Control of bleeding episodes in haemophilia A patients with Factor VIII Inhibitors and also in patients with acquired Factor VIII Inhibitors. Control of bleeding in hemophilia B patients with inhibitors, if no other specific treatment is available.
1955	FELDENE	FELDENE GEL 50GR	PIROXICAM	PIROXICAM 0.5%	GEL	RECIEPT	Variety of conditions characterized by pain and inflammation such as osteoarthritis of superficial joints, acute musculoskeletal injuries, periarthritis, tendinitis and tenosynovitis.
1954	FELDENE	FELDENE GEL	PIROXICAM	PIROXICAM 5MG/G	GEL	RECIEPT	Variety of conditions characterized by pain and inflammation such as osteoarthritis of superficial joints, acute musculoskeletal injuries, periarthritis, tendinitis and tenosynovitis.
1956	FEMARA	FEMARA	LETROZOLE	LETROZOLE 2.5MG	TABLETS	RECIEPT	Femara (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
1957	FEMINET	FEMINET	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.02MG;DESOGESTREL 0.15MG	TABLETS	RECIEPT	Contraceptive.
1958	FEMOSTON	FEMOSTON 1/10 MG	DYDROGESTERONE	DYDROGESTERONE 10MG Estradiol/dydrogesterone film-coated tablet;ESTRADIOL 1MG Estradiol film-coated tablet;ESTRADIOL 1MG Estradiol/dydrogesterone film-coated tablet	TABLETS	RECIEPT	Hormone replacement therapy (HRT) for estrogen deficiency symptoms in menopausal women at least 6 months since last menses. Prevention of osteoporosis in postmenopausal women at high risk of future fractures. Femoston 1/10 should only be used in patients who are intolerant of other products, approved for the prevention of osteoporosis or for whom these products are contra-indicated. Femoston is indicated for women with an intact uterus Experience with treatment of women older than 65 years is limited.
1960	FENIDERM	FENIDERM GEL	DIMETINDENE MALEATE	DIMETINDENE MALEATE 0.1%W/W	GEL		Urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
1963	FENISTIL	FENISTIL GEL 100GR	DIMETHINDENE MALEATE	DIMETHINDENE MALEATE 0.1%	GEL		Urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
1964	FENISTIL	FENISTIL GEL 30G	DIMETHINDENE MALEATE	DIMETHINDENE MALEATE 0.1%	GEL		Urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
1962	FENISTIL	FENISTIL GEL	DIMETHINDENE MALEATE	DIMETHINDENE MALEATE 0.1%W/W	GEL	RECIEPT	Urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
1961	FENISTIL	FENISTIL DROPS	DIMETHINDENE MALEATE	DIMETHINDENE MALEATE 1MG/ML	DROPS	RECIEPT	Antipruritic, antihistaminic and antiallergic.
1969	FENLIPS	FENLIPS COLOR 2GR	PENCICLOVIR	PENCICLOVIR 10MG	CREAM		For the topical treatment for cold sores (oral herpes)
1970	FENLIPS	FENLIPS CREAM 2GR	PENCICLOVIR	PENCICLOVIR 10MG	CREAM		For the topical treatment for cold sores (oral herpes)
1965	FENLIPS	FENLIPS	PENCICLOVIR	PENCICLOVIR 10MG/G	CREAM		For the topical treatment for cold sores (oral herpes).
1967	FENLIPS	FENLIPS COLOR	PENCICLOVIR	PENCICLOVIR 10MG/G	CREAM		For the topical treatment for cold sores (oral herpes)
1971	FENTA	FENTA 100	FENTANYL	FENTANYL 100MCG/HOUR	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.
1973	FENTA	FENTA 12	FENTANYL	FENTANYL 12.5MCG/HOUR	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fenta should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.
1975	FENTA	FENTA 25	FENTANYL	FENTANYL 25MCG/HOUR	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.
1977	FENTA	FENTA 50	FENTANYL	FENTANYL 50MCG/HOUR	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.
1979	FENTA	FENTA 75	FENTANYL	FENTANYL 75MCG/HOUR	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.
1981	FENTA	FENTA INJECTION	FENTANYL AS CITRATE	FENTANYL AS CITRATE 0.05MG/ML	SOLUTION	RECIEPT	For analgesic action of short duration during anesthtic periods (premedication induction and maintenance) and in the immediate postoperative period as need arises. As a narcotic analgesic supplement in general or regional anesthesia. For administration with neuroleptics (such as droperidol) as an anesthetic premedication for the induction of anesthesia and as an adjunct in the maintenance of general or regional anesthesia. For use as an anesthetic agent with oxygen in selected high-risk patients (open heart surgery or certain neurological or orthopedic procedures). By the epidural route for the postoperative management of pain following general surgical procedures and cesarean sections and as adjunct to general anesthesia.
1982	FENTA	FENTA SL 133 SUBLINGUAL TABLETS	FENTANYL AS CITRATE	FENTANYL AS CITRATE 133MCG	TABLETS	RECIEPT	Treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
1984	FENTA	FENTA SL 267 SUBLINGUAL TABLETS	FENTANYL AS CITRATE	FENTANYL AS CITRATE 267MCG	TABLETS	RECIEPT	Treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
1986	FENTA	FENTA SL 400 SUBLINGUAL TABLETS	FENTANYL AS CITRATE	FENTANYL AS CITRATE 400MCG	TABLETS	RECIEPT	Treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
1988	FENTA	FENTA SL 533 SUBLINGUAL TABLETS	FENTANYL AS CITRATE	FENTANYL AS CITRATE 533MCG	TABLETS	RECIEPT	Treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
1990	FENTA	FENTA SL 67 SUBLINGUAL TABLETS	FENTANYL AS CITRATE	FENTANYL AS CITRATE 67MCG	TABLETS	RECIEPT	Treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
1992	FENTA	FENTA SL 800 SUBLINGUAL TABLETS	FENTANYL AS CITRATE	FENTANYL AS CITRATE 800MCG	TABLETS	RECIEPT	Treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.
1998	FENTADOL	FENTADOL 75	FENTANYL	FENTANYL 12.6MG/PATCH	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.
1994	FENTADOL	FENTADOL 100	FENTANYL	FENTANYL 16.8MG/PATCH	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.
1995	FENTADOL	FENTADOL 12	FENTANYL	FENTANYL 2.1MG/PATCH	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.
1996	FENTADOL	FENTADOL 25	FENTANYL	FENTANYL 4.2MG/PATCH	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.
1997	FENTADOL	FENTADOL 50	FENTANYL	FENTANYL 8.4MG/PATCH	PATCHES	RECIEPT	Management of chronic pain and intractable pain requiring opioid analgesia. Fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.
1999	FENTANYL	FENTANYL PANPHARMA 0.05 MG/ML	FENTANYL AS CITRATE	FENTANYL AS CITRATE 0.05MG/ML	SOLUTION	RECIEPT	For analgesic action of short duration during anesthtic periods (premedication, induction and maintenance) and in the immediate postoperative period as need arises. As a narcotic analgesic supplement in general or regional anesthesia. For administration with neuroleptics (such as droperidol) as an anesthetic premedication for the induction of anesthesia and as an adjunct in the maintenance of general or regional anesthesia. For use as an anesthetic agent with oxygen in selected high-risk patients (open heart surgery or certain neurological or orthopedic procedures). By the epidural route for the postoperative management of pain following general surgical procedures and cesarean sections and as adjunct to general anesthesia.
2000	FENTANYL	FENTANYL -PIRAMAL	FENTANYL AS CITRATE	FENTANYL AS CITRATE 0.05MG/ML	SOLUTION	RECIEPT	For analgesic action of short duration during anesthtic periods (premedication dinduction and maintenance) and in the immediate postoperative period as need arises. As a narcotic analgesic supplement in general or regional anesthesia. For administration with neuroleptics (such as droperidol) as an anesthetic premedication for the induction of anesthesia and as an adjunct in the maintenance of general or regional anesthesia. For use as an anesthetic agent with oxygen in selected high-risk patients (open heart surgery or certain neurological or orthopedic procedures). By the epidural route for the postoperative management of pain following general surgical procedures and cesarean sections and as adjunct to general anesthesia.
2001	FENTORA	FENTORA 100 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 100MCG	TABLETS	RECIEPT	Fentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer
2002	FENTORA	FENTORA 200 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 200MCG	TABLETS	RECIEPT	Fentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer
2003	FENTORA	FENTORA 400 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 400MCG	TABLETS	RECIEPT	Fentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer
2004	FENTORA	FENTORA 600 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 600MCG	TABLETS	RECIEPT	Fentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer
2005	FENTORA	FENTORA 800 MCG	FENTANYL AS CITRATE	FENTANYL AS CITRATE 800MCG	TABLETS	RECIEPT	Fentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer
2006	FERINJECT	FERINJECT	FERRIC CARBOXYMALTOSE	FERRIC CARBOXYMALTOSE 1800MG/VIAL	SOLUTION	RECIEPT	Ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests. 28/10/2014 בקשה לשינוי משטר מינונים
2012	FERRIFOL	FERRIFOL 3 30CHEWTAB	FERROUS AS IRON(III)HYDROXIDE POLYMALTOSE	FERROUS AS IRON(III)HYDROXIDE POLYMALTOSE 100MG;FOLIC ACID 0.4MG	TABLETS		Prevention and treatment of anemia caused by iron and folic acid deficiency including anemia of pregnancy and lactation.
2011	FERRIFOL	FERRIFOL	FOLIC ACID	FOLIC ACID 0.4MG;FERROUS AS IRON III HYDROXIDE POLYMALTOSE COMPL. 100MG	TABLETS		Prevention and treatment of anemia caused by iron and folic acid deficiency including anemia of pregnancy and lactation.
2014	FERRIPEL	FERRIPEL-3 SYRUP	FERROUS AS IRON III HYDROXIDE POLYMALTOSE COMPL.	FERROUS AS IRON III HYDROXIDE POLYMALTOSE COMPL. 50MG/5ML	SYRUP		Prevention and treatment of iron deficiency anaemia.
2013	FERRIPEL	FERRIPEL 3 SYR 110ML	IRON(III)HYDROXYDE POLYMALTOSE	IRON(III)HYDROXYDE POLYMALTOSE 50MG/5ML	SYRUP		Prevention and treatment of iron deficiency anaemia.
2015	FERRIPROX	FERRIPROX ORAL SOLUTION 100 MG/ML	DEFERIPRONE	DEFERIPRONE 100MG/1ML	SOLUTION	RECIEPT	For the treatment of iron overload in patients over 6 years old with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.
2016	FERRIPROX	FERRIPROX TABLETS 500 MG	DEFERIPRONE	DEFERIPRONE 500MG	TABLETS	RECIEPT	For the treatment of iron overload in patients over 6 years old with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.
2017	FERRLECIT	FERRLECIT	IRON AS IRON III SODIUM FERRIC GLUGONATE COMPL.	IRON AS IRON III SODIUM FERRIC GLUGONATE COMPL. 62.5MG/5ML	SOLUTION	RECIEPT	Ferrlecit is indicated in adults and children 6 years and above. Severe iron deficiency states only when oral administration has been found impossible; in cases of gastrointestinal malabsorption which rules out oral iron therapy; patients treated by dialysis getting Erythropoietin.
2019	FERRO	FERRO 15 SYRUP	FERROUS GLUCONATE	FERROUS GLUCONATE 130MG/5ML	SYRUP	RECIEPT	For the treatment and prevention of anemic states and iron deficiency in infants.
2018	FERRO	FERRO 15 SYR 120ML	FERROUS GLUCONATE	FERROUS GLUCONATE 2.6% W/V	SYRUP		Severe iron deficiency only when oral administration has been found impossible. In cases of gastro- intestinal malobsorption which rules our oral therapy, patients on dialysis treated with erythropoietin.
2020	FERROCAL	FERROCAL 500MG 30 TAB	CALCIUM CITRATE	CALCIUM CITRATE 249MG;FERROUS CITRATE 246MG	TABLETS		Prevention and treatment of iron-deficiency anemia.
2021	FERROCAL	FERROCAL 500MG 50TAB	CALCIUM CITRATE	CALCIUM CITRATE 249MG;FERROUS CITRATE 246MG	TABLETS		Prevention and treatment of iron-deficiency anemia.
2022	FERROCAL	FERROCAL TABLETS	CALCIUM CITRATE	CALCIUM CITRATE 249MG;FERROUS CITRATE 246MG MONOHYDRATE	TABLETS		Prevention and treatment of iron-deficiency anemia.
2024	FERROGRAD FOLIC	FERROGRAD FOLIC 30T	FERROUS SULPHATE	FERROUS SULPHATE 325MG;FOLIC ACID 0.35MG	TABLETS		Adults (men) and non-pregnant women : Treatment and prevention of iron deficiency (anaemia) and to prevention folic acid deficiency . Pregnant women: Treatment and prevention of iron deficiency (anemia) only.
2023	FERROGRAD FOLIC	FERROGRAD FOLIC	FOLIC ACID	FOLIC ACID 0.35MG;FERROUS SULFATE 325.0MG	TABLETS		Adults (men) and non-pregnant women : Treatment and prevention of iron deficiency (anaemia) and to prevention folic acid deficiency . Pregnant women: Treatment and prevention of iron deficiency (anemia) only.
2025	FERROVIN	FERROVIN	IRON SUCROSE	IRON SUCROSE 20MG/ML	SOLUTION		Severe iron deficiency only when oral administration has been found impossible. In cases of gastro- intestinal malobsorption which rules our oral therapy, patients on dialysis treated with erythropoietin.
2026	FEXOFENADINE	FEXOFENADINE - TRIMA 120 MG	FEXOFENADINE HYDROCHLORIDE	FEXOFENADINE HYDROCHLORIDE 120MG	TABLETS	RECIEPT	Relief of symptoms associated with seasonal allergic rhinitis.
2027	FEXOFENADINE	FEXOFENADINE - TRIMA 180 MG	FEXOFENADINE HYDROCHLORIDE	FEXOFENADINE HYDROCHLORIDE 180MG	TABLETS	RECIEPT	Relief of symptoms associated with chronic idiopathic urticaria
2028	FIASP	FIASP	INSULIN ASPART	INSULIN ASPART 100U/ML	SOLUTION	RECIEPT	Treatment of diabetes mellitus in adults
2029	FIBROGAMMIN	FIBROGAMMIN 1250	FACTOR XIII	FACTOR XIII 1250 IU 1000 - 1600 IU	POWDER	RECIEPT	Fibrogammin is indicated for adult and paediatric patients • for prophylactic treatment of congenital FXIII deficiency and • for peri-operative management of surgical bleeding with congentital FXIII deficiency. Fibrogammin is furthermore indicated • for haemorrhagic diatheses caused completely or in part by acquired FXIII deficiency • for supportive therapy in case of disturbance in wound healing, especially in ulcus cruris, after large surgery or injuries.
2030	FIBROGAMMIN	FIBROGAMMIN 250	FACTOR XIII	FACTOR XIII 200 IU 250 IU	POWDER	RECIEPT	Fibrogammin is indicated for adult and paediatric patients • for prophylactic treatment of congenital FXIII deficiency and • for peri-operative management of surgical bleeding with congentital FXIII deficiency. Fibrogammin is furthermore indicated • for haemorrhagic diatheses caused completely or in part by acquired FXIII deficiency • for supportive therapy in case of disturbance in wound healing, especially in ulcus cruris, after large surgery or injuries.
2032	FINASTERIDE	FINASTERIDE TEVA 1 MG	FINASTERIDE	FINASTERIDE 1MG	TABLETS	RECIEPT	Finasteride Teva 1 mg is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss.
2033	FINGOLIMOD	FINGOLIMOD SANDOZ 0.5 MG	FINGOLIMOD AS HYDROCHLORIDE	FINGOLIMOD AS HYDROCHLORIDE 0.5MG	CAPSULES	RECIEPT	Fingolimod Sandoz is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( MS ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
2034	FINGOLIMOD	FINGOLIMOD TEVA	FINGOLIMOD AS HYDROCHLORIDE	FINGOLIMOD AS HYDROCHLORIDE 0.5MG	CAPSULES	RECIEPT	Indicated for the treatment of patients with relapsing forms of multiple sclerosis ( MS ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disabiliry.
2035	FINOLIM	FINOLIM 0.5 MG	FINGOLIMOD AS HYDROCHLORIDE	FINGOLIMOD AS HYDROCHLORIDE 0.5MG	CAPSULES	RECIEPT	Treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
2036	FIRAZYR	FIRAZYR 30 MG	ICATIBANT AS ACETATE	ICATIBANT AS ACETATE 30MG/3ML	SOLUTION	RECIEPT	Symptomatic treatment of acute attacks of hereditary angioedima (HAE) in adults, adolescents and children aged 2 years and older, with C1 -esterase-inhibitor deficiency
2038	FIRDAPSE	FIRDAPSE	AMIFAMPRIDINE	AMIFAMPRIDINE 10MG	TABLETS	RECIEPT	Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults
2039	FIRMAGON	FIRMAGON 120 MG	DEGARELIX AS ACETATE	DEGARELIX AS ACETATE 120MG	POWDER	RECIEPT	For the treatment of adult male patients with advanced hormone-dependent prostate cancer.
2043	FIRMAGON	FIRMAGON 80 MG	DEGARELIX AS ACETATE	DEGARELIX AS ACETATE 80MG	POWDER	RECIEPT	For the treatment of adult male patients with advanced hormone-dependent prostate cancer.
2047	FLAGYL	FLAGYL 250 MG TABLETS	METRONIDAZOLE	METRONIDAZOLE 250MG	TABLETS	RECIEPT	Trichomonias, acute intestinal amebiasis. Infections due to anaerobic bacteria, lambliasis.
2048	FLAGYL	FLAGYL SUSPENSION	METRONIDAZOLE BENZOATE	METRONIDAZOLE BENZOATE 40MG/ML	SUSPENSION	RECIEPT	Infections caused by anaerobic bacterias, amebiosis, lambliasis and trichomonas.
2049	FLAME	FLAME	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.02MG;GESTODENE 0.075MG	TABLETS	RECIEPT	Contraceptive.
2050	FLEBOGAMMA	FLEBOGAMMA 5 % DIF	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 0.5G/10ML	SOLUTION	RECIEPT	Replacement therapy in: Primary immunodeficiency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiency - Wiskott Aldrich syndrome Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. Children with congenital AIDS and recurrent infections. Immunomodulation : Idiopathic thrombocytopenic purpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count. Guillain Barré Syndrome. Kawasaki disease. Allogeneic bone marrow transplantation
2051	FLECAINIDE	FLECAINIDE RAFA 100 MG	FLECAINIDE ACETATE	FLECAINIDE ACETATE 100MG	TABLETS	RECIEPT	Serious sustained life threatening ventricular arrhytmias that have not responsed to other drugs. Paroxymal atrial flutter.
2052	FLECAINIDE	FLECAINIDE RAFA 50 MG	FLECAINIDE ACETATE	FLECAINIDE ACETATE 50MG	TABLETS	RECIEPT	Serious sustained life threatening ventricular arrhytmias that have not responsed to other drugs. Paroxymal atrial flutter.
2054	FLEET	FLEET ENEMA 133 ML	SODIUM PHOSPHATE ( MONOBASIC MONOHYDRATE )	SODIUM PHOSPHATE ( MONOBASIC MONOHYDRATE ) 160MG/ML;SODIUM PHOSPHATE ( DIBASIC HEPTAHYDRATE ) 60MG/ML	ENEMA		Cleaning the colon before surgery, child birth or medical examinations.
2053	FLEET	FLEET ENEMA 133	SODIUM PHOSPHATE	SODIUM PHOSPHATE 60MG/ML DIBASIC HEPTAHYDRATE;SODIUM PHOSPHATE 160MG/ML MONOBASIC MONOHYDRATE	ENEMA	RECIEPT	Cleaning the colon before surgery, child birth or medical examinations.
2055	FLEET	FLEET ENEMA 250	SODIUM PHOSPHATE	SODIUM PHOSPHATE 60MG/ML DIBASIC HEPTAHYDRATE;SODIUM PHOSPHATE 160MG/ML MONOBASIC MONOHYDRATE	ENEMA	RECIEPT	Cleaning the colon before surgery, child birth or medical examinations.
2056	FLIXERGY	FLIXERGY NASAL SPRAY	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.05%W/W	SUSPENSION	RECIEPT	Prophylaxis and treatment of seasonal allergic rhinitis including hay fever and perennial rhinitis in adults and children of the age of 4 years and above.
2057	FLIXONASE	FLIXONASE AQUEOUS NASAL SPRAY	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.05G/100 G	SUSPENSION	RECIEPT	Prophylaxis and treatment of seasonal allergic rhinitis including hayfever, and perennial rhinitis. Perenial rhinitis in children of the age of 4 years. בקשה לשינוי התוויה: 8/9//2019 Prophylaxis and treatment of seasonal allergic rhinitis including hay fever and perennial rhinitis in adults and children of the age of 4 years and above.
2058	FLIXONASE	FLIXONASE NASULE DROPS	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 400MCG/ACTUATION	SUSPENSION	RECIEPT	Flixonase nasule drops are indicated for the regular treatment of nasal polyps and associated symptoms of nasal obstruction.
2063	FLIXOTIDE CFC FREE	FLIXOTIDE INHALER CFC FREE 125 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 125MCG/DOSE	SUSPENSION	RECIEPT	Prophylactic management of all grades of asthma.
2064	FLIXOTIDE CFC FREE	FLIXOTIDE INHALER CFC FREE 250 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 250MCG/DOSE	SUSPENSION	RECIEPT	Prophylactic management of all grades of asthma. Symptomatic treatment of chronic obstructive pulmonary disease.
2065	FLIXOTIDE CFC FREE	FLIXOTIDE INHALER CFC FREE 50 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 50MCG/DOSE	SUSPENSION	RECIEPT	Prophylactic management of all grades of asthma. Children aged 1 to 4 years: Inhaled fluticasone propionate is of benefit to young children in the control of persistent asthma symptoms.
2059	FLIXOTIDE DISKUS	FLIXOTIDE DISKUS 100 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 100MCG	POWDER	RECIEPT	Prophylactic management of all grades of asthma.
2060	FLIXOTIDE DISKUS	FLIXOTIDE DISKUS 250 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 250MCG	POWDER	RECIEPT	Prophylactic management of all grades of asthma. Symptomatic treatment of chronic obstructive pulmonary disease.
2062	FLIXOTIDE DISKUS	FLIXOTIDE DISKUS 500 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 500MCG	POWDER	RECIEPT	Prophylactic management of all grades of asthma. Symptomatic treatment of chronic obstructive pulmonary disease.
2061	FLIXOTIDE DISKUS	FLIXOTIDE DISKUS 50 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 50MCG	POWDER	RECIEPT	Prophylactic management of all grades of asthma.
2066	FLIXOTIDE NEBULES	FLIXOTIDE NEBULES 0.5 MG/2 ML	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.5MG/2ML	INHALATION	RECIEPT	In adults and adolescents over 16 years Flixotide Nebules can be used: For prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. It reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy. Children and adolescents from 4 to 16 years of age: Treatment of acute exacerbations of asthma.
2067	FLIXOTIDE NEBULES	FLIXOTIDE NEBULES 2 MG/2 ML	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 2MG/2ML	INHALATION	RECIEPT	In adults and adolescents over 16 years Flixotide Nebules can be used: For prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. It reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.
2069	FLOLAN EPOPROSTENOL	FLOLAN INFUSION OF EPOPROSTENOL 500 MCG	EPOPROSTENOL AS SODIUM	EPOPROSTENOL AS SODIUM 0.5MG/VIAL	POWDER	RECIEPT	Flolan is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA class III and class IV patients who do not respond to conventional therapy.
2068	FLOLAN EPOPROSTENOL	FLOLAN INFUSION OF EPOPROSTENOL 1500 MCG	EPOPROSTENOL AS SODIUM	EPOPROSTENOL AS SODIUM 1.5MG/VIAL	POWDER	RECIEPT	Flolan is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA class III and class IV patients who do not respond to conventional therapy.
2070	FLORET	FLORET	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.03MG;GESTODENE 0.075MG	TABLETS	RECIEPT	Contraceptive.
2072	FLUAD	FLUAD	B/BRISBANE/60/2008 - LIKE VIRUS	B/BRISBANE/60/2008 - LIKE VIRUS 15MCG/0.5ML;A/HONG KONG/4801/2014 (H3N2) - LIKE VIRUS 15MCG/0.5ML;A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE VIRUS 15MCG/0.5ML	SUSPENSION	RECIEPT	Active immunisation against influenza in the elderly (65 years of age and over), especially for those with an infreased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).
2073	FLUANXOL	FLUANXOL 3 mg tablets	FLUPENTIXOL AS DIHYDROCHLORIDE	FLUPENTIXOL AS DIHYDROCHLORIDE 3MG	TABLETS		Schizophrenia, mania.
2074	FLUANXOL DEPOT	FLUANXOL DEPOT 100 MG/ML	FLUPENTIXOL DECANOATE	FLUPENTIXOL DECANOATE 100MG/ML	SOLUTION	RECIEPT	Schizophrenia, mania.
2075	FLUANXOL DEPOT	FLUANXOL DEPOT 20 MG/ML	FLUPENTIXOL DECANOATE	FLUPENTIXOL DECANOATE 20MG/ML	SOLUTION	RECIEPT	Schizophrenia, mania.
2076	FLUARIX TETRA	FLUARIX TETRA	B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE)	B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE) 15MCG/0.5ML;B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) 15MCG/0.5ML;A/KANSAS/14/2017 (H3N2) LIKE VIRUS 15MCG/0.5ML;A/BRISBANE/02/2018(H1N1)PDM09-LIKE VIRUS 15MCG/0.5ML	SUSPENSION	RECIEPT	Fluarix Tetra is indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.
2078	FLUCANOL	FLUCANOL 100	FLUCONAZOLE	FLUCONAZOLE 100MG	CAPSULES	RECIEPT	Fluconazole is indicated in the following fungal infections. Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis. • Coccidioidomycosis. • Invasive candidiasis. • Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. • Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate. • Candidal balanitis when local therapy is not appropriate. • Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated. • Tinea unguinium (onychomycosis) when other agents are not considered appropriate. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year). • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation). Fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis and cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
2079	FLUCANOL	FLUCANOL 150	FLUCONAZOLE	FLUCONAZOLE 150MG	CAPSULES	RECIEPT	Fluconazole is indicated in the following fungal infections. Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis. • Coccidioidomycosis. • Invasive candidiasis. • Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. • Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate. • Candidal balanitis when local therapy is not appropriate. • Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated. • Tinea unguinium (onychomycosis) when other agents are not considered appropriate. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year). • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation). Fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis and cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
2080	FLUCANOL	FLUCANOL 200	FLUCONAZOLE	FLUCONAZOLE 200MG	CAPSULES	RECIEPT	Fluconazole is indicated in the following fungal infections. Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis. • Coccidioidomycosis. • Invasive candidiasis. • Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. • Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate. • Candidal balanitis when local therapy is not appropriate. • Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated. • Tinea unguinium (onychomycosis) when other agents are not considered appropriate. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year). • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation). Fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis and cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
2081	FLUCANOL	FLUCANOL 50	FLUCONAZOLE	FLUCONAZOLE 50MG	CAPSULES	RECIEPT	Fluconazole is indicated in the following fungal infections: Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis. • Coccidioidomycosis. • Invasive candidiasis. • Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. • Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate. • Candidal balanitis when local therapy is not appropriate. • Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated. • Tinea unguinium (onychomycosis) when other agents are not considered appropriate. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year). • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation). Fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis and cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
2082	FLUCO AVENIR	FLUCO - AVENIR	FLUCONAZOLE	FLUCONAZOLE 2MG/ML	SOLUTION	RECIEPT	Cryptococcosis. Systemic candidiasis, mucosal candidiasis.
2086	FLUCONAZOLE	FLUCONAZOLE TEVA 150 MG	FLUCONAZOLE	FLUCONAZOLE 150MG	CAPSULES	RECIEPT	Cryptococcosis. - Systemic candidiasis. - Mucosal candidiasis. - Vaginal candidiasis. - Dermatomycosis.
2084	FLUCONAZOLE	FLUCONAZOLE BAXTER 2 MG/ML	FLUCONAZOLE	FLUCONAZOLE 200MG/100ML	SOLUTION	RECIEPT	Fluconazole is indicated in the following fungal infections. Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis. • Coccidioidomycosis. Invasive candidiasis. • Mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis). • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene topical treatment are insufficient. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Haematopoetic Stem Cell Transplantation). Fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
2083	FLUCONAZOLE	FLUCONAZOLE B.BRAUN 2 MG/ML	FLUCONAZOLE	FLUCONAZOLE 2MG/1ML	SOLUTION	RECIEPT	Fluconazole is indicated in the following fungal infections. Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis. • Coccidioidomycosis, Invasive candidiasis. • Mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis). • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene topical treatment are insufficient. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Haematopoetic Stem Cell Transplantation). Fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.
2085	FLUCONAZOLE	FLUCONAZOLE MBI 2 MG/ ML	FLUCONAZOLE	FLUCONAZOLE 2MG/1ML	SOLUTION	RECIEPT	Fluconazole is indicated in the following fungal infections (see section 5.1). Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis (see section 4.4). • Coccidioidomycosis (see section 4.4). • Invasive candidiasis. • Mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis). • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Haematopoetic Stem Cell Transplantation (see section 5.1)). Fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence (see section 4.4). Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
2087	FLUDARABIN	FLUDARABIN caretEBEWEcaret 50 MG/2 ML	FLUDARABINE PHOSPHATE	FLUDARABINE PHOSPHATE 50MG/DOSE	CONCENTRATE	RECIEPT	Palliative treatment of patients with CLL refractory to other therapy. Treatment of less malignant Non-Hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. Fludarabine is indicated for the initial treatment of patients with B- cell chronic lymphocytic leukaemia (CLL) or after first line therapy, in patients with sufficient bone marrow reserves.
2088	FLUDECATE	FLUDECATE	FLUPHENAZINE DECANOATE	FLUPHENAZINE DECANOATE 25MG/ML	SOLUTION	RECIEPT	Management of psychotic disorders.
2090	FLUMAZENIL	FLUMAZENIL MYLAN 0.1 MG/ML	FLUMAZENIL	FLUMAZENIL 0.1MG/ML	SOLUTION	RECIEPT	Benzodiazepine antagonist for reversal of benzodiazepine anesthesia, as well as for patients with benzodiazepine intoxication.
2092	FLUMIST QUADRIVALENT	FLUMIST QUADRIVALENT	B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE)	B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE) 7 ±0.5 LOG10 FFU^A;B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) 7 ±0.5 LOG10 FFU^A;A/SINGAPORE/INFIMH-16-0019/2016 (H3N2) - LIKE VIRUS 7 ±0.5 LOG10 FFU^A;A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE VIRUS 7 ±0.5 LOG10 FFU^A	SPRAY	RECIEPT	FluMist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses ad type B viruses contained in the vaccine. FluMist Quadrivalent is approved for use in persons 2 through 49 years of age.
2095	FLUORESCEINE	FLUORESCEINE SERB	FLUORESCEIN SODIUM	FLUORESCEIN SODIUM 10G/100ML	SOLUTION	RECIEPT	For examination of the retina by Fluorescent Angiography.
2097	FLUOROURACIL	FLUOROURACIL caretEBEWEcaret 50 MG/ML	FLUOROURACIL	FLUOROURACIL 50MG/ML	CONCENTRATE	RECIEPT	Palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas, in selected patients considered incurable by surgery or other means. As leucovorin-fluorouracil chemotherapy combination for cancer treatment.
2098	FLUOROURACIL	FLUOROURACIL TEVA	FLUOROURACIL	FLUOROURACIL 50MG/ML	SOLUTION	RECIEPT	Palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas, in selected patients considered incurable by surgery or other means. As leucovorin-fluorouracil chemotherapy combination for cancer treatment.
2101	FLUTIFORM	FLUTIFORM 50/5	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.05MG/DOSE;FORMOTEROL FUMARATE DIHYDRATE 0.005MG/DOSE	SUSPENSION	RECIEPT	The regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist. • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.
2099	FLUTIFORM	FLUTIFORM 125/5	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.125MG/DOSE;FORMOTEROL FUMARATE DIHYDRATE 0.005MG/DOSE	SUSPENSION	RECIEPT	The regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist. • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.
2100	FLUTIFORM	FLUTIFORM 250/10	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.25MG/DOSE;FORMOTEROL FUMARATE DIHYDRATE 0.01MG/DOSE	SUSPENSION	RECIEPT	The regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist. • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.
2102	FLUTINE	FLUTINE 20	FLUOXETINE AS HYDROCHLORIDE	FLUOXETINE AS HYDROCHLORIDE 20MG	CAPSULES	RECIEPT	Treatment of depression. Obsessive-compulsive disorders (OCD). Flutine is also indicated for the treatment of binge-eating and vomiting behaviors in bulimia nervosa.
2103	FLUTITRIM	FLUTITRIM	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 0.05%W/W	SOLUTION	RECIEPT	Prophylaxis and treatment of seasonal allergic rhinitis including hay fever and perenial rhinitis.
2104	FLUVOXAMINE	FLUVOXAMINE TEVA 100 MG	FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE 100MG	TABLETS	RECIEPT	For the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. Treatment of obsessive compulsive disorders (OCD).
2106	FLUVOXAMINE	FLUVOXAMINE TEVA 50 MG	FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE 50MG	TABLETS	RECIEPT	For the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. Treatment of obsessive compulsive disorders (OCD).
2108	FML LIQUIFILM	FML LIQUIFILM	FLUOROMETHOLONE	FLUOROMETHOLONE 0.1%W/V	SUSPENSION	RECIEPT	To treat eye inflammation.
2110	FOLEX	FOLEX 400MG 30 TAB	FERROUS (AS FUMARATE)	FERROUS (AS FUMARATE) 100MG;FOLIC ACID 400MCG	TABLETS		For the prevention and treatment of iron deficiency anemia and for maintaining the level of folic acid particular in pregnancy.
2109	FOLEX	FOLEX 400	FOLIC ACID	FOLIC ACID 400MCG;FERROUS AS FUMARATE 100MG	TABLETS		For the prevention and treatment of iron deficiency anemia and for maintaining the level of folic acid particular in pregnancy.
2111	FOLI	FOLI 5	FOLIC ACID	FOLIC ACID 5MG	TABLETS		Prevention and treatment of folic acid deficiency.
2112	FOLI	FOLI 5 30 TAB	FOLIC ACID	FOLIC ACID 5MG	TABLETS		Prevention and treatment of anemia caused by iron and folic acid deficiency including anemia of pregnancy and lactation
2113	FOLIC	FOLIC ACID 10 MG	FOLIC ACID	FOLIC ACID 10MG	TABLETS		Treatment of folic acid deficiency megaloblastic anemia in malabsorption states.
2115	FOLIC	FOLIC ACID 5 MG TABLETS	FOLIC ACID	FOLIC ACID 5.0MG	TABLETS		In folic acid deficiency.
2114	FOLIC	FOLIC ACID 5 MG	FOLIC ACID	FOLIC ACID 5MG	TABLETS		For the treatment of megaloblastic anemias caused by folic acid deficiency.
2116	FOLIC	FOLIC ACID 5MG 30TAB	FOLIC ACID	FOLIC ACID 5MG	TABLETS		In folic acid deficiency.
2118	FOLIRON	FOLIRON	FOLIC ACID	FOLIC ACID 0.4MG;IRON AS HYDROXIDE POLYMALTOSE COMPLEX 100MG	TABLETS		Prevention and treatment of anemia caused by iron and folic acid deficiency including anemia of pregnancy and lactation
2119	FOMINIC	FOMINIC	DESOGESTREL	DESOGESTREL 0.075MG	TABLETS	RECIEPT	Contraseptive.
2120	FORADIL	FORADIL CAPSULES FOR INHALATION	FORMOTEROL FUMARATE DIHYDRATE	FORMOTEROL FUMARATE DIHYDRATE 12MCG	POWDER	RECIEPT	Foradil is indicated in asthma ( including nocturnal asthma and exercise-induced symptoms) in those treated with inhaled corticosteroids who also require a long-acting beta agonist in accordance with current treatment guidelines. Prophylaxis and treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.
2122	FORIC PREGNANCY	FORIC PREGNANCY 30TAB	FERROUS (AS FUMARATE)	FERROUS (AS FUMARATE) 100MG;FOLIC ACID 400MCG	TABLETS		For the prevention and treatment of iron deficiency anemia and for maintaining the level of folic acid particular in pregnancy.
2123	FORIC PREGNANCY	FORIC PREGNANCY TABLETS	FOLIC ACID	FOLIC ACID 400MCG;FERROUS AS FUMARATE 100MG	TABLETS		For the prevention and treatment of iron deficiency anemia and for maintaining the level of folic acid particular in pregnancy.
2124	FOROL	FOROL 30 TABLETS	FERROUS (AS FUMARATE)	FERROUS (AS FUMARATE) 100MG;FOLIC ACID 400MCG	TABLETS		For the prevention and treatment of iron deficiency anemia and for maintaining the level of folic acid particular in pregnancy.
2125	FOROL	FOROL TABLETS	FOLIC ACID	FOLIC ACID 400MCG;FERROUS FUMARATE 100MG	TABLETS		For the prevention and treatment of iron deficiency anemia and for maintaining the level of folic acid particular in pregnancy.
2472	FORTE	IBUPRO FORTE 400	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	For the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. For the relief of mild to moderate pain and treatment of primary dysmenorrhea. For the treatment of pain associated with migraine.
2126	FORTEO	FORTEO INJECTION	TERIPARATIDE	TERIPARATIDE 250MCG/ML	SOLUTION	RECIEPT	Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture: Forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Forteo increases BMD reduces the risk of vertebral and nonvertebral fractures . Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture : Forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . Treatment of Men and Women with Glucocorticoid-Induced Osteoporosis at High Risk for Fracture: Forteo is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy .
2127	FORTUM	FORTUM 1 GRAM	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 1G/VIAL	POWDER	RECIEPT	Fortum is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). • Nosocomial pneumonia • Broncho-pulmonary infections in cystic fibrosis • Bacterial meningitis • Chronic suppurative otitis media • Malignant otitis externa • Complicated urinary tract infections • Complicated skin and soft tissue infections • Complicated intra-abdominal infections • Bone and joint infections • Peritonitis associated with dialysis in patient on CAPD. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP). The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria. Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity. Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
2128	FORTUM	FORTUM 2 GRAM	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 2G/VIAL	POWDER	RECIEPT	Fortum is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). • Nosocomial pneumonia • Broncho-pulmonary infections in cystic fibrosis • Bacterial meningitis • Chronic suppurative otitis media • Malignant otitis externa • Complicated urinary tract infections • Complicated skin and soft tissue infections • Complicated intra-abdominal infections • Bone and joint infections • Peritonitis associated with dialysis in patient on CAPD. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP). The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria. Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity. Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
2129	FORXIGA	FORXIGA 10 MG	DAPAGLIFLOZIN PROPANEDIOL	DAPAGLIFLOZIN PROPANEDIOL 12.30MG/DOSE	TABLETS	RECIEPT	Forxiga is indicated in adults aged 18 years and older for the treatment of insufficiency controlled type 2 diabetes mellitus as an adjunct to diet and exercise: • As monotherapy when metformin is considered inappropriate due to intolerance. • In addition to other medicinal products for the treatment of type 2 diabetes For study results with respect to combination of therapies, effects on glycemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1
2131	FORXIGA	FORXIGA 5 MG	DAPAGLIFLOZIN PROPANEDIOL	DAPAGLIFLOZIN PROPANEDIOL 6.150MG/DOSE	TABLETS	RECIEPT	Forxiga is indicated in adults aged 18 years and older for the treatment of insufficiency controlled type 2 diabetes mellitus as an adjunct to diet and exercise: • As monotherapy when metformin is considered inappropriate due to intolerance. • In addition to other medicinal products for the treatment of type 2 diabetes For study results with respect to combination of therapies, effects on glycemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1
2133	FOSALAN ONCE-WEEKLY	FOSALAN ONCE-WEEKLY 70 MG	ALENDRONATE AS SODIUM	ALENDRONATE AS SODIUM 70MG	TABLETS	RECIEPT	Fosalan is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures). Treatment to increase bone mass in men with osteoporosis.
2135	FOSAVANCE	FOSAVANCE 70 MG/5600 I.U. TABLETS	COLECALCIFEROL	COLECALCIFEROL 140MCG;ALENDRONIC ACID AS ALENDRONATE SODIUM TRIHYDRATE 70MG	TABLETS	RECIEPT	Fosavance is indicated for : - Treatment of Osteoporosis in postmenopausal women: Fosavance increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). - Treatment to increase bone mass in men with osteoporosis.
2137	FOSCAVIR	FOSCAVIR 24 MG/ML	FOSCARNET TRISODIUM HEXAHYDRATE	FOSCARNET TRISODIUM HEXAHYDRATE 24MG/ML	SOLUTION	RECIEPT	Treatment of CMV retinitis in patients with aquired immunodeficiency syndrome (AIDS).
2140	FOSRENOL	FOSRENOL 1000 MG CHEWABLE TABLETS	LANTHANUM AS CARBONATE HYDRATE	LANTHANUM AS CARBONATE HYDRATE 1000MG	TABLETS	RECIEPT	Fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in CRF patients on haemodyalisis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
2141	FOSRENOL	FOSRENOL 1000 MG ORAL POWDER	LANTHANUM AS CARBONATE HYDRATE	LANTHANUM AS CARBONATE HYDRATE 1000MG	POWDER	RECIEPT	Fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in CRF patients on haemodyalisis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
2142	FOSRENOL	FOSRENOL 500 MG CHEWABLE TABLETS	LANTHANUM AS CARBONATE HYDRATE	LANTHANUM AS CARBONATE HYDRATE 500MG	TABLETS	RECIEPT	Fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in CRF patients on haemodyalisis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
2143	FOSRENOL	FOSRENOL 750 MG CHEWABLE TABLETS	LANTHANUM AS CARBONATE HYDRATE	LANTHANUM AS CARBONATE HYDRATE 750MG	TABLETS	RECIEPT	Fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in CRF patients on haemodyalisis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
2144	FOSRENOL	FOSRENOL 750 MG ORAL POWDER	LANTHANUM AS CARBONATE HYDRATE	LANTHANUM AS CARBONATE HYDRATE 750MG	POWDER	RECIEPT	Fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in CRF patients on haemodyalisis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
2145	FOSTER	FOSTER 100/6	FORMOTEROL FUMARATE DIHYDRATE	FORMOTEROL FUMARATE DIHYDRATE 6MCG/DOSE;BECLOMETASONE DIPROPIONATE ANHYDROUS 100MCG/DOSE	SOLUTION	RECIEPT	Foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. COPD : Symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
2146	FOSTIMON	FOSTIMON 150 IU	UROFOLLITROPHIN	UROFOLLITROPHIN 150 IU/VIAL	POWDER	RECIEPT	A treatment with FSH followed by the administration of human chronic gonadotrophin (HCG) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. These women belong to the WHO group II and have generally already been treated with clomiphene citrate. Most have polycystic ovarian syndrome. FSH offers good therapeutic prospects for patients whose LH:FSH ratio has to be adjusted, avoiding an exogenous supply of LH FSH may be used alone or in concomitance with human menopausal gonadotropin (HMG) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (IVF-ET,GIFT).
2147	FOSTIMON	FOSTIMON 75 IU	UROFOLLITROPHIN	UROFOLLITROPHIN 75 IU/VIAL	POWDER	RECIEPT	A treatment with FSH followed by the administration of human chronic gonadotrophin (HCG) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. These women belong to the WHO group II and have generally already been treated with clomiphene citrate. Most have polycystic ovarian syndrome. FSH offers good therapeutic prospects for patients whose LH:FSH ratio has to be adjusted, avoiding an exogenous supply of LH FSH may be used alone or in concomitance with human menopausal gonadotropin (HMG) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (IVF-ET,GIFT).
2148	FRAGMIN	FRAGMIN 10000 IU/ML	DALTEPARIN SODIUM	DALTEPARIN SODIUM 10000 IU/ML	SOLUTION	RECIEPT	Prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. Treatment of acute deep venous thrombosis and/or pulmonary embolism. Unstable coronary artery disease. Thromboprophylaxis in conjunction with surgery. Prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. Cancer patients : Treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.
2149	FRAGMIN	FRAGMIN 2500 I.U /0.2 ML	DALTEPARIN SODIUM	DALTEPARIN SODIUM 2500 IU/0.2ML	SOLUTION	RECIEPT	Prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. Treatment of acute deep venous thrombosis and/or pulmonary embolism. Unstable coronary artery disease. Thromboprophylaxis in conjunction with surgery. Prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. Cancer patients : Treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.
2150	FRAGMIN	FRAGMIN 2500 I.U/ML	DALTEPARIN SODIUM	DALTEPARIN SODIUM 2500IU/ML	SOLUTION	RECIEPT	Prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. Treatment of acute deep venous thrombosis and/or pulmonary embolism. Unstable coronary artery disease. Thromboprophylaxis in conjunction with surgery. Prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. Cancer patients : Treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.
2151	FRAGMIN	FRAGMIN 25000 IU/ML	DALTEPARIN SODIUM	DALTEPARIN SODIUM 5000 IU/0.2ML	SOLUTION	RECIEPT	Prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. Treatment of acute deep venous thrombosis and/or pulmonary embolism. Unstable coronary artery disease. Thromboprophylaxis in conjunction with surgery. Prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. Cancer patients : Treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.
2152	FRESCO	FRESCO 40TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 500MG	TABLETS		Antacid.
2153	FRESCO	FRESCO TABLETS	CALCIUM CARBONATE	CALCIUM CARBONATE 500MG;MAGNESIUM CARBONATE 12MG	TABLETS		Antacid.
2154	FRISIUM	FRISIUM	CLOBAZAM	CLOBAZAM 10MG	TABLETS	RECIEPT	Treatment of anxiety states in adults.
2155	FROSSTIMAGE/DRAXIMAGE PREPARATION OF TC99M (MAA)	FROSSTIMAGE/DRAXIMAGE KIT FOR PREPARATION OF TC99M (MAA)	HUMAN SERUM ALBUMIN	HUMAN SERUM ALBUMIN 2.5MG/VIAL	SOLUTION	RECIEPT	Lung imaging evaluation of pulmonary perfusion.
2156	FROSSTIMAGE/DRAXIMAGE THE PREPARATION OF TC99M (DTPA )	FROSSTIMAGE/DRAXIMAGE KIT FOR THE PREPARATION OF TC99M (DTPA )	CALCIUM TRISODIUM PENTETATE	CALCIUM TRISODIUM PENTETATE 20MG/VIAL	SOLUTION	RECIEPT	Kidney, brain, aerosol imaging.
2157	FROSSTIMAGE/DRAXIMAGE THE PREPARATION OF TC99M (MDP)	FROSSTIMAGE/DRAXIMAGE KIT FOR THE PREPARATION OF TC99M (MDP)	MEDRONIC ACID	MEDRONIC ACID 10MG/VIAL	SOLUTION	RECIEPT	Bone imaging.
2158	FUCICORT	FUCICORT CREAM	FUSIDIC ACID	FUSIDIC ACID 2%;BETAMETHASONE AS VALERATE 0.1%	CREAM	RECIEPT	Treatment of eczematous dermatoses when secondary bacterial infection is confirmed.
2159	FUCIDIN	FUCIDIN CREAM	FUSIDIC ACID	FUSIDIC ACID 20MG/G	CREAM	RECIEPT	Local treatment of skin infections due to sensitive strains of staphylococus aureus.
2160	FUCIDIN	FUCIDIN H	FUSIDIC ACID	FUSIDIC ACID 20MG/G;HYDROCORTISONE ACETATE 10MG/G	CREAM	RECIEPT	Use in inflammatory dermatoses with secondary bacterial infection sensitive to fusidic acid. Treatment of eczematous dermatoses.
2162	FUCIDIN	FUCIDIN OINTMENT	SODIUM FUSIDATE	SODIUM FUSIDATE 20MG/G	OINTMENT	RECIEPT	Local treatment of skin infection due to sensitive strains of staphylococos.
2161	FUCIDIN	FUCIDIN LEO	SODIUM FUSIDATE	SODIUM FUSIDATE 250MG	TABLETS	RECIEPT	For the treatment of infections caused by Staphylococcus.
2163	FUCITHALMIC	FUCITHALMIC VISCOUS EYE DROPS	FUSIDIC ACID	FUSIDIC ACID 1%	DROPS	RECIEPT	Treatment of external eye infections caused by microorganisms sensitive to the preparation.
2164	FULVESTRANT	FULVESTRANT TEVA	FULVESTRANT	FULVESTRANT 250MG/5ML	SOLUTION	RECIEPT	Monotherapy : Fulvestrant Teva is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or with disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy. Combination Therapy with Palbociclib: Fulvestrant Teva is indicated for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy
2165	FUNGICARE	FUNGICARE	CLOTRIMAZOLE	CLOTRIMAZOLE 1%	CREAM	RECIEPT	Antifungal agent for the local treatment of skin infections caused by candida species or dermatophytes.
2166	FUNGIDERM	FUNGIDERM	MICONAZOLE NITRATE	MICONAZOLE NITRATE 2%	CREAM	RECIEPT	Skin and nail infections due to dermatophytes or candida.
2167	FUNGILAC	FUNGILAC CARE	CICLOPIROX	CICLOPIROX 80MG/G	LACQUE		For the treatment of fungal infections of the nails.
2168	FUNGIMON	FUNGIMON	UNDECENOIC ACID	UNDECENOIC ACID 3G/100 G;ALUMINIUM CHLOROHYDRATE 3G/100 G;ZINC UNDECENOATE 18G/100 G	POWDER		For prophylaxis and treatment of fungal infections of the skin especially "Athletes foot".
2169	FUNGINAIL	FUNGINAIL	CICLOPIROX	CICLOPIROX 80MG/G	LACQUE		For the treatment of fungal infections of the nails.
2170	FUNGINAIL NAIL	FUNGINAIL NAIL LACQER 6.6ML	CICLOPIROX	CICLOPIROX 8%(80MG/G)	LACQUE		Treatment of fungal infections of the nails.
2171	FUNGITRIM	FUNGITRIM	UNDECENOIC ACID	UNDECENOIC ACID 2%;ZINC UNDECENOATE 20%	POWDER		Prophylaxis and treatment of mycotic skin infections particulary athlete's foot.
2172	FUNGITRIM	FUNGITRIM PWDR 80GR	UNDECENOIC ACID	UNDECENOIC ACID 2%;ZINC UNDECENOATE 20%	POWDER		Prophylaxis and treatment of mycotic skin infections particulary athlete's foot.
2173	FUNGOFIN	FUNGOFIN	AMOROLFINE AS HYDROCHLORIDE	AMOROLFINE AS HYDROCHLORIDE 5%W/V	LACQUE	RECIEPT	Topical treatment of onycomycosis caused by dermatophytes, yeast and moulds.
2175	FUROSEMIDE	FUROSEMIDE BAXTER 20 MG/2 ML	FUROSEMIDE	FUROSEMIDE 10MG/ML	SOLUTION	RECIEPT	Furosemide baxter 20mg/2 ml Injection is a potent diuretic indicated for use when a prompt and effective diuresis is required. The Furosemide baxter 20 mg/2 ml injection is appropriate for use in emergencies or when oral therapy is not feasible. Indications include cardiac, pulmonary, hepatic and renal oedema.
2174	FUROSEMIDE	FUROSEMIDE - FRESENIUS 20 MG/ 2 ML	FUROSEMIDE	FUROSEMIDE 20MG/2ML	SOLUTION	RECIEPT	Furosemide is a potent diuretic indicated for use when a prompt and effective diuresis is required. Furosemide Injection 20mg/2ml is appropriate for use in emergencies or where oral therapy is not feasible. The indications include cardiac, pulmonary, hepatic and renal oedema.
2176	FUROSEMIDE	FUROSEMIDE S.A.L.F 20 MG/ 2 ML	FUROSEMIDE	FUROSEMIDE 20MG/2ML	SOLUTION	RECIEPT	Furosemide S.A.L.F 20mg/2ml is a potent diuretic indicated for use when a prompt and effective diuresis is required. Furosemide S.A.L.F 20mg/2ml is appropriate for use in emergencies or where oral therapy is not feasible. The indications include cardiac, pulmonary, hepatic and renal oedema.
2177	FUROVENIR	FUROVENIR 250 MG/25 ML	FUROSEMIDE	FUROSEMIDE 250MG/25ML	SOLUTION	RECIEPT	Furosemide is a potent diuretic indicated for use when a prompt and effective diuresis is required. Furosemide is appropriate for use in emergencies or where oral therapy is not feasible. The indications include cardiac, pulmonary, hepatic and renal oedema
2181	FUSID	FUSID TEVA 20 MG / 2 ML	FUROSEMIDE	FUROSEMIDE 20MG/2ML	SOLUTION	RECIEPT	Fusid Teva 20 mg / 2 ml is a potent diuretic indicated for use when a prompt and effective diuresis is required. Fusid Teva 20 mg / 2 ml is appropriate for use in emergencies or where oral therapy is not feasible. The indications include cardiac, pulmonary, hepatic and renal oedema.
2178	FUSID	FUSID	FUROSEMIDE	FUROSEMIDE 40MG	TABLETS	RECIEPT	Edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Adjunctive therapy in acute pulmonary edema. Treatment of hypertension.
2179	FUSID	FUSID TABLETS	FUROSEMIDE	FUROSEMIDE 40MG	TABLETS	RECIEPT	Edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Adjunctive therapy in acute pulmonary edema. Treatment of hypertension.
2182	FYCOMPA	FYCOMPA 10 MG FILM COATED TABLETS	PERAMPANEL AS ANHYDROUS	PERAMPANEL AS ANHYDROUS 10MG	TABLETS	RECIEPT	Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Fycompa is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older with idiopathic generalised epilepsy.
2184	FYCOMPA	FYCOMPA 12 MG FILM COATED TABLETS	PERAMPANEL AS ANHYDROUS	PERAMPANEL AS ANHYDROUS 12MG	TABLETS	RECIEPT	Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Fycompa is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older with idiopathic generalised epilepsy.
2186	FYCOMPA	FYCOMPA 2 MG FILM COATED TABLETS	PERAMPANEL AS ANHYDROUS	PERAMPANEL AS ANHYDROUS 2MG	TABLETS	RECIEPT	Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Fycompa is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older with idiopathic generalised epilepsy.
2188	FYCOMPA	FYCOMPA 4 MG FILM COATED TABLETS	PERAMPANEL AS ANHYDROUS	PERAMPANEL AS ANHYDROUS 4MG	TABLETS	RECIEPT	Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Fycompa is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older with idiopathic generalised epilepsy.
2190	FYCOMPA	FYCOMPA 6 MG FILM COATED TABLETS	PERAMPANEL AS ANHYDROUS	PERAMPANEL AS ANHYDROUS 6MG	TABLETS	RECIEPT	Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Fycompa is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older with idiopathic generalised epilepsy.
2192	FYCOMPA	FYCOMPA 8 MG FILM COATED TABLETS	PERAMPANEL AS ANHYDROUS	PERAMPANEL AS ANHYDROUS 8MG	TABLETS	RECIEPT	Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Fycompa is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older with idiopathic generalised epilepsy.
2194	GABAPENTIN	GABAPENTIN INOVAMED 300 MG	GABAPENTIN	GABAPENTIN 300MG	CAPSULES	RECIEPT	As adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy. For the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy (neuralgia).
2196	GABAPENTIN	GABAPENTIN TEVA 300 MG	GABAPENTIN	GABAPENTIN 300MG	CAPSULES	RECIEPT	Epilepsy : - Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy. - Treatment of neuropathic pain - Gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy (neuralgia) in adults.
2195	GABAPENTIN	GABAPENTIN INOVAMED 400 MG	GABAPENTIN	GABAPENTIN 400MG	CAPSULES	RECIEPT	As adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy. For the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy (neuralgia).
2198	GABAPENTIN	GABAPENTIN TEVA 400 MG	GABAPENTIN	GABAPENTIN 400MG	CAPSULES	RECIEPT	Epilepsy : - Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy. - Treatment of neuropathic pain - Gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy (neuralgia) in adults.
2200	GABAPENTIN	GABAPENTIN TEVA 600 MG	GABAPENTIN	GABAPENTIN 600MG	TABLETS	RECIEPT	Epilepsy : - Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy. - Treatment of neuropathic pain - Gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy (neuralgia) in adults.
2201	GABAPENTIN	GABAPENTIN TEVA 800 MG	GABAPENTIN	GABAPENTIN 800MG	TABLETS	RECIEPT	Epilepsy : - Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy. - Treatment of neuropathic pain - Gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy (neuralgia) in adults.
2202	GALAFOLD	GALAFOLD 123 MG	MIGALASTAT AS HYDROCHLORIDE	MIGALASTAT AS HYDROCHLORIDE 123MG	CAPSULES	RECIEPT	Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.
2206	GALLIUM	GALLIUM (GA 67) CITRATE	GALLIUM (67GA) CITRATE	GALLIUM (67GA) CITRATE 1.5MCI;SODIUM CITRATE 1.5MG	SOLUTION	RECIEPT	Inflammatory lesions and abscesses. Primary and metastatic tumors Hodgkin's disease. Lymphomas and brochogenic carcinoma.
2209	GALVUS	GALVUS 50 MG	VILDAGLIPTIN	VILDAGLIPTIN 50MG	TABLETS	RECIEPT	Galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus • As monotherapy, if diet and exercise are not sufficient, or • In combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose. As triple oral therapy in combination with • a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. Galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control. Galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus • In combination with a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.
2210	GAMMAPLEX	GAMMAPLEX	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 5G/100ML	SOLUTION	RECIEPT	Replacement therapy in adults, and children and adolescents in: - Primary immunodeficiency syndromes with impaired antibody production - Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed - Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation - Congenital AIDS with recurrent bacterial infections Immunomodulation in adults, and children and adolescents in: - Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count - Guillain Barré syndrome - Kawasaki disease
2211	GAMUNEX	GAMUNEX - C	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 0.1G/ML	SOLUTION	RECIEPT	Gamunex is indicated as replacement therapy of primary immunodeficiency (PI) states in which severe impaiment of antibody forming capacity has been shown, such as congential agammaglobulinemia, common variable immunodeficiency, X-limked immunodeficiency with hyper IgM, Wiskott- Aldrich syndrom, and severed combined immunodeficiencies. Gamunex is also indicated in Idiopathic Thrombocytopenia Purpura (ITP) to raise platelet counts to prevent bleeding or to allow a patient with ITP to undergo surgery. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
5566	GANCICLOVIR	VALGANCICLOVIR TEVA	VALGANCICLOVIR AS HYDROCHLORIDE	VALGANCICLOVIR AS HYDROCHLORIDE 450MG	TABLETS	RECIEPT	Valganciclovir Teva is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Valganciclovir Teva is indicated for the prevention of CMV disease in CMV-negative patients who have received a solid organ transplant from a CMV-positive donor.
2213	GANFORT	GANFORT	BIMATOPROST	BIMATOPROST 0.3MG/ML;TIMOLOL AS MALEATE 5MG/ML	DROPS	RECIEPT	Reduction of intraocular pressure in patients with open- angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
2215	GARDASIL	GARDASIL 9	HPV TYPE	HPV TYPE 58 L1 PROTEIN 20MCG/0.5ML;HPV TYPE 52 L1 PROTEIN 20MCG/0.5ML;HPV TYPE 45 L1 PROTEIN 20MCG/0.5ML;HPV TYPE 33 L1 PROTEIN 20MCG/0.5ML;HPV TYPE 31 L1 PROTEIN 20MCG/0.5ML;HPV TYPE 18 L1 PROTEIN 40MCG/0.5ML;HPV TYPE 16 L1 PROTEIN 60MCG/0.5ML;HPV TYPE 11 L1 PROTEIN 40MCG/0.5ML;HPV TYPE 6 L1 PROTEIN 30MCG/0.5ML	SUSPENSION	RECIEPT	Gardasil 9 is indicated for active immunisation of individuals at the age of 9-26 years old against the following HPV diseases: • Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types • Genital warts (Condyloma acuminata) caused by specific HPV types.
2214	GARDASIL	GARDASIL	PROTEIN L1 (TYPE	PROTEIN L1 (TYPE 18) 20MCG/0.5ML;PROTEIN L1 (TYPE 6) 20MCG/0.5ML;PROTEIN L1 (TYPE 11) 40MCG/0.5ML;PROTEIN L1 (TYPE 16) 40MCG/0.5ML	SUSPENSION	RECIEPT	GARDASIL is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18 (which are included in the vaccine). GARDASIL is indicated in males 9 through 26 years* of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by HPV types 6, 11, 16, and 18 (which are included in the vaccine). *Immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations..
2216	GASTRO	GASTRO 10	FAMOTIDINE	FAMOTIDINE 10MG	TABLETS	RECIEPT	For the treatment and prevention of heartburn and hyperacidity in the upper gastrointestinal tract.
2217	GASTRO	GASTRO 10MG 20TAB	FAMOTIDINE	FAMOTIDINE 10MG	TABLETS	RECIEPT	Conventional x-ray and CT examinations of the gastrointestinal tract, gastroduodenal radiography, opaque enema examinations, especially in cases in which barium is contraindicated.
2218	GASTRO	GASTRO 20	FAMOTIDINE	FAMOTIDINE 20MG	TABLETS	RECIEPT	For the treatment and prevention of heart burn and hyperacidity in the upper gastrointestinal tract.
2220	GASTRO	GASTRO 20MG 20TAB (OTC)	FAMOTIDINE	FAMOTIDINE 20MG	TABLETS	RECIEPT	Conventional x-ray and CT examinations of the gastrointestinal tract, gastroduodenal radiography, opaque enema examinations, especially in cases in which barium is contraindicated.
2221	GASTRO	GASTRO 40	FAMOTIDINE	FAMOTIDINE 40MG	TABLETS	RECIEPT	Treatment of gastric and duodenal ulcers, zollinger-ellison syndrome and oesophageal reflux disease.
2225	GAVISCON	GAVISCON LIQUID PEPPERMINT 300ML	ALGINIC ACID	ALGINIC ACID 50MG/ML;SODIUM BICARBONATE 26.7MG/ML;CALCIUM CARBONATE 16MG/ML	SUSPENSION		Gastro reflux, heartburn, flatulence associated with gastric reflux, heartburn of pregnancy, all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.
2223	GAVISCON	GAVISCON FORTE PEPPERMINT	ALGINIC ACID AS SODIUM	ALGINIC ACID AS SODIUM 100MG/ML;POTASSIUM HYDROGENCARBONATE 20MG/ML	SUSPENSION		Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn, indigestion occurring due to the reflux of stomach contents for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy or accompanying reflux oesophagitis.
2224	GAVISCON	GAVISCON LIQUID PEPPERMINT	ALGINIC ACID AS SODIUM	ALGINIC ACID AS SODIUM 50MG/ML;SODIUM BICARBONATE 26.7MG/ML;CALCIUM CARBONATE 16MG/ML	SUSPENSION		Gastro reflux, heartburn, flatulence associated with gastric reflux, heartburn of pregnancy, all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.
2226	GAVISCON	GAVISCON PEPPERMINT 16 TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 80MG;SODIUM BICARBONATE 133.5MG;ALGINIC ACID 250MG	TABLETS		Treatment of symptoms of gastro-oesophageal reflux such as acid regurgatation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis.
2227	GAVISCON	GAVISCON PEPPERMINT 48 TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 80MG;SODIUM BICARBONATE 133.5MG;ALGINIC ACID 250MG	TABLETS		Treatment of symptoms of gastro-oesophageal reflux such as acid regurgatation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis.
2228	GAVISCON	GAVISCON PEPPERMINT TABLETS	CALCIUM CARBONATE	CALCIUM CARBONATE 80MG;SODIUM BICARBONATE 133.5MG;ALGINIC ACID AS SODIUM 250MG	TABLETS		Treatment of symptoms of gastro-oesophageal reflux such as acid regurgatation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis.
2229	GAZIM	GAZIM X	SIMETHICONE	SIMETHICONE 125MG	TABLETS		Antiflatulence.
2230	GAZIM	GAZIM X 30TAB	SIMETHICONE	SIMETHICONE 125MG	TABLETS		Antiflatulence.
2231	GAZYVA	GAZYVA	OBINUTUZUMAB	OBINUTUZUMAB 1000MG/40ML	CONCENTRATE	RECIEPT	Chronic Lymphocytic Leukaemia (CLL) Gazyva, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic Leukaemia (CLL). Follicular Lymphoma (FL ) Gazyva, in combination with bendamustine followed by Gazyva monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with a rituximab-containing regimen. Gazyva in combination with chemotherapy, followed by Gazyva maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.
2233	GEMCITABINE	GEMCITABINE MEDAC 1000 MG	GEMCITABINE AS HYDROCHLORIDE	GEMCITABINE AS HYDROCHLORIDE 1000MG	POWDER	RECIEPT	Palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer. Gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. Breast cancer: Gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ovarian cancer: Gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
2234	GEMCITABINE	GEMCITABINE MEDAC 1500 MG	GEMCITABINE AS HYDROCHLORIDE	GEMCITABINE AS HYDROCHLORIDE 1500MG	POWDER	RECIEPT	Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can bee considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum - based, first- line therapy. Gemcitabine in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
2235	GEMCITABINE	GEMCITABINE MEDAC 200 MG	GEMCITABINE AS HYDROCHLORIDE	GEMCITABINE AS HYDROCHLORIDE 200MG	POWDER	RECIEPT	Palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer. Gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. Breast cancer: Gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ovarian cancer: Gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
2232	GEMCITABINE	GEMCITABINE caretEBEWEcaret 40MG/ML	GEMCITABINE AS HYDROCHLORIDE	GEMCITABINE AS HYDROCHLORIDE 40MG/1ML	CONCENTRATE	RECIEPT	Palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer. Gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. Breast cancer: Gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ovarian cancer: Gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
2236	GEMCITABINE	GEMCITABINE TEVA CONCENTRATE	GEMCITABINE AS HYDROCHLORIDE	GEMCITABINE AS HYDROCHLORIDE 40MG/ML	CONCENTRATE	RECIEPT	GEMCITABINE TEVA CONCENTRATE is indicated for the palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer. GEMCITABINE TEVA CONCENTRATE is indicated for the treatment of patients with bladder cancer at the invasive stage. Breast cancer: GEMCITABINE TEVA CONCENTRATE in combination with paclitaxel,is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant /neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ovarian cancer: GEMCITABINE TEVA CONCENTRATE in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed at least 6 months after platinum-based therapy.
2237	GEMZAR	GEMZAR 1 GR	GEMCITABINE AS HYDROCHLORIDE	GEMCITABINE AS HYDROCHLORIDE 1G/VIAL	POWDER	RECIEPT	Palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer. Gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. Breast cancer: Gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ovarian cancer: Gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
2239	GEMZAR	GEMZAR 200 MG	GEMCITABINE AS HYDROCHLORIDE	GEMCITABINE AS HYDROCHLORIDE 200MG/VIAL	POWDER	RECIEPT	Palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer. Gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. Breast cancer: Gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ovarian cancer: Gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
2241	GENDEVRA	GENDEVRA	TENOFOVIR ALAFENAMIDE	TENOFOVIR ALAFENAMIDE 10MG;EMTRICITABINE 200MG;COBICISTATE 150MG;ELVITEGRAVIR 150MG	TABLETS	RECIEPT	Gendevra is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows: • In adults and adolescents aged from 12 years and with body weight at least 35 kg • In children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.
2244	GENOTROPIN	GENOTROPIN 12 MG	SOMATROPIN	SOMATROPIN 36 IU/1ML	POWDER	RECIEPT	Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner`s syndrome. Short stature in children with renal insufficiency. Growth disturbance (height SDS<2.5 and parenteral adjusted height SDS < -1) in short children born SGA (SGA - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth witght and/or length < 2 SD who failed to show catch up growth (HV SDS < 0 during the last year) by 4 years of age or later. Prader willi syndrome for improvement of growth and body composition. Adults: For adults who have suffered from growth-hormone deficiency since childhood. For adults who have aquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.
2245	GENOTROPIN	GENOTROPIN 5.3 MG	SOMATROPIN	SOMATROPIN 5.3MG	POWDER	RECIEPT	Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner`s syndrome. Short stature in children with renal insufficiency. Growth disturbance (height SDS<2.5 and parenteral adjusted height SDS < -1) in short children born SGA (SGA - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 SD who failed to show catch up growth (HV SDS < 0 during the last year) by 4 years of age or later. Prader willi syndrome for improvement of growth and body composition. Adults: For adults who have suffered from growth-hormone deficiency since childhood. For adults who have aquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.
2247	GENTAMICIN	GENTAMICIN B. BRAUN 1 MG/ML	GENTAMICIN AS SULFATE	GENTAMICIN AS SULFATE 0.1G/100ML	SOLUTION	RECIEPT	Treatment of serious infections caused by susceptible microorganisms.
2248	GENTAMICIN	GENTAMICIN B. BRAUN 3 MG/ML	GENTAMICIN AS SULFATE	GENTAMICIN AS SULFATE 0.3G/100ML	SOLUTION	RECIEPT	Treatment of serious infections caused by susceptible microorganisms
2250	GENTAMICIN	GENTAMICIN TEVA 80 MG/2 ML	GENTAMICIN AS SULFATE	GENTAMICIN AS SULFATE 40MG/1ML	SOLUTION	RECIEPT	Gentamicin is indicated in bacteremia, urinary tract infections, endocarditis, chest infections and other serious systemic infections due to confirmed or expected bacteria that are susceptible to gentamicin, in adults and children, including neonates.
2249	GENTAMICIN	GENTAMICIN PANPHARMA 80 MG/2 ML	GENTAMICIN AS SULFATE	GENTAMICIN AS SULFATE 80MG/2ML	SOLUTION	RECIEPT	Gentamicin is indicated in bacteremia, urinary tract infections, endocarditis, chest infections and other serious systemic infections due to confirmed or expected bacteria that are susceptible to gentamicin, in adults and children, including neonates.
2251	GENTATRIM	GENTATRIM CREAM	GENTAMICIN AS SULFATE	GENTAMICIN AS SULFATE 0.10%W/W	CREAM	RECIEPT	For the treatment of wounds, burns, acne spots and dermatoses infected with bacteria sensitive to gentamycin.
2253	GENTATRIM	GENTATRIM OINTMENT	GENTAMICIN AS SULFATE	GENTAMICIN AS SULFATE 0.10%W/W	OINTMENT	RECIEPT	For the treatment of wounds, burns, acne spots and dermatoses infected with bacteria sensitive to gentamycin.
2257	GENTEAL	GENTEAL EYE DROPS 10ML	HYDROXYPROPYL METHYLCELLULOSE	HYDROXYPROPYL METHYLCELLULOSE 0.3MG	DROPS		For the temporary relief of discomfort due to minor irritations of the eye or to relieve dryness of the eye.
2256	GENTEAL	GENTEAL EYE DROPS	HYPROMELLOSE	HYPROMELLOSE 0.3 G/100ML	DROPS		For the temporary relief of discomfort due to minor irritations of the eye or to relieve dryness of the eye.
2258	GEODON	GEODON 20 MG CAPSULES	ZIPRASIDONE AS HYDROCHLORIDE MONOHYDRATE	ZIPRASIDONE AS HYDROCHLORIDE MONOHYDRATE 20MG	CAPSULES	RECIEPT	• Schizophrenia. Treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • Bipolar mania. Ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features. • Bipolar disorder. Maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.
2260	GEODON	GEODON 40 MG CAPSULES	ZIPRASIDONE AS HYDROCHLORIDE MONOHYDRATE	ZIPRASIDONE AS HYDROCHLORIDE MONOHYDRATE 40MG	CAPSULES	RECIEPT	• Schizophrenia. Treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • Bipolar mania. Ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features. • Bipolar disorder. Maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.
2262	GEODON	GEODON 60 MG CAPSULES	ZIPRASIDONE AS HYDROCHLORIDE MONOHYDRATE	ZIPRASIDONE AS HYDROCHLORIDE MONOHYDRATE 60MG	CAPSULES	RECIEPT	• Schizophrenia. Treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • Bipolar mania. Ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features. • Bipolar disorder. Maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.
2264	GEODON	GEODON 80 MG CAPSULES	ZIPRASIDONE AS HYDROCHLORIDE MONOHYDRATE	ZIPRASIDONE AS HYDROCHLORIDE MONOHYDRATE 80MG	CAPSULES	RECIEPT	• Schizophrenia. Treatment of schizophrenia and for maintenance of clinical improvement during continuation therapy. • Bipolar mania. Ziprasidone is indicated as monotherapy in the treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features. • Bipolar disorder. Maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate.
2266	GEODON	GEODON IM 20 MG	ZIPRASIDONE MESYLATE TRIHYDRATE	ZIPRASIDONE MESYLATE TRIHYDRATE 40.93MG	POWDER	RECIEPT	Rapid control of agitation in patients with schizophrenia, when oral therapy is not appropriate, for a maximum of 3 consecutive days.
2267	GESTONE	GESTONE 50 MG/ML	PROGESTERONE	PROGESTERONE 50MG/ML	SOLUTION	RECIEPT	Disfunctional uterine bleeding and in selected cases as an addition to treatment of infertility with techniques such as IVF, GIFT.
2268	GILENYA	GILENYA 0.5 MG	FINGOLIMOD AS HYDROCHLORIDE	FINGOLIMOD AS HYDROCHLORIDE 0.5MG	CAPSULES	RECIEPT	Gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( MS ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
2269	GILEX	GILEX 10 MG	DOXEPIN AS HYDROCHLORIDE	DOXEPIN AS HYDROCHLORIDE 10MG	CAPSULES	RECIEPT	Treatment of anxiety and/or depression.
2270	GILEX	GILEX 25 MG	DOXEPIN AS HYDROCHLORIDE	DOXEPIN AS HYDROCHLORIDE 25MG	CAPSULES	RECIEPT	Treatment of anxiety and/or depression.
2271	GIOTRIF	GIOTRIF 20 MG	AFATINIB AS DIMALEATE	AFATINIB AS DIMALEATE 20MG	TABLETS	RECIEPT	GIOTRIF as monotherapy is indicated for the treatment of: • EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); • locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
2272	GIOTRIF	GIOTRIF 30 MG	AFATINIB AS DIMALEATE	AFATINIB AS DIMALEATE 30MG	TABLETS	RECIEPT	GIOTRIF as monotherapy is indicated for the treatment of: • EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); • locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
2273	GIOTRIF	GIOTRIF 40 MG	AFATINIB AS DIMALEATE	AFATINIB AS DIMALEATE 40MG	TABLETS	RECIEPT	Giotrif as monotherapy is indicated for the treatment of: • EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); • locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
2274	GIOTRIF	GIOTRIF 50 MG	AFATINIB AS DIMALEATE	AFATINIB AS DIMALEATE 50MG	TABLETS	RECIEPT	Giotrif as monotherapy is indicated for the treatment of: • EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); • locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
2275	GIROFLOX	GIROFLOX	CIPROFLOXACIN	CIPROFLOXACIN 200MG/100ML	SOLUTION	RECIEPT	* Adults : Broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens. * Children and adolescents: • Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa • Complicated urinary tract infections and pyelonephritis • Inhalation anthrax (post-exposure prophylaxis and curative treatment) Ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no other alternative . Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents
2276	GLASSIA	GLASSIA	ALPHA-1-ANTITRYPSIN ( AAT)	ALPHA-1-ANTITRYPSIN ( AAT) 1G/50ML	SOLUTION	RECIEPT	Alpha1-Proteinase Inhibitor (Human), GLASSIA is indicated for chronic augmentation and maintenance therapy in individuals with congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema.
2277	GLAUPROST	GLAUPROST	LATANOPROST	LATANOPROST 0.05MG/1ML	DROPS	RECIEPT	Reduction of elevated intraocular pressure as a first line treatment in patients with open-angle galucoma and ocular hypertension.
2278	GLAUTAN	GLAUTAN	LATANOPROST	LATANOPROST 50MCG/ML	DROPS	RECIEPT	Reduction of elevated intraocular pressure as a first line treatment in patients with open-angle glaucoma and ocular hypertension.
2279	GLIADEL	GLIADEL	CARMUSTINE	CARMUSTINE 7.7MG	WAFER	RECIEPT	For use as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated. Gliadel implant is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. Gliadel implant is indicated for use as an adjunct to surgery in patients with Recurrent histogically proved glioblastoma multiforme for whom surgical resection is indicated.
2283	GLIMEPIRIDE	GLIMEPIRIDE TEVA 1 MG	GLIMEPIRIDE	GLIMEPIRIDE 1MG	TABLETS	RECIEPT	Non-insulin-dependent diabetes mellitus (adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.
2280	GLIMEPIRIDE	GLIMEPIRIDE TEVA 2 MG	GLIMEPIRIDE	GLIMEPIRIDE 2MG	TABLETS	RECIEPT	Non-insulin-dependent diabetes mellitus (adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.
2281	GLIMEPIRIDE	GLIMEPIRIDE TEVA 3 MG	GLIMEPIRIDE	GLIMEPIRIDE 3MG	TABLETS	RECIEPT	Non-insulin-dependent diabetes mellitus (adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.
2282	GLIMEPIRIDE	GLIMEPIRIDE TEVA 4 MG	GLIMEPIRIDE	GLIMEPIRIDE 4MG	TABLETS	RECIEPT	Non-insulin-dependent diabetes mellitus (adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.
2284	GLIOLAN	GLIOLAN	5-AMINOLEVULINIC ACID AS HYDROCHLORIDE	5-AMINOLEVULINIC ACID AS HYDROCHLORIDE 1.5G	POWDER	RECIEPT	Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV).
2286	GLIVEC	GLIVEC 100 MG	IMATINIB AS MESYLATE	IMATINIB AS MESYLATE 100MG	TABLETS	RECIEPT	Glivec is indicated for the treatment of adult patients and children 3 years of age and above with Ph+ chronic myeloid leukaemia (Ph+ -CML) in chronic phase accelerated phase or blast crisis. Glivec is also indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). Glivec is also indicated for the treament of : Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult patients with relapsed or refractory Ph + ALL as monotherapy. Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. Adult patients with myelodyspiastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR ( platelet - derived growth factor receptor ) gene re- arrangements. Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) who have the FIP1L1- PDGFRalfa fusion kinase (mutational analysis or FISH demonstration fo CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alfa fusion kinase negative . Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-kit mutation . Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
2287	GLIVEC	GLIVEC 400 MG	IMATINIB AS MESYLATE	IMATINIB AS MESYLATE 400MG	TABLETS	RECIEPT	Glivec is indicated for the treatment of adult patients and children 3 years of age and above with Ph+ chronic myeloid leukaemia (Ph+ -CML) in chronic phase accelerated phase or blast crisis. Glivec is also indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). Glivec is also indicated for the treament of : Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult patients with relapsed or refractory Ph + ALL as monotherapy. Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. Adult patients with myelodyspiastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR ( platelet - derived growth factor receptor ) gene re- arrangements. Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) who have the FIP1L1- PDGFRalfa fusion kinase (mutational analysis or FISH demonstration for CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alfa fusion kinase negative . Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-kit mutation . Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
2289	GLOVAN	GLOVAN	NONOXINOL	NONOXINOL 9 140MG;RICINOLEIC ACID 25MG	TABLETS		Spermicide for the control of conception.
2290	GLOVAN	GLOVAN 12 VAG OVULES	NONOXINOL	NONOXINOL;9 140MG;RICINOLEIC 25MG	TABLETS		Spermicide for the control of conception.
2291	GLUBEN	GLUBEN	GLIBENCLAMIDE	GLIBENCLAMIDE 5MG	TABLETS	RECIEPT	Control of hyperglycemia in stable, mild, nonketosis prone Glibenclamide responsive type II diabetes mellitus, which cannot be controlled by proper dietary management or when insulin therapy is inappropriate.
2292	GLUCAGEN HYPOKIT	GLUCAGEN HYPOKIT 1 MG	GLUCAGON AS HYDROCHLORIDE	GLUCAGON AS HYDROCHLORIDE 1MG	POWDER	RECIEPT	Treatment of severe hypoglycaemia reactions which may occur in the management of insulin treated persons with diabetes.
2293	GLUCOMIN	GLUCOMIN	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 850MG	TABLETS	RECIEPT	Glucomin is indicated in diet-failed, non-insulin dependent diabetic patients, especially if overweight, either alone as initial therapy or in combination with a sulfonylurea. Occasionally, as adjuvant therapy in insulin-dependent diabetic patients particularly who are usually obese and not well controlled with insulin.
2295	GLUCOPHAGE	GLUCOPHAGE	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 850MG	TABLETS	RECIEPT	Glucophage is indicated in diet-failed, non-insulin dependent diabetic patients, especially if overweight, either alone as initial therapy or in combination with a sulfonylyrea. Occasionally, as adjuvant therapy in insulin-dependent diabetic patients particularly who are usually obese and not well controlled with insulin.
2297	GLUCO-RITE	GLUCO-RITE	GLIPIZIDE	GLIPIZIDE 5MG	TABLETS	RECIEPT	Is indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with diabetes mellitus type II
2298	GLUCOSE	GLUCOSE 10 %	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 10%	SOLUTION	RECIEPT	Carbohydrate infusion therapy : - hypoglycaemic situations, - hypertonic dehydration , - hypertonic electrolyte disturbances. Vehicle solution for supplementary medication.
2299	GLUCOSE	GLUCOSE 20 %	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 20%	SOLUTION	RECIEPT	High caloric carbohydrate infusion hypoglycaemia.
2303	GLUCOSE	GLUCOSE 50 %	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 50%	SOLUTION	RECIEPT	High caloric carbohydrate infusion hypoglycaemia.
2300	GLUCOSE	GLUCOSE 5 % INTRAVENOUS INFUSION BP	GLUCOSE MONOHYDRATE	GLUCOSE MONOHYDRATE 5.5%W/V	SOLUTION	RECIEPT	For the treatment of carbohydrate and fluid depletion. Glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.
2310	GLYCERIN	GLYCERIN SUPPOSITORIES FOR CHILDREN	GLYCERIN	GLYCERIN 1.104G	SUPPOSITORIES		For relief of constipation.
2305	GLYCERIN	GLYCERIN FORTE 3.2G 10 SUPP	GLYCERIN	GLYCERIN 3.2G	SUPPOSITORIES		For relief of constipation.
2306	GLYCERIN	GLYCERIN FORTE SUPPOSITORIES	GLYCERIN	GLYCERIN 3.2G	SUPPOSITORIES		For relief of constipation.
2311	GLYCERIN	GLYCERINE CHILD 5SUP	GLYCERINE	GLYCERINE 1.33G	SUPPOSITORIES		For relief of constipation.
2312	GLYCERIN	GLYCERINE 1.33GR 5 SUP PEDIA	GLYCERINE	GLYCERINE 1.33G	SUPPOSITORIES		For relief of constipation.
2313	GLYCERIN	GLYCERINE 2.35GR 20 SUP ADULT	GLYCERINE	GLYCERINE 2.35G	SUPPOSITORIES		For relief of constipation.
2314	GLYCERIN	GLYCERINE ADULT 20SUP	GLYCERINE	GLYCERINE 2.35G	SUPPOSITORIES		For relief of constipation.
2307	GLYCERIN	GLYCERIN PEDIATRIC SUPPOSITORIES	GLYCEROL	GLYCEROL 1337MG	SUPPOSITORIES		For relief of constipation.
2308	GLYCERIN	GLYCERIN SUPPOSITORIES	GLYCEROL	GLYCEROL 2.35G	SUPPOSITORIES		For relief of constipation.
2309	GLYCERIN	GLYCERIN SUPPOSITORIES FOR ADULTS	GLYCEROL	GLYCEROL 2160MG	SUPPOSITORIES		For relief of constipation.
2315	GLYPRESSIN	GLYPRESSIN	TERLIPRESSIN ACETATE	TERLIPRESSIN ACETATE 1MG/DOSE	POWDER	RECIEPT	Bleeding oesophageal varices. Treatment of type I hepatorenal syndrome.
2317	GLYXAMBI	GLYXAMBI 10 MG/5 MG	LINAGLIPTIN	LINAGLIPTIN 5MG;EMPAGLIFLOZIN 10MG	TABLETS	RECIEPT	GLYXAMBI tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. Limitations of Use GLYXAMBI is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. GLYXAMBI has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using GLYXAMBI.
2318	GLYXAMBI	GLYXAMBI 25 MG/5 MG	LINAGLIPTIN	LINAGLIPTIN 5MG;EMPAGLIFLOZIN 25MG	TABLETS	RECIEPT	GLYXAMBI tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. Limitations of Use GLYXAMBI is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. GLYXAMBI has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using GLYXAMBI.
2319	GODAMED	GODAMED 100 TABLETS	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 100MG	TABLETS		For inhibition of platelet aggregation
2320	GODAMED	GODAMED 100MG 30TAB	ASPIRIN	ASPIRIN 100MG	TABLETS		For inhibition of platelet aggregation
2323	GONAL-F	GONAL-f 75 IU (5.5 MCG)	FOLLITROPIN ALFA	FOLLITROPIN ALFA 5.5MCG/DOSE	POWDER		1) Gonal-F followed by chorionic gonadotrophin (hCG) is recommended for the stimulation of follicular development and ovulation in women with hypothalamic-pituitary dysfunction who present with either oligomenorrhoea or amenorrhoea. These women are classified as W.H.O group II patients and usually receive clomiphene citrate as primary therapy. They have evidence of endogenous oestrogen production and thus will either spontaneously menstruate or experience withdrawal bleeding after progestagen administration. Polycystic ovarian disease (PCOD) is part of the WHO II classification and is present in the majority of these patients. 2) Gonal-F is indicated for stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertillization (IVF) gamete intra-fallopian transfer (GIFT) and zogote intra-fallopian transfer (ZIFT). 3) Gonal-F is indicated with concomitant human chorionic gonadotrophin (HCG) therapy for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism.
2322	GONAL-F	GONAL-F	FOLLITROPIN ALFA	FOLLITROPIN ALFA 600 IU/ML	SOLUTION	RECIEPT	In adult women: • Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate. • Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT). • Follitropin alfa in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/l. In adult men: • Follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy.
2325	GRAFALON	GRAFALON	RABBIT IMMUNOGLOBULIN	RABBIT IMMUNOGLOBULIN 20MG/ML	CONCENTRATE	RECIEPT	- Prophylaxis and therapy of rejection crises in organ and tissue transplantations. - Prevention of graft-versus-host disease (GVHD) in adults after allogeneic stem cell transplantation (SCT) Grafalon is indicated for prevention of graft-versus-host di
2326	GRAMSE PIRIN	GRAMSE PIRIN 325 MG 100TAB	ASPIRIN	ASPIRIN 325MG	TABLETS		Analgesic, antipyretic, treatment of non-infective inflammatory conditions.
2327	GRANUPAS	GRANUPAS	4-AMINOSALICYLIC ACID	4 - AMINOSALICYLIC ACID 4G	GRANULES	RECIEPT	GRANUPAS is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
2328	GYNERA	GYNERA	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.03MG;GESTODENE 0.075MG	TABLETS	RECIEPT	Hormonal contraception.
2330	GYNO DAKTARIN	GYNO DAKTARIN 7	MICONAZOLE NITRATE	MICONAZOLE NITRATE 20MG/G	CREAM	RECIEPT	Local treatment of vulvovaginal candidosis (monoliasis) and superinfection due to Gram positive bacteria (streptococci and staphylococci).
2331	GYNO PEVARYL	GYNO PEVARYL 150 MG	ECONAZOLE NITRATE	ECONAZOLE NITRATE 150MG	TABLETS	RECIEPT	Local treatment of fungal infections of the vagina.
2332	HAEMATE	HAEMATE P 1000 IU FVIII / 2400 IU VWF	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 1000 IU/15ML;VON WILLEBRAND FACTOR 2400 IU/15ML	POWDER	RECIEPT	Congenital and acquired deficiency of blood clotting factor VIII: severe or moderate haemophilia,prophylaxis during operation, Von Willebrands disease.
2333	HAEMATE	HAEMATE P 250 IU FVIII / 600 IU VWF	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 250 IU/5ML;VON WILLEBRAND FACTOR 600 IU/5ML	POWDER	RECIEPT	Congenital and acquired deficiency of blood clotting factor VIII: severe or moderate haemophilia, prophylaxis during operation, Von Willebrand's disease.
2334	HAEMATE	HAEMATE P 500 IU FVIII / 1200 IU VWF	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 500 IU/10ML;VON WILLEBRAND FACTOR 1200 IU/10ML	POWDER	RECIEPT	Congenital and acquired deficiency of blood clotting factor VIII: severe or moderate haemophilia, prophylaxis during operation, Von Willebrands disease.
2336	HAEMOCOM LETTAN	HAEMOCOMPLETTAN P 2 G	HUMAN FIBRINOGEN	HUMAN FIBRINOGEN 1800MG/1 VIALS	POWDER	RECIEPT	Haemocomplettan P 1g/2g, Fibrinogen Concentrate (Human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Haemocomplettan P 1g/2g is not indicated for dysfibrinogenemia.
2335	HAEMOCOM LETTAN	HAEMOCOMPLETTAN P 1 G	HUMAN FIBRINOGEN	HUMAN FIBRINOGEN 900MG/1 VIALS	POWDER	RECIEPT	Haemocomplettan P 1g/2g, Fibrinogen Concentrate (Human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Haemocomplettan P 1g/2g is not indicated for dysfibrinogenemia.
2337	HAEMOCTIN SDH	HAEMOCTIN SDH 1000 IU	HUMAN PLASMA COAGULATION FACTOR VIII	HUMAN PLASMA COAGULATION FACTOR VIII 100IU/ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding: in patients with haemophilia A (congenital factor VIII deficiency) in patient with acquired factor VIII deficiency. Haemoctin is not effective in controlling the bleeding of patients with Von Willebrond`s disease.
2338	HAEMOCTIN SDH	HAEMOCTIN SDH 250 IU	HUMAN PLASMA COAGULATION FACTOR VIII	HUMAN PLASMA COAGULATION FACTOR VIII 50IU/ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding: in patients with haemophilia A (congenital factor VIII deficiency) in patient with acquired factor VIII deficiency. Haemoctin is not effective in controlling the bleeding of patients with Von Willebrond`s disease.
2339	HAEMOCTIN SDH	HAEMOCTIN SDH 500 IU	HUMAN PLASMA COAGULATION FACTOR VIII	HUMAN PLASMA COAGULATION FACTOR VIII 50IU/ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding: in patients with haemophilia A (congenital factor VIII deficiency) in patient with acquired factor VIII deficiency. Haemoctin is not effective in controlling the bleeding of patients with Von Willebrond`s disease.
2340	HAIRGAIN	HAIRGAIN 5%	MINOXIDIL	MINOXIDIL 5%	SOLUTION	RECIEPT	Hair regrowth treatment for men.
2341	HAIRGAIN	HAIRGAIN FOAM	MINOXIDIL	MINOXIDIL 5%	FOAM	RECIEPT	Hair regrowth treatment in men
2342	HAIRGAINE	HAIRGAINE FOAM 5% 60ML	MINOXIDIL	MINOXIDIL 5%	SOLUTION	RECIEPT	Hair regrowth treatment in men
2343	HALAVEN	HALAVEN	ERIBULIN AS MESILATE	ERIBULIN AS MESILATE 0.44MG/ML	SOLUTION	RECIEPT	Halaven is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
2347	HALDOL	HALDOL 2 MG/ML DROPS	HALOPERIDOL	HALOPERIDOL 2MG/ML	SOLUTION	RECIEPT	Antipsychotic, psychomotor sedative. Additionally, in pediatrics, for short-term treatment of tics and vomiting (Gilles de la tourettes syndrome).
2348	HALDOL	HALDOL 5 MG	HALOPERIDOL	HALOPERIDOL 5MG	TABLETS	RECIEPT	Management of manifestations of psychotic disorders. Control of tics and vocal utterances of Tourette's disorder.
2349	HALDOL	HALDOL AMPOULES	HALOPERIDOL	HALOPERIDOL 5MG/ML	SOLUTION	RECIEPT	Psychomotor agitation encountered in different neuropsychotic affections, prophylaxis and therapy of acute and chronic vomiting.
2350	HALDOL	HALDOL DECANOAS	HALOPERIDOL AS DECANOATE	HALOPERIDOL AS DECANOATE 100MG/ML	SOLUTION	RECIEPT	Maintainance therapy of chronic schizophrenic patients.
2352	HALOPER	HALOPER 0.5 MG TABLETS	HALOPERIDOL	HALOPERIDOL 0.5MG	TABLETS	RECIEPT	Management of psychotic disorders. Control of tics and vocal utterances of Tourette's disorder in children.
2353	HALOPER	HALOPER 10 MG TABLETS	HALOPERIDOL	HALOPERIDOL 10MG	TABLETS	RECIEPT	Management of psychotic disorders . Control of tics and vocal utterances of Tourette's disorder in children and adults.
2354	HALOPER	HALOPER 5	HALOPERIDOL	HALOPERIDOL 5.00MG	TABLETS	RECIEPT	Management of psychotic disorders. Control of tics and vocal utterances of Touratte's disorder in children and adults.
2355	HARMONET	HARMONET	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.020MG;GESTODENE 0.075MG	TABLETS	RECIEPT	Contraceptive.
2356	HARVONI	HARVONI	LEDIPASVIR	LEDIPASVIR 90MG;SOFOSBUVIR 400MG	TABLETS	RECIEPT	Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adults.
2359	HAVRIX	HAVRIX 1440	HEPATITIS A VIRUS ANTIGEN, INACTIVATED	HEPATITIS A VIRUS ANTIGEN, INACTIVATED 1440E.L.U/ML	SUSPENSION	RECIEPT	Active immunisation against infections caused by Hepatitis A virus. The vaccine is particularly indicated for those at increased risk of infection or transmission.
2360	HAVRIX	HAVRIX 720 JUNIOR	HEPATITIS A VIRUS ANTIGEN, INACTIVATED	HEPATITIS A VIRUS ANTIGEN, INACTIVATED 720E.L.U/0.5ML	SUSPENSION	RECIEPT	Active immunisation against HAV infection from 1 year up to and including 15 years of age. The vaccine is particularly indicated for those at increased risk of infection or transmission. It is also indicated for use during outbreaks of hepatitis A infection.
2361	HEMAFER	HEMAFER	FERRIC HYDROXIDE POLYMALTOSE COMPLEX AS	FERRIC HYDROXIDE POLYMALTOSE COMPLEX AS 50MG/ML	DROPS		Prevention and treatment of iron deficiency anaemia.
2362	HEMAFER	HEMAFER 50mg/ml 30 ml	IRON(III)HYDROXYDE POLYMALTOSE	IRON(III)HYDROXYDE POLYMALTOSE 50MG/ML	DROPS		Prevention and treatment of iron deficiency anaemia.
2363	HEMANGIOL	HEMANGIOL	PROPRANOLOL AS HYDROCHLORIDE	PROPRANOLOL AS HYDROCHLORIDE 3.75MG/1ML	SOLUTION	RECIEPT	For the treatment of proliferating infantile haemangioma requiring systemic therapy: • Life- or function-threatening haemangioma, • Ulcerated haemangioma with pain and/or lack of response to simple wound care measures, • Haemangioma with a risk of permanent scars or disfigurement. It is to be initiated in infants aged 5 weeks to 5 months
2364	HEMLIBRA	HEMLIBRA 150 MG/ML	EMICIZUMAB	EMICIZUMAB 150MG/1ML	SOLUTION	RECIEPT	Hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
2365	HEMLIBRA	HEMLIBRA 30 MG/ML	EMICIZUMAB	EMICIZUMAB 30MG/1ML	SOLUTION	RECIEPT	Hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
2366	HEMO	HEMO 20SUPP	BISMUTH SUBGALLATE	BISMUTH SUBGALLATE 180MG;ZINC OXIDE 120MG;BENZOCAINE 15MG	SUPPOSITORIES	RECIEPT	As substitution solution in continuous haemofiltration and haemodiafiltration and as dialysis solution in continuous haemodialysis for acute renal failure.
2367	HEMO	HEMO SUPPOSITORIES	BISMUTH SUBGALLATE	BISMUTH SUBGALLATE 180MG;ZINC OXIDE 120MG;BENZOCAINE 15MG	SUPPOSITORIES	RECIEPT	For the relief of hemorrhoids.
2368	HEMOSOL B0	HEMOSOL B0	CALCIUM CHLORIDE DIHYDRATE	CALCIUM CHLORIDE DIHYDRATE 5.145G/1000ML electrolyte solution;MAGNESIUM CHLORIDE HEXAHYDRATE 2.033G/1000ML electrolyte solution;LACTIC ACID 5.400G/1000ML electrolyte solution;SODIUM CHLORIDE 6.45G/1000ML buffer solution;SODIUM CARBONATE HYDROGEN 3.090G/1000ML buffer solution	SOLUTION	RECIEPT	As substitution solution in continuous haemofiltration and haemodiafiltration and as dialysis solution in continuous haemodialysis for acute renal failure.
2369	HEPAGAM B	HEPAGAM B	HEPATITIS B IMMUNOGLOBULIN	HEPATITIS B IMMUNOGLOBULIN 312 IU/ML	SOLUTION	RECIEPT	Prevention of hepatitis B recurrence following liver transplantation : Hepagam B is indicated for the prevetion of hepatitis B recurrence following liver transplantation in HBsAg-positive liver transplant patients. Hepagam B should be administered intravenously for this indication. Postexposure prophylaxis : Hepagam B is indicated for the treatment of acute exposure to blood containing HBsAg perinatal exposure of infants born to HBsAg-positive mothers sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings: Acute exposure to blood containing HBsAg Following either parenteral exposure (needlestick bite sharps) direct mucous membrane contact (accidental splash) or oral ingestion (pipetting accident) involving HBsAg - positive materials such as blood plasma or serum. Perinatal exposure of infants born to HBsAg-positive mothers Infants born to mothers positive for HBsAg with or without HBeAg. Perinatal exposure of infants born to HBsAg-positive persons Sexual partners of HBsAg-positive persons. Household exposure to persons with acute HBV infection Infants less than 12 months old whose mother or primary caregiver is positive for HBsAg. Other household contacts with an identifiable blood exposure to the index patient. Hepagam B is indicated for intramuscular use only for these post-exposure prophylaxis indications.
2373	HEPARIN SODIUM	HEPARIN SODIUM TEVA 25000 IU/ 5 ML	HEPARIN SODIUM	HEPARIN SODIUM 25000 IU/5ML	SOLUTION	RECIEPT	- Prevention of thromboembolic disorders. - As part of the treatment of venous and arterial thromboembolic disorders (including early treatment of heart attacks as well as unstable angina pectoris) - For the anticoagulation in case of treatment or oper
2370	HEPARIN SODIUM	HEPARIN SODIUM IN 0.9 % SODIUM CHLORIDE INJECTION (2U/ML HEPARIN SOD.)	HEPARIN SODIUM	HEPARIN SODIUM 2U/ML	SOLUTION	RECIEPT	Anticoagulant in extracorporeal circulation, dialysis procedures, an aid in the maintenance of catheter patency.
2372	HEPARIN SODIUM	HEPARIN SODIUM ROVI 5,000 IU/ML	HEPARIN SODIUM	HEPARIN SODIUM 5000 IU/1ML	SOLUTION	RECIEPT	• Treatment and prevention of venous thromboembolism: deep vein thrombosis and pulmonary embolism. • Treatment and prevention of peripheral arterial thromboembolism. • Treatment of coronary heart disease: unstable angina and acute myocardial infarction. • Prevention of thrombosis in extracorporeal circulation circuit during heart and vascular surgery and haemodialysis. Heparin sodium ROVI is indicated for use in pediatric patients 28 days after birth and adults
2371	HEPARIN SODIUM	HEPARIN SODIUM PANPHARMA 5000 IU/ML	HEPARIN SODIUM	HEPARIN SODIUM 5000IU/ML	SOLUTION	RECIEPT	Treatment of thrombo-embolic disorders as deep vein thrombosis, acute arterial embolism or thrombosis, thrombophlebitis, pulmonary embolism , fat embolism. Prophylaxis of deep vein thrombosis and thromboembolic events.
2374	HEPATECT	HEPATECT CP	PROTEIN IMMUMOGLOBULIN	PROTEIN IMMUMOGLOBULIN 50MG/ML	SOLUTION	RECIEPT	Prophylaxis against hepatitis B in adults and children over 2 years of age who have not been vaccinated against hepatitis B (including persons whose vaccination is incomplete or missing) who are at risk of infection with hepatitis B by accidental contact with Hepatitis B virus containing material following: - percutaneous exposure (e.g. accidental needle stick). - direct mucous membrane contact. When the administration of an intramuscular hepatitis B immunoglobulin is not possible. The immunoglobulin should be administered in association with hepatitis B vaccine. Prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of the hepatitis B virus. Immunoprophylaxis of hepatitis B in the newborn of a hepatitis B virus carrier mother.
2375	HEPSERA	HEPSERA	ADEFOVIR DIPIVOXIL	ADEFOVIR DIPIVOXIL 10MG	TABLETS	RECIEPT	Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of hepatitis B viral replication. Reductions in viral replication and improvements in liver function have also been demonstrated in supportive studies in a limited number of chronic hepatitis B patients with genotypic evidence of lamivudine-resistance, including patients with compensated or decompensated liver disease and patients co-infected with HIV.
2376	HERCEPTIN	HERCEPTIN 440 MG I.V	TRASTUZUMAB	TRASTUZUMAB 440MG/ML	SOLUTION	RECIEPT	Herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2: 1. As a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. In combination with Paclitaxel or Docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. Herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. Early breast cancer (EBC) : Herceptin is indicated to treat patients with HER2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding Anthracyclines. Herceptin should only be used in patients whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay. HER2 metastatic gastric cancer (mGC) Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, as determined by an accurate and validated assay
2377	HERCEPTIN	HERCEPTIN 600 MG/ 5 ML S.C.	TRASTUZUMAB	TRASTUZUMAB 600MG/5ML	SOLUTION	RECIEPT	Breast cancer Metastatic breast cancer Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. - in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. Early breast cancer Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC). - following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) . - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. - in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter Herceptin should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay .
2378	HEXAKAPRON	HEXAKAPRON TABLETS	TRANEXAMIC ACID	TRANEXAMIC ACID 500MG	TABLETS	RECIEPT	Treatment of hemorrhage occuring in some forms of surgery, including prostatectomy. Hematuria. Menorrhagia. Hereditary angioneurotic edema.
2379	HEXAKAPRON	HEXAKAPRON INJECTION	TRANEXAMIC ACID	TRANEXAMIC ACID 500MG/5ML	SOLUTION	RECIEPT	General fibrinolysis. This may occur in prostatic and pancreatic carcinoma following thoracic surgery and other major operative procedures, in obstetrical complications such as abruptio placentae and post-partum hemorrhage, in connection with thrombolytic therapy, and in initial and follow-up treatment following prostatectomy and bladder surgery. Prior to, and following, dental surgery in hemophiliacs. Epistaxis. Conization of the cervix.
2381	HEXAXIM	HEXAXIM	DIPHTHERIA TOXOID Not less than	DIPHTHERIA TOXOID Not less than 20 IU/10.5 ml;TETANUS PROTEIN CONJUGATE 22MCG/0.5ML;HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE 12MCG/0.5ML (Polyribosylribitol Phosphate);HEPATITIS B VACCINES 10MCG/0.5ML (Hepatitis B surface antigen);POLIOVIRUS TYPE 3 INACTIVATED 32DU/0.5ML;POLIOVIRUS TYPE 2 INACTIVATED 8DU/0.5ML;POLIOVIRUS TYPE 1 INACTIVATED 40DU/0.5ML;FILAMENTOUS HAEMAGGLUTININ (FHA) 25MCG/0.5ML;PERTUSSIS TOXOID (PT) 25MCG/0.5ML;TETANUS TOXOID Not less than 40 IU/10.5 ml	SUSPENSION	RECIEPT	Hexaxim (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenza type b (Hib). The use of this vaccine should be in accordance with official recommendations.
2382	HEXIDYL	HEXIDYL ALCOHOL FREE MOUTHWASH	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 0.2%W/V	SOLUTION		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
2384	HEXIDYL	HEXIDYL MOUTHWASH	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 0.2%W/V	SOLUTION		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
2383	HEXIDYL	HEXIDYL ALCOHOL FREE MOUTHWASH 0.2% 300ml	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.2%	SOLUTION		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
2385	HEXIDYL	HEXIDYL MOUTHWASH 0.2% 300ml	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.2%	SOLUTION		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
2386	HEXVIX	HEXVIX 85 MG	HEXYL AMINOLEVULINATE AS HYDROCHLORIDE	HEXYL AMINOLEVULINATE AS HYDROCHLORIDE 85MG	POWDER	RECIEPT	This medicinal product is for diagnostic use only. Hexvix blue light fluorescence cystoscopy is indicated as adjunct to standard white light cystoscopy to contribute to the diagnosis and management of bladder cancer in patients with known or high suspicion of bladder cancer
2388	HISTADEX	HISTADEX 115ML	DEXCHLORPHENIRAMINE MALEATE	DEXCHLORPHENIRAMINE MALEATE 1MG/5ML;PSEUDOEPHEDRINE HCL 25MG/5ML	SYRUP	RECIEPT	Relief of congestion in the respiratory tract due to allergy.
2387	HISTADEX	HISTADEX	DEXCHLORPHENIRAMINE MALEATE	DEXCHLORPHENIRAMINE MALEATE 1MG/5ML;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG/5ML	SYRUP	RECIEPT	Relief of congestion in the respiratory tract due to allergy.
2392	HISTAFED	HISTAFED COMPOUND LINCTUS	CODEINE PHOSPHATE	CODEINE PHOSPHATE 5MG/5ML;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG/5ML;TRIPROLIDINE HYDROCHLRIDE 1.25MG/5ML	SYRUP	RECIEPT	Antitussive syrup for the symptomatic relief of cough accompanied by nasal congestion and congestion of the upper respiratory tract.
2394	HISTAFED	HISTAFED EXPECTORANT SYRUP	GUAIFENESIN	GUAIFENESIN 100MG/5ML;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG/5ML;TRIPROLIDINE HYDROCHLRIDE 1.25MG/5ML	SYRUP	RECIEPT	Histafed expectorant is a proven combination for providing an effective antiallergic action, decongestion with an added expectorant effect.
2395	HISTAFED	HISTAFED SYRUP	PSEUDOEPHEDRINE HYDROCHLORIDE	PSEUDOEPHEDRINE HYDROCHLORIDE 30MG/5ML;TRIPROLIDINE HYDROCHLRIDE 1.25MG/5ML	SYRUP	RECIEPT	For the symptomatic relief of congestion such as rhinitis and associated allergic conditions.
2389	HISTAFED	HISTAFED	PSEUDOEPHEDRINE HYDROCHLORIDE	PSEUDOEPHEDRINE HYDROCHLORIDE 60MG;TRIPROLIDINE HYDROCHLRIDE 2.5MG	TABLETS	RECIEPT	For the relief of congestion such as rhinitis and associated allergic conditions.
2393	HISTAFED	HISTAFED EXPECT 115ML	TRIPROLIDINE HCL	TRIPROLIDINE HCL 1.25MG/5ML;PSEUDOEPHEDRIN HCL 30MG/5ML;GUAIFENESIN 100MG/5ML	SYRUP		Histafed expectorant is a proven combination for providing an effective antiallergic action, decongestion with an added expectorant effect.
2396	HISTAFED	HISTAFED SYRUP 115ML	TRIPROLIDINE HCL	TRIPROLIDINE HCL 1.25MG;PSEUDOEPHEDRIN HCL 30MG	SYRUP		For the symptomatic relief of congestion such as rhinitis and associated allergic conditions.
2390	HISTAFED	HISTAFED 20 DRAG	TRIPROLIDINE HCL	TRIPROLIDINE HCL 2.5MG;PSEUDOEPHEDRINE HCL 60MG	DRAGEE	RECIEPT	For the symptomatic relief of congestion such as rhinitis and associated allergic conditions.
2391	HISTAFED	HISTAFED 30 DRAG	TRIPROLIDINE HCL	TRIPROLIDINE HCL 2.5MG;PSEUDOEPHEDRINE HCL 60MG	DRAGEE	RECIEPT	For the symptomatic relief of congestion such as rhinitis and associated allergic conditions.
2397	HISTAMINE	HISTAMINE-CARE	PSEUDOEPHEDRINE HYDROCHLORIDE	PSEUDOEPHEDRINE HYDROCHLORIDE 30MG/5ML;TRIPROLIDINE HYDROCHLRIDE 1.25MG/5ML	SYRUP	RECIEPT	For the symptomatic relief of congestion such as rhinitis and associated allergic conditions.
2402	HISTAZINE	HISTAZINE SYRUP 115ML	CETIRIZINE DIHYDROCHL.	CETIRIZINE DIHYDROCHL. 0.1%	SYRUP		Antihistaminic drug for the treatment of allergies. For the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in children aged 6 years and over and adults.
2398	HISTAZINE	HISTAZINE	CETIRIZINE DIHYDROCHLORIDE	CETIRIZINE DIHYDROCHLORIDE 10MG	TABLETS		Antihistaminic drug for the treatment of allergies. For the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in children aged 6 years and over and adults.
2400	HISTAZINE	HISTAZINE 10MG 10TAB	CETIRIZINE DIHYDROCHLORIDE	CETIRIZINE DIHYDROCHLORIDE 10MG	TABLETS		Antihistaminic drug for the treatment of allergies for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic uriticaria in children aged over 2 years and adults.
2401	HISTAZINE	HISTAZINE 10MG 20TAB	CETIRIZINE DIHYDROCHLORIDE	CETIRIZINE DIHYDROCHLORIDE 10MG	TABLETS		Antihistaminic drug for the treatment of allergies for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic uriticaria in children aged over 2 years and adults.
2403	HOLOXAN	HOLOXAN 1 G	IFOSFAMIDE	IFOSFAMIDE 1G/VIAL	POWDER	RECIEPT	Testicular tumour For combination chemotherapy in patients with advanced stage II to IV tumours according to the TNM classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy. Cervical cancer Palliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, FIGO stage IV B (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy. Breast cancer For palliative therapy in advanced, therapy-refractory or recurrent breast cancer. Non-small-cell lung cancer For mono- or combination chemotherapy of patients with inoperable or metastatic tumours. Small-cell lung cancer For combination chemotherapy. Soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma) For mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. For mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy. Ewing’s sarcoma For combination chemotherapy after failure of primary cytostatic therapy. Non-Hodgkin’s lymphoma For combination chemotherapy in patients with highly malignant non-Hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. For combination therapy of patients with recurrent tumours. Hodgkin’s lymphoma For the treatment of patients with primary progressive forms and early relapse of Hodgkin’s lymphoma (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radio-chemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the MINE protocol.
2404	HOLOXAN	HOLOXAN 2 G	IFOSFAMIDE	IFOSFAMIDE 2G/VIAL	POWDER	RECIEPT	Testicular tumour For combination chemotherapy in patients with advanced stage II to IV tumours according to the TNM classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy. Cervical cancer Palliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, FIGO stage IV B (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy. Breast cancer For palliative therapy in advanced, therapy-refractory or recurrent breast cancer. Non-small-cell lung cancer For mono- or combination chemotherapy of patients with inoperable or metastatic tumours. Small-cell lung cancer For combination chemotherapy. Soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma) For mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. For mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy. Ewing’s sarcoma For combination chemotherapy after failure of primary cytostatic therapy. Non-Hodgkin’s lymphoma For combination chemotherapy in patients with highly malignant non-Hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. For combination therapy of patients with recurrent tumours. Hodgkin’s lymphoma For the treatment of patients with primary progressive forms and early relapse of Hodgkin’s lymphoma (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radio-chemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the MINE protocol.
2405	HOUSE EXTRACT	HOUSE DUST EXTRACT	DUST EXTRACT	DUST EXTRACT אוסף אלרגנים	SOLUTION	RECIEPT	Skin testing and immunotherapy.
2406	HUMALOG	HUMALOG	INSULIN LISPRO	INSULIN LISPRO 100U/ML	SOLUTION	RECIEPT	Humalog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilization of diabetes mellitus.
2408	HUMALOG	HUMALOG KWIKPEN 100 U/ML	INSULIN LISPRO	INSULIN LISPRO 100U/ML	SOLUTION	RECIEPT	Humalog KwikPen is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabalization of diabetes mellitus.
2409	HUMALOG	HUMALOG KWIKPEN 200 U/ML	INSULIN LISPRO	INSULIN LISPRO 200U/ML	SOLUTION	RECIEPT	For the treatment of adults with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog KwikPen 200 units/ml is also indicated for the initial stabilisation of diabetes mellitus.
2411	HUMALOG	HUMALOG MIX 25 KWIKPEN	INSULIN LISPRO	INSULIN LISPRO 25%;INSULIN LISPRO AS PROTAMINE 75%	SUSPENSION	RECIEPT	Humalog Mix 25 KwikPen is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
2410	HUMALOG	HUMALOG MIX 25	INSULIN LISPRO	INSULIN LISPRO 25%;INSULIN LISPRO PROTAMINE 75%	SUSPENSION	RECIEPT	For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
2413	HUMALOG	HUMALOG MIX 50 KWIKPEN	INSULIN LISPRO	INSULIN LISPRO 50%;INSULIN LISPRO AS PROTAMINE 50%	SUSPENSION	RECIEPT	Humalog Mix 50 KwikPen is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
2412	HUMALOG	HUMALOG MIX 50	INSULIN LISPRO	INSULIN LISPRO 50%;INSULIN LISPRO PROTAMINE 50%	SUSPENSION	RECIEPT	For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
2415	HUMIRA	HUMIRA	ADALIMUMAB	ADALIMUMAB 100MG/1ML	SOLUTION	RECIEPT	• Rheumatoid arthritis: Humira in combination with methotrexate is indicated for: - The treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - The treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. • Polyarticular juvenile idiopathic arthritis: Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has not been studied in patients aged less than 2 years. • Enthesitis-related arthritis: Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. • Axial spondyloarthritis : Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. • Axial spondyloarthritis without radiographic evidence of AS: Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS, but with objective signs of inflammation by radiological and/or laboratory tests including MRI and serum CRP levels , who have had an inadequate response to, or are intolerant to, non - steroidal anti-inflammatory drugs. • Psoriatic arthritis: Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti rheumatic drug therapy has been inadequate. Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. • Psoriasis: Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. • Paediatric plaque psoriasis: Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. • Hidradenitis suppurativa (HS): Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy. • Crohn’s disease: Humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Humira is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. • Paediatric Crohn's disease: Humira is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6- years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and corticosteroid, and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies • Ulcerative colitis: Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. • Uveitis: Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. • Intestinal Behcet's disease: Humira is indicated for the treatment of intestinal Behcet’s disease in patients who have had an inadequate response to conventional therapy. • Paediatric Uveitis Humira is indicated for the treatment of chronic non-infectious uveitis in paediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. 25/12/2017 בקשה לשינוי משטר מינון
2416	HUMULIN	HUMULIN 70/30	INSULIN (HUMAN)	INSULIN (HUMAN) 100 IU/ML	SUSPENSION	RECIEPT	For the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
2418	HUMULIN	HUMULIN N	INSULIN (HUMAN)	INSULIN (HUMAN) 100 IU/ML	SUSPENSION	RECIEPT	For the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
2420	HUMULIN	HUMULIN R	INSULIN (HUMAN)	INSULIN (HUMAN) 100 IU/ML	SOLUTION	RECIEPT	For the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
2423	HURRICAINE	HURRICAINE oral gel 28.35 gr	BENZOCAINE	BENZOCAINE 20%	GEL		For temporary relief of occasional minor irritation and pain associated with: canker sores, sore mouth and throat , minor injury of the mouth and gums
2424	HURRICAINE	HURRICAINE oral gel 5.25 GR	BENZOCAINE	BENZOCAINE 20%	GEL		For temporary relief of occasional minor irritation and pain associated with: canker sores, sore mouth and throat , minor injury of the mouth and gums
2422	HURRICAINE	HURRICAINE	BENZOCAINE	BENZOCAINE 20%W/W	GEL	RECIEPT	Hurricaine is designed for any dental procedure in which topical anesthesia is desired. Hurricaine is also used for temporary relief of occasional minor irritation and pain associated with: canker sores, sore mouth and throat , minor injury of the mouth and gums caused by dentures or orthodentic appliances.
2425	HYALASE	HYALASE	HYALURONIDASE	HYALURONIDASE 1500IU/DOSE	POWDER	RECIEPT	To enhance permeation of subcutaneous or intramuscular injections, local anesthetics and subcutaneous infusions to promote resorption of excess fluids and blood in the tissues .
2426	HYCAMTIN	HYCAMTIN 0.25 MG	TOPOTECAN AS HYDROCHLORIDE	TOPOTECAN AS HYDROCHLORIDE 0.25MG	CAPSULES	RECIEPT	Indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.
2427	HYCAMTIN	HYCAMTIN 1 MG	TOPOTECAN AS HYDROCHLORIDE	TOPOTECAN AS HYDROCHLORIDE 1MG	CAPSULES	RECIEPT	Indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.
2428	HYCAMTIN	HYCAMTIN IV	TOPOTECAN AS HYDROCHLORIDE	TOPOTECAN AS HYDROCHLORIDE 4MG/VIAL	POWDER	RECIEPT	Topotecan monotherapy is indicated for the treatment of: • patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. • patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.
2429	HYCOMYCIN	HYCOMYCIN	NEOMYCIN AS SULFATE	NEOMYCIN AS SULFATE 0.5%;HYDROCORTISONE 2.5%	OINTMENT	RECIEPT	Allergic dermatoses and other corticosteroid responsive inflammatory skin diseases including atopic dermatitis, contact dermatitis, seborrheic dermatitis, anogenital pruritus, infantile eczema and external otitis.
2430	HYDROAGISTEN	HYDROAGISTEN CREAM	CLOTRIMAZOLE	CLOTRIMAZOLE 1%;HYDROCORTISONE ACETATE 1%	CREAM	RECIEPT	Skin inflammation involving fungal infection
2431	HYDROCORTISONE	HYDROCORTISONE 10 MG	HYDROCORTISONE	HYDROCORTISONE 10MG	TABLETS	RECIEPT	Anti inflammatory.
2432	HYDROCORTISONE	HYDROCORTISONE PANPHARMA 100 MG	HYDROCORTISONE AS SODIUM SUCCINATE	HYDROCORTISONE AS SODIUM SUCCINATE 100MG/DOSE	POWDER	RECIEPT	Hydrocortisone panpharma is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: - allergic states, - dermatologic diseases, - endocrine disorders, - gastrointestinal diseases, - hematologic disorders, - neoplastic diseases, - nervous system disorders, - ophthalmic diseases, - renal diseases, - respiratory diseases, - rheumatic disorders, - certain medical emergencies.
2433	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3% 50ML	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3%	LIQUID
2434	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3% 100CC	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3%	LIQUID
2435	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3% 50ML	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3%	LIQUID
2437	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3 % 100ML	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3%	LIQUID		Antiseptic
2438	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3 % VITAMED	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3%	SOLUTION		Cleaning and disinfecting of wounds.
2439	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3% 1L	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3%	LIQUID		Antiseptic
2436	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3 % FLORIS	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3%W/W	SOLUTION		Antiseptic.
2440	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3% LIFE	HYDROGEN PEROXIDE	HYDROGEN PEROXIDE 3%W/W	SOLUTION		Antiseptic
2441	HYPERHEP B S/D	HYPERHEP B S/D	HEPATITIS B IMMUNOGLOBULIN	HEPATITIS B IMMUNOGLOBULIN 15%	SOLUTION	RECIEPT	For post-exposure prophylaxis such as: - acute exposure to blood containing HBsAG, - perinatal exposure of infants born to HBsAg-positive mothers, - sexual exposure to HBsAg positive persons, - household exposure to persons with acute HBV infections.
2442	HYPERRAB S/D	HYPERRAB S/D	RABIES IMMUNOGLOBULIN	RABIES IMMUNOGLOBULIN 150 IU/ML	SOLUTION	RECIEPT	To be given in conjunction with Rabies vaccine as promptly as possible after exposure.
2443	HYPERTET S/D	HYPERTET S/D	TETANUS IMMUNE GLOBULIN (S/D TREATED)	TETANUS IMMUNE GLOBULIN (S/D TREATED) 250U/ML	SOLUTION	RECIEPT	Immunity against Tetanus toxin. Treatment of active cases of Tetanus.
2444	HYPNODORM	HYPNODORM	FLUNITRAZEPAM	FLUNITRAZEPAM 2MG	TABLETS	RECIEPT	Insomnia of various etiology.
2446	HYQVIA	HYQVIA	HUMAN NORMAL IMMUNOGLOBULIN	HUMAN NORMAL IMMUNOGLOBULIN 100MG/1ML	SOLUTION	RECIEPT	Replacement therapy in adults, children and adolescents (0-18 years) in: • Primary immunodeficiency syndromes with impaired antibody production • Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated. • Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients. • Hypogammaglobulinaemia in patients pre- and post-allogeneic hematopoietic stem cell transplantation (HSCT).
2447	HYSINGLA	HYSINGLA ER 100	HYDROCODONE BITARTRATE	HYDROCODONE BITARTRATE 100MG	TABLETS	RECIEPT	Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
2448	HYSINGLA	HYSINGLA ER 20	HYDROCODONE BITARTRATE	HYDROCODONE BITARTRATE 20MG	TABLETS	RECIEPT	Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
2449	HYSINGLA	HYSINGLA ER 30	HYDROCODONE BITARTRATE	HYDROCODONE BITARTRATE 30MG	TABLETS	RECIEPT	Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
2450	HYSINGLA	HYSINGLA ER 60	HYDROCODONE BITARTRATE	HYDROCODONE BITARTRATE 60MG	TABLETS	RECIEPT	Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
2451	HYTRIN	HYTRIN 10 MG TABLETS	TERAZOSIN AS MONOHYDRACHLORIDE DIHYDRATE	TERAZOSIN AS MONOHYDRACHLORIDE DIHYDRATE 10MG	TABLETS	RECIEPT	For symptomatic treatment of urinary obstruction caused by benign prostatic hypertrophy (BPH). For mild to moderate hypertension.
2452	HYTRIN	HYTRIN 5 MG TABLETS	TERAZOSIN AS MONOHYDRACHLORIDE DIHYDRATE	TERAZOSIN AS MONOHYDRACHLORIDE DIHYDRATE 5MG	TABLETS	RECIEPT	For symptomatic treatment of urinary obstruction caused by benign prostatic hypertrophy (BPH). For mild to moderate hypertension.
2453	IBOO	IBOO 2 % FOR CHILDREN	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
2457	IBOO	IBOO 2 % FOR CHILDREN SYR 100 ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain
2458	IBOO	IBOO 2 % FOR CHILDREN SYR 200 ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain
2459	IBOO	IBOO 4 % FOR CHILDREN	IBUPROFEN	IBUPROFEN 200MG/5ML	SUSPENSION	RECIEPT	For the reduction of fever and relief of mild to moderate pain
2463	IBOO	IBOO 4 % FOR CHILDREN 30 ML	IBUPROFEN	IBUPROFEN 200MG/5ML	SUSPENSION	RECIEPT	For the reduction of fever and relief of mild to moderate pain
2464	IBRANCE	IBRANCE 100 MG	PALBOCICLIB	PALBOCICLIB 100MG	CAPSULES	RECIEPT	IBRANCE is indicated for the treatment of HR positive, HER2 negative advanced or metastatic breast cancer in combination with: • letrozole as initial endocrine based therapy in postmenopausal women, or • fulvestrant in women with disease progression following endocrine therapy.
2465	IBRANCE	IBRANCE 125 MG	PALBOCICLIB	PALBOCICLIB 125MG	CAPSULES	RECIEPT	IBRANCE is indicated for the treatment of HR positive, HER2 negative advanced or metastatic breast cancer in combination with: • letrozole as initial endocrine based therapy in postmenopausal women, or • fulvestrant in women with disease progression following endocrine therapy.
2466	IBRANCE	IBRANCE 75 MG	PALBOCICLIB	PALBOCICLIB 75MG	CAPSULES	RECIEPT	IBRANCE is indicated for the treatment of HR positive, HER2 negative advanced or metastatic breast cancer in combination with: • letrozole as initial endocrine based therapy in postmenopausal women, or • fulvestrant in women with disease progression following endocrine therapy.
2467	IBUFEN	IBUFEN 400	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	For the relief of mild to moderate pain such as headache, toothache, primary dysmenorrhea, backache, muscular pain. Anti - inflammatory and relieves pain in reumatoid arthritis and osteo arthritis. For the treatment of pain associated with migraine.
2468	IBUFEN	IBUFEN 400 50 CAPLETS	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	For the relief of mild to moderate pain such as headache, toothache, primary dysmenorrhea, backache, muscular pain. Anti-inflammatory and analgesic in arthritis and osteo arthritis.
2469	IBUFEN	IBUFEN 600	IBUPROFEN	IBUPROFEN 600MG	TABLETS	RECIEPT	For the relief of mild to moderate pain such as headache, toothache, primary dysmenorrhea, backache, muscular pain. Anti-inflammatory and analgesic in arthritis and osteo arthritis.
2471	IBULEVE	IBULEVE GEL 50GR	IBUPROFEN	IBUPROFEN 5%	GEL	RECIEPT	Topical analgesic and anti-inflammatory for backache, rheumatic and muscular pain, sprains, strains, sports injuries.
2470	IBULEVE	IBULEVE	IBUPROFEN	IBUPROFEN 5%W/W	GEL	RECIEPT	Anti inflammatory and antirheumatic for the local treatment of non infections pain and inflammation.
2473	IBUPRO	IBUPRO 200	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	For the relief of mild to moderate pain such as headache, toothache, primary dysmenorrhea, backache, muscular pain. Anti - inflammatory and relieves pain in reumatoid arthritis and osteo arthritis. For the reduction of fever. For the treatment of pain associated with migraine.
2474	IBUPRO	IBUPRO LIQUI - GELS 200	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti - inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.
2475	IBUPROFEN	IBUPROFEN 200MG 30 CAPLETS	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti - inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.
2477	IBUPROFEN	IBUPROFEN LIQUIGEL 200MG 20CA	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti - inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.
2476	IBUPROFEN	IBUPROFEN FORTE 400MG 30 CAPLETS	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.
2478	ICATIBANT	ICATIBANT TEVA	ICATIBANT AS ACETATE	ICATIBANT AS ACETATE 30MG/3ML	SOLUTION	RECIEPT	Icatibant Teva is indicated for symptomatic treatment of acute attacks of hereditary angioedima (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.
2479	ICHTHAMOL	ICHTHAMMOL OINTMENT	ICHTHYOL	ICHTHYOL 10%W/W	OINTMENT		For the disinfection of skin diseases.
2481	ICHTHAMOL	ICHTHAMOL OINT 14GR	ICHTYOL	ICHTYOL 10%	OINTMENT		For the disinfection of skin diseases.
2482	ICLUSIG	ICLUSIG 15 MG	PONATINIB AS HYDROCHLORIDE	PONATINIB AS HYDROCHLORIDE 15MG	TABLETS	RECIEPT	Iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
2487	ICLUSIG	ICLUSIG 30 MG	PONATINIB AS HYDROCHLORIDE	PONATINIB AS HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
2489	ICLUSIG	ICLUSIG 45 MG	PONATINIB AS HYDROCHLORIDE	PONATINIB AS HYDROCHLORIDE 45MG	TABLETS	RECIEPT	Iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
2493	IDELVION	IDELVION 1000 IU	ALBUTREPENONACOG ALFA	ALBUTREPENONACOG ALFA 1000 IU	POWDER		Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
2494	IDELVION	IDELVION 2000 IU	ALBUTREPENONACOG ALFA	ALBUTREPENONACOG ALFA 2000 IU	POWDER		Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
2495	IDELVION	IDELVION 250 IU	ALBUTREPENONACOG ALFA	ALBUTREPENONACOG ALFA 250 IU	POWDER		Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
2496	IDELVION	IDELVION 500 IU	ALBUTREPENONACOG ALFA	ALBUTREPENONACOG ALFA 500 IU	POWDER		Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
2497	IFO-CELL	IFO-CELL 2 G	IFOSFAMIDE	IFOSFAMIDE 2G/50ML	SOLUTION	RECIEPT	• Testicular tumours For combination chemotherapy in patients with advanced stage II to IV tumours according to the TNM classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy. • Cervical cancer Palliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, FIGO stage IV B (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy. • Breast cancer For palliative therapy in advanced, therapy-refractory or recurrent breast cancer. • Non-small-cell lung cancer For mono- or combination chemotherapy of patients with inoperable or metastatic tumours. • Small-cell lung cancer For combination chemotherapy. • Soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma) For mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. For mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy. • Ewing’s sarcoma For combination chemotherapy after failure of primary cytostatic therapy. • Non-Hodgkin’s lymphoma For combination chemotherapy in patients with highly malignant non-Hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. For combination therapy of patients with recurrent tumours. • Hodgkin’s disease For the treatment of patients with primary progressive forms and early relapse of Hodgkin’s disease (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radiochemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the MINE protocol.
2499	IFO-CELL	IFO-CELL 5 G	IFOSFAMIDE	IFOSFAMIDE 5G/25ML	CONCENTRATE	RECIEPT	• Testicular tumours For combination chemotherapy in patients with advanced stage II to IV tumours according to the TNM classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy. • Cervical cancer Palliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, FIGO stage IV B (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy. • Breast cancer For palliative therapy in advanced, therapy-refractory or recurrent breast cancer. • Non-small-cell lung cancer For mono- or combination chemotherapy of patients with inoperable or metastatic tumours. • Small-cell lung cancer For combination chemotherapy. • Soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma) For mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. For mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy. • Ewing’s sarcoma For combination chemotherapy after failure of primary cytostatic therapy. • Non-Hodgkin’s lymphoma For combination chemotherapy in patients with highly malignant non-Hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. For combination therapy of patients with recurrent tumours. • Hodgkin’s disease For the treatment of patients with primary progressive forms and early relapse of Hodgkin’s disease (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radiochemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the MINE protocol.
2501	IKACLOMIN	IKACLOMIN	CLOMIFENE CITRATE	CLOMIFENE CITRATE 50MG	TABLETS	RECIEPT	In women : ovulatory failure in patients desiring pregnancy.
2503	IKACOR	IKACOR 120 MG	VERAPAMIL HYDROCHLORIDE	VERAPAMIL HYDROCHLORIDE 120MG	TABLETS	RECIEPT	Angina pectoris, cardiac arrhythmias, hypertension.
2505	IKACOR	IKACOR 40 MG	VERAPAMIL HYDROCHLORIDE	VERAPAMIL HYDROCHLORIDE 40MG	TABLETS	RECIEPT	Angina pectoris, cardiac arrhythmias, hypertension.
2507	IKACOR	IKACOR 80 MG	VERAPAMIL HYDROCHLORIDE	VERAPAMIL HYDROCHLORIDE 80MG	TABLETS	RECIEPT	- Angina pectoris. - Cardiac arrhythmias. - Hypertension.
2509	IKAPRESS	IKAPRESS 180 MG	VERAPAMIL HYDROCHLORIDE	VERAPAMIL HYDROCHLORIDE 180MG	TABLETS	RECIEPT	Mild to moderate hypertention. Angina pectoris.
2511	IKAPRESS	IKAPRESS SR	VERAPAMIL HYDROCHLORIDE	VERAPAMIL HYDROCHLORIDE 240MG	TABLETS	RECIEPT	Mild to moderate hypertension. Angina pectoris.
2513	ILARIS	ILARIS 150 MG/ML	CANAKINUMAB	CANAKINUMAB 150MG/1ML	POWDER	RECIEPT	Periodic Fever Syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-Associated Periodic Syndromes (CAPS) Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents and children aged 2 years and older with body weight of 7.5 kg or above, including: • Muckle-Wells Syndrome (MWS), • Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), • Severe forms of Familial Cold Autoinflammatory Syndrome (FCAS) / Familial Cold Urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash. Tumour Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) Ilaris is indicated for the treatment of Tumour Necrosis Factor (TNF) receptor Associated Periodic Syndrome (TRAPS). Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) Ilaris is indicated for the treatment of Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD). Familial Mediterranean Fever (FMF) Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF) in patients in whom colchicine is contraindicated, is not tolerated, or does not provide an adequate response despite the highest tolerable dose of colchicine. Ilaris can be given as monotherapy or in combination with colchicine. Gouty arthritis: Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. Systemic Juvenile Idiopathic Arthritis (SJIA): ILARIS is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 4 years and older.
2514	ILARIS	ILARIS 150 MG/ML SOLUTION FOR INJECTION	CANAKINUMAB	CANAKINUMAB 150MG/1ML	SOLUTION	RECIEPT	Periodic Fever Syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-Associated Periodic Syndromes (CAPS) Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents and children aged 2 years and older with body weight of 7.5 kg or above, including: • Muckle-Wells Syndrome (MWS), • Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), • Severe forms of Familial Cold Autoinflammatory Syndrome (FCAS) / Familial Cold Urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash. Tumour Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) Ilaris is indicated for the treatment of Tumour Necrosis Factor (TNF) receptor Associated Periodic Syndrome (TRAPS). Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) Ilaris is indicated for the treatment of Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD). Familial Mediterranean Fever (FMF) Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF) in patients in whom colchicine is contraindicated, is not tolerated, or does not provide an adequate response despite the highest tolerable dose of colchicine. Ilaris can be given as monotherapy or in combination with colchicine. Gouty arthritis: Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. Systemic Juvenile Idiopathic Arthritis (SJIA): ILARIS is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 4 years and older.
2515	ILOMEDIN	ILOMEDIN	ILOPROST	ILOPROST 0.1MG/ML	CONCENTRATE	RECIEPT	Peripheral arterial occlusive disease (stage 3 and 4 of Fontaine's classification) in advanced arteriosclerosis, in whom surgery or angioplasty therapy is not possible. Thromboangitis obliterans (Buerger's disease) with critical limb ischemia in cases where revascularisation is not indicated and Severe disabling Raynaud's phenomenon .
2516	ILUVIEN	ILUVIEN	FLUOCINOLONE ACETONIDE	FLUOCINOLONE ACETONIDE 190MCG	INJECTION	RECIEPT	ILUVIEN is indication for the treatment of vision impairment associated with chronic diabetic macular edema (DME), considered insufficiently responsive to available therapies
2519	IMATINIB	IMATINIB TEVA 100 MG	IMATINIB AS MESYLATE	IMATINIB AS MESYLATE 100MG	TABLETS	RECIEPT	For the treatment of adult patients and children 3 years of age and above with Ph+ chronic myeloid leukaemia (Ph+ -CML) in chronic phase accelerated phase or blast crisis. Imatinib Teva is also indicated for the treament of : Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult patients with relapsed or refractory Ph + ALL as monotherapy. Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. Adult patients with myelodyspiastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR ( platelet - derived growth factor receptor ) gene re- arrangements. Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) who have the FIP1L1- PDGFRalfa fusion kinase (mutational analysis or FISH demonstration fo CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alfa fusion kinase negative . Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-kit mutation.
2521	IMATINIB	IMATINIB TEVA 400 MG	IMATINIB AS MESYLATE	IMATINIB AS MESYLATE 400MG	TABLETS	RECIEPT	For the treatment of adult patients and children 3 years of age and above with Ph+ chronic myeloid leukaemia (Ph+ -CML) in chronic phase accelerated phase or blast crisis. Imatinib Teva is also indicated for the treament of : Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult patients with relapsed or refractory Ph + ALL as monotherapy. Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. Adult patients with myelodyspiastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR ( platelet - derived growth factor receptor ) gene re- arrangements. Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) who have the FIP1L1- PDGFRalfa fusion kinase (mutational analysis or FISH demonstration fo CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alfa fusion kinase negative . Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-kit mutation.
2517	IMATINIB	IMATINIB - TRIMA 100 MG	IMATINIB AS MESYLATE	IMATINIB AS MESYLATE 100MG	TABLETS	RECIEPT	Imatinib - Trima 100mg is indicated for the treatment of adult patients and children 3 years of age and above with Ph+ chronic myeloid leukaemia (Ph+ -CML) in chronic phase, accelerated phase or blast crisis. Imatinib - Trima 100mg is also indicated for the treament of : - Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. - Adult patients with relapsed or refractory Ph + ALL as monotherapy. - Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. - Adult patients with myelodyspiastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR ( platelet - derived growth factor receptor ) gene re- arrangements. - Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) who have the FIP1L1- PDGFRalfa fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alfa fusion kinase negative . - Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-kit mutation .
2518	IMATINIB	IMATINIB - TRIMA 400 MG	IMATINIB AS MESYLATE	IMATINIB AS MESYLATE 400MG	TABLETS	RECIEPT	Imatinib - Trima 400mg is indicated for the treatment of adult patients and children 3 years of age and above with Ph+ chronic myeloid leukaemia (Ph+ -CML) in chronic phase, accelerated phase or blast crisis. Imatinib - Trima 400mg is also indicated for the treament of : - Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. - Adult patients with relapsed or refractory Ph + ALL as monotherapy. - Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. - Adult patients with myelodyspiastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR ( platelet - derived growth factor receptor ) gene re- arrangements. - Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) who have the FIP1L1- PDGFRalfa fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alfa fusion kinase negative . - Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-kit mutation .
2523	IMBRUVICA	IMBRUVICA	IBRUTINIB	IBRUTINIB 140MG	CAPSULES	RECIEPT	* Mantle Cell Lymphoma: Imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. * Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma : Imbruvica is indicated for the first line treatment of adult patients, 65 years of age or older, with chronic lymphocytic leukemia (CLL)/SLL Imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior. * Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma with 17p deletion: Imbruvica is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) /Small Lymphocytic Lymphoma with 17p deletion. * Waldenström’s Macroglobulinemia : Imbruvica is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) .
2526	IMFINZI	IMFINZI 120 MG/2.4 ML	DURVALUMAB	DURVALUMAB 120MG/2.4ML	SOLUTION	RECIEPT	Urothelial Carcinoma: IMFINZI is indicated for the treatment of patients with PD-L1 high (Tumor cell ≥ 25% or IC ≥ 25%) locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy. Non-Small Cell Lung Cancer: IMFINZI is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
2527	IMFINZI	IMFINZI 500 MG/10 ML	DURVALUMAB	DURVALUMAB 500MG/10ML	SOLUTION	RECIEPT	Urothelial Carcinoma: IMFINZI is indicated for the treatment of patients with PD-L1 high (Tumor cell ≥ 25% or IC ≥ 25%) locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy. Non-Small Cell Lung Cancer: IMFINZI is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
2530	IMITREX	IMITREX TABLETS 100 MG	SUMATRIPTAN AS SUCCINATE	SUMATRIPTAN AS SUCCINATE 100MG	TABLETS	RECIEPT	Imitrex tablets are indicated for the acute relief of migraine attacks, with or without aura. Imitrex should only be used where there is a clear diagnosis of migraine.
2531	IMITREX	IMITREX TABLETS 50 MG	SUMATRIPTAN AS SUCCINATE	SUMATRIPTAN AS SUCCINATE 50MG	TABLETS	RECIEPT	Imitrex tablets are indicated for the acute relief of migraine attacks, with or without aura. Imitrex should only be used where there is a clear diagnosis of migraine.
2528	IMITREX	IMITREX INJECTION	SUMATRIPTAN AS SUCCINATE	SUMATRIPTAN AS SUCCINATE 6MG/0.5ML	SOLUTION	RECIEPT	Subcutaneous Injection is indicated for the acute relief of migraine attacks, with or without aura, and for the acute treatment of cluster headache. Imitrex should only be used where there is a clear diagnosis of migraine or cluster headache.
2529	IMITREX SPRAY	IMITREX NASAL SPRAY 20 MG	SUMATRIPTAN	SUMATRIPTAN 20MG/0.1ML	SOLUTION	RECIEPT	Imitrex nasal spray is indicated for the acute treatment of migraine attacks with or without aura.
2532	IMLYGIC	IMLYGIC 10^ 6 PFU/ML	TALIMOGENE LAHERPAREPVEC	TALIMOGENE LAHERPAREPVEC 10^6PFU/1ML	SOLUTION	RECIEPT	Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic ( stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
2533	IMLYGIC	IMLYGIC 10^ 8 PFU/ML	TALIMOGENE LAHERPAREPVEC	TALIMOGENE LAHERPAREPVEC 10^8PFU/1ML	SOLUTION	RECIEPT	Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic ( stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
2534	IMNOVID	IMNOVID 1 MG	POMALIDOMIDE	POMALIDOMIDE 1MG	CAPSULES	RECIEPT	Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
2540	IMNOVID	IMNOVID 2 MG	POMALIDOMIDE	POMALIDOMIDE 2MG	CAPSULES	RECIEPT	Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
2546	IMNOVID	IMNOVID 3 MG	POMALIDOMIDE	POMALIDOMIDE 3MG	CAPSULES	RECIEPT	Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
2552	IMNOVID	IMNOVID 4 MG	POMALIDOMIDE	POMALIDOMIDE 4MG	CAPSULES	RECIEPT	Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
2558	IMODIUM	IMODIUM 2MG 10 CAPSULES	LOPERAMIDE HCL	LOPERAMIDE HCL 2MG	CAPSULES		Control and symptomatic relief of acute diarrhea.
2559	IMODIUM	IMODIUM CAPSULES	LOPERAMIDE HYDROCHLORIDE	LOPERAMIDE HYDROCHLORIDE 2MG	CAPSULES	RECIEPT	Control and symptomatic relief of acute diarrhea.
2560	IMOVANE	IMOVANE	ZOPICLONE	ZOPICLONE 7.5MG	TABLETS	RECIEPT	Hypnotic when the disorder of insomnia is severe and disabling.
2561	IMOVAX DT	IMOVAX DT	DIPHTHERIA TOXOID	DIPHTHERIA TOXOID 2 IU/0.5ML;TETANUS TOXOID 20 IU/0.5ML;ALUMINIUM HYDROXIDE 0.6MG/0.5ML	SUSPENSION	RECIEPT	This vaccine is indicated for adults over 18 years of age in the following cases: - routine booster vaccinations against diphtheria and tetanus. The diphtheria toxoid content is reduced to one tenth of the normal dose to minimize the risks of a severe hypersensitivity reaction. - primary vaccination. - post-exposure prophylaxis following a tetanus-prone wound, if a booster diphtheria injection is required. This adsorbed diphtheria and tetanus vaccine may be administered as a booster vaccination in children over 10 years of age in whom poliomyelitis is prevented by separate administration of poliomyelitis vaccine.
2562	IMOVAX POLIO	IMOVAX POLIO	POLIOVIRUS TYPE	POLIOVIRUS TYPE 1 INACTIVATED 40U/VIAL;POLIOVIRUS TYPE 2 INACTIVATED 8U/VIAL;POLIOVIRUS TYPE 3 INACTIVATED 32U/VIAL	SUSPENSION	RECIEPT	Prophylaxis of poliomyelitis.
2563	IMPAVIDO	IMPAVIDO 10 MG	MILTEFOSINE	MILTEFOSINE 10MG	CAPSULES	RECIEPT	-Treatment of visceral Leishmaniasis caused by Leishmania donovani. -Treatment of cutaneous Leishmaniasis caused by Leishmania brasiliensis complex or Leishmania mexicana complex.
2565	IMPAVIDO	IMPAVIDO 50 MG	MILTEFOSINE	MILTEFOSINE 50MG	CAPSULES	RECIEPT	-Treatment of visceral Leishmaniasis caused by Leishmania donovani. -Treatment of cutaneous Leishmaniasis caused by Leishmania brasiliensis complex or Leishmania mexicana complex.
2567	IMURAN	IMURAN TABLETS 25 MG	AZATHIOPRINE	AZATHIOPRINE 25MG	TABLETS	RECIEPT	Immunosuppressive agent used in transplantation surgery for suppression of graft rejection. For special cases of rheumatoid arthritis- not responsive to other agents- and only by rheumatology experts in hospitals or rheumatic clinics.
2568	IMURAN	IMURAN TABLETS 50 MG	AZATHIOPRINE	AZATHIOPRINE 50MG	TABLETS	RECIEPT	Immunosupressive agent used in transplantation surgery for suppression of Graft rejection. For special cases of rheumatoid artritis, not responsive to other agents, and only by rheumatology experts in hospitals or rheumatic clinics.
2569	INCRELEX	INCRELEX	MECASERMIN	MECASERMIN 10MG/1ML	SOLUTION	RECIEPT	For the long-term treatment of growth failure in children and adolescents from 2 to 18 years with severe primary insulin-like growth factor-1 deficiency (Primary IGFD). Severe Primary IGFD is defined by: • height standard deviation score ≤ –3.0 and • basal IGF-1 levels below the 2.5th percentile for age and gender and • GH sufficiency. • Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. In some cases, when deemed necessary, the physician may decide to assist in the diagnosis by performing an IGF-I generation test.
2570	INCRUSE ELLIPTA	INCRUSE ELLIPTA 55 MCG	UMECLIDINIUM	UMECLIDINIUM 55MCG	POWDER	RECIEPT	INCRUSE is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
2571	INDOCOLLYRE	INDOCOLLYRE O.1 % EYE DROPS	INDOMETHACIN	INDOMETHACIN 0.1%	DROPS	RECIEPT	Inhibition of myosis during surgery. Prevention of inflammation subsequent to cataract surgery or surgery of the anterior chamber of the eye. Treatment of ocular pain following photorefractive keratectomy for the first few days after surgery.
2572	INDOVIS	INDOVIS CAPSULES	INDOMETHACIN	INDOMETHACIN 25MG	CAPSULES	RECIEPT	Non steroidal anti-inflammatory indicated for the active stages of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, degenerative joint disease of the hip, acute muscoloskeletal disorders, low back pain.
2573	INFANRIX	INFANRIX	DIPHTHERIA TOXOID NLT	DIPHTHERIA TOXOID NLT 30 IU D;TETANUS TOXOID NLT 40 IU T;PERTACTIN 8MCG/0.5ML 69 KDA Outer membrane protein-PRN;FILAMENTOUS HAEMAGGLUTININ (FHA) 25MCG/0.5ML;PERTUSSIS TOXOID (PT) 25MCG/0.5ML	SUSPENSION	RECIEPT	Infanrix is indicated as a booster dose for children 15 months to 7 years of age who have previously been immunised with three or four doses of either DTPa vaccine or diphtheria, tetanus and whole-cell pertussis (DTPw) vaccine. Active primary immunisation against diphteria, tetanus and pertussis from the age 2 months onward.
2575	INFANRIX	INFANRIX IPV HIB	DIPHTHERIA TOXOID NLT	DIPHTHERIA TOXOID NLT 30 IU/0.5ML;INACTIVATED POLIO VIRUS (IPV) TYPE 3 32DU/0.5ML;INACTIVATED POLIO VIRUS (IPV) TYPE 2 8DU/0.5ML;INACTIVATED POLIO VIRUS (IPV) TYPE 1 40DU/0.5ML;PERTUSSIS TOXOID (PT) 25MCG/0.5ML;FILLAMENTOUS HAEMAGGLUTININ (FHA) 25MCG/0.5ML;PERTACTIN 8MCG/0.5ML oter membrane protein;TETANUS TOXOID NLT 40 IU/0.5ML;HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE 10MCG/0.5ML	POWDER	RECIEPT	Active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and Haemophilus influenza type b. Booster dose for children who have previously been immunised with DTP, Polio and Hib antigens
2574	INFANRIX	INFANRIX HEXA	FILAMENTOUS HAEMAGGLUTININ (FHA)	FILAMENTOUS HAEMAGGLUTININ (FHA) 25MCG/DOSE;DIPHTHERIA TOXOID NLT 30IU/DOSE D;TETANUS TOXOID NLT 40IU/DOSE T;HEPATITIS B VACCINES 10MCG/DOSE r-DNA HEPATITIS B SURFACE ANTIGEN ( HBsAg);POLIOVIRUS TYPE 1 INACTIVATED 40DU/DOSE;POLIOVIRUS TYPE 2 INACTIVATED 8DU/DOSE;POLIOVIRUS TYPE 3 INACTIVATED 32DU/DOSE;HAEMOPHILUS B 10MCG/DOSE INFLUENZA TYPE B CAPSULAR;PERTACTIN 8MCG/DOSE 69 kDA Outer membrane protein - PRN;PERTUSSIS TOXOID (PT) 25MCG/DOSE	SUSPENSION	RECIEPT	Infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by haemophilus influenza type b for infants between 6 weeks and 36 months of age.
2576	INFASURF	INFASURF	CALFACTANT AS PHOSPHOLIPID	CALFACTANT AS PHOSPHOLIPID 35MG/ML	SUSPENSION	RECIEPT	Infasurf is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment (caretrescuecaret) of premature infants who develop RDS. Infasurf decreases the incidence of RDS mortality due to RDS and air leaks associated with RDS. Prophylaxis : Prophylaxis therapy at birth with Infasurf is indicated for premature infants <29 weeks of gestational age at significant risk for RDS. Infasurf prophylaxis should be administered as soon as possible preferably within 30 minutes after birth. Treatment: Infasurf therapy is indicated for infants 72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.
2578	INFLUVAC	INFLUVAC TETRA	A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE VIRUS	A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE VIRUS 15MCG/0.5ML;A/HONG KONG/4801/2014 (H3N2) - LIKE VIRUS 15MCG/0.5ML;B/PHUKET/3073/2013 LIKE VIRUS 15MCG/0.5ML;B/BRISBANE/60/2008 - LIKE VIRUS 15MCG/0.5ML	SUSPENSION	RECIEPT	Prophylaxis of influenza, especially those who run an increased risk of associated complications. Influvac Tetra is indicated in adults (18 years of age and older).
2577	INFLUVAC	INFLUVAC	B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE)	B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) 15MCG/DOSE;A/KANSAS/14/2017 (H3N2) LIKE VIRUS 15MCG/DOSE;A/BRISBANE/02/2018(H1N1)PDM09-LIKE VIRUS 15MCG/DOSE	SUSPENSION	RECIEPT	Influenza virus vaccine.
2579	INGESTANTS EXTRACTS	INGESTANTS EXTRACTS	FOOD EXTRACT	FOOD EXTRACT אוסף אלרגנים	SOLUTION	RECIEPT	Skin testing and immunotherapy.
2580	INHALANTS EPIDERMAL EXTRACS	INHALANTS AND EPIDERMAL EXTRACS	INHALANTS,EPIDERMAL EXTRACTS	INHALANTS,EPIDERMAL EXTRACTS אוסף אלרגנים	SOLUTION	RECIEPT	Skin testing and Immunotherapy.
2581	INLYTA	INLYTA 1 MG	AXITINIB	AXITINIB 1MG	TABLETS	RECIEPT	For the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
2582	INLYTA	INLYTA 5 MG	AXITINIB	AXITINIB 5MG	TABLETS	RECIEPT	For the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
2585	INOTYOL	INOTYOL OINT 50GR	ICHTHAMMOL	ICHTHAMMOL 1.474 G;ZINC OXIDE 14.763 G;TITANIUM 5.905 G;BENZOIN SIAM 0.1 G;HAMAMELIS 0.984 G/100 G	OINTMENT		Local treatment of eczema, feet ulcers, mild burns and skin irritations.
2583	INOTYOL	INOTYOL	ICHTHAMMOL	ICHTHAMMOL 1.474G/100 G;ZINC OXIDE 14.763G/100 G;HAMAMELIS 0.984G/100 G;BENZOIN SIAM 0.1G/100 G;TITANIUM DIOXIDE 5.905G/100 G	OINTMENT		Local treatment of eczema, feet ulcers, mild burns and skin irritations.
2586	INOVELON	INOVELON 100 MG TABLETS	RUFINAMIDE	RUFINAMIDE 100MG	TABLETS	RECIEPT	Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 1 year of age and older.
2587	INOVELON	INOVELON 200 MG TABLETS	RUFINAMIDE	RUFINAMIDE 200MG	TABLETS	RECIEPT	Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 1 year of age and older.
2588	INOVELON	INOVELON 400 MG TABLETS	RUFINAMIDE	RUFINAMIDE 400MG	TABLETS	RECIEPT	Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 1 year of age and older.
2589	INSECTS EXTRACTS	INSECTS EXTRACTS	INSECTS EXTRACTS	INSECTS EXTRACTS אוסף אלרגנים	SOLUTION	RECIEPT	Skin testing and immunotherapy.
2590	INSPRA	INSPRA 25 MG	EPLERENONE	EPLERENONE 25MG	TABLETS	RECIEPT	Inspra is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF < or = 40 % ) and clinical evidence of heart failure after recent myocardial infarction. Inspra is indicated in addition to standard optimal therapy, to reduce the risk of cardiovascular morbidity and mortality in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF < or = 30%).
2591	INSPRA	INSPRA 50 MG	EPLERENONE	EPLERENONE 50MG	TABLETS	RECIEPT	Inspra is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF < or = 40 % ) and clinical evidence of heart failure after recent myocardial infarction. Inspra is indicated in addition to standard optimal therapy, to reduce the risk of cardiovascular morbidity and mortality in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF < or = 30%).
2592	INSTILLAGEL	INSTILLAGEL	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 0.5MG/1 G;LIDOCAINE HYDROCHLORIDE 20.0MG/1 G	GEL	RECIEPT	Local anesthesia prior exploration in urology (ureteroscopy, cystoscopy, urethral dilation, catheterization). For use during gynaecological investigation.
2593	INSULATARD	INSULATARD PENFILL	INSULIN (HUMAN)	INSULIN (HUMAN) 100IU/ML	SUSPENSION	RECIEPT	Insulatard is indicated for treatment of diabetes mellitus
2594	INSULATARD	INSULATARD VIAL	INSULIN (HUMAN)	INSULIN (HUMAN) 100IU/ML	SUSPENSION	RECIEPT	Treatment of diabetes mellitus.
2595	INTEGRILIN	INTEGRILIN 0.75 MG/ML	EPTIFIBATIDE	EPTIFIBATIDE 0.75MG/ML	SOLUTION	RECIEPT	Integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. Integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. Integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). Integrilin is intended for use with aspirin and heparin.
2596	INTEGRILIN	INTEGRILIN 2 MG/ML	EPTIFIBATIDE	EPTIFIBATIDE 2MG/ML	SOLUTION	RECIEPT	Integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. Integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. Integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). Integrilin is intended for use with aspirin and heparin.
2597	INTELENCE	INTELENCE 100 MG	ETRAVIRINE	ETRAVIRINE 100MG	TABLETS	RECIEPT	Intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. Treatment history and when available resistance testing should guide the use of Intelence. In patients who have experienced virological failure on an NNRTI- and nucleoside or nucleotide reverse transcriptase inhibitor (N[t]RTI) - containing regimen Intelence is not recommended for use in combination with N(t)RTIs only.
2598	INTELENCE	INTELENCE 200 MG	ETRAVIRINE	ETRAVIRINE 200MG	TABLETS	RECIEPT	Intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. Treatment history and when available resistance testing should guide the use of Intelence. In patients who have experienced virological failure on an NNRTI- and nucleoside or nucleotide reverse transcriptase inhibitor (N[t]RTI)- containing regimen Intelence is not recommended for use in combination with N(t)RTIs only.
2599	INTRALIPID	INTRALIPID 20 %	SOYA OIL	SOYA OIL 200G/1000ML	EMULSION	RECIEPT	Intralipid is indicated for patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake. Intralipid should be used to supply energy and essential fatty acids in adult patients needing intravenous nutrition.
2601	INTRATECT	INTRATECT 50 g/l	HUMAN PLASMA PROTEIN	HUMAN PLASMA PROTEIN 50MG/1ML	SOLUTION		Replacement therapy in adults, and children and adolescents (0-18 years) in: - Primary immunodeficiency syndromes with impaired antibody production. - Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed. - Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation. - Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT). - Congenital AIDS with recurrent bacterial infections. Immunomodulation in adults, and children and adolescents (0-18 years) in: - Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - Guillain Barré syndrome. - Kawasaki disease.
2600	INTRATECT	INTRATECT 100 G/L	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 100MG/1ML	SOLUTION	RECIEPT	Replacement therapy in adults, and children and adolescents (0-18 years) in: - Primary immunodeficiency syndromes with impaired antibody production. - Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed. - Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation. - Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT). - Congenital AIDS with recurrent bacterial infections. Immunomodulation in adults, and children and adolescents (0-18 years) in: - Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - Guillain Barré syndrome. - Kawasaki disease.
2602	INVANZ	INVANZ	ERTAPENEM AS SODIUM	ERTAPENEM AS SODIUM 1G/VIAL	POWDER	RECIEPT	Invanz is indicated for the treatment of adult patients and pediatric patients ( 3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms. - Complicated intra-abdominal infections. - Complicated skin and skin structure infections including diabetic foot infections without osteomyelitis. - Community acquired pneumonia. - Complicated urinary tract infections including pyelonephritis. Acute pelvic infections including postpartum endomyometritis septic abortion and post surgical gynecologic infections.
2603	INVEGA	INVEGA 3 MG	PALIPERIDONE	PALIPERIDONE 3MG	TABLETS	RECIEPT	Invega is indicated for : -treatment of schizophrenia in adults and adolescents (12-17 years). -acute treatment of schizoaffective disorder as monotherapy -acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants
2604	INVEGA	INVEGA 6 MG	PALIPERIDONE	PALIPERIDONE 6MG	TABLETS	RECIEPT	Invega is indicated for : - treatment of schizophrenia in adults and adolescents (12-17 years). -acute treatment of schizoaffective disorder as monotherapy -acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants
2605	INVEGA	INVEGA 9 MG	PALIPERIDONE	PALIPERIDONE 9MG	TABLETS	RECIEPT	Invega is indicated for : - treatment of schizophrenia in adults and adolescents (12-17 years). -acute treatment of schizoaffective disorder as monotherapy -acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants
2606	INVOKANA	INVOKANA 100 MG	CANAGLIFLOZIN	CANAGLIFLOZIN 100MG	TABLETS	RECIEPT	Invokana is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Invokana is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
2607	INVOKANA	INVOKANA 300 MG	CANAGLIFLOZIN	CANAGLIFLOZIN 300MG	TABLETS	RECIEPT	Invokana is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Invokana is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
2608	IODICARE	IODICARE OINTMENT	POVIDONE-IODINE	POVIDONE-IODINE 10%	OINTMENT		Desinfection of wounds, scratches, minor burns and skin infections.
2609	IODICARE	IODICARE SOLUTION	POVIDONE-IODINE	POVIDONE-IODINE 10%W/V	SOLUTION		Antiseptic for treatment of wounds, skin infections in cases of mycosis, trichomonas and infections caused by sensitive microorganisms.
2612	IODIFLOR	IODIFLOR OINTMENT 15 GR	POVIDONE IODINE	POVIDONE IODINE 10%	OINTMENT		For the disinfection of skin infections and inflammations, wounds and superficial burns.
2613	IODIFLOR	IODIFLOR OINTMENT 250MG	POVIDONE IODINE	POVIDONE IODINE 10%	OINTMENT		For the disinfection of skin infections and inflammations, wounds and superficial burns.
2614	IODIFLOR	IODIFLOR OINTMENT 50 GR	POVIDONE IODINE	POVIDONE IODINE 10%	OINTMENT		For the disinfection of skin infections and inflammations, wounds and superficial burns.
2616	IODIFLOR	IODIFLOR SOL 1 LITER	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic, disinfection of infected skin, superficial wounds and burns.
2617	IODIFLOR	IODIFLOR SOL 20ML	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic, disinfection of infected skin, superficial wounds and burns.
2610	IODIFLOR	IODIFLOR CLEAN.200ML	POVIDONE IODINE	POVIDONE IODINE 7.5%	SOLUTION		Antiseptic for treatment of wounds, skin infections and vaginal douche in cases of mycosis, trichomonas and infections caused by sensitive microorganisms.
2611	IODIFLOR	IODIFLOR OINTMENT	POVIDONE-IODINE	POVIDONE-IODINE 10%	OINTMENT		For the disinfection of skin infections and inflammations, wounds and superficial burns.
2618	IODIFLOR	IODIFLOR SOLUTION	POVIDONE-IODINE	POVIDONE-IODINE 10%	SOLUTION		Antiseptic, disinfection of infected skin, superficial wounds and burns.
2615	IODIFLOR	IODIFLOR SOAP CLEANSER	POVIDONE-IODINE	POVIDONE-IODINE 7.5%	LOTION		Antiseptic , disinfection of infected skin superficial wounds and burns.
2620	IODINE	IODINE TINCTURE FLORIS	IODINE	IODINE 2.5%;POTASSIUM IODIDE 2.5%	LIQUID		Antiseptic for local application.
2619	IODINE	IODINE TINCTURE 10ML	IODINE	IODINE 2.5%;POTASSIUM IODINE 2.5%	DROPS		Antiseptic for local application.
2621	IODISPRAY	IODISPRAY	POVIDONE-IODINE	POVIDONE-IODINE 10%	SOLUTION		Skin antiseptic for wounds and mild burns.
2622	IODO-VIT	IODO-VIT OINT 15GR	POVIDONE IODINE	POVIDONE IODINE 10%	OINTMENT		Disinfection of wounds, scratches, minor burns and skin infections.
2623	IODO-VIT	IODO-VIT OINT 250GR	POVIDONE IODINE	POVIDONE IODINE 10%	OINTMENT		Disinfection of wounds, scratches, minor burns and skin infections.
2625	IODO-VIT	IODO-VIT SOL 1L	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic for treatment of wounds, skin infections and vaginal douche in cases of mycosis, trichomonas and infections caused by sensitive microorganisms.
2626	IODO-VIT	IODO-VIT SOL.20ML	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic for treatment of wounds, skin infections and vaginal douche in cases of mycosis, trichomonas and infections caused by sensitive microorganisms.
2628	IODO-VIT	IODO-VIT SOLUTION 300ML	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic for treatment of wounds, skin infections and vaginal douche in cases of mycosis, trichomonas and infections caused by sensitive microorganisms.
2624	IODO-VIT	IODO-VIT OINTMENT	POVIDONE-IODINE	POVIDONE-IODINE 10%	OINTMENT		Disinfection of wounds, scratches, minor burns and skin infections.
2627	IODO-VIT	IODO-VIT SOLUTION	POVIDONE-IODINE	POVIDONE-IODINE 10%W/V	SOLUTION		Antiseptic for treatment of wounds, skin infections and vaginal douche in cases of mycosis, trichomonas and infections caused by sensitive microorganisms.
2631	IOMERON	IOMERON 300	IOMEPROL	IOMEPROL 61.24 G/100ML	SOLUTION	RECIEPT	Contrast medium for diagnostic radiology. Intravenous urography ( in adults and paediatrics), peripheral phlebography, CT (brain and body), cavernosography, intravenous DSA, conventional angiography, intraarterial DSA, angiocardiography (in adults and paediatrics), conventional selective coronary arteriography, interventional coronary arteriography, ERCP, arthrography, hysterosalpingography, fistulography, discography, galactography, chloangiography, dacryocystography, sialography, retrograde urethrography, retrograde pyelo-ureterography.
2632	IOMERON	IOMERON 350	IOMEPROL	IOMEPROL 71.44%W/V	SOLUTION	RECIEPT	Contrast medium for diagnostic radiography. Intravenous urography (in adults and pediatrics), CT (body), intravenous DSA, conventional angiography, intraarterial DSA, angiocardiography (in adults and pediatrics), conventional selective coronary arteriography, interventional coronary arteriography , arthrography, hysterosalpingography, fistulography, galactography, retrograde chloangiography, dacryocystography, sialography.
2633	IOMERON	IOMERON 400	IOMEPROL	IOMEPROL 81.65%W/V	SOLUTION	RECIEPT	Contrast medium for diagnostic radiography. Intravenous urography (in adults ,including those with renal impairment or diabetes), CT (body), conventional angiography, intraarterial DSA, angiocardiography (in adults and pediatrics), conventional selective coronary arteriography, interventional coronary , arthrography, fistulography, galactography, dacryocystography, sialography.
2634	IOPAMIRO	IOPAMIRO 150	IOPAMIDOL	IOPAMIDOL 306.2MG/ML	SOLUTION	RECIEPT	X-ray contrast medium in neuroradiology, angiography, urography, ct scanning, arthrography, fistulography and pediatric radiology.
2635	IOPAMIRO	IOPAMIRO 300	IOPAMIDOL	IOPAMIDOL 612.4MG/ML	SOLUTION	RECIEPT	X-ray contrast medium in neuroradiology, angiography, urography, ct scanning, arthrography and fistulography
2636	IOPAMIRO	IOPAMIRO 370	IOPAMIDOL	IOPAMIDOL 755.3G/100ML	SOLUTION	RECIEPT	X-ray contrast medium in neuroradiology, angiography, urography, ct scanning, arthrography and fistulography
2637	IOPIDINE	IOPIDINE 0.5 %	APRACLONIDINE AS HYDROCHLORIDE	APRACLONIDINE AS HYDROCHLORIDE 5MG/ML	SOLUTION	RECIEPT	Short term adjunctive therapy in patients on maximally tolerated medical therapy who require additional itraocular pressure reduction.
2638	IPECAC	IPECAC	IPECACUANHA	IPECACUANHA 2.1G/30ML	SYRUP	RECIEPT	To induce vomiting in cases of poisoning from drugs or chemicals.
2639	IRESSA	IRESSA	GEFITINIB	GEFITINIB 250MG	TABLETS	RECIEPT	Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.
2641	IRINOTECAN	IRINOTECAN ACTAVIS 20MG/ML	IRINOTECAN HYDROCHLORIDE TRIHYDRATE	IRINOTECAN HYDROCHLORIDE TRIHYDRATE 20MG/ML	CONCENTRATE	RECIEPT	For the treatment of patients with metastatic colorectal cancer: In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. For the treatment of patients with small cell lung cancer. For the treatment of patients with gastric cancer.
2642	IRON	IRON CARE	IRON AS IRON III HYDROXIDE POLYMALTOSE COMPL.	IRON AS IRON III HYDROXIDE POLYMALTOSE COMPL. 50MG/5ML	SYRUP		Prevention and treatment of iron deficiency anemia.
2645	ISENTRESS	ISENTRESS 400 MG TABLETS	RALTEGRAVIR AS POTASSIUM	RALTEGRAVIR AS POTASSIUM 400MG	TABLETS	RECIEPT	Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. This indication is based on safety and efficacy data from two double-blind, placebo-controlled trials in treatment-experienced patients and one double-blind, active-controlled trial in treatment-naive patients.
2647	ISENTRESS	ISENTRESS 600 MG TABLETS	RALTEGRAVIR AS POTASSIUM SALT	RALTEGRAVIR AS POTASSIUM SALT 600MG	TABLETS	RECIEPT	ISENTRESS 600 mg tablets is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults.
2649	ISOCAINE	ISOCAINE 3 %	MEPIVACAINE HYDROCHLORIDE	MEPIVACAINE HYDROCHLORIDE 30MG/ML	SOLUTION	RECIEPT	Production of local anesthesia for dental procedures by infiltration or nerve block in adults and children.
2650	ISOFLURANE	ISOFLURANE USP, TERRELL TM	ISOFLURANE	ISOFLURANE 100%	LIQUID	RECIEPT	General inhalation anesthetic.
2651	ISOGEN	ISOGEN CREAM	ISOCONAZOLE NITRATE	ISOCONAZOLE NITRATE 1%	CREAM	RECIEPT	For fungal infections of hairless and hairy skin.
2652	ISOGEN	ISOGEN CREAM 20G	ISOCONAZOLE NITRATE	ISOCONAZOLE NITRATE 1%	CREAM	RECIEPT	For fungal infections of hairless and hairy skin.
2654	ISOKET	ISOKET SPRAY	ISOSORBIDE DINITRATE	ISOSORBIDE DINITRATE 1.25MG/DOSE	SPRAY	RECIEPT	Angina pectoris, congestive heart failure.
2653	ISOKET	ISOKET 0.1 % AMPOULES	ISOSORBIDE DINITRATE	ISOSORBIDE DINITRATE 1MG/ML	SOLUTION	RECIEPT	Isoket 0.1% is indicated in the treatment of unresponsive left ventricular failure secondary to acute myocardial infarction, unresponsive left ventricular failure of various aetiology and severe or unstable angina pectoris.
2655	ISTODAX	ISTODAX	ROMIDEPSIN	ROMIDEPSIN 10MG/VIAL	POWDER	RECIEPT	• Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. • Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.
2656	ITRANOL	ITRANOL	ITRACONAZOLE	ITRACONAZOLE 100MG	CAPSULES	RECIEPT	Blastomycosis (pulmonary and extrapulmonary). Histoplasmosis. Onchomycosis caused by dermatophytes and/or yeast. Dermatomycoses. Vulvovaginal candidosis. Oral candidosis.
2660	IXEL	IXEL 25 MG	MILNACIPRAN HYDROCHLORIDE	MILNACIPRAN HYDROCHLORIDE 25MG	CAPSULES	RECIEPT	Treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.
2661	IXEL	IXEL 50 MG	MILNACIPRAN HYDROCHLORIDE	MILNACIPRAN HYDROCHLORIDE 50.0MG	CAPSULES	RECIEPT	Treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.
2662	IXIARO	IXIARO	JAPANESE ENCEPHALITIS PURIFIED INACTIVATED VACCINE	JAPANESE ENCEPHALITIS PURIFIED INACTIVATED VACCINE 6AU/0.5ML	SUSPENSION	RECIEPT	Ixiaro is indicated for active immunization against Japanese encephalitis in adults, adolescents, children and infants aged 2 months and older. Ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.
2663	IXIFI	IXIFI	INFLIXIMAB	INFLIXIMAB 100MG	POWDER	RECIEPT	Rheumatoid arthritis: IXIFI, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: • adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs),including methotrexate, has been inadequate. • adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X ray, has been demonstrated. * Ankylosing spondylitis: IXIFI is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy. * Psoriatic arthritis: IXIFI is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. * IXIFI should be administered: • in combination with methotrexate • or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. Infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease. * Psoriasis: IXIFI is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A (PUVA) * Adult Crohn’s disease IXIFI is indicated for treatment : • of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. • treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy). * Ulcerative colitis • IXIFI is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
2664	JAKAVI	JAKAVI 10 MG	RUXOLITINIB AS PHOSPHATE	RUXOLITINIB AS PHOSPHATE 10MG	TABLETS	RECIEPT	* Myelofibrosis (MF) Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * Polycythaemia vera (PV) Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
2665	JAKAVI	JAKAVI 15 MG	RUXOLITINIB AS PHOSPHATE	RUXOLITINIB AS PHOSPHATE 15MG	TABLETS	RECIEPT	* Myelofibrosis (MF) Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * Polycythaemia vera (PV) Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
2666	JAKAVI	JAKAVI 20 MG	RUXOLITINIB AS PHOSPHATE	RUXOLITINIB AS PHOSPHATE 20MG	TABLETS	RECIEPT	* Myelofibrosis (MF) Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * Polycythaemia vera (PV) Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
2667	JAKAVI	JAKAVI 5 MG	RUXOLITINIB AS PHOSPHATE	RUXOLITINIB AS PHOSPHATE 5MG	TABLETS	RECIEPT	* Myelofibrosis (MF) Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * Polycythaemia vera (PV) Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
2668	JANESS	JANESS	LEVONORGESTREL	LEVONORGESTREL 13.5MG	INTRAUTERINE DEVICE	RECIEPT	Contraception for up to 3 years.
2670	JANUET	JANUET 50 MG/1000 MG	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE 50MG;METFORMIN HYDROCHLORIDE 1000MG	TABLETS	RECIEPT	Januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. Important limitations of use: Januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. Januet has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Januet.
2671	JANUET	JANUET 50 MG/500 MG	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE 50MG;METFORMIN HYDROCHLORIDE 500MG	TABLETS	RECIEPT	Januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. Important limitations of use: Januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. Januet has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Januet.
2673	JANUET	JANUET 50 MG/850 MG	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE 50MG;METFORMIN HYDROCHLORIDE 850MG	TABLETS	RECIEPT	Januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. Important limitations of use: Januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. Januet has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Januet.
2675	JANUET	JANUET XR 100/1000 MG TABLETS	SITAGLIPTIN AS PHOSPHATE SALT	SITAGLIPTIN AS PHOSPHATE SALT 100MG;METFORMIN HYDROCHLORIDE 1000MG	TABLETS	RECIEPT	Januet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate
2677	JANUET	JANUET XR 50/1000 MG TABLETS	SITAGLIPTIN AS PHOSPHATE SALT	SITAGLIPTIN AS PHOSPHATE SALT 50MG;METFORMIN HYDROCHLORIDE 1000MG	TABLETS	RECIEPT	Januet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate
2679	JANUET	JANUET XR 50/500 MG TABLETS	SITAGLIPTIN AS PHOSPHATE SALT	SITAGLIPTIN AS PHOSPHATE SALT 50MG;METFORMIN HYDROCHLORIDE 500MG	TABLETS	RECIEPT	Januet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate
2681	JANUVIA	JANUVIA 100 MG	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE 100MG	TABLETS	RECIEPT	Januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: Januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. Januvia has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Januvia.
2687	JANUVIA	JANUVIA 25 MG	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE 25MG	TABLETS	RECIEPT	Januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: Januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. Januvia has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Januvia.
2693	JANUVIA	JANUVIA 50 MG	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE	SITAGLIPTIN AS MONOHYDRATE PHOSPHATE 50MG	TABLETS	RECIEPT	Januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: Januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. Januvia has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Januvia.
2699	JARDIANCE	JARDIANCE 10 MG	EMPAGLIFLOZIN	EMPAGLIFLOZIN 10MG	TABLETS	RECIEPT	Jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. Limitation of Use Jardiance is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
2700	JARDIANCE	JARDIANCE 25 MG	EMPAGLIFLOZIN	EMPAGLIFLOZIN 25MG	TABLETS	RECIEPT	Jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. Limitation of Use Jardiance is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
2701	JARDIANCE DUO	JARDIANCE DUO 12.5 MG/1000 MG	EMPAGLIFLOZIN	EMPAGLIFLOZIN 12.5MG;METFORMIN HYDROCHLORIDE 1000MG	TABLETS	RECIEPT	Jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control • in patients inadequately controlled on their maximally tolerated dose of metformin alone. • in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin. • in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
2703	JARDIANCE DUO	JARDIANCE DUO 12.5 MG/500 MG	EMPAGLIFLOZIN	EMPAGLIFLOZIN 12.5MG;METFORMIN HYDROCHLORIDE 500MG	TABLETS	RECIEPT	Jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control • in patients inadequately controlled on their maximally tolerated dose of metformin alone. • in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin. • in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
2705	JARDIANCE DUO	JARDIANCE DUO 12.5 MG/850 MG	EMPAGLIFLOZIN	EMPAGLIFLOZIN 12.5MG;METFORMIN HYDROCHLORIDE 850MG	TABLETS	RECIEPT	Jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control • in patients inadequately controlled on their maximally tolerated dose of metformin alone. • in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin. • in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
2707	JARDIANCE DUO	JARDIANCE DUO 5 MG/1000 MG	EMPAGLIFLOZIN	EMPAGLIFLOZIN 5MG;METFORMIN HYDROCHLORIDE 1000MG	TABLETS	RECIEPT	Jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control • in patients inadequately controlled on their maximally tolerated dose of metformin alone. • in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin. • in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
2709	JARDIANCE DUO	JARDIANCE DUO 5 MG/500 MG	EMPAGLIFLOZIN	EMPAGLIFLOZIN 5MG;METFORMIN HYDROCHLORIDE 500MG	TABLETS	RECIEPT	Jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control • in patients inadequately controlled on their maximally tolerated dose of metformin alone. • in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin. • in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
2711	JARDIANCE DUO	JARDIANCE DUO 5 MG/850 MG	EMPAGLIFLOZIN	EMPAGLIFLOZIN 5MG;METFORMIN HYDROCHLORIDE 850MG	TABLETS	RECIEPT	Jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control • in patients inadequately controlled on their maximally tolerated dose of metformin alone. • in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin. • in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
2713	JAVLOR	JAVLOR	VINFLUNINE DITARTRATE	VINFLUNINE DITARTRATE 25MG/ML	CONCENTRATE	RECIEPT	Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinium-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with Performance Status ≥2.
2714	JEVTANA	JEVTANA	CABAZITAXEL	CABAZITAXEL 60MG/1.5ML	CONCENTRATE	RECIEPT	JEVTANA is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel- containing treatment regimen.
2715	JORVEZA	JORVEZA 1 MG	BUDESONIDE	BUDESONIDE 1MG	TABLETS	RECIEPT	Treatment of eosinophilic esophagitis (EoE) in adults.
2716	JULUCA	JULUCA	RILPIVIRINE AS HYDROCHLORIDE	RILPIVIRINE AS HYDROCHLORIDE 25MG;DOLUTEGRAVIR AS SODIUM 50MG	TABLETS	RECIEPT	Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor
2717	KADCYLA	KADCYLA	TRASTUZUMAB EMTANSINE	TRASTUZUMAB EMTANSINE 20MG/ML	POWDER	RECIEPT	KADCYLA, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: • Received prior therapy for metastatic disease, or • Developed disease recurrence during or within six months of completing adjuvant therapy.
2726	KALBETEN	KALBETEN SUSPENSION	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 1.75%W/V	SUSPENSION		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
2727	KALBETEN	KALBETEN TABLETS	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 262MG	TABLETS		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
2723	KALBETEN	KALBETEN FORTE SUSPENSION	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 262MG/7.5ML	SUSPENSION		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, upset stomach. As a preventative treatment of traveler's diarrhea.
2721	KALBETEN	KALBETEN FORTE CAPLETS	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 524MG	TABLETS		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
2718	KALBETEN	KALBETEN 10TAB	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG	TABLETS		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
2719	KALBETEN	KALBETEN 20TAB	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG	TABLETS		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
2724	KALBETEN	KALBETEN SUSP 100ML	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG/15ML( 1.75% )	SUPPOSITORIES		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
2725	KALBETEN	KALBETEN SUSP 200ML	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG/15ML( 1.75% )	SUPPOSITORIES		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
2722	KALBETEN	KALBETEN FORTE SUSP 100ML	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG/7.5ML	SYRUP		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, upset stomach. As a preventative treatment of traveler's diarrhea.
2720	KALBETEN	KALBETEN FORTE 10 CAPLETS	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 524MG	TABLETS		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, upset stomach. As a preventative treatment of traveler's diarrhea.
2730	KALETRA	KALETRA 100 MG/25 MG TABLETS	LOPINAVIR	LOPINAVIR 100MG;RITONAVIR 25MG	TABLETS	RECIEPT	Kaletra is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infections.
2731	KALETRA	KALETRA ORAL SOLUTION	RITONAVIR	RITONAVIR 20MG/ML;LOPINAVIR 80MG/ML	SOLUTION	RECIEPT	Kaletra is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
2728	KALETRA	KALETRA 200 MG/50 MG TABLETS	RITONAVIR	RITONAVIR 50MG;LOPINAVIR 200MG	TABLETS	RECIEPT	Kaletra is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
2733	KALGARON	KALGARON MINT	CETYLPYRIDINIUM CHLORIDE	CETYLPYRIDINIUM CHLORIDE 1.25MG;LIDOCAINE HYDROCHLORIDE ( AS MONOHYDRATE) 1MG	TABLETS		For the relief of severe sore throat. Relief of mouth and throat infections.
2734	KALGARON	KALGARON ORANGE	CETYLPYRIDINIUM CHLORIDE	CETYLPYRIDINIUM CHLORIDE 1.25MG;LIDOCAINE HYDROCHLORIDE ( AS MONOHYDRATE) 1MG	TABLETS		For the relief of severe sore throat. Relief of mouth and throat infections.
2735	KALGARON	KALGARON STRAWBERY	CETYLPYRIDINIUM CHLORIDE	CETYLPYRIDINIUM CHLORIDE 1.25MG;LIDOCAINE HYDROCHLORIDE ( AS MONOHYDRATE) 1MG	TABLETS		For the relief of severe sore throat. Relief of mouth and throat infections.
2732	KALGARON	KALGARON	TYROTHRICIN	TYROTHRICIN 1.00MG;LIDOCAINE AS HYDROCHLORIDE 1.00MG	TABLETS	RECIEPT	For the fast relief of severe sore throat. Relief of mouth and throat infections.
2736	KALOBA	KALOBA ® SYRUP 100ML	EXTRACTING AGENT : ETHANOL	EXTRACTING AGENT : ETHANOL 11% (W/W);PELARGONIUM SIDOIDES ROOTS1:8;10 20MG/7.5ML	SYRUP		Kaloba® is a sugar-free, colouring-free, non-drowsy formula that may be beneficial for the relief of cough and cold symptoms in adults and children 1 year and above*. It relieves the symptoms through its ability to support the body’s immune system against the infection. In addition, it may offer relief by removing phlegm. The benefit for patients taking Kaloba® is that it will help to speed up recovery. It has an excellent safety profile which allows it to be used in both adults and children.
2738	KALOBA	KALOBA TABLETS	PELARGONIUM SIDOIDES ROOTS (1:	PELARGONIUM SIDOIDES ROOTS (1: 8- 10) (EPS 7630) DRIED LIQUID EXTRACT;EXTRACTING AGENT : ETHANOL 11% (W/W) 20MG	TABLETS	RECIEPT	- Symptomatic treatment of acute bronchitis. - Traditional herbal medicinal product for use in the common cold.
2737	KALOBA	KALOBA SYRUP	PELARGONIUM SIDOIDES ROOTS (1:	PELARGONIUM SIDOIDES ROOTS (1: 8- 10) (EPS 7630) DRIED LIQUID EXTRACT;EXTRACTING AGENT : ETHANOL 11% (W/W) 20MG/7.5ML	SYRUP		Symptomatic treatment of acute bronchitis for adults and children form age of 1 years. Traditional herbal medicinal product for use in the common cold for adults and children form age of 1 years
2739	KALOBA	KALOBA TABLETS 21 TAB	PELARGONIUM SIDOIDES ROOTS (1:	PELARGONIUM SIDOIDES ROOTS (1: 8;10) (EPS® 7630) DRIED LIQUID EXTRACT;;EXTRACTING AGENT : ETHANOL 11% (W/W);20MG	TABLETS		- Symptomatic treatment of acute bronchitis. - Traditional herbal medicinal product for use in the common cold.
2741	KALSINUS	KALSINUS 60MG 10 TAB	PSEUDOEPHEDRINE (AS HYDROCHLORIDE)	PSEUDOEPHEDRINE (AS HYDROCHLORIDE) 60MG	TABLETS	RECIEPT	Symptomatic treatment of nasal congestion, to relieve eustachian tube congestion.
2740	KALSINUS	KALSINUS	PSEUDOEPHEDRINE HYDROCHLORIDE	PSEUDOEPHEDRINE HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Symptomatic treatment of nasal congestion, to relieve eustachian tube congestion.
2742	KALURIL	KALURIL	AMILORIDE AS HYDROCHLORIDE ANHYDROUS	AMILORIDE AS HYDROCHLORIDE ANHYDROUS 5MG;HYDROCHLOROTHIAZIDE 50MG	TABLETS	RECIEPT	Hypertension: Kaluril is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of the disease. Edema: Edema associated with congestive heart failure and hepatic cirrhosis.
2743	KALYDECO	KALYDECO 150 MG FILM COATED TABLETS	IVACAFTOR	IVACAFTOR 150MG	TABLETS	RECIEPT	Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. Limitations of use: Kalydeco is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene
2747	KALYDECO	KALYDECO 50 MG GRANULES	IVACAFTOR	IVACAFTOR 50MG	GRANULES	RECIEPT	Kalydeco granules are indicated for the treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. Limitations of use: Kalydeco is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene.
2749	KALYDECO	KALYDECO 75 MG GRANULES	IVACAFTOR	IVACAFTOR 75MG	GRANULES	RECIEPT	Kalydeco granules are indicated for the treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. Limitations of use: Kalydeco is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene.
2751	KAMRAB	KAMRAB	HUMAN-RABIES IMMUNOGLOBULIN	HUMAN-RABIES IMMUNOGLOBULIN 150IU/ML	SOLUTION	RECIEPT	KamRAB IM is indicated for passive, transient post-exposure prevention of rabies infection when given immediately to individuals in cases of contact with rabid or possibly rabid animal.
2752	KAM-RHO	KAM-RHO (D) I.V.	ANTI-D IMMUNOGLOBULINS	ANTI-D IMMUNOGLOBULINS 150MCG/1ML	SOLUTION	RECIEPT	Suppression of Rh immunization in non-sensitized Rho(D) negative women delivering an Rh positive baby, or when the baby's Rh type is unknown. Suppression of Rh immunization after spontaneous or induced abortions, threatened abortion associated with maternal bleeding amniocentesis, chorionic villus sampling ruptured tubal pregnancy, and significant abdominal trauma. KAM-Rho should be given within 72 hours of event. Immune thrombocytopenic purpura (ITP): Rho (d)-positive adults with chronic ITP, children with chronic or acute ITP, and patients with Thrombocytopenia secondary to HIV infection in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage.
2753	KAM-RHO	KAM-RHO D I.M.	ANTI-D IMMUNOGLOBULINS	ANTI-D IMMUNOGLOBULINS 150MCG/ML	SOLUTION	RECIEPT	Pregnancy/other obstetric conditions, Suppression of Rh immunization in non-sensitized Rh0 (D) negative women delivering an Rh0 positive baby or when the baby's Rh type is unknown. Suppression of Rh immunization after spontaneous or induced abortions threatened abortion associated with maternal bleeding amniocentesis chorionic villus sampling ruptured tubal pregnancy and significant abdominal trauma. Kam Rh0 -D IM should be given within 72 hours of the event. It may be given even after up to one month although efficacy may be somewhat reduced. Transfusion: Suppression of Rh isoimmunization in Rh0 (D) antigen-negative patients transfused with Rh0 (D) antigen-positive RBCs of blood components containing Rh0 (D) antigen-positive RBCs . Initate treatment within 72 hours of exposure.
2754	KANKA	KANKA 20% 10ML	BENZOCAINE	BENZOCAINE 20%;CETYLPYRIDINIUM CHLOR 0.1%;BENZOIN TINCT 0.5%	LIQUID	RECIEPT	For temporary relief of occasional minor irritation and pain associated with: canker sores, sore mouth and throat , minor injury of the mouth and gums
2755	KANUMA	KANUMA	SEBELIPASE ALFA	SEBELIPASE ALFA 2MG/1ML	CONCENTRATE	RECIEPT	KANUMA is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
2757	KARIN	KARIN 250	CLARITHROMYCIN	CLARITHROMYCIN 250MG	TABLETS	RECIEPT	Karin is indicated in the treatment of infections caused by one or more susceptible organisms. Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia. Upper respiratory tract infections for example, sinusitis and pharyngitis. Karin is also indicated in skin and soft tissue infections of mild to moderate severity. Karin is also indicated in combination with proton pump inhibitor for the eradication of H.pylori in patients with proven duodenal ulcers.
2759	KARIN	KARIN 500	CLARITHROMYCIN	CLARITHROMYCIN 500MG	TABLETS	RECIEPT	Karin is indicated in the treatment of infections caused by one or more susceptible organisms. Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia. Upper respiratory tract infections for example, sinusitis and pharyngitis. Karin is also indicated in skin and soft tissue infections of mild to moderate severity. Karin is also indicated in combination with proton pump inhibitor for the eradication of H.pylori in patients with proven duodenal ulcers. Treatment of Mycobacterium Avium Complex infection in AIDS patients
2761	KAYEXALATE	KAYEXALATE	POLYSTYRENE SULPHONATE SODIUM	POLYSTYRENE SULPHONATE SODIUM 99.934%	POWDER	RECIEPT	Treatment of hyperkalemia.
2762	KELAPROFEN	KELAPROFEN 10 % VETERINARY	KETOPROFEN	KETOPROFEN 100MG/1ML	SOLUTION	RECIEPT	Horses : - the alleviation of inflammation and pain associated with musculoskeletal disorders; - the alleviation of visceral pain associated with colic. Cattle : - the supportive treatment of parturient paresis associated with calving; - reducing the pyrexia and distress associated with bacterial respiratory disease when used in conjunction with antimicrobial therapy as appropriate; - improving the recovery rate in acute clinical mastitis, including acute endotoxin mastitis, caused by gram negative micro-organisms, in conjunction with antimicrobial therapy; - reducing oedema of the udder associated with calving.
2763	KEMADRIN	KEMADRIN TABLETS 5 MG	PROCYCLIDINE HYDROCHLORIDE	PROCYCLIDINE HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Indicated in all forms of parkinson's disease: idiopathic (paralysis agitans), post encephalitic and arteriosclerotic.
2764	KEPPRA	KEPPRA 1000 MG	LEVETIRACETAM	LEVETIRACETAM 1000MG	TABLETS	RECIEPT	- Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Keppra is indicated as adjunctive therapy in the treatment of myo
2767	KEPPRA	KEPPRA ORAL SOLUTION	LEVETIRACETAM	LEVETIRACETAM 100MG/ML	SOLUTION	RECIEPT	Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Keppra is indicated as adjunctive therapy - in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. - in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
2765	KEPPRA	KEPPRA 250 MG	LEVETIRACETAM	LEVETIRACETAM 250MG	TABLETS	RECIEPT	- Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Keppra is indicated as adjunctive therapy in the treatment of myo
2766	KEPPRA	KEPPRA 500 MG	LEVETIRACETAM	LEVETIRACETAM 500MG	TABLETS	RECIEPT	- Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Keppra is indicated as adjunctive therapy in the treatment of myo
2768	KERATOSPOR	KERATOSPOR	UREA	UREA 40%;BIFONAZOLE 1%	OINTMENT	RECIEPT	For nail stripping and antifungal treatment of fungal infections of the finger nails and toe nails.
2770	KETALAR	KETALAR INJECTION 10 MG/ML	KETAMINE AS HYDROCHLORIDE	KETAMINE AS HYDROCHLORIDE 10MG/ML	SOLUTION	RECIEPT	As the sole anaesthetic agent for diagnostic and surgical procedures. When used by intravenous or intramuscular injection, Ketalar is best suited for short procedures. With additional doses, or by intravenous infusion, Ketalar can be used for longer procedures. If skeletal muscle relaxation is desired a muscle relaxant should be used and respiration should be supported. For the induction of anaesthesia prior to the administration of other general anaesthetic agents. To supplement other anaesthetic agents. Specific areas of application or types of procedure: When the intramuscular route of administration is preferred. Debridement, painful dressings and skin grafting in burned patients as well as other superficial surgical procedures. Neurodiagnostic procedures such as pneumoencephalograms, ventriculograms, myelograms and lumbar punctures. Diagnostic and operative procedures of the eye, ear, nose and mouth including dental extractions.( Note: eye movement may persist during ophthalmological procedures). Anaesthesia in poor-risk patients with depression of vital functions or where depression of vital functions must be avoided if at all possible. Orthopaedic procedures such as closed reduction, manipulation femoral pinning, amputations and biopsies. Sigmoidoscopy and minor surgery of the anus and rectum, circumcision and pilonidal sinus. Cardiac catheterization procedures. Caesarian section: as an induction agent in the absence of elevated blood pressure. Anaesthesia in the asthmatic patient, either to minimise the risk of an attack of bronchospasm developing or in the presence of bronchospasm where anaesthesia cannot be delayed.
2769	KETALAR	KETALAR 50 MG/ML INJECTION	KETAMINE AS HYDROCHLORIDE	KETAMINE AS HYDROCHLORIDE 50MG/ML	SOLUTION	RECIEPT	As the sole anaesthetic agent for diagnostic and surgical procedures. When used by intravenous or intramuscular injection, Ketalar is best suited for short procedures. With additional doses, or by intravenous infusion, Ketalar can be used for longer procedures. If skeletal muscle relaxation is desired a muscle relaxant should be used and respiration should be supported. For the induction of anaesthesia prior to the administration of other general anaesthetic agents. To supplement other anaesthetic agents. Specific areas of application or types of procedure: When the intramuscular route of administration is preferred. Debridement, painful dressings and skin grafting in burned patients as well as other superficial surgical procedures. Neurodiagnostic procedures such as pneumoencephalograms, ventriculograms, myelograms and lumbar punctures. Diagnostic and operative procedures of the eye, ear, nose and mouth including dental extractions.( Note: eye movement may persist during ophthalmological procedures). Anaesthesia in poor-risk patients with depression of vital functions or where depression of vital functions must be avoided if at all possible. Orthopaedic procedures such as closed reduction, manipulation femoral pinning, amputations and biopsies. Sigmoidoscopy and minor surgery of the anus and rectum, circumcision and pilonidal sinus. Cardiac catheterization procedures. Caesarian section: as an induction agent in the absence of elevated blood pressure. Anaesthesia in the asthmatic patient, either to minimise the risk of an attack of bronchospasm developing or in the presence of bronchospasm where anaesthesia cannot be delayed.
2774	KETAMINE	KETAMINE PANPHARMA 50MG/1ML	KETAMINE AS HYDROCHLORIDE	KETAMINE AS HYDROCHLORIDE 50MG/1ML	SOLUTION	RECIEPT	As the sole anaesthetic agent for diagnostic and surgical procedures. When used by intravenous or intramuscular injection, Ketamin is best suited for short procedures. With additional doses, or by intravenous infusion, Ketamin can be used for longer procedures. If skeletal muscle relaxation is desired a muscle relaxant should be used and respiration should be supported. For the induction of anaesthesia prior to the administration of other general anaesthetic agents. To supplement other anaesthetic agents. Specific areas of application or types of procedure: When the intramuscular route of administration is preferred. Debridement, painful dressings and skin grafting in burned patients as well as other superficial surgical procedures. Neurodiagnostic procedures such as pneumoencephalograms, ventriculograms, myelograms and lumbar punctures. Diagnostic and operative procedures of the eye, ear, nose and mouth including dental extractions. (Note: eye movement may persist during ophthalmological procedures). Anaesthesia in poor-risk patients with depression of vital functions or where depression of vital functions must be avoided if at all possible. Orthopaedic procedures such as closed reduction, manipulation femoral pinning, amputations and biopsies. Sigmoidoscopy and minor surgery of the anus and rectum, circumcision and pilonidal sinus. Cardiac catheterization procedures. Caesarian section: as an induction agent in the absence of elevated blood pressure. Anaesthesia in the asthmatic patient, either to minimise the risk of an attack of bronchospasm developing or in the presence of bronchospasm
2773	KETAMINE	KETAMINE - HAMELN 50 MG/ML INJECTION	KETAMINE AS HYDROCHLORIDE	KETAMINE AS HYDROCHLORIDE 50MG/ML	SOLUTION	RECIEPT	As the sole anaesthetic agent for diagnostic and surgical procedures. When used by intravenous or intramuscular injection, Ketamine-Hameln is best suited for short procedures. With additional doses, or by intravenous infusion, Ketamine-Hameln can be used for longer procedures. If skeletal muscle relaxation is desired, a muscle relaxant should be used and respiration should be supported. For the induction of anesthesia prior to the administration of other general anesthetic agents. To supplement other anesthetic agents. Specific areas of application or types of procedures: When the intramuscular route of administration is preferred. Debridement, painful dressings, and skin grafting in burned patients, as well as other superficial surgical procedures. Neurodiagnostic procedures such as pneumoencephalograms, ventriculograms, myelograms, and lumbar punctures. Diagnostic and operative procedures of the eye, ear, nose, and mouth, including dental extractions. Note: Eye movements may persist during ophthalmological procedures. Anaesthesia in poor-risk patients with depression of vital functions or where depression of vital functions must be avoided, if at all possible. Orthopaedic procedures such as closed reductions, manipulations, femoral pinning, amputations, and biopsies. Sigmoidoscopy and minor surgery of the anus and rectum, circumcision and pilonidal sinus. Cardiac catheterization procedures. Caesarian section; as an induction agent in the absence of elevated blood pressure. Anaesthesia in the asthmatic patient, either to minimise the risks of an attack of bronchospasm developing, or in the presence of bronchospasm where anaesthesia cannot be delayed.
2777	KETOCONAZOLE	KETOCONAZOLE HRA 200 MG	KETOCONAZOLE	KETOCONAZOLE 200MG	TABLETS	RECIEPT	Treatment of endogenous Cushing's syndrome in adults and adolescents above the age of 12 years.
2779	KETOSPRAY	KETOSPRAY 10 %	KETOPROFEN	KETOPROFEN 10%	SPRAY	RECIEPT	Topical treatment for the symptomatic relief of soft tissue pain and inflammation due to strains, sprains, distortions, and contusions.
2780	KETOZOL	KETOZOL SHAMPOO	KETOCONAZOLE	KETOCONAZOLE 20MG/G	SHAMPOO	RECIEPT	Topical treatment of seborrhoeic dermatitis including dandruff resulting from proven fungal infection including Pityriasis versicolor.
2781	KEVZARA	KEVZARA 150 MG	SARILUMAB	SARILUMAB 131.6MG/1ML	SOLUTION	RECIEPT	Kevzara in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Kevzara can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.
2782	KEVZARA	KEVZARA 200 MG	SARILUMAB	SARILUMAB 175MG/1ML	SOLUTION	RECIEPT	Kevzara in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Kevzara can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.
2785	KEYTRUDA	KEYTRUDA 100 MG/4 ML	PEMBROLIZUMAB	PEMBROLIZUMAB 100MG/4ML	CONCENTRATE	RECIEPT	- Melanoma: Keytruda (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. - Non-Small Cell Lung Cancer: • KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated for the first-line tr
2786	KEYTRUDA	KEYTRUDA 50 MG	PEMBROLIZUMAB	PEMBROLIZUMAB 50MG/VIAL	POWDER	RECIEPT	- Melanoma: Keytruda (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. - Non-Small Cell Lung Cancer: • KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated for the first-line tr
2787	KIDROLASE	KIDROLASE	ASPARAGINASE	ASPARAGINASE 10000IU/VIAL	POWDER	RECIEPT	Acute lymphoblastic leukemia, acute myeloblastic leukemia.
2788	KINERET	KINERET 100 MG SOLUTION FOR INJECTION	ANAKINRA	ANAKINRA 150MG/ML	SOLUTION	RECIEPT	Kineret is indicated in adults for the treatment of the signs and symptoms of rheumatoid arthritis in combination with Methotrexate, in patients with an inadequate response to Methotrexate alone. Kineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including: - Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) - Muckle-Wells Syndrome (MWS) - Familial Cold Autoinflammatory Syndrome (FCAS)
2789	KIOVIG	KIOVIG 100 MG/ML	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 100MG/1ML	SOLUTION	RECIEPT	IVIg can be used in all age ranges, unless otherwise specified below. Replacement therapy in: Primary immunodeficiency syndromes with impaired antibody production. Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed. Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation. Children and adolescents (age 0-18) with congenital AIDS and recurrent bacterial infections. Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT). Immunomodulation Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count. Guillain Barré syndrome. Kawasaki disease.
2790	KISQALI	KISQALI 200 MG	RIBOCICLIB AS SUCCINATE	RIBOCICLIB AS SUCCINATE 200MG	TABLETS	RECIEPT	KISQALI is indicated in combination with: - a non-steroid aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; or - fulvestrant for the treatment of men and postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.
2791	KIT FOR TC-99m LABELED MDP	KIT FOR TC-99m LABELED MDP	MEDRONIC ACID	MEDRONIC ACID 7MG	POWDER		Bone imaging.
2792	KIVEXA	KIVEXA	ABACAVIR AS SULFATE	ABACAVIR AS SULFATE 600MG;LAMIVUDINE 300MG	TABLETS	RECIEPT	Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.
2794	KLACID	KLACID PAEDIATRIC SUSPENSION 125 MG/5 ML	CLARITHROMYCIN	CLARITHROMYCIN 125MG/5ML	GRANULES	RECIEPT	Bronchitis, Pharyngitis, Tonsilitis pneumonia skin infections due to susceptible microorganisms. Treatment of Mycobacterium avium complex in patients with AIDS. Treatment of Otitis Media.
2795	KLACID	KLACID SR TABLETS	CLARITHROMYCIN	CLARITHROMYCIN 500MG	TABLETS	RECIEPT	For treatment of infections caused by susceptible organisms. For lower respiratory tract infections, upper respiratory tract infections, skin and soft tissue infections
2796	KLARIDEX	KLARIDEX	CLARITHROMYCIN	CLARITHROMYCIN 250MG	TABLETS	RECIEPT	Klaridex is indicated in the treatment of infections caused by one or more susceptible organisms. Indications include: Lower respiratory tract infections, for example, acute and chronic bronchitis and pneumonia. Upper respiratory tract infections, for example, sinusitis and pharyngitis. Klaridex is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. Klaridex is also indicated in skin and soft tissue infections of mild to moderate severity. Klaridex is also indicated in combination with proton pump inhibitor for the eradication of H. Pylori in patients with proven duodenal ulcer. Treatment of Mycobacterium Avium Complex infection in AIDS patients.
2797	KOATE DVI	KOATE DVI 1000	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 1000 IU/VIAL	POWDER	RECIEPT	For the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor VIII . Koate-DVI provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
2798	KOATE DVI	KOATE DVI 250	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 250 IU/VIAL	POWDER	RECIEPT	For the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor VIII . Koate-DVI provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
2799	KOATE DVI	KOATE DVI 500	FACTOR VIII (HUMAN)	FACTOR VIII (HUMAN) 500 IU/VIAL	POWDER	RECIEPT	For the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor VIII . Koate-DVI provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
2802	KOGENATE FS	KOGENATE FS 1000 IU	ANTIHEMOPHILIC FACTOR (RECOMBINANT) SUCROSE	ANTIHEMOPHILIC FACTOR (RECOMBINANT) SUCROSE 1000 IU/VIAL	POWDER	RECIEPT	For the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor VIII. Routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children under with severe hemophilia A with no pre-existing joint damage. Kogenate FS is not indicated for the treatment of von Willebrand’s disease.
2803	KOGENATE FS	KOGENATE FS 500 IU	ANTIHEMOPHILIC FACTOR (RECOMBINANT) SUCROSE	ANTIHEMOPHILIC FACTOR (RECOMBINANT) SUCROSE 500 IU/VIAL	POWDER	RECIEPT	For the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor VIII. Routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia A with no pre-existing joint damage. Kogenate FS is not indicated for the treatment of von Willebrand’s disease.
2804	KOMBIGLYZE	KOMBIGLYZE ™ XR 2.5 MG/1000 MG	SAXAGLIPTIN	SAXAGLIPTIN 2.5MG;METFORMIN HYDROCHLORIDE 1000MG	TABLETS	RECIEPT	KOMBIGLYZE XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
2805	KOMBIGLYZE	KOMBIGLYZE ™ XR 5 MG/1000 MG	SAXAGLIPTIN	SAXAGLIPTIN 5MG;METFORMIN HYDROCHLORIDE 1000MG	TABLETS	RECIEPT	KOMBIGLYZE XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
2806	KONAKION	KONAKION MM 10 MG/ML	PHYTOMENADIONE	PHYTOMENADIONE 10MG/1ML	SOLUTION	RECIEPT	For the treatment and the prophylaxis of hemorrhage.
2807	KONAKION	KONAKION MM PAEDIATRIC 2 MG/0.2 ML	PHYTOMENADIONE	PHYTOMENADIONE 10MG/ML	SOLUTION	RECIEPT	Prophylaxis and treatment of haemorrhoagic disease of the newborn.
2812	KONSYL	KONSYL ORANGE SUGAR FREE	PSYLLIUM	PSYLLIUM 95% 3.5G	POWDER		For the treatment of constipation.
2808	KONSYL	KONSYL EASY MIX	PSYLLIUM	PSYLLIUM 95% 4.3G	POWDER		For the treatment of constipation.
2810	KONSYL	KONSYL ORANGE SF 300GR	PSYLLIUM HYDROPHILIC MUCILLOID	PSYLLIUM HYDROPHILIC MUCILLOID 3.5GR/DOSE	POWDER		For the treatment of constipation.
2811	KONSYL	KONSYL ORANGE SF 450GR	PSYLLIUM HYDROPHILIC MUCILLOID	PSYLLIUM HYDROPHILIC MUCILLOID 3.5GR/DOSE	POWDER		For the treatment of constipation.
2809	KONSYL	KONSYL EASY MIX 300GR	PSYLLIUM HYDROPHILIC MUCILLOID	PSYLLIUM HYDROPHILIC MUCILLOID 4.3GR/DOSE	POWDER		For the treatment of constipation.
2813	KOVALTRY	KOVALTRY 1000 IU	RECOMBINANT HUMAN COAGULATION FACTOR VIII	RECOMBINANT HUMAN COAGULATION FACTOR VIII 1000 IU	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
2814	KOVALTRY	KOVALTRY 2000 IU	RECOMBINANT HUMAN COAGULATION FACTOR VIII	RECOMBINANT HUMAN COAGULATION FACTOR VIII 2000 IU	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
2815	KOVALTRY	KOVALTRY 250 IU	RECOMBINANT HUMAN COAGULATION FACTOR VIII	RECOMBINANT HUMAN COAGULATION FACTOR VIII 250 IU	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
2816	KOVALTRY	KOVALTRY 500 IU	RECOMBINANT HUMAN COAGULATION FACTOR VIII	RECOMBINANT HUMAN COAGULATION FACTOR VIII 500 IU	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
2817	KRYSTEXXA	KRYSTEXXA	PEGLOTICASE	PEGLOTICASE 32MG/1ML uricase protein	CONCENTRATE	RECIEPT	KRYSTEXXA (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refactory to conventional therapy. Important limitations of use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.
2818	KUFFEX	KUFFEX DM	DEXTROMETHORPHAN HYDROBROMIDE	DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML;GUAIFENESIN 100MG/5ML	SYRUP	RECIEPT	For relief of cough and expecctorant.
2820	KUFFEX	KUFFEX DM 118ML	GUAIPHENESIN	GUAIPHENESIN 100MG/5ML;DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML	SYRUP	RECIEPT	For relief of cough and expecctorant.
2821	KUVAN	KUVAN	SAPROPTERIN DIHYDROCHLORIDE	SAPROPTERIN DIHYDROCHLORIDE 100MG	TABLETS	RECIEPT	Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment. Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment.
2823	KYLEENA	KYLEENA	LEVONORGESTREL	LEVONORGESTREL 19.5MG	INTRAUTERINE DEVICE	RECIEPT	Contraception for up to 5 years
2825	KYMRIAH	KYMRIAH	TISAGENLECLEUCEL	TISAGENLECLEUCEL 1.2 x 10^6 to 6 x 10^8 CAR-positive viable T cells	SOLUTION	RECIEPT	Kymriah is indicated for the treatment of: Paediatric and young adult patients up to 25 years of age with CD19+ B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary or secondary central nervous system lymphoma
2826	KYPROLIS	KYPROLIS	CARFILZOMIB	CARFILZOMIB 2MG/ML	POWDER	RECIEPT	Kyprolis (carfilzomib) is indicated: • in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy . • as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
2832	LACRIMOL	LACROMYCIN EYE DROPS	GENTAMICIN AS SULFATE	GENTAMICIN AS SULFATE 0.3%	DROPS	RECIEPT	For the treatment of eye infections susceptible to treatment with Gentamycin.
2830	LACRIMOL	LACRIMOL DROPS 15CC	HYDROXYETHYLCELLULOSE	HYDROXYETHYLCELLULOSE 0.31%;POVIDONE 1.6%	DROPS		A lubricating tear substitute for dry eyes when tear production is insufficient.
2831	LACRIMOL	LACRIMOL EYE DROPS	HYDROXYETHYLCELLULOSE	HYDROXYETHYLCELLULOSE 0.31%;POVIDONE 1.6%	DROPS		A lubricating tear substitute for dry eyes when tear production is insufficient.
2833	LACTATED RINGER'S (HARTMANN'S SOLUTION)	LACTATED RINGER'S INJECTION (HARTMANN'S SOLUTION)	SODIUM CHLORIDE	SODIUM CHLORIDE 6G/L;POTASSIUM CHLORIDE 0.3G/L;CALCIUM CHLORIDE 0.2G/L DIHYDRATE;LACTIC ACID AS SODIUM 3.1G/L	SOLUTION	RECIEPT	As a supply of water, for administration of electrolytes or calories, or as an alkalinizing agent.
2835	LAEVOLAC	LAEVOLAC 300ML	LACTULOSE	LACTULOSE 0.67G/ML (66.7%;66.7G/100ML)	SYRUP		Constipation. Acute and chronic hepatic encephalopathy.
2836	LAEVOLAC	LAEVOLAC 500ML	LACTULOSE	LACTULOSE 0.67G/ML (66.7%;66.7G/100ML)	SYRUP		Constipation. Acute and chronic hepatic encephalopathy.
2834	LAEVOLAC	LAEVOLAC	LACTULOSE	LACTULOSE 670MG/ML	SOLUTION		Constipation. Acute and chronic hepatic encephalopathy.
2837	LAMICAVIR	LAMICAVIR TEVA	LAMIVUDINE	LAMIVUDINE 300MG;ABACAVIR 600MG	TABLETS	RECIEPT	Lamicavir Teva is a fixed-dose combination of two nucleoside analogues (abacavir and lamivudine). Lamicavir Teva is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.
2838	LAMICTAL	LAMICTAL DISPERSIBLE/CHEWABLE TABLETS 100 MG	LAMOTRIGINE	LAMOTRIGINE 100MG	TABLETS	RECIEPT	Epilepsy: Monotherapy in adults and children over 12 years of age: 1. Simple partial seizures. 2. complex partial seizures. 3. generalised tonic clonic secondarily seizures. 4. Primary generalised tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: 1. Simple partial seizures. 2. Complex partial seizures. 3. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2840	LAMICTAL	LAMICTAL DISPERSIBLE/CHEWABLE TABLETS 200 MG	LAMOTRIGINE	LAMOTRIGINE 200MG	TABLETS	RECIEPT	Epilepsy: Monotherapy in adults and children over 12 years of age: 1. Simple partial seizures. 2. complex partial seizures. 3. generalised tonic clonic secondarily seizures. 4. Primary generalised tonic clonic secondarily seizures. Add-on therapy in adults and children over 2 years of age: 1. Simple partial seizures. 2. Complex partial seizures. 3. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2841	LAMICTAL	LAMICTAL DISPERSIBLE/CHEWABLE TABLETS 25 MG	LAMOTRIGINE	LAMOTRIGINE 25MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age: Simple partial seizures. Complex partial seizures. Generalised tonic clonic secondarily seizures. Primary generalised tonic clonic seisures. Add- on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.
2839	LAMICTAL	LAMICTAL DISPERSIBLE/CHEWABLE TABLETS 2 MG	LAMOTRIGINE	LAMOTRIGINE 2MG	TABLETS	RECIEPT	Epilepsy: monotherapy in adults and children over 12 years of age: 1. Simple partial seizures. 2. Complex partial seizures. 3. Generalized tonic clonic secondarily seizures. 4. Primary generalized tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: 1. Simple partial seizures. 2. Complex partial seizures. 3. Secondarily generalized tonic clonic seizures.
2843	LAMICTAL	LAMICTAL DISPERSIBLE/CHEWABLE TABLETS 50 MG	LAMOTRIGINE	LAMOTRIGINE 50MG	TABLETS	RECIEPT	Epilepsy: Monotherapy in adults and children over 12 years of age: 1. Simple partial seizures. 2. complex partial seizures. 3. generalised tonic clonic secondarily seizures. 4. Primary generalised tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: 1. Simple partial seizures. 2. Complex partial seizures. 3. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2842	LAMICTAL	LAMICTAL DISPERSIBLE/CHEWABLE TABLETS 5 MG	LAMOTRIGINE	LAMOTRIGINE 5MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age: Simple partial seizures. Complex partial seizures. Generalised tonic clonic secondarily seizures. Primary generalised tonic clonic seisures. Add- on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures.
2847	LAMISIL	LAMISIL DERMGEL	TERBINAFINE	TERBINAFINE 1%	GEL	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidemophyton floccosum. Pityriasis ( tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).
2849	LAMISIL	LAMISIL ONCE	TERBINAFINE AS HYDROCHLORIDE	TERBINAFINE AS HYDROCHLORIDE 10MG/G	SOLUTION	RECIEPT	For the treatment of athlete's foot.
2845	LAMISIL	LAMISIL CREAM 1% 15GR(GSL)	TERBINAFINE HCL	TERBINAFINE HCL 1%	CREAM	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.T. rubrum T. mentagrophytes T. verrucosum T. violaceum) Microsporum canis and Epidemophyton floccosum. Yeast infections of the skin principally those caused by the genus Candida (e.g. candida albicans). Pityriasis ( tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur). For the treatment of plantar-type tinea pedis (Moccasin type)
2846	LAMISIL	LAMISIL CREAM 1% 30GR	TERBINAFINE HCL	TERBINAFINE HCL 1%	CREAM	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.T. rubrum T. mentagrophytes T. verrucosum T. violaceum) Microsporum canis and Epidemophyton floccosum. Yeast infections of the skin principally those caused by the genus Candida (e.g. candida albicans). Pityriasis ( tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur). For the treatment of plantar-type tinea pedis (Moccasin type)
2848	LAMISIL	LAMISIL DERMGEL 15GR	TERBINAFINE HCL	TERBINAFINE HCL 1%	GEL	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidemophyton floccosum. Pityriasis ( tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).
2851	LAMISIL	LAMISIL ONCE SOL 10MG/G 4 GR	TERBINAFINE HCL	TERBINAFINE HCL 1%	SOLUTION	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum) , microsporum canis and epidermaphyton floccosum.Yeast infections of the skin, principally those caused by the genus Candida (e.g. candida albicans). Pityriasis (tinea) versicolor due to pityrosporum orbiculare (also known as malassezia furfur).
2853	LAMISIL	LAMISIL SPRAY 1% 30ML	TERBINAFINE HCL	TERBINAFINE HCL 1%	SPRAY	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum) , microsporum canis and epidermaphyton floccosum.Yeast infections of the skin, principally those caused by the genus Candida (e.g. candida albicans). Pityriasis (tinea) versicolor due to pityrosporum orbiculare (also known as malassezia furfur).
2844	LAMISIL	LAMISIL CREAM	TERBINAFINE HYDROCHLORIDE	TERBINAFINE HYDROCHLORIDE 1%	CREAM	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.T. rubrum T. mentagrophytes T. verrucosum T. violaceum) Microsporum canis and Epidemophyton floccosum. Yeast infections of the skin principally those caused by the genus Candida (e.g. candida albicans). Pityriasis ( tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur). For the treatment of plantar-type tinea pedis (Moccasin type)
2852	LAMISIL	LAMISIL SPRAY	TERBINAFINE HYDROCHLORIDE	TERBINAFINE HYDROCHLORIDE 1%	SOLUTION	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum) , microsporum canis and epidermaphyton floccosum.Yeast infections of the skin, principally those caused by the genus Candida (e.g. candida albicans). Pityriasis (tinea) versicolor due to pityrosporum orbiculare (also known as malassezia furfur).
2856	LAMIVUDINE	LAMIVUDINE TEVA 100 MG	LAMIVUDINE	LAMIVUDINE 100MG	TABLETS	RECIEPT	Lamivudine is indicated for the treatment of chronic hepatitis B associated with the evidence of hepatitis B viral (HBV) replication and active liver inflammation in aduls and also in children and adolescents aged 2 to 17 years old.
2854	LAMIVUDINE ZIDOVUDINE	LAMIVUDINE & ZIDOVUDINE INOVAMED 150 MG/300 MG	LAMIVUDINE	LAMIVUDINE 150MG;ZIDOVUDINE 300MG	TABLETS	RECIEPT	LAMIVUDINE & ZIDOVUDINE INOVAMED 150 MG / 300 MG is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.
2855	LAMIVUDINE ZIDOVUDINE	LAMIVUDINE / ZIDOVUDINE TEVA 150 MG / 300 MG	ZIDOVUDINE	ZIDOVUDINE 300MG;LAMIVUDINE AS ANHYDROUS 150MG	TABLETS	RECIEPT	Antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.
2857	LAMODEX	LAMODEX 100 MG DISPERSIBLE/CHEWABLE TABLETS	LAMOTRIGINE	LAMOTRIGINE 100MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age : Simple partial seizures. Complex partial seizures. Generalised tonic clonic secondarily seizures. Primary generalised tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2858	LAMODEX	LAMODEX 200 MG DISPERSIBLE/CHEWABLE TABLETS	LAMOTRIGINE	LAMOTRIGINE 200MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age : Simple partial seizures. Complex partial seizures. Generalised tonic clonic secondarily seizures. Primary generalised tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2859	LAMODEX	LAMODEX 25 MG DISPERSIBLE/CHEWABLE TABLETS	LAMOTRIGINE	LAMOTRIGINE 25MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age : Simple partial seizures. Complex partial seizures. Generalised tonic clonic secondarily seizures. Primary generalised tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2861	LAMODEX	LAMODEX 50 MG DISPERSIBLE/CHEWABLE TABLETS	LAMOTRIGINE	LAMOTRIGINE 50MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age : Simple partial seizures. Complex partial seizures. Generalised tonic clonic secondarily seizures. Primary generalised tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Adults (18 years of age and over) Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2860	LAMODEX	LAMODEX 5 MG DISPERSIBLE/CHEWABLE TABLETS	LAMOTRIGINE	LAMOTRIGINE 5MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age : Simple partial seizures. Complex partial seizures. Generalised tonic clonic secondarily seizures. Primary generalised tonic clonic seizures. Add-on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures.
2862	LAMOGINE	LAMOGINE 100 MG	LAMOTRIGINE	LAMOTRIGINE 100MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seiaures. Primary generalised tonic clonic seizures. Add- on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Primary generalised tonic clonic seizures. Adults ( 18 years of age and over) : Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2863	LAMOGINE	LAMOGINE 200 MG	LAMOTRIGINE	LAMOTRIGINE 200MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seiaures. Primary generalised tonic clonic seizures. Add- on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Primary generalised tonic clonic seizures. Adults ( 18 years of age and over) : Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2864	LAMOGINE	LAMOGINE 25 MG	LAMOTRIGINE	LAMOTRIGINE 25MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seiaures. Primary generalised tonic clonic seizures. Add- on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Primary generalised tonic clonic seizures. Adults ( 18 years of age and over) : Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2865	LAMOGINE	LAMOGINE 50 MG	LAMOTRIGINE	LAMOTRIGINE 50MG	TABLETS	RECIEPT	Epilepsy : Monotherapy in adults and children over 12 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seiaures. Primary generalised tonic clonic seizures. Add- on therapy in adults and children over 2 years of age: Simple partial seizures. Complex partial seizures. Secondarily generalised tonic clonic seizures. Primary generalised tonic clonic seizures. Adults ( 18 years of age and over) : Lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.
2868	LANOXIN	LANOXIN PG ELIXIR	DIGOXIN	DIGOXIN 0.25MG/5ML	LIQUID	RECIEPT	Lanoxin is indicated whenever digitalis therapy is required for the treatment of congestive heart failure, atrial fibrilation and/or flutter and supra-ventricular tachycardia.
2867	LANOXIN	LANOXIN INJECTION	DIGOXIN	DIGOXIN 0.5MG/2ML	SOLUTION	RECIEPT	For management of chronic cardiac failure,and certain supraventricular arrhythmias.
2869	LANSOPRAZOLE	LANSOPRAZOLE TEVA 15 MG	LANSOPRAZOLE	LANSOPRAZOLE 15MG	CAPSULES	RECIEPT	For the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. Healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (GORD) or duodenal ulcer. Prevention of relapse in patients with GORD or duodenal ulcer. Eradication of H. Pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). Short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. Long-term management of pathological hypersecretory conditions including Zollinger Ellison syndrome. Treatment and prophylaxis of NSAID- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued NSAID treatment.
2872	LANSOPRAZOLE	LANSOPRAZOLE TEVA 30 MG	LANSOPRAZOLE	LANSOPRAZOLE 30MG	CAPSULES	RECIEPT	For the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. Healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (GORD) or duodenal ulcer. Prevention of relapse in patients with GORD or duodenal ulcer. Eradication of H. Pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). Short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. Long-term management of pathological hypersecretory conditions including Zollinger Ellison syndrome. Treatment and prophylaxis of NSAID- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued NSAID treatment.
2875	LANTON	LANTON 15	LANSOPRAZOLE	LANSOPRAZOLE 15MG	CAPSULES	RECIEPT	For the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. Healing, long- term treatment and maintenance therapy for patients with gastro-oesophageal reflux disease (GERD) or duodenal ulcer. Prevention of relapse in patients with GERD or duodenal ulcer. Eradication of H. Pylori from the upper gastrointestinal tract in patients ,with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). Short- term- treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. Long-term management of pathological hypersecretory conditions including Zollinger Ellison syndrome. Treatment and prophylaxis of NSAID- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued NSAID treatment.
2876	LANTON	LANTON 30	LANSOPRAZOLE	LANSOPRAZOLE 30MG	CAPSULES	RECIEPT	For the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. Healing, long- term treatment and maintenance therapy for patients with gastro-oesophageal reflux disease (GERD) or duodenal ulcer. Prevention of relapse in patients with GERD or duodenal ulcer. Eradication of H. Pylori from the upper gastrointestinal tract in patients ,with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). Short- term- treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. Long-term management of pathological hypersecretory conditions including Zollinger Ellison syndrome. Treatment and prophylaxis of NSAID- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued NSAID treatment.
2877	LANTUS	LANTUS 100 UNITS/ML	INSULIN GLARGINE	INSULIN GLARGINE 100U/ML	SOLUTION	RECIEPT	Treatment of adult and pediatric patients, 6 years and over, with type 1 diabetes mellitus or adults patients with type 2 diabetes mellitus who require basal (long acting) insulin for the control of hyperglycemia.
2878	LANVIS	LANVIS TABLETS 40 MG	THIOGUANINE	THIOGUANINE 40MG	TABLETS	RECIEPT	Acute nonlymphocytic leukemia.
2879	LASEA	LASEA	LAVENDER OIL	LAVENDER OIL 80MG	CAPSULES	RECIEPT	Treatment of anxiety in adults.
2880	LATANO	LATANO-AVENIR	LATANOPROST	LATANOPROST 0.05MG/ML	DROPS	RECIEPT	Reduction of elevated intraocular pressure as a first line treatment in patients with open-angle galucoma and ocular hypertension.
2881	LATANOPROST TIMOLOL	LATANOPROST TIMOLOL TEVA	LATANOPROST	LATANOPROST 50MCG/ML;TIMOLOL AS MALEATE 5MG/ML	DROPS	RECIEPT	Reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers.
2882	LATARO	LATARO	LATANOPROST	LATANOPROST 0.05MG/1ML	DROPS	RECIEPT	Reduction of elevated intraocular pressure as a first line treatment in patients with open-angle galucoma and ocular hypertension.
2883	LATARO-TIM	LATARO-TIM	TIMOLOL AS MALEATE	TIMOLOL AS MALEATE 5.0MG/ML;LATANOPROST 0.05MG/ML	DROPS	RECIEPT	Reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta- blockers.
2884	LAXADIN	LAXADIN	BISACODYL	BISACODYL 5MG	TABLETS	RECIEPT	All types of constipation in ambulatory and bedridden in patients over the age of 6 years . Preparation of patients for abdominal radiography and proctoscopy.
2886	LAXATIVE COMPOUND	LAXATIVE COMPOUND	IPECACUANHA	IPECACUANHA 4MG;BELLADONNA DRY EXTRACT 2.7MG;ALOIN 4.5MG;ALOE 6MG;PHENOLPHTHALEIN 32MG	TABLETS	RECIEPT	Constipation.
6007	LAXIN FORTE	LAXIN FORTE	CASIA FISTULA	CASIA FISTULA 600MG	CAPSULES		CONSTIPATION
2887	LEDAGA	LEDAGA	CHLORMETHINE AS HYDROCHLORIDE	CHLORMETHINE AS HYDROCHLORIDE 160MCG/G	GEL	RECIEPT	Topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy
2888	LEDERMIX	LEDERMIX PASTE	DEMECLOCYCLINE CALCIUM	DEMECLOCYCLINE CALCIUM 30.21MG/G;TRIAMCINOLONE ACETONIDE 10MG/G	PASTE	RECIEPT	Compound for dental use, prophylaxis or treatment of acute pulpitis and periodontitis.
2889	LEMOCIN	LEMOCIN CHERRY	LIDOCAINE	LIDOCAINE 1MG;TYROTHRICIN 4MG;CETRIMONIUM BROMIDE 2MG	TABLETS	RECIEPT	For the relief of pain associated with severe sore throat and mouth infections.
2891	LEMOCIN	LEMOCIN LEMON	LIDOCAINE	LIDOCAINE 1MG;TYROTHRICIN 4MG;CETRIMONIUM BROMIDE 2MG	TABLETS	RECIEPT	For the relief of pain associated with severe sore throat and mouth infections.
2890	LEMOCIN	LEMOCIN CHERRY 24LOZ	LIGNOCAINE	LIGNOCAINE 1MG;CETRIMONIUM BROMIDE 2MG;TYROTHRICIN 4MG	DRAGEE	RECIEPT	For the relief of pain associated with severe sore throat and mouth infections.
2892	LEMOCIN	LEMOCIN LEMON 24LOZ	LIGNOCAINE	LIGNOCAINE 1MG;CETRIMONIUM BROMIDE 2MG;TYROTHRICIN 4MG	DRAGEE	RECIEPT	For the relief of pain associated with severe sore throat and mouth infections.
2893	LEMOCIN	LEMOCIN LEMON 50 LOZ	LIGNOCAINE	LIGNOCAINE 1MG;CETRIMONIUM BROMIDE 2MG;TYROTHRICIN 4MG	DRAGEE	RECIEPT	For the relief of pain associated with severe sore throat and mouth infections.
2894	LEMTRADA	LEMTRADA	ALEMTUZUMAB	ALEMTUZUMAB 12MG/1.2ML	CONCENTRATE	RECIEPT	LEMTRADA is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. 12/09/2018 בקשה לשינוי משטר מינון Posology The recommended dose of alemtuzumab is 12 mg/day administered by intravenous infusion for 2 initial treatment courses with up to 2 additional treatment courses if needed. Initial treatment of 2 courses: •First treatment course: 12 mg/day on 5 consecutive days (60 mg total dose) •Second treatment course: 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the first treatment course. Up to two additional treatment courses, as needed, may be considered (see section 5.1): •Third or fourth course: 12 mg/day on 3 consecutive days (36 mg total dose) administered at least 12 months after the prior treatment course in patients with MS disease activity defined by clinical or imaging features (see section 5.1). Missed doses should not be given on the same day as a scheduled dose. Follow-up of patients The therapy is recommended as an initial 2 treatment of 2 courses with up to 2 additional treatment courses if needed (see posology) with safety follow-up of patients from initiation of the first treatment course and until 48 months after the last infusion of the second treatment course. If an additional third or fourth course is administered, continue safety follow-up until 48 months after the last infusion (see section 4.4). Pre-treatment Patients should be pre-treated with corticosteroids immediately prior to LEMTRADA administration on each of the first 3 days of any treatment course. In clinical trials, patients were pre-treated with 1,000 mg methylprednisolone for the first 3 days of each LEMTRADA treatment course. Pretreatment with antihistamines and/or antipyretics prior to LEMTRADA administration may also be considered. Oral prophylaxis for herpes infection should be administered to all patients starting on the first day of each treatment course and continuing for a minimum of 1 month following treatment with LEMTRADA (see also under ‘Infections’ in section 4.4). In clinical trials, patients were administered aciclovir 200 mg twice a day or equivalent. Special polulations Elderly Clinical studies did not include any patients aged over 61 years old. It has not been determined whether they respond differently than younger patients. Renal or hepatic impairment LEMTRADA has not been studied in patients with renal or hepatic impairment. Paediatric population The safety and efficacy of LEMTRADA in children with MS aged 0 to 18 years have not yet been established. There is no relevant use of alemtuzumab in children aged from birth to less than 10 years for the treatment of multiple sclerosis. No data are available. Method of administration LEMTRADA must be diluted before infusion. The diluted solution should be administered by intravenous infusion over a period of approximately 4 hours. For instructions on dilution of the medicinal product before administration, see section 6.6.
2895	LENALIDOMIDE	LENALIDOMIDE TEVA 10 MG	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE 10MG	CAPSULES	RECIEPT	Lenalidomide Teva is indicated for: • Previously untreated multiple myeloma (MM) in adult patients who are not eligible for transplant. • In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy. • Patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. • The treatment of adults patients with relapsed and/or refractory mantle cell lymphoma (MCL).
2896	LENALIDOMIDE	LENALIDOMIDE TEVA 15 MG	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE 15MG	CAPSULES	RECIEPT	Lenalidomide Teva is indicated for: • Previously untreated multiple myeloma (MM) in adult patients who are not eligible for transplant. • In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy. • Patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. • The treatment of adults patients with relapsed and/or refractory mantle cell lymphoma (MCL).
2897	LENALIDOMIDE	LENALIDOMIDE TEVA 2.5 MG	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE 2.5MG	CAPSULES	RECIEPT	Lenalidomide Teva is indicated for: • Previously untreated multiple myeloma (MM) in adult patients who are not eligible for transplant. • In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy. • Patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. • The treatment of adults patients with relapsed and/or refractory mantle cell lymphoma (MCL).
2898	LENALIDOMIDE	LENALIDOMIDE TEVA 20 MG	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE 20MG	CAPSULES	RECIEPT	Lenalidomide Teva is indicated for: • Previously untreated multiple myeloma (MM) in adult patients who are not eligible for transplant. • In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy. • Patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. • The treatment of adults patients with relapsed and/or refractory mantle cell lymphoma (MCL).
2899	LENALIDOMIDE	LENALIDOMIDE TEVA 25 MG	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE 25MG	CAPSULES	RECIEPT	Lenalidomide Teva is indicated for: • Previously untreated multiple myeloma (MM) in adult patients who are not eligible for transplant. • In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy. • Patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. • The treatment of adults patients with relapsed and/or refractory mantle cell lymphoma (MCL).
2900	LENALIDOMIDE	LENALIDOMIDE TEVA 5 MG	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE 5MG	CAPSULES	RECIEPT	Lenalidomide Teva is indicated for: • Previously untreated multiple myeloma (MM) in adult patients who are not eligible for transplant. • In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy. • Patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. • The treatment of adults patients with relapsed and/or refractory mantle cell lymphoma (MCL).
2901	LENALIDOMIDE	LENALIDOMIDE TEVA 7.5 MG	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE	LENALIDOMIDE AS HYDROCHLORIDE HYDRATE 7.5MG	CAPSULES	RECIEPT	Lenalidomide Teva is indicated for: • Previously untreated multiple myeloma (MM) in adult patients who are not eligible for transplant. • In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy. • The treatment of adults patients with relapsed and/or refractory mantle cell lymphoma (MCL).
2902	LENVIMA	LENVIMA 10 MG	LENVATINIB AS MESILATE	LENVATINIB AS MESILATE 10MG	CAPSULES	RECIEPT	-LENVIMA is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). -LENVIMA is indicated in combi
2903	LENVIMA	LENVIMA 4 MG	LENVATINIB AS MESILATE	LENVATINIB AS MESILATE 4MG	CAPSULES	RECIEPT	-LENVIMA is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). -LENVIMA is indicated in combi
2904	LEPONEX	LEPONEX 100 MG TABLETS	CLOZAPINE	CLOZAPINE 100MG	TABLETS	RECIEPT	For treatment in resistant schizoprenic patients who are non-responsive to, or intolerant to classical neuroleptics. Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for diath.
2905	LEPONEX	LEPONEX 25 MG TABLETS	CLOZAPINE	CLOZAPINE 25MG	TABLETS	RECIEPT	Treatment of resistant schizophrenic patients who are non-responsive to, or intolerant of classic neuroleptics. Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.
2906	LERCANIDIPINE	LERCANIDIPINE TEVA 10 MG	LERCANIDIPINE HYDROCHLORIDE	LERCANIDIPINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Mild to moderate essential hypertension.
2907	LERCANIDIPINE	LERCANIDIPINE TEVA 20 MG	LERCANIDIPINE HYDROCHLORIDE	LERCANIDIPINE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Mild to moderate essential hypertension.
2908	LERCAPRESS	LERCAPRESS 10	LERCANIDIPINE HYDROCHLORIDE	LERCANIDIPINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Mild to moderate essential hypertension.
2910	LERCAPRESS	LERCAPRESS 20	LERCANIDIPINE HYDROCHLORIDE	LERCANIDIPINE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Mild to moderate essentioal hypertension.
2912	LESHCUTAN	LESHCUTAN OINTMENT	METHYLBENZETHONIUM CHLORIDE	METHYLBENZETHONIUM CHLORIDE 12%;PAROMOMYCIN AS SULFATE 15%	OINTMENT	RECIEPT	Topical treatment of cutaneous leishmaniasis.
2913	LETROZOLE	LETROZOLE DEXCEL	LETROZOLE	LETROZOLE 2.5MG	TABLETS	RECIEPT	Letrozole - Dexcel tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole - Dexcel is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
2914	LETROZOLE	LETROZOLE FARMOZ	LETROZOLE	LETROZOLE 2.5MG	TABLETS	RECIEPT	Letrozole Farmoz tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole Farmoz is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
2915	LETROZOLE	LETROZOLE TEVA	LETROZOLE	LETROZOLE 2.5MG	TABLETS	RECIEPT	Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
2916	LEUCOVORIN	LEUCOVORIN TEVA 10 MG/ML	CALCIUM FOLINATE	CALCIUM FOLINATE 10.8MG/ML equivalent to folinic acid 10mg/ml	SOLUTION	RECIEPT	To diminish the toxicity and counteract the action of folic acid antagonists in cytotoxic therapy. As Leucovorin-Fluorouracil chemotherapy combination for cancer treatment.
2917	LEUCOVORIN	LEUCOVORIN TEVA TABLETS	CALCIUM FOLINATE	CALCIUM FOLINATE 16.2MG equivalent to folinic acid 15 mg	TABLETS	RECIEPT	Counteracts the action of folic acid antagonists. Improves blood picture in megaloblastic anemias due to folate deficiency.
2918	LEUKERAN	LEUKERAN TABLETS 2 MG	CHLORAMBUCIL	CHLORAMBUCIL 2MG	TABLETS	RECIEPT	Leukeran is indicated in the treatment of: - Hodgkin's disease - Chronic lymphocytic leukaemia - malignant lymphomas including lymphosarcoma and giant follicular lymphoma.
2920	LEVEMIR	LEVEMIR	INSULIN DETEMIR	INSULIN DETEMIR 100U/ML	SOLUTION	RECIEPT	Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
2921	LEVETIRACETAM	LEVETIRACETAM DEXCEL 1000	LEVETIRACETAM	LEVETIRACETAM 1000MG	TABLETS	RECIEPT	Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Levetiracetam Dexcel is indicated as adjunctive therapy: • In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. • In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
2925	LEVETIRACETAM	LEVETIRACETAM G.E.S. 100 MG/ML	LEVETIRACETAM	LEVETIRACETAM 100MG/1ML	CONCENTRATE	RECIEPT	Levetiracetam G.E.S. 100 mg/ml is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam G.E.S. 100 mg/ml is indicated as adjunctive therapy •in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents patients and children from 4 years of age with epilepsy. •in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy •in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalized Epilepsy. Levetiracetam G.E.S. 100 mg/ml is an alternative for patients when oral administration is temporarily not feasible.
2922	LEVETIRACETAM	LEVETIRACETAM DEXCEL 250	LEVETIRACETAM	LEVETIRACETAM 250MG	TABLETS	RECIEPT	Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Levetiracetam Dexcel is indicated as adjunctive therapy: • In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. • In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
2923	LEVETIRACETAM	LEVETIRACETAM DEXCEL 500	LEVETIRACETAM	LEVETIRACETAM 500MG	TABLETS	RECIEPT	Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Levetiracetam Dexcel is indicated as adjunctive therapy: • In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. • In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
2924	LEVETIRACETAM	LEVETIRACETAM DEXCEL 750	LEVETIRACETAM	LEVETIRACETAM 750MG	TABLETS	RECIEPT	Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Levetiracetam Dexcel is indicated as adjunctive therapy: • In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. • In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
2926	LEVETRIM	LEVETRIM 1000	LEVETIRACETAM	LEVETIRACETAM 1000MG	TABLETS	RECIEPT	- Levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetrim is indicated as adjunctive therapy in the treatment of
2929	LEVETRIM	LEVETRIM SOLUTION	LEVETIRACETAM	LEVETIRACETAM 100MG/ML	SOLUTION	RECIEPT	Levetrim Solution is indicated as: - monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. - adjunctive therapy: in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy
2927	LEVETRIM	LEVETRIM 250	LEVETIRACETAM	LEVETIRACETAM 250MG	TABLETS	RECIEPT	- Levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetrim is indicated as adjunctive therapy in the treatment of
2928	LEVETRIM	LEVETRIM 500	LEVETIRACETAM	LEVETIRACETAM 500MG	TABLETS	RECIEPT	- Levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetrim is indicated as adjunctive therapy in the treatment of
2930	LEVITRA	LEVITRA 10 MG	VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE	VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE 10MG	TABLETS	RECIEPT	Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Levitra to be effective, sexual stimulation is required. Not indicated for use by women.
2931	LEVITRA	LEVITRA 10 MG ORODISPERSIBLE TABLETS	VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE	VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE 10MG	TABLETS	RECIEPT	Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Levitra to be effective, sexual stimulation is required. Not indicated for use by women.
2932	LEVITRA	LEVITRA 20 MG	VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE	VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE 20MG	TABLETS	RECIEPT	Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Levitra to be effective, sexual stimulation is required. Not indicated for use by women.
2933	LEVITRA	LEVITRA 5 MG	VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE	VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE 5MG	TABLETS	RECIEPT	Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Levitra to be effective, sexual stimulation is required. Not indicated for use by women.
2934	LEVO	LEVO	LEVOFLOXACIN HEMIHYDRATE	LEVOFLOXACIN HEMIHYDRATE 500MG	TABLETS	RECIEPT	In adults with infections of mild to moderate severity for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: Acute sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.
2936	LEVOFLOX	LEVOFLOX 5 MG/ML	LEVOFLOXACIN AS HEMIHYDRATE	LEVOFLOXACIN AS HEMIHYDRATE 5MG/1ML	SOLUTION	RECIEPT	In adults for whom intravenous therapy is considered to be appropriate, Levoflox 5mg/ml is indicated for the treatment of the following infections when due to levofloxacin-susceptible micro-organisms: - Community-acquired pneumonia; - complicated urinary tract infections including pyelonephritis; - skin and soft tissue infections.
2937	LEVOFLOXACIN	LEVOFLOXACIN FRESENIUS 5 MG/ML	LEVOFLOXACIN AS HEMIHYDRATE	LEVOFLOXACIN AS HEMIHYDRATE 5MG/ML	SOLUTION	RECIEPT	In adults for whom intravenous therapy is considered to be appropriate, Levofloxacin Fresenius 5mg/ml solution for infusion is indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: - Community- acquired pneumonia, - Complicated urinary tract infections including pyelonephritis, - Skin and soft tissue infections.
2938	LEVOPHED	LEVOPHED	NOREPINEPHRINE BITARTRATE AS MONOHYDRATE	NOREPINEPHRINE BITARTRATE AS MONOHYDRATE 2.0MG/1ML	SOLUTION	RECIEPT	Blood pressure control in certain acute hypotensive stages (e.g. pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infraction, septicemia, blood transfusion and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension.
2939	LICARBIUM	LICARBIUM	LITHIUM CARBONATE	LITHIUM CARBONATE 300MG	TABLETS	RECIEPT	Treatment of manic depressive states.
2940	LIDOCADREN	LIDOCADREN TEVA	LIDOCAINE HYDROCHLORIDE	LIDOCAINE HYDROCHLORIDE 36MG/1.8ML;EPINEPHRINE AS BITARTRATE 22.5MCG/1.8ML	SOLUTION	RECIEPT	Production of local anasthesia by nerve-block Infiltration technique.
2943	LIDOCAINE	LIDOCAINE HCL 2 % AND EPINEPHRIN 1:100000	LIDOCAINE AS MONOHYDRATE	LIDOCAINE AS MONOHYDRATE 20MG/ML;EPINEPHRINE AS BITARTRATE 10MCG/ML	SOLUTION	RECIEPT	Production of local anesthesia by nerve block or infiltration technique.
2941	LIDOCAINE	LIDOCAINE B.BRAUN 1 %	LIDOCAINE HYDROCHLORIDE MONOHYDRATE	LIDOCAINE HYDROCHLORIDE MONOHYDRATE 10MG/ML	SOLUTION	RECIEPT	Local and regional anaesthesia.
2942	LIDOCAINE	LIDOCAINE B.BRAUN 2%	LIDOCAINE HYDROCHLORIDE MONOHYDRATE	LIDOCAINE HYDROCHLORIDE MONOHYDRATE 20MG/ML	SOLUTION	RECIEPT	Local and regional anaesthesia. Severe symptomatic ventricular tachycardia or tachy-arrhythmia, if assessed to be life-threatening.
2944	LIDOPRI	LIDOPRI-AVENIR 5 %	PRILOCAINE	PRILOCAINE 2.5%;LIDOCAINE 2.5%	CREAM		Topical anaesthetic for superficial dermal analgesia in connection with insertion of IV catheters, blood sampling and superficial surgical procedures.
2945	LIDORICIN	LIDORICIN CARE	TYROTHRICIN	TYROTHRICIN 1MG;LIDOCAINE AS HYDROCHLORIDE 1MG	TABLETS	RECIEPT	For the fast relief of severe sore throat. Relief of mouth and throat infections.
2946	LIGNOSPAN	LIGNOSPAN SPECIAL	EPINEPHRINE AS ACID TARTRATE	EPINEPHRINE AS ACID TARTRATE 22.5MCG/1.8ML;LIDOCAINE HYDROCHLORIDE ( AS MONOHYDRATE) 36MG/1.8ML	SOLUTION	RECIEPT	For the production of local anaesthesia for dental procedures, by infiltration or nerve block injections.
2947	LINAGLIPTIN	LINAGLIPTIN TEVA	LINAGLIPTIN	LINAGLIPTIN 5MG	TABLETS	RECIEPT	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Linagliptin Teva should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. Linagliptin Teva has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using Linagliptin Teva.
2950	LINEX	LINEX FOR KIDS 0.05% 10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.05%	SPRAY		Rapid relief of nasal congestion for up to ten hours.
2951	LINEX	LINEX NASAL SPRAY 0.1% 10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	SPRAY		Rapid relief of nasal congestion for up to ten hours.
2949	LINEX	LINEX FOR KIDS	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 0.5MG/ML	SPRAY		Rapid relief of nasal congestion for up to ten hours.
2948	LINEX	LINEX	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 1MG/ML	SPRAY		Rapid relief of nasal congestion for up to ten hours.
2952	LINEZOLID	LINEZOLID TEVA 2 MG/ML	LINEZOLID	LINEZOLID 2MG/ML	SOLUTION	RECIEPT	Therapy is indicated only when an organism resistant to all other antibiotics is suspected. Linezolid 2 mg/ml is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) Pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (MDRSP). 2) Skin and soft tissue infections including diabetic foot infections. 3) Enterococcal infections. Combination therapy may be indicated if a concomitant Gram negative pathogen is documented or suspected.
2954	LIORESAL	LIORESAL TABLETS 10 MG	BACLOFEN	BACLOFEN 10MG	TABLETS	RECIEPT	Muscle spasticity of various origins.
2953	LIORESAL	LIORESAL 25 MG TABLETS	BACLOFEN	BACLOFEN 25MG	TABLETS	RECIEPT	Muscle spasticity of various origins.
2955	LIPANOR	LIPANOR	CIPROFIBRATE	CIPROFIBRATE 100MG	CAPSULES	RECIEPT	For the treatment of primary hyperlipidaemia resistant to appropriate dietary management, including hypercholesterolaemia, hypertriglyceridaemia and combined hyperlipidaemia.
2956	LIPIODOL ULTRA	LIPIODOL ULTRA FLUID	IODINE AS ETHYL ESTERS OF IODIZED FATTY ACIDS OF POPPY SEED OIL	IODINE AS ETHYL ESTERS OF IODIZED FATTY ACIDS OF POPPY SEED OIL 480MG/ML	SOLUTION	RECIEPT	Lymphography.
2958	LIPITOR	LIPITOR 10 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Lipitor is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Lipitor is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
2959	LIPITOR	LIPITOR 20 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Lipitor is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Lipitor is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
2960	LIPITOR	LIPITOR 40 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Lipitor is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Lipitor is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
2961	LIPITOR	LIPITOR 80 MG	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 80MG	TABLETS	RECIEPT	Lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Lipitor is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Lipitor is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
2962	LIPODOX	LIPODOX	DOXORUBICIN HYDROCHLORIDE	DOXORUBICIN HYDROCHLORIDE 2MG/1ML	CONCENTRATE	RECIEPT	1. First or second line therapy of AIDS related Kaposis sarcoma in patients with low CD 4 counts and extensive mucocutaneous or visceral disease. 2. The treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. Refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatment. 3. As monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. 4. In combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
2964	LIPOFUNDIN MCT/LCT	LIPOFUNDIN MCT/LCT 20 %	SOYA OIL	SOYA OIL 100G/L;TRIGLYCERIDES, MEDIUM-CHAIN 100G/L	EMULSION	RECIEPT	Source of calories and essential fatty oils for patients requiring parenteral nutrition.
2963	LIPOFUNDIN MCT/LCT	LIPOFUNDIN MCT/LCT 10 %	TRIGLYCERIDES, MEDIUM-CHAIN	TRIGLYCERIDES, MEDIUM-CHAIN 50G/L;SOYA OIL 50G/L	EMULSION	RECIEPT	Source of calories and essential fatty oils for patients requiring parenteral nutrition
2965	LIQUID POLIBAR PLUS	LIQUID POLIBAR PLUS	BARIUM SULFATE	BARIUM SULFATE 105%W/V	SUSPENSION	RECIEPT	For use only in x-ray departments. Single or double contrast radiographic visualization of the lower gastro intestinal tract.
2966	LITAK	LITAK 10	CLADRIBINE	CLADRIBINE 10MG/5ML	SOLUTION	RECIEPT	Hairy cell leukemia. Chronic lymphocytic leukemia. Second line treatment for low grade Non-Hodgkin's lymphoma.
2967	LITORVA	LITORVA 10	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Litorva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease, Litorva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
2969	LITORVA	LITORVA 20	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Litorva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease, Litorva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
2971	LITORVA	LITORVA 40	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Litorva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease, Litorva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
2973	LITORVA	LITORVA 80	ATORVASTATIN AS CALCIUM	ATORVASTATIN AS CALCIUM 80MG	TABLETS	RECIEPT	Litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Litorva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event such as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease, Litorva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
2975	LIVIAL	LIVIAL 2.5 MG	TIBOLONE	TIBOLONE 2.5MG	TABLETS	RECIEPT	• Complaints resulting from the natural or artificial menopause. Treatment of oestrogen deficiency symptoms in postmenopausal women, more than one year after menopause. Women above 60 years of age should only start with Livial treatment when they are intolerant of, or contraindicated for, other medicinal products approved for the treatment of oestrogen deficiency symptoms. • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. For all women the decision to prescribe tibolone Livial should be based on an assessment of the individual patient’s overall risks and, particularly in the over 60s, should include consideration of the risk of stroke.
2976	LIVOSTIN	LIVOSTIN DROPS 4ML	LEVOCABASTINE HCL	LEVOCABASTINE HCL 0.54MG	DROPS		Allergic conjunctivitis ( classic and vernal). Livostine eye drops is indicated for the rapid and long-lasting relief of eye complaints such as itching, redness, and watering eyes associated with allergies, for example to grass, pollen, moulds and dust.
2977	LIVOSTINE	LIVOSTINE	LEVOCABASTINE AS HYDROCHLORIDE	LEVOCABASTINE AS HYDROCHLORIDE 0.5MG/ML	DROPS		Allergic conjunctivitis ( classic and vernal). Livostine eye drops is indicated for the rapid and long-lasting relief of eye complaints such as itching, redness, and watering eyes associated with allergies, for example to grass, pollen, moulds and dust.
2978	LOANA	LOANA	PRILOCAINE	PRILOCAINE 25MG/1 G;LIDOCAINE 25MG/1 G	CREAM		Topical anaesthetic for superficial dermal analgesia in connection with insertion of IV catheters, blood sampling and superficial surgical procedures
2979	LOCALIN	LOCALIN DROPS	OXYBUPROCAINE HYDROCHLORIDE	OXYBUPROCAINE HYDROCHLORIDE 0.4%	DROPS	RECIEPT	Local anesthetic
2980	LOCATOP	LOCATOP 0.1 %	DESONIDE	DESONIDE 0.1%	CREAM	RECIEPT	Treatment of dermatoses which require treatment with topical corticosteroids e.g. psoriasis, lichenipication, atopic dermatitis, contact dermatitis
2981	LOCERYL	LOCERYL	AMOROLFINE AS HYDROCHLORIDE	AMOROLFINE AS HYDROCHLORIDE 5%W/V	LACQUE	RECIEPT	Topical treatment of onycomycosis caused by dermatophytes, yeast and moulds.
1093	LODERM	CICLODERM C	CICLOPIROX OLAMINE	CICLOPIROX OLAMINE 1%;GENTAMICIN (AS SULFATE) 0.1%;CLOBETASONE BUTYRATE 0.05%	CREAM	RECIEPT	For local treatment of skin inflammations accompanied by a mycotic and/or bacterial infection.
2982	LOJUXTA	LOJUXTA 10 MG	LOMITAPIDE AS MESYLATE	LOMITAPIDE AS MESYLATE 10MG	CAPSULES	RECIEPT	An adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
2983	LOJUXTA	LOJUXTA 20 MG	LOMITAPIDE AS MESYLATE	LOMITAPIDE AS MESYLATE 20MG	CAPSULES	RECIEPT	An adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
2984	LOJUXTA	LOJUXTA 5 MG	LOMITAPIDE AS MESYLATE	LOMITAPIDE AS MESYLATE 5MG	CAPSULES	RECIEPT	An adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
2985	LONQUEX	LONQUEX	LIPEGFILGRASTIM	LIPEGFILGRASTIM 6MG/0.6ML	SOLUTION	RECIEPT	Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
2986	LOPERID	LOPERID 2MG 10CAP	LOPERAMIDE HCL	LOPERAMIDE HCL 2MG	CAPSULES		Control and symptomatic relief of acute diarrhea.
2987	LOPERID	LOPERID CAPSULES	LOPERAMIDE HYDROCHLORIDE	LOPERAMIDE HYDROCHLORIDE 2MG	CAPSULES	RECIEPT	Control and symptomatic relief of acute diarrhea.
2988	LOPI-CARE	LOPI-CARE 10 TABLETS	LOPERAMIDE HCL	LOPERAMIDE HCL 2MG	TABLETS		Control and symptomatic relief of acute diarrhea.
2989	LOPI-CARE	LOPI-CARE TABLETS	LOPERAMIDE HYDROCHLORIDE	LOPERAMIDE HYDROCHLORIDE 2MG	TABLETS	RECIEPT	Control and symptomatic relief of acute diarrhea.
2990	LOPRESOR	LOPRESOR DIVITABS 200 MG	METOPROLOL TARTRATE	METOPROLOL TARTRATE 200MG	TABLETS	RECIEPT	Hypertension, angina pectoris, arrhythmia, prophylaxis of migrain, prophylaxis of reinfarction.
2992	LORAMIDE	LORAMIDE 12 CAPLETS	LOPERAMIDE HCL	LOPERAMIDE HCL 2MG	TABLETS		Control and symptomatic relief of acute diarrhea.
2991	LORAMIDE	LORAMIDE	LOPERAMIDE HYDROCHLORIDE	LOPERAMIDE HYDROCHLORIDE 2MG	TABLETS	RECIEPT	Control and symptomatic relief of acute diarrhea.
2993	LORASTINE	LORASTINE 10MG 10TAB	LORATADINE	LORATADINE 10MG	TABLETS		Seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
2994	LORASTINE	LORASTINE 10MG 20TAB	LORATADINE	LORATADINE 10MG	TABLETS		Seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
2996	LORASTINE	LORASTINE TABLETS	LORATADINE	LORATADINE 10MG	TABLETS		Seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
2995	LORASTINE	LORASTINE SYRUP	LORATADINE	LORATADINE 5MG/5ML	SYRUP		Antihistamine preparation for treatment of allergic rhinitis and urticaria.
2997	LORATADIM	LORATADIM	LORATADINE	LORATADINE 10MG	TABLETS	RECIEPT	Seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
2998	LORATADIM	LORATADIM 10MG 10TAB	LORATADINE	LORATADINE 10MG	TABLETS		Seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
2999	LORATADIM	LORATADIM 10MG 20TAB	LORATADINE	LORATADINE 10MG	TABLETS		Seasonal allergic rhinitis, perennial allergic rhinitis, chronic urticaria.
3000	LORATRIM	LORATRIM	LORATADINE	LORATADINE 0.1G/100ML	SYRUP	RECIEPT	Antihistamine preparation for treatment of allergic rhinitis and urticaria.
3001	LORATRIM	LORATRIM SYR 120ML	LORATADINE	LORATADINE 5MG/5ML	SYRUP		Antihistamine preparation for treatment of allergic rhinitis and urticaria.
3002	LORIVAN	LORIVAN	LORAZEPAM	LORAZEPAM 1MG	TABLETS	RECIEPT	Anxiety and tension.
3003	LORMYX	LORMYX 200 MG	RIFAXIMINE	RIFAXIMINE 200MG POLYMORPHIC FORM ALPHA	TABLETS	RECIEPT	• Casual treatment of diseases of grown-ups and youngsters from 12 years up, caused by bacteria in the gastrointestinal tract, sensitive to Rifaximin: • hepatic encephalopathy • traveller’s diarrhea, caused by not-invasive enteropathogeneous bacteria. • Non-complicated diverticular diseases.
3009	LOSARDEX	LOSARDEX PLUS	HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE 12.5MG;LOSARTAN POTASSIUM 50MG	TABLETS	RECIEPT	Losardex plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.
3004	LOSARDEX	LOSARDEX 100	LOSARTAN POTASSIUM	LOSARTAN POTASSIUM 100MG	TABLETS	RECIEPT	Hypertension: Losardex 100 is indicated for the treatment of hypertension Heart failure: Losardex 100 is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losardex 100 is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Losardex 100 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losardex 100 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Losardex 100 on the primary deposite endpoint was largely driven by reduction in the risk of stroke.
3006	LOSARDEX	LOSARDEX 12.5	LOSARTAN POTASSIUM	LOSARTAN POTASSIUM 12.5MG	TABLETS	RECIEPT	Heart failure: Losardex 12.5 mg is indicated for the treatment of heart failure, when treatment with an ACE inhibitor is no longer considered appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losardex 12.5 mg is not recommended.
3007	LOSARDEX	LOSARDEX 50	LOSARTAN POTASSIUM	LOSARTAN POTASSIUM 50MG	TABLETS	RECIEPT	Hypertension: Losardex 50 is indicated for the treatment of hypertension Heart failure: Losardex 50 is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losardex 50 is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Losardex 50 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losardex 50 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Losardex 50 on the primary deposite endpoint was largely driven by reduction in the risk of stroke.
3012	LOSARTA	LOSARTA PLUS	HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE 12.5MG;LOSARTAN AS POTASSIUM 50MG	TABLETS	RECIEPT	For the treatment of hypertension, for patients in whom combination therapy is appropriate. To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.
3010	LOSARTA	LOSARTA 12.5	LOSARTAN AS POTASSIUM	LOSARTAN AS POTASSIUM 12.5MG	TABLETS	RECIEPT	Heart failure: Losartan 12.5 mg is indicated for the treatment of heart failure, when treatment with an ACE inhibitor is no longer considered appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to losartan 12.5 mg is not recommended
3011	LOSARTA	LOSARTA 50	LOSARTAN AS POTASSIUM	LOSARTAN AS POTASSIUM 50MG	TABLETS	RECIEPT	Hypertension: Losarta 50 mg is indicated for the treatment of hypertension Heart failure: Losarta 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losarta 50 mg is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Losarta 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losarta 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Losarta 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.
3013	LOSARTAN	LOSARTAN PLUS TEVA	HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE 12.5MG;LOSARTAN POTASSIUM 50MG	TABLETS	RECIEPT	Losartan plus teva is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.
3015	LOSARTAN	LOSARTAN TEVA 12.5 MG	LOSARTAN POTASSIUM	LOSARTAN POTASSIUM 12.5MG	TABLETS	RECIEPT	Heart failure: Losartan 12.5 mg is indicated for the treatment of heart failure, when treatment with an ACE inhibitor is no longer considered appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losartan 12.5 mg is not recommended
3017	LOSARTAN	LOSARTAN TEVA 50 MG	LOSARTAN POTASSIUM	LOSARTAN POTASSIUM 50MG	TABLETS	RECIEPT	Hypertension: Losartan 50 mg is indicated for the treatment of hypertension Heart failure: Losartan 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Losartan 50 mg is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Losartan 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Losartanmg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Losartan 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.
3019	LOSEC	LOSEC 20 MG 14 CAPS (OTC)	OMEPRAZOLE	OMEPRAZOLE 20MG	CAPSULES	RECIEPT	Acute duodenal ulcer. Acute gastric ulcer. Helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. Reflux esophagitis: - Treatment ; - Long-term management; - Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Treatment of severe reflux oesophagitis in children from one year of age and older. - Maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. - Zollinger-ellison syndrome. - Treatment and prevention of NSAID - associated duodenal and gastric ulcers or erosions in high risk patients.
3020	LOSEC	LOSEC 20 MG 28 CAPS (OTC)	OMEPRAZOLE	OMEPRAZOLE 20MG	CAPSULES	RECIEPT	Acute duodenal ulcer. Acute gastric ulcer. Helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. Reflux esophagitis: - Treatment ; - Long-term management; - Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Treatment of severe reflux oesophagitis in children from one year of age and older. - Maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. - Zollinger-ellison syndrome. - Treatment and prevention of NSAID - associated duodenal and gastric ulcers or erosions in high risk patients.
3021	LOSEC	LOSEC 20 MG RX	OMEPRAZOLE	OMEPRAZOLE 20MG	CAPSULES	RECIEPT	Acute duodenal ulcer. Acute gastric ulcer. Helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. Reflux esophagitis: - Treatment ; - Long-term management; - Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Treatment of severe reflux oesophagitis in children from one year of age and older. - Maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. - Zollinger-ellison syndrome. - Treatment and prevention of NSAID - associated duodenal and gastric ulcers or erosions in high risk patients.
3022	LOSEC	LOSEC 20MG	OMEPRAZOLE	OMEPRAZOLE 20MG	CAPSULES	RECIEPT	Relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.
3024	LOSEC	LOSEC 20MG RX	OMEPRAZOLE	OMEPRAZOLE 20MG	CAPSULES	RECIEPT	Acute duodenal ulcer. Acute gastric ulcer. Helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. Reflux esophagitis: - Treatment ; - Long-term management; - Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Treatment of severe reflux oesophagitis in children from one year of age and older. - Maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. - Zollinger-ellison syndrome. - Treatment and prevention of NSAID - associated duodenal and gastric ulcers or erosions in high risk patients.
3025	LOTAN	LOTAN 100	LOSARTAN AS POTASSIUM	LOSARTAN AS POTASSIUM 100MG	TABLETS	RECIEPT	Hypertension: Lotan 100 is indicated for the treatment of hypertension. Heart failure: Lotan 100 is indicated for the treatment of heart failure, when treatment with an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Lotan 100 is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Lotan 100 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Lotan 100 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Lotan 100 on the primary deposite endpoint was largely driven by reduction in the risk of stroke.
3027	LOTAN	LOTAN 12.5	LOSARTAN AS POTASSIUM	LOSARTAN AS POTASSIUM 12.5MG	TABLETS	RECIEPT	Heart failure: Lotan 12.5 is indicated for the treatment of heart failure, when treatment with an ACE inhibitor is no longer considered appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Lotan 12.5 mg is not recommended
3029	LOTAN	LOTAN 50	LOSARTAN AS POTASSIUM	LOSARTAN AS POTASSIUM 50MG	TABLETS	RECIEPT	Hypertension: Lotan 50 mg is indicated for the treatment of hypertension Heart failure: Lotan 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Lotan 50 mg is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Lotan 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Lotan 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Lotan 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.
3031	LOTAN	LOTAN PLUS	LOSARTAN AS POTASSIUM	LOSARTAN AS POTASSIUM 50MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	Lotan plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.
3033	LOTEMAX	LOTEMAX GEL	LOTEPREDNOL ETABONATE	LOTEPREDNOL ETABONATE 5MG/1 G	GEL	RECIEPT	LOTEMAX is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
3034	LOTEMAX	LOTEMAX SUSPENSION	LOTEPREDNOL ETABONATE	LOTEPREDNOL ETABONATE 5MG/1ML	SUSPENSION	RECIEPT	Lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. Lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with Lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . The incidence of patients with clinically significant increases in IOP (> or = 10 mmHg) was 1 % with Lotemax adn 6 % with prednisolone acetate 1 %. Lotemax should not be used in patients who require a more potent corticosteroid for this indication. Lotemax is also indicated for the treatment of post - operative inflammation following ocular surgery.
3036	LOTIO ZINCI	LOTIO ZINCI FLORIS	ZINC AS OXIDE	ZINC AS OXIDE 20%	LOTION		Relief of various skin irritations.
3035	LOTIO ZINCI	LOTIO ZINCI 100ML	ZINC OXIDE	ZINC OXIDE 20%	LOTION		Relief of various skin irritations.
3040	LOZAPINE	LOZAPINE 100 MG	CLOZAPINE	CLOZAPINE 100MG	TABLETS	RECIEPT	Treatment of schizophrenic patients only in cases who are nonresponsive to conventional therapy.
3042	LOZAPINE	LOZAPINE 25 MG	CLOZAPINE	CLOZAPINE 25MG	TABLETS	RECIEPT	Treatment of schizophrenic patients only in cases who are nonresponsive to conventional therapy.
3044	LUCENTIS	LUCENTIS	RANIBIZUMAB	RANIBIZUMAB 10MG/ML	SOLUTION	RECIEPT	Treatment of patients with neovascular (wet) age-related macular degeneration (AMD). Treatment of adult patients with visual impairment due to diabetic macular oedema (DME) . The treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (RVO). The treatment of visual impaiment due to choroidal neovascularization (CNV) .
3045	LUCRIN PDS DEPOT	LUCRIN PDS DEPOT 11.25 MG	LEUPRORELIN ACETATE	LEUPRORELIN ACETATE 11.25MG	POWDER	RECIEPT	Endometriosis, prostatic cancer, treatment of uterine Fibroids for a period of up to six months. Treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.
3047	LUCRIN PDS DEPOT	LUCRIN PDS DEPOT 3.75 MG	LEUPRORELIN ACETATE	LEUPRORELIN ACETATE 3.75MG	POWDER	RECIEPT	Endometriosis prostatic cancer treatment of uterine Fibroids for a period of up to six months. Treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.
3049	LUMIGAN	LUMIGAN	BIMATOPROST	BIMATOPROST 0.3MG/ML	SOLUTION	RECIEPT	Reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
3050	LUSTRAL	LUSTRAL TABLETS 100 MG	SERTRALINE AS HYDROCHLORIDE	SERTRALINE AS HYDROCHLORIDE 100MG	TABLETS	RECIEPT	For the treatment of symptoms of depression in patients with or without a history of mania. Following satisfactory response, continuation with sertraline therapy is effective in prevention relapse of the initial episode of depression or recurrence of further depressive episodes.
3052	LUSTRAL	LUSTRAL TABLETS 50 MG	SERTRALINE AS HYDROCHLORIDE	SERTRALINE AS HYDROCHLORIDE 50MG	TABLETS	RECIEPT	For the treatment of symptoms of depression in patients with or without a history of mania. Following satisfactory response, continuation with sertraline therapy is effective in prevention relapse of the initial episode of depression or recurrence of further depressive episodes.
3054	LUTATHERA	LUTATHERA 370 MBq/ML SOLUTION FOR INFUSION	LUTETIUM (177LU) OXODOTREOTIDE	LUTETIUM (177LU) OXODOTREOTIDE 370MBQ/ML	SOLUTION		Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in adults.
3058	LUVERIS	LUVERIS 75 IU	LUTEINIZING HORMONE	LUTEINIZING HORMONE 75 IU/ML	POWDER	RECIEPT	Luveris in association with a follicle stimulating hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.
3059	LUXTURNA	LUXTURNA	VORETIGENE NEPARVOVEC	VORETIGENE NEPARVOVEC 5X10^12VECTOR GENOMES/ML	CONCENTRATE	RECIEPT	Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
3060	LYCLEAR	LYCLEAR DERMAL CREAM	PERMETHRIN	PERMETHRIN 5.0%W/W	CREAM	RECIEPT	Is indicated for the treatment of scabies.
3061	LYNPARZA	LYNPARZA 100 MG	OLAPARIB	OLAPARIB 100MG	TABLETS	RECIEPT	Ovarian cancer Lynparza is indicated as monotherapy for the: •maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2- mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. * Maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. Germline BRCA-mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated in patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)- positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.
3063	LYNPARZA	LYNPARZA 150 MG	OLAPARIB	OLAPARIB 150MG	TABLETS	RECIEPT	Ovarian cancer Lynparza is indicated as monotherapy for the: •maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2- mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. * Maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. Germline BRCA-mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated in patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)- positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.
3065	LYNPARZA	LYNPARZA 50 MG	OLAPARIB	OLAPARIB 50MG	CAPSULES	RECIEPT	Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, (including fallopian tube, or primary peritoneal) cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
3066	LYRICA	LYRICA 100 MG	PREGABALIN	PREGABALIN 100MG	CAPSULES	RECIEPT	LLyrica is indicated for the: - Treatment of peripheral and central neuropathic pain in adults. - Management of Fibromyalgia. - Treatment of Generalised Anxiety Disorder (GAD) in adults.
3067	LYRICA	LYRICA 150 MG	PREGABALIN	PREGABALIN 150MG	CAPSULES	RECIEPT	Lyrica is indicated for the: - Treatment of peripheral and central neuropathic pain in adults. - Management of Fibromyalgia. - Treatment of Generalised Anxiety Disorder (GAD) in adults.
3068	LYRICA	LYRICA 200 MG	PREGABALIN	PREGABALIN 200MG	CAPSULES	RECIEPT	Lyrica is indicated for the: - Treatment of peripheral and central neuropathic pain in adults. - Management of Fibromyalgia. - Treatment of Generalised Anxiety Disorder (GAD) in adults.
3069	LYRICA	LYRICA 225 MG	PREGABALIN	PREGABALIN 225MG	CAPSULES	RECIEPT	Lyrica is indicated for the: - Treatment of peripheral and central neuropathic pain in adults. - Management of Fibromyalgia. - Treatment of Generalised Anxiety Disorder (GAD) in adults.
3070	LYRICA	LYRICA 25 MG	PREGABALIN	PREGABALIN 25MG	CAPSULES	RECIEPT	Lyrica is indicated for the: - Treatment of peripheral and central neuropathic pain in adults. - Management of Fibromyalgia. - Treatment of Generalised Anxiety Disorder (GAD) in adults.
3071	LYRICA	LYRICA 300 MG	PREGABALIN	PREGABALIN 300MG	CAPSULES	RECIEPT	Lyrica is indicated for the: - Treatment of peripheral and central neuropathic pain in adults. - Management of Fibromyalgia. - Treatment of Generalised Anxiety Disorder (GAD) in adults. .
3072	LYRICA	LYRICA 50 MG	PREGABALIN	PREGABALIN 50MG	CAPSULES	RECIEPT	Lyrica is indicated for the: - Treatment of peripheral and central neuropathic pain in adults. - Management of Fibromyalgia. - Treatment of Generalised Anxiety Disorder (GAD) in adults.
3073	LYRICA	LYRICA 75 MG	PREGABALIN	PREGABALIN 75MG	CAPSULES	RECIEPT	Lyrica is indicated for the: - Treatment of peripheral and central neuropathic pain in adults. - Management of Fibromyalgia. - Treatment of Generalised Anxiety Disorder (GAD) in adults.
3074	LYRINEL	LYRINEL 10 MG	OXYBUTYNIN CHLORIDE	OXYBUTYNIN CHLORIDE 10MG	TABLETS	RECIEPT	Once daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
3075	LYRINEL	LYRINEL 5 MG	OXYBUTYNIN CHLORIDE	OXYBUTYNIN CHLORIDE 5MG	TABLETS	RECIEPT	Once daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
3077	LYTEERS	LYTEERS EYE DRPS15CC	HYDROXYETHYL CELLULOSE	HYDROXYETHYL CELLULOSE 0.19%	DROPS		A lubricating tear substitute for dry eyes when tear production is insufficient.
3076	LYTEERS	LYTEERS EYE DROPS	HYDROXYETHYLCELLULOSE	HYDROXYETHYLCELLULOSE 0.19%	DROPS		A lubricating tear substitute for dry eyes when tear production is insufficient.
3078	LYXUMIA	LYXUMIA 10 MCG	LIXISENATIDE	LIXISENATIDE 10MCG/0.2ML	SOLUTION	RECIEPT	For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
3079	LYXUMIA	LYXUMIA 20 MCG	LIXISENATIDE	LIXISENATIDE 20MCG/0.2ML	SOLUTION	RECIEPT	For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
3080	M.I.R.	M.I.R. 15	MORPHINE SULFATE	MORPHINE SULFATE 15MG	TABLETS	RECIEPT	For the relief of moderate to severe pain.
3081	M.I.R.	M.I.R. 30	MORPHINE SULFATE	MORPHINE SULFATE 30MG	TABLETS	RECIEPT	For the relief of moderate to severe pain.
3088	MAALOX	MAALOX SUSPENSION	ALUMINIUM HYDROXIDE	ALUMINIUM HYDROXIDE 175MG/5ML;MAGNESIUM HYDROXIDE 200MG/5ML	SUSPENSION		Antacid.
3085	MAALOX	MAALOX PLUS SUSPENSION	ALUMINIUM HYDROXIDE	ALUMINIUM HYDROXIDE 175MG/5ML;MAGNESIUM HYDROXIDE 200MG/5ML;SIMETHICONE 25MG/5ML	SUSPENSION		Antacid, antiflatulent, relief of sensation of heatburn.
3082	MAALOX	MAALOX PLUS 40 TAB	ALUMINIUM HYDROXIDE	ALUMINIUM HYDROXIDE 200MG;MAGNESIUM HYDROXIDE 200MG;SIMETHICONE 26.25	TABLETS		Antacid, antiflatulent, relief of sensation of heatburn.
3084	MAALOX	MAALOX PLUS SUSP 355ML	ALUMINIUM HYDROXIDE	ALUMINIUM HYDROXIDE 225MG;MAGNESIUM HYDROXIDE 200MG;SIMETHICONE 25MG/5ML	SUPPOSITORIES		Antacid, antiflatulent, relief of sensation of heatburn.
3087	MAALOX	MAALOX SUSP 355ML	ALUMINIUM HYDROXYDE	ALUMINIUM HYDROXYDE 225MG/5ML;MAGNESIUM HYDROXIDE 200MG/5ML	SUPPOSITORIES		Antacid.
3083	MAALOX	MAALOX PLUS CHEWABLE TABLETS	MAGNESIUM HYDROXIDE	MAGNESIUM HYDROXIDE 200MG;DIMETHICONE 25MG;ALUMINIUM OXIDE HYDRATED 200MG	TABLETS		Antacid, antiflatulent, relief of sensation of heartburn.
3090	MABTHERA	MABTHERA 10 MG/ML I.V	RITUXIMAB	RITUXIMAB 10MG/ML	CONCENTRATE	RECIEPT	MabThera is indicated for the following indications: * Non-Hodgkin’s lymphoma (NHL) MabThera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, B-cell non-hodgkin’s lymphoma. MabThera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy MabThera is indicated for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy. MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * Chronic lymphocytic leukaemia (CLL) MabThera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including MabThera or patients refractory to previous MabThera plus chemotherapy. * Rheumatoid arthritis MabThera is indicated, in combination with methotrexate, to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to one or more TNF antagonist therapies. * Granulomatosis with polyangiitis and Microscopic polyangiitis MabThera, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis (WG) and Microscopic polyangiitis (MPA). *Pemphigus vulgaris MabThera is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (PV).
3091	MABTHERA	MABTHERA 1400 MG S.C.	RITUXIMAB	RITUXIMAB 1400MG/11.7ML	SOLUTION	RECIEPT	MabThera subcutaneous formulation is indicated in adults for Non-Hodgkin`s lymphoma (NHL): • MabThera is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy. • MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. • MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
3096	MACCABIMOL	MACCABIMOL KID	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		Analgesic, antipyretic pediatric suppositories.
3097	MACCABIMOL	MACCABIMOL KID 12 SUPPOSITORIES	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		Analgesic and antipyretic.
3098	MACCABIMOL	MACCABIMOL KID FORTE	PARACETAMOL	PARACETAMOL 250MG	SUPPOSITORIES		Analgesic and antipyretic.
3099	MACCABIMOL	MACCABIMOL KID FORTE 12 SUP	PARACETAMOL	PARACETAMOL 250MG	SUPPOSITORIES		Analgesic and antipyretic.
3092	MACCABIMOL	MACCABIMOL	PARACETAMOL	PARACETAMOL 500MG	TABLETS		For temporary relief of pain and fever of different etiologics such as: headache, cold, influenza, dysmenorrhea, toothache and minor rheumatic pain.
3095	MACCABIMOL	MACCABIMOL 500mg 50 CAPLETS	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Analgesic and antipyretic.
3101	MACLIVAN	MACLIVAN 400 MG /5 ML	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 400MG/5ML;CLAVULANIC ACID AS POTASSIUM 57MG/5ML	POWDER	RECIEPT	Maclivan is indicated for the treatment of the following infections in adults and children: - Acute bacterial sinusitis (adequately diagnosed). - Acute otitis media. - Acute exacerbations of chronic bronchitis (adequately diagnosed). - Community acquired pneumonia. - Cystitis. - Pyelonephritis. - Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. - Bone and joint infections, in particular osteomyelitis. - Recurrent tonsillitis.
3102	MACLIVAN	MACLIVAN 500 MG	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 500MG;CLAVULANIC ACID AS POTASSIUM 125MG	TABLETS	RECIEPT	Maclivan is indicated for the treatment of the following infections in adults and children : • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. • Bone and joint infections, in particular osteomyelitis.
3100	MACLIVAN	MACLIVAN 250 MG/5 ML	CLAVULANIC ACID AS POTASSIUM	CLAVULANIC ACID AS POTASSIUM 62.5MG/5ML;AMOXICILLIN AS TRIHYDRATE 250MG/5ML	POWDER	RECIEPT	Maclivan is indicated for the treatment of the following infections in adults and children : • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. • Bone and joint infections, in particular osteomyelitis.
3104	MAGNETOL	MAGNETOL	GADOPENTETIC ACID DIMEGLUMINE	GADOPENTETIC ACID DIMEGLUMINE 469MG/ML	SOLUTION	RECIEPT	Injectable contrast medium for magnetic resonance imaging (MRI).
3106	MALARONE	MALARONE TABLETS FOR ADULTS	ATOVAQUONE	ATOVAQUONE 250MG;PROGUANIL HYDROCHLORIDE 100MG	TABLETS	RECIEPT	Prevention of malaria: For the prophylaxis of P.falciparum malaria, including in areas where chloroquine resistance has been reported. Treatment of malaria: For the treatment of acute, uncomplicated P.flaciparum malaria. Malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.
3105	MALARONE	MALARONE PAEDIATRIC TABLETS	ATOVAQUONE	ATOVAQUONE 62.5MG;PROGUANIL HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Prevention of malaria: For the prophylaxis of P.falciparum malaria, including in areas where chloroquine resistance has been reported. Treatment of malaria: For the treatment of acute, uncomplicated P.flaciparum malaria. Malarone has been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance. Malarone is recommended for paediatric patients who weigh over 11 kg.
3113	MARCAINE	MARCAINE 0.5 %	BUPIVACAINE HYDROCHLORIDE	BUPIVACAINE HYDROCHLORIDE 5MG/ML	SOLUTION	RECIEPT	Long acting local anaesthetic.
3114	MARCAINE	MARCAINE SPINAL 0.5 %	BUPIVACAINE HYDROCHLORIDE	BUPIVACAINE HYDROCHLORIDE 5MG/ML	SOLUTION	RECIEPT	Spinal anaesthesia for surgery.
3115	MARCAINE	MARCAINE SPINAL 0.5 % HEAVY	GLUCOSE	GLUCOSE 80MG/ML ANHYDROUS;BUPIVACAINE HYDROCHLORIDE 5MG/ML	SOLUTION	RECIEPT	Spinal anaesthesia for surgery, e.g. urological and lower limb surgery, lasting 2-3 hours, abdominal surgery lasting 45-60 minutes.
3116	MARONIL	MARONIL 25	CLOMIPRAMINE HYDROCHLORIDE	CLOMIPRAMINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Depression of varying origin. In children and adolescents there is not sufficient evidence of safety and efficacy of Maronil in the treatment of depressive states of varying aetiology and symptomatology. The use of Maronil in children and adolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. Obsessive compulcive syndromes. No experience is available in children younger than 5 years of age.
3117	MARONIL	MARONIL 75 S.R	CLOMIPRAMINE HYDROCHLORIDE	CLOMIPRAMINE HYDROCHLORIDE 75MG	TABLETS	RECIEPT	Treatment of depressive states. Obsessive compulsive disorders.
3118	MAVENCLAD	MAVENCLAD 10 MG TABLETS	CLADRIBINE	CLADRIBINE 10MG	TABLETS	RECIEPT	Mavenclad 10mg tablets is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features
3120	MAVIRET	MAVIRET	PIBRENTASVIR	PIBRENTASVIR 40MG;GLECAPREVIR 100MG	TABLETS	RECIEPT	Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and in adolescents aged 12 to <18 years
3122	MAXIAIR MEDICAL LIQUID NITROGEN ( EP )	MAXIAIR MEDICAL LIQUID NITROGEN ( EP )	NITROGEN	NITROGEN 99.5%	LIQUEFIED GAS	RECIEPT	Liquefied Nitrogen for treatment of skin lesions by freezing (cryotherapy).
3126	MAXIBONE	MAXIBONE 70	ALENDRONATE AS SODIUM	ALENDRONATE AS SODIUM 70MG	TABLETS	RECIEPT	Maxibone is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures). Treatment to increase bone mass in men with osteoporosis.
3125	MAXIBONE	MAXIBONE 10	ALENDRONIC ACID AS SODIUM	ALENDRONIC ACID AS SODIUM 10MG	TABLETS	RECIEPT	Treatment of osteoporosis in postmenopausal women: Maxibone is indicated for the treatment of osteoporosis to prevent fractures, including those of the hip, wrist and spine ( vertebral compression fractures). Prevention and treatment of glucocorticoid-induced osteoporosis: Maxibone is indicated for the prevention and treatment of glucocorticoid-induced osteoporosis in men and women. For the treatment of osteoporosis in men.
3128	MAXICOOL	MAXICOOL	NITROUS OXIDE	NITROUS OXIDE 99%	GAS	RECIEPT	General anasthetic, analgesic.
3130	MAXITROL	MAXITROL OPHTHALMIC SUSPENSION	DEXAMETHASONE	DEXAMETHASONE 1.0MG/ML;NEOMYCIN AS SULFATE 3,500 IU/ML;POLYMYXIN B SULFATE 6000 IU/ML	SUSPENSION	RECIEPT	Maxitrol is indicated in ocular inflammation when concurrent use of antimicrobial in judged necessary.
3129	MAXITROL	MAXITROL OPHTHALMIC OINTMENT	DEXAMETHASONE	DEXAMETHASONE 1MG/G;NEOMYCIN AS SULFATE 3500IU/G;POLYMYXIN B SULFATE 6000IU/G	OINTMENT	RECIEPT	For the treatment of eye infections which are responsive to steroids, when an antibiotic is also needed.
3132	MCR	MCR 100	MORPHINE SULFATE	MORPHINE SULFATE 100MG	TABLETS	RECIEPT	Prolonged relief of severe pain.
3131	MCR	MCR 10	MORPHINE SULFATE	MORPHINE SULFATE 10MG	TABLETS	RECIEPT	Prolonged relief of severe pain.
3133	MCR	MCR 30	MORPHINE SULFATE	MORPHINE SULFATE 30MG	TABLETS	RECIEPT	Prolonged relief of severe pain.
3147	MEDROL	MEDROL 4 MG	METHYLPREDNISOLONE	METHYLPREDNISOLONE 4MG	TABLETS	RECIEPT	Anti-allergic, anti-inflammatory for treatment of allergic conditions such as asthma and diverse skin disease, inflammatory states and arthritis.
4882	MEDROL	SOLU MEDROL 125 MG	METHYLPREDNISOLONE AS SODIUM SUCCINATE	METHYLPREDNISOLONE AS SODIUM SUCCINATE 125MG/VIAL	POWDER	RECIEPT	Solu Medrol is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.
4883	MEDROL	SOLU MEDROL 40 MG	METHYLPREDNISOLONE AS SODIUM SUCCINATE	METHYLPREDNISOLONE AS SODIUM SUCCINATE 40MG/VIAL	POWDER	RECIEPT	Solu Medrol is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.
4881	MEDROL	SOLU MEDROL 1000 MG	METHYLPREDNISOLONE AS SODIUM SUCCINATE	METHYLPREDNISOLONE AS SODIUM SUCCINATE 62.5MG/ML	POWDER	RECIEPT	Solu Medrol is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.
4884	MEDROL	SOLU MEDROL 500 MG	METHYLPREDNISOLONE AS SODIUM SUCCINATE	METHYLPREDNISOLONE AS SODIUM SUCCINATE 62.5MG/ML	POWDER	RECIEPT	Solu Medrol is indicated to treat any condition in which IM or IV corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.
3149	MEGALOTECT	MEGALOTECT CP	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 96% at least;HUMAN PLASMA PROTEIN 50MG/ML;CYTOMEGALOVIRUS ANTIBODY 100U/ML	SOLUTION	RECIEPT	Prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients.
3150	MEGAXIN	MEGAXIN IV	MOXIFLOXACIN	MOXIFLOXACIN 400MG/250ML	SOLUTION	RECIEPT	Megaxin IV is indicated for the treatment of adults (> 18 years of age) with Community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and Complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with Megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.
3152	MEGAXIN	MEGAXIN TABLETS	MOXIFLOXACIN AS HYDROCHLORIDE	MOXIFLOXACIN AS HYDROCHLORIDE 0.4G	TABLETS	RECIEPT	For the treatment of the following bacterial infections in patients of 18 years and older • Respiratory infections : - Uncomplicated Acute bacterial sinusitis (ABS) - Acute exacerbations of chronic bronchitis (AECB) Megaxin tablets should be used to treat adequately diagnosed ABS and AECB only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - Community acquired pneumonia, except severe cases. Megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • Community-acquired spontaneous and wound infections of the skin and skin structure. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with Megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
3154	MEKINIST	MEKINIST 0.5 MG	TRAMETINIB AS DIMETHYL SULFOXIDE	TRAMETINIB AS DIMETHYL SULFOXIDE 0.5MG	TABLETS	RECIEPT	Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. Non-small cell lung cancer (NSCLC) : Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. Adjuvant treatment of melanoma : Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
3155	MEKINIST	MEKINIST 2 MG	TRAMETINIB AS DIMETHYL SULFOXIDE	TRAMETINIB AS DIMETHYL SULFOXIDE 2MG	TABLETS	RECIEPT	Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. Non-small cell lung cancer (NSCLC) : Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. Adjuvant treatment of melanoma : Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
3156	MELIANE	MELIANE	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.020MG;GESTODENE 0.075MG	TABLETS	RECIEPT	Oral contraceptive.
3158	MELODIL	MELODIL 25	MAPROTILINE HYDROCHLORIDE	MAPROTILINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Treatment of depressive states and anxiety states associated with depression.
3159	MELODIL	MELODIL 50	MAPROTILINE HYDROCHLORIDE	MAPROTILINE HYDROCHLORIDE 50MG	TABLETS	RECIEPT	Treatment of depressive states and anxiety states associated with depression.
3160	MEMANTINE	MEMANTINE TEVA	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of patient with moderate to severe Alzheimer's disease.
3162	MEMORIT	MEMORIT 10	DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of mild to moderately severe Alzheimer`s dementia.
3164	MEMORIT	MEMORIT 5	DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Treatment of mild to moderately severe Alzheimer`s dementia.
3166	MEMOX	MEMOX 10	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of patient with moderate to severe Alzheimer's disease.
3168	MEMOX	MEMOX 20	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Treatment of patient with moderately severe to severe Alzheimer's disease.
3170	MENACTRA	MENACTRA	MENINGOCOCCAL VACCINES GROUP C	MENINGOCOCCAL VACCINES GROUP C 4MCG/0.5ML;MENINGOCOCCAL VACCINES GROUP Y 4MCG/0.5ML;MENINGOCOCCAL VACCINES GROUP W 4MCG/0.5ML;MENINGOCOCCAL VACCINES GROUP A 4MCG/0.5ML	SOLUTION	RECIEPT	Active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135 Menactra vaccine does not prevent N meningitidis serogroup B disease.
3171	MENOGON	MENOGON	FOLLICLE STIMULATING HORMONE (FSH)	FOLLICLE STIMULATING HORMONE (FSH) 75IU/VIAL;LUTEINIZING HORMONE 75IU/VIAL	POWDER	RECIEPT	Sterility in females with hypo or normogonadotropic ovarian insufficiency: stimulation of follicle growth. Sterility in males with hypo or normogonadotropic hypogonadism.
3173	MENOPUR	MENOPUR MULTIDOSE 1200 IU	MENOTROPHIN	MENOTROPHIN 1200 IU	POWDER	RECIEPT	Sterility in females with hypo or normogonadotropic ovarian insufficiency: stimulation of follicle growth. Sterility in males with hypo or normogonadotropic hypogonadism: In combination with HCG to spermatogenesis
3174	MENOPUR	MENOPUR MULTIDOSE 600 IU	MENOTROPHIN	MENOTROPHIN 600 IU	POWDER	RECIEPT	Sterility in females with hypo or normogonadotropic ovarian insufficiency : stimulation of follicle growth. Sterility in males with hypo or normogonadotropic hypogonadism: In combination with HCG to spermatogenesis.
3172	MENOPUR	MENOPUR 75 IU	MENOTROPHIN	MENOTROPHIN 75IU/DOSE	POWDER	RECIEPT	Sterility in females with hypo or normogonadotropic ovarian insufficiency : stimulation of follicle growth. Sterility in males with hypo or normogonadotropic hypogonadism: In combination with HCG to spermatogenesis.
3175	MENTAX	MENTAX CREAM	BUTENAFINE HYDROCHLORIDE	BUTENAFINE HYDROCHLORIDE 1%	CREAM	RECIEPT	Interdigital tinea pedis, tinea coporis, tinea cruris . (Treatment in tinea coporis and tinea cruris is limited to up to 4 weeks).
3176	MENVEO	MENVEO	MENINGOCOCCAL VACCINES GROUP Y	MENINGOCOCCAL VACCINES GROUP Y 5MCG/0.5ML;MENINGOCOCCAL VACCINES GROUP W 5MCG/0.5ML;MENINGOCOCCAL VACCINES GROUP C 5MCG/0.5ML;MENINGOCOCCAL VACCINES GROUP A 10MCG/0.5ML	POWDER	RECIEPT	Menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.
3177	MEPACT	MEPACT	MIFAMURTIDE	MIFAMURTIDE 4MG/VIAL	POWDER	RECIEPT	Mepact is indicated in children, adolescents and young adults for the treatment of high grade resectable non metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with post operative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis.
3179	MEPIVACAINE HCL	MEPIVACAINE HCL 3 % INJECTION	MEPIVACAINE HYDROCHLORIDE	MEPIVACAINE HYDROCHLORIDE 30MG/ML	SOLUTION	RECIEPT	Mepivacaine is indicated for production of local anesthesia for dental procedures by infiltration or nerve block in adults and pediatric patients.
3180	MEPIVASTESIN	MEPIVASTESIN 3 %	MEPIVACAINE HYDROCHLORIDE	MEPIVACAINE HYDROCHLORIDE 30MG/ML	SOLUTION	RECIEPT	Infiltration anesthesia and nerve-block in dentistry. Mepivastesin is indicated for simple extractions as well as cavity and stump preparations. Mepivastesin is especially suitable for patients to whom vasoconstricting additives are contra-indicated especially for the treatment of circulatory - labile patients.
3181	MERCAPTIZOL	MERCAPTIZOL	METHIMAZOLE	METHIMAZOLE 20MG	TABLETS	RECIEPT	For the treatment of hyperthyroidism.
3182	MERCILON	MERCILON	DESOGESTREL	DESOGESTREL 150MCG;ETHINYLESTRADIOL 20MCG	TABLETS	RECIEPT	Oral contraception
3184	MERFEN	MERFEN SPRAY 30ML	BENZOXONIUM CHLORIDE	BENZOXONIUM CHL.1MG/ML;CHLORHEXIDINE GLUCONATE 5MG/ML	SPRAY		To disinfect wounds and injuries, such as cuts, scratches, mild burns and insect stings.
3185	MERFEN FIRST	MERFEN SPRAY FIRST AID	BENZOXONIUM CHLORIDE	BENZOXONIUM CHLORIDE 1MG/ML;CHLORHEXIDINE GLUCONATE 5MG/ML	SOLUTION		To disinfect wounds and injuries, such as cuts, scratches, mild burns and insect stings.
3186	MERO	MERO-AVENIR 1000 MG	MEROPENEM AS TRIHYDRATE	MEROPENEM AS TRIHYDRATE 1000MG	POWDER	RECIEPT	Mero-Avenir is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infections in patients with cystic fibrosis. - Urinary tract infections. - Intra-abdominal infections. - Gynecological infections such as endometritis and pelvic inflammatory disease. - Skin and skin structure infections. - Meningitis. - Septicemia. Mero-Avenir has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
3187	MERO	MERO-AVENIR 500 MG	MEROPENEM AS TRIHYDRATE	MEROPENEM AS TRIHYDRATE 500MG	POWDER	RECIEPT	Mero-Avenir is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infections in patients with cystic fibrosis. - Urinary tract infections. - Intra-abdominal infections. - Gynecological infections such as endometritis and pelvic inflammatory disease. - Skin and skin structure infections. - Meningitis. - Septicemia. Mero-Avenir has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
3188	MEROKEN	MEROKEN	MACROGOLS	MACROGOLS 315.0 G;POTASSIUM CHLORIDE 1.1175 G;SODIUM BICARBONATE 4.2840 G;SODIUM CHLORIDE 8.4240 G	POWDER	RECIEPT	Bowel cleansing prior to colonoscopy and barium enema x-ray examinations.
3189	MERONEM	MERONEM 1 G.	MEROPENEM AS TRIHYDRATE	MEROPENEM AS TRIHYDRATE 1000MG/VIAL	POWDER	RECIEPT	Meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infections in patients with cystic fibrosis. - Urinary tract infections. - Intra-abdominal infections. - Gynecological infections such as endometritis and pelvic inflammatory disease. - Skin and skin structure infections. - Meningitis. - Septicemia. Meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
3193	MERONEM	MERONEM 500 MG	MEROPENEM AS TRIHYDRATE	MEROPENEM AS TRIHYDRATE 500MG/VIAL	POWDER	RECIEPT	Meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infections in patients with cystic fibrosis. - Urinary tract infections. - Intra-abdominal infections. - Gynecological infections such as endometritis and pelvic inflammatory disease. - Skin and skin structure infections. - Meningitis. - Septicemia. Meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
3201	MEROPENEM	MEROPENEM FRESENIUS 1000 MG	MEROPENEM AS ANHYDROUS	MEROPENEM AS ANHYDROUS 1000MG/VIAL	POWDER	RECIEPT	For treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to Meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infections in patients with cystic fibrosis. - Urinary tract infections. - Intra-abdominal infections. - Gynecological infections such as endometritis and pelvic inflammatory disease. - Skin and skin structure infections. - Meningitis. - Septicemia. Meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
3202	MEROPENEM	MEROPENEM FRESENIUS 500 MG	MEROPENEM AS ANHYDROUS	MEROPENEM AS ANHYDROUS 500MG/VIAL	POWDER	RECIEPT	For treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to Meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infections in patients with cystic fibrosis. - Urinary tract infections. - Intra-abdominal infections. - Gynecological infections such as endometritis and pelvic inflammatory disease. - Skin and skin structure infections. - Meningitis. - Septicemia. Meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
3197	MEROPENEM ANFARM	MEROPENEM / ANFARM 1 G	MEROPENEM AS TRIHYDRATE	MEROPENEM AS TRIHYDRATE 1000MG/VIAL	POWDER	RECIEPT	Meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infections in patients with cystic fibrosis. - Urinary tract infections. - Intra-abdominal infections. - Gynecological infections such as endometritis and pelvic inflammatory disease. - Skin and skin structure infections. - Meningitis -Septicemia. Meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency
3199	MEROPENEM ANFARM	MEROPENEM / ANFARM 500 MG	MEROPENEM AS TRIHYDRATE	MEROPENEM AS TRIHYDRATE 500MG/VIAL	POWDER	RECIEPT	Meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infections in patients with cystic fibrosis. - Urinary tract infections. - Intra-abdominal infections. - Gynecological infections such as endometritis and pelvic inflammatory disease. - Skin and skin structure infections. - Meningitis -Septicemia. Meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency
3203	MESNA-CELL	MESNA-CELL 100 MG/ML	MESNA	MESNA 100MG/1ML	SOLUTION	RECIEPT	Prevention of urinary tract toxicity of oxazaphosphorines (ifosfamide, cyclophosphamide or trofosfamide) in particular patients at risk. Risks are in particular previous radiation therapy in the area of the true pelvis, cystitis following previous therapy with ifosfamide, cyclophosphamide or trofosfamide and a history of uropathy.
3205	MESTINON DRAGEES	MESTINON DRAGEES 60 MG	PYRIDOSTIGMINE BROMIDE	PYRIDOSTIGMINE BROMIDE 60.0MG	DRAGEE	RECIEPT	Treatment of myasthenia gravis.
3206	MESULID	MESULID 100	NIMESULIDE	NIMESULIDE 100MG	TABLETS	RECIEPT	Acute pain. Primary dysmenorrhea.
3208	METASTRON	METASTRON	STRONTIUM (89SR) CHLORIDE	STRONTIUM (89SR) CHLORIDE 150MBQ/4ML	SOLUTION	RECIEPT	Adjunct and alternative to external beam radiotherapy for palliation of pain from bone metastases secondary to prostatic carcinoma at the stage of hormone therapy failure.
3209	METFORMIN	METFORMIN INOVAMED	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 850MG	TABLETS	RECIEPT	Treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. • In adults, Metformin may be used as monotherapy or in combination with other oral anti-diabetic agents or with insulin. • In children from 10 years of age and adolescents, Metformin may be used as monotherapy or in combination with insulin. A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet failure
3213	METFORMIN	METFORMIN TEVA	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 850MG	TABLETS	RECIEPT	Metformin Teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. Occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.
3214	METHADONE	METHADONE	METHADONE HYDROCHLORIDE	METHADONE HYDROCHLORIDE 50MG/ML	SOLUTION	RECIEPT	Relief of severe pain. Detoxification and withdrawal treatment in narcotic addiction.
3215	METHOTREXAT	METHOTREXAT caretEBEWEcaret 100 MG/ML	METHOTREXATE	METHOTREXATE 100MG/ML	CONCENTRATE	RECIEPT	Antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. Palliation of acute lymphocytic leukemia. In the treatment and prophylaxis of meningeal leukemia. Greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. In combination with other anticancer agents, Methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. Abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. Methotrexate is effective in the treatment of the advanced stages (III and IV Peter's Staging System) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. Psoriasis: because of the high risk attending its use, Methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. Rheumatoid Arthritis: Methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well established according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose NSAIDs and usually a trial of at least one or more disease-modifying antirheumatic drugs.
3216	METHOTREXAT	METHOTREXAT caretEBEWEcaret 2.5 MG TABLETS	METHOTREXATE	METHOTREXATE 2.5MG	TABLETS	RECIEPT	Active rheumatoid arthritis in adults, which can not be controlled with other forms of antirehumatic therapy. Disseminated chronic psoriasis when other therapy has failed. Maintenance therapy in acute lymphatic leukemia.
3217	METHOTREXATE	METHOTREXATE LEDERLE	METHOTREXATE	METHOTREXATE 2.5MG	TABLETS	RECIEPT	Antineoplastic chemotherapy, psoriasis. Rheumatoid arthritis. Methotrexate can be used in the treatment of selected adults with rheumatoid arthritis, only when the diagnosis has been well established according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy.
3218	METHYLPREDNISOLONE	METHYLPREDNISOLONE MYLAN 1 G	METHYLPREDNISOLONE AS HEMISUCCINATE	METHYLPREDNISOLONE AS HEMISUCCINATE 1G	POWDER	RECIEPT	When corticosteroid therapy is required, but the general oral administration route connot be used (vomiting, gastric aspiration, sensorial disturbances) and the parenteral route is necessary.
3219	METHYLPREDNISOLONE	METHYLPREDNISOLONE MYLAN 500 MG	METHYLPREDNISOLONE AS HEMISUCCINATE	METHYLPREDNISOLONE AS HEMISUCCINATE 500MG	POWDER	RECIEPT	When corticosteroid therapy is required, but the general oral administration route connot be used (vomiting, gastric aspiration, sensorial disturbances) and the parenteral route is necessary.
3221	METOCLOPRAMIDE	METOCLOPRAMIDE S.A.L.F 10 MG/2 ML	METOCLOPRAMIDE AS HYDROCHLORIDE MONOHYDRATE	METOCLOPRAMIDE AS HYDROCHLORIDE MONOHYDRATE 10MG/2ML	SOLUTION	RECIEPT	METOCLOPRAMIDE S.A.L.F 10 MG/2 ML is indicated in adults for: - Prevention of postoperative nausea and vomiting (PONV) - Prevention of delayed nausea and vomiting caused by chemotherapy (delayed CINV) - Prevention of nausea and vomiting caused by radiation therapy - Symptomatic treatment of nausea and vomiting, including nausea and vomiting caused by migraine attack. In migraine attacks, metoclopramide can be used concomitantly with oral analgesics to improve their absorption. - Diabetic gastroparesis - To faciliate diagnostic procedures (ie, to faciliate small bowel intubation and as an aid in radiological examinations) Pediatric population. METOCLOPRAMIDE S.A.L.F 10 MG/2 ML is indicated in children aged 1 to 18 years for: - Second line-therapy: Treatment of established postoperative nausea and vomiting (PONV) - Second-line therapy: Prevention of delayed nausea and vomiting caused by chemotherapy (delayed CINV) - To facilitate diagnostic procedures (ie, to faciliate small bowel intubation and as an aid in radiological examinations).
3222	METOJECT	METOJECT 50 MG/ML S.C	METHOTREXATE	METHOTREXATE 50MG/ML	SOLUTION	RECIEPT	Psoriasis in adult patients : because of the high risk attending its use, Methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. Rheumatoid Arthritis: Methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose NSAIDs and usually a trial of at least one or more disease-modifying antirheumatic drugs. Juvenile Idiopathic Arthritis: Treatment of Polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate Crohn’s Disease: Mild to moderate Crohn's disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.
3226	METOJECT	METOJECT PEN 50 MG/ML	METHOTREXATE	METHOTREXATE 50MG/ML	SOLUTION	RECIEPT	Psoriasis in adult patients: because of the high risk attending its use, Methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. Rheumatoid Arthritis: Methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose NSAIDs and usually a trial of at least one or more disease-modifying antirheumatic drugs. Juvenile Idiopathic Arthritis: Treatment of Polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate. Crohn’s Disease: Mild to moderate Crohn's disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.
3232	METOPIRONE	METOPIRONE 250	METYRAPONE	METYRAPONE 250MG	CAPSULES	RECIEPT	Diagnostic test of secondary adrenocortical insufficiency, treatment of resistant edema associated with increased aldosterone secretion.
3233	METRONIDAZOLE	METRONIDAZOLE	METRONIDAZOLE	METRONIDAZOLE 500MG/100ML	SOLUTION	RECIEPT	Treatment and prophylaxis of infection which are or may be due to anerobic bacteria,especially Bacteriodes species,including Bacteriodes fragilis, Fusobacterium,Eurobacterium and Clostridium species.
3235	METRONIDAZOLE	METRONIDAZOLE FRESENIUS 500 MG/100 ML	METRONIDAZOLE	METRONIDAZOLE 500MG/100ML	SOLUTION	RECIEPT	Treatment and prophylaxis of infection which are or may be due to anerobic bacteria, especially Bacteriodes species, including Bacteriodes fragilis, Fusobacterium, Eurobacterium and Clostridium species.
3236	MEZAVANT	MEZAVANT 1200 MG	MESALAZINE	MESALAZINE 1200MG	TABLETS	RECIEPT	For the induction of clinical and endoscopic remission in patients with mild to moderate, active ulcerative colitis. For maintenance of remission.
3237	MICAL	MICAL 375MG 20TAB	CARBOCYSTEINE	CARBOCYSTEINE 375MG	TABLETS		Cardiac arrhythmias.
3241	MICRODIOL	MICRODIOL	DESOGESTREL	DESOGESTREL 150MCG;ETHINYLESTRADIOL 30MCG	TABLETS	RECIEPT	Oral contraceptive.
3242	MICROGYNON	MICROGYNON 30	LEVONORGESTREL	LEVONORGESTREL 150MCG;ETHINYLESTRADIOL 30MCG	TABLETS	RECIEPT	Oral contraceptive.
3243	MICROLET	MICROLET	GLYCEROL	GLYCEROL 12.5%W/V;SODIUM CITRATE 9%W/V;LAURYLSULPHOACETATE SODIUM 0.9%W/V	ENEMA		For relief of constipation.
3244	MICROLET	MICROLET 12 TUBES	SODIUM LAURYL SULPHOACETATE	SODIUM LAURYL SULPHOACETATE 45MG;SODIUM CITRATE 450MG;GLYCEROL 625MG	TUBES		Constipation.
3245	MICROLUT	MICROLUT	LEVONORGESTREL	LEVONORGESTREL 0.03MG	TABLETS	RECIEPT	Oral contraception.
3246	MICROPIRIN	MICROPIRIN 100	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
3248	MICROPIRIN	MICROPIRIN 75	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 75MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
3247	MICROPIRIN	MICROPIRIN 100MG 30TAB	ASPIRIN	ASPIRIN 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
3249	MICROPIRIN	MICROPIRIN 75MG 30CAP	ASPIRIN	ASPIRIN 75MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
3250	MIDAZOLAM	MIDAZOLAM B.BRAUN 1 MG/ML	MIDAZOLAM AS HYDROCHLORIDE	MIDAZOLAM AS HYDROCHLORIDE 1MG/1ML	SOLUTION	RECIEPT	Premedication before induction of anesthesia (i.m). Basal sedation before diagnostic or surgical interventions carried out under local anesthesia (i.v. administration). Induction and maintenance of anesthesia. As an induction agent in inhalation anesthesia or a sleep-inducing component in combined anesthesia, including total intravenous anesthesia (i.v. injection, i.v. infusion). Ataralgesia in combination with ketamine in children (i.m. administration). Status epilepticus
3252	MIDAZOLAM	MIDAZOLAM B.BRAUN 5 MG/ML	MIDAZOLAM AS HYDROCHLORIDE	MIDAZOLAM AS HYDROCHLORIDE 5MG/1ML	SOLUTION	RECIEPT	Premedication before induction of anesthesia (i.m). Basal sedation before diagnostic or surgical interventions carried out under local anesthesia (i.v. administration). Induction and maintenance of anesthesia. As an induction agent in inhalation anesthesia or a sleep-inducing component in combined anesthesia, including total intravenous anesthesia (i.v. injection, i.v. infusion). Ataralgesia in combination with ketamine in children (i.m. administration). Status epilepticus
3253	MIDOLAM	MIDOLAM 1 MG/ML	MIDAZOLAM	MIDAZOLAM 1MG/ML	SOLUTION	RECIEPT	Premedication before induction of anesthesia (i.m). Basal sedation before diagnostic or surgical interventions carried out under local anesthesia (i.v. administration). Induction and maintenance of anesthesia. As an induction agent in inhalation anesthesia or a sleep-inducing component in combined anesthesia, including total intravenous anesthesia (i.v. injection, i.v. infusion). Ataralgesia in combination with ketamine in children (i.m. administration). Status epilepticus.
3254	MIDOLAM	MIDOLAM 5 MG/ML	MIDAZOLAM	MIDAZOLAM 5MG/ML	SOLUTION	RECIEPT	Premedication befor induction of anesthesia (i.m). Basal sedation before diagnostic or surgical interventions carried out under local anesthesia (i.v. administration). Induction and maintenance of anesthesia. As an induction agent in inhalation anesthesia or a sleep-inducing component in combined anesthesia, including total intravenous anesthesia (i.v. injection, i.v. infusion). Ataralgesia in combination with ketamine in children (i.m. administration). Status epilepticus.
3255	MIDRO TEA	MIDRO TEA	SENNAE FOLIUM	SENNAE FOLIUM 75%	LIQUID	RECIEPT	Laxative.
3256	MIFEGYNE	MIFEGYNE	MIFEPRISTONE	MIFEPRISTONE 200MG	TABLETS	RECIEPT	Medical termination of developing intra-uterine pregnancy. - In sequential use with a prostaglandin analogue up to 63 days of amenorrhea. - Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester. - Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester). - Labour induction in foetal death in utero. In patients where prostaglandin or oxytocin cannot be use.
3257	MIFLONIDE BREEZHALER	MIFLONIDE BREEZHALER 200 MCG	BUDESONIDE	BUDESONIDE 200MCG	CAPSULES	RECIEPT	Maintenance treatment of bronchial asthma.
3258	MIFLONIDE BREEZHALER	MIFLONIDE BREEZHALER 400 MCG	BUDESONIDE	BUDESONIDE 400MCG	CAPSULES	RECIEPT	Maintenance treatment of bronchial asthma.
3259	MIGRALEVE	MIGRALEVE	PARACETAMOL	PARACETAMOL 500MG;CODEINE PHOSPHATE 8MG;BUCLIZINE HYDROCHLORIDE 6.25MG	TABLETS	RECIEPT	Treatment of migraine attacks, including accompanying symptoms: headache, nausea and vomiting.
3261	MINERALI	MINERALI	GLUCOSE MONOHYDRATE	GLUCOSE MONOHYDRATE 14.85MG/1ML;SODIUM CITRATE 2.20MG/1ML;POTASSIUM CHLORIDE 1.50MG/1ML;SODIUM CHLORIDE 2.70MG/1ML	SOLUTION		For the prevention of dehydration by replacing fluids and electrolytes loss associated with conditions such as acute diarrhoea.
3262	MINESSE	MINESSE	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.015MG;GESTODENE 0.06MG	TABLETS	RECIEPT	Contraceptive.
3267	MINIRIN	MINIRIN TABLETS 0.1 MG	DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE 0.1MG	TABLETS	RECIEPT	Central diabetes insipidus. Nocturnal Enuresis. Treatment of nocturia in adults associated with nocturnal polyuria.
3266	MINIRIN	MINIRIN SOLUTION	DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE 0.1MG/ML	SOLUTION	RECIEPT	Treatment of cranial diabetes insipidus. Treatment of post hypophysectomy polyuria-polydypsia.
3268	MINIRIN	MINIRIN TABLETS 0.2 MG	DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE 0.2MG	TABLETS	RECIEPT	Central diabetes insipidus. Nocturnal Enuresis. Treatment of nocturia in adults associated with nocturnal polyuria.
3263	MINIRIN MELT	MINIRIN MELT 120 MCG	DESMOPRESSIN AS ACETATE	DESMOPRESSIN AS ACETATE 120MCG	TABLETS	RECIEPT	Diabetes insipidus.
3264	MINIRIN MELT	MINIRIN MELT 60 MCG	DESMOPRESSIN AS ACETATE	DESMOPRESSIN AS ACETATE 60MCG	TABLETS	RECIEPT	Diabetes insipidus.
3265	MINIRIN SPRAY	MINIRIN NASAL SPRAY	DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE 0.1MG/ML	SOLUTION	RECIEPT	Diabetes Insipidus.
3269	MINOCLIN	MINOCLIN CAPSULES	MINOCYCLINE AS HYDROCHLORIDE	MINOCYCLINE AS HYDROCHLORIDE 50MG	CAPSULES	RECIEPT	Antibiotic indicated against infections caused by bacteria sensitive to Minocycline, and for the treatment of acne.
3270	MINOCYCLINE	MINOCYCLINE 100 MG	MINOCYCLINE AS HYDROCHLORIDE	MINOCYCLINE AS HYDROCHLORIDE 100MG	CAPSULES	RECIEPT	Treatment of infections caused by minocycline-sensitive micro-organisms including acne, gonorrhea and prophylaxis of asymptomatic meningococcal carrie.
3271	MINOCYCLINE	MINOCYCLINE 50 MG	MINOCYCLINE AS HYDROCHLORIDE	MINOCYCLINE AS HYDROCHLORIDE 50MG	CAPSULES	RECIEPT	Treatment of infections caused by tetracycline sensitive organisms, including acne, gonnorrhea and prophylaxis of asymptomatic meningococcal carrier.
3273	MINOXI	MINOXI 2 80ML	MINOXIDIL	MINOXIDIL 2%	SOLUTION	RECIEPT	Androgenetic alopecia in males .
3272	MINOXI	MINOXI 2	MINOXIDIL	MINOXIDIL 2%W/V	SOLUTION	RECIEPT	Androgenetic alopecia in females.
3274	MINOXI	MINOXI 5	MINOXIDIL	MINOXIDIL 5%	SOLUTION	RECIEPT	Androgenetic alopecia in males .
3275	MINOXI	MINOXI 5 SOL 80ML	MINOXIDIL	MINOXIDIL 5%	SOLUTION	RECIEPT	Androgenetic alopecia in males .
3276	MINULET	MINULET	GESTODENE	GESTODENE 0.075MG;ETHINYLESTRADIOL 0.030MG	TABLETS	RECIEPT	Contraception.
3277	MIRCERA	MIRCERA 100 MCG/0.3 ML	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 100MCG/0.3ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic kidney disease (CKD).
3278	MIRCERA	MIRCERA 150 MCG/0.3 ML	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 150MCG/0.3ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic kidney disease (CKD).
3279	MIRCERA	MIRCERA 200 MCG/0.3 ML	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 200MCG/0.3ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic kidney disease (CKD).
3280	MIRCERA	MIRCERA 360 MCG/0.6 ML	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 360MCG/0.6ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic kidney disease (CKD).
3281	MIRCERA	MIRCERA 50 MCG/0.3 ML	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 50MCG/0.3ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic kidney disease (CKD).
3282	MIRCERA	MIRCERA 75 MCG/0.3 ML	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA 75MCG/0.3ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic kidney disease (CKD).
3283	MIRENA	MIRENA	LEVONORGESTREL	LEVONORGESTREL 52MG	INTRAUTERINE DEVICE	RECIEPT	Contraception and idiopathic menorrhagia. Protection from endometrial hyperplasia during estrogen replacement therapy.
3285	MIRO	MIRO 30	MIRTAZAPINE	MIRTAZAPINE 30MG	TABLETS	RECIEPT	Treatment of major depression.
3287	MIRO	MIRO 45	MIRTAZAPINE	MIRTAZAPINE 45MG	TABLETS	RECIEPT	Treatment of major depression.
3289	MIRTAZAPINE	MIRTAZAPINE TEVA 30 MG	MIRTAZAPINE	MIRTAZAPINE 30MG	TABLETS	RECIEPT	Episode of major depression.
3291	MIRTAZAPINE	MIRTAZAPINE TEVA 45 MG	MIRTAZAPINE	MIRTAZAPINE 45MG	TABLETS	RECIEPT	Episode of major depression.
3293	MISODEL	MISODEL	MISOPROSTOL	MISOPROSTOL 200MCG	VAGINAL INSERT	RECIEPT	For induction of labour in women with an unfavourable cervix, from 36 weeks gestation, in whom induction is clinically indicated.
3295	MITOMY	MITOMYCIN C 2 MG	MITOMYCIN C ( CRYSTALLINE )	MITOMYCIN C ( CRYSTALLINE ) 2MG/VIAL	POWDER	RECIEPT	Remission of subjective and objective symptoms assocciated with the following diseases: Chronic lymphocytic leukemia, chronic myelocytic leukemia, gastric cancer, colorectal cancer, lung cancer, pancreatic cancer, liver cancer, cervix cancer, cancer of the endometrium, breast cancer, head and neck tumor and bladder tumor.
3294	MITOMY	MITOMYCIN C 10 MG	MITOMYCIN C (CRYSTALLINE)	MITOMYCIN C (CRYSTALLINE) 10MG/VIAL	POWDER	RECIEPT	Remission of subjective and objective symptoms assocciated with the following diseases: - Chronic lymphocytic leukemia, - chronic myelocytic leukemia, - gastric cancer, - colorectal cancer, - lung cancer, - pancreatic cancer, - liver cancer, - cervix cancer, - cancer of the endometrium, - breast cancer, - head and neck tumor, - bladder tumor.
3296	MITOXANTRON	MITOXANTRON caretEBEWEcaret 2 MG/ML	MITOXANTRONE AS HYDROCHLORIDE	MITOXANTRONE AS HYDROCHLORIDE 2MG/ML	CONCENTRATE	RECIEPT	Treatment of advanced breast cancer, non-Hodgkin's lymphomas, acute non lymphocytic leukemia palliation of non resectable primary hepatocellular carcinoma. Mitoxantrone in combination with corticosterolds is indicated for inital chemotherapy in patients with pain due to advanced hormone-refractory prostate cancer. For reduction of neurologic disability and/or frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remmitting multiple sclerosis (patients whose neurologic status is significantly abnormal between relapses), for patients 18-55 years old.
3297	MIXTARD	MIXTARD 30 PENFILL	INSULIN (HUMAN)	INSULIN (HUMAN) 100IU/ML	SUSPENSION	RECIEPT	Therapeutic indications Mixtard is indicated for treatment of diabetes mellitus.
3298	MIXTARD	MIXTARD 30 VIAL	INSULIN (HUMAN)	INSULIN (HUMAN) 100IU/ML	SUSPENSION	RECIEPT	Treatment of diabetes mellitus.
3299	MIXTURE	MIXTURE 800 PPM NO IN NITROGEN	NITROUS OXIDE	NITROUS OXIDE 0.08%V/V	GAS	RECIEPT	Mixture 800 ppm NO in Nitrogen, in conjunction with ventilatory support and other appropriate active substances, is indicated: • for the treatment of newborn infants ≥ 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. • As part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.
3300	MIZOLLEN	MIZOLLEN TABLETS 10 MG	MIZOLASTINE	MIZOLASTINE 10MG	TABLETS	RECIEPT	Symptomatic treatment of seasonal allergic rhinoconjuctivitis (hay fever), perennial allergic rhino-conjuctivitis and urticaria.
3301	MODAFINIL	MODAFINIL MEDOCHEMIE	MODAFINIL	MODAFINIL 100MG	TABLETS	RECIEPT	To improve wakefulness in patients with excessive sleepiness associated with narcolepsy (with or without cataplexy), obstructive sleep apnea/hypopnea syndrome (OSAHS ) and shift work sleep disorder (SWDS).
3303	MODAL	MODAL FORTE TABLETS	SULPIRIDE	SULPIRIDE 200MG	TABLETS	RECIEPT	Anti - dopaminergic agent. 1) For use in vertigo and prepsychotic states. 2) At high doses - in psychiatric patients for treatment of depression and apathy.
3302	MODAL	MODAL CAPSULES	SULPIRIDE	SULPIRIDE 50MG	CAPSULES	RECIEPT	Anti - dopaminergic agent for use in vertigo and prepsychotic states.
3304	MOLD SMUTS EXTRACTS	MOLD & SMUTS EXTRACTS	MOLDS EXTRACTS	MOLDS EXTRACTS אוסף אלרגנים	SOLUTION	RECIEPT	Skin testing and immunotherapy.
3305	MONOCORD	MONOCORD 20	ISOSORBIDE MONONITRATE	ISOSORBIDE MONONITRATE 20MG	TABLETS	RECIEPT	For the treatment of angina pectoris and prevention of anginal attacks. Treatment of congestive heart failure.
3306	MONOCORD	MONOCORD 40	ISOSORBIDE MONONITRATE	ISOSORBIDE MONONITRATE 40MG	TABLETS	RECIEPT	For the treatment of angina pectoris and prevention of anginal attacks, treatment of congestive heart failure.
3307	MONOCORD	MONOCORD 50 S.R	ISOSORBIDE MONONITRATE	ISOSORBIDE MONONITRATE 50MG	TABLETS	RECIEPT	For the treatment of angina pectoris and prevention of angina attacks.
3308	MONOLONG	MONOLONG 40 MG	ISOSORBIDE-5-MONONITRATE	ISOSORBIDE-5-MONONITRATE 40MG	CAPSULES	RECIEPT	Prevention and treatment of angina pectoris.
3309	MONOLONG	MONOLONG 60 MG	ISOSORBIDE-5-MONONITRATE	ISOSORBIDE-5-MONONITRATE 60MG	CAPSULES	RECIEPT	Prevention and treatment of angina pectoris.
3310	MONONINE	MONONINE 1000	COAGULATION FACTOR IX (HUMAN)	COAGULATION FACTOR IX (HUMAN) 1000 IU/VIAL	POWDER	RECIEPT	For the prevention and control of bleeding in Factor IX deficiency, also known as Haemophilia B or Christmas disease.
3311	MONTAIR	MONTAIR 4 MG	MONTELUKAST AS SODIUM	MONTELUKAST AS SODIUM 4MG	TABLETS	RECIEPT	Montair is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. Montair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.
3312	MONTAIR	MONTAIR 5 MG	MONTELUKAST AS SODIUM	MONTELUKAST AS SODIUM 5MG	TABLETS	RECIEPT	Montair is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. Montair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.
3316	MONTELUKAST	MONTELUKAST TEVA 10 MG	MONTELUKAST AS SODIUM	MONTELUKAST AS SODIUM 10MG	TABLETS	RECIEPT	Montelukast Teva is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. Montelukast Teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montelukast Teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montelukast Teva is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.
3313	MONTELUKAST	MONTELUKAST - TRIMA 10 MG	MONTELUKAST AS SODIUM SALT	MONTELUKAST AS SODIUM SALT 10MG	TABLETS	RECIEPT	Montelukast - Trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. Montelukast - Trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montelukast - Trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montelukast - Trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.
3314	MONTELUKAST	MONTELUKAST - TRIMA 4 MG	MONTELUKAST AS SODIUM SALT	MONTELUKAST AS SODIUM SALT 4MG	TABLETS	RECIEPT	Montelukast - Trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. Montelukast - Trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montelukast - Trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montelukast - Trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.
3315	MONTELUKAST	MONTELUKAST - TRIMA 5 MG	MONTELUKAST AS SODIUM SALT	MONTELUKAST AS SODIUM SALT 5MG	TABLETS	RECIEPT	Montelukast - Trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. Montelukast - Trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montelukast - Trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montelukast - Trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.
3317	MONUROL	MONUROL	FOSFOMYCIN AS TROMETAMOL	FOSFOMYCIN AS TROMETAMOL 3G	POWDER	RECIEPT	A single-dose treatment for acute, uncomplicated urinary tract infection and as prophylaxis in diagnostic and surgical transurethral procedures.
3318	MORPHINE	MORPHINE INJECTIONS 1 MG/ML	MORPHINE SULFATE	MORPHINE SULFATE 1MG/ML	SOLUTION	RECIEPT	For the relief of pain that does not respond to treatment with non-opioid analgesics. Morphine injection is a systemic opioid analgesic administered by the IV , epidural and intrathecal routes. Morphine sulphate administered epidurally or intrathecally provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function
3319	MORPHINE	MORPHINE INJECTIONS 20 MG/ML	MORPHINE SULFATE	MORPHINE SULFATE 20MG/ML	SOLUTION	RECIEPT	Morphine injection 20 mg/ml is a systemic opioid analgesic indicated only for IV, epidural and intrathecal infusion in the treatment of intractable chronic pain. It was developed for use in continuous microinfusion devices and the dosage requirements of the individual patient. Morphine injetion 20 mg/ml is primarily intended for patients who are opioid -tolerant. Morphine sulfate administered epidurally or intrathecally provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function
3320	MOTILIUM	MOTILIUM	DOMPERIDONE	DOMPERIDONE 10MG	TABLETS	RECIEPT	Motilium is indicated for the relief of the symptoms of nausea and vomiting.
3321	MOVENTIG	MOVENTIG 12.5 MG	NALOXEGOL AS OXALATE	NALOXEGOL AS OXALATE 12.5MG	TABLETS	RECIEPT	Moventig is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
3323	MOVENTIG	MOVENTIG 25 MG	NALOXEGOL AS OXALATE	NALOXEGOL AS OXALATE 25MG	TABLETS	RECIEPT	Moventig is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
3326	MOVEX	MOVEX SOL INHALATION 50ML	BROMHEXINE HCL	BROMHEXINE HCL 2MG/ML	SOLUTION		Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g.: bronchitis asthma and sinusitis
3325	MOVEX	MOVEX 8MG 20TAB	BROMHEXINE HCL	BROMHEXINE HCL 8MG	TABLETS		Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g.: bronchitis asthma and sinusitis
3327	MOVEX	MOVEX SOLUTION	BROMHEXINE HYDROCHLORIDE	BROMHEXINE HYDROCHLORIDE 2.00MG/ML	SOLUTION	RECIEPT	Bronchial Mucolytic. It can also be given by inhalation as an aerosol solution.
3328	MOVEX	MOVEX TABLETS	BROMHEXINE HYDROCHLORIDE	BROMHEXINE HYDROCHLORIDE 8MG	TABLETS	RECIEPT	Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g.: bronchitis asthma and sinusitis
3329	MOVIPREP	MOVIPREP	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 1.015G sachet 1;SODIUM ASCORBATE 5.9G sachet 2;MACROGOLS 100G sachet 1;SODIUM CHLORIDE 2.691G sachet 1;SODIUM SULFATE ANHYDROUS 7.5G sachet 1;ASCORBIC ACID 4.7G sachet 2	POWDER	RECIEPT	For bowel cleansing prior to any clinical procedures requiring a clean bowel e.g. bowel endoscopy or radiology.
3330	MOXYPEN	MOXYPEN FORTE 250 mg powder for suspension	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 250MG/5ML	POWDER		Infections caused by amoxicillin - susceptible organisms and prevention of bacteremia in patients at risk of developing bacterial endocarditis.
3331	MOXYPEN	MOXYPEN FORTE 500 MG capsules	AMOXICILLIN TRIHYDRATE	AMOXICILLIN TRIHYDRATE 500MG	CAPSULES		Infections caused by amoxycillin - susceptible organisms. Prevention of bacteremia in patients at risk of developing bacterial endocarditis.
3332	MOXYVIT	MOXYVIT 250 CAPSULES	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 250MG	CAPSULES	RECIEPT	For the treatment of infections caused by microorganisms sensitive to Amoxycillin.
3333	MOXYVIT	MOXYVIT FORTE 250 SUSPENSION	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 250MG/5ML	SUSPENSION	RECIEPT	Antibiotic for the treatment of infections caused by bacteria sensitive to Amoxycillin.
3334	MOXYVIT	MOXYVIT FORTE 500 CAPSULES	AMOXICILLIN AS TRIHYDRATE	AMOXICILLIN AS TRIHYDRATE 500MG	CAPSULES	RECIEPT	Infections caused by amoxicillin susceptible organisms.
3335	MOZOBIL	MOZOBIL	PLERIXAFOR	PLERIXAFOR 24MG/1.2ML	SOLUTION	RECIEPT	Mozobil is indicated in combination with G-CSF to enhance mobilisation of haematopietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma .
3337	MUCOLESS	MUCOLESS SOL INHALATION 50ML	BROMHEXINE HCL	BROMHEXINE HCL 2MG/ML	SOLUTION		Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g.: bronchitis asthma and sinusitis
3336	MUCOLESS	MUCOLESS 8MG 20TAB	BROMHEXINE HCL	BROMHEXINE HCL 8MG	TABLETS		Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g.: bronchitis asthma and sinusitis
3338	MUCOLESS	MUCOLESS SOLUTION	BROMHEXINE HYDROCHLORIDE	BROMHEXINE HYDROCHLORIDE 2MG/ML	SOLUTION	RECIEPT	Bronchial mucolytic. It can also be given by inhalation as an aerosol solution.
3339	MUCOLESS	MUCOLESS TABLETS	BROMHEXINE HYDROCHLORIDE	BROMHEXINE HYDROCHLORIDE 8MG	TABLETS	RECIEPT	Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g.: bronchitis asthma and sinusitis
3345	MUCOLIT	MUCOLIT ORAL SOLUTION 250 MG/ 5 ML	CARBOCISTEINE	CARBOCISTEINE 250MG/5ML	SOLUTION	RECIEPT	Treatment of disorders of the repiratory tract characterized by excessive or viscous mucus.
3340	MUCOLIT	MUCOLIT 375 CAPSULES	CARBOCISTEINE	CARBOCISTEINE 375MG	CAPSULES	RECIEPT	Treatment of disorders of the respiratory tract characterised by excessive or viscous mucus.
3342	MUCOLIT	MUCOLIT 375 MG LOZENGES HONEY-LEMON FLAVOUR	CARBOCISTEINE	CARBOCISTEINE 375MG	TABLETS	RECIEPT	Treatment of disorders of the respiratory tract characterised by excessive or viscous mucus.
3341	MUCOLIT	MUCOLIT 250MG/4ML SYR 110ML	CARBOCYSTEINE	CARBOCYSTEINE 250MG/5ML(5%)	SYRUP		Treatment of disorders of the respiratory tract characterized by excessive or viscous mucus.
3343	MUCOLIT	MUCOLIT 375MG 18LOZ LEMON/HONEY	CARBOCYSTEINE	CARBOCYSTEINE 375MG	TABLETS		Treatment of disorders of the respiratory tract characterized by excessive or viscous mucus.
3344	MUCOLIT	MUCOLIT 375MG 20 CAPS	CARBOCYSTEINE	CARBOCYSTEINE 375MG	CAPSULES		Treatment of disorders of the respiratory tract characterized by excessive or viscous mucus.
3346	MULTAQ	MULTAQ	DRONEDARONE	DRONEDARONE 400MG	TABLETS	RECIEPT	MULTAQ is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered. MULTAQ should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.
3347	MULTI-12/K1 PEDIATRIC	MULTI-12/K1 PEDIATRIC	ASCORBIC ACID	ASCORBIC ACID 80MG/4ML vial I;VITAMIN A PALMITATE 2300 IU/4ML vial I;COLECALCIFEROL 400 IU/4ML vial I;THIAMINE (VIT B1) HYDROCHLORIDE 1.2MG/4ML vial I;RIBOFLAVINE 1.4MG/4ML vial I;NICOTINAMIDE 17MG/4ML vial I;PYRIDOXINE (VIT B6) HYDROCHLORIDE 1MG/4ML vial I;DEXPANTHENOL 5MG/4ML vial I;TOCOPHEROL (VIT E) (AS TOCOPHERYL ACETATE) 7 IU/4ML vial I;PHYTOMENADIONE 0.2MG/4ML vial I;FOLIC ACID 140MCG/ML vial II;BIOTIN 20MCG/ML vial II;CYANOCOBALAMIN 1MCG/ML vial II	LIQUID	RECIEPT	For use as a multiple vitamin supplement for infants and children up to 11 years of age. It is also indicated in other situations where there are increased requirements for vitamins due to stress situations such as surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. The use of a multivitamin product obviates the need to speculate on the status of individual vitamin nutriture.
3349	MULTIBIC	MULTIBIC 3 MMOL/L POTASSIUM	CALCIUM CHLORIDE DIHYDRATE	CALCIUM CHLORIDE DIHYDRATE 0.2205G/L mixed soution;GLUCOSE AS MONOHYDRATE 1G/L mixed soution;MAGNESIUM CHLORIDE HEXAHYDRATE 0.1017G/L mixed soution;POTASSIUM CHLORIDE 0.2237G/L mixed soution;SODIUM CARBONATE HYDROGEN 2.940G/L mixed soution;SODIUM CHLORIDE 6.136G/L mixed soution	SOLUTION	RECIEPT	For use in patients with acute renal failure, requiring continuous haemofiltration.
3350	MULTIBIC	MULTIBIC 4 MMOL/L POTASSIUM	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 1G/L mixed solution;MAGNESIUM CHLORIDE HEXAHYDRATE 0.1017G/L mixed solution;POTASSIUM CHLORIDE 0.2982G/L mixed solution;CALCIUM CHLORIDE DIHYDRATE 0.2205G/L mixed solution;SODIUM CARBONATE HYDROGEN 2.940G/L mixed solution;SODIUM CHLORIDE 6.136G/L mixed solution	SOLUTION	RECIEPT	For use in patients with acute renal failure, requiring continuous haemofiltration.
3348	MULTIBIC	MULTIBIC 2 MMOL/L POTASSIUM	SODIUM CARBONATE HYDROGEN	SODIUM CARBONATE HYDROGEN 2.940G/L mixed soution;GLUCOSE AS MONOHYDRATE 1G/L mixed soution;POTASSIUM CHLORIDE 0.1491G/L mixed soution;MAGNESIUM CHLORIDE HEXAHYDRATE 0.1017G/L mixed soution;CALCIUM CHLORIDE DIHYDRATE 0.2205G/L mixed soution;SODIUM CHLORIDE 6.136G/L mixed soution	SOLUTION	RECIEPT	For use in patients with acute renal failure, requiring continuous haemofiltration.
3351	MULTIBIC POTASSIUM FREE	MULTIBIC POTASSIUM - FREE	SODIUM CHLORIDE	SODIUM CHLORIDE 6.136G/L mixed soution;CALCIUM CHLORIDE DIHYDRATE 0.2205G/L mixed soution;SODIUM CARBONATE HYDROGEN 2.940G/L mixed soution;GLUCOSE AS MONOHYDRATE 1G/L mixed soution;MAGNESIUM CHLORIDE HEXAHYDRATE 0.1017G/L mixed soution	SOLUTION	RECIEPT	For use in patients with acute renal failure, requiring continuous haemofiltration.
3352	MULTIHANCE	MULTIHANCE	GADOBENIC ACID AS DIMEGLUMINE SALT	GADOBENIC ACID AS DIMEGLUMINE SALT 334MG/ML	SOLUTION	RECIEPT	MultiHance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) indicated for: • MRI of the liver for the detection of focal liver lesions in patients with known or suspected primary liver cancer (eg. hepatocellular carcinoma) or metastatic disease. • MRI of the brain and spine where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI. • Contrast-enhanced MR- angiography where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease in patients with suspected or known vascular disease of the abdominal or peripheral arteries. • MRI of the breast, for the detection of malignant lesions in patients where breast cancer is known or suspected on the basis of previous mammography or ultrasound results
3353	MUPHORAN	MUPHORAN POWDER & SOLVENT FOR INFUSION	FOTEMUSTINE	FOTEMUSTINE 208MG/4ML	POWDER	RECIEPT	Disseminated malignant melanoma.
3354	MUPIROCIN	MUPIROCIN TEVA	MUPIROCIN	MUPIROCIN 2%	OINTMENT	RECIEPT	Mupirocin Teva is a topical antibacterial agent, active against those organisms responsible for the majority of skin infections. Mupirocin Teva is used for skin infections, e.g. impetigo, folliculitis, furunculosis.
3355	MUSCOL	MUSCOL	PARACETAMOL	PARACETAMOL 500MG;ORPHENADRINE (CITRATE) 30MG	TABLETS	RECIEPT	Relief of mild to moderate pain of acute musculoskeletal disorders.
3357	MYCAMINE	MYCAMINE 100 MG	MICAFUNGIN AS SODIUM	MICAFUNGIN AS SODIUM 100MG	POWDER	RECIEPT	Adults, adolescents ≥ 16 years of age and elderly: - Treatment of invasive candidiasis. - Treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate. - Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. Children (including neonates) and adolescents < 16 years of age: - Treatment of invasive candidiasis. - Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. The decision to use Mycamine should take into account a potential risk for the development of liver. Mycamine should therefore only be used if other antifungals are not appropriate.
3358	MYCAMINE	MYCAMINE 50 MG	MICAFUNGIN AS SODIUM	MICAFUNGIN AS SODIUM 50MG	POWDER	RECIEPT	Adults, adolescents ≥ 16 years of age and elderly: - Treatment of invasive candidiasis. - Treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate. - Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. Children (including neonates) and adolescents < 16 years of age: - Treatment of invasive candidiasis. - Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. The decision to use Mycamine should take into account a potential risk for the development of liver. Mycamine should therefore only be used if other antifungals are not appropriate.
3359	MYCOBUTIN	MYCOBUTIN	RIFABUTIN	RIFABUTIN 150MG	CAPSULES	RECIEPT	For the treatment of chronic tuberculosis where there is evidence of acid fast bacteria resistant to rifampicin or to two other alternative drugs. For the treatment of infections caused by MAC or other atypical mycobacteria where there is evidence of resistant bacteria as above. For the treatment of infections caused by MAC or other atypical mycobacteria in AIDS patients in all cases not subject to the above restrictions. For prevention of MAC infections in AIDS patients whose CD4 counts lower or eqval to 200/mm3
3361	MYCONAIL	MYCONAIL NAIL LACQUER 6.6ML	CICLOPIROX	CICLOPIROX 8%(80MG/G)	LACQUE		Treatment of fungal infections of the nails.
3360	MYCONAIL	MYCONAIL	CICLOPIROX	CICLOPIROX 80MG/G	LACQUE		For the treatment of fungal infections of the nails.
3362	MYCOPHENOLATE	MYCOPHENOLATE TEVA 500 MG	MYCOPHENOLATE MOFETIL	MYCOPHENOLATE MOFETIL 500MG	TABLETS	RECIEPT	Prophylaxis of rejection in renal allograft recepients, in patients receiving allogenic cardiac transplants and in allogenic hepatic transplants. Mycophenolate Teva should be used concomitantly with ciclosporin and corticosteroids.
3363	MYCOSTER	MYCOSTER 8 % NAIL LACQUER	CICLOPIROX	CICLOPIROX 8%W/W	LACQUE		Treatment of fungal infections of the nails.
3365	MYDRAMIDE	MYDRAMIDE	TROPICAMIDE	TROPICAMIDE 0.5%	DROPS	RECIEPT	Mydriatic for diagnostic use.
3366	MYFORTIC	MYFORTIC 180 MG	MYCOPHENOLIC ACID	MYCOPHENOLIC ACID 180MG	TABLETS	RECIEPT	Myfortic is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.
3367	MYFORTIC	MYFORTIC 360 MG	MYCOPHENOLIC ACID	MYCOPHENOLIC ACID 360MG	TABLETS	RECIEPT	Myfortic is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.
3368	MYLERAN	MYLERAN TABLETS 2 MG	BUSULFAN	BUSULFAN 2MG	TABLETS	RECIEPT	For the palliative treatment of the chronic granulocytic leukemia.
3369	MYLOTARG	MYLOTARG	GEMTUZUMAB OZOGAMICIN	GEMTUZUMAB OZOGAMICIN 5MG/VIAL	POWDER	RECIEPT	MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults. MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older.
3370	MYOCET	MYOCET 50 MG	DOXORUBICIN HYDROCHLORIDE	DOXORUBICIN HYDROCHLORIDE 50MG VIALS	POWDER	RECIEPT	Myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women.
3371	MYOVIEW	MYOVIEW	TETROFOSMIN	TETROFOSMIN 0.23MG/VIAL	POWDER	RECIEPT	Indicated as an adjunct in the diagnosis and localization of myocardial ischaemia or infarction. Myoview is indicated as an adjunct to the initial assessments (e.g. palpation mammography or alternative imaging modalities and/or cytology) in characterisation of malignancy of suspected breast lesions where all these other recommended tests were inconclusive.
3373	MYOZYME	MYOZYME	ALGLUCOSIDASE ALFA	ALGLUCOSIDASE ALFA 50MG/VIAL	POWDER	RECIEPT	Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). The benefits of Myozyme in patients with late-onset Pompe disease have not been established.
3374	NABUCO	NABUCO	NABUMETONE	NABUMETONE 500MG	TABLETS	RECIEPT	Acute and chronic treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and similar conditions requiring anti-inflamatory treatment.
3375	NAFLOXIN	NAFLOXIN	CIPROFLOXACIN AS HYDROCHLORIDE	CIPROFLOXACIN AS HYDROCHLORIDE 3MG/1ML	SOLUTION	RECIEPT	Corneal ulcers and conjunctivitis caused by susceptible gram positive and gram negative microorganisms for adults and pediatric patients above the age of 1 year. For localized or diffuse otitis externa accompanied by a strong inflammatory reaction and of which the strains are susceptible to ciprofloxacin, and for the acute flare-up of a chronic otitis media. In this case, a mucopurulent secretion comes through the perforated eardrum. Pseudomonas aeruginosa is one of the organisms most likely to be found in this case. Also in other infections of the ear in which Pseudomonas aeruginosa and/or other susceptible strains may be demonstrated or suspected (for example with suppurating tympanic tubes), Nafloxin can be used under the strict supervision of an ear specialist. It must be understood that this is not a routine treatment and that improper use must be avoided.
3378	NAGLAZYME	NAGLAZYME	GALSULFASE	GALSULFASE 1MG/ML	CONCENTRATE	RECIEPT	Naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of MPSVI (N-acetylglactosamine 4 sulfatase deficiency Maroteaux-Lamy syndrome).
3379	N-ALERGYA	N-ALERGYA	CETIRIZINE DIHYDROCHLORIDE	CETIRIZINE DIHYDROCHLORIDE 10MG	TABLETS		Antihistaminic drug for the treatment of allergies. For the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in children aged 6 years and over and adults.
3380	NAPROXEN	NAPROXEN SODIUM SP	NAPROXEN SODIUM	NAPROXEN SODIUM 275MG	TABLETS	RECIEPT	Mild and moderate analgesic. Fever reduction. non-steroidal anti-inflammatory for the treatment of rheumatic inflammations, tendinitis and muscoloskeletal inflammations. Treatment of primary dysmenorrhea.
3381	NAPROXEN	NAPROXEN SODIUM SP 275MG 20TAB	NAPROXEN SODIUM	NAPROXEN SODIUM 275MG	TABLETS	RECIEPT	Mild and moderate analgesic. Fever reduction. non-steroidal anti-inflammatory for the treatment of rheumatic inflammations, tendinitis and muscoloskeletal inflammations. Treatment of primary dysmenorrhea.
3382	NARAMIG	NARAMIG TABLETS 2.5 MG	NARATRIPTAN AS HYDROCHLORIDE	NARATRIPTAN AS HYDROCHLORIDE 2.5MG	TABLETS	RECIEPT	Naramig tablets are indicated for the acute treatment of migraine attacks with or without aura.
3383	NAROCIN	NAROCIN	NAPROXEN SODIUM	NAPROXEN SODIUM 275MG	TABLETS	RECIEPT	Mild and moderate analgesic. Fever reduction. Non-steroidal anti-inflammatory for the treatment of rheumatic inflammations, tendinitis and muscloskeletal inflammations. Treatment of primary dysmenorrhea.
3387	NAROCIN	NAROCIN 275MG 10TAB	NAPROXEN SODIUM	NAPROXEN SODIUM 275MG	TABLETS	RECIEPT	Mild and moderate analgesic. Fever reduction. Non-steroidal anti-inflammatory for the treatment of rheumatic inflammations, tendinitis and muscloskeletal inflammations. Treatment of primary dysmenorrhea.
3388	NAROCIN	NAROCIN 275MG 20TAB	NAPROXEN SODIUM	NAPROXEN SODIUM 275MG	TABLETS	RECIEPT	Mild and moderate analgesic. Fever reduction. Non-steroidal anti-inflammatory for the treatment of rheumatic inflammations, tendinitis and muscloskeletal inflammations. Treatment of primary dysmenorrhea.
3389	NAROPIN	NAROPIN 10 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 10MG/ML	SOLUTION	RECIEPT	Naropin 10 mg/ml is indicated in adults and adolescents aged above 12 years of age for: Surgical anaesthesia: Lumbar epidural administration for surgery
3390	NAROPIN	NAROPIN 2 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 2MG/ML	SOLUTION	RECIEPT	Acute pain management : In adults and adolescents above 12 years of age for: - Continuous epidural infusion or intermittent bolus administration during postoperative or labour pain. - Field blocks. - Peripheral nerve block via a continuous infusion or intermittent bolus injections, e.g. postoperative pain management.
3391	NASOCORT AQUA	NASOCORT AQUA 32 MCG/DOSE	BUDESONIDE MICRONIZED	BUDESONIDE MICRONIZED 0.64MG/ML	SPRAY	RECIEPT	Seasonal and perennial allergic rhinitis, and vasomotor rhinitis. Preventively against nasal polyps after polypectomy. Symptomatic treatment in nasal polyposis.
3392	NASOCORT AQUA	NASOCORT AQUA 64 MCG/DOSE	BUDESONIDE MICRONIZED	BUDESONIDE MICRONIZED 1.28MG/ML	SPRAY	RECIEPT	Seasonal and perennial allergic rhinitis, and vasomotor rhinitis. Preventively against nasal polyps after polypectomy. Symptomatic treatment in nasal polyposis.
3393	NATPARA	NATPARA 100 MCG	RECOMBINANT HUMAN PARATHYROID HORMONE	RECOMBINANT HUMAN PARATHYROID HORMONE 100MCG	POWDER	RECIEPT	NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in adult patients with hypoparathyroidism
3394	NATPARA	NATPARA 25 MCG	RECOMBINANT HUMAN PARATHYROID HORMONE	RECOMBINANT HUMAN PARATHYROID HORMONE 25MCG	POWDER	RECIEPT	NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in adult patients with hypoparathyroidism
3395	NATPARA	NATPARA 50 MCG	RECOMBINANT HUMAN PARATHYROID HORMONE	RECOMBINANT HUMAN PARATHYROID HORMONE 50MCG	POWDER	RECIEPT	NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in adult patients with hypoparathyroidism
3396	NATPARA	NATPARA 75 MCG	RECOMBINANT HUMAN PARATHYROID HORMONE	RECOMBINANT HUMAN PARATHYROID HORMONE 75MCG	POWDER	RECIEPT	NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in adult patients with hypoparathyroidism
3397	NAVELBINE	NAVELBINE 10 MG/ML	VINORELBINE AS TARTRATE	VINORELBINE AS TARTRATE 10MG/ML	CONCENTRATE	RECIEPT	For the treatment of non small cell lung cancer. For the treatment of advanced breast cancer. Hormone- refractory prostate cancer, especially in combination with low dose oral corticoid therapy or Estramustin.
3398	NAVELBINE	NAVELBINE 20 MG	VINORELBINE AS TARTRATE	VINORELBINE AS TARTRATE 20MG	CAPSULES	RECIEPT	For the treatment of non small cell lung cancer. For the treatment of advanced breast cancer.
3399	NAVELBINE	NAVELBINE 30 MG	VINORELBINE AS TARTRATE	VINORELBINE AS TARTRATE 30MG	CAPSULES	RECIEPT	For the treatment of non small cell lung cancer. For the treatment of advanced breast cancer.
3400	NAXYN	NAXYN 250 MG	NAPROXEN	NAPROXEN 250MG	TABLETS	RECIEPT	Mild and moderate analgesic. Fever reduction. Non-steroidal anti-inflammatory for the treatment of rheumatic inflammations, tendinitis and muscloskeletal inflammations. Treatment of primary dysmenorrhea.
3401	NAXYN	NAXYN 250MG 50TAB	NAPROXEN	NAPROXEN 250MG	TABLETS	RECIEPT	- Relief of the signs and symptoms of rheumatic diseases including osteoarthritis ankylosing spondylitis of Rheumatoid arthritis both in the treatment of acute flares and in the long-term management of the disease. - Juvenile Rheumatoid Arthritis.
3402	NAXYN	NAXYN 500 MG	NAPROXEN	NAPROXEN 500MG	TABLETS	RECIEPT	- Relief of the signs and symptoms of rheumatic diseases including osteoarthritis ankylosing spondylitis of Rheumatoid arthritis both in the treatment of acute flares and in the long-term management of the disease. - Juvenile Rheumatoid Arthritis.
3404	NEBIDO	NEBIDO	TESTOSTERONE UNDECANOATE	TESTOSTERONE UNDECANOATE 250MG/ML	SOLUTION	RECIEPT	Testosterone replacement therpay in primary and secondary male hypogonadism.
3405	NEMDATINE	NEMDATINE 10 MG	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of patients with moderate to severe Alzheimer’s disease.
3406	NEMDATINE	NEMDATINE 20 MG	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Treatment of patients with moderate to severe Alzheimer’s disease.
3407	NEOBLOC	NEOBLOC	METOPROLOL TARTRATE	METOPROLOL TARTRATE 100MG	TABLETS	RECIEPT	Cardio-selective beta receptor blocker for the treatment of hypertension and angina pectoris, antiarrhithmic, prophlaxis of myocardial reinfarction and migraine.
3410	NEO-MEDROL ACNE	NEO-MEDROL ACNE LOTION	METHYLPREDNISOLONE ACETATE	METHYLPREDNISOLONE ACETATE 2.5MG/ML;NEOMYCIN SULFATE 2.5MG/ML;SULFUR 50MG/ML;ALUMINIUM CHLOROHYDROXIDE COMPLEX SOLUTION 200MG/ML	LOTION	RECIEPT	Acne.
3411	NEOMYCIN	NEOMYCIN TABLETS	NEOMYCIN AS SULFATE	NEOMYCIN AS SULFATE 500MG	TABLETS	RECIEPT	Diarrhea due to enteropathogenic escherichia coli. Supression of intestinal bacteria prior to intestinal surgery or as an adjunct in hepatic coma.
3412	NEOSTIGMINE	NEOSTIGMINE - HAMELN 2.5 MG/ML INJECTION	NEOSTIGMINE METHYLSULFATE	NEOSTIGMINE METHYLSULFATE 2.5MG/ML	SOLUTION	RECIEPT	Myasthenia Gravis, antagonist to non-depolarizing neuromuscular blockade, Paralytic Ileus.
3413	NEOTIGASON	NEOTIGASON 10 MG	ACITRETIN	ACITRETIN 10MG	CAPSULES	RECIEPT	Severe disorders of keratinization such as erythrodermic psoriasis local or generalized pustular psoriasis congenital ichthyosis pityriasis rubra pilaris darier's disease.
3415	NEOTIGASON	NEOTIGASON 25 MG	ACITRETIN	ACITRETIN 25MG	CAPSULES	RECIEPT	Severe disorders of keratinization such as erythrodermic psoriasis local or generalized pustular psoriasis congenital ichthyosis pityriasis rubra pilaris darier's disease.
3419	NERIDERM	NERIDERM CREAM	DIFLUCORTOLONE VALERATE	DIFLUCORTOLONE VALERATE 0.1G/100 G	CREAM	RECIEPT	Corticoid responsive dermatoses in the absence of infection
3420	NERIDERM	NERIDERM OINTMENT	DIFLUCORTOLONE VALERATE	DIFLUCORTOLONE VALERATE 0.1G/100 G	OINTMENT	RECIEPT	Corticoid responsive dermatoses in the absence of infection
3422	NERVEN	NERVEN 20 DRAGEES	CRATAEGUS HERBA	CRATAEGUS HERBA 90MG;CRATAEGUS FRUCTUS 21MG;LUPULI STROBULUS 42MG;VALERIANAE EXTRACT 90MG;PASSIFLORAE HERBA 60MG	DRAGEE		Sedative, anxiety and tension states, insomnia.
3421	NERVEN	NERVEN	VALERIAN NATIVE EXTRACT	VALERIAN NATIVE EXTRACT 67.5MG;HOP NATIVE EXTRACT 29.4MG;PASSION FLOWER HOWTHORN BERRIES (2.8:1) NATIVE EXTRACT 81MG;HAWTHORN LEAF AND FLOWER NATIVE EXTRACT 81MG	DRAGEE		Sedative, anxiety and tension states, insomnia.
3423	NEULASTIM	NEULASTIM	PEGFILGRASTIM	PEGFILGRASTIM 6MG/0.6ML	SOLUTION	RECIEPT	Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy. ( with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
3424	NEUPOGEN	NEUPOGEN 30 MU PRE-FILLED SYRINGE	FILGRASTIM	FILGRASTIM 30MU/0.5ML	SOLUTION	RECIEPT	- Reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ). - Reduction in the duration of neutrope
3425	NEUPOGEN	NEUPOGEN 30 MU Vials	FILGRASTIM	FILGRASTIM 30MU/ML	SOLUTION		- Reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ). - Reduction in the duration of neutrope
3426	NEUPOGEN	NEUPOGEN 48 MU Pre-filled syringe	FILGRASTIM	FILGRASTIM 48MU/0.5ML	SOLUTION		- Reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ). - Reduction in the duration of neutrope
3427	NEURONTIN	NEURONTIN 300 MG	GABAPENTIN	GABAPENTIN 300MG	CAPSULES	RECIEPT	Epilepsy : - Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy. - Treatment of neuropathic pain - Gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy (neuralgia) in adults.
3429	NEURONTIN	NEURONTIN 400 MG	GABAPENTIN	GABAPENTIN 400MG	CAPSULES	RECIEPT	Epilepsy : - Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy. - Treatment of neuropathic pain - Gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy (neuralgia) in adults.
3431	NEVANAC	NEVANAC	NEPAFENAC	NEPAFENAC 0.1%	SUSPENSION	RECIEPT	Prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
3432	NEXAVAR	NEXAVAR	SORAFENIB AS TOSYLATE	SORAFENIB AS TOSYLATE 200MG	TABLETS	RECIEPT	Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma. Treatment of patients with hepatocellular carcinoma. Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
3444	NEXIUM	NEXIUM TABLETS 20 MG	ESOMEPRAZOLE	ESOMEPRAZOLE 20MG	TABLETS	RECIEPT	Nexium tablets are indicated in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with an appropriate antibacterial therapeutic regimen for the eradication of Helicobacter pylori and: - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers. Patients requiring NSAID therapy - healing of gastric ulcers associated with NSAID therapy. - prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk. Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Nexium 20 mg tablets are indicated in adolescents from the age of 12 years for Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophgeal reflux disease (GERD) In combination with antibiotics in treatment of duodenal ulcer caused by Helicobactor pylori
3447	NEXIUM	NEXIUM TABLETS 40 MG	ESOMEPRAZOLE	ESOMEPRAZOLE 40MG	TABLETS	RECIEPT	Nexium tablets are indicated in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with an appropriate antibacterial therapeutic regimen for the eradication of Helicobacter pylori and: - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers. Patients requiring NSAID therapy - healing of gastric ulcers associated with NSAID therapy. - prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk. Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Nexium 40 mg tablets are indicated in adolescents from the age of 12 years for; Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis
3443	NEXIUM	NEXIUM POWDER FOR SOLUTION FOR INJ/INF 40 MG	ESOMEPRAZOLE AS SODIUM	ESOMEPRAZOLE AS SODIUM 40MG/DOSE	POWDER	RECIEPT	Nexium for iniection and infusion is indicated in adult for: • Gastroesophageal reflux disease (GERD) in patients with esophagitis and/or severe symptoms of reflux as an alternative to oral therapy when oral intake is not appropriate. • Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers. Nexium for injection and infusion is indicated in children and adolescents aged 1-18 years for: • Gastric antisecretory treatment when the oral route is not possible, such as: gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.
3450	NEXOBRID	NEXOBRID 2 G POWDER AND 20 G GEL	CONCENTRATE OF PROTEOLYTIC ENZYMES ENRICHED IN BROMELAIN	CONCENTRATE OF PROTEOLYTIC ENZYMES ENRICHED IN BROMELAIN 2G	POWDER	RECIEPT	NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.
3451	NEXOBRID	NEXOBRID 5 G POWDER AND 50 G GEL	CONCENTRATE OF PROTEOLYTIC ENZYMES ENRICHED IN BROMELAIN	CONCENTRATE OF PROTEOLYTIC ENZYMES ENRICHED IN BROMELAIN 5G	POWDER	RECIEPT	NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.
3453	NICOTINEL	NICOTINEL TTS 10 7S	NICOTINE HCL	NICOTINE HCL 17.5MG	PATCHES		Aid to smoking cessation.
3454	NICOTINEL	NICOTINEL TTS 20 7S	NICOTINE HCL	NICOTINE HCL 35MG	PATCHES		Aid to smoking cessation.
3455	NICOTINEL	NICOTINEL TTS 30 7S	NICOTINE HCL	NICOTINE HCL 52.5MG	PATCHES		Aid to smoking cessation.
3460	NICOTINELL	NICOTINELL 7mg / 24h patch	NICOTINE	NICOTINE 17.5MG	PATCHES		Aid to smoking cessation.
3476	NICOTINELL	NICOTINELL LOZENGES 1 MG	NICOTINE	NICOTINE 1MG	TABLETS		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3478	NICOTINELL	NICOTINELL LOZENGES 1MG 36 LOZ	NICOTINE	NICOTINE 1MG	DRAGEE		An aid to smoking cessation, relief of symptoms associated with nicotine withdrawal. In smokers currently unable or not ready to stop smoking abruptly the lozenges may also be used as part of a program to reduce smoking prior to stopping completely.
3462	NICOTINELL	NICOTINELL GUM 2 MG (FRUIT)	NICOTINE	NICOTINE 2MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3464	NICOTINELL	NICOTINELL GUM 2 MG (MINT)	NICOTINE	NICOTINE 2MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3466	NICOTINELL	NICOTINELL GUM 2 MG MINT 204 UNITS	NICOTINE	NICOTINE 2MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3467	NICOTINELL	NICOTINELL GUM 2MG FRUIT 204 UNITS	NICOTINE	NICOTINE 2MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3468	NICOTINELL	NICOTINELL GUM 2MG FRUIT 48 tab	NICOTINE	NICOTINE 2MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3474	NICOTINELL	NICOTINELL GUM MINT 2GR 48 tab	NICOTINE	NICOTINE 2MG	GUM		An aid to smoking cessation, relief of symptoms associated with nicotine withdrawal. In smokers currently unable or not ready to stop smoking abruptly the lozenges may also be used as part of a program to reduce smoking prior to stopping completely.
3479	NICOTINELL	NICOTINELL LOZENGES 2 MG	NICOTINE	NICOTINE 2MG	TABLETS		An aid to smoking cessation, relief of symptoms associated with nicotine withdrawal. In smokers currently unable or not ready to stop smoking abruptly the lozenges may also be used as part of a program to reduce smoking prior to stopping completely.
3481	NICOTINELL	NICOTINELL LOZENGES 2 MG 36 loz	NICOTINE	NICOTINE 2MG	DRAGEE		An aid to smoking cessation, relief of symptoms associated with nicotine withdrawal. In smokers currently unable or not ready to stop smoking abruptly the lozenges may also be used as part of a program to reduce smoking prior to stopping completely.
3456	NICOTINELL	NICOTINELL 14mg / 24h patch	NICOTINE	NICOTINE 35MG	PATCHES		Aid to smoking cessation.
3469	NICOTINELL	NICOTINELL GUM 4 MG (FRUIT )	NICOTINE	NICOTINE 4MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3470	NICOTINELL	NICOTINELL GUM 4 MG (FRUIT)	NICOTINE	NICOTINE 4MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3471	NICOTINELL	NICOTINELL GUM 4 MG (MINT )	NICOTINE	NICOTINE 4MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3472	NICOTINELL	NICOTINELL GUM 4 MG (MINT)	NICOTINE	NICOTINE 4MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3473	NICOTINELL	NICOTINELL GUM 4MG FRUIT 48 tab	NICOTINE	NICOTINE 4MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3475	NICOTINELL	NICOTINELL GUM MINT 4GR 48tab	NICOTINE	NICOTINE 4MG	GUM		As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely.
3458	NICOTINELL	NICOTINELL 21 mg / 24h patch	NICOTINE	NICOTINE 52.5MG	PATCHES		Aid to smoking cessation.
3482	NICOTINELL	NICOTINELL TTS 10 28 PATCHES	NICOTINE HCL	NICOTINE HCL 17.5MG	PATCHES		Aid to smoking cessation.
3483	NICOTINELL	NICOTINELL TTS 20 28 PATCHES	NICOTINE HCL	NICOTINE HCL 35MG	PATCHES		Aid to smoking cessation.
3484	NICOTINELL	NICOTINELL TTS 30 28 PATCHES	NICOTINE HCL	NICOTINE HCL 52.5MG	PATCHES		Aid to smoking cessation.
3485	NIFEDILONG	NIFEDILONG 30	NIFEDIPINE	NIFEDIPINE 30MG	TABLETS	RECIEPT	Chronic stable angina, hypertension.
3486	NIFEDILONG	NIFEDILONG 60	NIFEDIPINE	NIFEDIPINE 60MG	TABLETS	RECIEPT	Chronic stable angina, hypertension.
3488	NIMENRIX	NIMENRIX	NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE	NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE 5MCG conjugated to tetanus toxoid carrier protein 44 mcg;NEISSERIA MENINGITIDIS GROUP W - 135 POLYSACCHARIDE 5MCG conjugated to tetanus toxoid carrier protein 44 mcg;NEISSERIA MENINGITIDIS GROUP C POLYSACCHARIDE 5MCG conjugated to tetanus toxoid carrier protein 44 mcg;NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE 5MCG conjugated to tetanus toxoid carrier protein 44 mcg	POWDER	RECIEPT	Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135 and Y.
3489	NINLARO	NINLARO 2.3 MG	IXAZOMIB AS CITRATE	IXAZOMIB AS CITRATE 2.3MG	CAPSULES	RECIEPT	NINLARO is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
3491	NINLARO	NINLARO 3 MG	IXAZOMIB AS CITRATE	IXAZOMIB AS CITRATE 3MG	CAPSULES	RECIEPT	NINLARO is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
3493	NINLARO	NINLARO 4 MG	IXAZOMIB AS CITRATE	IXAZOMIB AS CITRATE 4MG	CAPSULES	RECIEPT	NINLARO is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
3496	NITHIODOTE	NITHIODOTE	SODIUM THIOSULFATE	SODIUM THIOSULFATE 250MG/1ML;SODIUM NITRITE 30MG/1ML	SOLUTION	RECIEPT	Nithiodote is indicated for the treatment of acute cyanide poisoning that is judged to be life threatening. When the diagnosis of cyanide poisoning is uncertain, the potentially life-threatening risks associated with Nithiodote should be carefully weighed against the potential benefits, especially if the patient is not in extremis.
3499	NITRODERM	NITRODERM TTS 5	GLYCERYL TRINITRATE	GLYCERYL TRINITRATE 25MG/PATCH	PATCHES	RECIEPT	Prophylaxis of angina pectoris.
3497	NITRODERM	NITRODERM TTS 10	GLYCERYL TRINITRATE	GLYCERYL TRINITRATE 50MG/PATCH	PATCHES	RECIEPT	Prophylaxis of angina pectoris.
3501	NITROGEN	NITROGEN MEDICAL LIQUID	NITROGEN	NITROGEN 99.5%	LIQUEFIED GAS	RECIEPT	Liquefied Nitrogen for treatment of skin lesions by freezing (cryotherapy).
3505	NITROLINGUAL	NITROLINGUAL SPRAY	GLYCERYL TRINITRATE	GLYCERYL TRINITRATE 0.4MG/DOSE	SOLUTION	RECIEPT	Relief of angina pectoris attacks, angina pectoris prophylaxis.
3135	NITROUS OXIDE	MEDICAL NITROUS OXIDE GAS	NITROUS OXIDE	NITROUS OXIDE 98%V/V	GAS	RECIEPT	Medical gas for analgesia and general anesthesia.
3136	NITROUS OXIDE	MEDICAL NITROUS OXIDE LIQUID	NITROUS OXIDE	NITROUS OXIDE 98%V/V	GAS	RECIEPT	Medical gas for analgesia and general anesthesia.
3507	NIZORAL	NIZORAL SHAMPOO	KETOCONAZOLE	KETOCONAZOLE 20MG/1 G	SHAMPOO	RECIEPT	Topical treatment of seborrhoeic dermatitis including dandruff resulting from proven fungal infection including Pityriasis versicolor.
3506	NIZORAL	NIZORAL CREAM	KETOCONAZOLE	KETOCONAZOLE 20MG/G	CREAM	RECIEPT	Nizoral cream is indicated for topical application in the treatment of dermatophyte infections of the skin: tinea corporis, tinea cruris, tinea manus and tinea pedis due to trichophyton rubrum, microsporum canis and epidermophyton floccosum, as well as in the treatment of cutaneous candidosis and tinea (pityriasis ) vesicolor. Nizoral cream is also indicated for the treatment of seborrheic dematitis caused by pityrosporum sp.
3508	N-KE'EV	N-KE'EV	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	For local treatment of rheumatic diseases, pain and non-infected inflammation.
3509	N-KE'EV	N-KE'EV 50GR	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	For local treatment of rheumatic diseases, pain and non-infected inflammation.
3510	NOCTURNO	NOCTURNO 3.75	ZOPICLONE	ZOPICLONE 3.75MG	TABLETS	RECIEPT	Hypnotic.
3512	NOCTURNO	NOCTURNO FORTE 7.5	ZOPICLONE	ZOPICLONE 7.5MG	TABLETS	RECIEPT	Hypnotic when the disorder of insomnia is severe and disabling.
3514	NORADRENALINE	NORADRENALINE SINTETICA 4 MG/4 ML	NOREPINEPHRINE AS BITARTRATE	NOREPINEPHRINE AS BITARTRATE 1MG/1ML	CONCENTRATE	RECIEPT	For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension.
3515	NORDITROPIN	NORDITROPIN 10 MG	SOMATROPIN	SOMATROPIN 10MG/1.5ML	SOLUTION	RECIEPT	Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner`s syndrome. Short stature in children with renal insufficiency. Growth disturbance (current height SDS < - 2.5 and parental adjusted height SDS < - 1) in short children born small for gestational age (SGA) with a birth weight and/or length below - 2 SD who failed to show catch-up growth (HV SDS < during the last year) by 4 years of age or later. Children with short stature associated with Noonan syndrome. Adults: Treatment of adults with Hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of G.H. deficiency.
3516	NORDITROPIN	NORDITROPIN 15 MG	SOMATROPIN	SOMATROPIN 10MG/1ML	SOLUTION	RECIEPT	Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner`s syndrome. Short stature in children with renal insufficiency. Growth disturbance (current height SDS < - 2.5 and parental adjusted height SDS < - 1) in short children born small for gestational age (SGA) with a birth weight and/or length below - 2 SD who failed to show catch-up growth (HV SDS < during the last year) by 4 years of age or later. Children with short stature associated with Noonan syndrome. Adults: Treatment of adults with Hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of G.H. deficiency.
3517	NORDITROPIN	NORDITROPIN 5 MG	SOMATROPIN	SOMATROPIN 3.3MG/1ML	SOLUTION	RECIEPT	Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner`s syndrome. Short stature in children with renal insufficiency. Growth disturbance (current height SDS < - 2.5 and parental adjusted height SDS < - 1) in short children born small for gestational age (SGA) with a birth weight and/or length below - 2 SD who failed to show catch-up growth (HV SDS < during the last year) by 4 years of age or later. Children with short stature associated with Noonan syndrome. Adults: Treatment of adults with Hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of G.H. deficiency.
3519	NORIT	NORIT 125MG 50TAB	CHARCOAL ACTIVATED	CHARCOAL ACTIVATED 125MG	TABLETS		Adsorption of intestinal gas as an aid in the treatment of diarrhea
3520	NORIT	NORIT TABLETS	CHARCOAL ACTIVATED	CHARCOAL ACTIVATED 125MG	TABLETS		Adsorption of intestinal gas as an aid in the treatment of diarrhea
3521	NORLEVO	NORLEVO 0.75 MG	LEVONORGESTREL	LEVONORGESTREL 0.75MG	TABLETS	RECIEPT	Emergency contraceptive.
3522	NORLEVO	NORLEVO 1.5 MG	LEVONORGESTREL	LEVONORGESTREL 1.5MG	TABLETS	RECIEPT	Emergency contraceptive.
3524	NORLEVO	NORLEVO 1.5MG 1TAB	LEVONORGESTREL	LEVONORGESTREL 1.5MG	TABLETS	RECIEPT	Emergency contraceptive.
3525	NORLIP	NORLIP	BEZAFIBRATE	BEZAFIBRATE 200MG	TABLETS	RECIEPT	Reduction of elevated blood levels of cholesterol and triglycerides.
3528	NORMALAX	NORMALAX 240 GR	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350	POWDER		For the treatment of constipation.
3529	NORMALAX	NORMALAX 70 GR	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350	POWDER		For the treatment of constipation.
3527	NORMALAX	NORMALAX	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350 100%W/W	POWDER		For the treatment of constipation.
3530	NORMALAX	NORMALAX KIDS	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350 4G	POWDER		For the treatment of constipation.
3531	NORMALOL	NORMALOL 100	ATENOLOL	ATENOLOL 100MG	TABLETS	RECIEPT	For the treatment of angina pectoris, acute myocardial infarction, hypertension.
3532	NORMALOL	NORMALOL 25	ATENOLOL	ATENOLOL 25MG	TABLETS	RECIEPT	Treatment of angina pectoris, acute myocardial infarction, hypertension .
3533	NORMALOL	NORMALOL 50	ATENOLOL	ATENOLOL 50MG	TABLETS	RECIEPT	For the treatment of angina pectoris, acute myocardial infarction, hypertension.
3534	NORMITEN	NORMITEN 100	ATENOLOL	ATENOLOL 100MG	TABLETS	RECIEPT	Management of angina pectoris and hypertension,including hypertension of renal origin. Late intervention after acute myocardial infarction.
3536	NORMITEN	NORMITEN 25	ATENOLOL	ATENOLOL 25MG	TABLETS	RECIEPT	Management of angina pectoris and hypertension, including hypertension of renal origin. Late intervention after acute myocardial infarction.
3538	NORMITEN	NORMITEN 50	ATENOLOL	ATENOLOL 50MG	TABLETS	RECIEPT	Management of angina pectoris and hypertension, including hypertension of renal origin. Late intervention after Acute Myocardial Infarction
3540	NORMOPRESAN	NORMOPRESAN	CLONIDINE HYDROCHLORIDE	CLONIDINE HYDROCHLORIDE 150MCG	TABLETS	RECIEPT	Antihypertensive.
3552	NORPROLAC	NORPROLAC 0.025 MG	QUINAGOLIDE AS HYDROCHLORIDE	QUINAGOLIDE AS HYDROCHLORIDE 0.025MG	TABLETS	RECIEPT	Second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).
3553	NORPROLAC	NORPROLAC 0.05 MG	QUINAGOLIDE AS HYDROCHLORIDE	QUINAGOLIDE AS HYDROCHLORIDE 0.05MG	TABLETS	RECIEPT	Second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).
3554	NORPROLAC	NORPROLAC 0.075 MG TABLETS	QUINAGOLIDE AS HYDROCHLORIDE	QUINAGOLIDE AS HYDROCHLORIDE 0.075MG	TABLETS	RECIEPT	Second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).
3555	NORPROLAC	NORPROLAC 0.15 MG TABLETS	QUINAGOLIDE AS HYDROCHLORIDE	QUINAGOLIDE AS HYDROCHLORIDE 0.15MG	TABLETS	RECIEPT	Second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).
3556	NORTYLIN	NORTYLIN 25 MG	NORTRIPTYLINE HYDROCHLORIDE	NORTRIPTYLINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Depressive states, endogenous depressions are more likely to be alleviated than other depressive states.
3557	NORVASC	NORVASC 10 MG TABLETS	AMLODIPINE AS BESYLATE	AMLODIPINE AS BESYLATE 10MG	TABLETS	RECIEPT	Mild to moderate hypertension. Vasospastic angina ( Prinzmetal's or variant angina). Chronic stable angina.
3560	NORVASC	NORVASC 5 MG TABLETS	AMLODIPINE AS BESYLATE	AMLODIPINE AS BESYLATE 5MG	TABLETS	RECIEPT	Mild to moderate hypertension. Vasospastic angina ( Prinzmetal's or variant angina). Chronic stable angina.
3563	NORVIR	NORVIR 100 MG TABLETS	RITONAVIR	RITONAVIR 100MG	TABLETS	RECIEPT	Is indicated alone or in combination with other antiretroviral agents for the treatment of patients with HIV infection when therapy is warranted based on clinical and/or immunological evidence of disease progression
3565	NOTENSYL	NOTENSYL TABLETS	DICYCLOMINE HYDROCHLORIDE	DICYCLOMINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Adjunctive therapy in irritable bowel syndrome, neurogenic bowel disturbance.
3564	NOTENSYL	NOTENSYL SYRUP	DICYCLOMINE HYDROCHLORIDE	DICYCLOMINE HYDROCHLORIDE 10MG/5ML	SYRUP	RECIEPT	Adjunctive therapy in irritable bowel syndrome, neurogenic bowel disturbance.
3566	NOVITROPAN	NOVITROPAN 5 MG TABLETS	OXYBUTYNIN HYDROCHLORIDE	OXYBUTYNIN HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Relief of symptoms associated with voiding in patients with uninhibited neurogenic and reflux neurogenic bladder.
3567	NOVOEIGHT	NOVOEIGHT 1000 IU	TUROCTOCOG ALFA	TUROCTOCOG ALFA 1000 IU/4ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). NovoEight can be used for all age groups.
3568	NOVOEIGHT	NOVOEIGHT 1500 IU	TUROCTOCOG ALFA	TUROCTOCOG ALFA 1500 IU/4ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). NovoEight can be used for all age groups.
3569	NOVOEIGHT	NOVOEIGHT 2000 IU	TUROCTOCOG ALFA	TUROCTOCOG ALFA 2000 IU/4ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). NovoEight can be used for all age groups.
3570	NOVOEIGHT	NOVOEIGHT 250 IU	TUROCTOCOG ALFA	TUROCTOCOG ALFA 250 IU/4ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). NovoEight can be used for all age groups.
3571	NOVOEIGHT	NOVOEIGHT 3000 IU	TUROCTOCOG ALFA	TUROCTOCOG ALFA 3000 IU/4ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). NovoEight can be used for all age groups.
3572	NOVOEIGHT	NOVOEIGHT 500 IU	TUROCTOCOG ALFA	TUROCTOCOG ALFA 500 IU/4ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). NovoEight can be used for all age groups.
3573	NOVOFEM	NOVOFEM	ESTRADIOL AS HEMIHYDRATE	ESTRADIOL AS HEMIHYDRATE 1MG;NORETHISTERONE ACETATE 1MG white tab	TABLETS	RECIEPT	Hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus. Prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. The experience treating women older than 65 years is limited.
3575	NOVOMIX	NOVOMIX 30 PENFILL	INSULIN ASPART	INSULIN ASPART 100IU/ML	SUSPENSION	RECIEPT	Treatment of diabetes mellitus.
3574	NOVOMIX	NOVOMIX 30 FLEXPEN	INSULIN ASPART	INSULIN ASPART 100U/ML	SUSPENSION	RECIEPT	NovoMix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
3576	NOVOMIX	NOVOMIX 50 FLEXPEN	INSULIN ASPART	INSULIN ASPART 100U/ML	SUSPENSION	RECIEPT	NovoMix 50 is indicated for treatment of diabetes mellitus in adults.
3577	NOVOMIX	NOVOMIX 70 FLEXPEN	INSULIN ASPART	INSULIN ASPART 100U/ML	SUSPENSION	RECIEPT	NovoMix 70 is indicated for treatment of diabetes mellitus in adults.
3578	NOVONORM	NOVONORM 0.5 MG	REPAGLINIDE	REPAGLINIDE 0.5MG	TABLETS	RECIEPT	Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2diabetes mellitus who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
3579	NOVONORM	NOVONORM 1 MG	REPAGLINIDE	REPAGLINIDE 1MG	TABLETS	RECIEPT	Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
3580	NOVONORM	NOVONORM 2 MG	REPAGLINIDE	REPAGLINIDE 2MG	TABLETS	RECIEPT	Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
3581	NOVORAPID	NOVORAPID	INSULIN ASPART	INSULIN ASPART 100U/ML	SOLUTION	RECIEPT	Treatment of patients with diabetes mellitus in adults, adolescents and children aged 2 years and above.
3582	NOVOSEVEN	NOVOSEVEN RT 1 MG/VIAL	EPTACOG ALFA (ACTIVATED)	EPTACOG ALFA (ACTIVATED) 1MG/VIAL	POWDER	RECIEPT	Treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 BU, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration, * in patients with acquired haemophilia, in patients with congenital FVII deficieny, * in patients with Glanzmann's thropnbastenia with antibodies to GP IIb-IIIa and/or HLA, and with past or present refractoriness to platelet transfusions.
3583	NOVOSEVEN	NOVOSEVEN RT 2 MG/VIAL	EPTACOG ALFA (ACTIVATED)	EPTACOG ALFA (ACTIVATED) 2MG/VIAL	POWDER	RECIEPT	Treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 BU, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration, * in patients with acquired haemophilia, in patients with congenital FVII deficieny, * in patients with Glanzmann's thropnbastenia with antibodies to GP IIb-IIIa and/or HLA, and with past or present refractoriness to platelet transfusions.
3584	NOVOSEVEN	NOVOSEVEN RT 5 MG/VIAL	EPTACOG ALFA (ACTIVATED)	EPTACOG ALFA (ACTIVATED) 5MG/VIAL	POWDER	RECIEPT	Treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 BU, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration, * in patients with acquired haemophilia, in patients with congenital FVII deficieny, * in patients with Glanzmann's thropnbastenia with antibodies to GP IIb-IIIa and/or HLA, and with past or present refractoriness to platelet transfusions.
3585	NOVOTHIRTEEN	NOVOTHIRTEEN	FACTOR XIII	FACTOR XIII 2500 IU/3ML	POWDER	RECIEPT	Long term prophylactic treatment of bleeding in patients age 1 year and above with congenital Factor XIII A-subunit deficiency
3586	NOXAFIL	NOXAFIL 100 MG GASTRO-RESISTANT TABLETS	POSACONAZOLE	POSACONAZOLE 100MG	TABLETS	RECIEPT	Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults: - Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; - Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; - Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; - Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. - Zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following patients: - Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.
3587	NOXAFIL	NOXAFIL 300 MG CONCENTRATE FOR SOLUTION FOR INFUSION	POSACONAZOLE	POSACONAZOLE 300MG/VIAL	CONCENTRATE	RECIEPT	Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults : - Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; - Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; - Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; - Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. - Zygomycosis, in patients intolerant of, or with disease that is refractory to, alternative therapy. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following patients: - Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.
3588	NOXAFIL	NOXAFIL SUSPENSION	POSACONAZOLE	POSACONAZOLE 40MG/ML	SUSPENSION	RECIEPT	Noxafil is indicated for use in the treatment of the following fungal infections in adults : - Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products - Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B - Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - Coccidioidomycosis in patients with disease that is refractory to amphotericin B itraconazole or fluconazole or in patients who are intolerant of these medicinal products - Oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Noxafil is also indicated for prophylaxis of invasive fungal infections in the following patients : - Patients receiving remission- induction chemotherapy for acute myelogenous leukemia ( AML) or myelodysplastic syndromes ( MDS ) expected to result in prologed neutropenia and who are at high risk of developing invasive fungal infections - Hematopoietic stem cell transplant ( HSCT) recipients who are undergoing high - dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. Zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy
3590	NOXIDIL	NOXIDIL 5 %	MINOXIDIL	MINOXIDIL 5%	SOLUTION	RECIEPT	Hair regrowth treatment for men.
3591	NOXIDIL	NOXIDIL 5% SOLUTION 120ML(2*60)	MINOXIDIL	MINOXIDIL 5%	SOLUTION	RECIEPT	Hair regrowth treatment for men.
3592	NPLATE	NPLATE 250 MCG	ROMIPLOSTIM	ROMIPLOSTIM 250MCG/VIAL	POWDER	RECIEPT	Nplate is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
3593	NPLATE	NPLATE 500 MCG	ROMIPLOSTIM	ROMIPLOSTIM 500MCG/VIAL	POWDER	RECIEPT	Nplate is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
3594	NUCALA	NUCALA	MEPOLIZUMAB	MEPOLIZUMAB 100MG	POWDER	RECIEPT	Nucala is indicated for: Severe Asthma as an add-on treatment for severe refractory eosinophilic asthma in adult patients Eosinophilic Granulomatosis with Polyangiitis: for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
3595	NUEDEXTA	NUEDEXTA	QUINIDINE SULFATE	QUINIDINE SULFATE 10MG;DEXTROMETHORPHAN HYDROBROMIDE 20MG	CAPSULES	RECIEPT	For the treatment of Pseudobulbar Affect (PBA) .
3605	NUROFEN	NUROFEN FOR CHILDREN ORANGE	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain. For infants and children aged 3 months to 12 years (i.e. weighing about 40 kg).
3606	NUROFEN	NUROFEN FOR CHILDREN ORANGE SYR 100ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
3607	NUROFEN	NUROFEN FOR CHILDREN ORANGE SYR 150ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
3608	NUROFEN	NUROFEN FOR CHILDREN ORANGE SYR 200ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
3609	NUROFEN	NUROFEN FOR CHILDREN STRABERRY SYR 100ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
3610	NUROFEN	NUROFEN FOR CHILDREN STRABERRY SYR 150ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
3611	NUROFEN	NUROFEN FOR CHILDREN STRABERRY SYR 200ML	IBUPROFEN	IBUPROFEN 100MG/5ML	SYRUP	RECIEPT	For the reduction of fever and relief of mild to moderate pain.
3612	NUROFEN	NUROFEN FOR CHILDREN STRAWBERRY	IBUPROFEN	IBUPROFEN 100MG/5ML	SUSPENSION	RECIEPT	For the reduction of fever and relief of mild to moderate pain. For infants and children aged 3 months to 12 years (i.e. weighing about 40 kg).
3613	NUROFEN	NUROFEN FOR CHILDREN SUPPOSITORIES 125 MG	IBUPROFEN	IBUPROFEN 125MG	SUPPOSITORIES	RECIEPT	For the symptomatic treatment of muld to moderate pain. For the symptomatic treatment of fever.
3599	NUROFEN	NUROFEN 200MG 24TAB	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.
3600	NUROFEN	NUROFEN 200MG 48TAB	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.
3621	NUROFEN	NUROFEN LIQUID 200MG 10 CAPS	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache,muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.
3622	NUROFEN	NUROFEN LIQUID 200MG 20 CAPS	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache,muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.
3623	NUROFEN	NUROFEN LIQUID 200MG 40 CAPS	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache,muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.
3624	NUROFEN	NUROFEN LIQUID CAPSULES 200 MG	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.
3625	NUROFEN	NUROFEN LIQUID CAPSULES 200 MG NEW FORMULATION	IBUPROFEN	IBUPROFEN 200MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache,muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.
3633	NUROFEN	NUROFEN TABLETS 200 MG	IBUPROFEN	IBUPROFEN 200MG	TABLETS	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic diseases, reduction of fever.
3626	NUROFEN	NUROFEN PLUS	IBUPROFEN	IBUPROFEN 200MG;CODEINE AS HEMIHYDRATE 10MG	TABLETS	RECIEPT	For short term use for the relief of acute (short lasting) moderate pain, such as rheumatic pain (arthritis), muscular pain, backaches, neuralgia, migraine, headache, dental pain and menstrual pain.
3628	NUROFEN	NUROFEN PLUS 12TAB	IBUPROFEN	IBUPROFEN 200MG;CODEINE PHOSPHATE 12.8MG	TABLETS	RECIEPT	For short term use for the relief of acute (short lasting) moderate pain, such as rheumatic pain (arthritis), muscular pain, backaches, neuralgia, migraine, headache, dental pain and menstrual pain.
3602	NUROFEN	NUROFEN COLD&FLU 24 TAB	IBUPROFEN	IBUPROFEN 200MG;PSEUDOEPHEDRINE HCL 30MG	TABLETS	RECIEPT	Temporarily relieves symptoms associated with the common cold, or flu: in the presence of fever or pain with associated congestion.
3601	NUROFEN	NUROFEN COLD AND FLU	IBUPROFEN	IBUPROFEN 200MG;PSEUDOEPHEDRINE HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Relief of symptoms of cold and flu in the presence of fever or pain with associated congestion.
3615	NUROFEN	NUROFEN FORTE 400MG 12TAB	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	Relief of mild to moderate pain, such as headache, toothache, menstrual pain, backache, muscular pain. For the relief of symptoms associated with rheumatic diseases.
3616	NUROFEN	NUROFEN FORTE LIQUID CAPSULES 400 MG	IBUPROFEN	IBUPROFEN 400MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever.
3617	NUROFEN	NUROFEN FORTE LIQUID GEL 20 CAPS	IBUPROFEN	IBUPROFEN 400MG	CAPSULES	RECIEPT	Relief of mild to moderate pain such as headache, toothache, menstrual pain, backache, muscular pain, anti-inflammatory for rheumatic disease, reduction of fever. For the treatment of pain associated with migraine.
3618	NUROFEN	NUROFEN FORTE TABLETS 400 MG	IBUPROFEN	IBUPROFEN 400MG	TABLETS	RECIEPT	Relief of mild to moderate pain, such as headache, toothache, menstrual pain, backache, muscular pain. For the relief of symptoms associated with rheumatic diseases.
3620	NUROFEN	NUROFEN GEL 5% 50GR	IBUPROFEN	IBUPROFEN 5%	GEL	RECIEPT	Topical analgesic and anti-inflammatory for backache, rheumatic and muscular pain, sprains, strains, sports injuries.
3619	NUROFEN	NUROFEN GEL 5 %	IBUPROFEN	IBUPROFEN 5%W/W	GEL	RECIEPT	Topical analgesic and anti-inflammatory for backache, rheumatic and muscular pain, sprains, strains, sports injuries.
3614	NUROFEN	NUROFEN FOR CHILDREN SUPPOSITORIES 60 MG	IBUPROFEN	IBUPROFEN 60MG	SUPPOSITORIES	RECIEPT	For the symptomatic treatment of mild to moderate pain. For the symptomatic treatment of fever.
3629	NUROFEN	NUROFEN QUICK 256 MG	IBUPROFEN SODIUM	IBUPROFEN SODIUM 256MG	TABLETS	RECIEPT	For the symptomatic relief of mild to moderate pain, such as hedache, backache, period pain, dental pain, neuralgia, rheumatic and muscular pain, the pain of non-serious arthritis, migraine, cold and flu symptoms, sore throat and fever.
3630	NUROFEN	NUROFEN QUICK 256 MG 24 TAB	IBUPROFEN SODIUM	IBUPROFEN SODIUM 256MG	TABLETS	RECIEPT	For the symptomatic relief of mild to moderate pain, such as hedache, backache, period pain, dental pain, neuralgia, rheumatic and muscular pain, the pain of non-serious arthritis, migraine, cold and flu symptoms, sore throat and fever.
3631	NUROFEN	NUROFEN QUICK 512 MG	IBUPROFEN SODIUM	IBUPROFEN SODIUM 512MG	TABLETS	RECIEPT	For the symptomatic relief of mild to moderate pain, such as hedache, backache, period pain, dental pain, neuralgia, rheumatic and muscular pain, the pain of non-serious arthritis, migraine, cold and flu symptoms, sore throat and fever.
3632	NUROFEN	NUROFEN QUICK 512 MG 12 TAB	IBUPROFEN SODIUM	IBUPROFEN SODIUM 512MG	TABLETS	RECIEPT	For the symptomatic relief of mild to moderate pain, such as hedache, backache, period pain, dental pain, neuralgia, rheumatic and muscular pain, the pain of non-serious arthritis, migraine, cold and flu symptoms, sore throat and fever.
3603	NUROFEN	NUROFEN FOR CHILDREN 125MG 10SUPP	IBUPROFEN	IBUPROFEN 125MG	SUPPOSITORIES		For the symptomatic treatment of mild to moderate pain. For the symptomatic treatment of fever.
3604	NUROFEN	NUROFEN FOR CHILDREN 60MG 10 SUPP	IBUPROFEN	IBUPROFEN 125MG	SUPPOSITORIES		For the symptomatic treatment of mild to moderate pain. For the symptomatic treatment of fever.
3636	NUSSIDEX	NUSSIDEX 20TAB	DEXCHLORPHENIRAMINE	DEXCHLORPHENIRAMINE 1MG;PSEUDOEPHEDRINE 25MG	TABLETS	RECIEPT	Symptomatic treatment of the common cold and allergic rhinitis (hay fever).
3637	NUSSIDEX	NUSSIDEX SYRUP 115ML	DEXCHLORPHENIRAMINE MALEATE	DEXCHLORPHENIRAMINE MALEATE 1MG/5ML;PSEUDOEPHEDRINE HCL 25MG/5ML	SYRUP	RECIEPT	Relief of congestion in the respiratory tract due to allergy.
3634	NUSSIDEX	NUSSIDEX	DEXCHLORPHENIRAMINE MALEATE	DEXCHLORPHENIRAMINE MALEATE 1MG;PSEUDOEPHEDRINE AS HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Symptomatic treatment of the common cold and allergic rhinitis (hay fever).
3638	NUTRINEAL PD4 WITH	NUTRINEAL PD4 WITH 1.1 % AMINO ACIDS	TYROSINE	TYROSINE 0.3G/L;TRYPTOPHAN 0.27G/L;PHENYLALANINE 0.57G/L;THREONINE 0.646G/L;SERINE 0.51G/L;PROLINE 0595G/L;GLYCINE 0.51G/L;L- ALANINE 0.951G/L;VALINE 1.393G/L;METHIONINE 0.85G/L;ISOLEUCINE 0.85G/L;LEUCINE 1.02G/L;HISTIDINE 0.714G/L;ARGININE 1.071G/L;SODIUM CHLORIDE 5.38G/L;LYSINE HYDROCHLORIDE 0.955G/L;CALCIUM CHLORIDE DIHYDRATE 0.184G/L;MAGNESIUM CHLORIDE HEXAHYDRATE 0.051G/L;SODIUM (S) - LACTATE 4.480G/L	SOLUTION	RECIEPT	Nutritional supplement for malnourished renal failure patients (albumin concentration lower then 35 g/liter) being maintained on peritoneal dialysis.
3639	NUTRYELT	NUTRYELT	FERROUS GLUCONATE	FERROUS GLUCONATE 7988.2MCG/10ML;CHROMIUM CHLORIDE 30.45MCG/10ML;SODIUM MOLYBDATE 42.93MCG/10ML;SODIUM SELENITE 153.32MCG/10ML;POTASSIUM IODIDE 170.06MCG/10ML;SODIUM FLUORIDE 2099.5MCG/10ML;MANGANESE GLUCONATE 445.69MCG/10ML;COPPER GLUCONATE 2142.4MCG/10ML;ZINC GLUCONATE 69700MCG/10ML	CONCENTRATE	RECIEPT	NUTRYELT is used as part of an intravenous nutrition regimen, to cover basal or moderately increased trace element requirements in parenteral nutrition. NUTRYELT is indicated in adults only
3640	NUVARING	NUVARING	ETHINYLESTRADIOL	ETHINYLESTRADIOL 2.7MG;ETONOGESTREL 11.7MG	PESSARY	RECIEPT	Contraception. The safety and efficacy has been established in women aged 18 to 40 years.
3642	NUVIGIL	NUVIGIL 150 MG	ARMODAFINIL	ARMODAFINIL 150MG	TABLETS	RECIEPT	Nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD).
3649	NUVIGIL	NUVIGIL 250 MG	ARMODAFINIL	ARMODAFINIL 250MG	TABLETS	RECIEPT	Nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD).
3656	NUVIGIL	NUVIGIL 50 MG	ARMODAFINIL	ARMODAFINIL 50MG	TABLETS	RECIEPT	Nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD).
3664	NYSTATIN	NYSTATIN TARO	NYSTATIN	NYSTATIN 100000 IU/1ML	SUSPENSION	RECIEPT	For the treatment of oral fungal infections.
3663	NYSTATIN	NYSTATIN READY MIX	NYSTATIN	NYSTATIN 100000IU/ML	SUSPENSION	RECIEPT	For the treatment of oral fungal infections.
3665	NYXOID	NYXOID 1.8 MG	NALOXONE AS HYDROCHLORIDE DIHYDRATE	NALOXONE AS HYDROCHLORIDE DIHYDRATE 1.8MG/0.1ML	SOLUTION	RECIEPT	Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid is indicated in adults and adolescents aged 14 years and over. Nyxoid is not a substitute for emergency medical care.
3666	N-ZAREVET	N-ZAREVET	CALCIUM CARBONATE	CALCIUM CARBONATE 500MG	TABLETS		Antacid.
3668	N-ZAREVET	N-ZAREVET 500mg 150 CHEW TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 500MG	TABLETS		Antacid.
3669	OCALIVA	OCALIVA™ 10 MG	OBETICHOLIC ACID	OBETICHOLIC ACID 10MG	TABLETS	RECIEPT	OCALIVA is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
3670	OCALIVA	OCALIVA™ 5 MG	OBETICHOLIC ACID	OBETICHOLIC ACID 5MG	TABLETS	RECIEPT	OCALIVA is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
3671	OCREVUS	OCREVUS	OCRELIZUMAB	OCRELIZUMAB 300MG/10ML	CONCENTRATE	RECIEPT	OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.
3672	OCSAAR	OCSAAR 50 MG TABLETS	LOSARTAN POTASSIUM	LOSARTAN POTASSIUM 50MG	TABLETS	RECIEPT	Hypertension: Ocsaar 50 mg is indicated for the treatment of hypertension Heart failure: Ocsaar 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor to Ocsaar 50 mg is not recommended. Renal protection in Type-2 diabetic patients with proteinuria: Ocsaar 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. Ocsaar 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of Ocsaar 50 mg on the primary deposite endpoint was largely driven by reduction in the risk of stroke.
3673	OCSAAR	OCSAAR PLUS TABLETS	LOSARTAN POTASSIUM	LOSARTAN POTASSIUM 50MG;HYDROCHLOROTHIAZIDE 12.50MG	TABLETS	RECIEPT	Ocsaar plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. To reduce the risk of stroke in patients with hyperfension adn left ventricular hypertrophy.
3675	OCTAGAM	OCTAGAM	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 50MG/ML	SOLUTION	RECIEPT	Replacement therapy in: • Primary immunodeficiency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiency - Wiskott Aldrich syndrome. • Children with congenital AIDS and recurrent bacterial infections. Immunomodulatory effect: • Idiopathic thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgery to correct the platelet count. • Guillain barre syndrome. • Kawasaki disease. Allogeneic bone marrow transplantation. • Myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.
3676	OCTANATE	OCTANATE 1000	FACTOR VIII	FACTOR VIII 1000IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). This preparation does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand’s disease.
3677	OCTANATE	OCTANATE 500	FACTOR VIII	FACTOR VIII 500IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) This preparation does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand's disease.
3678	OCTANINE	OCTANINE F 1000 IU	FACTOR IX	FACTOR IX 100IU/ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
3679	OCTANINE	OCTANINE F 500 IU	FACTOR IX	FACTOR IX 100IU/ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
3680	OCTAPLEX	OCTAPLEX 500 IU	COAGULATION FACTOR IX (HUMAN)	COAGULATION FACTOR IX (HUMAN) 25 IU/ML after reconstitution with 20 ml solvent;COAGULATION FACTOR II (HUMAN) 14IU/ML after reconstitution with 20 ml solvent;COAGULATION FACTOR VII (HUMAN) 9IU/ML after reconstitution with 20 ml solvent;COAGULATION FACTOR X (HUMAN) 18IU/ML after reconstitution with 20 ml solvent;PROTEIN 13MG/ML after reconstitution with 20 ml solvent;PROTEIN C 13IU/ML after reconstitution with 20 ml solvent;PROTEIN S ANTIGEN 12IU/ML after reconstitution with 20 ml solvent	POWDER	RECIEPT	Treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex coagulation factors such as deficiency caused by treatment with vitamin K antagonists or in case of overdose of vitamin K antagonists when rapid correction of the deficiency is required. Treatment of bleeding and perioperative prophylaxis in congenital deficiency of any of the vitamin K dependent coagulation factors when purified specific coagulation factor product is not available.
3681	OCTOCAINE	OCTOCAINE 100	EPINEPHRINE AS BITARTRATE	EPINEPHRINE AS BITARTRATE 0.01MG/ML;LIDOCAINE HYDROCHLORIDE ( AS MONOHYDRATE) 20MG/ML	SOLUTION	RECIEPT	Production of local anesthesia for dental procedures by nerve block or infiltration technique.
3682	OCTOSTIM	OCTOSTIM	DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE 15MCG/ML	SOLUTION	RECIEPT	Shortening/normalization/ control of bleeding in uremia, liver cirrhoses, congenital or drug induced thrombocyte dysfunction and of unknown aetiology before surgery. Mild haemophilia A and mild von willebrands except type IIB.
3683	ODEFSEY	ODEFSEY	TENOFOVIR ALAFENAMIDE AS FUMARATE	TENOFOVIR ALAFENAMIDE AS FUMARATE 25MG;EMTRICITABINE 200MG;RILPIVIRINE AS HYDROCHLORIDE 25MG	TABLETS	RECIEPT	ODEFSEY is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/mL
3685	ODNATRON	ODNATRON	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE 2MG/ML	SOLUTION	RECIEPT	Adults: Odnatron is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Odnatron is indicated for the prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: Odnatron is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months, and for the prevention and treatment of PONV in children aged ≥ 1 month.
3686	ODOMZO	ODOMZO 200 MG	SONIDEGIB AS DIPHOSPHATE	SONIDEGIB AS DIPHOSPHATE 200MG	CAPSULES	RECIEPT	Odomzo 200 mg is indicated for the treatment of adult patients with locally advanced basal cell carcinoma which cannot be treated with curative surgery or radiation therapy
3689	OESTROGEL	OESTROGEL	ESTRADIOL	ESTRADIOL 60MG/100 G	GEL	RECIEPT	Hormonal replacement therapy for the treatment of symptoms associated with estrogen deficiency in menopausal women. Prevention of postmenopausal osteoporosis in women with an increased risk for osteoporotic fractures and presenting intolerace or a contraindication to others treatments indicated in the prevention of osteoporosis.
3690	OFEV	OFEV 100 MG	NINTEDANIB AS ESILATE	NINTEDANIB AS ESILATE 100MG	CAPSULES	RECIEPT	For the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults.
3691	OFEV	OFEV 150 MG	NINTEDANIB AS ESILATE	NINTEDANIB AS ESILATE 150MG	CAPSULES	RECIEPT	For the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults.
3692	OFLO	OFLO-AVENIR	OFLOXACIN	OFLOXACIN 3MG/1ML	SOLUTION	RECIEPT	For the treatment of external ocular infections caused by ofloxacin sensitive organisms
3693	OFLODEX	OFLODEX	OFLOXACIN	OFLOXACIN 200MG	TABLETS	RECIEPT	Bacterial infections due to ofloxacin-susceptible microorganisms, such as: upper and lower urinary tract infections, lower respiratory tract infections uncomplicated urethral and cervical gonorrhoea, non-gonococcal urethritis and cervicitis, skin and soft tissue infections.
3694	OFLOX	OFLOX	OFLOXACIN	OFLOXACIN 0.3%	SOLUTION	RECIEPT	For the treatment of external ocular infections caused by ofloxacin sensitive organisms.
3695	OFLOXACIN	OFLOXACIN TEVA 200 MG	OFLOXACIN	OFLOXACIN 200MG	TABLETS	RECIEPT	Bacterial infections due to ofloxacin-susceptible microorganisms, such as: - acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - Chronic and recurrent infections of the ear, nose, and throat. Ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - Infections of soft tissues and skin. - Infections of the bones and joints. - Abdominal infections including infections in the pelvis minor and bacterial enteritis. - Infections of the kidney, urinary tract, and genital organs, gonorrhoea. Prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).
3696	OFLOXACINA	OFLOXACINA	OFLOXACIN AS HYDROCHLORIDE	OFLOXACIN AS HYDROCHLORIDE 2MG/ML	SOLUTION	RECIEPT	Infections of kidney, urinarty tract, genital organs, respiratory tract, chronic and recurrent ear, nose and throat, skin and soft tissues, bones and joints, bacterial enteritis, abdominal cavity, including pelvis minor and septicemia caused by ofloxacin sensitive microorganisms. Prevention of infections in patients with a signifcant reduction of resistance to infections.
3697	OGIVRI	OGIVRI 420 MG	TRASTUZUMAB	TRASTUZUMAB 420MG/VIAL	POWDER	RECIEPT	Ogivri is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2: 1. As a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. In combination with Paclitaxel or Docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. Early breast cancer (EBC) : Ogivri is indicated to treat patients with HER2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding Anthracyclines. Ogivri should only be used in patients whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.HER2 metastatic gastric cancer (mGC). Ogivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. Ogivri should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, as determined by an accurate and validated assay.
3700	OLANZAPINE	OLANZAPINE TEVA 10 MG	OLANZAPINE	OLANZAPINE 10MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Olanzapine Teva is indicated for the management of the manifestations of psychotic disorders. Olanzapine Teva is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Olanzapine Teva is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Olanzapine Teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
3701	OLANZAPINE	OLANZAPINE TEVA 5 MG	OLANZAPINE	OLANZAPINE 5MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Olanzapine Teva is indicated for the management of the manifestations of psychotic disorders. Olanzapine Teva is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to olanzapine treatment Olanzapine Teva is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder. The combination of Olanzapine Teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
3702	OLANZAPINE	OLANZAPINE TEVA 7.5 MG	OLANZAPINE	OLANZAPINE 7.5MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Olanzapine Teva is indicated for the management of the manifestations of psychotic disorders. Olanzapine Teva is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to olanzapine treatment Olanzapine Teva is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder. The combination of Olanzapine Teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
3698	OLANZAPINE	OLANZAPINE ODT TEVA 10 MG	OLANZAPINE	OLANZAPINE 10MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Olanza ODT Teva is indicated for the management of the manifestations of psychotic disorders. Olanza ODT Teva is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Olanza ODT Teva is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Olanza ODT Teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
3699	OLANZAPINE	OLANZAPINE ODT TEVA 5 MG	OLANZAPINE	OLANZAPINE 5MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Olanza ODT Teva is indicated for the management of the manifestations of psychotic disorders. Olanza ODT Teva is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Olanza ODT Teva is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Olanza ODT Teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
3704	OLICLINOMEL	OLICLINOMEL N6-900E	L- ALANINE	L- ALANINE 17.60G/1000ML 8.5% Amino Acids solution compartment with electrolytes;REFINED OLIVE OIL 200G/1000ML 20% Lipid emulsion compartment;CALCIUM CHLORIDE DIHYDRATE 0.74G/1000ML 30% Glucose solution compartment with electrolyte calcium;GLUCOSE AS MONOHYDRATE 300G/1000ML 30% Glucose solution compartment with electrolyte calcium;MAGNESIUM CHLORIDE HEXAHYDRATE 1.12G/1000ML 8.5% Amino Acids solution compartment with electrolytes;POTASSIUM CHLORIDE 4.47G/1000ML 8.5% Amino Acids solution compartment with electrolytes;SODIUM GLYCEROPHOSPHATE PENTAHYDRATE 5.36G/1000ML 8.5% Amino Acids solution compartment with electrolytes;SODIUM ACETATE TRIHYDRATE 6.12G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- VALINE 4.93G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- TYROSINE 0.34G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- TRYPTOPHAN 1.53G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- THREONINE 3.57G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- SERINE 4.25G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- PROLINE 5.78G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- PHENYLALANINE 4.76G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- METHIONINE 3.40G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- LYSINE AS HYDROCHLORIDE 4.93G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- LEUCINE 6.21G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L- ISOLEUCINE 5.10G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L-HISTIDINE 4.08G/1000ML 8.5% Amino Acids solution compartment with electrolytes;GLYCINE 8.76G/1000ML 8.5% Amino Acids solution compartment with electrolytes;L-ARGININE 9.78G/1000ML 8.5% Amino Acids solution compartment with electrolytes	EMULSION	RECIEPT	Parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
3703	OLICLINOMEL	OLICLINOMEL N5-800E	REFINED SOYA-BEAN OIL	REFINED SOYA-BEAN OIL 200.00G/1000ML 20% Lipid Emulsion compartment;CALCIUM CHLORIDE DIHYDRATE 0.74G/1000ML 25% Glucose solution compartment with electrolyte calcium;GLUCOSE AS MONOHYDRATE 250.00G/1000ML 25% Glucose solution compartment with electrolyte calcium;MAGNESIUM CHLORIDE HEXAHYDRATE 1.12G/1000ML 7% Amino Acids solution compartment with electrolytes;POTASSIUM CHLORIDE 4.47G/1000ML 7% Amino Acids solution compartment with electrolytes;SODIUM GLYCEROPHOSPHATE PENTAHYDRATE 5.36G/1000ML 7% Amino Acids solution compartment with electrolytes;SODIUM ACETATE TRIHYDRATE 6.12G/1000ML 7% Amino Acids solution compartment with electrolytes;L- VALINE 4.06G/1000ML 7% Amino Acids solution compartment with electrolytes;L- TYROSINE 0.28G/1000ML 7% Amino Acids solution compartment with electrolytes;L- TRYPTOPHAN 1.26G/1000ML 7% Amino Acids solution compartment with electrolytes;L- THREONINE 2.94G/1000ML 7% Amino Acids solution compartment with electrolytes;L- SERINE 3.50G/1000ML 7% Amino Acids solution compartment with electrolytes;L- PROLINE 4.76G/1000ML 7% Amino Acids solution compartment with electrolytes;L- PHENYLALANINE 3.92G/1000ML 7% Amino Acids solution compartment with electrolytes;L- METHIONINE 2.80G/1000ML 7% Amino Acids solution compartment with electrolytes;L- LYSINE AS HYDROCHLORIDE 4.06G/1000ML 7% Amino Acids solution compartment with electrolytes;L- LEUCINE 5.11G/1000ML 7% Amino Acids solution compartment with electrolytes;L- ISOLEUCINE 4.20G/1000ML 7% Amino Acids solution compartment with electrolytes;L-HISTIDINE 3.36G/1000ML 7% Amino Acids solution compartment with electrolytes;GLYCINE 7.21G/1000ML 7% Amino Acids solution compartment with electrolytes;L-ARGININE 8.05G/1000ML 7% Amino Acids solution compartment with electrolytes;L- ALANINE 14.49G/1000ML 7% Amino Acids solution compartment with electrolytes	EMULSION	RECIEPT	Parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
3706	OLICLINOMEL	OLICLINOMEL N7-1000E	REFINED SOYA-BEAN OIL	REFINED SOYA-BEAN OIL 200G/1000ML 20% Lipid emulsion compartment;CALCIUM CHLORIDE DIHYDRATE 0.74G/1000ML 40% Glucose solution compartment with electrolyte calcium;GLUCOSE AS MONOHYDRATE 4000.00G/1000ML 40% Glucose solution compartment with electrolyte calcium;MAGNESIUM CHLORIDE 1.12G/1000ML 10% Amino Acids solution compartment with electrolytes;POTASSIUM CHLORIDE 4.47G/1000ML 10% Amino Acids solution compartment with electrolytes;SODIUM GLYCEROPHOSPHATE 5.36G/1000ML 10% Amino Acids solution compartment with electrolytes;SODIUM ACETATE DIHYDRATE 6.12G/1000ML 10% Amino Acids solution compartment with electrolytes;L- VALINE 5.80G/1000ML 10% Amino Acids solution compartment with electrolytes;L- TYROSINE 0.40G/1000ML 10% Amino Acids solution compartment with electrolytes;L- TRYPTOPHAN 1.80G/1000ML 10% Amino Acids solution compartment with electrolytes;L- THREONINE 4.20G/1000ML 10% Amino Acids solution compartment with electrolytes;L- SERINE 5.00G/1000ML 10% Amino Acids solution compartment with electrolytes;L- PROLINE 6.80G/1000ML 10% Amino Acids solution compartment with electrolytes;L- PHENYLALANINE 5.60G/1000ML 10% Amino Acids solution compartment with electrolytes;L- METHIONINE 4.00G/1000ML 10% Amino Acids solution compartment with electrolytes;L- LYSINE AS HYDROCHLORIDE 5.80G/1000ML 10% Amino Acids solution compartment with electrolytes;L- LEUCINE 7.30G/1000ML 10% Amino Acids solution compartment with electrolytes;L- ISOLEUCINE 6.00G/1000ML 10% Amino Acids solution compartment with electrolytes;L-HISTIDINE 4.80G/1000ML 10% Amino Acids solution compartment with electrolytes;GLYCINE 10.30G/1000ML 10% Amino Acids solution compartment with electrolytes;L-ARGININE 11.50G/1000ML 10% Amino Acids solution compartment with electrolytes;L- ALANINE 20.70G/1000ML 10% Amino Acids solution compartment with electrolytes	EMULSION	RECIEPT	Parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
3705	OLICLINOMEL	OLICLINOMEL N7-1000	REFINED SOYA-BEAN OIL	REFINED SOYA-BEAN OIL 200G/1000ML 20% Lipid emulsion compartment;GLUCOSE AS MONOHYDRATE 400G/1000ML 40% Glucose solution compartment;L- VALINE 5.80G/1000ML 10% Amino Acids solution compartment;L- TYROSINE 0.40G/1000ML 10% Amino Acids solution compartment;L- TRYPTOPHAN 1.80G/1000ML 10% Amino Acids solution compartment;L- THREONINE 4.20G/1000ML 10% Amino Acids solution compartment;L- SERINE 5.00G/1000ML 10% Amino Acids solution compartment;L- PROLINE 6.80G/1000ML 10% Amino Acids solution compartment;L- PHENYLALANINE 5.60G/1000ML 10% Amino Acids solution compartment;L- METHIONINE 4.00G/1000ML 10% Amino Acids solution compartment;L- LYSINE AS HYDROCHLORIDE 5.80G/1000ML 10% Amino Acids solution compartment;L- LEUCINE 7.30G/1000ML 10% Amino Acids solution compartment;L- ISOLEUCINE 6.00G/1000ML 10% Amino Acids solution compartment;L-HISTIDINE 4.80G/1000ML 10% Amino Acids solution compartment;GLYCINE 10.30G/1000ML 10% Amino Acids solution compartment;L-ARGININE 11.50G/1000ML 10% Amino Acids solution compartment;L- ALANINE 20.70G/1000ML 10% Amino Acids solution compartment	EMULSION	RECIEPT	Parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
3707	OLUMIANT	OLUMIANT 2 MG	BARICITINIB	BARICITINIB 2MG	TABLETS	RECIEPT	Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.
3708	OLUMIANT	OLUMIANT 4 MG	BARICITINIB	BARICITINIB 4MG	TABLETS	RECIEPT	Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.
3709	OMACOR	OMACOR	OMEGA-3 ACID ETHYL ESTERS	OMEGA-3 ACID ETHYL ESTERS 1000MG	CAPSULES	RECIEPT	Post myocardial infarction: Adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, antiplatelet drugs, betablockers, ACE inhibitors). Hypertriglyceridaemia: Endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response: - type IV hypertriglyceridaemia. - type IIb/III hypertriglyceridaemia in combination with statin, when control of triglycerides by statins is insufficient.
3710	OMEGAVEN	OMEGAVEN	GLYCEROL	GLYCEROL 2.5G/100ML;PURIFIED EGG PHOSPHATIDE 1.2G/100ML;HIGHLY REFINED FISH OIL 10G/100ML	EMULSION	RECIEPT	Parenteral nutrition supplementation with long chain Omega-3-fatty acids, especially eicosapentaenoic and docosahexaenoic acids when oral or enternal nutrition is impossible, insufficient or contraindicated.
3713	OMEPRA	OMEPRA 20	OMEPRAZOLE	OMEPRAZOLE 20MG	CAPSULES	RECIEPT	Acute duodenal ulcer, Acute gastric ulcer, Helicobacter pylori associated peptic ulcer disease in combination with antibiotics. Reflux esophagitis: Treatment long-term management, Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Treatment of severe reflux esophagitis in children from one year of age and older. Maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. Zollinger-Ellison Syndrome. Treatment and prevention of NSAID-associated duodenal and gastric ulcer or erosions in high risk patients.
3714	OMEPRA	OMEPRA 40	OMEPRAZOLE	OMEPRAZOLE 40MG	CAPSULES	RECIEPT	Acute duodenal ulcer, Acute gastric ulcer, Helicobacter pylori associated peptic ulcer disease in combination with antibiotics. Reflux esophagitis: Treatment long-term management, Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Treatment of severe reflux esophagitis in children from one year of age and older. Maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. Zollinger-Ellison Syndrome. Treatment and prevention of NSAID-associated duodenal and gastric ulcer or erosions in high risk patients.
3716	OMEPRADEX	OMEPRADEX CAPLETS 10 MG	OMEPRAZOLE	OMEPRAZOLE 10MG	TABLETS	RECIEPT	Acute duodenal ulcer. Acute gastric ulcer. Reflux esophagitis: treatment , long - term management. Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. Zollinger-Ellison Syndrome. Treatment and prevention of NSAID-associated duodenal and gastric ulcers or erosions in high risk patients. Treatment of severe reflux oesophagitis in children overthe age of 6 year. Helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.
3715	OMEPRADEX	OMEPRADEX - Z	OMEPRAZOLE	OMEPRAZOLE 20MG	TABLETS	RECIEPT	Relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.
3717	OMEPRADEX	OMEPRADEX CAPLETS 20 MG	OMEPRAZOLE	OMEPRAZOLE 20MG	TABLETS	RECIEPT	Acute duodenal ulcer. Acute gastric ulcer. Reflux esophagitis: treatment , long - term management. Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. Zollinger-Ellison Syndrome. Treatment and prevention of NSAID-associated duodenal and gastric ulcers or erosions in high risk patients. Treatment of severe reflux oesophagitis in children overthe age of 6 year. Helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.
3719	OMEPRADEX	OMEPRADEX Z 20MG 14 CAPLETS	OMEPRAZOLE	OMEPRAZOLE 20MG	TABLETS	RECIEPT	Relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.
3718	OMEPRADEX	OMEPRADEX CAPLETS 40 MG	OMEPRAZOLE	OMEPRAZOLE 40MG	TABLETS	RECIEPT	Acute duodenal ulcer. Acute gastric ulcer. Reflux esophagitis: treatment , long - term management. Maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. Zollinger-Ellison Syndrome. Treatment and prevention of NSAID-associated duodenal and gastric ulcers or erosions in high risk patients. Treatment of severe reflux oesophagitis in children overthe age of 6 year. Helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.
3720	OMEPRIX	OMEPRIX	OMEPRAZOLE	OMEPRAZOLE 20MG	CAPSULES	RECIEPT	Relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.
3721	OMNIC	OMNIC 0.4	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE 0.4MG	CAPSULES	RECIEPT	Treatment of functional symptoms of benign prostatic hyperplasia (BPH).
3722	OMNIC	OMNIC OCAS 0.4	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE 0.4MG	TABLETS	RECIEPT	Lower urinary tract symptoms ( LUTS) associated with benign prostatic hyperplasia (BPH).
3723	OMNIPAQUE	OMNIPAQUE 240	IOHEXOL	IOHEXOL 518MG/ML	SOLUTION	RECIEPT	X-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT- enhancement. Lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERP), endoscopic retrograde cholangiopancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tract.
3724	OMNIPAQUE	OMNIPAQUE 300	IOHEXOL	IOHEXOL 647MG/ML	SOLUTION	RECIEPT	X-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT- enhancement. Lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERP), endoscopic retrograde cholangiopancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tract.
3725	OMNIPAQUE	OMNIPAQUE 350	IOHEXOL	IOHEXOL 755MG/ML	SOLUTION	RECIEPT	X-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT- enhancement. Lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERP), endoscopic retrograde cholangiopancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tract.
3726	OMNITROPE	OMNITROPE 10 MG/1.5 ML	SOMATROPIN RECOMBINANT	SOMATROPIN RECOMBINANT 10MG/1.5ML	SOLUTION	RECIEPT	Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner`s syndrome. Short stature in children with renal insufficiency. Growth disturbance (height SDS<2.5 and parenteral adjusted height SDS < -1) in short children born SGA (SGA - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 SD who failed to show catch up growth (HV SDS < 0 during the last year) by 4 years of age or later. Prader willi syndrome (PWS) for improvement of growth and body composition. Adults: For adults who have suffered from growth-hormone deficiency since childhood. For adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.
3727	OMNITROPE	OMNITROPE 15 MG/1.5 ML	SOMATROPIN RECOMBINANT	SOMATROPIN RECOMBINANT 15MG/1.5ML	SOLUTION	RECIEPT	Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner`s syndrome. Short stature in children with renal insufficiency. Growth disturbance (height SDS<2.5 and parenteral adjusted height SDS < -1) in short children born SGA (SGA - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 SD who failed to show catch up growth (HV SDS < 0 during the last year) by 4 years of age or later. Prader willi syndrome (PWS) for improvement of growth and body composition. Adults: For adults who have suffered from growth-hormone deficiency since childhood. For adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.
3728	OMNITROPE	OMNITROPE 5 MG/1.5 ML	SOMATROPIN RECOMBINANT	SOMATROPIN RECOMBINANT 5MG/1.5ML	SOLUTION	RECIEPT	Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner`s syndrome. Short stature in children with renal insufficiency. Growth disturbance (height SDS<2.5 and parenteral adjusted height SDS < -1) in short children born SGA (SGA - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 SD who failed to show catch up growth (HV SDS < 0 during the last year) by 4 years of age or later. Prader willi syndrome (PWS) for improvement of growth and body composition. Adults: For adults who have suffered from growth-hormone deficiency since childhood. For adults who have acquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.
3729	OMR-IGG-AM	OMR-IGG-AM 5 %	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 5 G/100ML	SOLUTION	RECIEPT	Replacement therapy * PRIMARY immunodeficiency (patients with PRIMARY defective antibody synthesis such as agammaglobulinemia OR hypogammaglobulinemia) * Myeloma OR chronic Lymphocytic Leukemia (CLL) with severe secondary hypogammaglobulinemia AND recurrent infections. * Children with congenital AIDS AND recurrent infections - Immunomodulation * Idiopathic Thrombocytopenic Purpura (ITP) * Guillain Barre Syndrome * Kawasaki Disease - Allogenic Bone Marrow Transplantation
3730	OMRI-HEP-B	OMRI-HEP-B 5 % IV	HUMAN IMMUNOGLOBULIN	HUMAN IMMUNOGLOBULIN 5G/100ML ANTI HBs AB CONTENT ? 50 IU/ML	SOLUTION	RECIEPT	Passive immunization for the prevention of Hepatitis B virus re-infection after liver transplantation.
3731	ONBREZ BREEZHALER	ONBREZ BREEZHALER 150 MCG	INDACATEROL AS MALEATE	INDACATEROL AS MALEATE 150MCG	INHALATION	RECIEPT	Maintenance of bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
3732	ONBREZ BREEZHALER	ONBREZ BREEZHALER 300 MCG	INDACATEROL AS MALEATE	INDACATEROL AS MALEATE 300MCG	INHALATION	RECIEPT	Maintenance of bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
3733	ONCOTICE	ONCOTICE	BCG STRAIN	BCG STRAIN 200MIU	POWDER	RECIEPT	OncoTICE is used as a treatment of flat urothelial cell carcinoma in situ (CIS) of the bladder and as an adjuvant therapy after transurethral resection (TUR) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage Ta (grade 2 or 3) or T1 (grade 1 2 or 3). OncoTICE is only recommended for stage Ta grade 1 papillary tumors when there is judged to be a high risk of tumor recurrence.
3734	ONDANSETRON	ONDANSETRON - FRESENIUS	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE 2MG/ML	SOLUTION	RECIEPT	Adults: For the mangement of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. For the prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: For the mangement of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥ 6 months, and for the prevention and treatment of PONV in children aged ≥ 1 month.
3735	ONDANSETRON	ONDANSETRON BAXTER 2 MG/ML	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE 2MG/ML	SOLUTION	RECIEPT	Adults: Odnasetron Baxter is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Odnasetron Baxter is indicated for the prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: Odnasetron Baxter is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged 6 months, and for the prevention and treatment of PONV in children aged 2 years.
3736	ONDANSETRON	ONDANSETRON INOVAMED 4 MG	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE 4MG	TABLETS	RECIEPT	Adults : Ondansetron Inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. For prevention and treatment of post operative nausea and vomiting (PONV). Pediatric population : Ondansetron Inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy.
3737	ONDANSETRON	ONDANSETRON INOVAMED 8 MG	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE 8MG	TABLETS	RECIEPT	Adults : Ondansetron Inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. For prevention and treatment of post operative nausea and vomiting (PONV). Pediatric population : Ondansetron Inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy.
3738	ONGLYZA	ONGLYZA 2.5 MG	SAXAGLIPTIN AS HYDROCHLORIDE	SAXAGLIPTIN AS HYDROCHLORIDE 2.5MG	TABLETS	RECIEPT	Monotherapy: Onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Onglyza should not be used in patients with ESRD Combination therapy: Add-on combination: Onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (TZD), or a sulfonylurea (SU), when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Initial combination: Onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate. Onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. In combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
3740	ONGLYZA	ONGLYZA 5 MG	SAXAGLIPTIN AS HYDROCHLORIDE	SAXAGLIPTIN AS HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Monotherapy: Onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Onglyza should not be used in patients with ESRD Combination therapy: Add-on combination: Onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (TZD), or a sulfonylurea (SU), when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Initial combination: Onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate. Onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. In combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
3742	OPDIVO	OPDIVO	NIVOLUMAB	NIVOLUMAB 10MG/ML	CONCENTRATE	RECIEPT	Unresectable or Metastatic Melanoma: Opdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Adjuvant Treatment of Melanoma: Opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection Metastatic Non-Small Cell Lung Cancer: Opdivo is indicated for the treatment of patients with metastatic nonsmall cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Renal Cell Carcinoma: Opdivo as a single agent is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. Opdivo in combination with ipilimumab is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC). Classical Hodgkin Lymphoma: Opdivo is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after: * autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or * 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck: Opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient(dMMR) Metastatic Colorectal Cancer: Opdivo, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Urothelial carcinoma: Opdivo (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Hepatocellular Carcinoma: Opdivo is indicated for the treatment of patients with hepatocellular carcinoma Child-Pugh A after sorafenib therapy. Small Cell Lung Cancer (SCLC): Opdivo is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum based chemotherapy and at least one other line of therapy.
3743	OPSUMIT	OPSUMIT	MACITENTAN	MACITENTAN 10MG	TABLETS	RECIEPT	Opsumit is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.
3756	OPTALGIN	OPTALGIN TEVA	DIPYRONE	DIPYRONE 1G/2ML	SOLUTION	RECIEPT	As an analgesic: Optalgin Teva injection, by intravenous administration, is indicated for the relief of severe and acute pain when oral treatment is not feasible or suitable, as in post-traumatic or post-surgical pain, biliary or renal colic, and pain associated with malignant diseases. As an antipyretic: Optalgin injection by intramuscular administration is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision.
3745	OPTALGIN	OPTALGIN 500MG 20TAB	DIPYRONE	DIPYRONE 500MG	TABLETS		As an analgesic: Optalgin Teva injection, by intravenous administration, is indicated for the relief of severe and acute pain when oral treatment is not feasible or suitable, as in post-traumatic or post-surgical pain, biliary or renal colic, and pain associated with malignant diseases. As an antipyretic: Optalgin injection by intramuscular administration is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision.
3746	OPTALGIN	OPTALGIN 500MG 21CAP	DIPYRONE	DIPYRONE 500MG	TABLETS		As an analgesic: Optalgin Teva injection, by intravenous administration, is indicated for the relief of severe and acute pain when oral treatment is not feasible or suitable, as in post-traumatic or post-surgical pain, biliary or renal colic, and pain associated with malignant diseases. As an antipyretic: Optalgin injection by intramuscular administration is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision.
3747	OPTALGIN	OPTALGIN 500MG 42CAPL	DIPYRONE	DIPYRONE 500MG	TABLETS		As an analgesic: Optalgin Teva injection, by intravenous administration, is indicated for the relief of severe and acute pain when oral treatment is not feasible or suitable, as in post-traumatic or post-surgical pain, biliary or renal colic, and pain associated with malignant diseases. As an antipyretic: Optalgin injection by intramuscular administration is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision.
3748	OPTALGIN	OPTALGIN 500MG 50 CAP	DIPYRONE	DIPYRONE 500MG	TABLETS		As an analgesic: Optalgin Teva injection, by intravenous administration, is indicated for the relief of severe and acute pain when oral treatment is not feasible or suitable, as in post-traumatic or post-surgical pain, biliary or renal colic, and pain associated with malignant diseases. As an antipyretic: Optalgin injection by intramuscular administration is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision.
3749	OPTALGIN	OPTALGIN CAPLETS	DIPYRONE	DIPYRONE 500MG	TABLETS		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
3754	OPTALGIN	OPTALGIN TABLETS	DIPYRONE	DIPYRONE 500MG	TABLETS		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
3752	OPTALGIN	OPTALGIN DROPS 10ML	DIPYRONE	DIPYRONE 500MG/1ML	LIQUID		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
3753	OPTALGIN	OPTALGIN DROPS 15ML	DIPYRONE	DIPYRONE 500MG/1ML	LIQUID		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
3751	OPTALGIN	OPTALGIN DROPS	DIPYRONE	DIPYRONE 500MG/ML	DROPS		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
3757	OPTI	OPTI GENTA	GENTAMICIN AS SULFATE	GENTAMICIN AS SULFATE 0.3%W/V	DROPS	RECIEPT	Infection of external eye and its adnexa caused by susceptible bacteria.
3758	OPTILAST	OPTILAST	AZELASTINE HYDROCHLORIDE	AZELASTINE HYDROCHLORIDE 0.05%	DROPS	RECIEPT	Symptomatic treatment and prevention of seasonal allergic conjunctivitis.
3759	OPTIVATE	OPTIVATE 1000 I.U	FACTOR VIII	FACTOR VIII 1000 IU/VIAL;VON WILLEBRAND FACTOR 2600 IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding with haemophilia A (congenital factor VIII deficiency).
3760	OPTIVATE	OPTIVATE 500 I.U	FACTOR VIII	FACTOR VIII 500 IU/VIAL;VON WILLEBRAND FACTOR 1300 IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding with haemophilia A (congenital factor VIII deficiency).
3761	OPTRYL	OPTRYL	BORIC ACID	BORIC ACID 2.2%;DIPHENHYDRAMINE HYDROCHLORIDE 0.1%;NAPHAZOLINE HYDROCHLORIDE 0.025%	DROPS	RECIEPT	Allergic conditions of the conjunctiva, conjunctivitis vernalis, conjunctivitis phylactaenulosa, kerato-conjunctivitis, episcleritis.
3763	ORACORT	ORACORT E	LIDOCAINE HYDROCHLORIDE MONOHYDRATE	LIDOCAINE HYDROCHLORIDE MONOHYDRATE 3G/100 G;TRIAMCINOLONE ACETONIDE 0.1G/100 G	PASTE	RECIEPT	Adjunctive treatment and temporary relief of pain and symptoms associated with oral inflammatory and ulcerative lesions.
3762	ORACORT	ORACORT	TRIAMCINOLONE ACETONIDE	TRIAMCINOLONE ACETONIDE 0.1%	PASTE	RECIEPT	Indicated for the adjunctive treatment and the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions.
3765	ORACORT	ORACORT PASTE 5G	TRIAMCINOLONE ACETONIDE	TRIAMCINOLONE ACETONIDE 0.1%	PASTE	RECIEPT	Indicated for the adjunctive treatment and the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions.
3764	ORACORT	ORACORT E PASTE 5G	TRIAMCINOLONE ACETONIDE	TRIAMCINOLONE ACETONIDE 0.1%;LIGNOCAINE HYDROCHLORIDE 3%	PASTE	RECIEPT	Indicated for the adjunctive treatment and the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions.
3766	ORAMORPH	ORAMORPH 20 MG/ML	MORPHINE AS SULFATE	MORPHINE AS SULFATE 20MG/ML	SOLUTION	RECIEPT	For the relief of moderate to severe pain
3768	ORAP	ORAP FORTE	PIMOZIDE	PIMOZIDE 4MG	TABLETS	RECIEPT	Neuroleptic.
3769	ORBENIL	ORBENIL 2 G	CLOXACILLIN AS SODIUM	CLOXACILLIN AS SODIUM 2G/VIAL	POWDER	RECIEPT	For the treatment of infections caused by penicillinase-producing staphylococci. Because of the high incidence of staphylococcal isolates resistant to penicillin G both within and outside the hospiral environment . Orbenil is recommended as initial therapy in patients with suspected staphylococcal infections. Orebenil is also effective in the treatment of other commonly encountered Gram-positive coccal infections. Typical indications include: - respiratory tract infections such as pneumonia and sinusitis - infected wounds and burns - osteomyelitis and septic arthritis - other infections due to staphylococci (including penicillin-resistant strains) such as septicemia endocarditis enterocolitis and urinary tract infections.
3770	ORBENIL	ORBENIL 500 MG	CLOXACILLIN AS SODIUM	CLOXACILLIN AS SODIUM 500MG/VIAL	POWDER	RECIEPT	Orbenil is indicated principally in the treatment of infections caused by penicillinase-producing staphylococci. Because of the high incidence of staphylococcal isolates resistant to penicillin G, both within and outside the hospital environment, Orbenil is recommended as initial therapy in patients with suspected staphylococcal infections. Orbenil is also effective in the treatment of other commonly encountered Gram-positive coccal infections. Typical indications include: Respiratory tract infections, such as pneumonia, sinusitis. Infected wounds and burns. Osteomyelitis and septic arthritis. Other infections due to staphylococci (including penicillin-resistant strains) such as staphylococcal septicemia, staphylococcal endocarditis, staphylococcal enterocolitis and staphylococcal urinary tract infections.
3771	ORENCIA	ORENCIA 125 MG SC	ABATACEPT	ABATACEPT 125MG/ML	SOLUTION	RECIEPT	ORENCIA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ORENCIA may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists. ORENCIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA).
3772	ORENCIA	ORENCIA 250 MG	ABATACEPT	ABATACEPT 250MG	POWDER	RECIEPT	ORENCIA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ORENCIA may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists. Polyarticular juvenile idiopathic arthritis: Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. Orencia has not been studied in children under 6 years old. ORENCIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA).
3773	ORFADIN	ORFADIN 10 MG HARD CAPSULES	NITISINONE	NITISINONE 10MG	CAPSULES	RECIEPT	Treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine 05/06/2018 בקשה לשינוי משטר מינון Once Daily
3774	ORFADIN	ORFADIN 2 MG HARD CAPSULES	NITISINONE	NITISINONE 2MG	CAPSULES	RECIEPT	Treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine 05/06/2018 בקשה לשינוי משטר מינון Once Daily
3775	ORFADIN	ORFADIN 5 MG HARD CAPSULES	NITISINONE	NITISINONE 5MG	CAPSULES	RECIEPT	Treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine 05/06/2018 בקשה לשינוי משטר מינון Once Daily
3776	ORFIRIL	ORFIRIL INJECTION	VALPROIC ACID AS SODIUM	VALPROIC ACID AS SODIUM 300MG/3ML	SOLUTION	RECIEPT	Treatment of generalized seizures in the form of absence, myoclonic and tonic-clonic seizures and partial and secondary generalized seizures.
3777	ORGALUTRAN	ORGALUTRAN 0.25 MG/0.5 ML	GANIRELIX	GANIRELIX 0.25MG/0.5ML	SOLUTION	RECIEPT	The prevention of premature luteinsing hormone (LT) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).
3778	ORKAMBI	ORKAMBI 100 MG/125 MG FILM COATED TABLETS	IVACAFTOR	IVACAFTOR 125MG;LUMACAFTOR 100MG	TABLETS	RECIEPT	Orkambi is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene Limitations of Use The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation
3780	ORKAMBI	ORKAMBI 200 MG / 125 MG FILM COATED TABLETS	IVACAFTOR	IVACAFTOR 125MG;LUMACAFTOR 200MG	TABLETS	RECIEPT	Orkambi is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. Limitations of Use The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.
3784	ORKAMBI	ORKAMBI 200 MG / 125 MG FILM COATED TABLTES	IVACAFTOR	IVACAFTOR 125MG;LUMACAFTOR 200MG	TABLETS	RECIEPT	Orkambi is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. Limitations of Use The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.
3785	ORKAMBI	ORKAMBI 200mg / 125mg FILM COATED TABLETS	IVACAFTOR	IVACAFTOR 125MG;LUMACAFTOR 200MG	TABLETS		Orkambi is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. Limitations of Use The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.
3789	OSPOLOT	OSPOLOT	SULTHIAME	SULTHIAME 200MG	TABLETS	RECIEPT	Treatment of epilepsy in adults and in treatment of the so called focal benign epilepsy of children, when other medication was not adequate.
3790	OSTEOMINE DICLOFENAC	OSTEOMINE DICLOFENAC GEL 1%	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of rheumatic diseases, non infected inflammations and pain.
3791	OTEZLA	OTEZLA 10 MG	APREMILAST	APREMILAST 10MG	TABLETS	RECIEPT	Otezla is indicated: - For treatment of adult patients with active psoriatic arthritis (PsA). - For adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy (PSOR). - For the treatment of adult patients with oral ulcers associated with Behçet’s disease (BD).
3797	OTEZLA	OTEZLA 20 MG	APREMILAST	APREMILAST 20MG	TABLETS	RECIEPT	Otezla is indicated: - For treatment of adult patients with active psoriatic arthritis (PsA). - For adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy (PSOR). - For the treatment of adult patients with oral ulcers associated with Behçet’s disease (BD).
3803	OTEZLA	OTEZLA 30 MG	APREMILAST	APREMILAST 30MG	TABLETS	RECIEPT	Otezla is indicated: - For treatment of adult patients with active psoriatic arthritis (PsA). - For adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy (PSOR). - For the treatment of adult patients with oral ulcers associated with Behçet’s disease (BD).
3810	OTIDIN	OTIDIN DROPS 10ML	ANTIPYRINE	ANTIPYRINE 5%;TETRACAINE HCL 0.5%	DROPS		Relief of pain in acute otitis media.
3809	OTIDIN	OTIDIN DROPS	PHENAZONE	PHENAZONE 5%W/W;TETRACAINE HYDROCHLORIDE 0.5%W/W	DROPS	RECIEPT	Relief of pain in acute otitis media.
3811	OTOMYCIN	OTOMYCIN	BENZOCAINE	BENZOCAINE 3%;NEOMYCIN AS SULFATE 0.35%;PHENYLEPHRINE HYDROCHLORIDE 0.25%;SODIUM PROPIONATE 5%	DROPS	RECIEPT	Antibacterial, antifungal ear drops.
3813	OTRIVIN	OTRIVIN COMPLETE	IPRATROPIUM BROMIDE	IPRATROPIUM BROMIDE 0.6MG/ML;XYLOMETAZOLINE HYDROCHLORIDE 0.5MG/ML	SPRAY	RECIEPT	Symptomatic treatment of nasal congestion and rhinorrhea in connection with common cold.
3825	OTRIVIN	OTRIVINI SALINE FOR BABIES MD 15ML	SODIUM CHLORIDE	SODIUM CHLORIDE 0.74%	SPRAY		Relief of nasal congestion, especially for babies.
3818	OTRIVIN	OTRIVIN MD SPY 10ML 0.05%	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.05%	SPRAY		Rapid relief of nasal congestion for up to ten hours.
3823	OTRIVIN	OTRIVIN PED DPS 0.05% 10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.05%	DROPS		Rapid relief of nasal congestion for up to ten hours.
3815	OTRIVIN	OTRIVIN DROPS 0.1% 10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	DROPS		Rapid relief of nasal congestion for up to ten hours.
3816	OTRIVIN	OTRIVIN GEL 0.1% 10G	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	GEL		Rapid relief of nasal congestion for up to ten hours.
3819	OTRIVIN	OTRIVIN MD SPY 10ML 0.1%	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	SPRAY		Rapid relief of nasal congestion for up to ten hours.
3821	OTRIVIN	OTRIVIN MENTHOL MDS 0.1% 10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	SPRAY		Rapid relief of nasal congestion for up to ten hours.
3824	OTRIVIN	OTRIVIN SPRAY 0.1% 10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	SPRAY		Rapid relief of nasal congestion for up to ten hours.
3814	OTRIVIN	OTRIVIN COMPLETE NASAL SPRAY 10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.5MG/ML;IPRATROPIUM BROMIDE 0.6MG/ML	SPRAY	RECIEPT	Rapid relief of nasal congestion for up to ten hours.
3822	OTRIVIN	OTRIVIN NASAL GEL	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 0.1%	GEL		Nasal congestion in acute colds, vasomotor rhinitis, hay fever, rapid relief of nasal congestion for up to ten hours.
3820	OTRIVIN	OTRIVIN MENTHOL	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 0.1%W/V	SOLUTION		Nasal congestion in acute colds, vasomotor rhinitis, hay fever, rapid relief of nasal congestion for up to ten hours.
3817	OTRIVIN	OTRIVIN KIDS	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 0.5MG/ML	SOLUTION		Rapid symptomatic relief of nasal decongestion up to 10 hours.
3812	OTRIVIN	OTRIVIN	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 1MG/ML	SOLUTION		Rapid relief of nasal congestion for up to ten hours.
3827	OVALEAP	OVALEAP	FOLLITROPIN ALFA	FOLLITROPIN ALFA 600 IU/1ML	SOLUTION	RECIEPT	In adult women: • Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate. • Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra fallopian transfer (ZIFT). • Ovaleap in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L. In adult men: • Ovaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hCG) therapy.
3828	OVESTIN	OVESTIN	ESTRIOL	ESTRIOL 0.1%	CREAM	RECIEPT	For the treatment of vulvo-vaginal complaints related to estrogen deficiency.
3830	OVITRELLE	OVITRELLE 250 MICROGRAMS	CHORIOGONADOTROPIN ALFA	CHORIOGONADOTROPIN ALFA 250MCG/0.5ML	SOLUTION	RECIEPT	- For women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilization (IVF) : Ovitrelle is administered to trigger final follicular maturation AND luteinisation AFTER stimulation of follicular growth. - Anov
3831	OXACATIN	OXACATIN	OXOMEMAZINE	OXOMEMAZINE 1.65MG/5ML;BENZOIC ACID AS SODIUM 33.3MG/5ML;GUAIACOLSULFONATE AS POTASSIUM 33.3MG/5ML	SYRUP	RECIEPT	Antitussive expectorant.
3832	OXALIPLATIN	OXALIPLATIN MEDAC 100 MG	OXALIPLATIN	OXALIPLATIN 100MG/VIAL	POWDER	RECIEPT	Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke‘s C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014).
3833	OXALIPLATIN	OXALIPLATIN MEDAC 150 MG	OXALIPLATIN	OXALIPLATIN 150MG/VIAL	POWDER	RECIEPT	Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke‘s C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014).
3834	OXALIPLATIN	OXALIPLATIN MEDAC 50 MG	OXALIPLATIN	OXALIPLATIN 50MG/VIAL	POWDER	RECIEPT	Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke‘s C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014).
3835	OXALIPLATIN	OXALIPLATIN MYLAN 100 MG	OXALIPLATIN	OXALIPLATIN 5MG/ML	POWDER	RECIEPT	Oxaliplatin in combination with 5 fluorouracil (5 FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumour. • Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014).
3836	OXALIPLATIN	OXALIPLATIN MYLAN 50 MG	OXALIPLATIN	OXALIPLATIN 5MG/ML	POWDER	RECIEPT	Oxaliplatin in combination with 5 fluorouracil (5 FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumour. • Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014).
3837	OXALIPLATIN	OXALIPLATIN TEVA	OXALIPLATIN	OXALIPLATIN 5MG/ML	CONCENTRATE	RECIEPT	Oxaliplatin in combination with 5- fluorouracil (5-FU) and folinic acid (FA) is indicated for : - Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of the primary tumour. - Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014).
3838	OXERVATE	OXERVATE	CENEGERMIN	CENEGERMIN 20MCG/1ML	DROPS	RECIEPT	Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
3839	OXIS TURBUHALER	OXIS TURBUHALER 9 MCG/DOSE	FORMOTEROL FUMARATE	FORMOTEROL FUMARATE 9MCG/DOSE DIHYDRATE	POWDER	RECIEPT	For the relief of broncho-obstructive symptoms and prevention of exercise-induced symptoms in asthmatics when adequate treatment with corticosteroids is not sufficient. For the relief of bronco-obstructive symptoms in patients with chronic obstructive pulmonary disease (COPD).
3841	OXOPURIN	OXOPURIN 400	PENTOXIFYLLINE	PENTOXIFYLLINE 400MG	TABLETS	RECIEPT	For the treatment of disorders of arterial and venous cirulation.
3843	OXYCOD	OXYCOD 2 MG/ML SYRUP	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 10MG/5ML	SYRUP	RECIEPT	For use in the relief of moderate to severe pain.
3844	OXYCOD	OXYCOD FORTE 10 MG/ML SYRUP	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 10MG/ML	SYRUP	RECIEPT	For the relief of moderate to severe pain.
3845	OXYCOD	OXYCOD INJECTIONS	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 10MG/ML	SOLUTION	RECIEPT	For the treatment of moderate to severe pain in patients with cancer and post-operative pain. For the treatment of severe pain requiring the use of a strong opioid.
3846	OXYCONTIN	OXYCONTIN 10	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	For the relief of moderate to severe chronic pain.
3847	OXYCONTIN	OXYCONTIN 20	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	For the relief of moderate severe chronic pain.
3848	OXYCONTIN	OXYCONTIN 40	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 40MG	TABLETS	RECIEPT	For the relief of moderate to severe chronic pain.
3849	OXYCONTIN	OXYCONTIN 5 MG	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 5MG	TABLETS	RECIEPT	For the relief of moderate to severe chronic pain.
3851	OXYCONTIN	OXYCONTIN 80	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 80MG	TABLETS	RECIEPT	For the relief of moderate to severe chronic pain.
3137	OXYGEN	MEDICAL OXYGEN	OXYGEN	OXYGEN 99.5%	GAS	RECIEPT	Breathing aid.
3142	OXYGEN	MEDICAL OXYGEN (O2)	OXYGEN	OXYGEN 99.5%	LIQUID	RECIEPT	Breathing aid.
3146	OXYGEN	MEDICAL OXYGEN LIQUID	OXYGEN	OXYGEN 99.5%	LIQUID	RECIEPT	Breathing aid.
3854	OXYTOCIN	OXYTOCIN INJECTION BP 10 I.U./ML	OXYTOCIN	OXYTOCIN 10IU/ML	CONCENTRATE	RECIEPT	Induction of labour for medical reasons stimulation of labour in hypotonic uterine inertia during caesarian section following the delivery ot the child prevention and treatment of postpartum uterine atony and haemorrhage. Oxytocin injection may also be indicated in early stages of pregnancy as an adjunctive therapy for the management of incomplete inevitable or missed abortion.
3858	OZEMPIC	OZEMPIC	SEMAGLUTIDE	SEMAGLUTIDE 1.34MG/1ML	SOLUTION	RECIEPT	Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes.
3859	OZURDEX	OZURDEX	DEXAMETHASONE	DEXAMETHASONE 0.7MG	IMPLANT	RECIEPT	Ozurdex is indicated for the treatment of adult patients with: • diabetic macular oedema (DME) • macular oedema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). • inflammation of the posterior segment of the eye presenting as non-infectious uveitis.
3860	PABAL	PABAL	CARBETOCIN	CARBETOCIN 100MCG/ML	SOLUTION	RECIEPT	For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia.
3862	PACLIAVENIR	PACLIAVENIR	PACLITAXEL	PACLITAXEL 6MG/ML	SOLUTION	RECIEPT	Paclitaxel is indicated alone or in combination, for the treatment of advanced carcinoma of the ovary. For the treatment of metastatic breast cancer after failure of combination chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Advanced non small cell lung cancer: Paclitaxel, associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Keposi's sarcoma: Paclitaxel is indicated in the second- line treatment of AID'S related Kaposi's sarcoma. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. For the treatment of advanced gastric carcinoma.
3863	PACLITAXEL	PACLITAXEL TEVA	PACLITAXEL	PACLITAXEL 6MG/ML	CONCENTRATE	RECIEPT	Ovarian carcinoma : Paclitaxel Teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. Breast carcinoma : Paclitaxel Teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. Paclitaxel Teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Advanced non small cell lung cancer : Paclitaxel Teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Kaposis sarcoma : Paclitaxel Teva is indicated in the second- line treatment of AID'S related Kaposi's sarcoma. Gastric carcinoma : Paclitaxel Teva for the treatment of advanced gastric carcinoma.
3864	PALLADONE	PALLADONE 10 MG/ML	HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HYDROCHLORIDE 20MG/2ML	SOLUTION	RECIEPT	Relief of moderate to severe pain such as that due to surgery or cancer.
3867	PALLADONE	PALLADONE SR 24 MG	HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HYDROCHLORIDE 24MG	CAPSULES	RECIEPT	For the relief of severe pain in cancer.
3868	PALLADONE	PALLADONE SR 4 MG	HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HYDROCHLORIDE 4MG	CAPSULES	RECIEPT	For the relief of severe pain in cancer.
3869	PALLADONE	PALLADONE SR 8 MG	HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HYDROCHLORIDE 8MG	CAPSULES	RECIEPT	For the relief of severe pain in cancer.
3865	PALLADONE NR	PALLADONE NR 1.3 MG	HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HYDROCHLORIDE 1.3MG	CAPSULES	RECIEPT	Treatment of severe cancer pain.
3866	PALLADONE NR	PALLADONE NR 2.6 MG	HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HYDROCHLORIDE 2.6MG	CAPSULES	RECIEPT	Treatment of severe cancer pain.
3870	PALONOSETRON S.K.	PALONOSETRON S.K.	PALONOSETRON AS HYDROCHLORIDE	PALONOSETRON AS HYDROCHLORIDE 250MCG/5ML	SOLUTION	RECIEPT	Palonosetron S.K. is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
3872	PALOXI	PALOXI INJECTION	PALONOSETRON AS HYDROCHLORIDE	PALONOSETRON AS HYDROCHLORIDE 0.25MG/VIAL	SOLUTION	RECIEPT	Paloxi is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
3871	PALOXI	PALOXI CAPSULES	PALONOSETRON AS HYDROCHLORIDE	PALONOSETRON AS HYDROCHLORIDE 0.5MG	CAPSULES	RECIEPT	Paloxi is indicated in adult for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
3874	PAMID	PAMID TABLETS	INDAPAMIDE	INDAPAMIDE 2.5MG	TABLETS	RECIEPT	Diuretic for the treatment of hypertension and fluid retention.
3876	PANADOL	PANADOL	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Analgesic and antipyretic. For use in the short-term management of headaches, musculoskeletal disorders, menstrual pain, toothache .
3877	PANTOAVENIR	PANTOAVENIR IV	PANTOPRAZOLE AS SODIUM	PANTOPRAZOLE AS SODIUM 40MG/VIAL	POWDER	RECIEPT	For the treatment of duodenal ulcer, gastric ulcer , moderate and severe forms of reflux oesophagitis. Zollinger Ellison Syndrome.
3878	PAPAVERINE	PAPAVERINE HCL 40 MG	PAPAVERINE HYDROCHLORIDE	PAPAVERINE HYDROCHLORIDE 40MG	TABLETS	RECIEPT	Treatment of arterial spasm.
3879	PAPAVERINE	PAPAVERINE HCL STEROP 40 MG/2 ML	PAPAVERINE HYDROCHLORIDE	PAPAVERINE HYDROCHLORIDE 40MG/2ML	SOLUTION	RECIEPT	Antispasmodic in visceral spasm, e.g. gastrointestinal colic, biliary and urinary tract spasms. Peripheral vascular disease with vasospastic element. Vascular spasm associated with acute myocardial infarction, angina pectoris, peripheral and pulmonary embolism.
3881	PAPAVERINE	PAPAVERINE TEVA INJECTION	PAPAVERINE HYDROCHLORIDE	PAPAVERINE HYDROCHLORIDE 40MG/2ML	SOLUTION	RECIEPT	Antispasmodic in visceral spasm, e.g. gastrointestinal colic, biliary and urinary tract spasms. Peripheral vascular disease with vasospastic element. Vascular spasm associated with acute myocardial infarcion, angina pectoris, peripheral and pulmonary embolism.
3880	PAPAVERINE	PAPAVERINE HYDROCHLORIDE 80 MG	PAPAVERINE HYDROCHLORIDE	PAPAVERINE HYDROCHLORIDE 80MG	TABLETS	RECIEPT	Antispasmodic. Vasodilator.
3882	PARACET	PARACET ELIXIR	PARACETAMOL	PARACETAMOL 120MG/5ML	LIQUID		Analgesic, antipyretic.
3888	PARACETAMOL	PARACETAMOL G.E.S. 10 MG/ML	PARACETAMOL	PARACETAMOL 10MG/1ML	SOLUTION	RECIEPT	Paracetamol G.E.S. is indicated for the short-term treatment of moderate pain, especially following surgery, and for the short-term treatment of fever, when intravenous administration is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.
3883	PARACETAMOL	PARACETAMOL B. BRAUN 10 MG/ML	PARACETAMOL	PARACETAMOL 10MG/ML	SOLUTION	RECIEPT	Paracetamol is indicated for the short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.
3884	PARACETAMOL	PARACETAMOL FRESENIUS 10 MG/ML	PARACETAMOL	PARACETAMOL 10MG/ML	SOLUTION	RECIEPT	Paracetamol – Fresenius is indicated for: - the short-term treatment of moderate pain, especially following surgery - the short-term treatment of fever. when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.
3890	PARACETAMOL	PARACETAMOL TARO I.V. 10 MG/ML	PARACETAMOL	PARACETAMOL 10MG/ML	SOLUTION	RECIEPT	Short term treatment of moderate pain, especially following surgery and for short term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.
6003	PARAFFIN OIL	PARAFFIN OIL	PARAFFIN OIL	PARAFFIN OIL	LIQUID		constipation
3907	PARAMOL	PARAMOL TARGET	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 250MG;CAFFEINE 65MG ANHYDROUS;PARACETAMOL 250MG	TABLETS		For temporary relief of the pain of headache mild to moderate pain associated with migraine, pain of menstrual discomfort and pain accompanied by fever.
3909	PARAMOL	PARAMOL TARGET 50 CAPLETS	ASPIRIN	ASPIRIN 250MG;PARACETAMOL 250MG;CAFFEINE 65MG	TABLETS		For temporary relief of the pain of headache mild to moderate pain associated with migraine, pain of menstrual discomfort and pain accompanied by fever.
3903	PARAMOL	PARAMOL KAT	PARACETAMOL	PARACETAMOL 250MG	TABLETS		Analgesic and antipyretic.
3904	PARAMOL	PARAMOL KAT 20 CHEWABLE TABLETS	PARACETAMOL	PARACETAMOL 250MG	TABLETS		Analgesic and antipyretic.
3895	PARAMOL	PARAMOL AF & SHIUL DAY CARE	PARACETAMOL	PARACETAMOL 325MG;GUAIFENESIN 200MG;DEXTROMETHORPHAN HYDROBROMIDE 10MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	For the symptomatic relief of cold, cough and nasal congestion accompanied by fever and pain, for day care.
3896	PARAMOL	PARAMOL AF & SHIUL DAY CARE 30 CAPLETS	PARACETAMOL	PARACETAMOL 325MG;GUAIPHENESIN 200MG;DEXTROMETORPHAN 10MG;PSEUDOEPHEDRINE 25MG	TABLETS	RECIEPT	For the symptomatic relief of cold, cough and nasal congestion accompanied by fever and pain, for day care.
3892	PARAMOL	PARAMOL	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
3893	PARAMOL	PARAMOL 500MG 20 TAB	PARACETAMOL	PARACETAMOL 500MG	TABLETS		For temporary relief of the pain of headache mild to moderate pain associated with migraine, pain of menstrual discomfort and pain accompanied by fever.
3894	PARAMOL	PARAMOL 500MG 50 TAB	PARACETAMOL	PARACETAMOL 500MG	TABLETS		For temporary relief of the pain of headache mild to moderate pain associated with migraine, pain of menstrual discomfort and pain accompanied by fever.
3905	PARAMOL	PARAMOL PLUS	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE 50MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
3906	PARAMOL	PARAMOL PLUS 20 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE 50MG	TABLETS		Relief of pain and fever of different etiologies such as headache, toothache, colds, influenza, rheumatic pain and dysmenorrhea.
3897	PARAMOL	PARAMOL AF & SHIUL NIGHT CARE	PARACETAMOL	PARACETAMOL 500MG;CHLORPHENIRAMINE MALEATE 2MG;DEXTROMETHORPHAN HYDROBROMIDE 10MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	For the symptomatic relief of cold, cough and nasal congestion accompanied by fever and pain, for treatment at night.
3901	PARAMOL	PARAMOL AF NIGHT CARE	PARACETAMOL	PARACETAMOL 500MG;CHLORPHENIRAMINE MALEATE 2MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain. Night care medicine.
3900	PARAMOL	PARAMOL AF DAY CARE 30 TAB	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain. Day care medicine.
3902	PARAMOL	PARAMOL AF NIGHT CARE 20 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG;CHLORPHENIRAMINE MALEATE 2MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain. Night care medicine.
3898	PARAMOL	PARAMOL AF & SHIUL NIGHT CARE 20 CAPLETS	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HCL 25MG;DEXTROMETHORPHAN 10MG;CHLORPENIRAMINE MALEATE 2MG	TABLETS	RECIEPT	For the symptomatic relief of cold, cough and nasal congestion accompanied by fever and pain, for treatment at night.
3899	PARAMOL	PARAMOL AF DAY CARE	PARACETAMOL	PARACETAMOL 500MG;PSEUDOEPHEDRINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Symptomatic relief of cold and nasal congestion accompanied by fever and pain. Day care medicine.
3910	PARICALCITOL	PARICALCITOL INOVAMED 5 MCG/ML	PARICALCITOL	PARICALCITOL 0.005MG/ML	SOLUTION	RECIEPT	Paricalcitol is indicated in adults for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure who are undergoing haemodialysis.
3911	PAROTIN	PAROTIN 20	PAROXETINE AS HYDROCHLORIDE	PAROXETINE AS HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. Treatment of symptoms of social phobia. Post traumatic stress disorder. Generalised anxiety disorders.
3912	PAROTIN	PAROTIN 30	PAROXETINE AS HYDROCHLORIDE	PAROXETINE AS HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. Treatment of symptoms of social phobia. Post traumatic stress disorder. Generalised anxiety disorders.
3913	PARSABIV	PARSABIV	ETELCALCETIDE AS HYDROCHLORIDE	ETELCALCETIDE AS HYDROCHLORIDE 5MG/1ML	SOLUTION	RECIEPT	Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy.
3914	PARTANE	PARTANE 5 MG	TRIHEXYPHENIDYL HYDROCHLORIDE	TRIHEXYPHENIDYL HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Partane tablet is an adjunct medicine in the therapy of all forms of Parkinsonism (postencephalitic, arteriosclerotic and idiopathic). It is also indicated to control extrapyramidal disorders due to central nervous system drugs such as phenothiazines.
3916	PATANOL	PATANOL	OLOPATADINE HYDROCHLORIDE	OLOPATADINE HYDROCHLORIDE 0.111%	DROPS	RECIEPT	For the temporary prevention of itching of the eye due to allergic conjunctivitis.
3917	PATENT	PATENT BLUE V	PATENT BLUE V SODIUM	PATENT BLUE V SODIUM 0.05G/2ML	SOLUTION	RECIEPT	Marking lymph vessels and arterial regions. Marking sentinel nodes before biopsy in patients with operable breast cancer.
3919	PATIR	PATIR CREAM 15GR	TERBINAFINE HCL	TERBINAFINE HCL 1%	CREAM	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum) , microsporum canis and epidermaphyton floccosum.Yeast infections of the skin, principally those caused by the genus Candida (e.g. candida albicans). Pityriasis (tinea) versicolor due to pityrosporum orbiculare (also known as malassezia furfur).
3918	PATIR	PATIR	TERBINAFINE HYDROCHLORIDE	TERBINAFINE HYDROCHLORIDE 1%	CREAM	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.T.rubrum, T. mentagrophytes, T. verrucosu, T. violaceum), Microsporum canis and Epidemophyton floccosum. Yeast infections of the skin, principally those caused by the genus Candida (e.g. candida albicans). Pityriasis (tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).
3920	PAXXET	PAXXET 20	PAROXETINE AS HYDROCHLORIDE	PAROXETINE AS HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. Treatment of symptoms of social phobia.
3922	PAXXET	PAXXET 30	PAROXETINE AS HYDROCHLORIDE	PAROXETINE AS HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. Treatment of symptoms of social phobia.
3924	PECFENT	PECFENT 100	FENTANYL AS CITRATE	FENTANYL AS CITRATE 1MG/1ML	SPRAY	RECIEPT	PecFent is indicated for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
3925	PECFENT	PECFENT 400	FENTANYL AS CITRATE	FENTANYL AS CITRATE 4MG/1ML	SPRAY	RECIEPT	PecFent is indicated for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
3926	PEDIACEL	PEDIACEL	PERTACTIN (PRN)	PERTACTIN (PRN) 3MCGML;DIPHTHERIA TOXOID 15LFML;TETANUS TOXOID 5LFML;PERTUSSIS TOXOID VACCINE 20MCGML;FILAMENTOUS HAEMAGGLUTININ (FHA) 20MCGML;FIMBRAE TUPES 2 + 3 (FIM) 5MCGML;POLIOVIRUS TYPE 1 40DUML;POLIOVIRUS TYPE 2 8DUML;POLIOVIRUS TYPE 3 32DUML;PRP OF HAEMOPHILUS INFL. TYPE B 10MCGML	SUSPENSION	RECIEPT	Pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7th birthday against diphtheria, tetanus, whooping cough, poliomyelitis and invasive Haemophilus influenzae type b disease. In infants, three infectons are to be given intramuscularly at 2, 4 and 6 months of age followed by a booster at 18 months of age. Children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity. Children who have had natural pertussis can continue to receive pertussis - containing vaccines. Human immunodeficiency virus (HIV) infected persons HIV- infected individuals, both asymptomatic and symptomatic, should be immunized with Pediacel vaccine according to standard schedules.
3927	PEDITRACE	PEDITRACE	SODIUM FLUORIDE	SODIUM FLUORIDE 126MCG/ML;SODIUM SELENITE ANHYDROUS 4.38MCG/ML;MANGANESE AS CHLORIDE 3.6MCG/ML;COPPER CHLORIDE 53.7MCG/ML;POTASSIUM IODIDE 1.31MCG/ML;ZINC CHLORIDE 521MCG/ML	CONCENTRATE	RECIEPT	Peditrace is indicated to meet the basal requirement of trace elements during intravenous nutrition of infants and children.
3929	PEGLAX NEUTRAL	PEGLAX NEUTRAL 250GR	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350	POWDER		Treatment of constipation.
3928	PEGLAX NEUTRAL	PEGLAX NEUTRAL	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350 99.973%W/W	POWDER		Treatment of constipation.
3931	PEGLAX ORANGE	PEGLAX ORANGE 250 GR	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350	POWDER		Treatment of constipation.
3930	PEGLAX ORANGE	PEGLAX ORANGE	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350 99.365%W/W	POWDER		Treatment of constipation.
3944	PEMETREXED	PEMETREXED TEVA 1000 MG	PEMETREXED	PEMETREXED 1000MG	POWDER	RECIEPT	Malignant pleural mesothelioma : Pemetrexed Teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Non-small cell lung cancer: Pemetrexed Teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
3940	PEMETREXED	PEMETREXED TARO 1000 MG	PEMETREXED	PEMETREXED 1000MG/VIAL	POWDER	RECIEPT	1.Pemetrexed Taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.Pemetrexed Taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.Pemetrexed Taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 4.Pemetrexed Taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
3942	PEMETREXED	PEMETREXED TEVA 100 MG	PEMETREXED	PEMETREXED 100MG	POWDER	RECIEPT	Malignant pleural mesothelioma : Pemetrexed Teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Non-small cell lung cancer: Pemetrexed Teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
3939	PEMETREXED	PEMETREXED TARO 100 MG	PEMETREXED	PEMETREXED 100MG/VIAL	POWDER	RECIEPT	1.Pemetrexed Taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.Pemetrexed Taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.Pemetrexed Taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 4.Pemetrexed Taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
3948	PEMETREXED	PEMETREXED TEVA RTU 25 MG/ML	PEMETREXED	PEMETREXED 25MG/1ML	CONCENTRATE	RECIEPT	Pemetrexed Teva RTU in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Pemetrexed Teva RTU in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Teva RTU is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Teva RTU is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
3946	PEMETREXED	PEMETREXED TEVA 500 MG	PEMETREXED	PEMETREXED 500MG	POWDER	RECIEPT	Malignant pleural mesothelioma : Pemetrexed Teva in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Non-small cell lung cancer: Pemetrexed Teva in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Teva is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Teva is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
3941	PEMETREXED	PEMETREXED TARO 500 MG	PEMETREXED	PEMETREXED 500MG/VIAL	POWDER	RECIEPT	1.Pemetrexed Taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.Pemetrexed Taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.Pemetrexed Taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 4.Pemetrexed Taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
3935	PEMETREXED	PEMETREXED SANDOZ 1000	PEMETREXED AS DISODIUM	PEMETREXED AS DISODIUM 1000MG/VIAL	POWDER	RECIEPT	Pemetrexed Sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Pemetrexed Sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
3933	PEMETREXED	PEMETREXED SANDOZ 100	PEMETREXED AS DISODIUM	PEMETREXED AS DISODIUM 100MG/VIAL	POWDER	RECIEPT	Pemetrexed Sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Pemetrexed Sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
3937	PEMETREXED	PEMETREXED SANDOZ 500	PEMETREXED AS DISODIUM	PEMETREXED AS DISODIUM 500MG/VIAL	POWDER	RECIEPT	Pemetrexed Sandoz in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Pemetrexed Sandoz in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Sandoz is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
3932	PEMETREXED	PEMETREXED S.K.	PEMETREXED AS DISODIUM HEMIPENTAHYDRATE	PEMETREXED AS DISODIUM HEMIPENTAHYDRATE 500MG	POWDER	RECIEPT	Pemetrexed S.K. in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. Pemetrexed S.K. in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed S.K. is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed S.K. is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
3951	PENEDIL	PENEDIL 10 MG EXTENDED-RELEASE TABLETS	FELODIPINE	FELODIPINE 10MG	TABLETS	RECIEPT	Moderate to severe hypertension. Angina pectoris.
3952	PENEDIL	PENEDIL 2.5 MG EXTENDED RELEASE TABLETS	FELODIPINE	FELODIPINE 2.5MG	TABLETS	RECIEPT	Hypertension. Angina pectoris.
3954	PENEDIL	PENEDIL 5 MG EXTENDED-RELEASE TABLETS	FELODIPINE	FELODIPINE 5MG	TABLETS	RECIEPT	Moderade to severe hypertension. Angina pectoris.
3955	PENIBRIN	PENIBRIN 1 G	AMPICILLIN AS SODIUM	AMPICILLIN AS SODIUM 1 G	POWDER	RECIEPT	Penibrin injection is recommended in serious infections when prompt, effective levels of the antibiotic must reach the site of infection. Such infections include meningitis, subacute bacterial endocarditis, peritonitis, septicemia, severe forms of chronic bronchitis, osteomyelitis, pneumonia and pyelonephritis due to susceptible organisms.
3956	PENIBRIN	PENIBRIN 2 G	AMPICILLIN AS SODIUM	AMPICILLIN AS SODIUM 2G/VIAL	POWDER	RECIEPT	Penibrin injection is recommended in serious infections when prompt, effective levels of the antibiotic must reach the site of infection. Such infections include meningitis, subacute bacterial endocarditis, peritonitis, septicemia, severe forms of chronic bronchitis, osteomyelitis, pneumonia and pyelonephritis due to susceptible organisms.
3957	PENIBRIN	PENIBRIN 500 MG	AMPICILLIN AS SODIUM	AMPICILLIN AS SODIUM 500MG/VIAL	POWDER	RECIEPT	Infections caused by susceptible organisms.
3958	PENICILLIN SODIUM	PENICILLIN G SODIUM 10 M.U.	BENZYLPENICILLIN SODIUM	BENZYLPENICILLIN SODIUM 10MU/VIAL	POWDER	RECIEPT	Infections due to penicillin - sensitive microorganisms.
3959	PENICILLIN SODIUM	PENICILLIN G SODIUM 5 MU	BENZYLPENICILLIN SODIUM	BENZYLPENICILLIN SODIUM 5MIU/VIAL	POWDER	RECIEPT	Infections due to penicillin sensitive organisms.
3961	PEN-RAFA	PEN-RAFA VK FORTE	PHENOXYMETHYLPENICILLIN AS POTASSIUM	PHENOXYMETHYLPENICILLIN AS POTASSIUM 250MG/5ML	POWDER	RECIEPT	Treatment of infections caused by susceptible micro-organisms.
3960	PEN-RAFA	PEN-RAFA VK 500	PHENOXYMETHYLPENICILLIN AS POTASSIUM	PHENOXYMETHYLPENICILLIN AS POTASSIUM 500MG	TABLETS	RECIEPT	For susceptible microorganisms. To treat group A haemolytic infections of the upper respiratory tract using a twice daily regimen (1 G. bid in adults, 0.5 G bid in children).
3971	PENTASA	PENTASA SUPPOSITORIES	MESALAZINE	MESALAZINE 1000MG	SUPPOSITORIES	RECIEPT	Ulcerative proctitis.
3964	PENTASA	PENTASA ENEMA	MESALAZINE	MESALAZINE 1G/100ML	ENEMA	RECIEPT	Ulcerative colitis - Chron's disease
3965	PENTASA RELEASE GRANULES	PENTASA SLOW RELEASE GRANULES 1 GR.	MESALAZINE	MESALAZINE 1G	GRANULES	RECIEPT	Treatment of mild to moderate ulcerative colitis or crohn's disease.
3966	PENTASA RELEASE GRANULES	PENTASA SLOW RELEASE GRANULES 2 G	MESALAZINE	MESALAZINE 2 G	GRANULES	RECIEPT	Mild to moderate ulcerative colitis or Crohn's disease.
3967	PENTASA RELEASE GRANULES	PENTASA SLOW RELEASE GRANULES 4 G.	MESALAZINE	MESALAZINE 4000MG	GRANULES	RECIEPT	Mild to moderate ulcerative colitis or crohn's disease.
3968	PENTASA RELEASE TABLETS	PENTASA SLOW RELEASE TABLETS 1 GRAM	MESALAZINE	MESALAZINE 1 G	TABLETS	RECIEPT	Mild to moderate ulcerative colitis. Crohn's disease.
3970	PENTASA RELEASE TABLETS	PENTASA SLOW RELEASE TABLETS 500 MG	MESALAZINE	MESALAZINE 500MG	TABLETS	RECIEPT	Ulcerative colitis. Crohn's disease.
3973	PENTOSTAM	PENTOSTAM	SODIUM STIBOGLUCONATE	SODIUM STIBOGLUCONATE 10G/100ML	SOLUTION	RECIEPT	Pentostam is indicated for the following diseases: Visceral leishmaniasis (kala azar). Cutaneous leishmaniasis. South American mucocutaneous leishmaniasis. Pentostam may also be of value in the treatment of leishmaniasis recidivans and diffuse cutaneous leishmaniasis in the new world.
3974	PEPTOLITE	PEPTOLITE CHEWABLE TABLETS	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 262MG	TABLETS		For relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.
3976	PEPTOLITE	PEPTOLITE SUSPENTION 237ML	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG/15ML( 1.75% )	SUPPOSITORIES		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
3977	PERCOCET	PERCOCET 10	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 10MG;PARACETAMOL 325MG	TABLETS	RECIEPT	For the relief of moderate to moderately severe pain.
3978	PERCOCET	PERCOCET 5	PARACETAMOL	PARACETAMOL 325MG;OXYCODONE HYDROCHLORIDE 5MG	TABLETS	RECIEPT	For the relief of moderate to moderately severe pain.
3979	PERGOVERIS	PERGOVERIS	FOLLITROPIN ALFA	FOLLITROPIN ALFA 150 IU;LUTROPIN ALFA 75 IU	POWDER	RECIEPT	Pergoveris is indicated for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level < 1.2 IU/l.
3980	PERGOVERIS	PERGOVERIS PRE-FILLED PEN	LUTROPIN ALFA	LUTROPIN ALFA 150 IU/0.48ML;FOLLITROPIN ALFA 300 IU/0.48ML	SOLUTION	RECIEPT	Pergoveris is indicated for the stimulation of follicular development in adult women with sever LH and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level < 1.2IU/l
3981	PERICATE	PERICATE	HALOPERIDOL AS DECANOATE	HALOPERIDOL AS DECANOATE 100MG/ML	SOLUTION	RECIEPT	Long term maintenance treatment of Schizophrenia and mental or behaivoral problems.
3982	PERINAL	PERINAL SPRAY	HYDROCORTISONE	HYDROCORTISONE 0.2%W/W;LIDOCAINE AS HYDROCHLORIDE 1%W/W	SPRAY	RECIEPT	For the symptomatic relief of anal and perianal pain and pruritis such as associated with haemorrhoids.
3983	PERIO-CHIP	PERIO-CHIP	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 2.5MG	CHIP	RECIEPT	The Perio- chip is indicated for reduction and/or elimination of pathogenic periodontal pocket microbiota, delaying and/or arresting recolonization of the subgingival microflora, reduction and/or elimination of inflammatory lesions in the periodontal pockets, and as an adjunct to mechanical treatment in Periodontitis.
3984	PERJETA	PERJETA	PERTUZUMAB	PERTUZUMAB 420MG/14ML	CONCENTRATE	RECIEPT	Early breast cancer Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (positive nodes). Metastatic Breast Cancer Perjeta is indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2 positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
3985	PERMIXON	PERMIXON 160 MG	LIPIDOSTEROLIC EXTRACT OF SERENOA REPENS	LIPIDOSTEROLIC EXTRACT OF SERENOA REPENS 160MG	CAPSULES	RECIEPT	Treatment of moderate micturation troubles related to benign hypertrophy of prostate.
3986	PERPHENAN	PERPHENAN 4 MG	PERPHENAZINE	PERPHENAZINE 4MG	TABLETS	RECIEPT	Tranquilizer,antiemetic.
3987	PERPHENAN	PERPHENAN 8 MG	PERPHENAZINE	PERPHENAZINE 8MG	TABLETS	RECIEPT	Tranquilizer, antiemetic.
3989	PERTUSSOL	PERTUSSOL SYRUP 115ML	CODEINE PHOSPHATE	COD.PHOS.2MG/5ML;GUAIACOL SULFONAT 125MG/5ML;BENZOIC ACID 20MG/5ML;EPHEDRINE HCL 6MG/5ML	SYRUP	RECIEPT	For relief of cough.
3988	PERTUSSOL	PERTUSSOL SYRUP	GUAIACOLSULFONATE AS POTASSIUM	GUAIACOLSULFONATE AS POTASSIUM 125MG/5ML;EPHEDRINE HYDROCHLORIDE 6MG/5ML;BENZOIC ACID AS SODIUM 20MG/5ML;CODEINE PHOSPHATE 2MG/5ML	SYRUP	RECIEPT	For relief of cough.
3992	PHEBURANE	PHEBURANE	SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE 483MG/G	GRANULES	RECIEPT	PHEBURANE is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.
3993	PHENICOL	PHENICOL	CHLORAMPHENICOL	CHLORAMPHENICOL 0.55%W/V	DROPS	RECIEPT	Treatment of eye infections caused by micro-organisms sensitive to chloramphenicol.
3994	PHENIDIN	PHENIDIN 18 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 18MG	TABLETS	RECIEPT	For the treatment of attention deficit hyperactivity disorder (ADHD).
3996	PHENIDIN	PHENIDIN 27 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 27MG	TABLETS	RECIEPT	For the treatment of attention deficit hyperactivity disorder (ADHD).
3998	PHENIDIN	PHENIDIN 36 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 36MG	TABLETS	RECIEPT	For the treatment of attention deficit hyperactivity disorder (ADHD).
4000	PHENIDIN	PHENIDIN 54 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 54MG	TABLETS	RECIEPT	For the treatment of attention deficit hyperactivity disorder (ADHD).
4002	PHENIMIXIN	PHENIMIXIN	CHLORAMPHENICOL	CHLORAMPHENICOL 0.2%;POLYMYXIN B SULFATE 2500U/ML	DROPS	RECIEPT	Treatment of bacterial eye infections caused by susceptible organisms to the product.
4003	PHENOBARBITONE	PHENOBARBITONE 100 MG	PHENOBARBITAL	PHENOBARBITAL 100MG	TABLETS	RECIEPT	Sedative, hypnotic.
4004	PHENOBARBITONE	PHENOBARBITONE 15 MG	PHENOBARBITAL	PHENOBARBITAL 15MG	TABLETS	RECIEPT	Sedative, hypnotic.
4005	PHENYLEPHRINE	PHENYLEPHRINE HYDROCHLORIDE GENFARMA 10 MG/ML	PHENYLEPHRINE HYDROCHLORIDE	PHENYLEPHRINE HYDROCHLORIDE 10MG/1ML	SOLUTION	RECIEPT	For the treatment of hypotensive states, e.g. septic shock, circulatory failure, during spinal anaesthesia or drug-induced hypotension.
4006	PHENYLEPHRINE	PHENYLEPHRINE SINTETICA 10 MG/ML	PHENYLEPHRINE HYDROCHLORIDE	PHENYLEPHRINE HYDROCHLORIDE 10MG/1ML	SOLUTION	RECIEPT	For the treatment of hypotensive states, e.g. septic shock, circulatory failure, during spinal anaesthesia or drug-induced hypotension.
4007	PHOXILIUM	PHOXILIUM 1.2 MMOL/L PHOSPHATE	DISODIUM PHOSPHATE DIHYDRATE	DISODIUM PHOSPHATE DIHYDRATE 0.225G/L Large compartment B (4,750 ml);POTASSIUM CHLORIDE 0.314G/L Large compartment B (4,750 ml);SODIUM CHLORIDE 6.44G/L Large compartment B (4,750 ml);MAGNESIUM CHLORIDE HEXAHYDRATE 2.44G/L Small compartment A (250 ml);CALCIUM CHLORIDE DIHYDRATE 3.68G/L Small compartment A (250 ml);SODIUM HYDROGEN CARBONATE 2.92G/L Large compartment B (4,750 ml)	SOLUTION	RECIEPT	Phoxilium is used for CRRT (continuous renal replacement therapy) in critically ill patients with ARF (acute renal failure) when pH and kalaemia have been restored to normal and when the patients need phosphate supplementation for loss of phosphate in the ultrafiltrate or to the dialysate during CRRT. Phoxilium may also be used in cases of drug poisoning or intoxications when the poisons are dialysable or pass through the membrane. Phoxilium is indicated for use in patients with normal kalaemia and normal or hypophosphataemia.
4008	PHYSICARE	PHYSICARE GEL	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of rheumatic diseases, non infected inflammations and pain.
4009	PHYSICARE	PHYSICARE GEL 100 GR	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of rheumatic diseases, non infected inflammations and pain.
4010	PHYSICARE	PHYSICARE GEL 50 GR	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of rheumatic diseases, non infected inflammations and pain.
4012	PHYSIONEAL	PHYSIONEAL 40 GLUCOSE 2.27 % W/V	SODIUM CHLORIDE	SODIUM CHLORIDE 5.38G/L final solution after mixture;GLUCOSE MONOHYDRATE (AS ANHYDROUS) 22.7G/L final solution after mixture;CALCIUM CHLORIDE DIHYDRATE 0.184G/L final solution after mixture;LACTIC ACID AS SODIUM 1.68G/L final solution after mixture;MAGNESIUM CHLORIDE HEXAHYDRATE 0.051G/L final solution after mixture;SODIUM BICARBONATE 2.10G/L final solution after mixture	SOLUTION	RECIEPT	Physioneal is indicated whenever peritoneal dialysis is employed including: Acute and chronic renal failure Severe water retention Severe electrolyte imbalance Drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. Bicarbonate/Lactate based physioneal peritoneal dialysis solutions with a physiological pH are particularly indicated in patients in whom solutions based on lactate buffer only with a low pH cause abdominal inflow pain or discomfort.
4013	PHYSIONEAL	PHYSIONEAL 40 GLUCOSE 3.86 % W/V	SODIUM CHLORIDE	SODIUM CHLORIDE 5.38G/L final solution after mixture;MAGNESIUM CHLORIDE HEXAHYDRATE 0.051G/L final solution after mixture;CALCIUM CHLORIDE DIHYDRATE 0.184G/L final solution after mixture;SODIUM BICARBONATE 2.10G/L final solution after mixture;GLUCOSE MONOHYDRATE (AS ANHYDROUS) 38.6G/L final solution after mixture;LACTIC ACID AS SODIUM 1.68G/L final solution after mixture	SOLUTION	RECIEPT	Physioneal is indicated whenever peritoneal dialysis is employed including: Acute and chronic renal failure; Severe water retention; Severe electrolyte imbalance; Drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. Bicarbonate/Lactate based physioneal peritoneal dialysis solutions with a physiological pH are particularly indicated in patients in whom solutions based on lactate buffer only with a low pH cause abdominal inflow pain or discomfort.
4011	PHYSIONEAL	PHYSIONEAL 40 GLUCOSE 1.36 % W/V	SODIUM CHLORIDE	SODIUM CHLORIDE 5.38G/L final solution after mixture;MAGNESIUM CHLORIDE HEXAHYDRATE 0.051G/L final solution after mixture;LACTIC ACID AS SODIUM 1.68G/L final solution after mixture;SODIUM BICARBONATE 2.10G/L final solution after mixture;GLUCOSE MONOHYDRATE (AS ANHYDROUS) 13.6G/L final solution after mixture;CALCIUM CHLORIDE DIHYDRATE 0.184G/L final solution after mixture	SOLUTION	RECIEPT	Physioneal is indicated whenever peritoneal dialysis is employed including: Acute and chronic renal failure Severe water retention Severe electrolyte imbalance Drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. Bicarbonate/Lactate based physioneal peritoneal dialysis solutions with a physiological pH are particularly indicated in patients in whom solutions based on lactate buffer only with a low pH cause abdominal inflow pain or discomfort.
4015	PHYTODERM	PHYTODERM OINT 15GR	TOLNAFTATE	TOLNAFTATE 1%;BENZOIC ACID 6%;SALICYLIC ACID 3%	OINTMENT		Superficial dermatomycosis where a keratolytic effect is also required
4014	PHYTODERM	PHYTODERM COMPOSITUM	TOLNAFTATE	TOLNAFTATE 10MG/G;BENZOIC ACID 60MG/G;SALICYLIC ACID 30MG/G	OINTMENT		Superficial dermatomycosis where a keratolytic effect is also required
4016	PICATO	PICATO 0.015%	INGENOL MEBUTATE	INGENOL MEBUTATE 150MCG/G	GEL	RECIEPT	For the topical treatment of actinic keratosis on the face and scalp in adults.
4017	PICATO	PICATO 0.05%	INGENOL MEBUTATE	INGENOL MEBUTATE 500MCG/G	GEL	RECIEPT	For the topical treatment of actinic keratosis on the trunk and extremities in adults.
4019	PICO SALAX	PICO SALAX CRANBERRY	CITRIC ACID ANHYDROUS	CITRIC ACID ANHYDROUS 12G;MAGNESIUM OXIDE 3.5G;SODIUM PICOSULFATE 10MG	POWDER	RECIEPT	To clean the bowel Prior to X-ray examination, endoscopy or surgery.
4018	PICO SALAX	PICO - SALAX ORANGE	SODIUM PICOSULFATE	SODIUM PICOSULFATE 10MG;CITRIC ACID ANHYDROUS 12G;MAGNESIUM OXIDE 3.5G	POWDER	RECIEPT	To clean the bowel Prior to X-ray examination, endoscopy or surgery.
4020	PILOCARPINE	PILOCARPINE 2 % VITAMED	PILOCARPINE HYDROCHLORIDE	PILOCARPINE HYDROCHLORIDE 2%	DROPS	RECIEPT	Miotic, for the treatment of glaucoma.
4022	PINK BISMUTH	PINK BISMUTH CHEWABLE TABLETS	BISMUTH SUB SALICYLATE	BISMUTH SUB SALICYLATE 262MG	TABLETS		For relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.
4021	PINK BISMUTH	PINK BISMUTH 30TAB	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG	TABLETS		For relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.
4024	PINK BISMUTH	PINK BISMUTH SUSP 237ML	BISMUTH SUBSALICYLATE	BISMUTH SUBSALICYLATE 262MG/15ML( 1.75% )	SUPPOSITORIES		Relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. As a preventative treatment of traveler's diarrhea.
4025	PIPERACILLIN /TAZOBACTAM	PIPERACILLIN /TAZOBACTAM - FRESENIUS 2 G/0.25 G	PIPERACILLIN AS SODIUM SALT	PIPERACILLIN AS SODIUM SALT 2.0G/VIAL;TAZOBACTAM AS SODIUM SALT 0.25G/VIAL	POWDER	RECIEPT	- Treatment of systemic and/or local infections caused by susceptible organisms. - Piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 y
4029	PIPERACILLIN /TAZOBACTAM	PIPERACILLIN /TAZOBACTAM - FRESENIUS 4 G/0.5 G	PIPERACILLIN AS SODIUM SALT	PIPERACILLIN AS SODIUM SALT 4.0G/VIAL;TAZOBACTAM AS SODIUM SALT 0.5G/VIAL	POWDER	RECIEPT	- Treatment of systemic and/or local infections caused by susceptible organisms. - Piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 y
4033	PIPERACILLIN/ TAZOBACTAM	PIPERACILLIN/ TAZOBACTAM PANPHARMA 4G/500MG	PIPERACILLIN AS SODIUM	PIPERACILLIN AS SODIUM 4G;TAZOBACTAM AS SODIUM 500MG	POWDER	RECIEPT	Antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. Pipoeracillin/tazobactam in combination with an aminoglycoside is indicated for suspected bacterial infections in neutropenic adults or children above 2 years . Appencicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.
4035	PITREX	PITREX	TOLNAFTATE	TOLNAFTATE 1%	CREAM		Topical treatment of superficial dermatomycoses.
4036	PITREX	PITREX CREAM 1% 15GR	TOLNAFTATE	TOLNAFTATE 1G/100G	CREAM		Topical treatment of superficial dermatomycoses.
4037	PITRION	PITRION	MICONAZOLE NITRATE	MICONAZOLE NITRATE 2%	CREAM	RECIEPT	Skin and nail infections due to dermatophytes or candida.
4038	PITRION	PITRION CR 2% 15GR	MICONAZOLE NITRATE	MICONAZOLE NITRATE 2%	CREAM	RECIEPT	Skin and nail infections due to dermatophytes or candida.
4039	PITRISOL	PITRISOL SOLUTION	BENZOIC ACID	BENZOIC ACID 6%;SALICYLIC ACID 3%;LIDOCAINE AS HYDROCHLORIDE 1%	SOLUTION		For antifungal treatment.
4040	PLAQUENIL	PLAQUENIL	HYDROXYCHLOROQUINE SULFATE	HYDROXYCHLOROQUINE SULFATE 200MG	TABLETS	RECIEPT	Plaquenil is indicated for the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, p. malaria. p. ovale and susceptible strains of p. falciparum it is also indicated for the treatment of discoid and sustemic lupus erythematosus and rheumatoid arthritis.
4041	PLASMA-LYTE	PLASMA-LYTE 148 (pH 7.4)	SODIUM GLUCONATE	SODIUM GLUCONATE 5.02G/L;SODIUM ACETATE TRIHYDRATE 3.68G/L;MAGNESIUM CHLORIDE HEXAHYDRATE 0.30G/L;POTASSIUM CHLORIDE 0.37G/L;SODIUM CHLORIDE 5.26G/L	SOLUTION		Indicated as a source of water and electrolytes or as an alkalinizing agent.
4043	PLATINOX-V	PLATINOX-V	OXALIPLATIN	OXALIPLATIN 5MG/1ML	CONCENTRATE	RECIEPT	Oxaliplatin in combination with 5- fluorouracil (5-FU) and folinic acid (FA) is indicated for : - Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumour. - Treatment of metastatic colorectal cancer. Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014).
4044	PLAVIX	PLAVIX 75 MG	CLOPIDOGREL AS HYDROGEN SULFATE	CLOPIDOGREL AS HYDROGEN SULFATE 75MG	TABLETS	RECIEPT	Prevention of atherotrobmotic events Clopidogrel is indicated in : • Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. • Adult Patients suffering from Acute Coronary Syndrome - Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy Prevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
4045	PLEGRIDY	PLEGRIDY 125	PEGINTERFERON BETA	PEGINTERFERON BETA 1A 125MCG/0.5ML	SOLUTION	RECIEPT	Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis
4046	PLEGRIDY	PLEGRIDY 63	PEGINTERFERON BETA	PEGINTERFERON BETA 1A 63MCG/0.5ML	SOLUTION	RECIEPT	Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis
4047	PLEGRIDY	PLEGRIDY 94	PEGINTERFERON BETA	PEGINTERFERON BETA 1A 94MCG/0.5ML	SOLUTION	RECIEPT	Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis
4048	PLUVITON	PLUVITON 30TAB	VITAMIN A	VITS( A10000IU	TABLETS		Vitamin A supplement.
4049	PNEUMO	PNEUMO 23	STREPTOCOCCUS PNEUMONIAE	STREPTOCOCCUS PNEUMONIAE 25MCG/0.5ML	SOLUTION	RECIEPT	Prevention of pneumococcal infections, particularly of the respiratory type, in patients presenting an increased risk over the age of 2 years.
4050	PNEUMOVAX	PNEUMOVAX 23	PNEUMOCOCCAL VACCINE POLYVALENT	PNEUMOCOCCAL VACCINE POLYVALENT 25MCG/0.5ML	SOLUTION	RECIEPT	For vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.
4051	POINT	POINT	NAPROXEN SODIUM	NAPROXEN SODIUM 275MG	TABLETS	RECIEPT	Non steroidal anti-inflammatory in rheumatic inflammations. For the treatment of tendinitis and skeletal muscle inflammation. Mild to moderate analgesic (including menstrual pains) and antipyretic.
4052	POINT	POINT 275MG 20TAB	NAPROXEN SODIUM	NAPROXEN SODIUM 275MG	TABLETS	RECIEPT	Non steroidal anti-inflammatory in rheumatic inflammations. For the treatment of tendinitis and skeletal muscle inflammation. Mild to moderate analgesic (including menstrual pains) and antipyretic.
4053	POINT	POINT 275MG 24TAB	NAPROXEN SODIUM	NAPROXEN SODIUM 275MG	TABLETS	RECIEPT	Non steroidal anti-inflammatory in rheumatic inflammations. For the treatment of tendinitis and skeletal muscle inflammation. Mild to moderate analgesic (including menstrual pains) and antipyretic.
4054	POLIBAR ACB	POLIBAR ACB	BARIUM SULFATE	BARIUM SULFATE 96.476%W/W	POWDER	RECIEPT	For rectal administration (enema) as a radio-opaque agent for x-ray visualisation of the lower gastro-intestinal tract. It is designed for both single contrast barium enema and air-double contrast enema usage.
4055	POLIO SABIN THREE	POLIO SABIN ONE AND THREE	POLIOMYELITIS VIRUS TYPE	POLIOMYELITIS VIRUS TYPE 3 NLT 10^6.0CCID50;POLIOMYELITIS VIRUS TYPE 1 NLT 10^5.8CCID50;POLIOMYELITIS VIRUS TYPE 1 NLT 10^6.0CCID50	SUSPENSION	RECIEPT	Active immunisation against poliomyelitis infection caused by types 1 and 3 poliomyelitis viruses at any age after receiving at least one dose of IPV.
4056	POLLEN EXTRACTS	POLLEN EXTRACTS	POLLEN EXTRACTS	POLLEN EXTRACTS אוסף אלרגנים	SOLUTION	RECIEPT	Skin testing and immunotherapy.
4057	POLYCUTAN	POLYCUTAN	CLOTRIMAZOLE	CLOTRIMAZOLE 1%;NEOMYCIN SULFATE 0.645%;DEXAMETHASONE ACETATE 0.044%	CREAM	RECIEPT	Treatment of dermatitis involving also a bacterial and/or fungal infection.
4062	POLYDINE	POLYDINE OINT 15GR	POVIDONE IODINE	POVIDONE IODINE 10%	OINTMENT		For the disinfection of skin infections , wounds and superficial burns.
4063	POLYDINE	POLYDINE OINT 250GR	POVIDONE IODINE	POVIDONE IODINE 10%	OINTMENT		For the disinfection of skin infections , wounds and superficial burns.
4064	POLYDINE	POLYDINE OINT 50GR	POVIDONE IODINE	POVIDONE IODINE 10%	OINTMENT		For the disinfection of skin infections , wounds and superficial burns.
4066	POLYDINE	POLYDINE SOL 1000CC	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic for use in first aid in wounds, scratches, mild burns. For treatment of skin infections caused by bacteria or fungi. Antiseptic vaginal douche.
4067	POLYDINE	POLYDINE SOL 100CC	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic for use in first aid in wounds, scratches, mild burns. For treatment of skin infections caused by bacteria or fungi. Antiseptic vaginal douche.
4068	POLYDINE	POLYDINE SOL 200CC	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic for use in first aid in wounds, scratches, mild burns. For treatment of skin infections caused by bacteria or fungi. Antiseptic vaginal douche.
4069	POLYDINE	POLYDINE SOL 20CC	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Antiseptic for use in first aid in wounds, scratches, mild burns. For treatment of skin infections caused by bacteria or fungi. Antiseptic vaginal douche.
4072	POLYDINE	POLYDINE TINCTURE 1L	POVIDONE IODINE	POVIDONE IODINE 10%	SOLUTION		Skin disinfection.
4058	POLYDINE	POLYDINE 12 VAG SUPP	POVIDONE IODINE	POVIDONE IODINE 5%	SUPPOSITORIES		Treatment of vaginal infections caused by fungi, trichomonas, bacteria or mixed infections.
4070	POLYDINE	POLYDINE SOLUTION	POVIDONE-IODINE	POVIDONE-IODINE 10%	SOLUTION		Antiseptic for use in first aid in wounds, scratches, mild burns. For treatment of skin infections caused by bacteria or fungi. Antiseptic vaginal douche.
4071	POLYDINE	POLYDINE TINCTURE	POVIDONE-IODINE	POVIDONE-IODINE 10%W/V	LIQUID		Skin disinfection.
4065	POLYDINE	POLYDINE OINTMENT	POVIDONE-IODINE	POVIDONE-IODINE 10%W/W	OINTMENT		For the disinfection of skin infections , wounds and superficial burns.
4073	POLYDINE	POLYDINE VAGINAL PESSARIES	POVIDONE-IODINE	POVIDONE-IODINE 5%	PESSARY		Treatment of vaginal infections caused by fungi, trichomonas, bacteria or mixed infections.
4059	POLYDINE CLEANS	POLYDINE CLEANS 200CC	POVIDONE IODINE	POVIDONE IODINE 7.5%	SOLUTION		Wound disinfection to prevent skin infections caused by bacteria and fungi, disinfection of infected skin conditions and sidinfection of the hands before medical procedures.
4061	POLYDINE CLEANSER	POLYDINE CLEANSER 1L	POVIDONE IODINE	POVIDONE IODINE 7.5%	SOLUTION		Wound disinfection to prevent skin infections caused by bacteria and fungi, disinfection of infected skin conditions and sidinfection of the hands before medical procedures.
4060	POLYDINE CLEANSER	POLYDINE CLEANSER	POVIDONE-IODINE	POVIDONE-IODINE 7.5%W/V	SOLUTION		Wound disinfection to prevent skin infections caused by bacteria and fungi, disinfection of infected skin conditions and sidinfection of the hands before medical procedures.
4078	POLYSEPT	POLYSEPT VAGINAL DOUCHE	POVIDONE-IODINE	POVIDONE-IODINE 10 G/100ML	SOLUTION		An antiseptic rinse for the vagina.
4076	POLYSEPT	POLYSEPT OINTMENT	POVIDONE-IODINE	POVIDONE-IODINE 10%	OINTMENT		For the disinfection of skin infections and inflammations, wounds and superficial burns.
4077	POLYSEPT	POLYSEPT SOLUTION	POVIDONE-IODINE	POVIDONE-IODINE 10%	SOLUTION		Antiseptic for use in first aid in wounds, scratches, mild burns. For treatment of skin infections caused by bacteria or fungi.
4079	POLYSKIN	POLYSKIN SOLUTION	POVIDONE-IODINE	POVIDONE-IODINE 10%	SOLUTION		Disinfection of infected skin, superficial wounds and burns.
4080	POLYSKIN	POLYSKIN SPRAY	POVIDONE-IODINE	POVIDONE-IODINE 10%	SOLUTION		Antiseptic for wounds and mild burns.
4081	PORTRAZZA	PORTRAZZA 800 MG	NECITUMUMAB	NECITUMUMAB 16MG/1ML	CONCENTRATE	RECIEPT	Portrazza is indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. Limitation of Use: Portrazza is not indicated for treatment of non-squamous non-small cell lung cancer
4083	POSTINOR	POSTINOR	LEVONORGESTREL	LEVONORGESTREL 1.5MG	TABLETS	RECIEPT	Emergency contraseptive.
4084	POSTINOR	POSTINOR NEW 1.5MG 1 TAB	LEVONORGESTREL	LEVONORGESTREL 1.5MG	TABLETS	RECIEPT	Emergency contraseptive.
4089	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 0.224 % IN 5% DEXTROSE INJECTION	GLUCOSE AS MONOHYDRATE	GLUCOSE AS MONOHYDRATE 5G/100ML;POTASSIUM CHLORIDE 0.224G/100ML	SOLUTION	RECIEPT	Replenishment of water, certain electrolytes and calories as required by the clinical condition of the patient.
4091	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 0.224% IN 5 % DEXTROSE AND 0.2% SODIUM CHLORIDE INJ	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 0.224G/100ML;SODIUM CHLORIDE 0.2G/100ML;GLUCOSE AS MONOHYDRATE 5G/100ML	SOLUTION	RECIEPT	Indicated for replenishing water, certain electrolyte and calories as required by the clinical condition of the patient.
4085	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE - FRESENIUS 15 %	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 1.5G/10ML	SOLUTION	RECIEPT	Potassium deficiency.
4087	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 0.15 % W/V AND SODIUM CHLORIDE 0.9% W/V	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 1.5MG/1ML;SODIUM CHLORIDE 9MG/1ML	SOLUTION	RECIEPT	Correction or maintenance of potassium, sodium, chloride and fluid balance, depending upon the clinical condition of the patient. The solution is particularly indicated in the treatment of hypokalaemia, hypotonic and isotonic dehydration, and hypochloraemic alkalosis.
4094	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 14.9 %	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 14.9G/100ML	CONCENTRATE	RECIEPT	Treatment of potassium deficiency states when oral replacement is not feasable.
4092	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 0.3% W/V AND SODIUM CHLORIDE 0.9% W/V	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 3MG/1ML;SODIUM CHLORIDE 9MG/1ML	SOLUTION	RECIEPT	Correction or maintenance of potassium, sodium, chloride and fluid balance, depending upon the clinical condition of the patient. The solution is particularly indicated in the treatment of hypokalaemia, hypotonic and isotonic dehydration, and hypochloraemic alkalosis.
4090	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 0.224% IN 5 % DEXTROSE & 0.45% SODIUM CHLORIDE INJ.	SODIUM CHLORIDE	SODIUM CHLORIDE 0.45G/100ML;POTASSIUM CHLORIDE 0.224G/100ML;GLUCOSE MONOHYDRATE 5G/100ML	SOLUTION	RECIEPT	Indicated for replenishing water, electrolytes and calories .
4086	POTASSIUM CHLORIDE	POTASSIUM CHLORIDE 0.15 % IN 5 % DEXTROSE AND 0.33% SODIUM CHLORIDE	SODIUM CHLORIDE	SODIUM CHLORIDE 330MG/100ML;POTASSIUM CHLORIDE 150MG/100ML;DEXTROSE MONOHYDRATE 5G/100ML	SOLUTION	RECIEPT	Indicated for replenishing water, certain electrolytes and calories required by the clinical condition of the patient.
4095	PRADAXA	PRADAXA 110	DABIGATRAN ETEXILATE AS MESILATE	DABIGATRAN ETEXILATE AS MESILATE 110MG	CAPSULES	RECIEPT	Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
4098	PRADAXA	PRADAXA 150	DABIGATRAN ETEXILATE AS MESILATE	DABIGATRAN ETEXILATE AS MESILATE 150MG	CAPSULES	RECIEPT	Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
4101	PRADAXA	PRADAXA 75	DABIGATRAN ETEXILATE AS MESILATE	DABIGATRAN ETEXILATE AS MESILATE 75MG	CAPSULES	RECIEPT	Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
4105	PRALUENT	PRALUENT150 MG	ALIROCUMAB	ALIROCUMAB 150MG/1ML	SOLUTION	RECIEPT	Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined.
4104	PRALUENT	PRALUENT 75 MG	ALIROCUMAB	ALIROCUMAB 75MG/1ML	SOLUTION	RECIEPT	Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined.
4107	PRAMIN	PRAMIN TABLETS	METOCLOPRAMIDE HYDROCHLORIDE	METOCLOPRAMIDE HYDROCHLORIDE 10.52MG	TABLETS	RECIEPT	Metoclopramide is an antiemetic and stimulates GI motility. Adult population : Pramin is indicated in adults for: - Prevention of postoperative nausea and vomiting (PONV) - Prevention of delayed nausea and vomiting caused by chemotherapy (delayed CINV) - Prevention of nausea and vomiting caused by radiation therapy - Symptomatic treatment of nausea and vomiting, including nausea and vomiting caused by migraine attack. In migraine attacks, metoclopramide can be used concomitantly with oral analgesics to improve their absorption. - Diabetic gastroparesis Pediatric population: Pramin is indicated in children aged 1 to 18 years for: - Second line-therapy: Treatment of established postoperative nausea and vomiting (PONV) - Second-line therapy: Prevention of delayed nausea and vomiting caused by chemotherapy (delayed CINV)
4106	PRAMIN	PRAMIN INJECTION	METOCLOPRAMIDE HYDROCHLORIDE	METOCLOPRAMIDE HYDROCHLORIDE 10MG/2ML	SOLUTION	RECIEPT	Metoclopramide is an antiemetic and stimulates GI motility. Adult population: Pramin is indicated in adults for: - Prevention of postoperative nausea and vomiting (PONV) - Prevention of delayed nausea and vomiting caused by chemotherapy (delayed CINV) - Prevention of nausea and vomiting caused by radiation therapy - Symptomatic treatment of nausea and vomiting, including nausea and vomiting caused by migraine attack. In migraine attacks, metoclopramide can be used concomitantly with oral analgesics to improve their absorption. - Diabetic gastroparesis - To faciliate diagnostic procedures (ie, to faciliate small bowel intubation and as an aid in radiological examinations) (injection only) Pediatric population. Pramin is indicated in children aged 1 to 18 years for: - Second line-therapy: Treatment of established postoperative nausea and vomiting (PONV) - Second-line therapy: Prevention of delayed nausea and vomiting caused by chemotherapy (delayed CINV) - To facilitate diagnostic procedures (ie, to faciliate small bowel intubation and as an aid in radiological examinations) (injection only)
4108	PRAVALIP	PRAVALIP 10	PRAVASTATIN SODIUM	PRAVASTATIN SODIUM 10MG	TABLETS	RECIEPT	Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) Reduce the risk of myocardial infarcton. 2) Reduce the risk for revascularization. 3) Reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. Secondary prevention of cardiovascular events: a) Atherosclerosis: In hypercholesterolemic patients with clinically evident coronary artery disease including prior MI pravastatin is indicated to: 1)Slow the progression of coronary atherosclerosis. 2) Reduce the risk of acute coronary events. b) Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. Pravastatin is indicated to: 1) Reduce the risk of recurrent myocardial infarction. 2)Reduce the risk of undergoing myocardial revascularization procedures. 3) Reduce the risk of stroke or transient ischemic attack (TIA). c) Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Type IIa and IIb).
4110	PRAVALIP	PRAVALIP 20	PRAVASTATIN SODIUM	PRAVASTATIN SODIUM 20MG	TABLETS	RECIEPT	Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) Reduce the risk of myocardial infarcton. 2) Reduce the risk for revascularization. 3) Reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. Secondary prevention of cardiovascular events: a) Atherosclerosis: In hypercholesterolemic patients with clinically evident coronary artery disease including prior MI pravastatin is indicated to: 1)Slow the progression of coronary atherosclerosis. 2) Reduce the risk of acute coronary events. b) Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. Pravastatin is indicated to: 1) Reduce the risk of recurrent myocardial infarction. 2)Reduce the risk of undergoing myocardial revascularization procedures. 3) Reduce the risk of stroke or transient ischemic attack (TIA). c) Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Type IIa and IIb).
4112	PRAVALIP	PRAVALIP 40	PRAVASTATIN SODIUM	PRAVASTATIN SODIUM 40MG	TABLETS	RECIEPT	Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) Reduce the risk of myocardial infarcton. 2) Reduce the risk for revascularization. 3) Reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. Secondary prevention of cardiovascular events: a) Atherosclerosis: In hypercholesterolemic patients with clinically evident coronary artery disease including prior MI pravastatin is indicated to: 1)Slow the progression of coronary atherosclerosis. 2) Reduce the risk of acute coronary events. b) Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. Pravastatin is indicated to: 1) Reduce the risk of recurrent myocardial infarction. 2)Reduce the risk of undergoing myocardial revascularization procedures. 3) Reduce the risk of stroke or transient ischemic attack (TIA). c) Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Type IIa and IIb).
4114	PRAVASTATIN	PRAVASTATIN TEVA 10 MG	PRAVASTATIN SODIUM	PRAVASTATIN SODIUM 10MG	TABLETS	RECIEPT	Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels Pravastatin is indicated to: - Reduce the risk of recurrent myocardial infarction. - Reduce the risk of undergoing myocardial revascularization procedures. - Reduce the risk of stroke and transient ischemic attack (TIA). *Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson type IIa and IIb).
4116	PRAVASTATIN	PRAVASTATIN TEVA 20 MG	PRAVASTATIN SODIUM	PRAVASTATIN SODIUM 20MG	TABLETS	RECIEPT	Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels Pravastatin is indicated to: - Reduce the risk of recurrent myocardial infarction. - Reduce the risk of undergoing myocardial revascularization procedures. - Reduce the risk of stroke and transient ischemic attack (TIA). *Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson type IIa and IIb).
4118	PRAVASTATIN	PRAVASTATIN TEVA 40 MG	PRAVASTATIN SODIUM	PRAVASTATIN SODIUM 40MG	TABLETS	RECIEPT	Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels Pravastatin is indicated to: - Reduce the risk of recurrent myocardial infarction. - Reduce the risk of undergoing myocardial revascularization procedures. - Reduce the risk of stroke and transient ischemic attack (TIA). *Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson type IIa and IIb).
4120	PRAXBIND	PRAXBIND	IDARUCIZUMAB	IDARUCIZUMAB 50MG/1ML	SOLUTION	RECIEPT	Idarucizumab is a specific reversal agent for dabigatran and is indicated in patients treated with dabigatran etexilate when rapid reversal of the anticoagulant effects of dabigatran is required: • for emergency surgery/urgent procedures • in life-threatening or uncontrolled bleeding
4123	PRED-FORTE	PRED-FORTE	PREDNISOLONE ACETATE	PREDNISOLONE ACETATE 1%W/V	SUSPENSION	RECIEPT	For steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
4124	PREDNISONE	PREDNISONE 1 MG TABLETS	PREDNISONE	PREDNISONE 1MG	TABLETS	RECIEPT	Anti-inflammatory.
4125	PREDNISONE	PREDNISONE 20 MG	PREDNISONE	PREDNISONE 20MG	TABLETS	RECIEPT	Anti-inflammatory for treatment of inflammation responsive to glucocorticosteroids such as: Acute Allergies, rheumataid arthritis.
4126	PREDNISONE	PREDNISONE 5 MG	PREDNISONE	PREDNISONE 5MG	TABLETS	RECIEPT	Anti-inflammatory.
4127	PREGABALIN	PREGABALIN DEXCEL 100 MG	PREGABALIN	PREGABALIN 100MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia
4140	PREGABALIN	PREGABALIN TARO 100 MG	PREGABALIN	PREGABALIN 100MG	CAPSULES	RECIEPT	Indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4146	PREGABALIN	PREGABALIN TEVA 100 MG	PREGABALIN	PREGABALIN 100MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4128	PREGABALIN	PREGABALIN DEXCEL 150 MG	PREGABALIN	PREGABALIN 150MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia
4138	PREGABALIN	PREGABALIN INOVAMED 150 MG	PREGABALIN	PREGABALIN 150MG	CAPSULES	RECIEPT	Pregabalin Inovamed is indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4141	PREGABALIN	PREGABALIN TARO 150 MG	PREGABALIN	PREGABALIN 150MG	CAPSULES	RECIEPT	Indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4147	PREGABALIN	PREGABALIN TEVA 150 MG	PREGABALIN	PREGABALIN 150MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4129	PREGABALIN	PREGABALIN DEXCEL 200 MG	PREGABALIN	PREGABALIN 200MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia
4142	PREGABALIN	PREGABALIN TARO 200 MG	PREGABALIN	PREGABALIN 200MG	CAPSULES	RECIEPT	Indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4148	PREGABALIN	PREGABALIN TEVA 200 MG	PREGABALIN	PREGABALIN 200MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4130	PREGABALIN	PREGABALIN DEXCEL 225 MG	PREGABALIN	PREGABALIN 225MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia
4143	PREGABALIN	PREGABALIN TARO 225 MG	PREGABALIN	PREGABALIN 225MG	CAPSULES	RECIEPT	Indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4149	PREGABALIN	PREGABALIN TEVA 225 MG	PREGABALIN	PREGABALIN 225MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4131	PREGABALIN	PREGABALIN DEXCEL 25 MG	PREGABALIN	PREGABALIN 25MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia
4139	PREGABALIN	PREGABALIN INOVAMED 25 MG	PREGABALIN	PREGABALIN 25MG	CAPSULES	RECIEPT	Pregabalin Inovamed is indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4150	PREGABALIN	PREGABALIN TEVA 25 MG	PREGABALIN	PREGABALIN 25MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4132	PREGABALIN	PREGABALIN DEXCEL 300 MG	PREGABALIN	PREGABALIN 300MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia
4135	PREGABALIN	PREGABALIN INOVAMED 300 MG	PREGABALIN	PREGABALIN 300MG	CAPSULES	RECIEPT	Pregabalin Inovamed is indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4144	PREGABALIN	PREGABALIN TARO 300 MG	PREGABALIN	PREGABALIN 300MG	CAPSULES	RECIEPT	Indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4151	PREGABALIN	PREGABALIN TEVA 300 MG	PREGABALIN	PREGABALIN 300MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4133	PREGABALIN	PREGABALIN DEXCEL 50 MG	PREGABALIN	PREGABALIN 50MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia
4136	PREGABALIN	PREGABALIN INOVAMED 50 MG	PREGABALIN	PREGABALIN 50MG	CAPSULES	RECIEPT	Pregabalin Inovamed is indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4152	PREGABALIN	PREGABALIN TEVA 50 MG	PREGABALIN	PREGABALIN 50MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4134	PREGABALIN	PREGABALIN DEXCEL 75 MG	PREGABALIN	PREGABALIN 75MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia
4137	PREGABALIN	PREGABALIN INOVAMED 75 MG	PREGABALIN	PREGABALIN 75MG	CAPSULES	RECIEPT	Pregabalin Inovamed is indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4145	PREGABALIN	PREGABALIN TARO 75 MG	PREGABALIN	PREGABALIN 75MG	CAPSULES	RECIEPT	Indicated for the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4153	PREGABALIN	PREGABALIN TEVA 75 MG	PREGABALIN	PREGABALIN 75MG	CAPSULES	RECIEPT	For the treatment of peripheral and central neuropathic pain in adults. Management of Fibromyalgia.
4157	PREGNYL	PREGNYL 5000 I.U.	HUMAN CHORIONIC GONADOTROPIN	HUMAN CHORIONIC GONADOTROPIN 5000IU/ML	POWDER	RECIEPT	In the female: Ovulation induction in infertility due to anovulation or impaired follicle-ripening. Preparation of follicles for puncture in controlled ovarian hyperstimulation programs. Luteal phase support. In the male: Hypogonadotropic hypogonadism (also cases of idiopathic dysspermias have shown a positive response to gonadotropins). Delayed puberty associated with insufficient gonadotropic pituitary function. Cryptorchidism not due to anatomical obstruction.
4158	PRENATAL	PRENATAL	BETACAROTENE	BETACAROTENE 1500 IU;VITAMIN A 1500 IU;ASCORBIC ACID 100MG;FOLIC ACID 1MG;RIBOFLAVINE 3.4MG;NICOTINAMIDE 20MG;CYANOCOBALAMIN 12MCG;COLECALCIFEROL 250 IU;BIOTIN 30MCG;COPPER 2MG;SODIUM MOLYBDATE 25MCG;MANGANESE AS SULFATE 5MG;ZINC AS OXIDE 25MG;FERROUS FUMARATE 60MG;POTASSIUM IODIDE 0.15MG;MAGNESIUM OXIDE 50MG;CHROMIUM AS CHLORIDE 25MCG;CALCIUM PANTOTHENATE 10MG;PYRIDOXINE (VIT B6) HYDROCHLORIDE 10MG;THIAMINE (VIT B1) MONONITRATE 3MG;TOCOPHEROL (VIT E) (AS TOCOPHERYL ACETATE) 30 IU;CALCIUM CARBONATE 250MG;SODIUM SELENATE 25MCG	TABLETS	RECIEPT	Vitamin and mineral supplement for use during pregnancy and lactation.
4159	PRENATAL	PRENATAL 30TAB	BETACORTENE	BETACORTENE 1500IU;VIT A 1500IU;TOCOPHERYL ACET 30IU	TABLETS		Vitamin and mineral supplement for use during pregnancy and lactation.
4160	PRESSOLAT	PRESSOLAT 10	NIFEDIPINE	NIFEDIPINE 10MG	TABLETS	RECIEPT	Treatment of Hypertension.
4161	PREVENAR	PREVENAR 13	PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE	PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19 F 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B 4.4MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C 2.2MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A 2.2MCG/0.5ML	SUSPENSION	RECIEPT	Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age. Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly
4164	PREZISTA	PREZISTA 150 MG	DARUNAVIR AS ETHANOLATE	DARUNAVIR AS ETHANOLATE 150MG	TABLETS	RECIEPT	Adult Patients: Prezista, co-administered with ritonavir (Prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV -1) infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients . Pediatric patients: Prezista, co-administered with ritonavir (Prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in treatment-experienced pediatric patients 6 years of age and older . This indication is based on 24 Week analyses of plasma HIV-1 RNA levels and CD4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. In treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with Prezista/rtv: - Treatment history and, when available, genotypic or phenotypic testing, should guide the use of Prezista/rtv. - The use of other active agents with Prezista/rtv is associated with a greater likelihood of treatment response.
4165	PREZISTA	PREZISTA 400 MG	DARUNAVIR AS ETHANOLATE	DARUNAVIR AS ETHANOLATE 400MG	TABLETS	RECIEPT	Prezista , co-administered with 100 mg ritonavir (Prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection for over 18 years of age.
4166	PREZISTA	PREZISTA 600 MG	DARUNAVIR AS ETHANOLATE	DARUNAVIR AS ETHANOLATE 600MG	TABLETS	RECIEPT	Prezista , co-administered with 100 mg ritonavir (Prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection for over 18 years of age.
4167	PREZISTA	PREZISTA 75 MG	DARUNAVIR AS ETHANOLATE	DARUNAVIR AS ETHANOLATE 75MG	TABLETS	RECIEPT	Adult Patients: Prezista, co-administered with ritonavir (Prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV -1) infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients . Pediatric patients: Prezista, co-administered with ritonavir (Prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in treatment-experienced pediatric patients 6 years of age and older . This indication is based on 24 Week analyses of plasma HIV-1 RNA levels and CD4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. In treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with Prezista/rtv: - Treatment history and, when available, genotypic or phenotypic testing, should guide the use of Prezista/rtv. - The use of other active agents with Prezista/rtv is associated with a greater likelihood of treatment response.
4168	PRIDE	PRIDE 100	AMISULPRIDE	AMISULPRIDE 100MG	TABLETS	RECIEPT	Treatment of schizophrenia.
4170	PRIDE	PRIDE 400	AMISULPRIDE	AMISULPRIDE 400MG	TABLETS	RECIEPT	Treatment of schizophrenia.
4172	PRILIDAN	PRILIDAN	PRILOCAINE	PRILOCAINE 25MG/1 G;LIDOCAINE 25MG/1 G	CREAM		Topical anaesthetic for superficial dermal analgesia in connection with insertion of IV catheters, blood sampling and superficial surgical procedures.
4173	PRIMACOR	PRIMACOR INJECTION	MILRINONE	MILRINONE 1MG/ML	SOLUTION	RECIEPT	For the treatment of refractory heart failure immediately (up to 72 hours) following cardiac surgery. For the short term ( up to 48 hours) intravenous therapy of severe refractory congestive heart failure. In pediatric population Primacor is indicated for the short-term treatment (up to 35 hours) of severe congestive heart failure unresponsive to conventional maintenance therapy (glycosides, diuretics, vasodilators and/or angiotensin converting enzyme (ACE) inhibitors), and for the short-term treatment (up to 35 hours) of pediatric patients with acute heart failure, including low output states following cardiac surgery.
4174	PRIMENE	PRIMENE 10 %	L- VALINE	L- VALINE 0.76G/100ML;L- TYROSINE 0.045G/100ML;L- TRYPTOPHAN 0.2G/100ML;L- THREONINE 0.37G/100ML;TAURINE 0.06G/100ML;L- SERINE 0.4G/100ML;L- PROLINE 0.3G/100ML;L- PHENYLALANINE 0.42G/100ML;L- ORNITHINE HYDROCHLORIDE 0.318G/100ML;L- METHIONINE 0.24G/100ML;L- LYSINE 1.1G/100ML;L- LEUCINE 1.0G/100ML;L- ISOLEUCINE 0.67G/100ML;L-HISTIDINE 0.38G/100ML;GLYCINE 0.4G/100ML;L- GLUTAMIC ACID 1.0G/100ML;L- CYSTEINE 0.189G/100ML;L- ASPARTIC ACID 0.6G/100ML;L-ARGININE 0.84G/100ML;L- ALANINE 0.8G/100ML	SOLUTION	RECIEPT	Primene 10 % is indicated in 1) children and infants 2) neonates at term or premature of normal or low birth weight when oral or enteral nutrition is impossible insufficient or contraindicated.
4175	PRIMOLUT-NOR	PRIMOLUT-NOR	NORETHISTERONE ACETATE	NORETHISTERONE ACETATE 5MG	TABLETS	RECIEPT	Oral progestron for: Dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.
4176	PRIORIX	PRIORIX	LIVE ATTENUATED MUMPS VIRUS	LIVE ATTENUATED MUMPS VIRUS 10^3.7CCID50 Not less then;LIVE ATTENUATED RUBELLA VACCINE 10^3.0CCID50 Not less then;LIVE ATTENUATED MEASLES VIRUS 10^3.0CCID50 Not less then	POWDER	RECIEPT	Priorix is indicated for active immunisation of children from the age of 9 months or older, adolescents and adults against measles, mumps and rubella.
4177	PRIORIX TETRA	PRIORIX TETRA	LIVE ATTENUATED MEASLES VIRUS NLT	LIVE ATTENUATED MEASLES VIRUS NLT 10^ 3CCID;LIVE ATTENUATED MUMPS VIRUS NLT 10^ 4.4CCID;LIVE ATTENUATED RUBELLA VACCINE NLT 10^ 3CCID;VARICELLA VIRUS, LIVE ATTENUATED >=10 ^ 3.3PFU	POWDER	RECIEPT	Priorix-Tetra is indicated for active immunisation against measles, mumps, rubella and varicella in children from the age of 12 months up and including 12 years of age.
4179	PRISMASOL	PRISMASOL 4 MMOL/L POTASSIUM	CALCIUM CHLORIDE DIHYDRATE	CALCIUM CHLORIDE DIHYDRATE 5.145G/L small compartment A;MAGNESIUM CHLORIDE HEXAHYDRATE 2.033G/L small compartment A;GLUCOSE ANHYDROUS 22.00G/L small compartment A;LACTIC ACID 5.400G/L small compartment A;SODIUM CHLORIDE 6.45G/L large compartment B;SODIUM HYDROGEN CARBONATE 3.090G/L large compartment B;POTASSIUM CHLORIDE 0.314G/L large compartment B	SOLUTION	RECIEPT	Prismasol 4 mmol/l Potassium is used in the treatment of renal failure, as substitution solution in haemofiltration and haemodiafiltration and as dialysis solution in continuous haemodialysis or continuous haemodiafiltration. Prismasol 4 mmol/l Potassium solution may also be used in case of drug poisoning with dialysable or filterable substances. Prismasol 4 mmol/l Potassium solution is indicated in patients who are normokalaemic.
4178	PRISMASOL	PRISMASOL 2 MMOL/L POTASSIUM	CALCIUM CHLORIDE DIHYDRATE	CALCIUM CHLORIDE DIHYDRATE 5.145G/L Small compartment A;MAGNESIUM CHLORIDE HEXAHYDRATE 2.033G/L Small compartment A;GLUCOSE ANHYDROUS AS MONOHYDRATE 22.00G/L Small compartment A;LACTIC ACID 5.400G/L Small compartment A;SODIUM CHLORIDE 6.45G/L Large compartment B;SODIUM HYDROGEN CARBONATE 3.090G/L Large compartment B;POTASSIUM CHLORIDE 0.157G/L Large compartment B	SOLUTION	RECIEPT	Prismasol 2 mmol/l Potassium is used in the treatment of renal failure, as substitution solution in haemofiltration and haemodiafiltration and as dialysis solution in continuous haemodialysis or continuous haemodiafiltration. Prismasol 2 mmol/l Potassium solution may also be used in case of drug poisoning with dialysable or filterable substances. Prismasol 2 mmol/l Potassium solution is indicated in patients who have tendency to hyperkalaemia.
4180	PRIVIGEN	PRIVIGEN	IMMUNOGLOBULIN NORMAL HUMAN	IMMUNOGLOBULIN NORMAL HUMAN 100G/L	SOLUTION	RECIEPT	Replacement therapy in • Primary immunodeficiency syndromes (PID) such as: – congenital agammaglobulinaemia and hypogammaglobulinaemia – common variable immunodeficiency – severe combined immunodeficiency – Wiskott-Aldrich syndrome • Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections • Children with congenital AIDS and recurrent infections Immunomodulation • Immune thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgical interventions to correct the platelet count • Guillain-Barré syndrome • Kawasaki disease • Chronic inflammatory demyelinating polyneuropathy (CIDP) Allogeneic bone marrow transplantation
4181	PRIZMA	PRIZMA	FLUOXETINE AS HYDROCHLORIDE	FLUOXETINE AS HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Prizma is indicated for the treatment of Depression and Obsessive-Compulsive disorders (OCD). For the treatment of binge-eating and vomiting behaviors in bulimia nervosa.
4185	PRIZMA	PRIZMA SOLUTION	FLUOXETINE AS HYDROCHLORIDE	FLUOXETINE AS HYDROCHLORIDE 20MG/5ML	SOLUTION	RECIEPT	Major Depressive Disorder Prizma solution is indicated for the treatment of Major Depressive disorder. The usefulness of the drug in patients receiving fluoxetine for extended periods should periodically be re-evaluated. Obsessive Compulsive Disorder Prizma solution is indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD). The effectiveness of Prizma solution in long term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo controlled trials. Therefore, the physician who elects to use Prizma solution for extended periods should periodically re-evaluate the long term usefulness of the drug for the individual patient. Bulimia Nervosa Prizma solution is indicated for the acute and maintenance treatment of binge eating and vomiting behaviors in adult patients with moderate to severe Bulimia Nervosa. The physician who elects to use Prizma solution for extended periods should periodically re-evaluate the long term usefulness of the drug for the individual patient.
4183	PRIZMA	PRIZMA FORTE	FLUOXETINE AS HYDROCHLORIDE	FLUOXETINE AS HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Prizma is indicated for the treatment of Depression and Obsessive-Compulsive disorders (OCD). For the treatment of binge-eating and vomiting behaviors in bulimia nervosa.
4186	PROAVENIR	PROAVENIR	FINASTERIDE	FINASTERIDE 1MG	TABLETS	RECIEPT	ProAvenir is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss.
4188	PROCOR	PROCOR	AMIODARONE HYDROCHLORIDE	AMIODARONE HYDROCHLORIDE 200MG	TABLETS	RECIEPT	Coronary insufficiency, arrhythmias resistant to other treatments.
4190	PROCTOFOAM H.C.	PROCTOFOAM H.C.	HYDROCORTISONE ACETATE	HYDROCORTISONE ACETATE 1%;PRAMOCAINE HYDROCHLORIDE 1%	FOAM	RECIEPT	Proctofoam HC is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses of the anal region.
4194	PROCTO-GLYVENOL	PROCTO-GLYVENOL SUPPOSITORIES	TRIBENOSIDE	TRIBENOSIDE 400MG;LIDOCAINE 40MG	SUPPOSITORIES		Local relief of haemorrhoids.
4191	PROCTO-GLYVENOL	PROCTO-GLYVENOL 10 SUPP	TRIBENOSIDE	TRIBENOSIDE 400MG;LIGNOCAINE 40MG	SUPPOSITORIES	RECIEPT	Local relief of haemorrhoids.
4192	PROCTO-GLYVENOL	PROCTO-GLYVENOL CREAM	TRIBENOSIDE	TRIBENOSIDE 5%;LIDOCAINE HYDROCHLORIDE 2.12%	CREAM		External & internal haemorrhoids
4193	PROCTO-GLYVENOL	PROCTO-GLYVENOL CREAM 30GR	TRIBENOSIDE	TRIBENOSIDE 5%;LIGNOCAINE 2.12G	CREAM	RECIEPT	External & internal haemorrhoids
4195	PRO-CURE	PRO-CURE 5 MG	FINASTERIDE	FINASTERIDE 5MG	TABLETS	RECIEPT	For the treatment and control of benign prostatic hyperplasia (BPH) and for the prevention of urologic events to: reduce the risk of acute urinary retention. Reduce the risk of surgery including transurethral resection of the prostate (TURP)and prostatectomy. Pro-cure causes regression of the enlarged prostate, improves urinary flow and improves the symptoms assocciated with BPH. Patients with an enlarged prostate are the appropriate candidates for therapy with Pro-cure.
4196	PROFEX	PROFEX 150 MG	PROPAFENONE HYDROCHLORIDE	PROPAFENONE HYDROCHLORIDE 150MG	TABLETS	RECIEPT	Prophylaxis and treatment of ventricular arrhythmias. Prophylaxis and treatment of atrial fibrillation and flutter. Prophylaxis and treatment of Paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms.
4197	PROFEX	PROFEX 300 MG	PROPAFENONE HYDROCHLORIDE	PROPAFENONE HYDROCHLORIDE 300MG	TABLETS	RECIEPT	Prophylaxis and treatment of ventricular arrhythmias. Prophylaxis and treatment of atrial fibrillation and flutter. Prophylaxis and treatment of Paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms.
4199	PROFITEN	PROFITEN TABLETS	KETOTIFEN AS FUMARATE	KETOTIFEN AS FUMARATE 1MG	TABLETS	RECIEPT	Prophylactic treatment of bronchial asthma. Symptomatic treatment of allergic conditions such as rhinitis, hay fever, bronchitis and urticaria.
4198	PROFITEN	PROFITEN SYRUP	KETOTIFEN AS FUMARATE	KETOTIFEN AS FUMARATE 1MG/5ML	SYRUP	RECIEPT	Prophylactic treatment of bronchial asthma. Symptomatic treatment of allergic conditions including bronchitis, rhinitis, hay fever and urticaria.
4200	PROGRAF	PROGRAF 0.5 MG	TACROLIMUS	TACROLIMUS 0.5MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in liver kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
4202	PROGRAF	PROGRAF 1 MG	TACROLIMUS	TACROLIMUS 1MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in liver kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
4204	PROGRAF	PROGRAF 5 MG	TACROLIMUS	TACROLIMUS 5MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in liver kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
4206	PROGRAF	PROGRAF AMPOULES	TACROLIMUS	TACROLIMUS 5MG/ML	CONCENTRATE	RECIEPT	Prophylaxis of transplant rejection in liver kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
4207	PROGYLUTON	PROGYLUTON	ESTRADIOL VALERATE	ESTRADIOL VALERATE 2MG 10 light brown tablets;NORGESTREL 0.5MG 10 light brown tablets;ESTRADIOL VALERATE 2MG 11 white tablets	TABLETS	RECIEPT	Two phase preparation for climacteric and cycle disturbances.
4209	PROLIA	PROLIA 60 MG	DENOSUMAB	DENOSUMAB 60MG/1ML	SOLUTION	RECIEPT	Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy of a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 3 months, in adult patients at high risk of fracture.
4210	PROLOL	PROLOL 10	PROPRANOLOL HYDROCHLORIDE	PROPRANOLOL HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Management of angina pectoris, control of essential and renal hypertension, control of essential tremor, control of most forms of cardiac dysrhythmias, adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises, management of hypertrophic obstructive cardiomyopathy, management of pheochromocytoma (with an alpha blocker). Prolol is also indicated for the long term prophylaxis after recovery from acute myocardial infarction (treatment to be initiated by a hospital physician), migraine prophylaxis.
4211	PROLOL	PROLOL 40	PROPRANOLOL HYDROCHLORIDE	PROPRANOLOL HYDROCHLORIDE 40MG	TABLETS	RECIEPT	Management of angina pectoris, control of essential and renal hypertension, control of essential tremor, control of most forms of cardiac dysrhythmias, adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises, management of hypertrophic obstructive cardiomyopathy, management of pheochromocytoma (with an alpha blocker). Prolol is also indicated for the long term prophylaxis after recovery from acute myocardial infarction (treatment to be initiated by a hospital physician), migraine prophylaxis.
4213	PROMETHAZINE	PROMETHAZINE EXPECTORANS SYRUP	IPECACUANHA	IPECACUANHA 200MG/100ML;PROMETHAZINE HYDROCHLORIDE 100MG/100ML;GUAIACOLSULFONATE AS POTASSIUM 1G/100ML	SYRUP	RECIEPT	For temporary relief of cough, increases the output of upper resperatory tract fluids.
4212	PROMETHAZINE	PROMETHAZINE 0.1 % VITAMED	PROMETHAZINE HYDROCHLORIDE	PROMETHAZINE HYDROCHLORIDE 5MG/5ML	SYRUP	RECIEPT	Antihistaminic, antiemetic.
4214	PROMNIX	PROMNIX 0.4	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE 0.4MG	CAPSULES	RECIEPT	Treatment of functional symptoms of benign prostatic hyperplasia (BPH).
4217	PROPECIA	PROPECIA	FINASTERIDE	FINASTERIDE 1MG	TABLETS	RECIEPT	Propecia is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss
4218	PROPESS	PROPESS	DINOPROSTONE	DINOPROSTONE 10MG	PESSARY	RECIEPT	Initiation and/or continuation of cervical ripening in patients at term, from 38th week of gestation, with bishop score of 6 or less.
4219	PROPOFOL	PROPOFOL - LIPURO 1 %	PROPOFOL	PROPOFOL 10MG/ML	EMULSION	RECIEPT	Propofol-Lipuro 1% is a short-acting intravenous general anaesthetic for • induction and maintenance of general anaesthesia in adults and children > 1 month • sedation of ventilated patients >16 years of age in the intensive care unit • sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > 1 month.
4221	PROPOFOL	PROPOFOL 1 % FRESENIUS	PROPOFOL	PROPOFOL 1G/100ML	EMULSION	RECIEPT	Propofol 1% is a short-acting intravenous general anaesthetic for: • induction and maintenance of general anaesthesia in adults and children > 1 month • sedation of ventilated patients >16 years of age in the intensive care unit • sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > 1 month.
4224	PROPOFOL	PROPOFOL 1% MCT FRESENIUS	PROPOFOL	PROPOFOL 1G/100ML	EMULSION	RECIEPT	Propofol 1% MCT Fresenius is a short-acting intravenous general anaesthetic for -induction and maintenance of general anaesthesia in adults and children > 1 month -sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > 1 month -sedation of ventilated patients > 16 years of age in the intensive care unit
4231	PROPOFOL	PROPOFOL LIPURO 2 %	PROPOFOL	PROPOFOL 20MG/ML	EMULSION	RECIEPT	Propofol-Lipuro 2% is a short-acting intravenous general anaesthetic for ● induction and maintenance of general anaesthesia in adults and children > 3 years ● sedation of ventilated patients >16 years of age in the intensive care unit ● sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > 3 years.
4227	PROPOFOL	PROPOFOL 2 % MCT FRESENIUS	PROPOFOL	PROPOFOL 2G/100ML	EMULSION	RECIEPT	Propofol 2% MCT Fresenius is a short-acting intravenous general anaesthetic for -induction and maintenance of general anaesthesia in adults and children > 3 years -sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children > 3 years -sedation of ventilated patients > 16 years of age in the intensive care unit
4232	PROPYL-THIOCIL	PROPYL-THIOCIL	PROPYLTHIOURACIL	PROPYLTHIOURACIL 50MG	TABLETS	RECIEPT	Hyperthyroidism.
4233	PROQUAD	PROQUAD	MEASLES VIRUS ENDERS’ EDMONSTON STRAIN (LIVE, ATTENUATED) not less than	MEASLES VIRUS ENDERS’ EDMONSTON STRAIN (LIVE, ATTENUATED) not less than 3.00 log10 TCID50;VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED) not less than 3.99 log10 PFU;RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) not less than 3.00 log10 TCID50;MUMPS VIRUS JERYL LYNN™ (LEVEL B) STRAIN (LIVE, ATTENUATED) not less than 4.30 log10 TCID50	POWDER	RECIEPT	ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella, and varicella in individuals from 12 months of age to 12 years of age. ProQuad can be administered to individuals from 9 months of age under special circumstances: outbreak situations, or travel to a region with high prevalence of measles.
4238	PROSTIN	PROSTIN VR	ALPROSTADIL	ALPROSTADIL 0.5MG/ML	CONCENTRATE	RECIEPT	For palliative therapy to maintain the patency of the ductus arteriosus.
4237	PROSTIN	PROSTIN E2 VAGINAL GEL 2 MG	DINOPROSTONE	DINOPROSTONE 2MG/3 G	GEL	RECIEPT	For labour induction in term and near term pregnant women who have favorable induction features and who have a singleton pregnancy with vertex presentation
4234	PROSTIN E2	PROSTIN E2 10 MG/ML	DINOPROSTONE	DINOPROSTONE 10MG/ML	SOLUTION	RECIEPT	Therapeutic termination of pregnancy, missed abortion.
4236	PROSTIN E2	PROSTIN E2 VAGINAL GEL 1 MG	DINOPROSTONE	DINOPROSTONE 1MG/3 G	GEL	RECIEPT	For labour induction in term and near term pregnant women who have favorable induction features and who have a singleton pregnancy with vertex presentation
4235	PROSTIN E2	PROSTIN E2 3 MG	DINOPROSTONE	DINOPROSTONE 3MG	TABLETS	RECIEPT	Induction of labour.
4239	PROSULF	PROSULF	PROTAMINE SULFATE	PROTAMINE SULFATE 50MG/5ML	SOLUTION	RECIEPT	To counteract the anticoagulant effect of Heparin, before surgery, after renal dialysis, after open heart surgery, if excessive bleeding occurs and when an overdose has inadvertently been given.
4240	PROTHIAZINE	PROTHIAZINE 25 MG	PROMETHAZINE HYDROCHLORIDE	PROMETHAZINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Antihistaminic, antiemetic, sedative.
4242	PROTHIAZINE	PROTHIAZINE SYRUP	PROMETHAZINE HYDROCHLORIDE	PROMETHAZINE HYDROCHLORIDE 5MG/5ML	SYRUP	RECIEPT	Antihistaminic, Antiemetic, Sedative.
4241	PROTHIAZINE	PROTHIAZINE EXPECTORANT SYRUP	PROMETHAZINE HYDROCHLORIDE	PROMETHAZINE HYDROCHLORIDE 5MG/5ML;GUAIFENESIN 45MG/5ML;IPECACUANHA 10MG/5ML	SYRUP	RECIEPT	For temporary relief of cough due to colds, allergies.
4243	PROTOCIDE	PROTOCIDE	TINIDAZOLE	TINIDAZOLE 500MG	TABLETS	RECIEPT	For the oral treatment of Trichomonas Vaginals infections of the genito urinary tract in both female and male. For the prevention of anerobic infections after gynocological operations and stomach operations.
4245	PROTOPIC	PROTOPIC 0.03 %	TACROLIMUS	TACROLIMUS 0.03%	OINTMENT	RECIEPT	-Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies. -Treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who are not adequatel
4246	PROTOPIC	PROTOPIC 0.1 %	TACROLIMUS	TACROLIMUS 0.1%	OINTMENT	RECIEPT	Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies. Maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).
4247	PROVERA	PROVERA 5 MG	MEDROXYPROGESTERONE ACETATE	MEDROXYPROGESTERONE ACETATE 5MG	TABLETS	RECIEPT	In cases requiring progesterone supplement.
4248	PROVIGIL	PROVIGIL	MODAFINIL	MODAFINIL 100MG	TABLETS	RECIEPT	To improve wakefulness in patients with excessive sleepiness associated with narcolepsy (with or without cataplexy), obstructive sleep apnea/hypopnea syndrome ( OSAHS ) and shift work sleep disorder (SWDS).
4251	PROVIRON	PROVIRON	MESTEROLONE	MESTEROLONE 25MG	TABLETS	RECIEPT	Androgen therapy. Androgen deficiency or male infertility when associated with primary or secondary male hypogonadism.
4252	PROVOCHOLINE	PROVOCHOLINE	METHACHOLINE CHLORIDE	METHACHOLINE CHLORIDE 100MG/VIAL	POWDER	RECIEPT	For the diagnosis of bronchial airway hyperactivity in subjects who do not have clinically apparent asthma.
4253	PROZAC	PROZAC	FLUOXETINE AS HYDROCHLORIDE	FLUOXETINE AS HYDROCHLORIDE 20MG	CAPSULES	RECIEPT	Treatment of depression. Obsessive-compulsive disorders (OCD). Fluoxetine is also indicated for the treatment of binge-eating and vomiting behaviors in bulimia nervosa.
4254	PRYSOLINE	PRYSOLINE TABLETS	PRIMIDONE	PRIMIDONE 250MG	TABLETS	RECIEPT	Anticonvulsant.
4257	PULMOZYME	PULMOZYME	RECOMBINANT HUMAN DEOXYRIBONUCLEASE	RECOMBINANT HUMAN DEOXYRIBONUCLEASE 1MG/ML	SOLUTION	RECIEPT	Management of cystic fibrosis not for patients under 5 years of age or with FVC<40% .
4258	PUREGON INJECTION	PUREGON SOLUTION FOR INJECTION	FOLLITROPIN BETA	FOLLITROPIN BETA 833 IU/1ML	SOLUTION	RECIEPT	Puregon is indicated for the treatment of female infertility in the following clinical situations: Anovulation (including polycystic ovarian disease, PCOD) in women who have beenunresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [ e.g. in vitro fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)]. In the male : Deficient spermatogenesis due to hypogonadotrophic hypogonadism.
4259	PURI-NETHOL	PURI-NETHOL TABLETS 50 MG	MERCAPTOPURINE	MERCAPTOPURINE 50MG	TABLETS	RECIEPT	For the treatment of acute Leukemia and also in cases of chronic myelogenous Leukemia.
4260	PYRIDOSTIGMINE	PYRIDOSTIGMINE 30	PYRIDOSTIGMINE BROMIDE	PYRIDOSTIGMINE BROMIDE 30MG	TABLETS	RECIEPT	Pyridostigmine belongs to the cholinesterase inhibitor group and is indicated for the treatment of myasthenia gravis.
4261	PYRIDOSTIGMINE	PYRIDOSTIGMINE 60	PYRIDOSTIGMINE BROMIDE	PYRIDOSTIGMINE BROMIDE 60MG	TABLETS	RECIEPT	Pyridostigmine belons to the cholinesterase inhibitor group and is indicated for the treatment of myasthenia gravis.
4262	QARZIBA	QARZIBA	DINUTUXIMAB BETA	DINUTUXIMAB BETA 4.5MG/1ML	CONCENTRATE	RECIEPT	Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin-2 (IL-2).
4263	QLAIR	QLAIR	ESTRADIOL VALERATE	ESTRADIOL VALERATE 1MG 2 dark red tablets;ESTRADIOL VALERATE 3MG 2 dark yellow tablets;DIENOGEST 2MG 5 medium red tablets;DIENOGEST 3MG 17 light yellow tablets;ESTRADIOL VALERATE 2MG 5 medium red tab. and 17 light yellow tab.	TABLETS	RECIEPT	Oral contraception. Treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception.
4264	QTERN	QTERN	DAPAGLIFLOZIN AS PROPANEDIOL	DAPAGLIFLOZIN AS PROPANEDIOL 10MG;SAXAGLIPTIN AS HYDROCHLORIDE MONOHYDRATE 5MG	TABLETS	RECIEPT	Qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus: - to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern do not provide adequate glycaemic control, - when already being treated with the free combination of dapagliflozin and saxagliptin.
4269	QUETIAPINE	QUETIAPINE TEVA 100 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 100MG	TABLETS	RECIEPT	Ttreatment of schizophrenia. Treatment of manic episodes associated with bipolar disorder. Treatment of major depressive episodes in bipolar disorders.
4270	QUETIAPINE	QUETIAPINE TEVA 200 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 200MG	TABLETS	RECIEPT	Ttreatment of schizophrenia. Treatment of manic episodes associated with bipolar disorder. Treatment of major depressive episodes in bipolar disorders.
4268	QUETIAPINE	QUETIAPINE TEVA 25 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 25MG	TABLETS	RECIEPT	- Indicated for the treatment of schizophrenia. - Treatment of manic episodes Associated with bipolar disorder. - Treatment of major depressive episodes in bipolar disorders.
4271	QUETIAPINE	QUETIAPINE TEVA 300 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 300MG	TABLETS	RECIEPT	Ttreatment of schizophrenia. Treatment of manic episodes associated with bipolar disorder. Treatment of major depressive episodes in bipolar disorders.
4273	QUINIDINE SULFATE	QUINIDINE SULFATE	QUINIDINE SULFATE	QUINIDINE SULFATE 200MG	TABLETS	RECIEPT	Treatment of certain cardiac arrhythmias: atrial fibrillation / flutter and ventricular arrhythmias
4274	QUININE SULFATE	QUININE SULFATE 300 MG	QUININE SULFATE	QUININE SULFATE 300MG	TABLETS	RECIEPT	Antimalarial.
4276	QVAR	QVAR 100	BECLOMETASONE DIPROPIONATE	BECLOMETASONE DIPROPIONATE 100MCG/DOSE	INHALATION	RECIEPT	Prophylaxis and treatment of bronchial asthma in adults and children 5 years of age and obove.
4279	QVAR	QVAR 50	BECLOMETASONE DIPROPIONATE	BECLOMETASONE DIPROPIONATE 50MCG/DOSE	INHALATION	RECIEPT	Prophylaxis and treatment of bronchial asthma in adults and children 5 years of age and obove.
4281	RABIPUR	RABIPUR	RABIES, INACTIVATED, WHOLE VIRUS	RABIES, INACTIVATED, WHOLE VIRUS 2.5IU/ML	POWDER	RECIEPT	Rabipur is indicated for active immunization against Rabies in individuals of all ages.
4284	RADIAN B	RADIAN B SPRAY	MENTHOL	MENTHOL 1.4%;ACETYLSALICYLIC ACID 1.2%;CAMPHOR 0.6%;METHYL SALICYLATE 0.6%	SPRAY		Relief of light muscular and rheumatic pains.
4285	RADIAN B	RADIAN B SPRAY 100ML	MENTHOL	MENTHOL 1.4%;ACETYLSALICYLIC ACID 1.2%;CAMPHOR 0.6%;METHYL SALICYLATE 0.6%	SPRAY		Relief of light muscular and rheumatic pains.
4282	RADIAN B	RADIAN B CREAM 40GR	MENTHOL	MENTHOL 2.54%;CAMPHOR 1.43%;METHYL SALICYLATE 0.42%	CREAM		Relief of rheumatic pains and mild muscle pains.
4283	RADIAN B	RADIAN B MUSCLE RUB	MENTHOL	MENTHOL 2.54%W/W;CAMPHOR 1.43%W/W;CAPSICUM OLEORESIN 0.005%W/W;METHYL SALICYLATE 0.42%W/W	CREAM		Relief of rheumatic pains and mild muscle pains.
4292	RAFASSAL	RAFASSAL 1.5 GRAM GRANULES	MESALAZINE (5 - AMINOSALICYLIC ACID)	MESALAZINE (5 - AMINOSALICYLIC ACID) 1.5G	GRANULES	RECIEPT	For the treatment of acute episodes and the maintenance of remission of ulcerative colitis.
4289	RAFASSAL	RAFASSAL 1 GRAM GRANULES	MESALAZINE (5 - AMINOSALICYLIC ACID)	MESALAZINE (5 - AMINOSALICYLIC ACID) 1G	GRANULES	RECIEPT	For the treatment of acute episodes and the maintenance of remission of ulcerative colitis.
4295	RAFASSAL	RAFASSAL 3 GRAM GRANULES	MESALAZINE (5 - AMINOSALICYLIC ACID)	MESALAZINE (5 - AMINOSALICYLIC ACID) 3G	GRANULES	RECIEPT	For the treatment of acute episodes and the maintenance of remission of ulcerative colitis.
4286	RAFASSAL	RAFASSAL 1 GRAM ENEMA	MESALAZINE	MESALAZINE 1 G 5 - Aminosalicylic acid	ENEMA	RECIEPT	Treatment and prevention of ulcerative colitis and Crohn's disease.
4288	RAFASSAL	RAFASSAL 1 GRAM CAPLETS	MESALAZINE	MESALAZINE 1000.0MG 5 - Aminosalicylic acid	TABLETS	RECIEPT	Treatment and prevention of ulcerative colitis and Crohn's disease.
4287	RAFASSAL	RAFASSAL 1 GRAM SUPPOSITORIES	MESALAZINE	MESALAZINE 1000MG 5 - Aminosalicylic acid	SUPPOSITORIES	RECIEPT	Treatment and prevention of ulcerative colitis and Crohn's disease.
4297	RAFASSAL	RAFASSAL 4 GRAM ENEMA	MESALAZINE	MESALAZINE 4G/60 G 5 - Aminosalicylic acid	ENEMA	RECIEPT	Treatment and prevention of ulcerative colitis and Crohn's disease.
4298	RAFASSAL	RAFASSAL 500 MG CAPLETS	MESALAZINE	MESALAZINE 500MG 5 - Aminosalicylic acid	TABLETS	RECIEPT	Treatment and prevention of ulcerative colitis and Crohn's disease.
4299	RAFASSAL	RAFASSAL 500 MG SUPPOSITORIES	MESALAZINE	MESALAZINE 500MG 5 - Aminosalicylic acid	SUPPOSITORIES	RECIEPT	Treatment and prevention of ulcerative colitis and Crohn's disease.
4300	RAFATHRICIN WITH LIDOCAINE	RAFATHRICIN WITH LIDOCAINE	TYROTHRICIN	TYROTHRICIN 1MG;LIDOCAINE AS HYDROCHLORIDE 1MG	TABLETS	RECIEPT	For the fast relief of severe sore throat. Relief of mouth and throat infections.
4301	RALOXIFENE	RALOXIFENE TEVA	RALOXIFENE HYDROCHLORIDE	RALOXIFENE HYDROCHLORIDE 60MG	TABLETS	RECIEPT	- Treatment of osteoporosis in post menopausal women. - Prevention of osteoporosis in post menopausal women. - Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. - Reduction in risk of invasive breast cancer in post
4308	RAMIPRIL	RAMIPRIL TEVA 10 MG	RAMIPRIL	RAMIPRIL 10MG	TABLETS	RECIEPT	Hypertension . Congestive heart failure . Reduction of mortality in patients after MI with left ventricular dysfunction For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) high total cholesterol (>5.2 mmol/L) low HDL (LESS THAN 0.9 mmol PER L) current smoker known microalbuminuria clinical evidence of previous vascular disease. Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g A day.
4310	RAMIPRIL	RAMIPRIL TEVA 2.5 MG	RAMIPRIL	RAMIPRIL 2.5MG	TABLETS	RECIEPT	Hypertension congestive heart failure reduction of mortality in patients after MI with left ventricular dysfunction For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : - hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) - high total cholesterol (>5.2 mmol/L) - low HDL ( LESS THAN 0.9 mmol/L) - current smoker - known microalbuminuria - clinical evidence of previous vascular disease. Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
4304	RAMIPRIL	RAMIPRIL PLUS TEVA 2.5 MG/12.5 MG	RAMIPRIL	RAMIPRIL 2.5MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	Essential hypertension. Ramipril plus is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.
4311	RAMIPRIL	RAMIPRIL TEVA 5 MG	RAMIPRIL	RAMIPRIL 5MG	TABLETS	RECIEPT	- Hypertension - Congestive heart failure - Reduction of mortality in patients after MI with left ventricular dysfunction For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patient
4306	RAMIPRIL	RAMIPRIL PLUS TEVA 5 MG/25 MG	RAMIPRIL	RAMIPRIL 5MG;HYDROCHLOROTHIAZIDE 25MG	TABLETS	RECIEPT	Essential hypertension. Ramipril plus is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.
4313	RAMITENS	RAMITENS 10	RAMIPRIL	RAMIPRIL 10MG	CAPSULES	RECIEPT	Hypertension congestive heart failure reduction of mortality in patients after MI with left ventricular dysfunction. For reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : - hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) - high total cholesterol (>5.2 mmol/L) - low HDL ( less than 0.9 mmol/L) - current smoker - known microalbuminuria - clinical evidence of previous vascular disease. Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
4314	RAPAMUNE	RAPAMUNE 1 MG TABLETS	SIROLIMUS	SIROLIMUS 1MG	TABLETS	RECIEPT	Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.
4316	RAPAMUNE	RAPAMUNE SOLUTION	SIROLIMUS	SIROLIMUS 1MG/ML	SOLUTION	RECIEPT	Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.
4318	RASAGILINE	RASAGILINE - TRIMA	RASAGILINE AS MESYLATE	RASAGILINE AS MESYLATE 1MG	TABLETS	RECIEPT	Treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
4319	RAVICTI	RAVICTI 1.1 G/ML	GLYCEROL PHENYLBUTYRATE	GLYCEROL PHENYLBUTYRATE 1.1G/1ML	LIQUID	RECIEPT	RAVICTI is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).
4327	RAXONE IDEBENONE	RAXONE IDEBENONE	IDEBENONE	IDEBENONE 150MG	TABLETS	RECIEPT	Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON)
4331	RAZALAX	RAZALAX CHILDREN 2.25 GR 6ENEMA	GLYCEROL	GLYCEROL 2.25 GR	ENEMA		For relief of constipation.
4330	RAZALAX	RAZALAX CHILDREN	GLYCEROL	GLYCEROL 2.25G	ENEMA		For relief of constipation.
4328	RAZALAX	RAZALAX ADULT	GLYCEROL	GLYCEROL 6.75G	ENEMA		For relief of constipation.
4329	RAZALAX	RAZALAX ADULT 6 ENEMA	GLYCEROL	GLYCEROL 6.75G	ENEMA		For relief of constipation.
4332	RAZAMOL	RAZAMOL 500 MG 10 SUPP	PARACETAMOL	PARACETAMOL 500MG	SUPPOSITORIES		Analgesic and antipyretic.
4333	RAZAMOL	RAZAMOL 500 MG SUPPOSITORIES	PARACETAMOL	PARACETAMOL 500MG	SUPPOSITORIES		Analgesic and antipyretic.
4334	RAZIN	RAZIN	PHENTERMINE AS RESINATE	PHENTERMINE AS RESINATE 15MG	CAPSULES	RECIEPT	For the treatment of severe obesity that has not responded to an appropriate diet - a minimal body mass index of 30 kg/m2 is required.
4335	RBC-KIT LABELING WITH TC-99M	RBC-KIT FOR LABELING WITH TC-99m	CALCIUM GLUCOHEPTONATE	CALCIUM GLUCOHEPTONATE 200.00MG;STANNOUS CHLORIDE 0.10MG	POWDER		Blood pool imaging. Assessment of myocardial perfusion first pass and multiple gated acquisition study . Delineation of lesions affecting blood flow. Localization and evaluation of space-occupying lesions of the liver. Localization and evaluation of internal bleeding. Evaluation of varicose veins and follow-up after treatment . Evaluation of splenic function
4336	REAGILA	REAGILA 1.5 MG	CARIPRAZINE AS HYDROCHLORIDE	CARIPRAZINE AS HYDROCHLORIDE 1.5MG	CAPSULES	RECIEPT	For the treatment of schizophrenia in adult patients
4337	REAGILA	REAGILA 3 MG	CARIPRAZINE AS HYDROCHLORIDE	CARIPRAZINE AS HYDROCHLORIDE 3MG	CAPSULES	RECIEPT	For the treatment of schizophrenia in adult patients
4338	REAGILA	REAGILA 4.5 MG	CARIPRAZINE AS HYDROCHLORIDE	CARIPRAZINE AS HYDROCHLORIDE 4.5MG	CAPSULES	RECIEPT	For the treatment of schizophrenia in adult patients
4339	REAGILA	REAGILA 6 MG	CARIPRAZINE AS HYDROCHLORIDE	CARIPRAZINE AS HYDROCHLORIDE 6MG	CAPSULES	RECIEPT	For the treatment of schizophrenia in adult patients
4340	REBETOL	REBETOL	RIBAVIRIN	RIBAVIRIN 200MG	CAPSULES	RECIEPT	Tritherapy: Rebetol in combination with boceprevir and peginterferon alfa-2b is indicated for the treatment of chronic hepatitis C (CHC) genotype1 infection in adults patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy. Bitherapy: Rebetol is indicated for the treatment of chronic hepatitis C virus infection in adults and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b .Rebetol monotherapy must not be used. There is no safety or efficacy information on the use of Rebetol with other forms of interferon (i.e., not alfa-2b). Previously untreated (naïve) patients Adult patients (18 years of age or older): Rebetol is indicated for: • tritherapy- in combination with peginterferon alfa-2b and boceprevir for the treatment of adult patients with chronic hepatitis C genotype1 infection with compensated liver disease. • bitherapy- in combination with interferon alfa-2b or peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis C, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid (HCV-RNA). • bitherapy- for the treatment of CHC infection in combination with peginterferon alfa-2b for patients with compensated cirrhosis and/or clinically stable HIV co-infection. • Previously treated patients Adult patients: Rebetol is indicated for: • tritherapy- in combination with peginterferon alfa-2b and boceprevir for the treatment of adult patients having CHC genotype 1 infection with compensated liver disease. • bitherapy- in combination with peginterferon alfa-2b, for the treatment of patients with chronic hepatitis C who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin. • bitherapy-in combination with interferon alfa-2b, for the treatment of patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed.
4341	REBIF	REBIF 22 MCG	INTERFERON BETA	INTERFERON BETA 1A 22MCG/0.5ML	SOLUTION	RECIEPT	Rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. Efficacy of Rebif in chronic progressive multiple sclerosis has not been established.
4342	REBIF	REBIF 44 MCG	INTERFERON BETA	INTERFERON BETA 1A 44MCG/0.5ML	SOLUTION	RECIEPT	Rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. Efficacy of Rebif in chronic progressive multiplbe sclerosis has not been established. Rebif is indicated for the treatment of patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.These patients should have MRI findings which are compatible with the diagnosis of multiple sclerosis.
4343	RECITAL	RECITAL 20	CITALOPRAM AS HYDROBROMIDE	CITALOPRAM AS HYDROBROMIDE 20MG	TABLETS	RECIEPT	For the treatment of states of depression or panic disorder.
4345	RECITAL	RECITAL 40	CITALOPRAM AS HYDROBROMIDE	CITALOPRAM AS HYDROBROMIDE 40MG	TABLETS	RECIEPT	For the treatment of states of depression or panic disorder.
4347	RECORMON	RECORMON 10000 IU	EPOETIN BETA	EPOETIN BETA 10000 IU/0.6ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. Treatment of symptomatic renal anemia in patients not yet undergoing dialysis. Increasing the yield of autologous blood from patients in a pre-donation program. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Treatment of anemia in adult patients with solid tumors and treated with chemotherapy. Treatment of anemia in adult patients with multiple myeloma low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * Deficiency is defined as an inappropriately low serum erythropoietin level in relation to the degree of anemia.
4348	RECORMON	RECORMON 30000 IU	EPOETIN BETA	EPOETIN BETA 30000 IU/0.6ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. Treatment of symptomatic renal anemia in patients not yet undergoing dialysis. Increasing the yield of autologous blood from patients in a pre-donation program. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Treatment of anemia in adult patients with solid tumors and treated with chemotherapy . Treatment of anemia in adult patients with multiple myeloma low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency and are receiving anti-tumor therapy. Deficiency is defined as an inappropriately low serum erythropoietin level in relation to the degree of anemia.
4349	RECORMON	RECORMON 4000 IU	EPOETIN BETA	EPOETIN BETA 4000 IU/0.3ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. Treatment of symptomatic renal anemia in patients not yet undergoing dialysis. Increasing the yield of autologous blood from patients in a pre-donation program. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). Treatment of anemia in adult patients with multiple myeloma low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency and are receiving anti-tumor therapy.
4350	RECORMON	RECORMON 5000 IU	EPOETIN BETA	EPOETIN BETA 5000 IU/0.3ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. Treatment of symptomatic renal anemia in patients not yet undergoing dialysis. Increasing the yield of autologous blood from patients in a pre-donation program. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). Treatment of anemia in adult patients with multiple myeloma low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * Deficiency is defined as an inappropriately low serum erythropoietin level in relation to the degree of anemia.
4351	RECORMON	RECORMON 6000 IU	EPOETIN BETA	EPOETIN BETA 6000 IU/0.3ML	SOLUTION	RECIEPT	Treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. Treatment of symptomatic renal anemia in patients not yet undergoing dialysis. Increasing the yield of autologous blood from patients in a pre-donation program. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). Treatment of anemia in adult patients with multiple myeloma low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency and are receiving anti-tumor therapy.
4352	RECTOGESIC	RECTOGESIC	GLYCERYL TRINITRATE	GLYCERYL TRINITRATE 0.4%	OINTMENT	RECIEPT	For relief of pain associated with chronic anal fissure. In the clinical development of the drug a modest effect has shown on improvement in average daily pain intensity.
4354	RECTOZORIN	RECTOZORIN OINT 50GR	BISMUTH OXYCHLORIDE	BISMUTH OXYCHLORIDE 8%;THYMOL BIIODIDE 2%;ZINC OXIDE 10%;BENZOCAINE 4%	OINTMENT	RECIEPT	Symptomatic relief of pain and discomfort in irritated anorectal tissues in: hemorrhoids, proctitis, papillitis, cryptitis, fissures and following anorectal surgery.
4357	RECTOZORIN	RECTOZORIN SUPPOSITORIES	BISMUTH SUBGALLATE	BISMUTH SUBGALLATE 100MG;BENZOCAINE 100MG;MENTHOL 5MG;TANNIC ACID 20MG;THYMOL BIIODIDE 150MG;ZINC OXIDE 100MG	SUPPOSITORIES	RECIEPT	Symptomatic relief of pain and discomfort in hemorrhoids.
4353	RECTOZORIN	RECTOZORIN 12 SUPP	BISMUTH SUBGALLATE	BISMUTH SUBGALLATE 100MG;THYMOL BIIODIDE 150MG;ZINC OXIDE 100MG;BENZOCAINE 100MG	SUPPOSITORIES	RECIEPT	Symptomatic relief of pain and discomfort in hemorrhoids.
4355	RECTOZORIN	RECTOZORIN OINTMENT	ZINC OXIDE	ZINC OXIDE 10%;BENZOCAINE 4%;MENTHOL 0.25%;BISMUTH OXYCHLORIDE 8%;THYMOL BIIODIDE 2%	OINTMENT	RECIEPT	Symptomatic relief of pain and discomfort in irritated anorectal tissues in: hemorrhoids, proctitis, papillitis, cryptitis, fissures and following anorectal surgery.
4358	REGAINE	REGAINE 5 %	MINOXIDIL	MINOXIDIL 5%	SOLUTION	RECIEPT	Hair regrowth treatment for men.
4359	REGAINE	REGAINE FOAM 5%	MINOXIDIL	MINOXIDIL 5%W/W	FOAM	RECIEPT	For alopecia androgenetica in men
4361	REGULAX	REGULAX 250gr	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350	POWDER		Treatment of constipation.
4360	REGULAX	REGULAX	POLYETHYLENE GLYCOL	POLYETHYLENE GLYCOL 3350 99.973%W/W	POWDER		Treatment of constipation.
4363	REKAMID	REKAMID 2MG 10TAB	LOPERAMIDE HCL	LOPERAMIDE HCL 2MG	TABLETS		Control and symptomatic relief of acute diarrhea.
4364	REKAMIDE	REKAMIDE	LOPERAMIDE HYDROCHLORIDE	LOPERAMIDE HYDROCHLORIDE 2MG	TABLETS	RECIEPT	Control and symptomatic relief of acute diarrhea.
4365	REKOD	REKOD TABLETS	CODEINE PHOSPHATE	CODEINE PHOSPHATE 20MG	TABLETS	RECIEPT	Indicated as an analgesic for the relief of mild to moderate pain. For the symptomatic relief of unproductive cough
4366	REKOVELLE	REKOVELLE 12	FOLLITROPIN DELTA	FOLLITROPIN DELTA 12MCG/0.36ML	SOLUTION	RECIEPT	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. There is no clinical trial experience with Rekovelle in the long GnRH agonist protocol
4367	REKOVELLE	REKOVELLE 36	FOLLITROPIN DELTA	FOLLITROPIN DELTA 36MCG/1.08ML	SOLUTION	RECIEPT	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. There is no clinical trial experience with Rekovelle in the long GnRH agonist protocol
4368	REKOVELLE	REKOVELLE 72	FOLLITROPIN DELTA	FOLLITROPIN DELTA 72MCG/2.16ML	SOLUTION	RECIEPT	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. There is no clinical trial experience with Rekovelle in the long GnRH agonist protocol
4369	RELAXINE	RELAXINE	VALERIAN DRY EXTRACT	VALERIAN DRY EXTRACT 500MG	TABLETS		Sedative in states of tension, nervousness and insomnia.
4370	RELAXINE	RELAXINE 15TAB	VALERIAN DRY EXTRACT	VALERIAN DRY EXTRACT 500MG	TABLETS		Sedative in states of tension, nervousness and insomnia.
4371	RELENZA	RELENZA	ZANAMIVIR MICRONIZED	ZANAMIVIR MICRONIZED 5MG	POWDER	RECIEPT	Zanamivir is indicated for the treatment of both uncomplicated acute illness due to influenza A and B virus in adults and adolescents (> or = 12 years) who have been symptomatic for no more than 48 hours and pediatric patients 7 years and older who have been symptomatic for no more than 36 hours.
4373	RELERT	RELERT 20 MG	ELETRIPTAN HYDROBROMIDE	ELETRIPTAN HYDROBROMIDE 24.242MG	TABLETS	RECIEPT	Acute treatment of the headache phase of migraine attacks, with or without aura.
4375	RELERT	RELERT 40 MG	ELETRIPTAN HYDROBROMIDE	ELETRIPTAN HYDROBROMIDE 48.485MG	TABLETS	RECIEPT	Acute treatment of the headache phase of migraine attacks, with or without aura.
4377	RELERT	RELERT 80 MG	ELETRIPTAN HYDROBROMIDE	ELETRIPTAN HYDROBROMIDE 96.97MG	TABLETS	RECIEPT	Acute treatment of the headache phase of migraine attacks, with or without aura.
4379	RELESTAT	RELESTAT	EPINASTINE HYDROCHLORIDE	EPINASTINE HYDROCHLORIDE 0.05%W/V	SOLUTION	RECIEPT	Treatment of the symptoms of seasonal allergic conjunctivitis.
1906	RELIEF	EYE RELIEF 10ML	TETRAHYDROZOLINE HCL	TETRAHYDROZOLINE HCL 0.05%	DROPS		For relief in cases of redness in the eye as a result of irritation, caused by various materials such as dust, smoke, plants, etc.
1905	RELIEF	EYE RELIEF	TETRAHYDROZOLINE HYDROCHLORIDE	TETRAHYDROZOLINE HYDROCHLORIDE 0.05%W/V	DROPS		For relief in cases of redness in the eye as a result of irritation, caused by various materials such as dust, smoke, plants, etc.
5059	RELIEF DUAL	SWISS RELIEF DUAL RELEASE	DICLOFENAC SODIUM	DICLOFENAC SODIUM 75MG	CAPSULES	RECIEPT	As a non-steroidal anti-inflamatory analgesic in symptomatic management of rheumatoid arthritis osteoarthritis and ankylosying spondylitis acute musculo-skeletal disorders such as periarthritis tendenitis tensynovitis bursitis sprains strains and dislocations relief of pain in fractures low back pain acute gout psoriatic arthropathy. In the management of pain and inflammation associated with orthopaedic dental and minor surgery.
5061	RELIEF GEL	SWISS RELIEF SPRAY GEL 12.50GR	DICLOFENAC SODIUM	DICLOFENAC SODIUM 4%	GEL	RECIEPT	For the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures.
5062	RELIEF GEL	SWISS RELIEF SPRAY GEL 25GR	DICLOFENAC SODIUM	DICLOFENAC SODIUM 4%	GEL	RECIEPT	For the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures.
5060	RELIEF GEL	SWISS RELIEF SPRAY GEL	DICLOFENAC SODIUM	DICLOFENAC SODIUM 4%W/W	SOLUTION	RECIEPT	For the local symptomatic relief of mild to moderate pain and inflammation following acute blunt trauma of small and medium-sized joints and periarticular structures.
4380	RELVAR ELLIPTA	RELVAR ELLIPTA 184/22 MCG	VILANTEROL	VILANTEROL 22MCG;FLUTICASONE FUROATE 184MCG	POWDER	RECIEPT	Asthma Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonists. • patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.
4381	RELVAR ELLIPTA	RELVAR ELLIPTA 92/22 MCG	VILANTEROL	VILANTEROL 22MCG;FLUTICASONE FUROATE 92MCG	POWDER	RECIEPT	Asthma Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonists. • patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist. COPD (Chronic Obstructive Pulmonary Disease) Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
4382	REMICADE	REMICADE	INFLIXIMAB	INFLIXIMAB 100.0MG/VIAL	POWDER	RECIEPT	- Adult : - Crohn's disease: Treatment of moderate to severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn
4383	REMIFENTANIL	REMIFENTANIL B.BRAUN 1 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 1MG	POWDER	RECIEPT	Remifentanil B.Braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Remifentanil B.Braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
4389	REMIFENTANIL	REMIFENTANIL BIOAVENIR 1 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 1MG	POWDER	RECIEPT	Remifentanil Bioavenir is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Remifentanil Bioavenir is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
4385	REMIFENTANIL	REMIFENTANIL B.BRAUN 2 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 2MG	POWDER	RECIEPT	Remifentanil B.Braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Remifentanil B.Braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
4390	REMIFENTANIL	REMIFENTANIL BIOAVENIR 2 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 2MG	POWDER	RECIEPT	Remifentanil Bioavenir is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Remifentanil Bioavenir is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
4387	REMIFENTANIL	REMIFENTANIL B.BRAUN 5 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 5MG	POWDER	RECIEPT	Remifentanil B.Braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Remifentanil B.Braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
4391	REMIFENTANIL	REMIFENTANIL BIOAVENIR 5 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 5MG	POWDER	RECIEPT	Remifentanil Bioavenir is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Remifentanil Bioavenir is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
4392	REMINYL PRC	REMINYL PRC 16 MG	GALANTAMINE AS HYDROBROMIDE	GALANTAMINE AS HYDROBROMIDE 16MG	CAPSULES	RECIEPT	Reminyl is indicated for the smptomatic treatment of mild to moderately severe dementia of the Alzheimer type.
4393	REMINYL PRC	REMINYL PRC 24 MG	GALANTAMINE AS HYDROBROMIDE	GALANTAMINE AS HYDROBROMIDE 24MG	CAPSULES	RECIEPT	Reminyl is indicated for the smptomatic treatment of mild to moderately severe dementia of the Alzheimer type.
4394	REMINYL PRC	REMINYL PRC 8 MG	GALANTAMINE AS HYDROBROMIDE	GALANTAMINE AS HYDROBROMIDE 8MG	CAPSULES	RECIEPT	Reminyl is indicated for the smptomatic treatment of mild to moderately severe dementia of the Alzheimer type.
4395	REMODULIN	REMODULIN 10 MG/ML	TREPROSTINIL AS SODIUM	TREPROSTINIL AS SODIUM 10MG/ML	SOLUTION	RECIEPT	Remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. Pulmonary hypertension associated with congenital systemic to pulmonary shunts.
4396	REMODULIN	REMODULIN 2.5 MG/ML	TREPROSTINIL AS SODIUM	TREPROSTINIL AS SODIUM 2.5MG/ML	SOLUTION	RECIEPT	Remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. Pulmonary hypertension associated with congenital systemic to pulmonary shunts.
4397	REMODULIN	REMODULIN 5 MG/ML	TREPROSTINIL AS SODIUM	TREPROSTINIL AS SODIUM 5MG/ML	SOLUTION	RECIEPT	Remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. Pulmonary hypertension associated with congenital systemic to pulmonary shunts.
4398	REMOTIV	REMOTIV 250	HYPERICI HERBA EXTRACTUM SICCUM	HYPERICI HERBA EXTRACTUM SICCUM 250MG	TABLETS	RECIEPT	Symptoms of mild to moderate depression including: dejected mood, mood lability, inner restlessness, anxiety, states of tension and the difficulty in falling asleep and sleeping through the night which is associated with these conditions. Treatment is recommended for up to 24 weeks.
4400	REMOTIV	REMOTIV 500	HYPERICI HERBA EXTRACTUM SICCUM	HYPERICI HERBA EXTRACTUM SICCUM 500MG	TABLETS	RECIEPT	Symptoms of mild to moderate depression including: dejected mood, mood lability, inner restlessness, anxiety, states of tension and the difficulty in falling asleep and sleeping through the night which is associated with these conditions. Treatment is recommended for up to 24 weeks.
4402	REMSIMA	REMSIMA 100 MG	INFLIXIMAB	INFLIXIMAB 100MG/VIAL	POWDER	RECIEPT	* Rheumatoid arthritis: Remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: • adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs),including methotrexate, has been inadequate. • adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X ray,has been demonstrated. * Ankylosing spondylitis: Remsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy. * Psoriatic arthritis: Remsima is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. * Remsima should be administered: • in combination with methotrexate • or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. Infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease. * Psoriasis: Remsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A (PUVA) * Adult Crohn’s disease Remsima is indicated for treatment : • of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. • treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy). * Ulcerative colitis • Remsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
4404	RENNIE	RENNIE ICE 48 TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 680MG;MAGNESIUM CARBONATE 80MG	TABLETS		Relief of hyperacidity and heartburn.
4406	RENNIE	RENNIE ORANGE 36TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 680MG;MAGNESIUM CARBONATE 80MG	TABLETS		Relief of hyperacidity and heartburn.
4408	RENNIE	RENNIE PEPPERMINT 48TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 680MG;MAGNESIUM CARBONATE 80MG	TABLETS		Relief of hyperacidity and heartburn.
4409	RENNIE	RENNIE PEPPERMINT 96TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 680MG;MAGNESIUM CARBONATE 80MG	TABLETS		Relief of hyperacidity and heartburn.
4403	RENNIE	RENNIE ICE	CALCIUM CARBONATE	CALCIUM CARBONATE 680MG;MAGNESIUM CARBONATE 80MG HEAVY	TABLETS		Relief of hyperacidity and heartburn.
4405	RENNIE	RENNIE ORANGE	CALCIUM CARBONATE	CALCIUM CARBONATE 680MG;MAGNESIUM CARBONATE 80MG HEAVY	TABLETS		Relief of hyperacidity and heartburn.
4407	RENNIE	RENNIE PEPPERMINT	CALCIUM CARBONATE	CALCIUM CARBONATE 680MG;MAGNESIUM CARBONATE 80MG HEAVY	TABLETS		Relief of hyperacidity and heartburn.
4410	RENVELA	RENVELA 2.4 G POWDER	SEVELAMER CARBONATE ANHYDROUS	SEVELAMER CARBONATE ANHYDROUS 2.4G/SACHET	POWDER	RECIEPT	For the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l. Should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
4411	RENVELA	RENVELA 800 MG TABLETS	SEVELAMER CARBONATE ANHYDROUS	SEVELAMER CARBONATE ANHYDROUS 800MG	TABLETS	RECIEPT	For the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l. Should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
4412	REOLIN	REOLIN EFFER 200MG 30TAB	ACETYLCYSTEINE	ACETYLCYSTEINE 200MG	TABLETS	RECIEPT	Mucolytic in respiratory tract disorders where reduction of sputum viscosity is required.
4413	REOLIN	REOLIN EFFERVESCENT TABLETS 200 MG	ACETYLCYSTEINE	ACETYLCYSTEINE 200MG	TABLETS	RECIEPT	Mucolytic in respiratory tract disorders where reduction of sputum viscosity is required.
4414	REPAGLINIDE	REPAGLINIDE TEVA 0.5 MG	REPAGLINIDE	REPAGLINIDE 0.5MG	TABLETS	RECIEPT	Treatment of type II diabetes.
4416	REPAGLINIDE	REPAGLINIDE TEVA 1 MG	REPAGLINIDE	REPAGLINIDE 1MG	TABLETS	RECIEPT	Treatment of type II diabetes.
4418	REPAGLINIDE	REPAGLINIDE TEVA 2 MG	REPAGLINIDE	REPAGLINIDE 2MG	TABLETS	RECIEPT	Treatment of type II diabetes.
4420	REPATHA	REPATHA	EVOLOCUMAB	EVOLOCUMAB 140MG/ML	SOLUTION	RECIEPT	Hypercholesterolaemia and mixed dyslipidaemia Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet: • in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Homozygous familial hypercholesterolaemia Repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies. Established atherosclerotic cardiovascular disease Repatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infraction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: • in combination with the maximum tolerated dose of a statin with or without other lipid lowering therapies or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
4421	REPHENIDATE	REPHENIDATE 10 MG	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Attention Deficit Hyperactivity Disorder (ADHD). Narcolepsy.
4422	REPLAGAL	REPLAGAL	AGALSIDASE ALFA	AGALSIDASE ALFA 1MG/ML	CONCENTRATE	RECIEPT	Replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alfa-galactosidase A deficiency).
4423	REPLENINE VF	REPLENINE - VF 1000	FACTOR IX	FACTOR IX 50IU/ML;FACTOR II 0.2IU/ML;FACTOR X 1IU/ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia B ( congenital factor IX deficiency).
4424	REPLENINE -VF	REPLENINE -VF 500	FACTOR IX	FACTOR IX 50IU/ML;FACTOR II 0.2IU/ML;FACTOR X 1IU/ML	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia B ( congenital factor IX deficiency).
4425	REQUIP MODUTAB	REQUIP MODUTAB 2 MG	ROPINIROLE AS HYDROCHLORIDE	ROPINIROLE AS HYDROCHLORIDE 2MG	TABLETS	RECIEPT	Ropinirole is indicated for the treatment of Parkinson's disease. Ropinirole is effective as early therapy in patients requiring dopaminergic therapy. As adjunctive treatment to L-dopa, ropinirole enhances the efficacy of L-dopa, including control of careton-offcaret fluctuations and caretend of dosecaret effects associated with chronic L-dopa therapy and permits reduction in daily L-dopa dose.
4426	REQUIP MODUTAB	REQUIP MODUTAB 4 MG	ROPINIROLE AS HYDROCHLORIDE	ROPINIROLE AS HYDROCHLORIDE 4MG	TABLETS	RECIEPT	Ropinirole is indicated for the treatment of Parkinson's disease. Ropinirole is effective as early therapy in patients requiring dopaminergic therapy. As adjunctive treatment to L-dopa, ropinirole enhances the efficacy of L-dopa, including control of careton-offcaret fluctuations and caretend of dosecaret effects associated with chronic L-dopa therapy and permits reduction in daily L-dopa dose.
4427	REQUIP MODUTAB	REQUIP MODUTAB 8 MG	ROPINIROLE AS HYDROCHLORIDE	ROPINIROLE AS HYDROCHLORIDE 8MG	TABLETS	RECIEPT	Ropinirole is indicated for the treatment of Parkinson's disease. Ropinirole is effective as early therapy in patients requiring dopaminergic therapy. As adjunctive treatment to L-dopa, ropinirole enhances the efficacy of L-dopa, including control of careton-offcaret fluctuations and caretend of dosecaret effects associated with chronic L-dopa therapy and permits reduction in daily L-dopa dose.
4429	RESOLOR	RESOLOR 1 MG	PRUCALOPRIDE AS SUCCINATE	PRUCALOPRIDE AS SUCCINATE 1MG	TABLETS	RECIEPT	Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief
4430	RESOLOR	RESOLOR 2 MG	PRUCALOPRIDE AS SUCCINATE	PRUCALOPRIDE AS SUCCINATE 2MG	TABLETS	RECIEPT	Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief
4431	RESPRIM	RESPRIM	SULPHAMETHOXAZOLE	SULPHAMETHOXAZOLE 200MG/5ML;TRIMETHOPRIM 40MG/5ML	SUSPENSION	RECIEPT	Treatment of urinary tract infections due to susceptible strains of the following organisms: - Escherichia coli - Klebsiella - Enterobacter - Proteus mirabilis - Proteus vulgaris - Proteus morganii. Treatment of acute otitis media in children due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. To date there are limited data available as to the safety of repeated use of Resprim in infants under 2 years of age. Resprim is not indicated for prophylactic or prolonged administration in otitis media at any age. Treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Haemophilus influenzae or Streptococcus pneumoniae. Treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei. Resprim is also indicated in the treatment of documented Pneumocystis carinii pneumonitis.
4432	RESTASIS	RESTASIS	CICLOSPORIN	CICLOSPORIN 0.05%	LIQUID	RECIEPT	To increase tear production in patients whose tear production is presumed to be supressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
4433	RESYL	RESYL SYRUP	GUAIFENESIN	GUAIFENESIN 100MG/5ML	SYRUP		Expectorant, relieves cough.
4434	RESYL	RESYL SYRUP 2% 100ML	GUAIPHENESIN	GUAIPHENESIN 100MG/5ML	SYRUP		Expectorant, relieves cough.
4435	RET-AVIT	RET-AVIT CREAM 0.025 %	TRETINOIN	TRETINOIN 0.025%W/W	CREAM	RECIEPT	Treatment of acne vulgaris.
4437	RET-AVIT	RET-AVIT GEL 0.025 %	TRETINOIN	TRETINOIN 0.025%W/W	GEL	RECIEPT	Treatment of acne vulgaris.
4436	RET-AVIT	RET-AVIT CREAM 0.05 %	TRETINOIN	TRETINOIN 0.05%W/W	CREAM	RECIEPT	Acne vulgaris.
4438	RET-AVIT	RET-AVIT GEL 0.05 %	TRETINOIN	TRETINOIN 0.05%W/W	GEL	RECIEPT	Treatment acne vulgaris.
4439	RETROVIR	RETROVIR CAPSULES 100 MG	ZIDOVUDINE	ZIDOVUDINE 100MG	CAPSULES	RECIEPT	Retrovir oral formulations are indicated in anti-retroviral combination therapy for Human Immunodeficiency Virus (HIV) infected adults and children. Retrovir chemoprophylaxis is indicated for use in HIV-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal HIV transmission and for primary prophylaxis of HIV infection in newborn infants.
4443	RETROVIR	RETROVIR ORAL SOLUTION	ZIDOVUDINE	ZIDOVUDINE 10MG/1ML	SOLUTION	RECIEPT	Retrovir oral formulations are indicated in anti-retroviral combination therapy for Human Immunodeficiency Virus (HIV) infected adults and children. Retrovir chemoprophylaxis is indicated for use in HIV-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal HIV transmission and for primary prophylaxis of HIV infection in newborn infants.
4442	RETROVIR	RETROVIR IV FOR INFUSION	ZIDOVUDINE	ZIDOVUDINE 200MG/20ML	SOLUTION	RECIEPT	Retrovir IV for infusion is indicated for the short term management of serious manifestations of Human immunodeficiency Virus (HIV) infection in patients with Acquired Immuno Deficiency Syndrome (AIDS) or AIDS who are unable to take Retrovir oral formulations. Retrovir chemoprophylaxis, is indicated for use in HIV-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal HIV transmission and for primary prophylaxis of HIV infection in newborn infants. Retrovir I.V. should only be used when oral treatment is not possible (except during labour and delivery).
4440	RETROVIR	RETROVIR CAPSULES 250 MG	ZIDOVUDINE	ZIDOVUDINE 250MG	CAPSULES	RECIEPT	Retrovir oral formulations are indicated in anti-retroviral combination therapy for Human Immunodeficiency Virus (HIV) infected adults and children. Retrovir chemoprophylaxis is indicated for use in HIV-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal HIV transmission and for primary prophylaxis of HIV infection in newborn infants.
4444	REVATIO	REVATIO	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 20MG	TABLETS	RECIEPT	For adults > 18 years: Treatment of primary pulmonary hypertension (PPH) pulmonary hypertension (PH) associated with connective tissue disease (CTD) or PH following surgical repair at least 5 years previously of atrial septal defect (ASD) ventricular septal defect (VSD) patent ductus arteriosus (PDA) or aorto-pulmonary window.
4445	REVLIMID	REVLIMID 10 MG	LENALIDOMIDE	LENALIDOMIDE 10MG	CAPSULES	RECIEPT	Multiple Myeloma Revlimid is indicated for: • The maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation. • previously untreated multiple myeloma in adult patients who are not eligible for transplant. • in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy. Myelodysplastic Syndromes REVLIMID is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid 7.5 mg is not indicated for treatment in MDS. Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
4449	REVLIMID	REVLIMID 15 MG	LENALIDOMIDE	LENALIDOMIDE 15MG	CAPSULES	RECIEPT	Multiple Myeloma Revlimid is indicated for: • The maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation. • previously untreated multiple myeloma in adult patients who are not eligible for transplant. • in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy. Myelodysplastic Syndromes REVLIMID is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid 7.5 mg is not indicated for treatment in MDS. Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
4453	REVLIMID	REVLIMID 2.5 MG	LENALIDOMIDE	LENALIDOMIDE 2.5MG	CAPSULES	RECIEPT	Multiple Myeloma Revlimid is indicated for: • The maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation. • previously untreated multiple myeloma in adult patients who are not eligible for transplant. • in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy. Myelodysplastic Syndromes REVLIMID is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid 7.5 mg is not indicated for treatment in MDS. Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
4455	REVLIMID	REVLIMID 20 MG	LENALIDOMIDE	LENALIDOMIDE 20MG	CAPSULES	RECIEPT	Multiple Myeloma Revlimid is indicated for: • The maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation. • previously untreated multiple myeloma in adult patients who are not eligible for transplant. • in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy. Myelodysplastic Syndromes REVLIMID is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid 7.5 mg is not indicated for treatment in MDS. Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
4458	REVLIMID	REVLIMID 25 MG	LENALIDOMIDE	LENALIDOMIDE 25MG	CAPSULES	RECIEPT	Multiple Myeloma Revlimid is indicated for: • The maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation. • previously untreated multiple myeloma in adult patients who are not eligible for transplant. • in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy. Myelodysplastic Syndromes REVLIMID is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid 7.5 mg is not indicated for treatment in MDS. Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
4462	REVLIMID	REVLIMID 5 MG	LENALIDOMIDE	LENALIDOMIDE 5MG	CAPSULES	RECIEPT	Multiple Myeloma Revlimid is indicated for: • The maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation. • previously untreated multiple myeloma in adult patients who are not eligible for transplant. • in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy. Myelodysplastic Syndromes REVLIMID is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid 7.5 mg is not indicated for treatment in MDS. Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
4466	REVLIMID	REVLIMID 7.5 MG	LENALIDOMIDE	LENALIDOMIDE 7.5MG	CAPSULES	RECIEPT	Multiple Myeloma Revlimid is indicated for: • The maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation. • previously untreated multiple myeloma in adult patients who are not eligible for transplant. • in combination with dexamethasone treatment of multiple myeloma patients who have received at least one prior therapy. Myelodysplastic Syndromes REVLIMID is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid 7.5 mg is not indicated for treatment in MDS. Mantle Cell Lymphoma REVLIMID is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
4468	REVOLADE	REVOLADE 25 MG	ELTROMBOPAG AS OLAMINE	ELTROMBOPAG AS OLAMINE 25MG	TABLETS	RECIEPT	Revolade is indicated for the treatment of patients aged 6 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) Revolade is indicated for the treatment of adult patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy. Revolade is indicated for the treatment of thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.
4469	REVOLADE	REVOLADE 50 MG	ELTROMBOPAG AS OLAMINE	ELTROMBOPAG AS OLAMINE 50MG	TABLETS	RECIEPT	Revolade is indicated for the treatment of patients aged 6 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) Revolade is indicated for the treatment of adult patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy. Revolade is indicated for the treatment of thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.
4472	REXTOL	REXTOL 5 MCG/ML	PARICALCITOL	PARICALCITOL 5MCG/1ML	SOLUTION	RECIEPT	Rextol 5 mcg/ml is indicated for the prevention and treatment of secondary hyperparathyrodism in patients with chronic renal failure who are undergoing haemodialysis.
4473	REXULTI	REXULTI 0.5 MG	BREXPIPRAZOLE	BREXPIPRAZOLE 0.5MG	TABLETS	RECIEPT	REXULTI is indicated in adults: - As adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) - For treatment of schizophrenia
4474	REXULTI	REXULTI 1 MG	BREXPIPRAZOLE	BREXPIPRAZOLE 1MG	TABLETS	RECIEPT	REXULTI is indicated in adults: - As adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) - For treatment of schizophrenia
4475	REXULTI	REXULTI 2 MG	BREXPIPRAZOLE	BREXPIPRAZOLE 2MG	TABLETS	RECIEPT	REXULTI is indicated in adults: - As adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) - For treatment of schizophrenia
4476	REXULTI	REXULTI 3 MG	BREXPIPRAZOLE	BREXPIPRAZOLE 3MG	TABLETS	RECIEPT	REXULTI is indicated in adults: - As adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) - For treatment of schizophrenia
4477	REXULTI	REXULTI 4 MG	BREXPIPRAZOLE	BREXPIPRAZOLE 4MG	TABLETS	RECIEPT	REXULTI is indicated in adults: - As adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) - For treatment of schizophrenia
4478	REYATAZ	REYATAZ 150 MG	ATAZANAVIR AS SULFATE	ATAZANAVIR AS SULFATE 150MG	CAPSULES	RECIEPT	Reyataz is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
4479	REYATAZ	REYATAZ 200 MG	ATAZANAVIR AS SULFATE	ATAZANAVIR AS SULFATE 200MG	CAPSULES	RECIEPT	Reyataz is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
4480	REYATAZ	REYATAZ 300 MG	ATAZANAVIR AS SULFATE	ATAZANAVIR AS SULFATE 300MG	CAPSULES	RECIEPT	Reyataz is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
4481	REZOLSTA	REZOLSTA	COBICISTATE	COBICISTATE 150MG;DARUNAVIR AS ETHANOLATE 800MG	TABLETS	RECIEPT	REZOLSTA is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV 1) infection in treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions (V11i, V32i, L33F, i47V, i50V, i54L, i54M, T74P, L76V, i84V, L89V).
4484	RHINOCLIR	RHINOCLIR	OXYMETAZOLINE HYDROCHLORIDE	OXYMETAZOLINE HYDROCHLORIDE 0.05%	SOLUTION		Relief of nasal congestion, which is a result of common colds, sinusitis, hay fever or allergies of the upper respiratory system.
4485	RHINOLAST	RHINOLAST	AZELASTINE HYDROCHLORIDE	AZELASTINE HYDROCHLORIDE 0.1%W/V	SOLUTION	RECIEPT	Treatment of seasonal allergic rhinitis and perennial allergic rhinitis for adults and children 6 years and older.
4488	RHOPHYLAC	RHOPHYLAC 300	ANTI-D IMMUNOGLOBULINS	ANTI-D IMMUNOGLOBULINS 300MCG/2ML	SOLUTION	RECIEPT	Prophylaxis of Rh (D) immunisation in Rh (D)-negative women: Anti-D immune globulin is administered for the prevention of Rh (D) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. Treatment is not necessary when it is assured that the child or the father are Rh (D)- negative. Criteria for a rhesus-incompatible pregnancy and the administration of anti-D immune globulin are : a) the mother is Rh (D) -negative b) the child is either Rh (D)-positive Rh (D)weak - positive or its rhesus type is not known. Routine antepartum prophylaxis : To prevent Rh (D) immunisation due to spontaneous fetomaternal haemorrhage (FMH) during the last trimester of pregnancy. Postpartum prophylaxis To prevent Rh (D) immunisation of the Rh (D)-negative mother following delivery of a Rh (D)-positive child. Complications of pregnancy: Interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood sampling) or other intrauterine procedures (e.g. insertion of shunts embryo reduction) external version of the fetus and therapeutic abortion. Incidents during pregnancy such as antepartum haemorrhage spontaneous abortion ruptured tubal pregnancy ectopic pregnancy stillbirths intrauterine death and abdominal trauma. Treatment of Rh (D) -negative persons after incompatible transfusions of Rh (D)-positive blood or erythrocyte concentrate: Prevention of Rh (D) immunisation in Rh (D)-negative persons who for any reason have been given blood or blood components containing Rh (D)-positive red cells.
4489	RIBOMUSTIN	RIBOMUSTIN 100 MG	BENDAMUSTINE HYDROCHLORIDE	BENDAMUSTINE HYDROCHLORIDE 100MG	POWDER	RECIEPT	First-line of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotheraphy is not appropiate. Indolent non-Hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.
4491	RIBOMUSTIN	RIBOMUSTIN 25 MG	BENDAMUSTINE HYDROCHLORIDE	BENDAMUSTINE HYDROCHLORIDE 25MG	POWDER	RECIEPT	First-line of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotheraphy is not appropiate. Indolent non-Hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. Follicular non-Hodgkin’s lymphoma as first line treatment in combination with rituximab.
4495	RIBONE	RIBONE 35	RISEDRONIC ACID	RISEDRONIC ACID 35MG	TABLETS	RECIEPT	Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.
4493	RIBONE	RIBONE 150	RISEDRONIC ACID AS SODIUM	RISEDRONIC ACID AS SODIUM 150MG	TABLETS	RECIEPT	Treatment of postmenopausal osteoporosis. Prevention of postmenopausal osteoporosis.
4498	RIDAZIN	RIDAZIN 100 MG	THIORIDAZINE HYDROCHLORIDE	THIORIDAZINE HYDROCHLORIDE 100MG	TABLETS	RECIEPT	Ridazin is indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects. Thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.
4497	RIDAZIN	RIDAZIN 10 MG	THIORIDAZINE HYDROCHLORIDE	THIORIDAZINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Ridazin is indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects. Thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.
4499	RIDAZIN	RIDAZIN 25 MG	THIORIDAZINE HYDROCHLORIDE	THIORIDAZINE HYDROCHLORIDE 25MG	TABLETS	RECIEPT	Ridazin is indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects. Thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.
4500	RILUTEK	RILUTEK	RILUZOLE	RILUZOLE 50MG	TABLETS	RECIEPT	Rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).
4505	RIPALID	RIPALID 0.5 MG	REPAGLINIDE	REPAGLINIDE 0.5MG	TABLETS	RECIEPT	Ripalid is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Ripalid is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
4506	RIPALID	RIPALID 1 MG	REPAGLINIDE	REPAGLINIDE 1MG	TABLETS	RECIEPT	Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
4507	RIPALID	RIPALID 2 MG	REPAGLINIDE	REPAGLINIDE 2MG	TABLETS	RECIEPT	Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
4508	RIPOL	RIPOL 10 MG/ML	PROPOFOL	PROPOFOL 10MG/ML	EMULSION	RECIEPT	Ripol 10 mg/ml is a short-acting intravenous general anaesthetic for: - Induction and maintenance of general anaesthesia in adults and paediatric patients > 1 month of age - Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and paediatric patients > 1 month of age - Sedation of ventilated patients > 16 years of age in the intensive care unit
4509	RIPOL	RIPOL 20 MG/ML	PROPOFOL	PROPOFOL 20MG/ML	EMULSION	RECIEPT	Ripol 20 mg/ml is a short-acting intravenous general anaesthetic for: - Induction and maintenance of general anaesthesia in adults and paediatric patients > 3 years of age - Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and paediatric patients > 3 years of age - Sedation of ventilated patients > 16 years of age in the intensive care unit
4511	RISEDRONATE	RISEDRONATE TEVA 35 MG	RISEDRONIC ACID AS SODIUM	RISEDRONIC ACID AS SODIUM 35MG	TABLETS	RECIEPT	Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.
4510	RISEDRONATE S.K.	RISEDRONATE S.K.	RISEDRONIC ACID AS SODIUM HEMIPENTAHYDRATE	RISEDRONIC ACID AS SODIUM HEMIPENTAHYDRATE 150MG	TABLETS	RECIEPT	Treatment of postmenopausal osteoporosis. Prevention of postmenopausal osteoporosis.
4512	RISPERDAL	RISPERDAL 1 MG	RISPERIDONE	RISPERIDONE 1MG	TABLETS	RECIEPT	Risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperdal is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4513	RISPERDAL	RISPERDAL 1 MG/ML	RISPERIDONE	RISPERIDONE 1MG/1ML	SOLUTION	RECIEPT	Risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperdal is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4514	RISPERDAL	RISPERDAL 2 MG	RISPERIDONE	RISPERIDONE 2MG	TABLETS	RECIEPT	Risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperdal is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4515	RISPERDAL	RISPERDAL 3 MG	RISPERIDONE	RISPERIDONE 3MG	TABLETS	RECIEPT	Risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperdal is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4516	RISPERDAL	RISPERDAL 4 MG	RISPERIDONE	RISPERIDONE 4MG	TABLETS	RECIEPT	Risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperdal is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4517	RISPERDAL CONSTA	RISPERDAL CONSTA 25 MG	RISPERIDONE	RISPERIDONE 25MG/VIAL	POWDER	RECIEPT	Risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders. Risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar I disorder to delay occurrence of mood episodes. Risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.
4519	RISPERDAL CONSTA	RISPERDAL CONSTA 37.5 MG	RISPERIDONE	RISPERIDONE 37.5MG/VIAL	POWDER	RECIEPT	Risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders. Risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar I disorder to delay occurrence of mood episodes. Risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.
4521	RISPERDAL CONSTA	RISPERDAL CONSTA 50 MG	RISPERIDONE	RISPERIDONE 50MG/VIAL	POWDER	RECIEPT	Risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders. Risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar I disorder to delay occurrence of mood episodes. Risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.
4523	RISPERIDEX	RISPERIDEX 1 MG	RISPERIDONE	RISPERIDONE 1MG	TABLETS	RECIEPT	Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4524	RISPERIDEX	RISPERIDEX 2 MG	RISPERIDONE	RISPERIDONE 2MG	TABLETS	RECIEPT	Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4525	RISPERIDEX	RISPERIDEX 3 MG	RISPERIDONE	RISPERIDONE 3MG	TABLETS	RECIEPT	Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4526	RISPERIDEX	RISPERIDEX 4 MG	RISPERIDONE	RISPERIDONE 4MG	TABLETS	RECIEPT	Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4527	RISPOND	RISPOND 1	RISPERIDONE	RISPERIDONE 1MG	TABLETS	RECIEPT	Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4535	RISPOND	RISPOND SOLUTION	RISPERIDONE	RISPERIDONE 1MG/ML	SOLUTION	RECIEPT	Rispond is indicated for the management of schizophrania and manifestation of psychotic disorders. The antipsychotic efficacy of Rispond was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. Rispond is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Rispond is indicated for the treatment of psychotic manifestations of dementia. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Rispond is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distractibility or poor judgment including disruptibe or aggressive behaviors.
4529	RISPOND	RISPOND 2	RISPERIDONE	RISPERIDONE 2MG	TABLETS	RECIEPT	Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4531	RISPOND	RISPOND 3	RISPERIDONE	RISPERIDONE 3MG	TABLETS	RECIEPT	Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4533	RISPOND	RISPOND 4	RISPERIDONE	RISPERIDONE 4MG	TABLETS	RECIEPT	Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors
4536	RITALIN	RITALIN 10 MG TABLETS	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Attention deficit hyperactivity disorder (ADHD). Narcolepsy.
4537	RITALIN	RITALIN LA 10 MG MODIFIED-RELEASE CAPSULES	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 10MG	CAPSULES	RECIEPT	Attention Deficit Hyperactivity Disorder (ADHD) .
4538	RITALIN	RITALIN LA 20 MG MODIFIED-RELEASE CAPSULES	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 20MG	CAPSULES	RECIEPT	Attention Deficit Hyperactivity Disorder (ADHD).
4541	RITALIN	RITALIN SR 20 MG TABLETS	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Attention deficit hyperactivity disorders . Narcolepsy.
4539	RITALIN	RITALIN LA 30 MG MODIFIED-RELEASE CAPSULES	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 30MG	CAPSULES	RECIEPT	Attention Deficit Hyperactivity Disorder (ADHD).
4540	RITALIN	RITALIN LA 40 MG MODIFIED-RELEASE CAPSULES	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE 40MG	CAPSULES	RECIEPT	Attention Deficit Hyperactivity Disorder (ADHD).
4542	RIVAROXABAN	RIVAROXABAN TARO 10 MG	RIVAROXABAN	RIVAROXABAN 10MG	TABLETS	RECIEPT	Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), adults (following completion of at least 6 months therapy for DVT or PE).
4543	RIVAROXABAN	RIVAROXABAN TARO 15 MG	RIVAROXABAN	RIVAROXABAN 15MG	TABLETS	RECIEPT	Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT),and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
4544	RIVAROXABAN	RIVAROXABAN TARO 20 MG	RIVAROXABAN	RIVAROXABAN 20MG	TABLETS	RECIEPT	Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT),and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
4550	RIVASTIGMINE	RIVASTIGMINE PATCH DEXCEL 9.5 MG/24 H	RIVASTIGMINE	RIVASTIGMINE 13.8MG	PATCHES	RECIEPT	Treatment of mild to moderate dementia of the Alzheimer's type.
4549	RIVASTIGMINE	RIVASTIGMINE PATCH DEXCEL 4.6 MG/24 H	RIVASTIGMINE	RIVASTIGMINE 6.9MG	PATCHES	RECIEPT	Treatment of mild to moderate dementia of the Alzheimer's type.
4545	RIVASTIGMINE	RIVASTIGMINE DEXCEL 1.5 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 1.5MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the Alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
4555	RIVASTIGMINE	RIVASTIGMINE TEVA 1.5 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 1.5MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
4546	RIVASTIGMINE	RIVASTIGMINE DEXCEL 3 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 3MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the Alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
4556	RIVASTIGMINE	RIVASTIGMINE TEVA 3 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 3MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
4547	RIVASTIGMINE	RIVASTIGMINE DEXCEL 4.5 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 4.5MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the Alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
4557	RIVASTIGMINE	RIVASTIGMINE TEVA 4.5 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 4.5MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
4548	RIVASTIGMINE	RIVASTIGMINE DEXCEL 6 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 6MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the Alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
4558	RIVASTIGMINE	RIVASTIGMINE TEVA 6 MG	RIVASTIGMINE AS HYDROGEN TARTRATE	RIVASTIGMINE AS HYDROGEN TARTRATE 6MG	CAPSULES	RECIEPT	Treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease. Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia associated with Parkinson's disease.
4551	RIVASTIGMINE	RIVASTIGMINE PATCH TEVA 4.6 MG/24 H	RIVASTIGMINE BASE	RIVASTIGMINE BASE 4.6MG/24 HOUR	PATCHES	RECIEPT	Treatment of mild to moderate dementia of the Alzheimer's type
4553	RIVASTIGMINE	RIVASTIGMINE PATCH TEVA 9.5 MG/24 H	RIVASTIGMINE BASE	RIVASTIGMINE BASE 9.5MG/24 HOUR	PATCHES	RECIEPT	Treatment of mild to moderate dementia of the Alzheimer's type
4559	RIVOTRIL	RIVOTRIL	CLONAZEPAM	CLONAZEPAM 2.5MG/ML	DROPS	RECIEPT	Anti-epileptic. Panic disorder.
4560	RIXATHON	RIXATHON	RITUXIMAB	RITUXIMAB 10MG/1ML	CONCENTRATE	RECIEPT	Rixathon is indicated for the following indications: * Non-Hodgkin’s lymphoma (NHL): Rixathon is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, B-cell non-hodgkin’s lymphoma. Rixathon is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy. Rixathon is indicated for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy. Rixathon maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * Chronic lymphocytic leukaemia (CLL): Rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Rixathon or patients refractory to previous Rixathon plus chemotherapy. * Granulomatosis with polyangiitis and Microscopic polyangiitis: Rixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis (WG) and Microscopic polyangiitis (MPA).
4562	RIZALT	RIZALT 10 MG TABLETS	RIZATRIPTAN AS BENZOATE	RIZATRIPTAN AS BENZOATE 10MG	TABLETS	RECIEPT	Rizalt is indicated for the acute treatment of migraine attacks with or without aura in adults.
4564	RIZALT	RIZALT 5 MG TABLETS	RIZATRIPTAN AS BENZOATE	RIZATRIPTAN AS BENZOATE 5MG	TABLETS	RECIEPT	Rizalt is indicated for the acute treatment of migraine attacks with or without aura in adults
4561	RIZALT RPD	RIZALT RPD 10 MG WAFERS	RIZATRIPTAN AS BENZOATE	RIZATRIPTAN AS BENZOATE 10MG	TABLETS	RECIEPT	Rizalt is indicated for the acute treatment of migraine attacks with or without aura in adults.
4565	RIZATRIPTAN	RIZATRIPTAN INOVAMED 10 MG	RIZATRIPTAN AS BENZOATE	RIZATRIPTAN AS BENZOATE 10MG	TABLETS	RECIEPT	For the acute treatment of migraine attacks with or without aura in adults.
4566	RIZATRIPTAN	RIZATRIPTAN MELT INOVAMED 10 MG	RIZATRIPTAN AS BENZOATE	RIZATRIPTAN AS BENZOATE 10MG	TABLETS	RECIEPT	For the acute treatment of migraine attacks with or without aura in adults.
4568	ROCURIM	ROCURIM	ROCURONIUM BROMIDE	ROCURONIUM BROMIDE 10MG/1ML	SOLUTION	RECIEPT	Rocurim is indicated in adult and paediatric patients (from term neonates to adolescents [0 to <18 years]) as an adjunct to general anaesthesia to facilitate tracheal intubation during routine sequence induction and to provide skeletal muscle relaxation during surgery. In adults Rocurim is also indicated to facilitate tracheal intubation during rapid sequence induction and as an adjunct in the intensive care unit (ICU) to facilitate intubation and mechanical ventilation.
4569	ROCURONIUM	ROCURONIUM TEVA	ROCURONIUM BROMIDE	ROCURONIUM BROMIDE 10MG/ML	SOLUTION	RECIEPT	Rocuronium Teva is indicated as and adjunct to general anaesthesia to facilitate tracheal intubation during routine and rapid sequence induction, to provide skeletal muscle relaxation during surgery. Rocuronium Teva is also indicated as an adjunct in the intensive care unit (ICU) to facilitate tracheal intubation and mechanical ventilation.
4570	RODENAL	RODENAL 2 MG TBLETS	TRIHEXYPHENIDYL HYDROCHLORIDE	TRIHEXYPHENIDYL HYDROCHLORIDE 2MG	TABLETS	RECIEPT	Rodenal tablet is an adjunct medicine in the therapy of all forms of Parkinsonism (postencephalitic, arteriosclerotic and idiopathic), It is also indicated to control extrapyramidal disorders due to central nervous system drugs such as phenothiazines.
4571	RODENAL	RODENAL 5 MG TABLETS	TRIHEXYPHENIDYL HYDROCHLORIDE	TRIHEXYPHENIDYL HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Rodenal tablet is an adjunct medicine in the therapy of all forms of Parkinsonism (postencephalitic, arteriosclerotic and idiopathic), It is also indicated to control extrapyramidal disorders due to central nervous system drugs such as phenothiazines.
4572	ROKA-CARE	ROKA-CARE	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE 30MG;CODEINE PHOSPHATE 10MG	TABLETS		For the relief of pain and coughs and for the reduction of fever accompanied by pain.
4573	ROKACET	ROKACET	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE 30MG ANHYDROUS;CODEINE PHOSPHATE 10MG	TABLETS		For the relief of pain and coughs and for the reduction of fever accompanied by pain.
4574	ROKACET	ROKACET 20 CAPLIOT	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE 30MG;CODEINE PHOSPHATE 10MG	TABLETS		For the relief of pain and coughs and for the reduction of fever accompanied by pain.
4575	ROKACET	ROKACET PLUS	PARACETAMOL	PARACETAMOL 500MG;CAFFEINE ANHYDROUS 50MG;CODEINE PHOSPHATE 15MG	TABLETS	RECIEPT	For the relief of pain and coughs and for the reduction of fever accompanied by pain.
4576	RONEXINE	RONEXINE 100 MG TABLETS	LEVOMEPROMAZINE AS MALEATE	LEVOMEPROMAZINE AS MALEATE 100MG	TABLETS	RECIEPT	Treatment of psychotic disorders, particulary to produce a tranquillizing effect on hyperactive or excited psychotic patients and in patients suffering from anxiety, tension and behavioural disorders.
4577	RONEXINE	RONEXINE 25 MG TABLETS	LEVOMEPROMAZINE AS MALEATE	LEVOMEPROMAZINE AS MALEATE 25MG	TABLETS	RECIEPT	Treatment of psychotic disorders, particulary to produce a tranquillizing effect on hyperactive or excited psychotic patients and in patients suffering from anxiety, tension and behavioural disorders.
4578	ROPINIROLE	ROPINIROLE TEVA 0.25 MG	ROPINIROLE AS HYDROCHLORIDE	ROPINIROLE AS HYDROCHLORIDE 0.25MG	TABLETS	RECIEPT	Treatment of idiopathic Parkinson's disease : Ropinirole may be used alone in the treatment of idiopathic Parkinson's disease. Addition of ropinirole to levodopa may be used to control caret on - off caret fluctuations and permit a reduction in the total daily dose of levodopa.
4579	ROPINIROLE	ROPINIROLE TEVA 2 MG	ROPINIROLE AS HYDROCHLORIDE	ROPINIROLE AS HYDROCHLORIDE 2MG	TABLETS	RECIEPT	Treatment of idiopathic Parkinson's disease : Ropinirole may be used alone in the treatment of idiopathic Parkinson's disease. Addition of ropinirole to levodopa may be used to control caret on - off caret fluctuations and permit a reduction in the total daily dose of levodopa.
4591	ROPIVACAINE	ROPIVACAINE FRESENIUS 2 MG/ML SOLUTION FOR INFUSION	ROPIVACAINE AS HYDROCHLORIDE	ROPIVACAINE AS HYDROCHLORIDE 2MG/ML	SOLUTION	RECIEPT	Acute pain management : In adults and adolescents above 12 years of age for: - Continuous epidural infusion or intermittent bolus administration during postoperative or labour pain. - Field blocks. - Peripheral nerve block via a continuous infusion or intermittent bolus injections, e.g. postoperative pain management.
4592	ROPIVACAINE	ROPIVACAINE FRESENIUS 2 MG/ML SOLUTION FOR INJECTION	ROPIVACAINE AS HYDROCHLORIDE	ROPIVACAINE AS HYDROCHLORIDE 2MG/ML	SOLUTION	RECIEPT	Acute pain management : In adults and adolescents above 12 years of age for: - Continuous epidural infusion or intermittent bolus administration during postoperative or labour pain. - Field blocks. - Peripheral nerve block via a continuous infusion or intermittent bolus injections, e.g. postoperative pain management.
4593	ROPIVACAINE	ROPIVACAINE G.E.S. 10 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 10MG/1ML	SOLUTION	RECIEPT	Ropivacaine G.E.S. 10 mg/ml is indicated in adults and adolescents aged above 12 years of age for:Surgical anaesthesia: Lumbar epidural administration for surgery
4580	ROPIVACAINE	ROPIVACAINE B.BRAUN 10 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 10MG/ML	SOLUTION	RECIEPT	Ropivacaine B. Braun 10 mg/ml is indicated in adults and adolescents aged above 12 years of age for: Surgical anaesthesia Lumbar epidural administration for surgery
4582	ROPIVACAINE	ROPIVACAINE BIOAVENIR 10 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 10MG/ML	SOLUTION	RECIEPT	Ropivacaine 10 mg/ml is indicated in adults and adolescents above 12 years of age for: Surgical anaesthesia: - Lumbar Epidural Administration for surgery
4594	ROPIVACAINE	ROPIVACAINE G.E.S. 2 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 2MG/1ML	SOLUTION	RECIEPT	Acute pain management :In adults and adolescents above 12 years of age for: - Continuous epidural infusion or intermittent bolus administration during postoperative or labour pain - Field blocks - Peripheral nerve block via a continuous infusion or intermittent bolus injections, e.g. postoperative pain management
4581	ROPIVACAINE	ROPIVACAINE B.BRAUN 2 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 2MG/ML	SOLUTION	RECIEPT	Ropivacaine B. Braun 2mg/ml is indicated for: Acute pain management: In adults and adolescents above 12 years of age for: • Continuous epidural infusion or intermittent bolus administration during postoperative or labour pain. • Field blocks. • Peripheral nerve block via continuous infusion or intermittent bolus injections, e.g. postoperative pain management.
4584	ROPIVACAINE	ROPIVACAINE BIOAVENIR 2 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 2MG/ML	SOLUTION	RECIEPT	In adults and adolescents above 12 years of age for: - Continuous epidural infusion or intermittent bolus administration during post-operative or labour pain. - Field blocks. - Peripheral nerve blocks via continuous infusion or intermittent bolus injections, e.g. postoperative pain management.
4589	ROPIVACAINE	ROPIVACAINE BIOAVENIR 7.5 MG/ML	ROPIVACAINE HYDROCHLORIDE	ROPIVACAINE HYDROCHLORIDE 7.5MG/ML	SOLUTION	RECIEPT	Ropivacaive 7.5 mg/ml is indicated in adults and adolescents above 12 years of age for: Surgical anaesthesia: - epidural block for surgery, including Caesarean section. - Major nerve blocks. - Field blocks.
4596	ROSUVASTATIN	ROSUVASTATIN SANDOZ 10 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4602	ROSUVASTATIN	ROSUVASTATIN TEVA 10 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4598	ROSUVASTATIN	ROSUVASTATIN SANDOZ 20 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4603	ROSUVASTATIN	ROSUVASTATIN TEVA 20 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4595	ROSUVASTATIN	ROSUVASTATIN TEVA 40 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4600	ROSUVASTATIN	ROSUVASTATIN SANDOZ 40 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4604	ROSUVASTATIN	ROSUVASTATIN TEVA 5 MG	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 5MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4605	ROTARIX	ROTARIX SUSPENSION	LIVE ATTENUATED HUMAN ROTAVIRUS RIX4414 STRAIN Not less than	LIVE ATTENUATED HUMAN ROTAVIRUS RIX4414 STRAIN Not less than 1000000 CCID50	SUSPENSION	RECIEPT	Rotarix is indicated for the active immunization of infants from the age of 6 weeks for prevention of gastro-enteritis due to rotavirus infection. In clinical trials, efficacy was demonstrated against gastro-enteritis due to rotavirus of types G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8]. The use of Rotarix should be based on official recommendations.
4606	ROTATEQ (ROTAVIRUS VACCINE, LIVE, ORAL, PENTAVALENT)	ROTATEQ (ROTAVIRUS VACCINE, LIVE, ORAL, PENTAVALENT)	ROTAVIRUS P1 REASSORTANT	ROTAVIRUS P1 REASSORTANT 2.3 X10 ^6IU/DOSE;ROTAVIRUS G2 REASSORTANT 2.8 X10 ^6IU/DOSE;ROTAVIRUS G4 REASSORTANT 2.0 X10^ 6 IU/DOSE;ROTAVIRUS G3 REASSORTANT 2.2 X10 ^6IU/DOSE;ROTAVIRUS G1 REASSORTANT 2.2 X10 ^6IU/DOSE	SUSPENSION	RECIEPT	RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age
4607	ROVAMYCIN	ROVAMYCIN	SPIRAMYCIN	SPIRAMYCIN 1.5MIU	TABLETS	RECIEPT	Respiratory tract infections, infections caused by clamydia, cryptosporidiosis pregnancy toxoplasmosis.
4616	ROWACHOL	ROWACHOL 50 CAPS	MENTHOL	MENTHOL 32MG;MEMTHONE 6MG;PINENE 17MG;BORNEOL 5MG;CAMPHENE 5MG;CINEOLE 2MG	CAPSULES		An adjuvant in the treatment of gall-bladder stones and liver diseases.
4608	ROWACHOL	ROWACHOL	MENTHOL	MENTHOL 32MG;MENTHONE 6MG;PINENE 3.4MG ? PINENE;BORNEOL 5MG;CAMPHENE 5MG;CINEOLE 2MG;PINENE 13.6MG ? PINENE	CAPSULES		An adjuvant in the treatment of gall-bladder stones and liver diseases.
4617	ROWATINEX	ROWATINEX	CAMPHENE	CAMPHENE 15MG;CINEOLE 3MG;FENCHONE 4MG;BORNEOL 10MG;ANETHOLE 4MG;PINENE BETA 6.2MG;PINENE ALFA 24.8MG	CAPSULES		As an adjuvant in infections of kidenys and urinary tract.
4625	ROWATINEX	ROWATINEX 50CAPS	PINENE	PINENE 31MG;CAMPHENE 15MG;BORNEOL 10MG;ANETHOL 4MG;FENCHONE 4MG;CINEOLE 3MG	CAPSULES		As an adjuvant in infections of kidenys and urinary tract.
4626	ROXO	ROXO 150	ROXITHROMYCIN	ROXITHROMYCIN 150MG	TABLETS	RECIEPT	For the treatment of infections caused by microorganisms sensitive to roxithromycin e.g: ENT bronchopulmonary, genital and skin manifestations.
4628	ROZEX	ROZEX	METRONIDAZOLE	METRONIDAZOLE 7.5MG/G	GEL	RECIEPT	Topical application for the treatment of inflammatory papules, pustules and erythema of rosacea.
4629	RUBRACA	RUBRACA 200 MG	RUCAPARIB AS CAMSYLATE	RUCAPARIB AS CAMSYLATE 200MG	TABLETS	RECIEPT	• For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. • For the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
4630	RUBRACA	RUBRACA 250 MG	RUCAPARIB AS CAMSYLATE	RUCAPARIB AS CAMSYLATE 250MG	TABLETS	RECIEPT	• For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. • For the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
4631	RUBRACA	RUBRACA 300 MG	RUCAPARIB AS CAMSYLATE	RUCAPARIB AS CAMSYLATE 300MG	TABLETS	RECIEPT	• For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. • For the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
4632	RUCONEST	RUCONEST - POWDER FOR SOLUTION FOR INJECTION	CONESTAT ALFA	CONESTAT ALFA 2100U/VIAL	POWDER	RECIEPT	Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.
4633	RULID	RULID 150 MG	ROXITHROMYCIN	ROXITHROMYCIN 150MG	TABLETS	RECIEPT	For the treatment of infections caused by microorganisms sensitive to roxithromycin e.g: ENT bronchopulmonary, genital and skin manifestations.
4634	RYDAPT	RYDAPT 25 MG	MIDOSTAURIN	MIDOSTAURIN 25MG	CAPSULES	RECIEPT	Acute myeloid leukaemia (AML) : Rydapt is indicated in combination with standard induction and consolidation chemotherapy followed by single-agent maintenance therapy for adults with newly diagnosed acute myeloid leukaemia (AML) who have an FLT3 mutation. Advanced systemic mastocytosis (advanced SM) : Rydapt is indicated for the treatment of adult patients with advanced systemic mastocytosis (advanced SM).
4635	RYTHMEX	RYTHMEX 150 MG	PROPAFENONE HYDROCHLORIDE	PROPAFENONE HYDROCHLORIDE 150MG	TABLETS	RECIEPT	Prophylaxis and treatment of ventricular arrhythmias. Prophylaxis and treatment of atrial fibrillation and flutter. Prophylaxis and treatment of Paroxysmal supraventricular tachycardia (PSVT) associated with Disabling symptoms.
4636	RYTHMEX	RYTHMEX 300 MG	PROPAFENONE HYDROCHLORIDE	PROPAFENONE HYDROCHLORIDE 300MG	TABLETS	RECIEPT	Prophylaxis and treatment of ventricular arrhythmias. Prophylaxis and treatment of atrial fibrillation and flutter. Prophylaxis and treatment of Paroxysmal supraventricular tachycardia (PSVT) associated with Disabling symptoms.
4637	RYTHMICAL	RYTHMICAL 100	DISOPYRAMIDE AS PHOSPHATE	DISOPYRAMIDE AS PHOSPHATE 100MG	CAPSULES	RECIEPT	Treatment of cardiac arrhythmias.
4638	RYTHMICAL	RYTHMICAL 150	DISOPYRAMIDE AS PHOSPHATE	DISOPYRAMIDE AS PHOSPHATE 150MG	CAPSULES	RECIEPT	Cardiac arrhythmias.
4639	RYTMONORM	RYTMONORM 150 MG	PROPAFENONE HYDROCHLORIDE	PROPAFENONE HYDROCHLORIDE 150MG	TABLETS	RECIEPT	Prophylaxis and treatment of ventricular arrhythmias. Prophylaxis and treatment of atrial fibrillation and flutter. Prophylaxis and treatment of Paroxysmal supraventricular tachycardia (PSVT) associated with Disabling symptoms.
4640	RYTMONORM	RYTMONORM 300 MG	PROPAFENONE HYDROCHLORIDE	PROPAFENONE HYDROCHLORIDE 300MG	TABLETS	RECIEPT	Prophylaxis and treatment of ventricular arrhythmias. Prophylaxis and treatment of atrial fibrillation and flutter. Prophylaxis and treatment of Paroxysmal supraventricular tachycardia (PSVT) associated with Disabling symptoms.
4641	RYZODEG	RYZODEG	INSULIN DEGLUDEC	INSULIN DEGLUDEC 70U/ML;INSULIN ASPART 30U/ML	SOLUTION	RECIEPT	Treatment of diabetes mellitus in adults, adolescents and children from the age of 12 years.
4645	SABRILAN	SABRILAN	VIGABATRIN	VIGABATRIN 500MG	TABLETS	RECIEPT	Treatment in combination with other anti epileptic drugs for patients with resistant partial epilepsy with or without secondary generalisation, that is where all other appropriate drug combinations have proven inadeqate or have not been tolerated.
4647	SAFLUTAN	SAFLUTAN	TAFLUPROST	TAFLUPROST 15MCG/ML	SOLUTION	RECIEPT	Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. As monotherapy in patients • who would benefit from preservative free eye drops • insufficiently responsive to first line therapy • intolerant or contra-indicated to first line therapy As adjunctive therapy to beta-blockers.
4648	SALAGEN	SALAGEN	PILOCARPINE HYDROCHLORIDE	PILOCARPINE HYDROCHLORIDE 5MG	TABLETS	RECIEPT	For the treatment of symptoms of xerostomia and salivary gland hypofunction caused by radiotherapy for cancer of the head and neck. Sjogren detected by biopsy.
4650	SALATAC	SALATAC GEL 8GR	SALICYLIC ACID	SALICYLIC ACID 12%;LACTIC ACID 4%;CAMPHOR 2%;PYRAXYLIN 7%	GEL		For topical treatment of warts, corns or callouses.
4649	SALATAC	SALATAC GEL	SALICYLIC ACID	SALICYLIC ACID 12%;LACTIC ACID 4%;CAMPHOR 2%;PYROXYLIN 7%	GEL	RECIEPT	For topical treatment of warts, corns or callouses.
4651	SALAZOPYRIN	SALAZOPYRIN	SULFASALAZINE	SULFASALAZINE 500MG	TABLETS	RECIEPT	Treatment of ulcerative colitis and Crohn's disease.
4652	SALAZOPYRIN	SALAZOPYRIN EN	SULFASALAZINE	SULFASALAZINE 500MG	TABLETS	RECIEPT	For active rheumatoid arthritis which is not controlled by antiinflammatory drugs. Ulcerative colitis, Crohn's disease, Pyoderma gangrenosum.
4653	SALBUTRIM	SALBUTRIM	SALBUTAMOL AS SULFATE	SALBUTAMOL AS SULFATE 100MCG/DOSE	INHALATION	RECIEPT	Salbutrim is a short-acting (4 to 6 hour) bronchodilator with fast (within 5 minutes) onset in reversible airways obstruction. It is particularly suitable for the relief and prevention of asthma symptoms It should be used to relieve symptoms when they occur, and to prevent them in those circumstances recognized by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure). Salbutrim is particularly valuable as relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.
4924	SALICYL	SPIRIT SALICYL 2% 100ML	SALICYLIC ACID	SALICYLIC ACID 2%	LIQUID		Topical antiseptic and keratolytic.
4925	SALICYL	SPIRIT SALICYL 2% 1OOML	SALICYLIC ACID	SALICYLIC ACID 2%	LIQUID		Topical antiseptic and keratolytic.
4926	SALICYL	SPIRIT SALICYL 2% FLORIS	SALICYLIC ACID	SALICYLIC ACID 2%	LIQUID	RECIEPT	Topical antiseptic and keratolytic.
4923	SALICYL	SPIRIT SALICYL 2%	SALICYLIC ACID	SALICYLIC ACID 2G/100ML	LIQUID	RECIEPT	Keratolytic - for the treatment of acne.
4654	SALIKAREN	SALIKAREN	SALICYLIC ACID	SALICYLIC ACID 3%	OINTMENT	RECIEPT	Topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including dandruff, keratosis palmaris and plantaris, psoriasis - keratin of scalp, hands, legs and elbows.
4655	SALIKAREN	SALIKAREN OINT 20GR	SALICYLIC ACID	SALICYLIC ACID 3%	OINTMENT		Topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including dandruff, keratosis palmaris and plantaris, psoriasis - keratin of scalp, hands, legs and elbows.
4656	SALINE OTRIVINI BABIES	SALINE OTRIVINI FOR BABIES	SODIUM CHLORIDE	SODIUM CHLORIDE 0.74%W/V	SPRAY		Relief of nasal decongestion especially for babies.
4657	SALVAKAL	SALVAKAL	PILOCARPINE HYDROCHLORIDE	PILOCARPINE HYDROCHLORIDE 5MG	TABLETS	RECIEPT	For the treatment of symptoms of xerostomia and salivary gland hypofunction caused by radiotherapy for cancer of the head and neck. Sjogren detected by biopsy
4659	SANDIMMUN	SANDIMMUN NEORAL 100 MG CAPSULES	CICLOSPORIN	CICLOSPORIN 100MG	CAPSULES	RECIEPT	Prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that did not respond to other treatment. Atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis: Severe cases in which standard treatments are ineffective or inappropriate. Nephrotic syndrom type MCD (minimal change disease) in cases where conventional therapy has failed.
4661	SANDIMMUN	SANDIMMUN NEORAL 100 MG/ML ORAL SOLUTION	CICLOSPORIN	CICLOSPORIN 100MG/ML	SOLUTION	RECIEPT	Prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that did not respond to other treatment. Atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis: Severe cases in which standard treatments are ineffective or inappropriate. Nephrotic syndrom type MCD (minimal change disease) in cases where conventional therapy has failed.
4662	SANDIMMUN	SANDIMMUN NEORAL 25 MG CAPSULES	CICLOSPORIN	CICLOSPORIN 25MG	CAPSULES	RECIEPT	Prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that did not respond to other treatment. Atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis: Severe cases in which standard treatments are ineffective or inappropriate. Nephrotic syndrom type MCD (minimal change disease) in cases where conventional therapy has failed.
4664	SANDIMMUN	SANDIMMUN NEORAL 50 MG CAPSULES	CICLOSPORIN	CICLOSPORIN 50MG	CAPSULES	RECIEPT	Prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that did not respond to other treatment. Atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis: Severe cases in which standard treatments are ineffective or inappropriate. Nephrotic syndrom type MCD (minimal change disease) in cases where conventional therapy has failed.
4658	SANDIMMUN	SANDIMMUN CONCENTRATE FOR INFUSION	CICLOSPORIN	CICLOSPORIN 50MG/ML	SOLUTION	RECIEPT	Prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation.
4666	SANDOSTATIN	SANDOSTATIN 0.05 MG/ML	OCTREOTIDE	OCTREOTIDE 0.05MG/ML	SOLUTION	RECIEPT	Prevention of complications following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - Carcinoid tumours with features of the carcinoid syndrome - VIPomas - Glucagonomas - Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy - Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - GRFomas. Sandostatin is not an antitumour therapy and is not curative in these patients. Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
4667	SANDOSTATIN	SANDOSTATIN 0.1 MG/ML	OCTREOTIDE	OCTREOTIDE 0.1MG/ML	SOLUTION	RECIEPT	Prevention of complications following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - Carcinoid tumours with features of the carcinoid syndrome - VIPomas - Glucagonomas - Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy - Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - GRFomas. Sandostatin is not an antitumour therapy and is not curative in these patients. Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
4668	SANDOSTATIN	SANDOSTATIN 0.2 MG/ML	OCTREOTIDE	OCTREOTIDE 0.2MG/ML	SOLUTION	RECIEPT	Prevention of complications following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - Carcinoid tumours with features of the carcinoid syndrome - VIPomas - Glucagonomas - Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy - Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - GRFomas. Sandostatin is not an antitumour therapy and is not curative in these patients. Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
4669	SANDOSTATIN	SANDOSTATIN 0.5 MG/1ML	OCTREOTIDE	OCTREOTIDE 0.5MG/ML	SOLUTION	RECIEPT	Prevention of complications following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: Carcinoid tumours with features of the carcinoid syndrome. VIPomas . Glucagonomas . Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy . Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . GRFomas. Sandostatin is not an antitumour therapy and is not curative in these patients. Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
4670	SANDOSTATIN	SANDOSTATIN LAR 10 MG	OCTREOTIDE	OCTREOTIDE 10MG	SUSPENSION	RECIEPT	Treatment of acromegaly in: Patients already adequately controlled on standard doses of Sandostatin s.c. Patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. Endocrine gastro-entero- pancreatic (GEP) tumors, carcinoid tumors.
4671	SANDOSTATIN	SANDOSTATIN LAR 20 MG	OCTREOTIDE	OCTREOTIDE 20MG	SUSPENSION	RECIEPT	Treatment of acromegaly in: Patients already adequately controlled on standard doses of Sandostatin s.c. Patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. Endocrine gastro-entero- pancreatic (GEP) tumors, carcinoid tumors.
4672	SANDOSTATIN	SANDOSTATIN LAR 30 MG	OCTREOTIDE	OCTREOTIDE 30MG	SUSPENSION	RECIEPT	Treatment of acromegaly in: Patients already adequately controlled on standard doses of Sandostatin s.c. Patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. Endocrine gastro-entero- pancreatic (GEP) tumors, carcinoid tumors.
4673	SAPHRIS	SAPHRIS 10 MG	ASENAPINE AS MALEATE	ASENAPINE AS MALEATE 10MG	TABLETS	RECIEPT	Schizophrenia SAPHRIS is indicated for the treatment of schizophrenia in adults. The efficacy of SAPHRIS was established in two 6-week trials and one maintenance trial in adults Bipolar Disorder Monotherapy: SAPHRIS is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Efficacy was established in two 3-week monotherapy trials in adults Adjunctive Therapy: SAPHRIS is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Efficacy was established in one 3-week adjunctive trial in adults.
4674	SAPHRIS	SAPHRIS 5 MG	ASENAPINE AS MALEATE	ASENAPINE AS MALEATE 5MG	TABLETS	RECIEPT	Schizophrenia SAPHRIS is indicated for the treatment of schizophrenia in adults. The efficacy of SAPHRIS was established in two 6-week trials and one maintenance trial in adults Bipolar Disorder Monotherapy: SAPHRIS is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Efficacy was established in two 3-week monotherapy trials in adults Adjunctive Therapy: SAPHRIS is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Efficacy was established in one 3-week adjunctive trial in adults.
4675	SATIVEX	SATIVEX	CANNABIDIOL DRUG SUBSTANCE ( CBD BDS )	CANNABIDIOL DRUG SUBSTANCE ( CBD BDS ) 25MG/1ML;DELTA-9-TETRAHYDROCANNABINOL DRUG SUBSTANCE ( THC BDS ) 27MG/1ML	SPRAY	RECIEPT	Sativex is indicated, as add-on treatment, for symptom relief in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other medication and who demonstrate at least 20 % improvement in spasticity related symptoms during a four week trial of therapy. Sativex is indicated as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis in adults. Sativex may be useful as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.
4677	SAVIOR	SAVIOR 10GR	CETRIMIDE	CETRIMIDE 0.5%;CHLORHEXIDINE GLUCONATE 0.1%	CREAM		Antiseptic for external use.
4676	SAVIOR	SAVIOR	CETRIMIDE	CETRIMIDE 0.5%W/W;CHLORHEXIDINE HYDROCHLORIDE 0.1%W/W	CREAM		First aid antiseptic for external use in treatment for minor injuries, wounds and burns.
4678	SAVIOR FIRST	SAVIOR FIRST AID SOL 100ML	CETRIMIDE	CETRIMIDE 0.5%;CHLORHEXIDINE GLUCONATE 0.05%	SOLUTION		First aid antiseptic treatment for minor injuries, wounds and burns.
4679	SAVIOR FIRST	SAVIOR FIRST AID SOLUTION	CETRIMIDE	CETRIMIDE 0.5%W/V;CHLORHEXIDINE GLUCONATE 0.05%W/V	SOLUTION		First aid antiseptic treatment for minor injuries, wounds and burns.
4680	SAVIOR HOSPITAL	SAVIOR HOSPITAL CONCENTRATED SOLUTION	CETRIMIDE	CETRIMIDE 15%;CHLORHEXIDINE GLUCONATE 1.5%	SOLUTION		Antiseptic for external use.
4681	SAXENDA	SAXENDA	LIRAGLUTIDE	LIRAGLUTIDE 6MG/1ML	SOLUTION	RECIEPT	Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of • ≥ 30 kg/m² (obese), or • ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension or dyslipidaemia, and who have failed a previous weight management intervention. Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.
4682	SAYANA	SAYANA	MEDROXYPROGESTERONE ACETATE	MEDROXYPROGESTERONE ACETATE 104MG/0.65ML	SUSPENSION	RECIEPT	* SAYANA is indicated for long-term female contraception. Each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). However, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year . Since loss of bone mineral density may occur in females of all ages who use SAYANA long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered. * Use in Adolescents (12-18 years) In adolescents, use of SAYANA is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with SAYANA during the critical period of bone accretion. SAYANA has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.
4683	SCABIEX	SCABIEX	BENZYL BENZOATE	BENZYL BENZOATE 25%	EMULSION		Treatment of scabies.
4684	SCANDONEST	SCANDONEST 3% WITHOUT VASOCONSTRICTOR	MEPIVACAINE HYDROCHLORIDE	MEPIVACAINE HYDROCHLORIDE 54MG/1.8ML	SOLUTION	RECIEPT	For the production of local anaesthesia for dental procedures, by infiltration or nerve block.
4685	SCI-B-VAC	SCI-B-VAC 10 MCG/ML	HEPATITIS B VACCINES	HEPATITIS B VACCINES 10MCG/ML	SUSPENSION	RECIEPT	For active immunization against Hepatitis B virus. In high dose: it is indicated for imunization of neonates & children in highly endemic areas.
4686	SCI-B-VAC	SCI-B-VAC 2.5 MCG/0.5 ML	HEPATITIS B VACCINES	HEPATITIS B VACCINES 2.5MCG/0.5ML	SUSPENSION	RECIEPT	For active immunization against Hepatitis B virus. In high dose: it is indicated for immunization of neonates & children in highly endemic areas.
4687	SCI-B-VAC	SCI-B-VAC 5 MCG/0.5 ML	HEPATITIS B VACCINES	HEPATITIS B VACCINES 5MCG/0.5ML	SUSPENSION	RECIEPT	For active immunization against Hepatitis B virus. In high dose: it is indicated for immunization of neonates & children in highly endemic areas.
4688	SEBOSEL	SEBOSEL	SELENIUM SULFIDE	SELENIUM SULFIDE 25MG/ML	SUSPENSION		For the treatment of dandruff, seborrheic dermatitis of the scalp and tinea versicolor.
4689	SEBOSEL	SEBOSEL SHAMP 100ML	SELENIUM SULPHIDE	SELENIUM SULPHIDE 2.5%	LIQUID		For the treatment of dandruff, seborrheic dermatitis of the scalp and tinea versicolor.
4692	SEDURAL	SEDURAL	PHENAZOPYRIDINE HYDROCHLORIDE	PHENAZOPYRIDINE HYDROCHLORIDE 100MG	TABLETS	RECIEPT	Analgesic for the urinary tract.
4693	SEEBRI BREEZHALER	SEEBRI BREEZHALER 50 MCG	GLYCOPYRRONIUM AS BROMIDE	GLYCOPYRRONIUM AS BROMIDE 50MCG	INHALATION	RECIEPT	Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
4695	SEGLUROMET	SEGLUROMET 7.5/1000 MG	METFORMIN	METFORMIN 1000MG;ERTUGLIFLOZIN (L-PGA) 7.5MG	TABLETS	RECIEPT	Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: • in patients not adequately controlled on their maximally tolerated dose of metformin alone • in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes • in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
4694	SEGLUROMET	SEGLUROMET 2.5/1000 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 1000MG;ERTUGLIFLOZIN (L-PGA) 2.5MG	TABLETS	RECIEPT	Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: • in patients not adequately controlled on their maximally tolerated dose of metformin alone • in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes • in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
4696	SELGIN	SELGIN	SELEGILINE HYDROCHLORIDE	SELEGILINE HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Treatment of Parkinson's disease or symptomatic parkinsonism.
4697	SELINCRO	SELINCRO 18 MG	NALMEFENE AS HYDROCHLORIDE DIHYDRATE	NALMEFENE AS HYDROCHLORIDE DIHYDRATE 18.06MG	TABLETS	RECIEPT	Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification. Selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Selincro should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.
4703	SENSAMOL	SENSAMOL JUNIOR GRAPE 118ML	PARACETAMOL	PARACETAMOL 160MG/5ML	SYRUP		Antipyretic, analgesic.
4704	SENSAMOL	SENSAMOL JUNIOR GRAPE FLAVOUR	PARACETAMOL	PARACETAMOL 160MG/5ML	SUSPENSION		Antipyretic, analgesic.
4699	SENSAMOL	SENSAMOL	PARACETAMOL	PARACETAMOL 500MG	TABLETS		For temporary relief of pain and fever of different etiologics such as: headache, cold, influenza, dysmenorrhea, toothache and minor rheumatic pain.
4702	SENSAMOL	SENSAMOL 500MG 50CAPLIOTS	PARACETAMOL	PARACETAMOL 500MG	TABLETS		Antipyretic, analgesic.
4713	SEPTA	SEPTANEST N	ARTICAINE HYDROCHLORIDE	ARTICAINE HYDROCHLORIDE 68MG/1.7ML;EPINEPHRINE TARTRATE 15.47MG/1.7ML	SOLUTION	RECIEPT	For infiltration anaesthesia and nerve block anaesthesia in clinical dentistry. This includes local or loco-regional dental anaesthesia.
4705	SEPTADINE	SEPTADINE	CHLORHEXIDINE DICLUCONATE	CHLORHEXIDINE DICLUCONATE 0.5%W/V;ALCOHOL 70%V/V	SOLUTION		For quick disinfection of hands, also before invasive procedures.
4706	SEPTADINE	SEPTADINE SOL 500ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Disinfection of skin.
4707	SEPTADINE	SEPTADINE SOL 1LITER	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Disinfection of skin.
4709	SEPTADINE	SEPTADINE TARHITZ 4% 100ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 4%	SCRUB		Antiseptic hand rub and for the disinfection of skin prior to invasive procedures.
4708	SEPTADINE TARHITZ	SEPTADINE TARHITZ	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 4%	LOTION	RECIEPT	Antiseptic hand rub and for the disinfection of skin prior to invasive procedures.
4711	SEPTAL	SEPTAL SCRUB 500ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 4%	SCRUB		Surgical scrub: Hand wash for health-care personnel pre-operative skin disinfection for patients undergoing elective surgery antimicrobial cleanser for minor skin wounds.
4710	SEPTAL	SEPTAL SCRUB	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 4%W/V	SOLUTION	RECIEPT	Surgical scrub: Hand wash for health-care personnel pre-operative skin disinfection for patients undergoing elective surgery antimicrobial cleanser for minor skin wounds.
4712	SEPTALONE HOSPITAL	SEPTALONE HOSPITAL CONCENTRATE	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 5%	SOLUTION	RECIEPT	Preoperative skin disinfection, hand rinse to prevent cross infection, disinfection prior to cathererization and of instruments, treatment of wounds and burns and wetting of pressure wounds. Disinfection in obstetrics.
4714	SEPTANEST	SEPTANEST SP	ARTICAINE HYDROCHLORIDE	ARTICAINE HYDROCHLORIDE 68MG/1.7ML;EPINEPHRINE TARTRATE 30.94MG/1.7ML	SOLUTION	RECIEPT	For infiltration anaesthesia and nerve block anaesthesia in clinical dentistry. This includes local or loco-regional dental anaesthesia.
4715	SEPTAX	SEPTAX 1 G	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 1000MG	POWDER	RECIEPT	Septax is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). • Nosocomial pneumonia • Broncho-pulmonary infections in cystic fibrosis • Bacterial meningitis • Chronic suppurative otitis media • Malignant otitis externa • Complicated urinary tract infections • Complicated skin and soft tissue infections • Complicated intra-abdominal infections • Bone and joint infections • Peritonitis associated with dialysis in patient on CAPD. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP). The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria. Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity. Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
4716	SEPTAX	SEPTAX 2 G	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 2000MG/VIAL	POWDER	RECIEPT	Septax is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). • Nosocomial pneumonia • Broncho-pulmonary infections in cystic fibrosis • Bacterial meningitis • Chronic suppurative otitis media • Malignant otitis externa • Complicated urinary tract infections • Complicated skin and soft tissue infections • Complicated intra-abdominal infections • Bone and joint infections • Peritonitis associated with dialysis in patient on CAPD. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP). The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria. Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity. Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
4717	SEPTOL	SEPTOL	ALCOHOL	ALCOHOL 70% 70%W/V;CHLORHEXIDINE GLUCONATE 0.5%W/V	SOLUTION		Antiseptic hand rub .
4718	SEPTOL	SEPTOL 500ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Antiseptic hand rub .
4719	SEPTRIN	SEPTRIN FOR INFUSION	SULPHAMETHOXAZOLE	SULPHAMETHOXAZOLE 400MG/5ML;TRIMETHOPRIM 80MG/5ML	SOLUTION	RECIEPT	Bacterial infections of respiratory tract, gastrointestinal tracts and skin, susceptible to the drug.
4720	SERDOLECT	SERDOLECT 16 MG	SERTINDOLE	SERTINDOLE 16MG	TABLETS	RECIEPT	For the treatment of schizophrenia. Due to cardiovascular safety concerns serntidole should only be used for patients intolerant to at least one other anti-psychotic agent. Sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients.
4721	SERDOLECT	SERDOLECT 4 MG	SERTINDOLE	SERTINDOLE 4MG	TABLETS	RECIEPT	For the treatment of schizophrenia. Due to cardiovascular safety concerns serntidole should only be used for patients intolerant to at least one other anti-psychotic agent. Sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients.
4722	SERENADA	SERENADA 100	SERTRALINE AS HYDROCHLORIDE	SERTRALINE AS HYDROCHLORIDE 100MG	TABLETS	RECIEPT	For the treatment of symptoms of depression in patients with or without a history of mania. Following satisfactory respose, continuation with sertaline therapy is effective in preventon relapse of the initial episode of depression or recurrence of further depressive episodes.
4724	SERENADA	SERENADA 50	SERTRALINE AS HYDROCHLORIDE	SERTRALINE AS HYDROCHLORIDE 50MG	TABLETS	RECIEPT	For the treatment of symptoms of depression in patients with or without a history of mania. Following satisfactory respose, continuation with sertaline therapy is effective in preventon relapse of the initial episode of depression or recurrence of further depressive episodes.
4726	SERETIDE DISKUS	SERETIDE DISKUS 50/100 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 100MCG;SALMETEROL AS XINAFOATE 50MCG	POWDER	RECIEPT	Seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate.
4728	SERETIDE DISKUS	SERETIDE DISKUS 50/250 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 250MCG;SALMETEROL AS XINAFOATE 50MCG	POWDER	RECIEPT	Seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. Seretide (50/250 mcg) is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
4730	SERETIDE DISKUS	SERETIDE DISKUS 50/500 MCG	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE 500MCG;SALMETEROL AS XINAFOATE 50MCG	POWDER	RECIEPT	Seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. Seretide (50/500 mcg) is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
4733	SEREVENT CFC FREE	SEREVENT INHALER CFC FREE	SALMETEROL AS XINAFOATE	SALMETEROL AS XINAFOATE 25MCG/ACTUATION	SUSPENSION	RECIEPT	Asthma: Serevent is indicated for the regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. Serevent is also indicated in the prevention of exercise-induced asthma. Chronic Obstructive Pulmonary Disease (COPD): Serevent is indicated in the treatment of patients with COPD.
4732	SEREVENT DISKUS	SEREVENT DISKUS	SALMETEROL AS XINAFOATE	SALMETEROL AS XINAFOATE 50MCG	POWDER	RECIEPT	Salmeterol is a selective beta-2-agonist indicated for reversible airways obstruction in patients with asthma and chronic obstructive pulmonary disease (COPD). In asthma (including nocturnal asthma and exercise induced symptoms) it is indicated for those treated with inhaled corticosteroids who require a long-acting beta agonist in accordance with current treatment guidelines.
4734	SEROQUEL	SEROQUEL 100 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 100MG	TABLETS	RECIEPT	Indicated for the treatment of schizophrenia. Treatment of manic episodes associated with bipolar disorder. Treatment of major depressive episodes in bipolar disorders.
4738	SEROQUEL	SEROQUEL XR 150 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 150MG	TABLETS	RECIEPT	Seroquel XR is indicated for the treatment of Schizophrenia. Seroquel XR is effective in preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR. Seroquel XR is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. Seroquel XR is indicated for the treatment of major depressive episodes in bipolar disorder. Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for add-on treatment of major depressive episods in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 Pharmacodynamic properties). Prior to initiating treatment, clinicians should consider the safety profile of Seroquel XR.
4735	SEROQUEL	SEROQUEL 200 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 200MG	TABLETS	RECIEPT	Indicated for the treatment of schizophrenia. Treatment of manic episodes associated with bipolar disorder. Treatment of major depressive episodes in bipolar disorders.
4736	SEROQUEL	SEROQUEL 25 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 25MG	TABLETS	RECIEPT	Indicated for the treatment of schizophrenia. Treatment of manic episodes associated with bipolar disorder. Treatment of major depressive episodes in bipolar disorders.
4737	SEROQUEL	SEROQUEL 300 MG	QUETIAPINE AS FUMARATE	QUETIAPINE AS FUMARATE 300MG	TABLETS	RECIEPT	Indicated for the treatment of schizophrenia. Treatment of manic episodes associated with bipolar disorder. Treatment of major depressive episodes in bipolar disorders.
4740	SEROQUEL	SEROQUEL XR 200 MG	QUETIAPINE FUMARATE	QUETIAPINE FUMARATE 200MG	TABLETS	RECIEPT	Seroquel XR is indicated for the treatment of Schizophrenia . Seroquel XR is effective in preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR. Seroquel XR is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for the treatment of major depressive episodes in bipolar disorder. Seroquel XR is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for add-on treatment of major depressive episods in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 Pharmacodynamic properties). Prior to initiating treatment, clinicians should consider the safety profile of Seroquel XR (see section 4.4 Special warnings and precautions for use).
4742	SEROQUEL	SEROQUEL XR 300 MG	QUETIAPINE FUMARATE	QUETIAPINE FUMARATE 300MG	TABLETS	RECIEPT	Seroquel XR is indicated for the treatment of Schizophrenia . Seroquel XR is effective in preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR. Seroquel XR is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for the treatment of major depressive episodes in bipolar disorder. Seroquel XR is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for add-on treatment of major depressive episods in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 Pharmacodynamic properties). Prior to initiating treatment, clinicians should consider the safety profile of Seroquel XR (see section 4.4 Special warnings and precautions for use).
4744	SEROQUEL	SEROQUEL XR 400 MG	QUETIAPINE FUMARATE	QUETIAPINE FUMARATE 400MG	TABLETS	RECIEPT	Seroquel XR is indicated for the treatment of Schizophrenia . Seroquel XR is effective in preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR. Seroquel XR is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for the treatment of major depressive episodes in bipolar disorder. Seroquel XR is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for add-on treatment of major depressive episods in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 Pharmacodynamic properties). Prior to initiating treatment, clinicians should consider the safety profile of Seroquel XR (see section 4.4 Special warnings and precautions for use).
4745	SEROQUEL	SEROQUEL XR 50 MG	QUETIAPINE FUMARATE	QUETIAPINE FUMARATE 50MG	TABLETS	RECIEPT	Seroquel XR is indicated for the treatment of Schizophrenia . Seroquel XR is effective in preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR. Seroquel XR is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. Treatment of acute mania associated with bipolar I disorder as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for the treatment of major depressive episodes in bipolar disorder. Seroquel XR is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. Seroquel XR is indicated for add-on treatment of major depressive episods in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 Pharmacodynamic properties). Prior to initiating treatment, clinicians should consider the safety profile of Seroquel XR (see section 4.4 Special warnings and precautions for use).
4747	SEROXAT	SEROXAT	PAROXETINE AS HYDROCHLORIDE	PAROXETINE AS HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. Treatment of symptoms of social phobia. Post traumatic stress disorder. Generalised anxiety disorders.
4748	SERTRALINE	SERTRALINE TEVA 100 MG	SERTRALINE AS HYDROCHLORIDE	SERTRALINE AS HYDROCHLORIDE 100MG	TABLETS	RECIEPT	For the treatment of symptoms of depression in patients with or without a history of mania. Following satisfactory response, continuation with sertaline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.
4749	SERTRALINE	SERTRALINE TEVA 50 MG	SERTRALINE AS HYDROCHLORIDE	SERTRALINE AS HYDROCHLORIDE 50MG	TABLETS	RECIEPT	For the treatment of symptoms of depression in patients with or without a history of mania. Following satisfactory response, continuation with sertaline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.
4750	SETRON	SETRON 1 MG	GRANISETRON AS HYDROCHLORIDE	GRANISETRON AS HYDROCHLORIDE 1MG	TABLETS	RECIEPT	Prevention of nausea and vomiting induced by cytostatic therapy.
4751	SEVELAMER	SEVELAMER TARO 800 MG	SEVELAMER CARBONATE ANHYDROUS	SEVELAMER CARBONATE ANHYDROUS 800MG	TABLETS	RECIEPT	For the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l. Should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
4753	SEVORANE	SEVORANE	SEVOFLURANE	SEVOFLURANE 100%	SOLUTION	RECIEPT	Induction and maintenance of general anesthesia.
4755	SHALOSH B	SHALOSH B	THIAMINE (VIT B1) HYDROCHLORIDE	THIAMINE (VIT B1) HYDROCHLORIDE 100MG;PYRIDOXINE (VIT B6) HYDROCHLORIDE 250MG;CYANOCOBALAMIN 0.25MG	TABLETS		For the treatment of neurologic pain and metabolic disorders. Vitamin B supplement.
4756	SHELLY	SHELLY	ETHINYLESTRADIOL	ETHINYLESTRADIOL 0.03MG;GESTODENE 0.075MG	TABLETS	RECIEPT	Oral contraception.
4761	SIFROL	SIFROL TABLETS 0.25 MG	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.25MG	TABLETS	RECIEPT	Treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with lovodopa. For symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome.
4757	SIFROL	SIFROL ER 0.375 mg	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.375MG	TABLETS		Treatment of signs and symptoms of idiopathic Parkinson's disease, as monotherapy or in combination with levodopa.
4758	SIFROL	SIFROL ER 0.75 MG	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.75MG	TABLETS	RECIEPT	Treatment of signs and symptoms of idiopathic Parkinson's disease, as monotherapy or in combination with levodopa.
4759	SIFROL	SIFROL ER 1.5 MG	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.5MG	TABLETS	RECIEPT	Treatment of signs and symptoms of idiopathic Parkinson's disease, as monotherapy or in combination with levodopa.
4762	SIFROL	SIFROL TABLETS 1 MG	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1MG	TABLETS	RECIEPT	Treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with lovodopa.
4760	SIFROL	SIFROL ER 4.5 MG	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE	PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 4.5MG	TABLETS	RECIEPT	Treatment of signs and symptoms of idiopathic Parkinson’s disease, as monotherapy or in combination with lovodopa.
4763	SIGNIFOR	SIGNIFOR 0.3 MG/ 1 ML	PASIREOTIDE AS DIASPARTATE	PASIREOTIDE AS DIASPARTATE 0.3MG/ML	SOLUTION	RECIEPT	Treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.
4764	SIGNIFOR	SIGNIFOR 0.6 MG/ 1 ML	PASIREOTIDE AS DIASPARTATE	PASIREOTIDE AS DIASPARTATE 0.6MG/ML	SOLUTION	RECIEPT	Treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.
4765	SIGNIFOR	SIGNIFOR 0.9 MG/ 1 ML	PASIREOTIDE AS DIASPARTATE	PASIREOTIDE AS DIASPARTATE 0.9MG/ML	SOLUTION	RECIEPT	Treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.
4766	SIGNIFOR	SIGNIFOR LAR 20 MG	PASIREOTIDE AS EMBONATE	PASIREOTIDE AS EMBONATE 20MG	POWDER	RECIEPT	Signifor LAR is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
4767	SIGNIFOR	SIGNIFOR LAR 40 MG	PASIREOTIDE AS EMBONATE	PASIREOTIDE AS EMBONATE 40MG	POWDER	RECIEPT	Signifor LAR is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
4768	SIGNIFOR	SIGNIFOR LAR 60 MG	PASIREOTIDE AS EMBONATE	PASIREOTIDE AS EMBONATE 60MG	POWDER	RECIEPT	Signifor LAR is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
4769	SILDENAFIL	SILDENAFIL TEVA 100 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 100MG	TABLETS	RECIEPT	Sildenafil Teva 100 mg FC Tablets is indicated for the treatment of erectile dysfunction.
4770	SILDENAFIL	SILDENAFIL TEVA 25 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 25MG	TABLETS	RECIEPT	Sildenafil Teva 25 mg FC Tablets is indicated for the treatment of erectile dysfunction.
4771	SILDENAFIL	SILDENAFIL TEVA 50 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 50MG	TABLETS	RECIEPT	Sildenafil Teva 50 mg FC Tablets is indicated for the treatment of erectile dysfunction.
4772	SILVEROL	SILVEROL CREAM	SULPHADIAZINE SILVER	SULPHADIAZINE SILVER 1%	CREAM	RECIEPT	Treatment of infected burn wounds, leg ulcers and pressure sores.
4774	SIMBRINZA	SIMBRINZA	BRIMONIDINE TARTRATE	BRIMONIDINE TARTRATE 2MG/1ML;BRINZOLAMIDE 10MG/1ML	DROPS	RECIEPT	Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
4776	SIMDAX	SIMDAX 2.5 MG/ML	LEVOSIMENDAN	LEVOSIMENDAN 2.5MG/ML	CONCENTRATE	RECIEPT	Therapeutic indications: Short-term treatment of acutely decompensated severe chronic heart failure. Simdax should only be used as add-on therapy in situations where conventional therapy with e.g. diuretics, ACE-inhibitors and digitalis is not sufficient and where there is a need for inotropic support.
4777	SIMICOL	SIMICOL TABLETS	SIMETHICONE	SIMETHICONE 125MG	TABLETS		Antiflatulence.
4788	SIMPONI	SIMPONI	GOLIMUMAB	GOLIMUMAB 50MG/0.5ML	SOLUTION	RECIEPT	Rheumatoid Arthritis : Simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. Juvenile idiopathic arthritis: Polyarticular juvenile idiopathic arthritis (pJIA) Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with MTX. Simponi 100 mg is not recommended in children aged less than 18. Psoriatic Arthritis : Simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Ankylosing Spondylitis : Simponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA): Simponi is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDS). Ulcerative colitis (UC) : Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
4789	SIMULECT	SIMULECT 20 MG	BASILIXIMAB	BASILIXIMAB 20MG/VIAL	POWDER	RECIEPT	Prophylaxis of acute organ rejection in de novo renal transplantation in combination with cyclosporin and corticosteroid based immunosuppression
4790	SIMVACOR	SIMVACOR 10	SIMVASTATIN	SIMVASTATIN 10MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvacor is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvacor is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvacor therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4792	SIMVACOR	SIMVACOR 20	SIMVASTATIN	SIMVASTATIN 20MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvacor is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvacor is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvacor therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4794	SIMVACOR	SIMVACOR 40	SIMVASTATIN	SIMVASTATIN 40MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvacor is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvacor is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvacor therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). In patients at a high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular disease Simvacor is indicated to: - Reduce the risk of total mortalily by reducing CHD deaths. - Reduce the risk of non-fatal myocardial infarction and stroke. - Reduce the need for coronary and non-coronary revascularization procedures.
4796	SIMVACOR	SIMVACOR 80	SIMVASTATIN	SIMVASTATIN 80MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvacor is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvacor is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvacor therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). In patients at a high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular disease Simvacor is indicated to: - Reduce the risk of total mortalily by reducing CHD deaths. - Reduce the risk of non-fatal myocardial infarction and stroke. - Reduce the need for coronary and non-coronary revascularization procedures.
4798	SIMVASTATIN	SIMVASTATIN TEVA 10 MG	SIMVASTATIN	SIMVASTATIN 10MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvastatin-teva is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures. - Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvastatin-teva is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvastatin-teva therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvastatin-teva is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4799	SIMVASTATIN	SIMVASTATIN TEVA 20 MG	SIMVASTATIN	SIMVASTATIN 20MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvastatin-teva is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures. - Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvastatin-teva is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvastatin-teva therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvastatin-teva is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4800	SIMVASTATIN	SIMVASTATIN TEVA 40 MG	SIMVASTATIN	SIMVASTATIN 40MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvastatin-teva is indicated to: Reduce the risk of total mortality by reducing coronary death ; Reduce the risk of non-fatal myocardial infarction ; Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvastatin-teva is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvastatin-teva therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvastatin-teva is indicated for the treatment of patients with hypertriglyceridemia ( Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvastatin-teva is also indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4801	SIMVASTATIN	SIMVASTATIN TEVA 80 MG	SIMVASTATIN	SIMVASTATIN 80MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvastatin-teva is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvastatin-teva is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvastatin-teva therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvastatin-teva is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvastatin-teva is also indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4802	SIMVAXON	SIMVAXON 10	SIMVASTATIN	SIMVASTATIN 10MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia): Simvaxon is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvaxon is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4803	SIMVAXON	SIMVAXON 20	SIMVASTATIN	SIMVASTATIN 20MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia): Simvaxon is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvaxon is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4804	SIMVAXON	SIMVAXON 40	SIMVASTATIN	SIMVASTATIN 40MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia): Simvaxon is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvaxon is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
4806	SIMVAXON	SIMVAXON 80	SIMVASTATIN	SIMVASTATIN 80MG	TABLETS	RECIEPT	Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvaxon is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). In patients at a high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular disease Simvaxon is indicated to: - Reduce the risk of total mortality by reducing CHD deaths. - Reduce the risk of non-fatal myocardial infarction and stroke. - Reduce the need for coronary and non-coronary revascularization procedures
4807	SINAF	SINAF DROPS 30CC	OXYMETHAZOLIN	OXYMETHAZOLIN 0.05%;PHENYLEPHRINEHCL 0.25%	DROPS		For temporary relief of nasal congestion due to cold or sinusitis or allergies of the upper respiratory tract.
4808	SINAF	SINAF NASAL SPRAY M.DOSE 10ML	OXYMETHAZOLIN	OXYMETHAZOLIN 0.05%;PHENYLEPHRINEHCL 0.25%	SPRAY		For temporary relief of nasal congestion due to cold or sinusitis or allergies of the upper respiratory tract.
4809	SINEMET	SINEMET CR	LEVODOPA	LEVODOPA 200MG;CARBIDOPA AS MONOHYDRATE 50MG	TABLETS	RECIEPT	Idiopathic parkinson's disease. Postencephalitic parkinsonism. Symptomatic parkinsonism. To reduce caretoffcaret time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration (caretwearing-offcaret phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.
4811	SINGULAIR	SINGULAIR 10 MG TABLETS	MONTELUKAST AS SODIUM	MONTELUKAST AS SODIUM 10MG	TABLETS	RECIEPT	Singulair 10 mg is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. Singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Singular is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and padiatric patients 2 years of age and older.
4812	SINGULAIR	SINGULAIR 4 MG CHEWABLE TABLETS FOR PRESCHOOL KIDS	MONTELUKAST AS SODIUM	MONTELUKAST AS SODIUM 4MG	TABLETS	RECIEPT	Singulair is indicated in pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. Singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Singulair and inhaled carticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Singular is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and padiatric patients 2 years of age and older.
4813	SINGULAIR	SINGULAIR 4 MG GRANULES FOR KIDDIES	MONTELUKAST AS SODIUM	MONTELUKAST AS SODIUM 4MG	GRANULES	RECIEPT	Singulair is indicated in adult and pediatric patients 12 months of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treament of aspirin - sensitive asthmatic patients, and the prevention of exercise - induced bronchoconstriction. Singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Singulair and inhaled corticosteroids may be used concomitatly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.
4814	SINGULAIR	SINGULAIR 5 MG CHEWABLE TABLETS	MONTELUKAST AS SODIUM	MONTELUKAST AS SODIUM 5MG	TABLETS	RECIEPT	Singulair 5 mg is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. Singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Singular is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and padiatric patients 2 years of age and older.
4816	SINUCLEAR	SINUCLEAR 20 TAB	COMMON SORREL HERB	COMMON SORREL HERB 36MG;ELDER FLOWER 36MG;GENTIAN ROOT 12MG;PRIMULA FLOWER WITH CALYX 36MG;VERBENA HERB 36MG	TABLETS		Provides relief of symptoms in the nose and its sinuses in connection with common cold, in adults and children older than 12 years.
4815	SINUCLEAR	SINUCLEAR	COMMON SORREL HERB	COMMON SORREL HERB 36MG;GENTIAN ROOT 12MG;PRIMULA FLOWER WITH CALYX 36MG;ELDER FLOWER 36MG;VERBENA HERB 36MG	TABLETS		Provides relief of symptoms in the nose and its sinuses in connection with common cold, in adults and children older than 12 years.
4817	SINUFED	SINUFED 10 TAB	PSEUDOEPHEDRINE (AS HYDROCHLORIDE)	PSEUDOEPHEDRINE (AS HYDROCHLORIDE) 60MG	TABLETS	RECIEPT	Symptomatic treatment of nasal congestion, to relieve eustachian tube congestion.
4819	SINUFED	SINUFED SYRUP 115ML	PSEUDOEPHEDRINE HCL	PSEUDOEPHEDRINE HCL 30MG/5ML	SYRUP	RECIEPT	Symptomatic treatment of nasal congestion, to relief eustachian tube congestion.
4818	SINUFED	SINUFED SYRUP	PSEUDOEPHEDRINE HYDROCHLORIDE	PSEUDOEPHEDRINE HYDROCHLORIDE 30MG/5ML	SYRUP	RECIEPT	Symptomatic treatment of nasal congestion, to relief eustachian tube congestion.
4820	SINUFED	SINUFED TABLETS	PSEUDOEPHEDRINE HYDROCHLORIDE	PSEUDOEPHEDRINE HYDROCHLORIDE 60MG	TABLETS	RECIEPT	Symptomatic treatment of nasal congestion, to relieve eustachian tube congestion.
4821	SIRAN	SIRAN 200 MG EFFERVESCENT TABLETS	ACETYLCYSTEINE	ACETYLCYSTEINE 200MG	TABLETS	RECIEPT	Mucolytic in respiratory tract disorders where reduction of sputum viscosity is required.
4822	SIRAN	SIRAN 200MG EFFERVESCENT 20TAB	ACETYLCYSTEINE	ACETYLCYSTEINE 200MG	TABLETS	RECIEPT	Mucolytic in respiratory tract disorders where reduction of sputum viscosity is required.
4823	SIRTURO	SIRTURO	BEDAQUILINE AS FUMARATE	BEDAQUILINE AS FUMARATE 100MG	TABLETS	RECIEPT	SIRTURO is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
4824	SITAGLIPTIN	SITAGLIPTIN TEVA 100 MG	SITAGLIPTIN AS MALATE	SITAGLIPTIN AS MALATE 100MG	TABLETS	RECIEPT	Sitagliptin Teva is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: Sitagliptin Teva should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. Sitagliptin Teva has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitagliptin Teva.
4825	SITAGLIPTIN	SITAGLIPTIN TEVA 25 MG	SITAGLIPTIN AS MALATE	SITAGLIPTIN AS MALATE 25MG	TABLETS	RECIEPT	Sitagliptin Teva is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: Sitagliptin Teva should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. Sitagliptin Teva has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitagliptin Teva.
4826	SITAGLIPTIN	SITAGLIPTIN TEVA 50 MG	SITAGLIPTIN AS MALATE	SITAGLIPTIN AS MALATE 50MG	TABLETS	RECIEPT	Sitagliptin Teva is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: Sitagliptin Teva should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. Sitagliptin Teva has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitagliptin Teva.
4827	SKYRIZI	SKYRIZI 75 MG	RISANKIZUMAB	RISANKIZUMAB 75MG/0.83ML	SOLUTION	RECIEPT	SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
4828	SLEEP AID	SLEEP AID	DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE 25MG	TABLETS		Aid to the relief of temporary sleep disturbance.
4830	SLEEP AID	SLEEP AID 16 CAPLIOTS	DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE 25MG	TABLETS		Aid to the relief of temporary sleep disturbance.
4831	SLIDER	SLIDER	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 20MG	TABLETS	RECIEPT	For adults > 18 years: Indicated for treatment of primary pulmonary hypertension (PPH) pulmonary hypertension (PH) associated with connective tissue disease (CTD) or PH following surgical repair at least 5 years previously of atrial septal defect (ASD) ventricular septal defect (VSD) patent ductus arteriosus (PDA) or aorto-pulmonary window.
4845	SMOFKABIVEN	SMOFKABIVEN PERIPHERAL	GLUCOSE MONOHYDRATE	GLUCOSE MONOHYDRATE 143G/1000ML Glucose 13%;SOYA OIL 60G/1000ML Lipid emulsion;TRIGLYCERIDES, MEDIUM-CHAIN 60G/1000ML Lipid emulsion;OLIVE OIL 50G/1000ML Lipid emulsion;FISH OIL 30G/1000ML Lipid emulsion;L- ALANINE 14.0G/1000ML Amino acid solution;L-ARGININE 12.0G/1000ML Amino acid solution;L-HISTIDINE 3.0G/1000ML Amino acid solution;L- ISOLEUCINE 5.0G/1000ML Amino acid solution;L- LEUCINE 7.4G/1000ML Amino acid solution;L- METHIONINE 4.3G/1000ML Amino acid solution;L- PHENYLALANINE 5.1G/1000ML Amino acid solution;L- PROLINE 11.2G/1000ML Amino acid solution;L- SERINE 6.5G/1000ML Amino acid solution;TAURINE 1.0G/1000ML Amino acid solution;L- THREONINE 4.4G/1000ML Amino acid solution;L- TRYPTOPHAN 2.0G/1000ML Amino acid solution;L- TYROSINE 0.4G/1000ML Amino acid solution;L- VALINE 6.2G/1000ML Amino acid solution;CALCIUM CHLORIDE DIHYDRATE 0.74G/1000ML Amino acid solution;SODIUM GLYCEROPHOSPHATE HYDRATE 4.18G/1000ML Amino acid solution;MAGNESIUM SULFATE HEPTAHYDRATE 2.47G/1000ML Amino acid solution;POTASSIUM CHLORIDE 4.48G/1000ML Amino acid solution;SODIUM ACETATE TRIHYDRATE 5.62G/1000ML Amino acid solution;ZINC SULFATE HEPTAHYDRATE 0.023G/1000ML Amino acid solution;L- LYSINE ACETATE 9.3G/1000ML Amino acid solution;AMINOACETIC ACID 11.0G/1000ML Amino acid solution;L- LYSINE ACETATE 9.3G/1000ML Amino acid solution;AMINOACETIC ACID 11.0G/1000ML Amino acid solution	EMULSION	RECIEPT	Parenteral nutrition for adults and children aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.
4837	SMOFKABIVEN	SMOFKABIVEN	L- ALANINE	L- ALANINE 14.0G/1000ML Amino acid solution;L-ARGININE 12.0G/1000ML Amino acid solution;L-HISTIDINE 3.0G/1000ML Amino acid solution;L- ISOLEUCINE 5.0G/1000ML Amino acid solution;L- LEUCINE 7.4G/1000ML Amino acid solution;L- METHIONINE 4.3G/1000ML Amino acid solution;L- PHENYLALANINE 5.1G/1000ML Amino acid solution;L- PROLINE 11.2G/1000ML Amino acid solution;L- SERINE 6.5G/1000ML Amino acid solution;TAURINE 1.0G/1000ML Amino acid solution;L- THREONINE 4.4G/1000ML Amino acid solution;L- TRYPTOPHAN 2.0G/1000ML Amino acid solution;L- TYROSINE 0.40G/1000ML Amino acid solution;L- VALINE 6.2G/1000ML Amino acid solution;CALCIUM CHLORIDE DIHYDRATE 0.74G/1000ML Amino acid solution;SODIUM GLYCEROPHOSPHATE HYDRATE 4.18G/1000ML Amino acid solution;MAGNESIUM SULFATE HEPTAHYDRATE 2.47G/1000ML Amino acid solution;POTASSIUM CHLORIDE 4.48G/1000ML Amino acid solution;SODIUM ACETATE TRIHYDRATE 5.62G/1000ML Amino acid solution;ZINC SULFATE HEPTAHYDRATE 0.023G/1000ML Amino acid solution;SOYBEAN OIL 60G/1000ML Lipid emulsion;TRIGLYCERIDES, MEDIUM-CHAIN 60G/1000ML Lipid emulsion;OLIVE OIL 50G/1000ML Lipid emulsion;FISH OIL 30G/1000ML Lipid emulsion;GLUCOSE MONOHYDRATE 462G/1000ML Glucose 42%;L- LYSINE ACETATE 9.3G/1000ML Amino acid solution;AMINOACETIC ACID 11.0G/1000ML Amino acid solution;GLUCOSE MONOHYDRATE 462G/1000ML Glucose 42%;L- LYSINE ACETATE 9.3G/1000ML Amino acid solution;AMINOACETIC ACID 11.0G/1000ML Amino acid solution	EMULSION	RECIEPT	Parenteral nutrition for adults and children aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.
4841	SMOFKABIVEN	SMOFKABIVEN ELECTROLYTE FREE	OLIVE OIL	OLIVE OIL 50G/1000ML Lipid emulsion;TRIGLYCERIDES, MEDIUM-CHAIN 60G/1000ML Lipid emulsion;SOYBEAN OIL 60G/1000ML Lipid emulsion;GLUCOSE MONOHYDRATE 462G/1000ML Glucose 42%;L- VALINE 6.2G/1000ML Amino acid solution;L- TYROSINE 0.4G/1000ML Amino acid solution;L- TRYPTOPHAN 2.0G/1000ML Amino acid solution;L- THREONINE 4.4G/1000ML Amino acid solution;TAURINE 1.0G/1000ML Amino acid solution;L-SERINE 6.5G/1000ML Amino acid solution;L- PROLINE 11.2G/1000ML Amino acid solution;L- PHENYLALANINE 5.1G/1000ML Amino acid solution;L- METHIONINE 4.3G/1000ML Amino acid solution;L- LYSINE ACETATE 9.3G/1000ML Amino acid solution;L-LEUCINE 7.4G/1000ML Amino acid solution;L- ISOLEUCINE 5.0G/1000ML Amino acid solution;L-HISTIDINE 3.0G/1000ML Amino acid solution;AMINOACETIC ACID 11.0G/1000ML Amino acid solution;L-ARGININE 12.0G/1000ML Amino acid solution;L- ALANINE 14.0G/1000ML Amino acid solution;FISH OIL 30G/1000ML Lipid emulsion	EMULSION	RECIEPT	Parenteral nutrition for adults and children aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.
4846	SMOFLIPID	SMOFLIPID 200 MG/ML	TRIGLYCERIDES, MEDIUM-CHAIN	TRIGLYCERIDES, MEDIUM-CHAIN 60G/L;SOYA OIL 60G/L;REFINED OLIVE OIL 50G/L;PURIFIED FISH OIL 30G/L	EMULSION	RECIEPT	Supply of energy and essential fatty acids and omega-3 fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated
4849	SODIUM BICARBONATE	SODIUM BICARBONATE 500 MG	SODIUM BICARBONATE	SODIUM BICARBONATE 500MG	TABLETS	RECIEPT	Antacid.
4850	SODIUM BICARBONATE	SODIUM BICARBONATE 500MG 100TAB	SODIUM BICARBONATE	SODIUM BICARBONATE 500MG	TABLETS		Metabolic acidosis, urine alkalization.
4851	SODIUM BICARBONATE	SODIUM BICARBONATE 8.4%	SODIUM BICARBONATE	SODIUM BICARBONATE 8.4%W/V	SOLUTION	RECIEPT	Metabolic acidosis, urine alkalization.
4863	SODIUM CHLORIDE	SODIUM CHLORIDE INJECTION 0.9%	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9 G/100ML	SOLUTION	RECIEPT	A source of water and electrolytes. Also indicated for use as priming solutions in hemodialysis procedures.
4857	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9 % INJECTION USP	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%	SOLUTION	RECIEPT	A source of water and electrolytes. Also indicated for use as priming solutions in hemodialysis procedures.
4862	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9% WITH DEXTROSE 5%	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%;GLUCOSE AS MONOHYDRATE 5%	SOLUTION	RECIEPT	Dehydration, sodium and chloride depletion, caloric supply.
4858	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9 % INTRAVENOUS INFUSION BP	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%W/V	SOLUTION	RECIEPT	Treatment of isotonic extracellular dehydration. Treatment of sodium depletion. Vehicle or diluent of compatible drugs for parenteral administration.
4854	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9 %	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9G/100ML	SOLUTION	RECIEPT	Plasma isotonic fluid repacement. Vehicle solution for supplementary medication Fluid and electrolyte replacement ,hypochloremic alkalosis and chloride losses, externally for wound irrigation and moistening of wound dressings,
4852	SODIUM CHLORIDE	SODIUM CHLORIDE 0.45 % INJECTION	SODIUM CHLORIDE	SODIUM CHLORIDE 450MG/100ML	SOLUTION	RECIEPT	Supply of water and electrolytes.
6005	SODIUM CHLORIDE	TAB SODIUM CHLORIDE 500MG	SODIUM CHLORIDE	SODIUM CHLORIDE 500MG	TABLETS	RECIEPT	HYPNATREMIA
4861	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9% - FRESENIUS	SODIUM CHLORIDE	SODIUM CHLORIDE 9MG/ML	SOLUTION	RECIEPT	Vehicle or diluent for parenteral administration of medicines for intravenous route.
4864	SODIUM IODIDE (I-131)	SODIUM IODIDE (I-131) CAPSULE T	IODINE SODIUM	IODINE SODIUM 37MBQ	CAPSULES	RECIEPT	Treatment of graves disease, toxic multinodular goite or autonomous nodules. Treatment of papillary and follicular thyroid carcinoma including metastatic disease. Sodium Iodide (I-131) Therapy is often combined with surgical intervention and with antithyroid medications.
4865	SODIUM NITRITE	SODIUM NITRITE 30 MG/ML	SODIUM NITRITE	SODIUM NITRITE 30MG/1ML	SOLUTION	RECIEPT	Sodium nitrite is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potentially life-threatening risks associated with sodium nitrite should be carefully weighed against the potential benefits, especially if the patient is not in extremis.
4866	SODIUM THIOSULFATE	SODIUM THIOSULFATE 250 MG/ML	SODIUM THIOSULFATE	SODIUM THIOSULFATE 250MG/1ML	SOLUTION	RECIEPT	Sodium thiosulfate is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potentially life-threatening risks associated with sodium thiosulfate should be carefully weighed against the potential benefits, especially if the patient is not in extremis.
4867	SODIUM VALPROATE WOCKHARDT	SODIUM VALPROATE WOCKHARDT	VALPROIC ACID AS SODIUM	VALPROIC ACID AS SODIUM 100MG/ML	SOLUTION	RECIEPT	Treatment of generalized seizures in the form of absence, myoclonic and tonic-clonic seizures and partial and secondary generalized seizures.
4868	SOFTA-MAN VISCORUB	SOFTA-MAN VISCORUB	PROPANOL	PROPANOL 18%W/V;ETHANOL 45%W/V	SOLUTION		For hygienic and surgical hand disinfection.
4869	SOJOURN SEVOFLURANE	SOJOURN SEVOFLURANE USP	SEVOFLURANE	SEVOFLURANE 100%V/V	LIQUID	RECIEPT	General inhalation anesthetic.
4870	SOLEZOL	SOLEZOL	ESOMEPRAZOLE AS SODIUM	ESOMEPRAZOLE AS SODIUM 40MG/VIAL	POWDER	RECIEPT	Solezol is indicated in adult for: : • Gastroesophageal reflux disease (GERD) in patients with esophagitis and/or severe symptoms of reflux as an alternative to oral therapy when oral intake is not appropriate. • Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers. Solezol is indicated in children and adolescents aged 1-18 years for: • Gastric antisecretory treatment when the oral route is not possible, such as: gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.
4871	SOLIAN	SOLIAN 100 MG	AMISULPRIDE	AMISULPRIDE 100MG	TABLETS	RECIEPT	Treatment of schizophrenia .
4872	SOLIAN	SOLIAN 400 MG	AMISULPRIDE	AMISULPRIDE 400MG	TABLETS	RECIEPT	Treatment of schizophrenia.
4873	SOLIFENACIN	SOLIFENACIN TEVA 10 MG	SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE 10MG	TABLETS	RECIEPT	Solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
4875	SOLIFENACIN	SOLIFENACIN TRIMA 10	SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE 10MG	TABLETS	RECIEPT	For symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome
4874	SOLIFENACIN	SOLIFENACIN TEVA 5 MG	SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE 5MG	TABLETS	RECIEPT	Solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
4876	SOLIFENACIN	SOLIFENACIN TRIMA 5	SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE 5MG	TABLETS	RECIEPT	For symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome
4877	SOLIRIS	SOLIRIS	ECULIZUMAB	ECULIZUMAB 10MG/ML	CONCENTRATE	RECIEPT	Soliris is indicated for the treatment of patients with: - Paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history. Eculizumab has not been studied in clinical trials in patients with PNH below 11 years of age. - Atypical haemolytic uremic syndrome (aHUS). Soliris is indicated in adults for the treatment of: - Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive.
4878	SOLODENT	SOLODENT MOUTHWASH	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 0.2%W/V	SOLUTION		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
4886	SOLUVIT	SOLUVIT N	THIAMINE (VIT B1) MONONITRATE	THIAMINE (VIT B1) MONONITRATE 3.1MG/VIAL;RIBOFLAVINE 4.9MG/VIAL;PYRIDOXINE (VIT B6) HYDROCHLORIDE 4.9MG/VIAL;ASCORBIC ACID AS SODIUM 100MG/VIAL;BIOTIN 60MCG/VIAL;FOLIC ACID 0.4MG/VIAL;CYANOCOBALAMIN 5MCG/VIAL;PANTOTHENIC ACID AS SODIUM 15MG/VIAL;NICOTINAMIDE 40MG/VIAL	POWDER	RECIEPT	Supplement in intravenous nutrition in order to meet the daily requirments of water soluble vitamins.
4892	SOLVEX	SOLVEX SOL INHALATION 50ML	BROMHEXINE HCL	BROMHEXINE HCL 2MG/ML	SOLUTION		Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g.: bronchitis asthma and sinusitis
4891	SOLVEX	SOLVEX ELIXIR 100ML	BROMHEXINE HCL	BROMHEXINE HCL 4.0MG/5ML	LIQUID		Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g.: bronchitis asthma and sinusitis
4890	SOLVEX	SOLVEX 8MG 20TAB	BROMHEXINE HCL	BROMHEXINE HCL 8MG	TABLETS		Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g. :bronchitis asthma and sinusitis.
4888	SOLVEX	SOLVEX	BROMHEXINE HYDROCHLORIDE	BROMHEXINE HYDROCHLORIDE 8MG	TABLETS	RECIEPT	Mucolitic expectorant in conditions associated with the retention of viscid mucoid secretion in the respiratory tract e.g. :bronchitis asthma and sinusitis.
4896	SOMATULINE	SOMATULINE P.R. 30 MG	LANREOTIDE ACETATE	LANREOTIDE ACETATE 0.03G/VIAL	POWDER	RECIEPT	Treatment of acromegaly (when the treatment of growth hormone is not normalized after surgery and/or radiotherapy). Treatment of the clinical symptoms of carcinoid tumors (after a test injection). Treatment of primary thyrotropic adenomas responsible for hypethyroidism as a preparation for / or as a complement to surgery and/or radiotherapy or where these therapies are unsuitable.
4893	SOMATULINE	SOMATULINE AUTOGEL 120 MG	LANREOTIDE AS ACETATE	LANREOTIDE AS ACETATE 120MG/DOSE	SOLUTION	RECIEPT	Somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or insulin like growth factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent . The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalize these values. Somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors. Somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
4894	SOMATULINE	SOMATULINE AUTOGEL 60 MG	LANREOTIDE AS ACETATE	LANREOTIDE AS ACETATE 60MG/DOSE	SOLUTION	RECIEPT	Somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or insulin like growth factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent . The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalize these values. Somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors. Somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
4895	SOMATULINE	SOMATULINE AUTOGEL 90 MG	LANREOTIDE AS ACETATE	LANREOTIDE AS ACETATE 90MG/DOSE	SOLUTION	RECIEPT	Somatuline autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or insulin like growth factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatmfent . The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalize these values. Somatuline autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors. Somatuline autogel is also indicated for the treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
4897	SOMAVERT	SOMAVERT 10 MG	PEGVISOMANT	PEGVISOMANT 10MG	POWDER	RECIEPT	Treatment of adult patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated.
4898	SOMAVERT	SOMAVERT 15 MG	PEGVISOMANT	PEGVISOMANT 15MG	POWDER	RECIEPT	Treatment of adult patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not narmalize IGF-I concentrations or was not tolerated.
4899	SOMAVERT	SOMAVERT 20 MG	PEGVISOMANT	PEGVISOMANT 20MG	POWDER	RECIEPT	Treatment of adult patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not narmalize IGF-I concentrations or was not tolerated.
4900	SOMAVERT	SOMAVERT 25 MG	PEGVISOMANT	PEGVISOMANT 25MG/VIAL	POWDER	RECIEPT	Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy, and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated.
4901	SOMAVERT	SOMAVERT 30 MG	PEGVISOMANT	PEGVISOMANT 30MG/VIAL	POWDER	RECIEPT	Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy, and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated.
4902	SONGHA NIGHT	SONGHA NIGHT	VALERIAN DRY EXTRACT	VALERIAN DRY EXTRACT 120MG;MELISSA OFFICINALIS 80MG	TABLETS		Sedative in states of tension, nervousness and insomnia.
4904	SONGHA NIGHT	SONGHA NIGHT 30 TAB	VALERIAN DRY EXTRACT	VALERIAN DRY EXTRACT120MG;MELISSA 80MG	TABLETS		Sedative in states of tension, nervousness and insomnia.
4905	SONOVUE	SONOVUE	SULPHUR HEXAFLUORIDE	SULPHUR HEXAFLUORIDE 8MCL/ML	POWDER	RECIEPT	This medicinal product is for diagnostic use only. SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, which results in an improved signal to noise ratio. SonoVue should only be used in patients where study without contrast enhancement is inconclusive. Echocardiography: SonoVue is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation. Doppler of macrovasculature: SonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries by improving the Doppler signal to noise ratio. SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment. Doppler of microvasculature: SonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography, leading to more specific lesion characterisation.
4906	SORBON	SORBON 10	BUSPIRONE HYDROCHLORIDE	BUSPIRONE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	For the short-term management of anxiety disorders.
4908	SOVALDI	SOVALDI	SOFOSBUVIR	SOFOSBUVIR 400MG	TABLETS	RECIEPT	Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. For hepatitis C virus (HCV) genotype specific activity, see physician leaflet .
4911	SPASMALGIN	SPASMALGIN	PARACETAMOL	PARACETAMOL 150MG;ATROPINE SULFATE 0.4MG;PAPAVERINE HYDROCHLORIDE 80MG;CODEINE PHOSPHATE 10MG	TABLETS	RECIEPT	Analgesic and antispasmodic for the digestive system, the kidneys and the gall bladder.
4912	SPASMEX	SPASMEX 15	TROSPIUM CHLORIDE	TROSPIUM CHLORIDE 15MG	TABLETS	RECIEPT	For the treatment of vegetative bladder dysfunction accompanied by urgency and/or frequency and/or urinary incontinence.
4913	SPASMEX	SPASMEX 30	TROSPIUM CHLORIDE	TROSPIUM CHLORIDE 30MG	TABLETS	RECIEPT	For the treatment of vegetative bladder dysfunction accompanied by urgency and/or frequency and/or urinary incontinence.
4914	SPASMO-LYT	SPASMO-LYT 20 MG	TROSPIUM CHLORIDE	TROSPIUM CHLORIDE 20MG	TABLETS	RECIEPT	Symptomatic treatment of urge incontinence and /or increased urinary frequency and urgency as may occur in patients with overactive bladder (e.g. idiopathic or neurologic detrusor overactivity) .
4915	SPASMOMEN	SPASMOMEN TABLETS	OTILONIUM BROMIDE	OTILONIUM BROMIDE 40MG	TABLETS	RECIEPT	Treatment of irritable bowel, pain and spasm of the distal enteric tract.
4918	SPINRAZA	SPINRAZA	NUSINERSEN	NUSINERSEN 2.4MG/1ML	SOLUTION	RECIEPT	Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy except type 0 and type IV.
4922	SPIOLTO RESPIMAT	SPIOLTO RESPIMAT	OLODATEROL AS HYDROCHLORIDE	OLODATEROL AS HYDROCHLORIDE 2.5MCG;TIOTROPIUM BROMIDE AS MONOHYDRATE 2.5MCG	SOLUTION	RECIEPT	Spiolto Respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
4927	SPIRIT WHITFIELD	SPIRIT WHITFIELD 100ML	BENZOIC ACID	BENZOIC ACID 6%;SALICYLIC ACID 3%	LIQUID		Antifungal, antiseptic.
4928	SPIRIT WHITFIELD	SPIRIT WHITFIELD FLORIS	BENZOIC ACID	BENZOIC ACID 6%;SALICYLIC ACID 3%	LIQUID		Antifungal, antiseptic.
4929	SPIRIVA	SPIRIVA	TIOTROPIUM BROMIDE	TIOTROPIUM BROMIDE 18MCG	INHALATION	RECIEPT	Tiotropium is a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
4930	SPIRIVA	SPIRIVA RESPIMAT	TIOTROPIUM BROMIDE AS MONOHYDRATE	TIOTROPIUM BROMIDE AS MONOHYDRATE 2.5MCG	SOLUTION	RECIEPT	Maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). COPD: Tiotropium is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). Asthma: Spiriva Respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.
4931	SPIRONOLACTONE	SPIRONOLACTONE TEVA 100 MG	SPIRONOLACTONE	SPIRONOLACTONE 100MG	TABLETS	RECIEPT	Edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. Essential hypertention. Primary hyperaldostronism. Hypokalemia.
4933	SPIRONOLACTONE	SPIRONOLACTONE TEVA 25 MG	SPIRONOLACTONE	SPIRONOLACTONE 25MG	TABLETS	RECIEPT	Edematous conditions: - congestive heart failure; - cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. Essential hypertention. Primary hyperaldostronism. Hypokalemia.
4935	SPORANOX	SPORANOX ORAL SOLUTION	ITRACONAZOLE	ITRACONAZOLE 10MG/ML	SOLUTION	RECIEPT	Sporanox oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. Prevention of fungal infection during neutropenia of immunodeficient patients.
4936	SPRYCEL	SPRYCEL 100 MG	DASATINIB	DASATINIB 100MG	TABLETS	RECIEPT	Treatment of adult patients with : * Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. * Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate. * Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
4937	SPRYCEL	SPRYCEL 20 MG	DASATINIB	DASATINIB 20MG	TABLETS	RECIEPT	Treatment of adult patients with : * Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. * Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate. * Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
4938	SPRYCEL	SPRYCEL 50 MG	DASATINIB	DASATINIB 50MG	TABLETS	RECIEPT	Treatment of adult patients with : * Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. * Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate. * Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
4939	SPRYCEL	SPRYCEL 70 MG	DASATINIB	DASATINIB 70MG	TABLETS	RECIEPT	Treatment of adult patients with : * Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. * Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate. * Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
4940	STABILANOL	STABILANOL	FLUCONAZOLE	FLUCONAZOLE 2MG/ML	SOLUTION	RECIEPT	Stabilanol is indicated in the following fungal infections . Stabilanol is indicated in adults for the treatment of: • Cryptococcal meningitis . • Coccidioidomycosis. Invasive candidiasis. • Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. Stabilanol is indicated in adults for the prophylaxis of: • Relapse of crytopcoccal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation ). Stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: Stabilanol is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. stabilanol can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
4955	STALEVO	STALEVO 75/18.75/200	CARBIDOPA AS MONOHYDRATE	CARBIDOPA AS MONOHYDRATE 18.75MG;ENTACAPONE 200MG;LEVODOPA 75MG	TABLETS	RECIEPT	Treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (DDC) inhibitor treatment.
4945	STALEVO	STALEVO 100/25/200 MG	LEVODOPA	LEVODOPA 100MG;CARBIDOPA 25MG;ENTACAPONE 200MG	TABLETS	RECIEPT	Treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
4947	STALEVO	STALEVO 125/31.25/200 MG	LEVODOPA	LEVODOPA 125MG;ENTACAPONE 200MG;CARBIDOPA AS MONOHYDRATE 31.25MG	TABLETS	RECIEPT	Treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (DDC) inhibitor treatment.
4949	STALEVO	STALEVO 150/37.5/200 MG	LEVODOPA	LEVODOPA 150MG;CARBIDOPA 37.5MG;ENTACAPONE 200MG	TABLETS	RECIEPT	Treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
4951	STALEVO	STALEVO 200/50/200 MG	LEVODOPA	LEVODOPA 200MG;ENTACAPONE 200MG;CARBIDOPA AS MONOHYDRATE 50MG	TABLETS	RECIEPT	Treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
4953	STALEVO	STALEVO 50/12.5/200 MG	LEVODOPA	LEVODOPA 50MG;CARBIDOPA 12.5MG;ENTACAPONE 200MG	TABLETS	RECIEPT	Treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
4957	STAMARIL	STAMARIL	YELLOW FEVER VIRUS STRAIN	YELLOW FEVER VIRUS STRAIN 17D204 (SUBSTRAIN AB237) bigger than or equal to 1000 IU	POWDER	RECIEPT	Prevention of yellow fever.
4958	STAMICIS	STAMICIS 1 MG KIT FOR RADIOPHARMACEUTICAL PREPATION	TETRAKIS COPPER (I) TETRAFLUOROBORATE	TETRAKIS COPPER (I) TETRAFLUOROBORATE 1MG/VIAL	POWDER	RECIEPT	This medicinal product is for diagnostic use only. After reconstitution with sodium pertechnetate (99mTc) solution for injection, the solution of technetium (99mTc) sestamibi obtained is indicated for: Myocardial perfusion scintigraphy Detection and localisation of coronary artery disease and myocardial infarction. Assessment of global ventricular function First-pass technique for determination of ejection fraction and/or ECG-triggered, gated SPECT for evaluation of left ventricular ejection fraction, volumes and regional wall motion. Scinti-mammography for the detection of suspected breast cancer Detection of suspected breast cancer when mammography is equivocal, inadequate or indeterminate. Localisation of hyperfunctioning parathyroid tissue in patients with recurrent or persistent hyperparathyroidism, and in patients scheduled to undergo surgery of the parathyroid glands.
4959	STAPHIDERM	STAPHIDERM CREAM	FUSIDIC ACID	FUSIDIC ACID 2%	CREAM	RECIEPT	Local treatment of skin infections due to sensitive strains of Staphylococcus Aureus
4960	STAQUIS	STAQUIS	CRISABOROLE	CRISABOROLE 2%W/W	OINTMENT	RECIEPT	Staquis is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
4961	STATOR	STATOR 10	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 10MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4963	STATOR	STATOR 20	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 20MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4965	STATOR	STATOR 40	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 40MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. Homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
4967	STATOR	STATOR 5	ROSUVASTATIN AS CALCIUM	ROSUVASTATIN AS CALCIUM 5MG	TABLETS	RECIEPT	Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia ) or mixed dyslipidaemia ( type IIb ) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. Hormozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatment are not appropriate.
4969	STEGLATRO	STEGLATRO 15 MG	ERTUGLIFLOZIN (L-PGA)	ERTUGLIFLOZIN (L-PGA) 15MG	TABLETS	RECIEPT	Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: • as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. • in addition to other medicinal products for the treatment of diabetes.
4970	STEGLATRO	STEGLATRO 5 MG	ERTUGLIFLOZIN (L-PGA)	ERTUGLIFLOZIN (L-PGA) 5MG	TABLETS	RECIEPT	Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: • as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. • in addition to other medicinal products for the treatment of diabetes.
4972	STELARA	STELARA 45 MG VIAL	USTEKINUMAB	USTEKINUMAB 45MG/0.5ML	SOLUTION	RECIEPT	* Pque Poriasis STELARA is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen plus U.V (PUVA). * Psoriatic Arthritis Stelara, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate Pediatric plaque psoriasis: STELARA is indicated for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. * Crohn’s Disease: STELARA is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.
4973	STELARA	STELARA PREFILLED SYRINGE	USTEKINUMAB	USTEKINUMAB 45MG/0.5ML	SOLUTION	RECIEPT	* Pque Poriasis STELARA is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen plus U.V (PUVA). * Psoriatic Arthritis Stelara, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate Pediatric plaque psoriasis: STELARA is indicated for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. * Crohn’s Disease: STELARA is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.
4971	STELARA	STELARA 130 MG	USTEKINUMAB	USTEKINUMAB 5MG/1ML	CONCENTRATE	RECIEPT	STELARA is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies
4974	STERETS TISEPT SACHETS	STERETS TISEPT SACHETS	CETRIMIDE	CETRIMIDE 0.15%W/V;CHLORHEXIDINE DIGLUCONATE 0.015%W/V	SOLUTION		A broad spectrum antiseptic with detergent properties for swabbing in obstetrics and during dressing changes. For disinfecting and cleansing traumatic and surgical wounds and burns
4975	STERETS UNISEPT	STERETS UNISEPT	CHLORHEXIDINE DIGLUCONATE	CHLORHEXIDINE DIGLUCONATE 0.05%W/V	SOLUTION		Chlorhexidine gluconate is a potent antibacterial agent for general antiseptic purposes. It is bactericidal to a broad spectrum of organisms. Sterets Unisept is recommended for use in obstetrics and for swabbing burns and wounds.
4976	STERILE WATER FOR INJECTION	STERILE WATER FOR INJECTION	WATER FOR INJECTIONS	WATER FOR INJECTIONS 3000ML	LIQUID		Indicated in the aseptic preparation of parenteral admixtures.
4977	STEROCORT	STEROCORT 4 MG	TRIAMCINOLONE	TRIAMCINOLONE 4MG	TABLETS	RECIEPT	Rheumatology: - Active phases of systemic vasculitis: Panarteritis nodosa (in patients with concomitant positive hepatitis B serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (PMR), PMR with giant cell arteritis, arteritis temporalis with acute visual loss; - Active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease; - Severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations; - Other forms of inflammatory rheumatic arthritis, provided that the severity of symptoms requires it and non-steroidal anti-inflammatory drugs (NSAIDs) cannot be used: Spondylarthritis (ankylosing spondylitis with involvement of peripheral joints, psoriatic arthritis, enteropathic arthropathy with high inflammatory activity); - Reactive forms of arthritis; - Arthritis in sarcoidosis; - Severe systemic form of juvenile idiopathic arthritis (Still’s disease) or with iridocyclitis refractory to topical treatment. Pulmonary and respiratory tract disorders: - Bronchial asthma: For the long-term treatment of severe chronic asthma (category 4) and for treatment of exacerbations in adults and children. - Chronic obstructive pulmonary disease (COPD): For short-term treatment (max. 14 days) of exacerbations; - Upper respiratory tract disorders: For short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids. Dermatology: - Oral initial treatment of extensive, severe, acute skin conditions responsive to glucocorticoids, such as: Allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris. Nephrology: - Minimal change glomerulonephritis; - Extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in Goodpasture’s syndrome; for all other forms, long-term continuation of treatment; - Idiopathic retroperitoneal fibrosis.
4978	STERODEX	STERODEX EYE DROPS	DEXAMETHASONE AS SODIUM PHOSPHATE	DEXAMETHASONE AS SODIUM PHOSPHATE 0.1%	DROPS	RECIEPT	For the treatment of conjuctivitis and cornea inflammation.
4979	STEROFUNDIN	STEROFUNDIN ISO	L-MALIC ACID	L-MALIC ACID 0.67G/1000ML;SODIUM ACETATE TRIHYDRATE 3.27G/1000ML;CALCIUM CHLORIDE DIHYDRATE 0.37G/1000ML;MAGNESIUM CHLORIDE HEXAHYDRATE 0.20G/1000ML;POTASSIUM CHLORIDE 0.30G/1000ML;SODIUM CHLORIDE 6.80G/1000ML	SOLUTION	RECIEPT	Replacement of extracellular fluid losses in the case of isotonic dehydration, where acidosis is present or imminent.
4981	STERONASE AQ	STERONASE AQ NASAL SPRAY	TRIAMCINOLONE ACETONIDE	TRIAMCINOLONE ACETONIDE 0.055%W/W	SUSPENSION	RECIEPT	For the treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 2 years of age and older.
4983	STILLA	STILLA EYE DROPS 10ml	TETRAHYDROZOLINE HCL	TETRAHYDROZOLINE HCL 0.05%	DROPS		For relief in cases of redness in the eye as a result of irritation, caused by various materials such as dust, smoke, plants, etc.
4985	STILLA	STILLA SINGLES 10*0.3ML EYES DROPS	TETRAHYDROZOLINE HCL	TETRAHYDROZOLINE HCL 0.05%	DROPS		Irritation, burning, reddening, itching of the eye due to allergic or physical causes such as dust, smoke, plants,sun rays.
4986	STILLA	STILLA SINGLES 20*0.3ML	TETRAHYDROZOLINE HCL	TETRAHYDROZOLINE HCL 0.05%	DROPS		Irritation, burning, reddening, itching of the eye due to allergic or physical causes such as dust, smoke, plants,sun rays.
4984	STILLA	STILLA SINGLES	TETRAHYDROZOLINE HYDROCHLORIDE	TETRAHYDROZOLINE HYDROCHLORIDE 0.05%	DROPS		Irritation, burning, reddening, itching of the eye due to allergic or physical causes such as dust, smoke, plants,sun rays.
4982	STILLA	STILLA	TETRAHYDROZOLINE HYDROCHLORIDE	TETRAHYDROZOLINE HYDROCHLORIDE 0.5MG/ML	DROPS		Irritation, burning, reddening, itching of the eye due to allergic or physical causes such as dust, smoke, plants,sun rays.
4987	STILNOX	STILNOX 10 MG TABLETS	ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE 10MG	TABLETS	RECIEPT	Indications are limited to treatment of severe sleep disorders in the following cases: - Occasional insomnia - Transient insomnia.
4988	STIVARGA	STIVARGA	REGORAFENIB	REGORAFENIB 40MG	TABLETS	RECIEPT	Stivarga is indicated as monotherapy for the treatment of adults patients: - with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if KRAS wild- type, an anti-EGFR therapy. - with locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. - hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
4989	STOCRIN	STOCRIN 600 MG TABLETS	EFAVIRENZ	EFAVIRENZ 600MG	TABLETS	RECIEPT	Stocrin in combination with other antiretroviral agents, is indicated for the treatment of HIV-1-infection .
4992	STOPIT	STOPIT 2MG 10CAPS	LOPERAMIDE HCL	LOPERAMIDE HCL 2MG	CAPSULES		Acute diarrhoea.
4991	STOPIT	STOPIT	LOPERAMIDE HYDROCHLORIDE	LOPERAMIDE HYDROCHLORIDE 2MG	CAPSULES	RECIEPT	Acute diarrhoea.
4997	STRATTERA	STRATTERA 4 MG/ML ORAL SOLUTION	ATOMOXETINE	ATOMOXETINE 4MG/1ML	SOLUTION	RECIEPT	Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
4994	STRATTERA	STRATTERA 100 MG	ATOMOXETINE AS HYDROCHLORIDE	ATOMOXETINE AS HYDROCHLORIDE 100MG	CAPSULES	RECIEPT	Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
4993	STRATTERA	STRATTERA 10 MG	ATOMOXETINE AS HYDROCHLORIDE	ATOMOXETINE AS HYDROCHLORIDE 10MG	CAPSULES	RECIEPT	Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
4995	STRATTERA	STRATTERA 18 MG	ATOMOXETINE AS HYDROCHLORIDE	ATOMOXETINE AS HYDROCHLORIDE 18MG	CAPSULES	RECIEPT	Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
4996	STRATTERA	STRATTERA 25 MG	ATOMOXETINE AS HYDROCHLORIDE	ATOMOXETINE AS HYDROCHLORIDE 25MG	CAPSULES	RECIEPT	Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
4998	STRATTERA	STRATTERA 40 MG	ATOMOXETINE AS HYDROCHLORIDE	ATOMOXETINE AS HYDROCHLORIDE 40MG	CAPSULES	RECIEPT	Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
4999	STRATTERA	STRATTERA 60 MG	ATOMOXETINE AS HYDROCHLORIDE	ATOMOXETINE AS HYDROCHLORIDE 60MG	CAPSULES	RECIEPT	Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
5000	STRATTERA	STRATTERA 80 MG	ATOMOXETINE AS HYDROCHLORIDE	ATOMOXETINE AS HYDROCHLORIDE 80MG	CAPSULES	RECIEPT	Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.
5001	STREFEN	STREFEN - ORANGE FLAVOUR - SUGAR FREE	FLURBIPROFEN	FLURBIPROFEN 8.75MG	TABLETS	RECIEPT	For the short term relief of symptoms of sore throat such as throat pain and soreness in adults and children over the age of 12 years
5002	STREFEN	STREFEN - ORANGE FLAVOUR - SUGAR FREE 16 lozenges	FLURBIPROFEN	FLURBIPROFEN 8.75MG	TABLETS		For the short term relief of symptoms of sore throat such as throat pain and soreness in adults and children over the age of 12 years
5003	STREFEN	STREFEN HONEY AND LEMON	FLURBIPROFEN	FLURBIPROFEN 8.75MG	TABLETS	RECIEPT	For the short term relief of symptoms of sore throat such as throat pain and soreness in adults and children over the age of 12 years
5004	STREFEN	STREFEN HONEY AND LEMON 8.75MG 16 LOZENGES	FLURBIPROFEN	FLURBIPROFEN 8.75MG	TABLETS	RECIEPT	For the short term relief of symptoms of sore throat such as throat pain and soreness in adults and children over the age of 12 years
5005	STRENSIQ	STRENSIQ 100 MG/ML	ASFOTASE ALFA	ASFOTASE ALFA 100MG/1ML	SOLUTION	RECIEPT	Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
5006	STRENSIQ	STRENSIQ 40 MG/ML	ASFOTASE ALFA	ASFOTASE ALFA 40MG/1ML	SOLUTION	RECIEPT	Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
5008	STREPSILS	STREPSILS GINGER	AMYLMETACRESOL	AMYLMETACRESOL 0.6MG;DICHLOROBENZYL ALCOHOL 1.2MG	TABLETS		Antiseptic for the relief of sore throat in children and adults.
5012	STREPSILS	STREPSILS LEMON SUGAR FREE 16 LOZENGES	AMYLMETACRESOL	AMYLMETACRESOL 0.6MG;DICHLOROBENZYL ALCOHOL 1.2MG	DRAGEE		Antiseptic for the relief of sore throat in children and adults.
5019	STREPSILS	STREPSILS STRAW S. FREE 16LOZ	AMYLMETACRESOL	AMYLMETACRESOL 0.6MG;DICHLOROBENZYL ALCOHOL 1.2MG	DRAGEE		Antiseptic for the relief of sore throat in children and adults.
5020	STREPSILS	STREPSILS STRAW S. FREE 24LOZ	AMYLMETACRESOL	AMYLMETACRESOL 0.6MG;DICHLOROBENZYL ALCOHOL 1.2MG	DRAGEE		Antiseptic for the relief of sore throat in children and adults.
5022	STREPSILS	STREPSILS SUGAR FREE LEMON 24 LOZENGES	AMYLMETACRESOL	AMYLMETACRESOL 0.6MG;DICHLOROBENZYL ALCOHOL 1.2MG	DRAGEE		Antiseptic for the relief of sore throat in children and adults.
5023	STREPSILS	STREPSILS SUGAR FREE STRAWBERRY	AMYLMETACRESOL	AMYLMETACRESOL 0.6MG;DICHLOROBENZYL ALCOHOL 1.2MG	TABLETS		Antiseptic for the relief of sore throat in children and adults.
5017	STREPSILS	STREPSILS PLUS	AMYLMETACRESOL	AMYLMETACRESOL 0.6MG;DICHLOROBENZYL ALCOHOL 1.2MG;LIDOCAINE AS HYDROCHLORIDE 10MG	TABLETS		Antiseptic for the throat, fast relief of severe sore throat.
5013	STREPSILS	STREPSILS MENTHOL & EUCALYPTUS	AMYLMETACRESOL	AMYLMETACRESOL 0.6MG;DICHLOROBENZYL ALCOHOL 1.2MG;MENTHOL 8MG	TABLETS		Antiseptic for the relief of sore throat in children and adults.
5014	STREPSILS	STREPSILS ORANGE WITH VITAMIN C 36 LOZ	ASCORBIC ACID	ASCORBIC ACID 100MG;DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG	DRAGEE		Sore throat
5016	STREPSILS	STREPSILS ORANGE+VIT C 24 LOZ	ASCORBIC ACID	ASCORBIC ACID 100MG;DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG	DRAGEE		Sore throat
5007	STREPSILS	STREPSILS MENTHOL&EUCA 24LOZ	DICHLOROBENZYL ALCOHOL	DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG	DRAGEE		Antiseptic for the relief of sore throat in children and adults.
5009	STREPSILS	STREPSILS GINGER 24 tab	DICHLOROBENZYL ALCOHOL	DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG	DRAGEE		Antiseptic for the relief of sore throat in children and adults.
5010	STREPSILS	STREPSILS HONEY AND LEMON 24 LOZ	DICHLOROBENZYL ALCOHOL	DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG	DRAGEE		Antiseptic for the relief of sore throat in children and adults.
5011	STREPSILS	STREPSILS HONEY AND LEMON 36 LOZ	DICHLOROBENZYL ALCOHOL	DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG	DRAGEE		Antiseptic for the relief of sore throat in children and adults.
5021	STREPSILS	STREPSILS SUGAR FREE LEMON	DICHLOROBENZYL ALCOHOL	DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG	TABLETS		Antiseptic for the relief of sore throat in children and adults.
5024	STREPSILS	STREPSILS WITH HONEY AND LEMON	DICHLOROBENZYL ALCOHOL	DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG	TABLETS		Antiseptic for the relief of sore throat in children and adults.
5015	STREPSILS	STREPSILS ORANGE WITH 100 MG VITAMIN C	DICHLOROBENZYL ALCOHOL	DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETACRESOL 0.6MG;ASCORBIC ACID 100MG	TABLETS		Antiseptic. To relieve throat pain in children and adults.
5018	STREPSILS	STREPSILS PLUS 24 LOZ	DICHLOROBENZYL ALCOHOL	DICHLOROBENZYL ALCOHOL 1.2MG;AMYLMETTACRESOL 0.6MG	DRAGEE		Antiseptic for the throat, fast relief of severe sore throat.
5025	STREPTASE	STREPTASE 1,500000 IU	STREPTOKINASE	STREPTOKINASE 1500000 IU	POWDER	RECIEPT	Systemic administration: in deep vein thromboses, lung embolism, acute myocardial infarction for re-opening of coronary vessels. In acute and subacute thromboses of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein. Local administration: in acute myocardial infarction for re-opening of coronary vessels, in acute, subacute and chronic thromboses as well as embolisms of peripheral arteries.
5026	STREPTASE	STREPTASE 750000 I.U.	STREPTOKINASE	STREPTOKINASE 750000IU/VIAL	POWDER	RECIEPT	Acute myocardial infarction, deep vein thrombosis, pulmonary embolism, acute or subacute thrombosis of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein.
5027	STRIBILD	STRIBILD	TENOFOVIR DISOPROXIL AS FUMARATE	TENOFOVIR DISOPROXIL AS FUMARATE 245MG;EMTRICITABINE 200MG;COBICISTATE 150MG;ELVITEGRAVIR 150MG	TABLETS	RECIEPT	Stribild is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.
5029	STRIVERDI RESPIMAT	STRIVERDI RESPIMAT	OLODATEROL AS HYDROCHLORIDE	OLODATEROL AS HYDROCHLORIDE 2.5MCG	SOLUTION	RECIEPT	Maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).
5031	STUD	STUD 100 SPRAY FOR MEN 12GR	LIDOCAINE	LIDOCAINE 9.6%	SPRAY		To reduce tacticle sensitivity of the penis in advance of intercourse.
5030	STUD	STUD 100	LIDOCAINE	LIDOCAINE 9.6%W/W	SPRAY	RECIEPT	To reduce tacticle sensitivity of the penis in advance of intercourse.
5032	STUNARONE	STUNARONE TABLETS	CINNARIZINE	CINNARIZINE 25MG	TABLETS	RECIEPT	Symptomatic treatment of nausea and vertigo due to meniere's disease and other labyrinthine disturbances and for travel sickness.
5034	SUBOXONE	SUBOXONE 2 MG/0.5 MG	BUPRENORPHINE HYDROCHLORIDE	BUPRENORPHINE HYDROCHLORIDE 2.16MG;NALOXONE HYDROCHLORIDE DIHYDRATE 0.61MG	TABLETS	RECIEPT	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.
5035	SUBOXONE	SUBOXONE 8 MG / 2 MG	BUPRENORPHINE HYDROCHLORIDE	BUPRENORPHINE HYDROCHLORIDE 8.64MG;NALOXONE HYDROCHLORIDE DIHYDRATE 2.44MG	TABLETS	RECIEPT	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction
5036	SUBUTEX	SUBUTEX 2 MG	BUPRENORPHINE AS HYDROCHLORIDE	BUPRENORPHINE AS HYDROCHLORIDE 2MG	TABLETS	RECIEPT	Substitution treatment for opioid dependence within a Framework of medical, social and psychological treatment.
5037	SUBUTEX	SUBUTEX 8 MG	BUPRENORPHINE AS HYDROCHLORIDE	BUPRENORPHINE AS HYDROCHLORIDE 8MG	TABLETS	RECIEPT	Substitution treatment for opioid dependence within a Framework of medical, social and psychological treatment.
5038	SULFACID	SULFACID	SULFACETAMIDE SODIUM	SULFACETAMIDE SODIUM 10%	DROPS	RECIEPT	Eye infections caused by micro-organisms sensitive to sulfacetamide.
5042	SULIQUA	SULIQUA 100/33	LIXISENATIDE	LIXISENATIDE 33MCG/1ML;INSULIN GLARGINE 100UNITS/1ML	SOLUTION	RECIEPT	Suliqua is indicated in combination with metformin for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin.
5043	SULIQUA	SULIQUA 100/50	LIXISENATIDE	LIXISENATIDE 50MCG/1ML;INSULIN GLARGINE 100UNITS/1ML	SOLUTION	RECIEPT	Suliqua is indicated in combination with metformin for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin.
5044	SUMATRIDEX	SUMATRIDEX 100	SUMATRIPTAN AS SUCCINATE	SUMATRIPTAN AS SUCCINATE 100MG	TABLETS	RECIEPT	Sumatridex caplets are indicated for the acute relief of migraine attacks, with or without aura. Sumatridex should only be used where there is a clear diagnosis of migraine.
5045	SUMATRIDEX	SUMATRIDEX 50	SUMATRIPTAN AS SUCCINATE	SUMATRIPTAN AS SUCCINATE 50MG	TABLETS	RECIEPT	Sumatridex caplets are indicated for the acute relief of migraine attacks, with or without aura. Sumatridex should only be used where there is a clear diagnosis of migraine.
5046	SUNACTIC	SUNACTIC	DICLOFENAC SODIUM	DICLOFENAC SODIUM 3%	GEL	RECIEPT	For the treatment of Actinic Keratoses
5049	SUPRAMOL	SUPRAMOL M 150MG 12 SUPP	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		Analgesic and antipyretic.
5050	SUPRAMOL	SUPRAMOL 'M' PEDIATRIC SUPPOSITORIES	PARACETAMOL	PARACETAMOL 150MG	SUPPOSITORIES		Analgesic, antipyretic.
5047	SUPRAMOL	SUPRAMOL 500 SUPPOSITORIES	PARACETAMOL	PARACETAMOL 500MG	SUPPOSITORIES		Analgesic and Antipyretic.
5048	SUPRAMOL	SUPRAMOL 500MG 20SUP	PARACETAMOL	PARACETAMOL 500MG	SUPPOSITORIES		Analgesic, antipyretic.
5052	SUPRANE	SUPRANE	DESFLURANE	DESFLURANE 100%	SOLUTION	RECIEPT	Sulorane is indicated as an inhalation agent for induction and/or maintenance of anesthesia in adults and maintenance of anesthesia in infants and children.
5053	SUPREFACT DEPOT	SUPREFACT DEPOT 3-MONTHS	BUSERELIN ACETATE	BUSERELIN ACETATE 9.9MG	RODS FOR IMPLANT	RECIEPT	Treatment of advanced hormone dependent prostatic carcinoma. However not after bilateral orchiectomy ( no further reduction of testosterone level by buserelin to be expected).
5056	SUTENT	SUTENT 12.5 MG	SUNITINIB AS MALATE	SUNITINIB AS MALATE 12.5MG	CAPSULES	RECIEPT	Sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Sutent is indicated for the treatment of advanced renal cell carcinoma. Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pNET) with disease progression.
5057	SUTENT	SUTENT 25 MG	SUNITINIB AS MALATE	SUNITINIB AS MALATE 25MG	CAPSULES	RECIEPT	Sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Sutent is indicated for the treatment of advanced renal cell carcinoma. Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pNET) with disease progression.
5058	SUTENT	SUTENT 50 MG	SUNITINIB AS MALATE	SUNITINIB AS MALATE 50MG	CAPSULES	RECIEPT	Sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Sutent is indicated for the treatment of advanced renal cell carcinoma. Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pNET) with disease progression.
5063	SYLVANT	SYLVANT 100 MG	SILTUXIMAB	SILTUXIMAB 100MG	POWDER	RECIEPT	Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
5064	SYLVANT	SYLVANT 400 MG	SILTUXIMAB	SILTUXIMAB 400MG	POWDER	RECIEPT	Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
5066	SYMBICORT	SYMBICORT TURBUHALER 160/4.5 MCG/DOSE	BUDESONIDE MICRONIZED	BUDESONIDE MICRONIZED 160MCG/DOSE;FORMOTEROL FUMARATE 4.5MCG/DOSE DIHYDRATE	POWDER	RECIEPT	Asthma Symbicort Turbuhaler 160/4.5 mcg/dose is indicated in adults and adolescents (12 years and older), for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor agonist) is appropriate: Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor agonists. Or Patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptor-agonists. Chronic Obstructive Pulmonary Disease (COPD) Symbicort Turbuhaler 160/4.5 mcg/dose is indicated in adults, aged 18 years and older, for the Symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1)< 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy
5067	SYMBICORT	SYMBICORT TURBUHALER 320/9 MCG/DOSE	BUDESONIDE MICRONIZED	BUDESONIDE MICRONIZED 320MCG/DOSE;FORMOTEROL FUMARATE 9MCG/DOSE DIHYDRATE	POWDER	RECIEPT	Symbicort Turbuhaler 320/9 mcg/dose is indicated in adults and adolescents, age 12 -17 for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor-agonist) is appropriate: -Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor-agonists. Or - Patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptoragonists. Chronic Obstructive Pulmonary Disease (COPD) Symbicort Turbuhaler 320/9 mcg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in I second (FEV1) < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy
5068	SYMBICORT	SYMBICORT TURBUHALER 80/4.5 MCG/DOSE	BUDESONIDE MICRONIZED	BUDESONIDE MICRONIZED 80MCG/DOSE;FORMOTEROL FUMARATE 4.5MCG/DOSE DIHYDRATE	POWDER	RECIEPT	Symbicort turbuhaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - Patients not adequaterly controlled with inhaled corticosteroids and caret as neededcaret inhaled short acting beta2- agonists. - Or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. NOTE: Symbicort turbuhaler 80/4.5 mcg/dose is not appropriate in patients with severe asthma.
5065	SYMBICORT	SYMBICORT RAPIHALER 160/4.5	FORMOTEROL FUMARATE DIHYDRATE	FORMOTEROL FUMARATE DIHYDRATE 4.5MCG/ACTUATION;BUDESONIDE 160MCG/ACTUATION	SUSPENSION	RECIEPT	Chronic Obstructive Pulmonary Disease (COPD) Symbicort is indicated in adults, aged 18 and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEVI) < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy
5069	SYMDEKO	SYMDEKO 100 MG/150 MG & 150 MG	IVACAFTOR	IVACAFTOR 150MG;TEZACAFTOR 100MG	TABLETS	RECIEPT	SYMDEKO is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. If the patient’s genotype is unknown, a health authority cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
5070	SYMDEKO	SYMDEKO 100MG/ 150MG & 150MG	IVACAFTOR	IVACAFTOR 150MG;TEZACAFTOR 100MG	TABLETS	RECIEPT	SYMDEKO is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. If the patient’s genotype is unknown, a health authority cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
5073	SYMPHOCAL	SYMPHOCAL RASPBERRY FLAVOUR	OXOLAMINE CITRATE	OXOLAMINE CITRATE 10MG/ML	SYRUP		Cough suppressant.
5071	SYMPHOCAL	SYMPHOCAL H/L SF 115ML	OXOLAMINE CITRATE	OXOLAMINE CITRATE 10MG/ML (1%)	SYRUP		Cough suppressant.
5074	SYMPHOCAL	SYMPHOCAL RASPBERRY SF 100ML	OXOLAMINE CITRATE	OXOLAMINE CITRATE 10MG/ML (1%)	SYRUP		Cough suppressant.
5072	SYMPHOCAL	SYMPHOCAL HONEY AND LEMON FLAVOUR	OXOLAMINE CITRATE	OXOLAMINE CITRATE 1G/100ML	SYRUP		Cough suppressant.
5075	SYNAREL	SYNAREL	NAFARELIN ACETATE	NAFARELIN ACETATE 2MG/ML	SOLUTION	RECIEPT	- Controlled ovarian stimulation programmes prior to in-vitro fertilisation. - Hormonal management of endometriosis, including pain relief and reduction of endometrial lesions. - Uterine fibroids.
5080	SYNFLORIX	SYNFLORIX	PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE	PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19 F 3MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 1MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 3MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 1MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B 1MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F 1MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V 1MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 1MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C 3MCG/0.5ML;PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F 1MCG/0.5ML	SUSPENSION	RECIEPT	Active immunisation against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F in infants and children from 6 weeks up to 5 years of age. The use of Synflorix should be determined on the basis of official recommendations taking into consideration the impact on pneumococcal diseases in different age groups as well as the variability of the epidemiology in different geographical areas.
5081	SYNTHOMYCINE	SYNTHOMYCINE 3 %	CHLORAMPHENICOL	CHLORAMPHENICOL 3%	OINTMENT	RECIEPT	Antibiotic.
5082	SYNTHOMYCINE	SYNTHOMYCINE 5%	CHLORAMPHENICOL	CHLORAMPHENICOL 5%	OINTMENT	RECIEPT	For eye infections due to chloramphenicol susceptible microorganisms.
5083	SYNTHROID	SYNTHROID 100 MCG TABLETS	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM 100MCG	TABLETS	RECIEPT	Hypothyroidism, Pituitary TSH Suppression
5084	SYNTHROID	SYNTHROID 50 MCG TABLETS	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM 50MCG	TABLETS	RECIEPT	Hypothyroidism, Pituitary TSH Suppression
5091	T.A.	T.A. 1.0 MG	ATROPINE AS SULFATE	ATROPINE AS SULFATE 1.0MG;TRIMEDOXIME BROMIDE (TMB-4) 40MG	SOLUTION	RECIEPT	For the treatment of organophosphate cholinesterase inhibitors, chemical warfare and nerve gas.
5090	T.A.	T.A. 0.5 MG	TRIMEDOXIME BROMIDE (TMB-4)	TRIMEDOXIME BROMIDE (TMB-4) 20MG;ATROPINE SULFATE 0.5MG	SOLUTION	RECIEPT	For the treatment of organophosphate cholinesterase inhibitors, chemical warfare and nerve gas.
5092	T.A.	T.A. 2.0 MG	TRIMEDOXIME BROMIDE (TMB-4)	TRIMEDOXIME BROMIDE (TMB-4) 80MG;ATROPINE SULFATE 2MG	SOLUTION	RECIEPT	For the treatment of organophosphate cholinesterase inhibitors, chemical warfare and nerve gas.
3238	TABLETS	MICAL TABLETS	CARBOCISTEINE	CARBOCISTEINE 375MG	TABLETS	RECIEPT	Treatment of disorders of the respiratory tract characterised by excessive or viscous mucus.
5095	TACHOSIL	TACHOSIL	THROMBIN	THROMBIN 2IU/CM2;HUMAN FIBRINOGEN 5.5MG/CM2	SEALANT MATRIX	RECIEPT	Tachosil is indicated for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for sutute support in vascular surgery where standard techniques are insufficient.
5096	TACROCEL	TACROCEL 0.5 MG	TACROLIMUS AS MONOHYDRATE	TACROLIMUS AS MONOHYDRATE 0.5MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in liver kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immuonosuppressive medicinal products.
5097	TACROCEL	TACROCEL 1 MG	TACROLIMUS AS MONOHYDRATE	TACROLIMUS AS MONOHYDRATE 1MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in liver kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immuonosuppressive medicinal products.
5098	TACROCEL	TACROCEL 5 MG	TACROLIMUS AS MONOHYDRATE	TACROLIMUS AS MONOHYDRATE 5MG	CAPSULES	RECIEPT	Prophylaxis of transplant rejection in liver kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immuonosuppressive medicinal products.
5099	TADAIR	TADAIR	TADALAFIL	TADALAFIL 20MG	TABLETS	RECIEPT	Tadair is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.
5101	TADALAFIL	TADALAFIL TEVA	TADALAFIL	TADALAFIL 20MG	TABLETS	RECIEPT	Tadalafil Teva is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.
5102	TADALIS	TADALIS TEVA 10 MG	TADALAFIL	TADALAFIL 10MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men.
5103	TADALIS	TADALIS TEVA 20 MG	TADALAFIL	TADALAFIL 20MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men.
5104	TADAM	TADAM 10	TADALAFIL	TADALAFIL 10MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men.
5106	TADAM	TADAM 20	TADALAFIL	TADALAFIL 20MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men.
5108	TADAM	TADAM 5	TADALAFIL	TADALAFIL 5MG	TABLETS	RECIEPT	For the treatment of erectile dysfunction in adult men. Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) Treatment of ED and the signs and symptoms of BPH (ED/BPH)
5111	TAFINLAR	TAFINLAR 50 MG	DABRAFENIB AS MESILATE	DABRAFENIB AS MESILATE 50MG	CAPSULES	RECIEPT	Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Non-small cell lung cancer (NSCLC) : Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. Adjuvant treatment of melanoma : Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with BRAF V600 mutation, following complete resection. BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
5113	TAFINLAR	TAFINLAR 75 MG	DABRAFENIB AS MESILATE	DABRAFENIB AS MESILATE 75MG	CAPSULES	RECIEPT	Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Non-small cell lung cancer (NSCLC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. Adjuvant treatment of melanoma : Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with BRAF V600 mutation, following complete resection. BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
5114	TAGRISSO	TAGRISSO 40 MG	OSIMERTINIB AS MESYLATE	OSIMERTINIB AS MESYLATE 40MG	TABLETS	RECIEPT	Tagrisso as monotherapy is indicated for: • the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. • the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
5115	TAGRISSO	TAGRISSO 80 MG	OSIMERTINIB AS MESYLATE	OSIMERTINIB AS MESYLATE 80MG	TABLETS	RECIEPT	Tagrisso as monotherapy is indicated for: • the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. • the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC
5116	TAKHZYRO	TAKHZYRO	LANADELUMAB	LANADELUMAB 150MG/ML	SOLUTION	RECIEPT	Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
5117	TALTZ	TALTZ 80 MG	IXEKIZUMAB	IXEKIZUMAB 80MG/1ML	SOLUTION	RECIEPT	Plaque psoriasis : Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis : Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies
5118	TAMBOCOR	TAMBOCOR 100 MG TABLETS	FLECAINIDE ACETATE	FLECAINIDE ACETATE 100MG	TABLETS	RECIEPT	Serious sustained life threatening ventricular arrhytmias that have not responsed to other drugs. Paroxymal atrial flutter.
5120	TAMBOCOR	TAMBOCOR INJECTION	FLECAINIDE ACETATE	FLECAINIDE ACETATE 10MG/ML	SOLUTION	RECIEPT	Serious sustained life threatening ventricular arrhthymias that have not respoded to other drugs.
5119	TAMBOCOR	TAMBOCOR 50 MG TABLETS	FLECAINIDE ACETATE	FLECAINIDE ACETATE 50MG	TABLETS	RECIEPT	Serious sustained life threatening supraventricular arrhythmias that have not responded to other drugs. Paroxysmal atrial fibrillation and atrial flutter
5122	TAMIFLU	TAMIFLU 30 MG	OSELTAMIVIR AS PHOSPHATE	OSELTAMIVIR AS PHOSPHATE 30MG	CAPSULES	RECIEPT	Treatment of influenza : Treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. Prophylaxis of influenza : Post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. The appropriate use of Tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.
5124	TAMIFLU	TAMIFLU 45 MG	OSELTAMIVIR AS PHOSPHATE	OSELTAMIVIR AS PHOSPHATE 45MG	CAPSULES	RECIEPT	Treatment of influenza : Treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. Prophylaxis of influenza : Post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. The appropriate use of Tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.
5121	TAMIFLU	TAMIFLU 75 MG	OSELTAMIVIR AS PHOSPHATE	OSELTAMIVIR AS PHOSPHATE 75MG	CAPSULES	RECIEPT	- Treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - Post exposure prevention in adults and patients who weight more the
5126	TAMIFLU	TAMIFLU 75 MG	OSELTAMIVIR AS PHOSPHATE	OSELTAMIVIR AS PHOSPHATE 75MG	CAPSULES	RECIEPT	Treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - Post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - The appropriate use of Tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.
5128	TAMOXIFEN	TAMOXIFEN TEVA 20 MG	TAMOXIFEN AS CITRATE	TAMOXIFEN AS CITRATE 20MG	TABLETS	RECIEPT	For the palliative treatment of breast cancer generally in post menopausal women, either alone or in combination with other modalities.
5129	TAMSULIN	TAMSULIN	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE 0.4MG	CAPSULES	RECIEPT	Treatment of functional symptoms of benign prostatic hyperplasia (BPH).
5131	TAMSULOSIN	TAMSULOSIN INOVAMED	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE 0.4MG	TABLETS	RECIEPT	Lower urinary tract symptoms ( LUTS) associated with benign prostatic hyperplasia (BPH).
5132	TAMSULOSIN	TAMSULOSIN TEVA	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE 0.4MG	CAPSULES	RECIEPT	Treatment of functional symptoms of benign prostatic hyperplasia (BPH).
5135	TANTUM VERDE	TANTUM VERDE MOUTHWASH 240 ML	BENZYDAMINE HYDROCHLORIDE	BENZYDAMINE HYDROCHLORIDE 0.15%(1.5MG/ML)	LIQUID		Locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions of the mouth and throat influding: Traumatic conditions : Pharyngitis following tonsillectomy or the use of a naso-gastric tube . Inflammatory conditions : Pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy. Dentistry : For use after dental operations.
5134	TANTUM VERDE	TANTUM VERDE	BENZYDAMINE HYDROCHLORIDE	BENZYDAMINE HYDROCHLORIDE 0.15%W/V	LIQUID		Locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions of the mouth and throat influding: Traumatic conditions : Pharyngitis following tonsillectomy or the use of a naso-gastric tube . Inflammatory conditions : Pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy. Dentistry : For use after dental operations.
5136	TARCEVA	TARCEVA 100 MG	ERLOTINIB	ERLOTINIB 100MG	TABLETS	RECIEPT	Non-Small Cell Lung Cancer (NSCLC): Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations. Tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Pancreatic cancer: Tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
5139	TARCEVA	TARCEVA 150 MG	ERLOTINIB	ERLOTINIB 150MG	TABLETS	RECIEPT	Non-Small Cell Lung Cancer (NSCLC): Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations. Tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Pancreatic cancer: Tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
5142	TARDYFERON	TARDYFERON	FERROUS SULFATE	FERROUS SULFATE 247.25MG	TABLETS		Prevention and treatment of Iron deficiency anemia.
5143	TARDYFERON	TARDYFERON 30TAB	FERROUS SULPHATE	FERROUS SULPHATE 256.3MG ( 80MG IRON)	TABLETS		Prevention and treatment of Iron deficiency anemia.
5146	TARGIN	TARGIN 30	NALOXONE HYDROCHLORIDE (AS DIHYDRATE)	NALOXONE HYDROCHLORIDE (AS DIHYDRATE) 15MG;OXYCODONE HYDROCHLORIDE 30MG	TABLETS	RECIEPT	Targin is indicated for the relief of moderate to severe pain. The oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around the- clock opioid analgesia for several days or more. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.
5147	TARGIN	TARGIN 40	NALOXONE HYDROCHLORIDE (AS DIHYDRATE)	NALOXONE HYDROCHLORIDE (AS DIHYDRATE) 20MG;OXYCODONE HYDROCHLORIDE 40MG	TABLETS	RECIEPT	Targin is indicated for the relief of moderate to severe pain. The oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut
5144	TARGIN	TARGIN 10	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 10MG;NALOXONE HYDROCHLORIDE (AS DIHYDRATE) 5MG	TABLETS	RECIEPT	Targin is indicated for the relief of moderate to severe pain. The oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut
5145	TARGIN	TARGIN 20	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 20MG;NALOXONE HYDROCHLORIDE (AS DIHYDRATE) 10MG	TABLETS	RECIEPT	Targin is indicated for the relief of moderate to severe pain. The oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut
5148	TARGIN	TARGIN 5	OXYCODONE HYDROCHLORIDE	OXYCODONE HYDROCHLORIDE 5MG;NALOXONE HYDROCHLORIDE (AS DIHYDRATE) 2.5MG	TABLETS	RECIEPT	Targin is indicated for the relief of moderate to severe pain. The oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.
5149	TARGOCID	TARGOCID 200 MG	TEICOPLANIN	TEICOPLANIN 200MG	POWDER	RECIEPT	For treatment of potentially serious gram-positive infections including those which cannot be treated with other antimicrobial drugs e.g.penicillins and cephalosporins.
5150	TARIM	TARIM 100	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 100MG	TABLETS	RECIEPT	TARIM is indicated for the treatment of erectile dysfunction.
5152	TARIM	TARIM 25	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 25MG	TABLETS	RECIEPT	TARIM is indicated for the treatment of erectile dysfunction.
5154	TARIM	TARIM 50	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 50MG	TABLETS	RECIEPT	TARIM is indicated for the treatment of erectile dysfunction.
5156	TAROCLINDIN	TAROCLINDIN GEL	BENZOYL PEROXIDE AS HYDROUS	BENZOYL PEROXIDE AS HYDROUS 5%W/W;CLINDAMYCIN AS PHOSPHATE 1%W/W	GEL	RECIEPT	Mild to moderate acne vulgaris, particulary inflammatory lesions.
5158	TARODENT	TARODENT MOUTHWASH	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.2%W/V	SOLUTION	RECIEPT	Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
5157	TARODENT MINT	TARODENT MINT 0.2% SOL 300ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.2%	SOLUTION		Antibacterial solution for the disinfection of the mouth: 1) As an aid to maintaining oral hygiene. 2) As an aid in the treatment and prevention of gingivitis. 3) Inhibition of formation of dental plaque. 4) For use in aphtous ulceration and oral candidal infections (e.g., denture stomatitis and thrush). 5) For use in a post- periodontal surgery or treatment regimen to promote gingival healing.
5159	TASIGNA	TASIGNA 150 MG	NILOTINIB AS HYDROCHLORIDE MONOHYDRATE	NILOTINIB AS HYDROCHLORIDE MONOHYDRATE 150MG	CAPSULES	RECIEPT	Treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. .
5160	TASIGNA	TASIGNA 200 MG	NILOTINIB AS MONOHYDRATE	NILOTINIB AS MONOHYDRATE 200MG	CAPSULES	RECIEPT	Treatment of Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib. Treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. 11/12/2017 בקשה לשינוי משטר מינון - Addition of TFR regimen לפירוט אנא ראו הצעת עלונים.
5162	TAVANIC	TAVANIC TABLETS 500 MG	LEVOFLOXACIN AS HEMIHYDRATE	LEVOFLOXACIN AS HEMIHYDRATE 500MG	TABLETS	RECIEPT	In adults with infections of mild to moderate severity Tavanic tablets are indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: Acute sinusitis, Acute exacerbation of chronic bronchitis, Community-acquired pneumonia, Complicated urinary tract infections including pyelonephritis, Skin and soft tissue infections.
5161	TAVANIC	TAVANIC 500 MG solution for i.v. infusion	LEVOFLOXACIN AS HEMIHYDRATE	LEVOFLOXACIN AS HEMIHYDRATE 5MG/ML	SOLUTION		In adults for whom intravenous therapy is considered to be appropriate, Tavanic solution for infusion is indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: Community- acquired pneumonia, Complicated urinary tract infections including pyelonephritis, Skin and soft tissue infections.
5163	TAZO-PIP	TAZO-PIP AVENIR 4.5 G	TAZOBACTAM AS SODIUM SALT	TAZOBACTAM AS SODIUM SALT 500MG;PIPERACILLIN AS SODIUM SALT 4000MG	POWDER	RECIEPT	Antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. Tazo-Pip Avenir in combination with an aminoglycoside, is indicated for the treatment of suspected bacterial infections in neutropenic adults and children. Appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.
5166	TEARS NATURAL	TEARS NATURAL FREE 32 AMP*0.9ML	DEXTRAN	DEXTRAN 70 0.1%;HYDROXYPROPYL METHYLCELLULOSE 0.3%;!	DROPS		Dry eye syndromes. Deficient tears secretion.
5165	TEARS NATURAL	TEARS NATURAL FREE	DEXTRAN	DEXTRAN 70 0.1%;HYPROMELLOSE 0.3%	DROPS		Dry eye syndromes. Deficient tears secretion.
5164	TEARS NATURAL	TEARS NATURAL 2 EYE DROPS 15ML	HYPROMELLOSE	HYPROMELLOSE 0.3%;DEXTRAN 70 0.1%	DROPS		Dry eye syndromes. deficient tear secretion.
5167	TEARS NATURAL	TEARS NATURAL II	HYPROMELLOSE	HYPROMELLOSE 3MG/ML;DEXTRAN 70 1MG/ML	DROPS		Dry eye syndromes. deficient tear secretion.
5168	TECENTRIQ	TECENTRIQ	ATEZOLIZUMAB	ATEZOLIZUMAB 60MG/1ML	CONCENTRATE	RECIEPT	- Locally Advanced or Metastatic Urothelial Carcinoma • TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumo
5170	TECFIDERA	TECFIDERA 120 MG	DIMETHYL FUMARATE	DIMETHYL FUMARATE 120MG	CAPSULES	RECIEPT	Tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
5175	TECFIDERA	TECFIDERA 240 MG	DIMETHYL FUMARATE	DIMETHYL FUMARATE 240MG	CAPSULES	RECIEPT	Tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
5181	TECHNETIUM TC-99M	TECHNETIUM Tc-99M GENERATOR	MOLYBDATE (CONTAINING MO-99)	MOLYBDATE (CONTAINING MO-99) 400MG	RADIO-PHARMA GENERATOR		Diagnostic agent for IV injection producer of Tc-99 for imaging of different organs.
5182	TEEJEL	TEEJEL GEL	CETALKONIUM CHLORIDE	CETALKONIUM CHLORIDE 0.01%;CHOLINE SALICYLATE 8.7%	GEL		As an antiseptic and local pain reliever for mouth ulcers, teething pain, denture irritation, and cold sores.
5183	TEEJEL	TEEJEL GEL 10GR	CHOLINE SALICYLATE	CHOLINE SALICYLATE 8.7%;CETALKONIUM 0.01%	GEL		As an antiseptic and local pain reliever for mouth ulcers, teething pain, denture irritation, and cold sores.
5184	TEGLUTIK	TEGLUTIK 5 MG/ML ORAL SUSPENSION	RILUZOLE	RILUZOLE 5MG/1ML	SUSPENSION	RECIEPT	TEGLUTIK 5 mg/ml oral suspension is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).
5188	TEGRETOL	TEGRETOL SYRUP 2%	CARBAMAZEPINE	CARBAMAZEPINE 100MG/5ML	SYRUP	RECIEPT	Epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic-depressive illness.
5185	TEGRETOL	TEGRETOL 200 MG	CARBAMAZEPINE	CARBAMAZEPINE 200MG	TABLETS	RECIEPT	Epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic depressive illness.
5186	TEGRETOL	TEGRETOL CR 200 MG	CARBAMAZEPINE	CARBAMAZEPINE 200MG	TABLETS	RECIEPT	Epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic-depressive illness
5187	TEGRETOL	TEGRETOL CR 400 MG	CARBAMAZEPINE	CARBAMAZEPINE 400MG	TABLETS	RECIEPT	Epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in mania depressive illness.
5189	TEKCIS	TEKCIS 2-50 GBQ RADIONUCLIDE GENERATOR	MOLYBDENUM	MOLYBDENUM 2.5GBq;TECHNETIUM-99M 2GBq	RADIONUCLIDE GENERATOR	RECIEPT	This medicinal product is for diagnostic use only. The eluate from the radionuclide generator is indicated for: • Labelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such solution. • Thyroid scintigraphy: direct imaging and measurement of thyroid uptake to give information on the size, position, nodularity and function of the gland in thyroid disease. • Salivary gland scintigraphy: diagnosis of chronic sialadenitis (e.g. Sjögren Syndrom) as well as to assess salivary gland function and duct patency in salivary glands disorders and monitoring of the response to therapeutic interventions (in particular radio iodine therapy).
5191	TELEBRIX	TELEBRIX 30 MEGLUMINE	MEGLUMINE IOXITALAMATE	MEGLUMINE IOXITALAMATE 66.03G/100ML	SOLUTION	RECIEPT	For urograph, selective angiography, peripheral angiography, arthrography, hysterosalpingography and digestive exploration.
5194	TELEBRIX	TELEBRIX GASTRO	MEGLUMINE IOXITALAMATE	MEGLUMINE IOXITALAMATE 66.03G/100ML equivalent to Iodine 30 g/100 ml	SOLUTION	RECIEPT	Conventional x-ray and CT examinations of the gastrointestinal tract, gastroduodenal radiography, opaque enema examinations, especially in cases in which barium is contraindicated.
5190	TELEBRIX	TELEBRIX 12 SODIUM	SODIUM IOXITALAMATE	SODIUM IOXITALAMATE 21 G/100ML	SOLUTION	RECIEPT	contrast medium for retrograd cystography.
5192	TELEBRIX	TELEBRIX 35	SODIUM IOXITALAMATE	SODIUM IOXITALAMATE 9.66%;MEGLUMINE IOXITALAMATE 65.09%	SOLUTION	RECIEPT	Angiocardiography (ventriculography - coronary angiography) - digital substraction angiography - computerized tomography - intravenous urography.
5195	TELFAST	TELFAST 120 MG	FEXOFENADINE HYDROCHLORIDE	FEXOFENADINE HYDROCHLORIDE 120MG	TABLETS	RECIEPT	Relief of symptoms associated with seasonal allergic rhinitis
5196	TELFAST	TELFAST 180 MG	FEXOFENADINE HYDROCHLORIDE	FEXOFENADINE HYDROCHLORIDE 180MG	TABLETS	RECIEPT	Relief of symptoms associated with chronic idiopathic urticaria.
5197	TEMO	TEMO 100 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 100MG	CAPSULES	RECIEPT	Temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5199	TEMO	TEMO 140 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 140MG	CAPSULES	RECIEPT	Temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5201	TEMO	TEMO 20 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 20MG	CAPSULES	RECIEPT	Temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5203	TEMO	TEMO 250 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 250MG	CAPSULES	RECIEPT	Temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5205	TEMO	TEMO 5 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 5MG	CAPSULES	RECIEPT	Temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5207	TEMODAL	TEMODAL 100 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 100MG	CAPSULES	RECIEPT	Temodal capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5208	TEMODAL	TEMODAL 20 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 20MG	CAPSULES	RECIEPT	Temodal capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5209	TEMODAL	TEMODAL 250 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 250MG	CAPSULES	RECIEPT	Temodal capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5210	TEMODAL	TEMODAL 5 MG	TEMOZOLOMIDE	TEMOZOLOMIDE 5MG	CAPSULES	RECIEPT	Temodal capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.
5212	TENOFOVIR	TENOFOVIR TEVA	TENOFOVIR DISOPROXIL AS FUMARATE	TENOFOVIR DISOPROXIL AS FUMARATE 245MG	TABLETS	RECIEPT	Indicated for the treatment of : 1. HIV 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of HIV. 2. Chronic hepatitis B in adults with: • Compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. • Decompensated liver disease.
5213	TEPADINA	TEPADINA 100 MG	THIOTEPA	THIOTEPA 100MG	POWDER	RECIEPT	TEPADINA is indicated, in combination with other chemotherapy medicinal products: 1. with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; 2. when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
5216	TEPADINA	TEPADINA 15 MG	THIOTEPA	THIOTEPA 15MG	POWDER	RECIEPT	TEPADINA is indicated, in combination with other chemotherapy medicinal products: 1. with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; 2. when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
5219	TERAZOSIN	TERAZOSIN TEVA 2 MG	TERAZOSIN AS HYDROCHLORIDE DIHYDRATE	TERAZOSIN AS HYDROCHLORIDE DIHYDRATE 2MG	TABLETS	RECIEPT	For symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (BPH). For mild to moderate hypertension.
5221	TERAZOSIN	TERAZOSIN TEVA 5 MG	TERAZOSIN AS HYDROCHLORIDE DIHYDRATE	TERAZOSIN AS HYDROCHLORIDE DIHYDRATE 5MG	TABLETS	RECIEPT	For symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (BPH). For mild to moderate hypertension.
5223	TERBINAFINE	TERBINAFINE TEVA 250 MG	TERBINAFINE AS HYDROCHLORIDE	TERBINAFINE AS HYDROCHLORIDE 250MG	TABLETS	RECIEPT	Fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum. Oral Terbinafine should only be used to treat extensive, severe ringworm infections ( tinea corporis, tinea cruris and tinea pedis). Oral Terbinafine is not effective against vaginal candidiasis or pityriasis (tinea) versicolor. Onychomycoses ( tinea unguium, ringworm of the nails) due to infection with dermatophyte organisms ( hyphomycetes).
5225	TERBULIN	TERBULIN SYRUP	TERBUTALINE SULFATE	TERBUTALINE SULFATE 30MG/100ML	SYRUP	RECIEPT	Bronchodilator for the treatment of acute attacks of Asthma.
5224	TERBULIN RESPIRATORY	TERBULIN RESPIRATORY SOLUTION	TERBUTALINE SULFATE	TERBUTALINE SULFATE 150MG/15ML	SOLUTION	RECIEPT	Bronchodilator for the treatment of acute attacks of Asthma.
5226	TERIFLUNOMIDE	TERIFLUNOMIDE TEVA	TERIFLUNOMIDE	TERIFLUNOMIDE 14MG	TABLETS	RECIEPT	Teriflunomide Teva is indicated for the treatment of adult patients with relapsing remitting forms of Multiple Sclerosis (MS) to reduce the frequency of clinical relapses and to delay the progression of physical disability.
5227	TERIL	TERIL 200	CARBAMAZEPINE	CARBAMAZEPINE 200MG	TABLETS	RECIEPT	Epilepsy, trigeminal neurolgia, diabetes insipidus, mania, prophylactic in manic depressive illness.
5228	TERIL	TERIL CR 200 MG	CARBAMAZEPINE	CARBAMAZEPINE 200MG	TABLETS	RECIEPT	Epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic depressive illness.
5229	TERIL	TERIL CR 400 MG	CARBAMAZEPINE	CARBAMAZEPINE 400MG	TABLETS	RECIEPT	Epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic depressive illness.
5230	TERIPARATIDE	TERIPARATIDE TEVA	TERIPARATIDE AS ACETATE	TERIPARATIDE AS ACETATE 250MCG/ML	SOLUTION	RECIEPT	Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture: Teriparatide Teva is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide Teva increases BMD reduces the risk of vertebral and nonvertebral fractures . Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture : Teriparatide Teva is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . Treatment of Men and Women with Glucocorticoid-Induced Osteoporosis at High Risk for Fracture: Teriparatide Teva is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy
5231	TESALIN	TESALIN	PETASINS	PETASINS 8MG	TABLETS	RECIEPT	For the treatment of symptoms of allergic rhinitis (hay-fever) as well as related symptoms in eyes, nose and throat.
5232	TESTOMAX	TESTOMAX 25 MG	TESTOSTERONE	TESTOSTERONE 25MG/DOSE	GEL	RECIEPT	Testosterone replacement therapy for males hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
5233	TESTOMAX	TESTOMAX 50 MG	TESTOSTERONE	TESTOSTERONE 50MG/DOSE	GEL	RECIEPT	Testosterone replacement therapy for males hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
5234	TESTOVIRON DEPOT	TESTOVIRON DEPOT	TESTOSTERONE ENANTATE	TESTOSTERONE ENANTATE 250MG/ML	SOLUTION	RECIEPT	Testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests . Puberty induction in boys with delayed puberty (pubertas tarda).
5236	TEVACOLD	TEVA - COLD TABLETS	PARACETAMOL	PARACETAMOL 300MG;CHLORPHENIRAMINE MALEATE 2.0MG;PHENYLEPHRINE HYDROCHLORIDE 10MG;CAFFEINE ANHYDROUS 30MG	TABLETS		Symptomatic relief of common cold, congestion associated with sinusitis, allergic rhinitis accompanied by fever and pain.
5235	TEVACOLD	TEVA - COLD CAPLETS	PARACETAMOL	PARACETAMOL 300MG;CHLORPHENIRAMINE MALEATE 2MG;PHENYLEPHRINE HYDROCHLORIDE 10MG;CAFFEINE 30MG ANHYDROUS	TABLETS		Symptomatic relief of common cold, congestion associated with sinusitis, allergic rhinitis accompanied by fever and pain.
5237	TEVACUTAN	TEVACUTAN	CLOTRIMAZOLE	CLOTRIMAZOLE 1%;DEXAMETHASONE ACETATE 0.044%;NEOMYCIN SULFATE 0.645%	CREAM	RECIEPT	Tevacutan is indicated for the treatment of mycotic infections of the skin complicated by inflammation and/or secondary infection.
5238	TEVADERM	TEVADERM	DIFLUCORTOLONE VALERATE	DIFLUCORTOLONE VALERATE 0.1%;ISOCONAZOLE NITRATE 1%	CREAM	RECIEPT	For the local treatment of inflammatory skin conditions accompanied by secondary fungal infections.
5239	TEVAGRASTIM	TEVAGRASTIM	FILGRASTIM	FILGRASTIM 0.6MG/ML	SOLUTION	RECIEPT	Tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Tevagrastim are similar in adults and children receiving cytotoxic chemotherapy. Tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic PBPC). In patients children or adults with severe congenital neutropenia cyclic or idiopathic neutropenia with an absolute nuetrophil count (ANC) less than or equal to 0.5 x 1000000000 /l and a history of severe or recurrent infections long term administration of Tevagrastim is indicated to increase neutophil count and to reduce the incidence and duration of infection-related events. Tevagrastim in indicated for the treatment of persistent neutopenia (ANC less than or equal to 1.0 x 1000000000/l ) in patients with advanced HIV infection in order to reduce the risk of bacterial infections when other options to manage neutopenia are inappropriate.
5241	TEVALFA	TEVALFA D3 0.25 MCG	ALFACALCIDOL	ALFACALCIDOL 0.25MCG	CAPSULES	RECIEPT	- Renal bone disease (renal osteodystrophy). - Hypoparathyroidism. - Hyperparathyroidism (with bone disease) - primary and tertiary. - Rickets and osteomalacia. - Osteoporosis.
5240	TEVALFA	TEVALFA 1.0 MCG	ALFACALCIDOL	ALFACALCIDOL 1MCG	CAPSULES	RECIEPT	- Renal bone disease (renal osteodystrophy). - Hypoparathyroidism. - Hyperparathyroidism (with bone disease) - primary and tertiary. - Rickets and osteomalacia. - Osteoporosis.
5242	TEVANATE	TEVANATE	ALENDRONIC ACID AS MONOHYDRATE	ALENDRONIC ACID AS MONOHYDRATE 10MG	TABLETS	RECIEPT	For the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip, wrist and spine (vertebral compression fractures). For the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. For the treatment to increase bone mass in men with osteoporosis.
5243	TEVAPIRIN	TEVAPIRIN	ACETYLSALICYLIC ACID	ACETYLSALICYLIC ACID 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
5247	TEVAPIRIN	TEVAPIRIN 100MG 30TAB	ASPIRIN	ASPIRIN 100MG	TABLETS		The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
5248	THALIDOMIDE	THALIDOMIDE CELGENE 50 MG HARD CAPSULES	THALIDOMIDE	THALIDOMIDE 50MG	CAPSULES	RECIEPT	Multiple myeloma : 1. For the treatment of multiple myeloma after failure of standars therapies. 2. Thalidomide Celgene 50 mg hard capsules in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma. 3. Thalidomide Celgene in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma > or = 65 years or ineligible for high dose chemotherapy. Erythema Nodosum Leprosum: 4. For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Thalidomide is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. It is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
5250	THALLIUM CHLORIDE TL-201	THALLIUM CHLORIDE TL-201	THALLIUM (201TL) CHLORIDE	THALLIUM (201TL) CHLORIDE	SOLUTION	RECIEPT	Myocardial perfusion imaging.
5251	THEOTARD	THEOTARD 100	THEOPHYLLINE	THEOPHYLLINE 100MG ANHYDROUS	CAPSULES	RECIEPT	For prevention and relief of bronchospasm.
5252	THEOTARD	THEOTARD 200	THEOPHYLLINE	THEOPHYLLINE 200MG ANHYDROUS	CAPSULES	RECIEPT	F0r prevention and relief of Bronchospasm.
5253	THEOTARD	THEOTARD 300	THEOPHYLLINE	THEOPHYLLINE 300MG	CAPSULES	RECIEPT	For prevention and relief of bronchospasm.
5254	THEOTRIM	THEOTRIM 100	THEOPHYLLINE ANHYDROUS	THEOPHYLLINE ANHYDROUS 100MG	TABLETS	RECIEPT	Long acting bronchodilator in the symptomatic relief and/or prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema
5255	THEOTRIM	THEOTRIM 200	THEOPHYLLINE ANHYDROUS	THEOPHYLLINE ANHYDROUS 200MG	TABLETS	RECIEPT	Long acting bronchodilator in the symptomatic relief and/or prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema
5256	THEOTRIM	THEOTRIM 300	THEOPHYLLINE ANHYDROUS	THEOPHYLLINE ANHYDROUS 300MG	TABLETS	RECIEPT	Long acting bronchodilator in the symptomatic relief and/or prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema
5257	THERACAP	THERACAP 131	SODIUM IODIDE (131 I)	SODIUM IODIDE (131 I) 37MBQ	CAPSULES	RECIEPT	Theracap 131 is a radioiodine thyroid therapy indicated for: 1.Treatment of Grave's disease, toxic multinodular goitre or autonomous nodules. 2.Treatmernt of papilary and follicular thyroid carcinoma including metastastic desease.
5259	THIO	THIO GEL 40G	ISOTHIPENDYL HCL	ISOTHIPENDYL HCL 0.7%	GEL		For the temporary relief of itching due to minor skin disorders, insect bites (non poisonous) and stings, sunburn, hives, ivy and oak poisoning.
5258	THIO	THIO GEL	ISOTHIPENDYL HYDROCHLORIDE	ISOTHIPENDYL HYDROCHLORIDE 0.75%	GEL		For the temporary relief of itching due to minor skin disorders, insect bites (non poisonous) and stings, sunburn, hives, ivy and oak poisoning.
5260	THIOPENTAL	THIOPENTAL INJECTION BP 1 G	THIOPENTAL SODIUM	THIOPENTAL SODIUM 1G	POWDER	RECIEPT	Anaesthesia of short duration without assisted ventilation. - Initiation of general Anaesthesia with OR without assisted ventilation. - It is also used as an adjunct For Control of convulsive disorders of various aetiology including those CAUSED BY local anaesthetics.
5261	THIOPENTAL	THIOPENTAL INJECTION BP 500 MG	THIOPENTAL SODIUM	THIOPENTAL SODIUM 500MG	POWDER	RECIEPT	Anaesthesia of short duration without assisted ventilation. - Initiation of general Anaesthesia with OR without assisted ventilation. - It is also used as an adjunct For Control of convulsive disorders of various aetiology including those CAUSED BY local anaesthetics.
5262	THREOLONE	THREOLONE	PREDNISOLONE	PREDNISOLONE 0.5%;CHLORAMPHENICOL 3%	OINTMENT	RECIEPT	Infected eczema, pruritic lesions, angular stomatitis, impetigo, external otitis and pyoderma and other skin infections caused by chloramphenicol susceptible organisms.
5263	THYMOGLOBULINE	THYMOGLOBULINE	IMMUNOGLOBULIN RABBIT ANTI-HUMAN THYMOCYTE	IMMUNOGLOBULIN RABBIT ANTI-HUMAN THYMOCYTE 25MG/VIAL/1	POWDER	RECIEPT	Immunosuppression in transplantation: prevention and treatment of graft rejection. Treatment of acute graft versus host disease (GvHD). Hematology treatment of aplastic anemia.
5264	THYROGEN	THYROGEN	THYROTROPIN ALFA	THYROTROPIN ALFA 0.9MG/ML	POWDER	RECIEPT	Adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.
5265	TICOVAC	TICOVAC 0.5 ML	ENCEPHALITIS, TICK BORNE, INACTIVATED, WHOLE VIRUS	ENCEPHALITIS, TICK BORNE, INACTIVATED, WHOLE VIRUS 2.4MCG/0.5ML	SUSPENSION	RECIEPT	Ticovac 0.5 ml is indicated for the active (prophylactic) immunization of adolescents from 16 years of age and adults against tick-borne encephalitis (TBE).
5266	TICOVAC JUNIOR	TICOVAC JUNIOR 0.25 ML	ENCEPHALITIS, TICK BORNE, INACTIVATED, WHOLE VIRUS	ENCEPHALITIS, TICK BORNE, INACTIVATED, WHOLE VIRUS 1.2MCG/0.25ML	SUSPENSION	RECIEPT	Ticovac Junior 0.25 ml is indicated for the active (prophylactic) immunization of children aged from 1 year to 15 years against tick-borne encephalitis (TBE).
5267	TIENAM	TIENAM 500 MG/ 500 MG	CILASTATIN SODIUM	CILASTATIN SODIUM 500MG/VIAL;IMIPENEM AS MONOHYDRATE 500MG/VIAL	POWDER	RECIEPT	1.1 Lower Respiratory Tract Infections TIENAM for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella species, Serratia marcescens. 1.2 Urinary Tract Infections (complicated and uncomplicated) TIENAM is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa. 1.3 Intra-Abdominal Infections TIENAM is indicated for the treatment of intra-abdominal infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis, Fusobacterium species. 1.4 Gynecologic Infections TIENAM is indicated for the treatment of gynecologic infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species, Escherichia coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis. 1.5 Bacterial Septicemia TIENAM is indicated for the treatment of bacterial septicemia caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species including B. fragilis. 1.6 Bone and Joint Infections TIENAM is indicated for the treatment of bone and joint infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa. 1.7 Skin and Skin Structure Infections TIENAM is indicated for the treatment of skin and skin structure infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species. 1.8 Endocarditis TIENAM is indicated for the treatment of endocarditis caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates). 1.9 Limitations of Use • TIENAM is not indicated in patients with meningitis because safety and efficacy have not been established. • TIENAM is not recommended in pediatric patients with CNS infections because of the risk of seizures. • TIENAMN is not recommended in pediatric patients less than 30 kg with impaired renal function, as no data are available. • Periodic assessment of organ system functions, including renal, hepatic and hematopoietic, is advisable during prolonged therapy. 1.10 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of TIENAM and other antibacterial drugs, TIENAM should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
5269	TIGER BALM	TIGER BALM RED OINT 19G	CAMPHOR	CAMPHOR 11%;MENTHOL 10%;CAJUPUT OIL 7%;CLOVE OIL 5%	OINTMENT		For the temporary relief of muscular aches and pains.
5271	TIGER BALM	TIGER BALM WHITE OINT 19G	CAMPHOR	CAMPHOR 11%;MENTHOL 8%;CAJUPUT 13%;CLOVE OIL1.5%	OINTMENT		For the temporary relief of muscular aches and pains.
5268	TIGER BALM	TIGER BALM RED	CAMPHOR	CAMPHOR 11%W/W;MENTHOL 10%W/W;CAJUPUT OIL 7%W/W;DEMENTHOLISED MINT OIL 6%W/W;CLOVE OIL 5%W/W	OINTMENT		For the temporary relief of muscular aches and pains.
5270	TIGER BALM	TIGER BALM WHITE	CAMPHOR	CAMPHOR 11%W/W;MENTHOL 8%W/W;CAJUPUT OIL 13%W/W;CLOVE OIL 1.5%W/W;DEMENTHOLISED MINT OIL 16%W/W	OINTMENT		For the temporary relief of muscular aches and pains.
5274	TILOPTIC	TILOPTIC 0.5 %	TIMOLOL AS MALEATE	TIMOLOL AS MALEATE 5MG/ML	DROPS	RECIEPT	For the reduction of elevated intraocular pressure may be used in patients with chronic open-angle glaucoma, aphakic glaucoma, some patients with secondary glaucoma and patients with ocular hypertension
5275	TIMOLAN	TIMOLAN-AVENIR	TIMOLOL AS MALEATE	TIMOLOL AS MALEATE 5MG/1ML;LATANOPROST 0.05MG/1ML	SOLUTION	RECIEPT	Reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers.
5276	TIMONIL	TIMONIL 300 RETARD	CARBAMAZEPINE	CARBAMAZEPINE 300MG	TABLETS	RECIEPT	Epilepsy, trigeminal neuralgia, diabetes insipidus mania, prophylactic in manic depressive illness.
5277	TIMONIL	TIMONIL 600 RETARD	CARBAMAZEPINE	CARBAMAZEPINE 600MG	TABLETS	RECIEPT	Treatment of epilepsy, trigeminal neuralgia, mania, prophylactic in manic depressive illness .
5280	TINDEN	Tinden Gel 100g	DIMETHINDENE MALEATE	DIMETHINDENE MALEATE 0.1%	GEL		Urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
5281	TINDEN	TINDEN GEL 30g	DIMETHINDENE MALEATE	DIMETHINDENE MALEATE 0.1%	GEL		Urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
5279	TINDEN	TINDEN GEL	DIMETINDENE MALEATE	DIMETINDENE MALEATE 0.1%W/W	GEL		Urticaria, pruritis, dermatoses, burns, insect bites, allergic dermatitis and eczema.
5278	TINDEN	TINDEN DROPS	DIMETINDENE MALEATE	DIMETINDENE MALEATE 1MG/1ML	DROPS	RECIEPT	Antipruritic, antihistaminic and antiallergic.
5282	TINOK-AF	TINOK-AF	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%	DROPS	RECIEPT	Relief of nasal decongestion especially for babies.
213	TIPONET SALINE FOR BABIES	AF TIPONET SALINE SOLUTION FOR BABIES	SODIUM CHLORIDE	SODIUM CHLORIDE 0.9%W/V	DROPS	RECIEPT	For the relief of nasal congestion in children and infants.
5283	TIPTIPOT AFALPI	TIPTIPOT AFALPI	PSEUDOEPHEDRINE AS HYDROCHLORIDE	PSEUDOEPHEDRINE AS HYDROCHLORIDE 15MG/ML	DROPS	RECIEPT	Symptomatic treatment of nasal congestion, to relief eustachian tube congestion.
5284	TIPTIPOT AFALPI DROPS	TIPTIPOT AFALPI ORAL DROPS 15MG/ML 15ML	PSEUDOEPHEDRINE HCL	PSEUDOEPHEDRINE HCL 15MG/ML	DROPS	RECIEPT	Symptomatic treatment of nasal congestion, to relief eustachian tube congestion.
5285	TIPTIPOT FERRIPEL	TIPTIPOT FERRIPEL + D	COLECALCIFEROL	COLECALCIFEROL 1333IU/ML;FERROUS AS IRON III HYDROXIDE POLYMALTOSE COMPL. 50MG/ML	DROPS		Prevention of iron deficiency anemia and vitamin D supplement for infants from 6-12 months of age.
5287	TIPTIPOT FERRIPEL	TIPTIPOT FERRIPEL-3	FERROUS AS IRON III HYDROXIDE POLYMALTOSE COMPL.	FERROUS AS IRON III HYDROXIDE POLYMALTOSE COMPL. 50MG/ML	DROPS		Prevention and treatment of iron deficiency anaemia.
5286	TIPTIPOT FERRIPEL	TIPTIPOT FERRIPEL 3 DROPS 15ML	IRON(III)HYDROXYDE POLYMALTOSE	IRON(III)HYDROXYDE POLYMALTOSE 50MG/ML	DROPS		Prevention and treatment of iron deficiency anaemia.
5288	TIPTIPOT MUCOLIT	TIPTIPOT MUCOLIT	CARBOCISTEINE	CARBOCISTEINE 75MG/ML	DROPS	RECIEPT	Treatment of disorders of the respiratory tract characterized by excessive or viscous mucus.
5289	TIPTIPOT MUCOLIT	TIPTIPOT MUCOLIT ORAL DROPS 15ML	CARBOCYSTEINE	CARBOCYSTEINE 75MG/ML	DROPS		Treatment of disorders of the respiratory tract characterized by excessive or viscous mucus.
5290	TIPTIPOT NOVIMOL	TIPTIPOT NOVIMOL	PARACETAMOL	PARACETAMOL 100MG/ML	SUSPENSION		Analgesic and antipyretic.
5291	TIPTIPOT NOVIMOL	TIPTIPOT NOVIMOL SUSP 15ML	PARACETAMOL	PARACETAMOL 100MG/ML	SUSPENSION		Analgesic and antipyretic.
5292	TIPTIPOT SIMICOL	TIPTIPOT SIMICOL	SIMETHICONE	SIMETHICONE 40MG/0.6ML	DROPS		Antiflatulent for relief of gripping pain, infant colic or wind due to swallowed air.
5293	TIPTIPOT SIMICOL	TIPTIPOT SIMICOL DROPS 30ML	SIMETHICONE	SIMETHICONE 40MG/0.6ML	DROPS		Antiflatulent for relief of gripping pain, infant colic or wind due to swallowed air.
5295	TISSEEL FROZEN	TISSEEL FROZEN	CALCIUM CHLORIDE DIHYDRATE	CALCIUM CHLORIDE DIHYDRATE 40MCMOL/ML;HUMAN THROMBIN 500 IU/1ML;APROTININ ACETATE 3000KIU/1ML;HUMAN FIBRINOGEN 91MG/1ML	SOLUTION	RECIEPT	Supportive treatment in adults and children from 1 month of age where standard surgical techniques appear insufficient: * For improvement of Hemostasis. * As a tissue glue to improve wound healing or to support sutures in vascular surgery and in gastrointestinal anastomoses. * For tissue sealing, to improve adhesion of the separated tissue (e.g. tissue flaps, grafts, split skin grafts [mesh grafts]). Efficacy in fully heparinized patients has been proven.
5296	TIVICAY	TIVICAY 10 MG	DOLUTEGRAVIR AS SODIUM	DOLUTEGRAVIR AS SODIUM 10MG	TABLETS	RECIEPT	Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.
5297	TIVICAY	TIVICAY 25 MG	DOLUTEGRAVIR AS SODIUM	DOLUTEGRAVIR AS SODIUM 25MG	TABLETS	RECIEPT	Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.
5298	TIVICAY	TIVICAY 50 MG	DOLUTEGRAVIR AS SODIUM	DOLUTEGRAVIR AS SODIUM 50MG	TABLETS	RECIEPT	Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.
5301	TOBI	TOBI PODHALER 28 MG	TOBRAMYCIN	TOBRAMYCIN 28MG	INHALATION	RECIEPT	Suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis.
5302	TOBI	TOBI SOLUTION FOR INHALATION	TOBRAMYCIN	TOBRAMYCIN 300MG/5ML	SOLUTION	RECIEPT	For the management of cystic fibrosis patients with Pseudomonas aeruginosa.
5303	TOBREX	TOBREX 2X	TOBRAMYCIN	TOBRAMYCIN 0.3%	DROPS	RECIEPT	Antibiotic for the treatment of superficial eye infections caused by bacteria sensitive to Tobramycin.
5304	TOBREX	TOBREX OPHTHALMIC OINTMENT	TOBRAMYCIN	TOBRAMYCIN 0.3%	OINTMENT	RECIEPT	Antibiotic for the treatment of eye infections caused by bacteria sensitive to Tobramycin.
5305	TOCARE	TOCARE SYRUP	BENZOIC ACID AS SODIUM	BENZOIC ACID AS SODIUM 20MG/5ML;EPHEDRINE HYDROCHLORIDE 6MG/5ML;GUAIACOLSULFONATE AS POTASSIUM 125MG/5ML;CODEINE PHOSPHATE 2MG/5ML	SYRUP	RECIEPT	For relief of cough.
5306	TOCTINO	TOCTINO 10 MG	ALITRETINOIN	ALITRETINOIN 10MG	CAPSULES	RECIEPT	For use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids . Patients in whom the eczema has predominantly hyperkeratotic features are more likely to respond to treatment than in those in whom the eczema predominantly presents as pompholyx .
5307	TOCTINO	TOCTINO 30 MG	ALITRETINOIN	ALITRETINOIN 30MG	CAPSULES	RECIEPT	For use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids . Patients in whom the eczema has predominantly hyperkeratotic features are more likely to respond to treatment than in those in whom the eczema predominantly presents as pompholyx .
5311	TOLTERODINE	TOLTERODINE E.R. TEVA 2 MG	TOLTERODINE TARTRATE	TOLTERODINE TARTRATE 2MG	CAPSULES	RECIEPT	For the treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence.
5312	TOLTERODINE	TOLTERODINE E.R. TEVA 4 MG	TOLTERODINE TARTRATE	TOLTERODINE TARTRATE 4MG	CAPSULES	RECIEPT	For the treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence.
5313	TONIGHT	TONIGHT	DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE 25MG	TABLETS		An aid to the relief of temporary sleep disturbance.
5314	TONIGHT	TONIGHT 10TAB	DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE 25MG	TABLETS		An aid to the relief of temporary sleep disturbance.
5315	TOOKAD	TOOKAD SOLUBLE 200 MG	PADELIPORFIN DIPOTASSIUM	PADELIPORFIN DIPOTASSIUM 200MG	POWDER	RECIEPT	TOOKAD soluble is indicated for adult patients with unilateral low risk localised prostate cancer and with a life expectancy ≥ 10 years and: - - Clinical stage up to T2a, - Gleason Score ≤ 6, based on high-resolution biopsy strategies, - PSA ≤ 10 ng/mL, - Up to 3 independent positive cores - mpMRI by 3T without endo-rectal coil showing normal MRI or unilateral tumor without evidence of capsular or seminal vesicle involvement or metastatic tumor to lymph nodes. TOOKAD is administered as part of focal Vascular-Targeted Photodynamic therapy (VTP).
5316	TOOKAD	TOOKAD SOLUBLE 400 MG	PADELIPORFIN DIPOTASSIUM	PADELIPORFIN DIPOTASSIUM 400MG	POWDER	RECIEPT	TOOKAD soluble is indicated for adult patients with unilateral low risk localised prostate cancer and with a life expectancy ≥ 10 years and: - - Clinical stage up to T2a, - Gleason Score ≤ 6, based on high-resolution biopsy strategies, - PSA ≤ 10 ng/mL, - Up to 3 independent positive cores - mpMRI by 3T without endo-rectal coil showing normal MRI or unilateral tumor without evidence of capsular or seminal vesicle involvement or metastatic tumor to lymph nodes. TOOKAD is administered as part of focal Vascular-Targeted Photodynamic therapy (VTP).
5317	TOPAMAX	TOPAMAX 100	TOPIRAMATE	TOPIRAMATE 100MG	TABLETS	RECIEPT	In adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. In adjunctive therapy of seizures with Lennox-Gastaut syndrome in adults and children. Topamax is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topamax is indicated in adults for the prevention of migraines. The use of Topamax in the acute treatment of migraine has not been studied.
5318	TOPAMAX	TOPAMAX 200	TOPIRAMATE	TOPIRAMATE 200MG	TABLETS	RECIEPT	In adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. In adjunctive therapy of seizures with Lennox-Gastaut syndrome in adults and children. Topamax is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topamax is indicated in adults for the prevention of migraines. The use of Topamax in the acute treatment of migraine has not been studied.
5319	TOPAMAX	TOPAMAX 25	TOPIRAMATE	TOPIRAMATE 25MG	TABLETS	RECIEPT	In adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. In adjunctive therapy of seizures with Lennox-Gastaut syndrome in adults and children. Topamax is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topamax is indicated in adults for the prevention of migraines. The use of Topamax in the acute treatment of migraine has not been studied.
5320	TOPAMAX	TOPAMAX 50	TOPIRAMATE	TOPIRAMATE 50MG	TABLETS	RECIEPT	In adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. In adjunctive therapy of seizures with Lennox-Gastaut syndrome in adults and children. Topamax is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topamax is indicated in adults for the prevention of migraines. The use of Topamax in the acute treatment of migraine has not been studied.
5321	TOPIRAMATE	TOPIRAMATE TEVA 100 MG	TOPIRAMATE	TOPIRAMATE 100MG	TABLETS	RECIEPT	Topiramate Teva is indicated as adjunctive therapy for adults and children from 2 years and above with partial onset seizures or generalized tonic-clonic seizures. Topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome . Topiramate Teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topiramate Teva is indicated in adults for the prevention of migraines. The use of Topiramate Teva in the acute treatment of migraine has not been studied .
5323	TOPIRAMATE	TOPIRAMATE TEVA 200 MG	TOPIRAMATE	TOPIRAMATE 200MG	TABLETS	RECIEPT	Topiramate Teva is indicated as adjunctive therapy for adults and children from 2 years and above with partial onset seizures or generalized tonic-clonic seizures. Topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome . Topiramate Teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topiramate Teva is indicated in adults for the prevention of migraines. The use of Topiramate Teva in the acute treatment of migraine has not been studied .
5325	TOPIRAMATE	TOPIRAMATE TEVA 25 MG	TOPIRAMATE	TOPIRAMATE 25MG	TABLETS	RECIEPT	Topiramate Teva is indicated as adjunctive therapy for adults and children aged 6 and above with partial onset seizures or generalized tonic-clonic seizures. Topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome . Topiramate Teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topiramate Teva is indicated in adults for the prevention of migraines. The use of Topiramate Teva in the acute treatment of migraine has not been studied .
5327	TOPIRAMATE	TOPIRAMATE TEVA 300 MG	TOPIRAMATE	TOPIRAMATE 300MG	TABLETS	RECIEPT	Topiramate Teva is indicated as adjunctive therapy for adults and children from 2 years and above with partial onset seizures or generalized tonic-clonic seizures. Topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome . Topiramate Teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topiramate Teva is indicated in adults for the prevention of migraines. The use of Topiramate Teva in the acute treatment of migraine has not been studied .
5329	TOPIRAMATE	TOPIRAMATE TEVA 400 MG	TOPIRAMATE	TOPIRAMATE 400MG	TABLETS	RECIEPT	Topiramate Teva is indicated as adjunctive therapy for adults and children from 2 years and above with partial onset seizures or generalized tonic-clonic seizures. Topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome . Topiramate Teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topiramate Teva is indicated in adults for the prevention of migraines. The use of Topiramate Teva in the acute treatment of migraine has not been studied .
5331	TOPIRAMATE	TOPIRAMATE TEVA 50 MG	TOPIRAMATE	TOPIRAMATE 50MG	TABLETS	RECIEPT	Topiramate Teva is indicated as adjunctive therapy for adults and children aged 6 and above with partial onset seizures or generalized tonic-clonic seizures. Topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome . Topiramate Teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topiramate Teva is indicated in adults for the prevention of migraines. The use of Topiramate Teva in the acute treatment of migraine has not been studied .
5333	TOPISALEN	TOPISALEN	SALICYLIC ACID	SALICYLIC ACID 3%W/W;FLUMETASONE PIVALATE 0.02%W/W	OINTMENT	RECIEPT	For the treatment of corticosteroid responsive dermatoses especially in hyperkeratotic conditions.
5334	TOPITRIM	TOPITRIM 100 MG	TOPIRAMATE	TOPIRAMATE 100MG	TABLETS	RECIEPT	In adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. In adjunctive therapy of seizures with Lennox-Gastaut syndrome in adults and children. Topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topitrim is indicated in adults for the prevention of migraines. The use of Topitrim in the acute treatment of migraine has not been studied.
5335	TOPITRIM	TOPITRIM 200 MG	TOPIRAMATE	TOPIRAMATE 200MG	TABLETS	RECIEPT	In adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. In adjunctive therapy of seizures with Lennox-Gastaut syndrome in adults and children. Topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topitrim is indicated in adults for the prevention of migraines. The use of Topitrim in the acute treatment of migraine has not been studied.
5336	TOPITRIM	TOPITRIM 25 MG	TOPIRAMATE	TOPIRAMATE 25MG	TABLETS	RECIEPT	In adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. In adjunctive therapy of seizures with Lennox-Gastaut syndrome in adults and children. Topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topitrim is indicated in adults for the prevention of migraines. The use of Topitrim in the acute treatment of migraine has not been studied.
5337	TOPITRIM	TOPITRIM 50 MG	TOPIRAMATE	TOPIRAMATE 50MG	TABLETS	RECIEPT	In adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. In adjunctive therapy of seizures with Lennox-Gastaut syndrome in adults and children. Topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. Topitrim is indicated in adults for the prevention of migraines. The use of Topitrim in the acute treatment of migraine has not been studied.
5338	TORID	TORID 10	ATORVASTATIN AS MAGNESIUM	ATORVASTATIN AS MAGNESIUM 10MG	TABLETS	RECIEPT	Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorvastatin is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
5339	TORID	TORID 20	ATORVASTATIN AS MAGNESIUM	ATORVASTATIN AS MAGNESIUM 20MG	TABLETS	RECIEPT	Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorvastatin is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
5340	TORID	TORID 40	ATORVASTATIN AS MAGNESIUM	ATORVASTATIN AS MAGNESIUM 40MG	TABLETS	RECIEPT	Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorvastatin is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
5341	TORID	TORID 80	ATORVASTATIN AS MAGNESIUM	ATORVASTATIN AS MAGNESIUM 80MG	TABLETS	RECIEPT	Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorvastatin is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorvastatin is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event sush as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorvastatin is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.
5342	TORISEL	TORISEL	TEMSIROLIMUS	TEMSIROLIMUS 25MG/ML	CONCENTRATE	RECIEPT	First line treatment of patients with advanced renal cell carcinoma. Torisel is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma.
5343	TOUJEO	TOUJEO	INSULIN GLARGINE	INSULIN GLARGINE 300U/ML	SOLUTION	RECIEPT	Treatment of diabetes mellitus in adults.
5344	TOVIAZ	TOVIAZ 4 MG	FESOTERODINE FUMARATE	FESOTERODINE FUMARATE 4MG	TABLETS	RECIEPT	Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.
5345	TOVIAZ	TOVIAZ 8 MG	FESOTERODINE FUMARATE	FESOTERODINE FUMARATE 8MG	TABLETS	RECIEPT	Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.
5346	TRACLEER	TRACLEER 125 MG	BOSENTAN	BOSENTAN 125MG	TABLETS	RECIEPT	Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV. Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
5348	TRACLEER	TRACLEER 62.5 MG	BOSENTAN	BOSENTAN 62.5MG	TABLETS	RECIEPT	Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV. Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
5350	TRACRIUM	TRACRIUM INJECTION	ATRACURIUM BESYLATE	ATRACURIUM BESYLATE 10MG/ML	SOLUTION	RECIEPT	Atracurium is a highly selective, competitive or non-depolarising neuromuscular blocking agent which is used as an adjunct to general anaesthesia to enable tracheal intubation to be performed and to relax skeletal muscles during surgery or controlled ventilation.
5355	TRAJENTA	TRAJENTA DUO 2.5 MG/ 1000 MG	LINAGLIPTIN	LINAGLIPTIN 2.5MG;METFORMIN HYDROCHLORIDE 1000MG	TABLETS	RECIEPT	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. TRAJENTA-DUO should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. TRAJENTA-DUO has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRAJENTA-DUO.
5351	TRAJENTA	TRAJENTA	LINAGLIPTIN	LINAGLIPTIN 5MG	TABLETS	RECIEPT	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. TRAJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. TRAJENTA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRAJENTA.
5352	TRAJENTA	TRAJENTA DUO 2.5 MG/ 500 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 500MG;LINAGLIPTIN 2.5MG	TABLETS	RECIEPT	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. TRAJENTA-DUO should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. TRAJENTA-DUO has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRAJENTA-DUO.
5353	TRAJENTA	TRAJENTA DUO 2.5 MG / 850 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 850MG;LINAGLIPTIN 2.5MG	TABLETS	RECIEPT	As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. TRAJENTA-DUO should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. TRAJENTA-DUO has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRAJENTA-DUO.
5357	TRAMA	TRAMA INJECTION	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 100MG/2ML	SOLUTION	RECIEPT	Moderate to severe pain.
5361	TRAMADEX	TRAMADEX OD 100	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 100MG	TABLETS	RECIEPT	Treatment of moderate to severe pain.
5367	TRAMADEX	TRAMADEX TABLETS	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 100MG	TABLETS	RECIEPT	Short to medium term treatment of moderate to severe pain.
5358	TRAMADEX	TRAMADEX DROPS	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 100MG/ML	DROPS	RECIEPT	Short to medium term treatment of moderate to severe pain.
5363	TRAMADEX	TRAMADEX OD 200	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 200MG	TABLETS	RECIEPT	Treatment of moderate to severe pain.
5365	TRAMADEX	TRAMADEX OD 300	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 300MG	TABLETS	RECIEPT	Treatment of moderate to severe pain.
5360	TRAMADEX	TRAMADEX FLASHTAB	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 50MG	TABLETS	RECIEPT	Treatment of moderate to severe pain.
5368	TRAMADOL	TRAMADOL 100 MG ROTEXMEDICA	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 100MG/2ML	SOLUTION	RECIEPT	Moderate severe to severe pain .
5369	TRAMADOL	TRAMADOL MEDOCHEMIE 100 MG/2 ML	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 50MG/1ML	SOLUTION	RECIEPT	Moderate to severe pain
5372	TRAMAL	TRAMAL RETARD 100	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 100MG	TABLETS	RECIEPT	Moderate to severe pain.
5374	TRAMAL	TRAMAL SUPPOSITORIES	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 100MG	SUPPOSITORIES	RECIEPT	Moderate to severe pain.
5371	TRAMAL	TRAMAL INJECTION 100	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 100MG/2ML	SOLUTION	RECIEPT	Moderate to severe pain.
5370	TRAMAL	TRAMAL CAPSULES	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 50MG	CAPSULES	RECIEPT	Moderate to severe pain.
5373	TRAMAL	TRAMAL RETARD 50	TRAMADOL HYDROCHLORIDE	TRAMADOL HYDROCHLORIDE 50MG	TABLETS	RECIEPT	Moderate to severe pain.
5375	TRAMARAZ	TRAMARAZ 100 MG/ML	TRAMADOL	TRAMADOL 100MG	DROPS	RECIEPT	Moderate to severe pain.
5377	TRANDATE	TRANDATE TABLETS 100 MG	LABETALOL HYDROCHLORIDE	LABETALOL HYDROCHLORIDE 100MG	TABLETS	RECIEPT	Treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.
5378	TRANDATE	TRANDATE TABLETS 200 MG	LABETALOL HYDROCHLORIDE	LABETALOL HYDROCHLORIDE 200MG	TABLETS	RECIEPT	Treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.
5376	TRANDATE	TRANDATE INJECTION	LABETALOL HYDROCHLORIDE	LABETALOL HYDROCHLORIDE 5MG/ML	SOLUTION	RECIEPT	Treatment of hypertension when rapid control of blood pressure is essential.
5379	TRANEX	TRANEX INJECTION	TRANEXAMIC ACID	TRANEXAMIC ACID 500MG/5ML	SOLUTION	RECIEPT	General fibrinolysis. This may occur in prostatic and pancreatic carcinoma following thoracic surgery and other major operative procedures, in obstetrical complications such as abruptio placentae and post-partum hemorrhage, in connection with thrombolytic therapy, and in initial and follow-up treatment following prostatectomy and bladder surgery. Prior to, and following, dental surgery in hemophiliacs. Epistaxis.
5380	TRANEXAMIC	TRANEXAMIC - MEDO INJECTION	TRANEXAMIC ACID	TRANEXAMIC ACID 100MG/1ML	SOLUTION	RECIEPT	General fibrinolysis. This may occur in prostatic and pancreatic carcinoma following thoracic surgery and other major operative procedures, in obstetrical complications such as abruptio placentae and post-partum hemorrhage, in connection with thrombolytic therapy, and in initial and follow-up treatment following prostatectomy and bladder surgery. Prior to, and following, dental surgery in hemophiliacs. Epistaxis. Conization of the cervix.
5381	TRANSLARNA	TRANSLARNA 1000 MG	ATALUREN	ATALUREN 1000MG	GRANULES	RECIEPT	Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
5389	TRANSLARNA	TRANSLARNA 125 MG	ATALUREN	ATALUREN 125MG	GRANULES	RECIEPT	Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing
5397	TRANSLARNA	TRANSLARNA 250 MG	ATALUREN	ATALUREN 250MG	GRANULES	RECIEPT	Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
5405	TRANXAL	TRANXAL 15 MG	POTASSIUM CLORAZEPATE	POTASSIUM CLORAZEPATE 15MG	CAPSULES	RECIEPT	For the management and relief of anxiety, symptomatic relief of acute alcohol withdrawal, adjunctive therapy in the management of partial seizures.
5406	TRANXAL	TRANXAL 5 MG	POTASSIUM CLORAZEPATE	POTASSIUM CLORAZEPATE 5MG	CAPSULES	RECIEPT	For the management and relief of anxiety, symptomatic relief of acute alcohol withdrawal, adjunctive therapy in the management of partial seizures.
5407	TRASENTAN	TRASENTAN 125	BOSENTAN AS MONOHYDRATE	BOSENTAN AS MONOHYDRATE 125MG	TABLETS	RECIEPT	Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV. Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
5409	TRASENTAN	TRASENTAN 62.5	BOSENTAN AS MONOHYDRATE	BOSENTAN AS MONOHYDRATE 62.5MG	TABLETS	RECIEPT	Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV. Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
5411	TRAUMAPLANT	TRAUMAPLANT	COMFREY (SYMPHYTUM) CONCENTRATE	COMFREY (SYMPHYTUM) CONCENTRATE 10G/100 G	CREAM		Traumaplant is a phytodrug (extract of plants) for external treatment of ankle sprains and muscle pains (in case of sports and accidental injuries).
5412	TRAUMAPLANT	TRAUMAPLANT CREAM 50GR	COMFREY CONCENTRATE	COMFREY CONCENTRATE 10G/100G	CREAM		Traumaplant is a phytodrug (extract of plants) for external treatment of ankle sprains and muscle pains (in case of sports and accidental injuries).
5414	TRAVAMIN	TRAVAMIN 10 TAB	DIMENHYDRINATE	DIMENHYDRINATE 100MG	TABLETS		For prevention and treatment of motion sickness (air, sea, car sickness) and radiation sickness.
5415	TRAVAMIN	TRAVAMIN TABLETS	DIMENHYDRINATE	DIMENHYDRINATE 100MG	TABLETS		For prevention and treatment of motion sickness (air, sea, car sickness) and radiation sickness.
5416	TRAVATAN	TRAVATAN	TRAVOPROST	TRAVOPROST 0.004%W/V	SOLUTION	RECIEPT	For the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another IOP lowering medication.
5417	TRAVOPROST	TRAVOPROST INOVAMED	TRAVOPROST	TRAVOPROST 40MCG/1ML	SOLUTION	RECIEPT	For the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another IOP lowering medication.
5419	TRAVOPROST S.K.	TRAVOPROST S.K.	TRAVOPROST	TRAVOPROST 0.04MG/ML	SOLUTION	RECIEPT	For the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another IOP lowering medication
5420	TRAZODIL	TRAZODIL 100	TRAZODONE HYDROCHLORIDE	TRAZODONE HYDROCHLORIDE 100MG	TABLETS	RECIEPT	For the treatment of depression and anxiety.
5422	TRAZODIL	TRAZODIL 50	TRAZODONE HYDROCHLORIDE	TRAZODONE HYDROCHLORIDE 50MG	TABLETS	RECIEPT	For the treatment of depression and anxiety.
5424	TREGLUDEC	TREGLUDEC 100U/ML	INSULIN DEGLUDEC	INSULIN DEGLUDEC 100U/ML	SOLUTION	RECIEPT	Treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.
5425	TREGLUDEC	TREGLUDEC 200 U/ML	INSULIN DEGLUDEC	INSULIN DEGLUDEC 200U/ML	SOLUTION	RECIEPT	Treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.
5426	TRELEGY ELLIPTA	TRELEGY ELLIPTA 92 / 55 / 22 MCG	VILANTEROL AS TRIFENATATE	VILANTEROL AS TRIFENATATE 22MCG/INH;UMECLIDINIUM BROMIDE 65MCG/INH equivalent to 55 mcg umeclidinium;FLUTICASONE FUROATE 92MCG/INH	POWDER	RECIEPT	TRELEGY ELLIPTA is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. TRELEGY ELLIPTA is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. Important Limitations of Use: TRELEGY ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.
5427	TREMFYA	TREMFYA	GUSELKUMAB	GUSELKUMAB 100MG/1ML	SOLUTION	RECIEPT	Tremfya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
5428	TREPROSTINIL S.K	TREPROSTINIL S.K 2.5 MG/ML	TREPROSTINIL	TREPROSTINIL 2.5MG/1ML	SOLUTION	RECIEPT	Treprostinil s.k. is indicated for the treatment of: * Primary pulmonary arterial hypertension. * Pulmonary arterial hypertension associated with connective tissue disorders. * Pulmonary hypertension associated with congenital systemic to pulmonary shunts.
5429	TREPROSTINIL S.K.	TREPROSTINIL S.K. 10 MG/ML	TREPROSTINIL	TREPROSTINIL 10MG/1ML	SOLUTION	RECIEPT	Treprostinil s.k. is indicated for the treatment of: * Primary pulmonary arterial hypertension. * Pulmonary arterial hypertension associated with connective tissue disorders. * Pulmonary hypertension associated with congenital systemic to pulmonary shunts.
5430	TREPROSTINIL S.K.	TREPROSTINIL S.K. 5 MG/ML	TREPROSTINIL	TREPROSTINIL 5MG/1ML	SOLUTION	RECIEPT	Treprostinil s.k. is indicated for the treatment of: * Primary pulmonary arterial hypertension. * Pulmonary arterial hypertension associated with connective tissue disorders. * Pulmonary hypertension associated with congenital systemic to pulmonary shunts.
5431	TREVICTA	TREVICTA	PALIPERIDONE AS PALMITATE	PALIPERIDONE AS PALMITATE 200MG/1ML	SUSPENSION	RECIEPT	TREVICTA, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product
5433	TRI - TEVA	TRI - TEVA	EFAVIRENZ	EFAVIRENZ 600MG;EMTRICITABINE 200MG;TENOFOVIR DISOPROXIL AS FUMARATE 245MG	TABLETS	RECIEPT	TRI-TEVA is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
5435	TRIBEMIN	TRIBEMIN TABLETS	PYRIDOXINE (VIT B6) HYDROCHLORIDE	PYRIDOXINE (VIT B6) HYDROCHLORIDE 250MG;THIAMINE (VIT B1) HYDROCHLORIDE 100MG;CYANOCOBALAMIN 250MCG	TABLETS		For the treatment of neurologic pain and metabolic disorders. Vitamin B supplement.
5434	TRIBEMIN	TRIBEMIN 20TAB	PYRIDOXINE HCL	PYRIDOXINE HCL 250MG;THIAMINE HCL 100MG;CYANOCOBALAMINE 250MG	TABLETS		For the treatment of neurologic pain and metabolic disorders. Vitamin B supplement.
5436	TRICAN	TRICAN 200 MG CAPSULES	FLUCONAZOLE	FLUCONAZOLE 200MG	CAPSULES	RECIEPT	Fluconazole is indicated in the following fungal infections. Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis. • Coccidioidomycosis. • Invasive candidiasis. • Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. • Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate. • Candidal balanitis when local therapy is not appropriate. • Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated. • Tinea unguinium (onychomycosis) when other agents are not considered appropriate. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year). • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation). Fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
5437	TRICLONAM	TRICLONAM ELIXIR	TRICLOFOS SODIUM	TRICLOFOS SODIUM 500MG/5ML	LIQUID	RECIEPT	Insomnia, daytime sedation and pre-medication in EEC.
5438	TRIDERM	TRIDERM CREAM	CLOTRIMAZOLE	CLOTRIMAZOLE 10MG/G;BETAMETHASONE AS DIPROPIONATE 0.5MG/G;GENTAMICIN (AS SULFATE) 1MG/G	CREAM	RECIEPT	Treatment of corticosteroid-responsive dermatoses when complicated by infections caused by bacteria (sensitive to gentamicin) and fungi (sensitive to clotrimazole) or when the possibility of such infections is suspected. The cream is suitable for the use of oozing eczema.
5441	TRIFLUCAN	TRIFLUCAN I.V.	FLUCONAZOLE	FLUCONAZOLE 2MG/ML	SOLUTION	RECIEPT	Fluconazole is indicated in the following fungal infections . Fluconazole is indicated in adults for the treatment of: • Cryptococcal meningitis . • Coccidioidomycosis . Invasive candidiasis. • Mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis). • Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene topical treatment are insufficient. Fluconazole is indicated in adults for the prophylaxis of: • Relapse of cryptococcal meningitis in patients with high risk of recurrence. • Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Haematopoetic Stem Cell Transplantation ). Fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals.
5442	TRILEPTIN	TRILEPTIN 300 MG	OXCARBAZEPINE	OXCARBAZEPINE 300MG	TABLETS	RECIEPT	Treatment of primary generalised tonic-clonic seizures and partial seizures with or without secondary generalization.
5443	TRILEPTIN	TRILEPTIN 600 MG	OXCARBAZEPINE	OXCARBAZEPINE 600MG	TABLETS	RECIEPT	Treatment of primary generalized tonic-clonic seizures and partial seizures with or without secondary generalization.
5447	TRIOMEL	TRIOMEL 5G/L NITROGEN 990 Kcal/L WITH ELECTROLYTES	ALANINE	ALANINE 11.90G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;ARGININE 8.06G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;ASPARTIC ACID 2.38G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;GLUTAMIC ACID 4.11G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;GLYCINE 5.70G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;HISTIDINE 4.91G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;ISOLEUCINE 4.11G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;LEUCINE 5.70G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;LYSINE 6.47G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;METHIONINE 4.11G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;PHENYLALANINE 5.70G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;PROLINE 4.91G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;SERINE 3.25G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;THREONINE 4.11G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;TRYPTOPHAN 1.37G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;TYROSINE 0.21G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;VALINE 5.26G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;SODIUM ACETATE TRIHYDRATE 3.74G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;POTASSIUM CHLORIDE 5.59G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;MAGNESIUM CHLORIDE 2.03G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;SODIUM GLYCEROPHOSPHATE HYDRATE 9.18G/1 L chamber A: 8.2% amino acids solution compartment with electrolytes;SOYA BEAN OIL REFINED + OLIVE OIL REFINED 200G/1 L chamber C: 20% lipid emulsion compartment;CALCIUM CHLORIDE DIHYDRATE 1.29G/1 L chamber B: 28.75% glucose solution compartment with electrolyte calcium;GLUCOSE MONOHYDRATE 316.25G/1 L chamber B: 28.75% glucose solution compartment with electrolyte calcium	EMULSION		Triomel is indicated for parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
5449	TRIOMEL	TRIOMEL 7 G/L NITROGEN 1140 Kcal/L WITH ELECTROLYTES	ALANINE	ALANINE 16.02G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;ARGININE 10.85G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;ASPARTIC ACID 3.20G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;GLUTAMIC ACID 5.53G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;GLYCINE 7.67G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;HISTIDINE 6.61G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;ISOLEUCINE 5.53G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;LEUCINE 7.67G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;LYSINE 8.71G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;METHIONINE 5.53G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;PHENYLALANINE 7.67G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;PROLINE 6.61G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;SERINE 4.37G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;THREONINE 5.53G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;TRYPTOPHAN 1.84G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;TYROSINE 0.28G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;VALINE 7.08G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;SODIUM ACETATE TRIHYDRATE 3.74G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;POTASSIUM CHLORIDE 5.59G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;MAGNESIUM CHLORIDE 2.03G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;SODIUM GLYCEROPHOSPHATE HYDRATE 9.18G/1 L chamber A: 11.1% amino acids solution compartment with electrolytes;SOYA BEAN OIL REFINED + OLIVE OIL REFINED 200G/1 L chamber C: 20% lipid emulsion compartment;CALCIUM CHLORIDE DIHYDRATE 1.29G/1 L chamber B: 35% glucose solution compartment with electrolyte calcium;GLUCOSE MONOHYDRATE 385G/1 L chamber B: 35% glucose solution compartment with electrolyte calcium	EMULSION		Triomel is indicated for parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
5448	TRIOMEL	TRIOMEL 7 G/L NITROGEN 1140 Kcal/L	ALANINE	ALANINE 16.02G/1 L chamber A: 11.1% amino acids solution compartment;ARGININE 10.85G/1 L chamber A: 11.1% amino acids solution compartment;ASPARTIC ACID 3.20G/1 L chamber A: 11.1% amino acids solution compartment;GLUTAMIC ACID 5.53G/1 L chamber A: 11.1% amino acids solution compartment;GLYCINE 7.67G/1 L chamber A: 11.1% amino acids solution compartment;HISTIDINE 6.61G/1 L chamber A: 11.1% amino acids solution compartment;ISOLEUCINE 5.53G/1 L chamber A: 11.1% amino acids solution compartment;LEUCINE 7.67G/1 L chamber A: 11.1% amino acids solution compartment;LYSINE 8.71G/1 L chamber A: 11.1% amino acids solution compartment;METHIONINE 5.53G/1 L chamber A: 11.1% amino acids solution compartment;PHENYLALANINE 7.67G/1 L chamber A: 11.1% amino acids solution compartment;PROLINE 6.61G/1 L chamber A: 11.1% amino acids solution compartment;SERINE 4.37G/1 L chamber A: 11.1% amino acids solution compartment;THREONINE 5.53G/1 L chamber A: 11.1% amino acids solution compartment;TRYPTOPHAN 1.84G/1 L chamber A: 11.1% amino acids solution compartment;TYROSINE 0.28G/1 L chamber A: 11.1% amino acids solution compartment;VALINE 7.08G/1 L chamber A: 11.1% amino acids solution compartment;SOYA OIL 200G/1 L chamber C: 20% lipid emulsion compartment;GLUCOSE MONOHYDRATE 385G/1 L chamber B: 35% glucose solution compartment	EMULSION		Triomel is indicated for parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
5451	TRIOMEL	TRIOMEL 9 G/L NITROGEN 1070 Kcal/L WITH ELECTROLYTES	ALANINE	ALANINE 20.60G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;ARGININE 13.95G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;ASPARTIC ACID 4.12G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;GLUTAMIC ACID 7.11G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;GLYCINE 9.87G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;HISTIDINE 8.49G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;ISOLEUCINE 7.11G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;LEUCINE 9.87G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;LYSINE 11.20G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;METHIONINE 7.11G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;PHENYLALANINE 9.87G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;PROLINE 8.49G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;SERINE 5.62G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;THREONINE 7.11G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;TRYPTOPHAN 2.37G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;TYROSINE 0.37G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;VALINE 9.11G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;SODIUM ACETATE TRIHYDRATE 3.74G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;POTASSIUM CHLORIDE 5.59G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;MAGNESIUM CHLORIDE 2.03G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;SODIUM GLYCEROPHOSPHATE HYDRATE 9.18G/1 L chamber A: 14.2% amino acids solution compartment with electrolytes;SOYA BEAN OIL REFINED + OLIVE OIL REFINED 200G/1 L chamber C: 20% lipid emulsion compartment;CALCIUM CHLORIDE DIHYDRATE 1.29G/1 L chamber B: 27.5% glucose solution compartment with electrolyte calcium;GLUCOSE MONOHYDRATE 302.5G/1 L chamber B: 27.5% glucose solution compartment with electrolyte calcium	EMULSION		Triomel is indicated for parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
5450	TRIOMEL	TRIOMEL 9 G/L NITROGEN 1070 Kcal/L	ALANINE	ALANINE 20.60G/1 L chamber A: 14.2% amino acids solution compartment;ARGININE 13.95G/1 L chamber A: 14.2% amino acids solution compartment;ASPARTIC ACID 4.12G/1 L chamber A: 14.2% amino acids solution compartment;GLUTAMIC ACID 7.11G/1 L chamber A: 14.2% amino acids solution compartment;GLYCINE 9.87G/1 L chamber A: 14.2% amino acids solution compartment;HISTIDINE 8.49G/1 L chamber A: 14.2% amino acids solution compartment;ISOLEUCINE 7.11G/1 L chamber A: 14.2% amino acids solution compartment;LEUCINE 9.87G/1 L chamber A: 14.2% amino acids solution compartment;LYSINE 11.20G/1 L chamber A: 14.2% amino acids solution compartment;METHIONINE 7.11G/1 L chamber A: 14.2% amino acids solution compartment;PHENYLALANINE 9.87G/1 L chamber A: 14.2% amino acids solution compartment;PROLINE 8.49G/1 L chamber A: 14.2% amino acids solution compartment;SERINE 5.62G/1 L chamber A: 14.2% amino acids solution compartment;THREONINE 7.11G/1 L chamber A: 14.2% amino acids solution compartment;TRYPTOPHAN 2.37G/1 L chamber A: 14.2% amino acids solution compartment;TYROSINE 0.37G/1 L chamber A: 14.2% amino acids solution compartment;VALINE 9.11G/1 L chamber A: 14.2% amino acids solution compartment;SOYA OIL 200G/1 L chamber C: 20% lipid emulsion compartment;GLUCOSE MONOHYDRATE 302.5G/1 L chamber B: 27.5% glucose solution compartment	EMULSION		Triomel is indicated for parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
5452	TRIOMEL	TRIOMEL PERIPHERAL 4G/L NITROGEN 700 Kcal/L WITH ELECTROLYTES	ALANINE	ALANINE 9.16G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;ARGININE 6.20G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;ASPARTIC ACID 1.83G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;GLUTAMIC ACID 3.16G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;GLYCINE 4.39G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;HISTIDINE 3.77G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;ISOLEUCINE 3.16G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;LEUCINE 4.39G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;LYSINE 4.98G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;METHIONINE 3.16G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;PHENYLALANINE 4.39G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;PROLINE 3.77G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;SERINE 2.50G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;THREONINE 3.16G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;TRYPTOPHAN 1.06G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;TYROSINE 0.16G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;VALINE 4.05G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;SODIUM ACETATE TRIHYDRATE 2.89G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;POTASSIUM CHLORIDE 2.98G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;MAGNESIUM CHLORIDE 1.12G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;SODIUM GLYCEROPHOSPHATE HYDRATE 4.78G/1 L chamber A: 6.3% amino acids solution compartment with electrolytes;SOYA BEAN OIL REFINED + OLIVE OIL REFINED 150G/1 L chamber C: 15% lipid emulsion compartment;CALCIUM CHLORIDE DIHYDRATE 0.74G/1 L chamber B: 18.75% glucose solution compartment with electrolyte calcium;GLUCOSE MONOHYDRATE 206.25G/1 L chamber B: 18.75% glucose solution compartment with electrolyte calcium	EMULSION		Triomel is indicated for parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
5453	TRIPACEL	TRIPACEL	PERTUSSIS ACELLULAR	PERTUSSIS ACELLULAR 10MCG/0.5ML;FILAMENTOUS HAEMAGGLUTININ (FHA) 5MCG/0.5ML;FIMBRAE TUPES 2 + 3 (FIM) 5MCG/0.5ML;PERTACTIN 3MCG/0.5ML;DIPHTHERIA TOXOID 30 IU/0.5ML;TETANUS TOXOID 40 IU/0.5ML	SUSPENSION	RECIEPT	Is indicated for the primary immunization of infants at or above the age of 2 months and as a booster in children up to their 6th birthday against diphtheria, tetanus and pertussis.
5454	TRISENOX	TRISENOX	ARSENIC TRIOXIDE	ARSENIC TRIOXIDE 1MG/ML	SOLUTION	RECIEPT	TRISENOX is indicated for induction of remission, and consolidation in adult patients with: • Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (ATRA) • Relapsed/refractory acute promyelocytic leukaemia (APL)(Previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.
5455	TRITACE	TRITACE 1.25 MG	RAMIPRIL	RAMIPRIL 1.25MG	TABLETS	RECIEPT	Hypertension congestive heart failure reduction of mortality in patients after MI with left ventricular dysfunction. For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) high total cholesterol (>5.2 mmol/L) low HDL ( less than 0.9 mmol/L) current smoker known microalbuminuria clinical evidence of previous vascular disease. Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
5456	TRITACE	TRITACE 2.5 MG	RAMIPRIL	RAMIPRIL 2.5MG	TABLETS	RECIEPT	Hypertension congestive heart failure reduction of mortality in patients after MI with left ventricular dysfunction. For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) high total cholesterol (>5.2 mmol/L) low HDL ( less than 0.9 mmol/L) current smoker known microalbuminuria clinical evidence of previous vascular disease. Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
5458	TRITACE	TRITACE COMP 2.5 MG/12.5 MG	RAMIPRIL	RAMIPRIL 2.5MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	Essential hypertension. Tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.
5457	TRITACE	TRITACE 5 MG	RAMIPRIL	RAMIPRIL 5MG	TABLETS	RECIEPT	Hypertension congestive heart failure reduction of mortality in patients after MI with left ventricular dysfunction. For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) high total cholesterol (>5.2 mmol/L) low HDL ( less than 0.9 mmol/L) current smoker known microalbuminuria clinical evidence of previous vascular disease. Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
5459	TRITACE	TRITACE COMP 5 MG/25 MG	RAMIPRIL	RAMIPRIL 5MG;HYDROCHLOROTHIAZIDE 25MG	TABLETS	RECIEPT	Essential hypertension. Tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.
5460	TRIUMEQ	TRIUMEQ	DOLUTEGRAVIR AS SODIUM	DOLUTEGRAVIR AS SODIUM 50MG;ABACAVIR AS SULFATE 600MG;LAMIVUDINE 300MG	TABLETS	RECIEPT	Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B5701 allele.
5465	TROSMOLYT	TROSMOLYT 20 MG	TROSPIUM CHLORIDE	TROSPIUM CHLORIDE 20MG	TABLETS	RECIEPT	Symptomatic treatment of urge incontinence and /or increased urinary frequency and urgency as may occur in patients with overactive bladder (e.g. idiopathic or neurologic detrusor overactivity)
5466	TROSPAS	TROSPAS 15 MG	TROSPIUM CHLORIDE	TROSPIUM CHLORIDE 15MG	TABLETS	RECIEPT	For the treatment of vegetative bladder dysfunction accompanied by urgency and/or frequency and/or urinary incontinence.
5467	TROSPAS	TROSPAS 30 MG	TROSPIUM CHLORIDE	TROSPIUM CHLORIDE 30MG	TABLETS	RECIEPT	For the treatment of vegetative bladder dysfunction accompanied by urgency and/or frequency and/or urinary incontinence.
5468	TRUE TEST 24	TRUE TEST 24	ALERGENS (CHEMICAL)	ALERGENS (CHEMICAL) 24	PLASTER	RECIEPT	Diagnosis of allergic contact dermatitis.
5469	TRULICITY	TRULICITY 0.75 MG	DULAGLUTIDE	DULAGLUTIDE 0.75MG/0.5ML	SOLUTION	RECIEPT	Trulicity is indicated in adults with type 2 diabetes mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. Add on therapy: In combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
5470	TRULICITY	TRULICITY 1.5 MG	DULAGLUTIDE	DULAGLUTIDE 1.5MG/0.5ML	SOLUTION	RECIEPT	Trulicity is indicated in adults with type 2 diabetes mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. Add on therapy: In combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. 08/02/ 2018 בקשה לשינוי משטר מינון הרחבת אוכלוסיית החולים לחולי כליה חמורים ]([severe renal impairment (eGFR <90 to ≥15
5471	TRUSOPT	TRUSOPT	DORZOLAMIDE AS HYDROCHLORIDE	DORZOLAMIDE AS HYDROCHLORIDE 20MG/ML	SOLUTION	RECIEPT	For the treatment of eleveated intraocular pressure in patients with ocular hypertension, open-angle glaucoma and in some patients secondary glaucoma.
5472	TRUVADA	TRUVADA	EMTRICITABINE	EMTRICITABINE 200MG;TENOFOVIR DISOPROXIL AS FUMARATE 245MG	TABLETS	RECIEPT	Truvada is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults over 18 years of age. Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk .
5475	TRUXIMA	TRUXIMA	RITUXIMAB	RITUXIMAB 10MG/ML	CONCENTRATE	RECIEPT	Truxima is indicated in adults for the following indications: * Non-Hodgkin’s lymphoma (NHL) Truxima is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, B-cell non-hodgkin’s lymphoma. Truxima is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy. Truxima is indicated for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy. Truxima maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * Chronic lymphocytic leukaemia (CLL) Truxima in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy. * Granulomatosis with polyangiitis and microscopic polyangiitis Truxima, in combination with glucocorticoids, is indicated for the treatment of adult patients with granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis (WG)) and microscopic polyangiitis (MPA).
5476	TUBERSOL	TUBERSOL	TUBERCULIN PURIFIED PROTEIN	TUBERCULIN PURIFIED PROTEIN 5TU/0.1ML	SOLUTION	RECIEPT	An aid in the detection of infection with mycobacterium tuberculosis.
5487	TUMS	TUMS ULTRA ASSORTED BERRIES	CALCIUM CARBONATE	CALCIUM CARBONATE 1000MG	TABLETS		Antacid.
5486	TUMS	TUMS ULTRA 1G ASSORTED 160TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 1040.08MG	TABLETS		Antacid.
5479	TUMS	TUMS MINT 500MG 3*12 ROLL	CALCIUM CARBONATE	CALCIUM CARBONATE 500MG	TABLETS		Antacid.
5480	TUMS	TUMS REGULAR STRENGTH PEPPERMINT	CALCIUM CARBONATE	CALCIUM CARBONATE 500MG	TABLETS		Antacid.
5478	TUMS	TUMS EX SUGAR FREE	CALCIUM CARBONATE	CALCIUM CARBONATE 750MG	TABLETS		Antacid.
5481	TUMS	TUMS SMOOTHIES EX BERRY FUSION	CALCIUM CARBONATE	CALCIUM CARBONATE 750MG	TABLETS		Treatment of heartburn.
5482	TUMS	TUMS SMOOTHIES EX BERRY FUSION 60 TABS 750MG	CALCIUM CARBONATE	CALCIUM CARBONATE 750MG	TABLETS		Treatment of heartburn.
5483	TUMS	TUMS SMOOTHIES EX PEPERMINT 60 TABS 750MG	CALCIUM CARBONATE	CALCIUM CARBONATE 750MG	TABLETS		Antacid.
5484	TUMS	TUMS SMOOTHIES EX PEPPERMINT	CALCIUM CARBONATE	CALCIUM CARBONATE 750MG	TABLETS		Antacid.
5485	TUMS	TUMS SMOOTHIES EX TROPICAL FRUIT 750MG 60 TABS	CALCIUM CARBONATE	CALCIUM CARBONATE 750MG	TABLETS		Antacid.
5477	TUMS	TUMS EX 750MG SF 80TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 750MG SF	TABLETS		Antacid.
5488	TUSSIN	TUSSIN DM	DEXTROMETHORPHAN HYDROBROMIDE	DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML;GUAIFENESIN 100MG/5ML	SYRUP	RECIEPT	For relief of cough and expecctorant.
5490	TUSSIN	TUSSIN DM 118ML	GUAIPHENESIN	GUAIPHENESIN 100MG/5ML;DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML	SYRUP	RECIEPT	For relief of cough and expecctorant.
5491	TUSSOPHEDRINE	TUSSOPHEDRINE NEW FORMULA 115ML	EPHEDRIN	EPHEDRIN 6MG;SODIUM BENZOAT 20MG;POT.SULPHONATE 120MG;DEXTROMETHORPHAN 5/5ML	SYRUP		Relief of cough.
5492	TUSSOPHEDRINE	TUSSOPHEDRINE NF	EPHEDRINE HYDROCHLORIDE	EPHEDRINE HYDROCHLORIDE 6MG/5ML;DEXTROMETHORPHAN HYDROBROMIDE 5MG/5ML;GUAIACOLSULFONATE AS POTASSIUM 120MG/5ML;BENZOIC ACID AS SODIUM 20MG/5ML	SYRUP	RECIEPT	Relief of cough.
5493	TYGACIL	TYGACIL	TIGECYCLINE	TIGECYCLINE 50MG/DOSE	POWDER	RECIEPT	TYGACIL is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older: Complicated Skin and Skin Structure Infections: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates ), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis . Complicated Intra-abdominal Infections: Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros. Community-Acquired Bacterial Pneumonia: Community-acquired bacterial pneumonia caused by Streptococcus pneumoniae (penicillin susceptible isolates), including cases with concurrent bacteremia, Haemophilus influenzae (beta-lactamase negative isolates), and Legionella pneumophila.
5495	TYKERB	TYKERB	LAPATINIB AS DITOSYLATE MONOHYDRATE	LAPATINIB AS DITOSYLATE MONOHYDRATE 250MG	TABLETS	RECIEPT	Tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2); • in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting . • Tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
5501	TYPHIM	TYPHIM VI	PURIFIED VI CAPSULAR POLYSACCHARIDE OF S.TYPHI	PURIFIED VI CAPSULAR POLYSACCHARIDE OF S.TYPHI 0.025MG/0.5ML	SOLUTION	RECIEPT	Typhim Vi vaccine is indicated for active immunization against typhoid fever for persons two years of age or older.
5502	TYSABRI	TYSABRI	NATALIZUMAB	NATALIZUMAB 300MG/15ML	CONCENTRATE	RECIEPT	Tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . To delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. The safety and efficacy of Tysabri beyond two years are unknown. Because Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. Safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.
5503	TYVASO	TYVASO	TREPROSTINIL AS SODIUM SALT	TREPROSTINIL AS SODIUM SALT 1.74MG/2.9ML	SOLUTION		Treatment of pulmonary arterial hypertension in patients with NYHA class III symptoms, to increase walk distance.
5505	TZAREVET	TZAREVET X MELON FLAVOUR	CALCIUM AS CARBONATE	CALCIUM AS CARBONATE 500MG	TABLETS		Antacid, calcium supplement.
5507	TZAREVET	TZAREVET X MINT FLAVOUR	CALCIUM AS CARBONATE	CALCIUM AS CARBONATE 500MG	TABLETS		Antacid, calcium supplement.
5506	TZAREVET	TZAREVET X MENTHOL 36 TAB	CALCIUM CARBONATE	CALCIUM CARBONATE 500MG	TABLETS		Antacid.
5508	UBISTESIN	UBISTESIN	EPINEPHRINE HYDROCHLORIDE	EPINEPHRINE HYDROCHLORIDE 0.006MG/ML;ARTICAINE HYDROCHLORIDE 40MG/ML	SOLUTION	RECIEPT	Infiltration anesthesia and nerve-block in dentistry. Ubistesin is especially indicated for routine interventions such as: Uncomplicated single and serial extractions. Cavity and coronal stump preparations.
5509	UBISTESIN	UBISTESIN FORTE	EPINEPHRINE HYDROCHLORIDE	EPINEPHRINE HYDROCHLORIDE 0.012MG/ML;ARTICAINE HYDROCHLORIDE 40MG/ML	SOLUTION	RECIEPT	Infiltration anesthesia and nerve-block in dentistry. Ubistesin is especially indicated for interventions requiring deep anesthesia and pronounced restriction of blood flow such as: - Gingival and bone surgery - Pulp surgery (amputation and extirpation) - Extraction and trepanation of desmotic teeth and extraction of fractured teeth (osteotomy) - Protracted surgical procedures i.e. caldwell-luc operation percutaneous osteosynthesis cystectomy mucogingival operations apicectomy.
5510	ULCERON	ULCERON	PANTOPRAZOLE AS SODIUM	PANTOPRAZOLE AS SODIUM 40MG/VIAL	POWDER	RECIEPT	For the treatment of duodenal ulcer, gastric ulcer, moderate and severe forms of reflux oesophagitis. Zollinger Ellison Syndrome.
5511	ULTIBRO BREEZHALER	ULTIBRO BREEZHALER 110/50 MCG	INDACATEROL AS MALEATE	INDACATEROL AS MALEATE 110MCG;GLYCOPYRRONIUM AS BROMIDE 50MCG	INHALATION	RECIEPT	Ultibro Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
5512	ULTIVA	ULTIVA 1 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 1MG/VIAL	POWDER	RECIEPT	Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
5513	ULTIVA	ULTIVA 2 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 2MG/VIAL	POWDER	RECIEPT	Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
5514	ULTIVA	ULTIVA 5 MG	REMIFENTANIL AS HYDROCHLORIDE	REMIFENTANIL AS HYDROCHLORIDE 5MG/VIAL	POWDER	RECIEPT	Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
5515	ULTOMIRIS	ULTOMIRIS	RAVULIZUMAB	RAVULIZUMAB 10MG/1ML	CONCENTRATE	RECIEPT	ULTOMIRIS is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): • in patients with haemolysis with clinical symptom(s) indicative of high disease activity • in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.
5516	ULTRAVIST	ULTRAVIST 300	IOPROMIDE	IOPROMIDE 623.4MG/1ML	SOLUTION	RECIEPT	Contrast enhancement in computerized tomography (CT) , digital subtraction angiography (DSA), intravenous urography, arteriography ,phlebography of the extremities, venography, visualization of body cavities (e.g. arthrography, hysterosalpingography,fistulography) with the exception of myelography, ventriculography, cisternography.
5517	ULTRAVIST	ULTRAVIST 370	IOPROMIDE	IOPROMIDE 768.86MG/ML	SOLUTION	RECIEPT	Contrast enhancement in computerized tomography (CT) , digital subtraction angiography (DSA), intravenous urography, arteriography and especially angiocardiography, visualization of body cavities (e.g. arthrography, fistulography) with the exception of myelography, ventriculography, cisternography.
5519	UNASYN	UNASYN 1.5 G.	AMPICILLIN AS SODIUM	AMPICILLIN AS SODIUM 1000MG;SULBACTAM AS SODIUM 500MG	POWDER	RECIEPT	Sulbactam sodium/ampicillin sodium IM/IV is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) Skin and Skin Structure Infections. 2) Intra-Abdominal Infections. 3) Gynecological Infections.
5520	UNASYN	UNASYN 3 G.	AMPICILLIN AS SODIUM	AMPICILLIN AS SODIUM 2000MG;SULBACTAM AS SODIUM 1000MG	POWDER	RECIEPT	Sulbactam sodium/ampicillin sodium IM/IV is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) Skin and Skin Structure Infections. 2) Intra-Abdominal Infections. 3) Gynecological Infections.
5523	UNDECYL	UNDECYL POWDER	UNDECENOIC ACID	UNDECENOIC ACID 2%;ZINC UNDECENOATE 20%	POWDER		Prophylaxis and treatment of mycotic skin infections particulary athlete's foot.
5524	UNDECYL	UNDECYL POWDER 30GR	UNDECENOIC ACID	UNDECENOIC ACID 2%;ZINC UNDECENOATE 20%	POWDER		Prophylaxis and treatment of mycotic skin infections particulary athlete's foot.
5525	UNDECYL	UNDECYL POWDER 80GR	UNDECENOIC ACID	UNDECENOIC ACID 2%;ZINC UNDECENOATE 20%	POWDER		Prophylaxis and treatment of mycotic skin infections particulary athlete's foot.
5521	UNDECYL	UNDECYL OINT 25GR	UNDECENOIC ACID	UNDECENOIC ACID 2%;ZINC UNDECENOATE 21%	OINTMENT		Prophylaxis and treatment of mycotic skin infections particularly athlete's foot.
5522	UNDECYL	UNDECYL OINTMENT	UNDECENOIC ACID	UNDECENOIC ACID 2%;ZINC UNDECENOATE 21%	OINTMENT		Prophylaxis and treatment of mycotic skin infections particularly athlete's foot.
5526	UPTRAVI	UPTRAVI 1000 MCG	SELEXIPAG	SELEXIPAG 1000MCG	TABLETS	RECIEPT	Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
5527	UPTRAVI	UPTRAVI 1200 MCG	SELEXIPAG	SELEXIPAG 1200MCG	TABLETS	RECIEPT	Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
5528	UPTRAVI	UPTRAVI 1400 MCG	SELEXIPAG	SELEXIPAG 1400MCG	TABLETS	RECIEPT	Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
5529	UPTRAVI	UPTRAVI 1600 MCG	SELEXIPAG	SELEXIPAG 1600MCG	TABLETS	RECIEPT	Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
5530	UPTRAVI	UPTRAVI 200 MCG	SELEXIPAG	SELEXIPAG 200MCG	TABLETS	RECIEPT	Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
5531	UPTRAVI	UPTRAVI 400 MCG	SELEXIPAG	SELEXIPAG 400MCG	TABLETS	RECIEPT	Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
5532	UPTRAVI	UPTRAVI 600 MCG	SELEXIPAG	SELEXIPAG 600MCG	TABLETS	RECIEPT	Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
5533	UPTRAVI	UPTRAVI 800 MCG	SELEXIPAG	SELEXIPAG 800MCG	TABLETS	RECIEPT	Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
5534	URALYT-U	URALYT-U	POTASSIUM SODIUM HYDROGEN CITRATE	POTASSIUM SODIUM HYDROGEN CITRATE 2.427G/2.5 G	GRANULES	RECIEPT	To dissolve uric acid stones in the urinary tract. Prevention of further stone formation.
5536	URAMOX	URAMOX	ACETAZOLAMIDE	ACETAZOLAMIDE 250MG	TABLETS	RECIEPT	For adjunctive treatment of drug induced edema and edema due to congestive heart failure. Chronic simple (open angle) glaucoma, secondary glaucoma and pre operatively in acute angle closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acute mountain sickness.
5537	UROCIT-K	UROCIT-K 10 mEq	POTASSIUM CITRATE	POTASSIUM CITRATE 1080MG	TABLETS		Urocit-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology Uric acid lithiasis with or without calcium stones
5539	UROKINASE	UROKINASE MEDAC 100,000 IU	UROKINASE	UROKINASE 100,000 IU	POWDER	RECIEPT	Peripheral arterial thrombosis ; Acute and subacute deep vein thrombosis ; Acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; Thrombosed arteriovenous shunt.
5538	UROKINASE	UROKINASE MEDAC 10,000 IU	UROKINASE	UROKINASE 10000 IU	POWDER	RECIEPT	Peripheral arterial thrombosis ; Acute and subacute deep vein thrombosis ; Acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; Thrombosed arteriovenous shunt.
5540	UROKINASE	UROKINASE MEDAC 250,000 IU	UROKINASE	UROKINASE 250000 IU	POWDER	RECIEPT	Peripheral arterial thrombosis ; Acute and subacute deep vein thrombosis ; Acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; Thrombosed arteriovenous shunt.
5541	UROKINASE	UROKINASE MEDAC 50,000 IU	UROKINASE	UROKINASE 50000 IU	POWDER	RECIEPT	Peripheral arterial thrombosis ; Acute and subacute deep vein thrombosis ; Acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; Thrombosed arteriovenous shunt.
5542	UROKINASE	UROKINASE MEDAC 500,000 IU	UROKINASE	UROKINASE 500000 IU	POWDER	RECIEPT	Peripheral arterial thrombosis ; Acute and subacute deep vein thrombosis ; Acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; Thrombosed arteriovenous shunt.
5543	UROMITEXAN	UROMITEXAN 400 MG	MESNA	MESNA 400MG/VIAL	SOLUTION	RECIEPT	Prevention of urinary passage toxicity of oxazaphosphorines (Ifosfamide ,Cyclophosphamide, Trofosamide), in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous Ifosfamide, Cyclophosphamide or Trofosamide , urinary passage diseases in anamnesis.
6008	URO-TAINER SALINE	URO-TAINER SALINE 100ML	SODIUM CHLORIDE	SODIUM CHLORIDE 100ML	SOLUTION	RECIEPT	URINARY TRACT IRRIGATION
5546	URSOFALK	URSOFALK CAPSULES 250	URSODEOXYCHOLIC ACID	URSODEOXYCHOLIC ACID 250MG	CAPSULES	RECIEPT	Treatment of chronic liver diseases Primary Biliary Cirrhosis & Primary Sclerosing Cholangitis.
5544	URSOFALK	URSOFALK 500	URSODEOXYCHOLIC ACID	URSODEOXYCHOLIC ACID 500MG	TABLETS	RECIEPT	For the symptomatic treatment of primary biliary cirrhosis (PBC), in patients without decompensated hepatic cirrhosis.
5549	URSOLIT	URSOLIT 100	URSODEOXYCHOLIC ACID	URSODEOXYCHOLIC ACID 100MG	TABLETS	RECIEPT	Dissolution or reductin in size of radiolucent cholesterol in patient with a functioning gallbladder. Treatment of chronic liver diseases including primary billiary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia, chronic hepatitis, and alcohol cirrhosis.
5550	URSOLIT	URSOLIT 300	URSODEOXYCHOLIC ACID	URSODEOXYCHOLIC ACID 300MG	TABLETS	RECIEPT	Dissolution or reduction in size of radiolucent cholesterol gallstones in patients with a functioning gallbladder. Treatment of chronic liver diseases including primary biliary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia chronic hepatitis and alcoholic cirrhosis.
5551	UTROGESTAN	UTROGESTAN 100	PROGESTERONE	PROGESTERONE 100MG	CAPSULES	RECIEPT	Vaginal or oral addministration: Disorders related to progesterone deficit in particular menopause ( in association with estrogen therapy). Vaginal administration: Progesterone substitution for ovary deprived women in situation of total progesterone deficiency. Supplementation of the luteal phase during in vitro fertilization cycles. Supplementation of the luteal phase during spontaneous or induced cycles, in cases of hypofertility or primary or secondary ovarain failure, particulary through dysovulation. In cases of threatning abortion or prevention of repeated abortions due to proven luteal insufficiency. For all other progesterone indications, in the case of : Adverse events due to progesterone, contraindication of the oral route of administration hepatopathy.
5553	UTROGESTAN	UTROGESTAN 200	PROGESTERONE MICRONIZED	PROGESTERONE MICRONIZED 200MG	CAPSULES	RECIEPT	Vaginal administration: Progesterone substitution for ovary deprived women in situation of total progesterone deficiency. Supplementation of the luteal phase during in vitro fertilization cycles. Supplementation of the luteal phase during spontaneous or induced cycles, in cases of hypofertility or primary or secondary ovarain failure, particulary through dysovulation. In cases of threatning abortion or prevention of repeated abortions due to proven luteal insufficiency. For all other progesterone indication, in the case of : Adverse events due to progesterone, contraindication of the oral route of administration hepatopathy. Vaginal or oral addministration: Disorders related to progesterone deficit in particular menopause ( in association with estrogen therapy).
5555	V.CRIMA	V.CRIMA 15ML	HYDROXYETHYLCELLULOSE	HYDROXYETHYLCELLULOSE 0.4%;PVP 1.65%	DROPS		A lubricating tear substitute for dry eyes when tear production is insufficient.
5556	V.TEARS	V.TEARS 15ML	HYDROETHYLCELLULOSE	HYDROETHYLCELLULOSE 0.4%	DROPS		Dry eye syndromes. deficient tear secretion.
5557	VABEN	VABEN TABLETS	OXAZEPAM	OXAZEPAM 10MG	TABLETS	RECIEPT	Anxiolytic.
5558	VAGIFEM	VAGIFEM 10 MCG	ESTRADIOL HEMIHYDRATE	ESTRADIOL HEMIHYDRATE 10MCG	TABLETS		Treatment of atrophic vaginitis due to estrogen deficiency in postmenopausal women. The experience treating women older than 65 years is limited.
5559	VAGIFEM	VAGIFEM 10MCG 24PACKS (4 BLISTER CARDS OF 6 APPLICATORS WITH TAB)	ESTRADIOL HEMIHYDRATE	ESTRADIOL HEMIHYDRATE 10MCG	TABLETS		Treatment of atrophic vaginitis due to estrogen deficiency in postmenopausal women. The experience treating women older than 65 years is limited.
5560	VALDIPINE	VALDIPINE TEVA 10 MG/160 MG	AMLODIPINE AS BESYLATE	AMLODIPINE AS BESYLATE 10MG;VALSARTAN 160MG	TABLETS	RECIEPT	Treatment of essential hypertension. Valdipine Teva is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
5563	VALERIANE	VALERIANE TINCTURA FLORIS	VALERIAN DRY EXTRACT	VALERIAN DRY EXTRACT 2.5G/100ML	DROPS		Tranquilizer.
5561	VALERIANE	VALERIANE TINCTURA DROPS 10ML	VALERIANE DRY EXTRACT	VALERIANE DRY EXTRACT 2.5 G/100.00ML	DROPS		Sedative, anxiety and tension states, insomnia.
5562	VALERIANE	VALERIANE TINCTURA DROPS 20ML	VALERIANE DRY EXTRACT	VALERIANE DRY EXTRACT 2.5 G/100.00ML	DROPS		Sedative, anxiety and tension states, insomnia.
5565	VALETON	VALETON DROPS	VALERIAN DRY EXTRACT	VALERIAN DRY EXTRACT 25MG/1ML	DROPS		For relief of nervousness and tension.
5564	VALETON	VALETON 25ML	VALERIANE DRY EXTRACT	VALERIANE DRY EXTRACT 2.5 G/100.00ML	DROPS		For relief of nervousness and tension.
5568	VALPORAL	VALPORAL CAPSULES	VALPROIC ACID	VALPROIC ACID 200MG	CAPSULES	RECIEPT	Sole or adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures. May also be used adjunctively in patients with multiple seizure types which include absence seizures.
5567	VALPORAL	VALPORAL	VALPROIC ACID AS SODIUM	VALPROIC ACID AS SODIUM 200MG/5ML	SYRUP	RECIEPT	Sole or adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures. Valporal may also be used adjunctively in patients with multiple seizure types which include absence seizures.
5570	VALSARTAN	VALSARTAN DEXCEL 160	VALSARTAN	VALSARTAN 160MG	TABLETS	RECIEPT	Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Valsartan significantly reduced hospitalisations for heart failure. There is no evidence that Valsartan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction. For treatment of hypertension.
5571	VALSARTAN	VALSARTAN DEXCEL 40	VALSARTAN	VALSARTAN 40MG	TABLETS	RECIEPT	Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Valsartan significantly reduced hospitalisations for heart failure. There is no evidence that Valsartan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.
5572	VALSARTAN	VALSARTAN DEXCEL 80	VALSARTAN	VALSARTAN 80MG	TABLETS	RECIEPT	Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Valsartan significantly reduced hospitalisations for heart failure. There is no evidence that Valsartan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction. For treatment of hypertension.
5573	VALTREX	VALTREX TABLETS 500 MG	VALACICLOVIR AS HYDROCHLORIDE	VALACICLOVIR AS HYDROCHLORIDE 500MG	TABLETS	RECIEPT	Varicella zoster virus (VZV) infections – herpes zoster: Valtrex is indicated for the treatment of herpes zoster (shingles) and ophthalmic zoster in immunocompetent adults. Valtrex is indicated for the treatment of herpes zoster in adult patients with mild or moderate immunosuppression. Herpes simplex virus (HSV) infections: Valtrex is indicated for the treatment and suppression of HSV infections of the skin and mucous membranes including - treatment of first-episode of genital herpes in immunocompetent adults and adolescents and in immunocompromised adults - treatment of recurrences of genital herpes in immunocompetent adults and adolescents, and in immunocompromised adults - suppression of recurrent genital herpes in immunocompetent adults and adolescents and in immunocompromised adults Treatment and suppression of recurrent ocular HSV infections in immunocompetent adults and adolescents and in immunocompromised adults Clinical studies have not been conducted in HSV-infected patients immunocompromised for other causes than HIV-infection. Cytomegalovirus (CMV) infections: Valtrex is indicated for the prophylaxis of CMV infection and disease following solid organ transplantation in adults and adolescents
5584	VANCO	VANCO-TEVA 1 GR	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 1G/VIAL	POWDER	RECIEPT	Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral Therapy : Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection.
5585	VANCO	VANCO-TEVA 500 MG	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 500MG/VIAL	POWDER	RECIEPT	Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral Therapy: Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection.
5574	VANCOAVENIR	VANCOAVENIR 1 G	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 1G/VIAL	POWDER	RECIEPT	Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral Therapy Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection.
5575	VANCOAVENIR	VANCOAVENIR 500 MG	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 500MG/VIAL	POWDER	RECIEPT	Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral Therapy Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection.
5576	VANCOMYCIN	VANCOMYCIN - FRESENIUS 1000 MG	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 1000MG	POWDER	RECIEPT	Intravenous infusion: Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral administration: Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic- associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection. Vancomycin is ineffective in these diseases if given parenterally.
5578	VANCOMYCIN	VANCOMYCIN LYOMARK 1000 MG	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 1000MG	POWDER	RECIEPT	Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - structure infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral Therapy: Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection.
5580	VANCOMYCIN	VANCOMYCIN MYLAN 1 G.	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 1G/VIAL	POWDER	RECIEPT	Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral Therapy Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection.
5577	VANCOMYCIN	VANCOMYCIN - FRESENIUS 500 MG	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 500MG	POWDER	RECIEPT	Intravenous infusion: Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral administration: Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic- associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection. Vancomycin is ineffective in these diseases if given parenterally.
5579	VANCOMYCIN	VANCOMYCIN LYOMARK 500 MG	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 500MG	POWDER	RECIEPT	Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - structure infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral Therapy: Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection.
5582	VANCOMYCIN	VANCOMYCIN MYLAN 500 MG	VANCOMYCIN AS HYDROCHLORIDE	VANCOMYCIN AS HYDROCHLORIDE 500MG/VIAL	POWDER	RECIEPT	Vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-Iactam-resistant) staphylococci. It is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. Antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. For endocarditis due to Streptococcus viridans or Streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. Vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg Enterococcus fecalis). Vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. In early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. Bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. Oral Therapy Vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated Pseudomembrannous colitis due to Staphylococcus enterocolitis and Clostridium difficile. Vancomycin hydrochloride is not effective orally when administered for other types of infection.
5586	VANIQA	VANIQA	EFLORNITHINE AS HYDROCHLORIDE ANHYDROUS	EFLORNITHINE AS HYDROCHLORIDE ANHYDROUS 11.5 G/100 G	CREAM	RECIEPT	Vaniqa is indicated for the reduction of unwanted facial hair in women.
5587	VAQTA	VAQTA 25 U / 0.5 ML	HEPATITIS A VIRUS ANTIGEN, INACTIVATED	HEPATITIS A VIRUS ANTIGEN, INACTIVATED 25UNITS/0.5ML	SUSPENSION	RECIEPT	Vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis A virus in children and adolescents 12 months of age and older .
5588	VAQTA	VAQTA 50 U/ML	HEPATITIS A VIRUS ANTIGEN, INACTIVATED	HEPATITIS A VIRUS ANTIGEN, INACTIVATED 50U/ML	SUSPENSION	RECIEPT	Vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis A virus in persons 2 years of age and older.
5589	VARGATEF	VARGATEF 100 MG	NINTEDANIB AS ESILATE	NINTEDANIB AS ESILATE 100MG	CAPSULES	RECIEPT	In combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumor histology after first line chemotherapy.
5590	VARGATEF	VARGATEF 150 MG	NINTEDANIB AS ESILATE	NINTEDANIB AS ESILATE 150MG	CAPSULES	RECIEPT	In combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumor histology after first line chemotherapy.
5591	VARILRIX	VARILRIX	VARICELLA VIRUS, LIVE ATTENUATED NLT	VARICELLA VIRUS, LIVE ATTENUATED NLT 10^3.3PFU	POWDER	RECIEPT	Varilrix is intended for the active immunization against varicella of the categories of persons listed below, where there is no history of varicella. - Healthy subjects, from the age of 12 months. - Patients at high risk of severe varicella, such as patients with acute leukemia or a chronic condition, those on immunosuppressive therapy or those for whom an organ transplant is being considered. Healthy persons living in close contact with patients with varicella and high-risk patients.
5592	VASODIP	VASODIP 10	LERCANIDIPINE HYDROCHLORIDE	LERCANIDIPINE HYDROCHLORIDE 10.0MG	TABLETS	RECIEPT	Mild to moderate essential hypertension.
5593	VASODIP	VASODIP COMBO 10	LERCANIDIPINE HYDROCHLORIDE	LERCANIDIPINE HYDROCHLORIDE 10MG;ENALAPRIL MALEATE 10MG	TABLETS	RECIEPT	Treatment of essential hypertension in patients whose blood pressure cannot be adequately controlled under Lercanidipine monotherapy.
5594	VASODIP	VASODIP COMBO 20	LERCANIDIPINE HYDROCHLORIDE	LERCANIDIPINE HYDROCHLORIDE 10MG;ENALAPRIL MALEATE 20MG	TABLETS	RECIEPT	Treatment of essential hypertension in patients whose blood pressure cannot be adequately controlled under Enalapril monotherapy.
5596	VAXIGRIP	VAXIGRIP TETRA	B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE)	B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) 15MCG/0.5ML;B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE) 15MCG/0.5ML;A/BRISBANE/02/2018(H1N1)PDM09-LIKE VIRUS 15MCG/0.5ML;A/KANSAS/14/2017 (H3N2) LIKE VIRUS 15MCG/0.5ML	SUSPENSION	RECIEPT	Vaxigrip Tetra is indicated for active immunisation of adults and children from 6 months of age and older for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine. The use of Vaxigrip Tetra should be based on official recommendations.
5595	VAXIGRIP	VAXIGRIP	B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE)	B/PHUKET/3073/2013 - LIKE VIRUS (B/YAMAGATA/16/88 LINEAGE) 15MCG/DOSE;B/COLORADO/06/2017- LIKE VIRUS (B/VICTORIA/2/87 LINEAGE) 15MCG/DOSE;A/SINGAPORE/INFIMH-16-0019/2016 (H3N2) - LIKE VIRUS 15MCG/DOSE;A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE VIRUS 15MCG/DOSE	SUSPENSION	RECIEPT	For the prevention of influenza.
5597	V-CRIMA	V-CRIMA	POVIDONE	POVIDONE 1.65%;HYDROXYETHYLCELLULOSE 0.4%	SOLUTION		Artificial tears.
5601	V-DALGIN	V-DALGIN SYRUP 50ML	DIPYRONE	DIPYRONE 1.25G/5ML	SYRUP		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
5600	V-DALGIN	V-DALGIN DROPS 10ML	DIPYRONE	DIPYRONE 500MG/1ML	LIQUID		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
5599	V-DALGIN	V-DALGIN DROPS	DIPYRONE	DIPYRONE 500MG/ML	DROPS		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
5598	V-DALGIN SYRUP ADULTS	V-DALGIN CONCENTRATED SYRUP FOR ADULTS	DIPYRONE	DIPYRONE 1.25G/5ML	SYRUP		Relief of moderate to severe pain as in headache, toothache, dysmenorrhea and for high fever that does not respond to other measures.
5603	VECTIBIX	VECTIBIX 20 MG/ML	PANITUMUMAB	PANITUMUMAB 20MG/1ML	CONCENTRATE	RECIEPT	In combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mCRC) with wild-type RAS. Monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type RAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
5604	VECTOR	VECTOR 160	VALSARTAN	VALSARTAN 160MG	TABLETS	RECIEPT	For treatment of hypertension. Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Valsartan significantly reduced hospitalizations for heart failure. There is no evidence that Valsartan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.
5608	VECTOR	VECTOR PLUS 160/12.5	VALSARTAN	VALSARTAN 160MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	For the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. This fixed combination should be used as second-line therapy.
5610	VECTOR	VECTOR PLUS 160/25	VALSARTAN	VALSARTAN 160MG;HYDROCHLOROTHIAZIDE 25MG	TABLETS	RECIEPT	For the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. This fixed combination should be used as second-line therapy.
5606	VECTOR	VECTOR 80	VALSARTAN	VALSARTAN 80MG	TABLETS	RECIEPT	For treatment of hypertension. Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Valsartan significantly reduced hospitalizations for heart failure. There is no evidence that Valsartan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.
5612	VECTOR	VECTOR PLUS 80/12.5	VALSARTAN	VALSARTAN 80MG;HYDROCHLOROTHIAZIDE 12.5MG	TABLETS	RECIEPT	For the treatment of hypertension for patients in whom combination therapy is appropriate.
5614	VELCADE	VELCADE 3.5 MG	BORTEZOMIB	BORTEZOMIB 3.5MG	POWDER	RECIEPT	Velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma. Velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
5617	VELPHORO	VELPHORO	SUCROFERRIC OXYHYDROXIDE	SUCROFERRIC OXYHYDROXIDE 500MG	TABLETS	RECIEPT	Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.
5618	VELTASSA	VELTASSA 16.8 G	PATIROMER AS SORBITEX CALCIUM	PATIROMER AS SORBITEX CALCIUM 16.8G	POWDER	RECIEPT	Veltassa is indicated for the treatment of hyperkalaemia in adults
5620	VELTASSA	VELTASSA 8.4 G	PATIROMER AS SORBITEX CALCIUM	PATIROMER AS SORBITEX CALCIUM 8.4G	POWDER	RECIEPT	Veltassa is indicated for the treatment of hyperkalaemia in adults
5622	VEMLIDY	VEMLIDY	TENOFOVIR ALAFENAMIDE	TENOFOVIR ALAFENAMIDE 25MG	TABLETS	RECIEPT	Vemlidy is indicated for the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg)
5625	VENCLEXTA	VENCLEXTA 100 MG TABLETS	VENETOCLAX	VENETOCLAX 100MG	TABLETS	RECIEPT	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma VENCLEXTA in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), who have received at least one prior therapy. VENCLEXTA in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Acute Myeloid Leukemia VENCLEXTA in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
5623	VENCLEXTA	VENCLEXTA 10 MG TABLETS	VENETOCLAX	VENETOCLAX 10MG	TABLETS	RECIEPT	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma VENCLEXTA in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), who have received at least one prior therapy. VENCLEXTA in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Acute Myeloid Leukemia VENCLEXTA in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
5627	VENCLEXTA	VENCLEXTA 50 MG TABLETS	VENETOCLAX	VENETOCLAX 50MG	TABLETS	RECIEPT	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma VENCLEXTA in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), who have received at least one prior therapy. VENCLEXTA in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Acute Myeloid Leukemia VENCLEXTA in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
5629	VENLA	VENLA 37.5	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 37.5MG	TABLETS	RECIEPT	For treatment of depression.
5631	VENLA	VENLA 75	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 75MG	TABLETS	RECIEPT	For the treatment of depression.
5633	VENLAFAXINE XR	VENLAFAXINE DEXCEL XR 150	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 150MG	TABLETS	RECIEPT	For the treatment of depression. Maintenance of recurrent depression. Generalized anxiety disorder (GAD) - short term and long-term. Social anxiety Disorder (SAD).
5635	VENLAFAXINE XR	VENLAFAXINE XR TEVA 150 MG	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 150MG	CAPSULES	RECIEPT	For the treatment of depression. Maintenance of recurrent depression. Generalized anxiety disorder (GAD) - short term and long-term. Social anxiety Disorder (SAD).
5634	VENLAFAXINE XR	VENLAFAXINE DEXCEL XR 225	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 225MG	TABLETS	RECIEPT	For the treatment of depression. Maintenance of recurrent depression. Generalized anxiety disorder (GAD) - short term and long-term. Social anxiety Disorder (SAD).
5636	VENLAFAXINE XR	VENLAFAXINE XR TEVA 75 MG	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 75MG	CAPSULES	RECIEPT	For the treatment of depression. Maintenance of recurrent depression. Generalized anxiety disorder (GAD) - short term and long-term. Social anxiety Disorder (SAD).
5637	VENOFER	VENOFER	FERROUS AS IRON III HYDROXIDE SUCROSE COMPLEX	FERROUS AS IRON III HYDROXIDE SUCROSE COMPLEX 100MG/5ML	SOLUTION	RECIEPT	Venofer is indicated for the treatment of iron deficiency in the following indications: • Where there is a clinical need for a rapid iron supply, • In patients who cannot tolerate oral iron therapy or who are non-compliant, • In active inflammatory bowel disease where oral iron preparations are ineffective, • In chronic kidney disease when oral iron preparations are less effective. The diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. Hb, serum ferritin, TSAT, serum iron, etc.) (Hb haemoglobin, TSAT transferrin saturation)
5641	VENORUTON	VENORUTON GEL 2% 40G	MONOXERUTIN	MONOXERUTIN 2G/100G(2%)	GEL		For the adjunctive treatment of varicose veins in all stages.
5639	VENORUTON	VENORUTON 300MG 20CAPS	MONOXERUTIN	MONOXERUTIN 300MG	CAPSULES		For the adjunctive treatment of varicose veins in all stages.
5640	VENORUTON	VENORUTON CAPSULES 300 MG	MONOXERUTIN	MONOXERUTIN 300MG	CAPSULES		For the adjunctive treatment of varicose veins in all stages.
5642	VENTAVIS	VENTAVIS	ILOPROST	ILOPROST 0.01MG/ML	SOLUTION	RECIEPT	Treatment of patients with primary pulmonary hypertension (PPH) or secondary pulmonary hypertension (SPH) . Due to connective tissue disease or drug - induced, in moderate or severe stages of the disease. In addition, treatment of moderate or severe secondary pulmonary hypertension due to chronic pulmonary thromboembolism, where surgery is not possible.
5645	VENTOLIN	VENTOLIN INJECTION	SALBUTAMOL AS SULFATE	SALBUTAMOL AS SULFATE 0.5MG/ML	SOLUTION	RECIEPT	For relief of severe bronchospasm associated with asthma and bronchitis status asthmaticus.
5648	VENTOLIN	VENTOLIN TABLETS 2 MG	SALBUTAMOL AS SULFATE	SALBUTAMOL AS SULFATE 2MG	TABLETS	RECIEPT	Relief of bronchospasm in bronchial asthma of all types, chronic bronchitis, emphysema.
5647	VENTOLIN	VENTOLIN SYRUP	SALBUTAMOL AS SULFATE	SALBUTAMOL AS SULFATE 2MG/5ML	SYRUP	RECIEPT	Relief of bronchospasm in bronchial asthma of all types,chronic bronchitis,efmphysema.
5646	VENTOLIN	VENTOLIN RESPIRATOR SOLUTION	SALBUTAMOL AS SULFATE	SALBUTAMOL AS SULFATE 5MG/ML	SOLUTION	RECIEPT	Treatment of severe acute asthma (status asthmaticus) and other forms of bronchospasm.
5644	VENTOLIN CFC FREE	VENTOLIN INHALER CFC FREE	SALBUTAMOL AS SULFATE	SALBUTAMOL AS SULFATE 100MCG/DOSE	INHALATION	RECIEPT	Ventolin Inhaler CFC Free is a short-acting (4 to 6 hour) bronchodilator with fast (within 5 minutes) onset in reversible airways obstruction. It is particularly suitable for the relief and prevention of asthma symptoms It should be used to relieve symptoms when they occur, and to prevent them in those circumstances recognized by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure). Ventolin Inhaler CFC Free is particularly valuable as relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.
5643	VENTOLIN DISKUS	VENTOLIN DISKUS	SALBUTAMOL AS SULFATE	SALBUTAMOL AS SULFATE 200MCG/DOSE	POWDER	RECIEPT	Relief of bronchospasm in broncial asthma of all types, chronic, bronchitis and emphysema.
5649	VERAPRESS	VERAPRESS 240 SR	VERAPAMIL HYDROCHLORIDE	VERAPAMIL HYDROCHLORIDE 240MG	TABLETS	RECIEPT	Treatment of hypertension, angina pectoris
5650	VERDYE	VERDYE	INDOCYANINE GREEN AS MONOSODIUM SALT	INDOCYANINE GREEN AS MONOSODIUM SALT 25MG/VIAL	POWDER	RECIEPT	In cardiac, ciculatory and micro-circulatory diagnostics: measurement of circulation times, measurement of cardiac output and stroke volume, measurement of end-systolic ventricular volume, measurement of intrathoracic blood volume, measurement of circulationg blood volume, measurement of partial volumes, measurement of organ perfusion-measurement of intra-and extracardiac shunts, measurement of intracardiac valvular insufficiency, measurement of peripheral perfusion (e.g. perfusion of extremities, eyes). In liver function diagnostics: measurement of excretory function of the liver, determination of partial functions of the liver.
5654	VERMOX	VERMOX TABLETS	MEBENDAZOLE	MEBENDAZOLE 100MG	TABLETS	RECIEPT	Treatment of trichuris trichiura (whipworm). Ascaris lumbricoides (roundworm). Ancylostoma duodenale (common hookworm). Necator americanus (american hookworm), strongyloidiasis, enterobius vermicularis (pinworm) and teniasis in single or mixed infections.
5653	VERMOX	VERMOX SUSPENSION	MEBENDAZOLE	MEBENDAZOLE 20MG/ML	SUSPENSION	RECIEPT	Treatment of single or mixed infections of Trichuris trichura (whipworm), Ascaris lumbricoides (large roundworm), Ancylostoma duodenale, Necator americanus (hookworm), Strongyloides stercoralis, Enterobius vermicularis (threadworm/pinworm) and Taenia spp.
5656	VERORAB	VERORAB	RABIES, INACTIVATED, WHOLE VIRUS	RABIES, INACTIVATED, WHOLE VIRUS 2.5 IU	POWDER	RECIEPT	Prevention of rabies in children and adults. It can be used before and after exposure, as a primary vaccination or as a booster dose.
5657	VERRUMAL	VERRUMAL SOLUTION	SALICYLIC ACID	SALICYLIC ACID 10G/100 G;FLUOROURACIL 0.5G/100 G	SOLUTION	RECIEPT	Common warts ( special form : plantar warts, on areas of the sole of the foot that are subjected to pressure), plane juvenile warts of the extremities.
5658	VERSATIS	VERSATIS 700 MG	LIDOCAINE	LIDOCAINE 700MG	PLASTER	RECIEPT	Versatis 700 mg is indicated for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) in adults
5659	VERZENIO	VERZENIO 100 MG	ABEMACICLIB	ABEMACICLIB 100MG	TABLETS	RECIEPT	VERZENIO™ (abemaciclib) is indicated: •In combination with a non-steroidal aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. •in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. •as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in the metastatic setting and prior chemotherapy in the metastatic setting including taxane in adjuvant or metastatic setting. Verzenio should not be used in women after prior treatment with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) inhibitor.
5660	VERZENIO	VERZENIO 150 MG	ABEMACICLIB	ABEMACICLIB 150MG	TABLETS	RECIEPT	VERZENIO™ (abemaciclib) is indicated: •In combination with a non-steroidal aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. •in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. •as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in the metastatic setting and prior chemotherapy in the metastatic setting including taxane in adjuvant or metastatic setting. Verzenio should not be used in women after prior treatment with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) inhibitor. .
5661	VERZENIO	VERZENIO 200 MG	ABEMACICLIB	ABEMACICLIB 200MG	TABLETS	RECIEPT	VERZENIO™ (abemaciclib) is indicated: •In combination with a non-steroidal aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. •in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. •as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in the metastatic setting and prior chemotherapy in the metastatic setting including taxane in adjuvant or metastatic setting. Verzenio should not be used in women after prior treatment with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) inhibitor.
5662	VERZENIO	VERZENIO 50 MG	ABEMACICLIB	ABEMACICLIB 50MG	TABLETS	RECIEPT	VERZENIO™ (abemaciclib) is indicated: •In combination with a non-steroidal aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. •in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. •as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in the metastatic setting and prior chemotherapy in the metastatic setting including taxane in adjuvant or metastatic setting. Verzenio should not be used in women after prior treatment with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) inhibitor.
5663	VESANOID	VESANOID	TRETINOIN	TRETINOIN 10MG	CAPSULES	RECIEPT	Induction of remission in acute promyelocytic leukemia.
5669	VESICARE	VESICARE 10 MG	SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE 10MG	TABLETS	RECIEPT	Vesicare is indicated for symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
5670	VESICARE	VESICARE 5 MG	SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE 5MG	TABLETS	RECIEPT	Vesicare is indicated for symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
5671	VESOMNI	VESOMNI	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE 0.4MG;SOLIFENACIN SUCCINATE 6MG	TABLETS	RECIEPT	Treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy.
5677	VFEND	VFEND 200 MG FILM-COATED TABLETS	VORICONAZOLE	VORICONAZOLE 200MG	TABLETS	RECIEPT	Treatment of: - invasive aspergillosis, - fluconazole-resistant serious invasive Candida infections (including C. krusei), - serious fungal infections caused by scedosporium spp. and fusarium spp. - Vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - Treatment of candidemia in non neutropenic patients. - Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
5679	VFEND	VFEND 200 MG POWDER FOR SOLUTION FOR INFUSION	VORICONAZOLE	VORICONAZOLE 200MG/VIAL	POWDER	RECIEPT	Treatment of : - invasive aspergillosis fluconazole-resistant serious invasive Candida infections (including C. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp. Vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - Treatment of candidemia in non neutropenic patients. - Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
5680	VFEND	VFEND 40 MG/ML POWDER FOR ORAL SUSPENSION	VORICONAZOLE	VORICONAZOLE 40MG/ML	SUSPENSION	RECIEPT	Treatment of : - invasive aspergillosis, - fluconazole-resistant serious invasive Candida infections (including C. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp. - Vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - Treatment of candidemia in non neutropenic patients. - Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
5681	VFEND	VFEND 50 MG FILM-COATED TABLETS	VORICONAZOLE	VORICONAZOLE 50MG	TABLETS	RECIEPT	Treatment of: - invasive aspergillosis, - fluconazole-resistant serious invasive Candida infections (including C. krusei) - serious fungal infections caused by scedosporium spp. and fusarium spp. - Vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - Treatment of candidemia in non neutropenic patients. - Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
5683	VIA-AVENIR	VIA-AVENIR 100 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 100MG	TABLETS	RECIEPT	Treatment of erectile dysfunction.
5685	VIA-AVENIR	VIA-AVENIR 25 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 25MG	TABLETS	RECIEPT	Treatment of erectile dysfunction.
5687	VIA-AVENIR	VIA-AVENIR 50 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 50MG	TABLETS	RECIEPT	Treatment of erectile dysfunction.
5689	VIAGRA	VIAGRA 100 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 100MG	TABLETS	RECIEPT	Treatment of erectile dysfunction.
5690	VIAGRA	VIAGRA 25 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 25MG	TABLETS	RECIEPT	Treatment of erectile dysfunction.
5691	VIAGRA	VIAGRA 50 MG	SILDENAFIL AS CITRATE	SILDENAFIL AS CITRATE 50MG	TABLETS	RECIEPT	Treatment of erectile dysfunction.
5692	VIBATIV	VIBATIV 250 MG	TELAVANCIN HYDROCHLORIDE	TELAVANCIN HYDROCHLORIDE 250MG	POWDER	RECIEPT	VIBATIV is indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA). VIBATIV should be used only in situations where it is known or suspected that other alternatives are not suitable.
5693	VIBATIV	VIBATIV 750 MG	TELAVANCIN HYDROCHLORIDE	TELAVANCIN HYDROCHLORIDE 750MG	POWDER	RECIEPT	VIBATIV is indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA). VIBATIV should be used only in situations where it is known or suspected that other alternatives are not suitable.
5695	VIBROCIL MICRODOSER	VIBROCIL MICRODOSER 15ML	DIMETHINDENE MALEATE	DIMETHINDENE MALEATE 0.025%;PHENYLEPHRINE 0.25%	SPRAY		Symptomatic treatment of common cold, nasal congestio, acute rhinitis, seasonal (hay fever) and non seasonal allergic rhinitis, acute sinusitis. Adjunctive therapy in case of acute otitis media.
5694	VIBROCIL MICRODOSER	VIBROCIL MICRODOSER	DIMETHINDENE MALEATE	DIMETHINDENE MALEATE 0.025%W/V;PHENYLEPHRINE 0.25%W/V	SOLUTION	RECIEPT	Symptomatic treatment of common cold, nasal congestio, acute rhinitis, seasonal (hay fever) and non seasonal allergic rhinitis, acute sinusitis. Adjunctive therapy in case of acute otitis media.
5696	VICTOZA	VICTOZA	LIRAGLUTIDE	LIRAGLUTIDE 6.0MG/ML	SOLUTION	RECIEPT	Victoza is indicated for: • Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: 1. As monotherapy when metformin is considered inappropriate due to intolerance or contraindications 2. In addition to other medicinal products for the treatment of diabetes. • To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
5697	VIDAZA	VIDAZA	AZACITIDINE	AZACITIDINE 100MG/VIAL	POWDER	RECIEPT	For the treatment of patients with the following FAB myelodysplastic syndromes subtypes: refractory anemia or refractory anemia with ringed sideroblasts ( if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anaemia with excess blasts, refractory anaemia with excess blasts in transformation, and chronic myelomonocytic leukaema.
5700	VIEPAX	VIEPAX XR 150	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 150MG	TABLETS	RECIEPT	For the treatment of depression. Maintenance of recurrent depression, generalized anxiety disorder (GAD) - short term and long-term, social anxiety disorder (SAD).
5698	VIEPAX	VIEPAX 37.5	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 37.5MG	TABLETS	RECIEPT	For the treatment of depression.
5699	VIEPAX	VIEPAX 75	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 75MG	TABLETS	RECIEPT	For the treatment of depression.
5701	VIEPAX	VIEPAX XR 75	VENLAFAXINE AS HYDROCHLORIDE	VENLAFAXINE AS HYDROCHLORIDE 75MG	TABLETS	RECIEPT	For the treatment of depression. Maintenance of recurrent depression, generalized anxiety disorder (GAD) - short term and long-term, social anxiety disorder (SAD).
5703	VIEW	VIEW EYE DROPS 15 ML	TETRAHYDROZOLINE HCL	TETRAHYDROZOLINE HCL 0.05%	DROPS		For relief in cases of redness in the eye as a result of irritation, caused by various materials such as dust, smoke, plants, etc.
5702	VIEW	VIEW	TETRAHYDROZOLINE HYDROCHLORIDE	TETRAHYDROZOLINE HYDROCHLORIDE 0.05%	DROPS		For the relief of irritation, burning, reddening or itching of the eye due to allergic or physical causes such as dust, smoke, pollen, sunlight.
5704	VIGAMOX	VIGAMOX	MOXIFLOXACIN AS HYDROCHLORIDE	MOXIFLOXACIN AS HYDROCHLORIDE 0.5%	SOLUTION	RECIEPT	For the treatment of bacterial conjunctivitis caused by susceptible strains or organisms.
5705	VIMIZIM	VIMIZIM	ELOSULFASE ALFA	ELOSULFASE ALFA 1MG/ML	CONCENTRATE	RECIEPT	Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome ,MPS IVA) in patients of all ages.
5708	VIMPAT	VIMPAT 100 MG	LACOSAMIDE	LACOSAMIDE 100MG	TABLETS	RECIEPT	Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
5706	VIMPAT	VIMPAT 10 MG/ML	LACOSAMIDE	LACOSAMIDE 10MG/1ML	SOLUTION	RECIEPT	Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
5716	VIMPAT	VIMPAT SYRUP	LACOSAMIDE	LACOSAMIDE 10MG/ML	SYRUP	RECIEPT	Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
5710	VIMPAT	VIMPAT 150 MG	LACOSAMIDE	LACOSAMIDE 150MG	TABLETS	RECIEPT	Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
5712	VIMPAT	VIMPAT 200 MG	LACOSAMIDE	LACOSAMIDE 200MG	TABLETS	RECIEPT	Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
5714	VIMPAT	VIMPAT 50 MG	LACOSAMIDE	LACOSAMIDE 50MG	TABLETS	RECIEPT	Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
5717	VINCRISTINE	VINCRISTINE TEVA	VINCRISTINE SULFATE	VINCRISTINE SULFATE 1MG/ML	SOLUTION	RECIEPT	Vincristine may be used either as sole agent or in combination therapy in the treatment of acute leukemias. Malignant lymphomas including Hodgkin's disease lymphosarcoma and reticulum cell sarcoma, neuroblastoma, Wilm's tumor, rhabdomyosarcoma.
5718	VINORELBIN	VINORELBIN caretEBEWEcaret 10 MG/ML	VINORELBINE AS TARTRATE	VINORELBINE AS TARTRATE 10MG/ML	CONCENTRATE	RECIEPT	For the treatment of non small cell lung cancer. For the treatment of advanced breast cancer. Hormone- refractory prostate cancer, especially in combination with low dose oral corticoid therapy or Estramustin.
5719	VINORELBINE	VINORELBINE ACTAVIS 10 MG/ML	VINORELBINE AS TARTRATE	VINORELBINE AS TARTRATE 10MG/ML	CONCENTRATE	RECIEPT	For the treatment of non small cell lung cancer. For the treatment of advanced breast cancer. Hormone- refractory prostate cancer, especially in combination with low dose oral corticoid therapy or Estramustin.
5720	VINORELBINE	VINORELBINE- TRIMA 10 MG/ML	VINORELBINE AS TARTRATE	VINORELBINE AS TARTRATE 10MG/ML	CONCENTRATE	RECIEPT	For the treatment of non small cell lung cancer. For the treatment of advanced breast cancer. Hormone - refractory prostate cancer, especially in combination with low dose oral corticoid therapy or Estramustin.
5723	VIRAMUNE	VIRAMUNE TABLETS	NEVIRAPINE	NEVIRAPINE 200MG	TABLETS	RECIEPT	For use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
5722	VIRAMUNE	VIRAMUNE ORAL SUSPENSION	NEVIRAPINE ANHYDROUS (AS HEMIHYDRATE)	NEVIRAPINE ANHYDROUS (AS HEMIHYDRATE) 50MG/5ML	SUSPENSION	RECIEPT	For use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
5724	VIREAD	VIREAD	TENOFOVIR DISOPROXIL AS FUMARATE	TENOFOVIR DISOPROXIL AS FUMARATE 245MG	TABLETS	RECIEPT	Viread is indicated for the treatment of : 1. HIV 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of HIV. 2. Chronic hepatitis B in adults with: • Compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. • Decompensated liver disease
5727	VISABELLE	VISABELLE	DIENOGEST	DIENOGEST 2MG	TABLETS		Treatment of endometriosis.
5728	VISCOTEARS	VISCOTEARS	CARBOMER	CARBOMER 2MG/G	GEL		Artificial tears.
5731	VISINE	VISINE ORIGINAL EYE DROPS15ML	TETRAHYDROZOLINE HCL	TETRAHYDROZOLINE HCL 0.05%	DROPS		Relief from soreness, burning, itching, irritation redness due to congestion of the eyes.
5730	VISINE	VISINE ORIGINAL EYE DROPS	TETRAHYDROZOLINE HYDROCHLORIDE	TETRAHYDROZOLINE HYDROCHLORIDE 0.05%	DROPS		Relief from soreness, burning, itching, irritation redness due to congestion of the eyes.
5729	VISINE	VISINE A.C.	TETRAHYDROZOLINE HYDROCHLORIDE	TETRAHYDROZOLINE HYDROCHLORIDE 0.05%W/W;ZINC SULFATE 0.25%W/W	DROPS		For relief of minor eye irritation caused by the common cold or by allergens including smoke, pollen, dust, plants, etc.
5732	VISIPAQUE	VISIPAQUE 270	IODIXANOL	IODIXANOL 550MG/1ML	SOLUTION	RECIEPT	X- ray contrast medium for use in adults and children for cardioangiography peripheral arteriography (conventional and i.a. DSA) abdominal angiography (i.a. DSA) urography venography and CT- enhancement. Pediatric use: cardioangiography urography and CT-enhancement. Myelography - Lumbar thoracic and cervical myelography.
5733	VISIPAQUE	VISIPAQUE 320	IODIXANOL	IODIXANOL 652MG/1ML	SOLUTION	RECIEPT	X- ray contrast medium for use in adults for cardioangiography peripheral arteriography (conventional and i.a. DSA) abdominal angiography (i.a. DSA) urography venography and CT- enhancement. Pediatric use: cardioangiography urography and CT-enhancement. Myelography - Lumbar thoracic and cervical myelography.
5734	VITALIPID ADULT	VITALIPID N ADULT	PHYTOMENADIONE	PHYTOMENADIONE 15MCG/ML;ERGOCALCIFEROL 0.5MCG/ML;TOCOPHEROL 0.91MG/ML;RETINOL PALMITATE 194.1MCG/ML	CONCENTRATE	RECIEPT	Vitalipid N adult is indicated in adult and children above 11 years of age as a supplement in IV nutrition to meet the daily requirement of the fat soluble vitamins A, D2, E,K1.
5735	VITALIPID N INFANT	VITALIPID N INFANT	PHYTOMENADIONE	PHYTOMENADIONE 20MCG/ML;ERGOCALCIFEROL 1MCG/ML;TOCOPHEROL 0.64MG/ML;RETINOL PALMITATE 135.3MCG/ML	CONCENTRATE	RECIEPT	Vitalipid N infants is indicated in infants and children up to 11 years of age as a supplement in IV nutrition to meet the daily requirement of the fat soluble vitamins A, D2, E,K1.
5736	VITA-MERFEN	VITA-MERFEN OINT 20GR	BENZOXONIUM CHLORIDE	BENZOXONIUM CHL 1MG;CHLORHEXIDINE GLUCONATE 5MG;VITAMINE A 2000IU	OINTMENT		To disinfect wounds and injuries, such as cuts, scratches, mild burns and insect stings.
5737	VITA-MERFEN	VITA-MERFEN OINT 40GR	BENZOXONIUM CHLORIDE	BENZOXONIUM CHL 1MG;CHLORHEXIDINE GLUCONATE 5MG;VITAMINE A 2000IU	OINTMENT		To disinfect wounds and injuries, such as cuts, scratches, mild burns and insect stings.
5738	VITAMIN D3	VITAMIN D3 1000	VITAMIN D3	VITAMIN D3 1000 IU	TABLETS		Vitamin D3 supplement. An adjuvant treatment for Osteoporosis patients.
5739	VITAMIN D3	VITAMIN D3 1000 IU 30 TAB	VITAMIN D3	VITAMIN D3 1000 IU (COLECALCIFEROL)	TABLETS		Vitamin D3 supplement. An adjuvant treatment for Osteoporosis patients.
5740	VITAMINE B12	VITAMINE B12 STEROP 1 MG/ML	CYANOCOBALAMIN	CYANOCOBALAMIN 1MG/1ML	SOLUTION	RECIEPT	Pernicious anemia and its neurological complications, subacute combined degeneration of the spinal cord. Treatment of vitamin B12 deficiency states and macrocytic anemias associated with nutritional deficiencies, gastrectomy and abnormalities of, or malabsorption from, the gastrointestinal tract such as celiac disease, sprue and accompanying folic acid deficiency. Also suitable for use as the flushing dose in the schilling test for pernicious anemia.
5741	V-MANTINE	V-MANTINE 10 MG	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of patients with moderate to severe Alzheimer's disease.
5742	V-MANTINE	V-MANTINE 20 MG	MEMANTINE HYDROCHLORIDE	MEMANTINE HYDROCHLORIDE 20MG	TABLETS	RECIEPT	Treatment of patients with moderate to severe Alzheimer's disease.
5743	VOLIBRIS	VOLIBRIS 10 MG	AMBRISENTAN	AMBRISENTAN 10MG	TABLETS	RECIEPT	Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment with tadalafil. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.
5744	VOLIBRIS	VOLIBRIS 5 MG	AMBRISENTAN	AMBRISENTAN 5MG	TABLETS	RECIEPT	Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment with tadalafil. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.
5745	VOLTAREN	VOLTAREN ACTI-GO	DICLOFENAC AS POTASSIUM	DICLOFENAC AS POTASSIUM 12.5MG	TABLETS	RECIEPT	Short term analgesic and antipyretic in adults for a maximum of 3 days treatment for the relief of headache dental pain backache , period pain, rhematic and muscular pain, and fever reduction.
5757	VOLTAREN	VOLTAREN EMULGEL FORTE 100GR	DICLOFENAC DIETHYLAMINE	DICLOFENAC DIETHYLAMINE 2.32%	EMULGEL		Local treatment of pain, inflammation and swelling in adults and adolescents aged 12 years and over due to: • Soft tissue injuries: Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. • By physician's order - Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers The gel should not be used for more than 14 days
5759	VOLTAREN	VOLTAREN EMULGEL FORTE 2% 150GR	DICLOFENAC DIETHYLAMINE	DICLOFENAC DIETHYLAMINE 2.32%	EMULGEL		Local treatment of pain, inflammation and swelling in adults and adolescents aged 12 years and over due to: • Soft tissue injuries: Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. • By physician's order - Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers The gel should not be used for more than 14 days
5746	VOLTAREN	VOLTAREN ACTI-GO 12.5MG 20 LIQUID GEL CAPS	DICLOFENAC POTASSIUM	DICLOFENAC POTASSIUM 12.5MG	CAPSULES	RECIEPT	Short term analgesic and antipyretic in adults and adolescents aged 14 years and over for a maximum of 3 days treatment for the relief of headache dental pain backache , period pain, rhematic and muscular pain, and fever reduction.
5747	VOLTAREN	VOLTAREN ACTI-GO 20TAB	DICLOFENAC POTASSIUM	DICLOFENAC POTASSIUM 12.5MG	TABLETS	RECIEPT	Short term analgesic and antipyretic in adults and adolescents aged 14 years and over for a maximum of 3 days treatment for the relief of headache dental pain backache , period pain, rhematic and muscular pain, and fever reduction.
5748	VOLTAREN	VOLTAREN ACTI-GO LIQUID GEL CAPS	DICLOFENAC POTASSIUM	DICLOFENAC POTASSIUM 12.5MG	CAPSULES	RECIEPT	Short term analgesic and antipyretic in adults and adolescents aged 14 years and over for a maximum of 3 days treatment for the relief of headache dental pain backache , period pain, rhematic and muscular pain, and fever reduction.
5754	VOLTAREN	VOLTAREN EMULGEL 100G	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of pain, inflammation and swelling in adults and adolescents aged 12 years and over due to: • Soft tissue injuries: Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. • By physician's order - Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers The gel should not be used for more than 14 days
5755	VOLTAREN	VOLTAREN EMULGEL 150G	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of pain, inflammation and swelling in adults and adolescents aged 12 years and over due to: • Soft tissue injuries: Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. • By physician's order - Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers The gel should not be used for more than 14 days
5756	VOLTAREN	VOLTAREN EMULGEL 50G	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1%	GEL	RECIEPT	Local treatment of pain, inflammation and swelling in adults and adolescents aged 12 years and over due to: • Soft tissue injuries: Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. • By physician's order - Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers The gel should not be used for more than 14 days
5750	VOLTAREN	VOLTAREN EMULGEL 1%	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1% AS DICLOFENAC DIETHYLAMINE	GEL	RECIEPT	Self medication for the following indications: Local treatment of pain, inflammation and swelling due to: • Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. By Physicians order : • Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers
5760	VOLTAREN	VOLTAREN OPHTHA EYE DROPS	DICLOFENAC SODIUM	DICLOFENAC SODIUM 1MG/ML	DROPS	RECIEPT	Post-operative inflammation following cataract extraction. Control of ocular pain and discomfort associated with corneal epithelial defects after laser excimer PRK or accidental trauma.
5758	VOLTAREN	VOLTAREN EMULGEL FORTE 2%	DICLOFENAC SODIUM	DICLOFENAC SODIUM 2% AS DICLOFENAC DIETHYLAMINE	GEL	RECIEPT	Local treatment of pain, inflammation and swelling in adults and adolescents aged 12 years and over due to: • Soft tissue injuries: Pain and inflammation and swelling in trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises and/or backache (e.g. sports injuries). • Localized forms of soft tissue rheumatism such as tendonitis (e.g.tennis elbow), bursitis. • By physician's order - Pain caused by osteoarthrosis of the peripheral joints, as of the knee or fingers The gel should not be used for more than 14 days
5761	VOLUVEN	VOLUVEN	STARCH ETHERIFIED	STARCH ETHERIFIED 60G/L;SODIUM CHLORIDE 9G/L	SOLUTION	RECIEPT	Therapy and prophylaxis of hypovolemia, acute normovolaemic haemodilution technique.
5762	V-OPTIC	V-OPTIC 0.25%	TIMOLOL AS MALEATE	TIMOLOL AS MALEATE 2.5MG/ML	DROPS	RECIEPT	Reduction of elevated intraocular pressure in glaucoma and in ocular hypertension.
5763	V-OPTIC	V-OPTIC 0.5%	TIMOLOL AS MALEATE	TIMOLOL AS MALEATE 5MG/ML	DROPS	RECIEPT	Reduction of elevated intraocular pressure in glaucoma and in ocular hypertension.
5764	VORICONAZOLE	VORICONAZOLE-TRIMA 200MG	VORICONAZOLE	VORICONAZOLE 200MG	TABLETS	RECIEPT	Treatment of: invasive aspergillosis, Candidemia in non-neutropenic patients, Fluconazole-resistant serious invasive Candida infections (including C. krusei), serious fungal infections caused by Scedosporium spp. and Fusarium spp. Voriconazole should be administered primarily to immunocompromised patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
5765	VORTIMAL	VORTIMAL	VORICONAZOLE	VORICONAZOLE 200MG/VIAL	POWDER	RECIEPT	Vortimal is a broad spectrum, triazole antifungal agent and is indicated as follows: - Treatment of invasive aspergillosis. - Treatment of candidaemia in non-neutropenic patients. - Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei). - Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp. Vortimal should be administered primarily to immunocompromised patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients
5766	VOSEVI	VOSEVI	VOXILAPREVIR	VOXILAPREVIR 100MG;VELPATASVIR 100MG;SOFOSBUVIR 400MG	TABLETS	RECIEPT	Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults.
5767	VOTRIENT	VOTRIENT 200 MG	PAZOPANIB AS HYDROCHLORIDE	PAZOPANIB AS HYDROCHLORIDE 200MG	TABLETS	RECIEPT	Renal cell carcinoma (RCC) Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
5768	VOTRIENT	VOTRIENT 400 MG	PAZOPANIB AS HYDROCHLORIDE	PAZOPANIB AS HYDROCHLORIDE 400MG	TABLETS	RECIEPT	Renal cell carcinoma (RCC) Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
5769	VPRIV	VPRIV 400	VELAGLUCERASE ALFA	VELAGLUCERASE ALFA 400U/VIAL	POWDER	RECIEPT	VPRIV is a hydrolytic glucocerebroside – specific enzyme indicated for the long term replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.
5770	V-TABUR	V-TABUR	ALCOHOL	ALCOHOL 70% 70%V/V;CHLORHEXIDINE GLUCONATE 0.5%V/V	SOLUTION		Disinfection of the skin, and for the cleaning of babies umbillical cords until detached.
5771	V-TABUR	V-TABUR 60ML	CHLORHEXIDINE GLUCONATE	CHLORHEXIDINE GLUCONATE 0.5%;ALCOHOL 70%	SOLUTION		Disinfection of the skin, and for the cleaning of babies umbillical cords until detached.
5772	V-TEARS	V-TEARS	HYDROXYETHYLCELLULOSE	HYDROXYETHYLCELLULOSE 0.4%W/V	SOLUTION		To protect the eyes and for lubrication in dry eye conditions, when tear production is inadaquate.
5773	VYNDAQEL	VYNDAQEL	TAFAMIDIS AS MEGLUMINE	TAFAMIDIS AS MEGLUMINE 20MG	CAPSULES	RECIEPT	For the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
5774	VYVANSE	VYVANSE 30 MG	LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE 30MG	CAPSULES	RECIEPT	Vyvanse is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years and above. Vyvanse is indicated for the treatment of Moderate to Severe Binge Eating Disorder (BED) for patient over 18 years. Limitation of Use: Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established
5775	VYVANSE	VYVANSE 50 MG	LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE 50MG	CAPSULES	RECIEPT	Vyvanse is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years and above. Vyvanse is indicated for the treatment of Moderate to Severe Binge Eating Disorder (BED) for patient over 18 years. Limitation of Use: Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established
5776	VYVANSE	VYVANSE 70 MG	LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE 70MG	CAPSULES	RECIEPT	Vyvanse is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years and above. Vyvanse is indicated for the treatment of Moderate to Severe Binge Eating Disorder (BED) for patient over 18 years. Limitation of Use: Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established
5777	V-ZOLIN	V-ZOLIN 10ML	TETRAHYDROZOLINE HCL	TETRAHYDROZOLINE HCL 0.05%	DROPS		For relief in cases of redness in the eye as a result of irritation, caused by various materials such as dust, smoke, plants, etc.
5778	V-ZOLIN	V-ZOLINE	TETRAHYDROZOLINE HYDROCHLORIDE	TETRAHYDROZOLINE HYDROCHLORIDE 0.05%W/V	DROPS		For relief in cases of redness in the eye as a result of irritation, caused by various materials such as dust, smoke, plants, etc.
5779	WATER FOR INJECTION	WATER FOR INJECTION	WATER FOR INJECTIONS	WATER FOR INJECTIONS 100%	LIQUID		For the preparation of parenterals, vehicle solution for supplementary medication, as a diluent or as water for injection
5783	WATER FOR INJECTION	WATER FOR INJECTIONS - FRESENIUS	WATER FOR INJECTIONS	WATER FOR INJECTIONS 100%	LIQUID		Vehicle for dilution and reconstitution of medicinal products for parenteral administration
5784	WATER FOR INJECTION	WATER FOR INJECTIONS "FLEXIVIALS"	WATER FOR INJECTIONS	WATER FOR INJECTIONS 1G/ML	LIQUID		Vehicle for dilution and reconstitution of medicinal products for parenteral administration.
5785	WELLBUTRIN XR	WELLBUTRIN XR 150 MG	BUPROPION HYDROCHLORIDE	BUPROPION HYDROCHLORIDE 150MG	TABLETS	RECIEPT	Wellbutrin XR is indicated for the treatment of major depressive episodes.
5786	WELLBUTRIN XR	WELLBUTRIN XR 300 MG	BUPROPION HYDROCHLORIDE	BUPROPION HYDROCHLORIDE 300MG	TABLETS	RECIEPT	Wellbutrin XR is indicated for the treatment of major depressive episodes.
5787	WILATE	WILATE 1000	VON WILLEBRAND FACTOR	VON WILLEBRAND FACTOR 1000IU/VIAL;FACTOR VIII (HUMAN) 1000IU/VIAL	POWDER	RECIEPT	Von Willebrand disease (VWD) : Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated. Haemophilia A : Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency).
5788	WILATE	WILATE 500	VON WILLEBRAND FACTOR	VON WILLEBRAND FACTOR 500IU/VIAL;FACTOR VIII (HUMAN) 500IU/VIAL	POWDER	RECIEPT	Von Willebrand disease (VWD) : Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated. Haemophilia A : Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency).
5789	XALACOM	XALACOM EYE DROPS	LATANOPROST	LATANOPROST 50MCG/ML;TIMOLOL AS MALEATE 5MG/ML	DROPS	RECIEPT	Reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers.
5790	XALATAN	XALATAN EYE DROPS	LATANOPROST	LATANOPROST 50MCG/ML	DROPS	RECIEPT	Reduction of elevated intraocular pressure as a first line treatment in patients with open-angle galucoma and ocular hypertension.
5791	XALKORI	XALKORI 200 MG	CRIZOTINIB	CRIZOTINIB 200MG	CAPSULES	RECIEPT	XALKORI is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Xalkori is indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive.
5793	XALKORI	XALKORI 250 MG	CRIZOTINIB	CRIZOTINIB 250MG	CAPSULES	RECIEPT	XALKORI is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Xalkori is indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive.
5795	XAMIOL	XAMIOL	BETAMETHASONE AS DIPROPIONATE	BETAMETHASONE AS DIPROPIONATE 0.5MG/1 G;CALCIPOTRIOL AS HYDRATE 50MCG/1 G	GEL	RECIEPT	Topical treatment of psoriasis vulgaris on the scalp and topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults 18 years of age and older.
5796	XANAGIS	XANAGIS 0.25 MG	ALPRAZOLAM	ALPRAZOLAM 0.25MG	TABLETS	RECIEPT	Treatment of anxiety accompanied by depression. Treatment of panic states with or without accompanying phobia.
5798	XANAGIS	XANAGIS 0.5 MG	ALPRAZOLAM	ALPRAZOLAM 0.5MG	TABLETS	RECIEPT	Treatment of anxiety accompanied by depression. Treatment of panic states with or without accompanying phobia.
5800	XANAGIS	XANAGIS 1 MG	ALPRAZOLAM	ALPRAZOLAM 1MG	TABLETS	RECIEPT	Treatment of anxiety accompanied by depression. Treatment of panic states with or without accompanying phobia.
5802	XANAX X.R.	XANAX X.R. 0.5 MG	ALPRAZOLAM	ALPRAZOLAM 0.5MG	TABLETS	RECIEPT	For the treatment of anxiety and anxiety associated with depression. Treatment of panic disorder with or without phobic avoidance
5804	XANAX X.R.	XANAX X.R. 1 MG	ALPRAZOLAM	ALPRAZOLAM 1MG	TABLETS	RECIEPT	For the treatment of anxiety and anxiety associated with depression. Treatment of panic disorder with or without phobic avoidance
5806	XANAX X.R.	XANAX X.R. 2 MG	ALPRAZOLAM	ALPRAZOLAM 2MG	TABLETS	RECIEPT	For the treatment of anxiety and anxiety associated with depression. Treatment of panic disorder with or without phobic avoidance
5808	XARELTO	XARELTO 10 MG	RIVAROXABAN	RIVAROXABAN 10MG	TABLETS	RECIEPT	Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), adults (following completion of at least 6 months therapy for DVT or PE).
5816	XARELTO	XARELTO 2.5 MG	RIVAROXABAN	RIVAROXABAN 2.5MG	TABLETS	RECIEPT	Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel , is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.
5812	XARELTO	XARELTO 15 MG	RIVAROXABAN MICRONIZED	RIVAROXABAN MICRONIZED 15MG	TABLETS	RECIEPT	Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT),and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
5820	XARELTO	XARELTO 20 MG	RIVAROXABAN MICRONIZED	RIVAROXABAN MICRONIZED 20MG	TABLETS	RECIEPT	Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT),and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
5825	XATRAL	XATRAL XL 10 MG	ALFUZOSIN HYDROCHLORIDE	ALFUZOSIN HYDROCHLORIDE 10MG	TABLETS	RECIEPT	Treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. Adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.
5824	XATRAL	XATRAL SR 5 MG	ALFUZOSIN HYDROCHLORIDE	ALFUZOSIN HYDROCHLORIDE 5MG	TABLETS	RECIEPT	Treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason
5826	XEFO	XEFO 8 MG TABLETS	LORNOXICAM	LORNOXICAM 8MG	TABLETS	RECIEPT	Short term treatment of moderate pain such as pain after dental surgery. Treatment of pain associated with acute lumbo-sciatica. Symptomatic treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis.
5828	XEFO	XEFO RAPID	LORNOXICAM	LORNOXICAM 8MG	TABLETS	RECIEPT	Short term relief of acute mild to moderate pain.
5827	XEFO	XEFO 8 MG/2 ML INJECTION	LORNOXICAM	LORNOXICAM 8MG/VIAL	POWDER	RECIEPT	Short term treatment of moderate postoperative pain.
5830	XELJANZ	XELJANZ 5 MG	TOFACITINIB	TOFACITINIB 5MG	TABLETS	RECIEPT	Rheumatoid Arthritis XELJANZ (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). •Limitations of Use: Use of XELJANZ in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. Psoriatic Arthritis XELJANZ (tofacitinib) is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). •Limitations of Use: Use of XELJANZ in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. Ulcerative colitis XELJANZ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. • Limitations of Use: Use of XELJANZ in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
5832	XENAZINE	XENAZINE 25 MG	TETRABENAZINE	TETRABENAZINE 25MG	TABLETS	RECIEPT	Movement disorders, associated with organic central nervous system conditions, e.g. Huntington's chorea, hemiballismus and senile chorea. Moderate to severe tardive dyskinesia, which is disabling and/or socially embanassing. The condition should be persistent despite a switch to atypical antipsychotic medication and/or reduction in dosage of antipsychotic medication, when withdrawal of antipsychotic medication is not a realistic option.
5833	XENETIX	XENETIX 250	IOBITRIDOL	IOBITRIDOL 250MG/ML	SOLUTION	RECIEPT	For adults and children undergoing: phlebography, chest CT scan, intra - arterial digital subtraction angiography.
5834	XENETIX	XENETIX 300	IOBITRIDOL	IOBITRIDOL 300MG/ML	SOLUTION	RECIEPT	For adults and children undergoing: intravenous urography, brain or whole body CT scan, intravenous digital subtraction angiography, arteriography, angiocardiography
5835	XENETIX	XENETIX 350	IOBITRIDOL	IOBITRIDOL 350MG/ML	SOLUTION	RECIEPT	For adults and children undergoing: intravenous urography, brain or whole body CT scan, intravenous digital subtraction angiography, arteriography, angiocardiography.
5836	XENICAL	XENICAL	ORLISTAT	ORLISTAT 120MG	CAPSULES	RECIEPT	Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors.
5838	XEOMIN	XEOMIN 50	BOTULINUM TOXIN TYPE A	BOTULINUM TOXIN TYPE A 0.2NG 50 LD50 UNITS/VIAL	POWDER	RECIEPT	Xeomin is indicated for the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adult. Xeomin is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between eyebrows seen at frown (glabellar frown lines) in adults below 65 years when the severity of these lines has an important psychological impact for the patient
5837	XEOMIN	XEOMIN 100	BOTULINUM TOXIN TYPE A	BOTULINUM TOXIN TYPE A 0.8NG 100 LD50 UNITS/VIAL not less than	POWDER	RECIEPT	Xeomin is indicated for the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adult. Xeomin is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between eyebrows seen at frown (glabellar frown lines) in adults below 65 years when the severity of these lines has an important psychological impact for the patient
5839	XEPLION	XEPLION	PALIPERIDONE AS PALMITATE	PALIPERIDONE AS PALMITATE 100MG/1ML	SUSPENSION	RECIEPT	Xeplion is indicated for the acute and maintenance treatment of schizophrenia in adults. Xeplion is indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and antidepressants
5840	XERMELO	XERMELO 250 MG	TELOTRISTAT ETHYL AS ETIPRATE	TELOTRISTAT ETHYL AS ETIPRATE 250MG	TABLETS	RECIEPT	Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
5841	XGEVA	XGEVA	DENOSUMAB	DENOSUMAB 120MG/1.7ML	SOLUTION	RECIEPT	Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma and in adults with bone metastases from solid tumours. Treatment of adult and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
5842	XIAPEX	XIAPEX	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM 0.9MG/VIAL	POWDER	RECIEPT	Xiapex is indicated for the treatment of Dupuytren’s contracture in adult patients with a palpable cord. The treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
5843	XIGDUO XR	XIGDUO XR 10 MG/1000 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 1005.04MG with 0.5% magnesium stearete;DAPAGLIFLOZIN PROPANEDIOL 12.30MG	TABLETS	RECIEPT	XIGDUO XR (dapagliflozin and metformin HCl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
5847	XIGDUO XR	XIGDUO XR 5 MG/1000 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 1005.04MG with 0.5% magnesium stearete;DAPAGLIFLOZIN PROPANEDIOL 6.150MG	TABLETS	RECIEPT	XIGDUO XR (dapagliflozin and metformin HCl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
5845	XIGDUO XR	XIGDUO XR 10 MG/500 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 502.61MG with 0.5% magnesium stearete;DAPAGLIFLOZIN PROPANEDIOL 12.30MG	TABLETS	RECIEPT	XIGDUO XR (dapagliflozin and metformin HCl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
5849	XIGDUO XR	XIGDUO XR 5 MG/500 MG	METFORMIN HYDROCHLORIDE	METFORMIN HYDROCHLORIDE 502.61MG with 0.5% magnesium stearete;DAPAGLIFLOZIN PROPANEDIOL 6.150MG	TABLETS	RECIEPT	XIGDUO XR (dapagliflozin and metformin HCl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
5851	XOFIGO	XOFIGO	RADIUM-223 DICHLORIDE	RADIUM-223 DICHLORIDE 1100KBQ/ML AT REFERENCE DATE	SOLUTION	RECIEPT	Treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.
5855	XOFLUZA	XOFLUZA 20 MG	BALOXAVIR MARBOXIL	BALOXAVIR MARBOXIL 20MG	TABLETS	RECIEPT	Xofluza is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. Limitations of Use: Influenza viruses change over time and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use Xofluza.
5856	XOFLUZA	XOFLUZA 40 MG	BALOXAVIR MARBOXIL	BALOXAVIR MARBOXIL 40MG	TABLETS	RECIEPT	Xofluza is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. Limitations of Use: Influenza viruses change over time and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use Xofluza.
5857	XOLAIR	XOLAIR 150 MG	OMALIZUMAB	OMALIZUMAB 150MG/DOSE	POWDER	RECIEPT	Allergic Asthma: Xolair is indicated for patients 12 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair has been shown to decrease the incidence of asthma exacerbations in these patients. Limitations of use: Xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. Xolair is not indicated for the treatment of other allergic conditions. Chronic Spontaneous Urticaria (CSU): Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment
5858	XTANDI	XTANDI 40 MG	ENZALUTAMIDE	ENZALUTAMIDE 40MG	CAPSULES	RECIEPT	xtandi is indicated for: • the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). • the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. • the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.
5860	XULTOPHY	XULTOPHY	INSULIN DEGLUDEC	INSULIN DEGLUDEC 100U/ML;LIRAGLUTIDE 3.6MG/ML	SOLUTION	RECIEPT	Xultophy is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control.
5861	XYLOCAINE SPRAY	XYLOCAINE PUMP SPRAY 10 %	LIDOCAINE	LIDOCAINE 10MG/0.1ML	SOLUTION	RECIEPT	Surface anaesthesia in dental practice otorhinolaryngology, obstetric and anaesthesiology.
5863	XYLONOR	XYLONOR EPINEPHRINE	EPINEPHRINE AS ACID TARTRATE	EPINEPHRINE AS ACID TARTRATE 22.5MCG/1.8ML;LIDOCAINE HYDROCHLORIDE ( AS MONOHYDRATE) 36MG/1.8ML	SOLUTION	RECIEPT	For the production of local anaesthesia for dental procedures by infiltration or nerve block injections.
5862	XYLONOR	XYLONOR	LIDOCAINE	LIDOCAINE 15G/100 G;CETRIMIDE 0.15G/100 G	SOLUTION	RECIEPT	Surface anaesthetic in dentistry.
5865	XYLO-POS	XYLO-POS 0.1% 15 ml	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	SPRAY		Rapid relief of nasal congestion for up to ten hours.
5864	XYLO-POS	XYLO-POS	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 1MG/ML	SPRAY		Rapid relief of nasal congestion for up to ten hours.
5867	XYLOVIT	XYLOVIT 0.05% DRP10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.05%	DROPS		Rapid relief of nasal congestion for up to 10 hours.
5868	XYLOVIT	XYLOVIT 0.05%SPY10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.05%	SPRAY		Rapid relief of nasal congestion for up to 10 hours.
5870	XYLOVIT	XYLOVIT 0.1% DRP10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	DROPS		Rapid relief of nasal congestion for up to 10 hours.
5871	XYLOVIT	XYLOVIT 0.1% SPY10ML	XYLOMETAZOLINE HCL	XYLOMETAZOLINE HCL 0.1%	SPRAY		Rapid relief of nasal congestion for up to 10 hours.
5866	XYLOVIT	XYLOVIT 0.05%	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 0.05%	DROPS		Rapid relief of nasal congestion for up to 10 hours.
5869	XYLOVIT	XYLOVIT 0.1%	XYLOMETAZOLINE HYDROCHLORIDE	XYLOMETAZOLINE HYDROCHLORIDE 0.1%	DROPS		Rapid relief of nasal congestion for up to 10 hours.
5873	XYNTHA	XYNTHA 1000 IU	MOROCTOCOG ALFA	MOROCTOCOG ALFA 1000IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)
5874	XYNTHA	XYNTHA 2000 IU	MOROCTOCOG ALFA	MOROCTOCOG ALFA 2000IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)
5875	XYNTHA	XYNTHA 250 IU	MOROCTOCOG ALFA	MOROCTOCOG ALFA 250IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)
5872	XYNTHA	XYNTHA 500 IU	MOROCTOCOG ALFA	MOROCTOCOG ALFA 500IU/VIAL	POWDER	RECIEPT	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)
5876	YASMIN	YASMIN	DROSPIRENONE	DROSPIRENONE 3MG;ETHINYLESTRADIOL 0.03MG	TABLETS	RECIEPT	Oral contraception.
5877	YASMIN	YASMIN PLUS	LEVOMEFOLATE CALCIUM	LEVOMEFOLATE CALCIUM 0.451MG Hormonal + Levomefolate tablet;ETHINYLESTRADIOL AS BETADEX CLATHRATE 0.03MG Hormonal + Levomefolate tablet;DROSPIRENONE 3MG Hormonal + Levomefolate tablet;LEVOMEFOLATE CALCIUM 0.451MG Levomefolate tablet	TABLETS	RECIEPT	Oral contraceptive. In women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.
5878	YAZ	YAZ	DROSPIRENONE	DROSPIRENONE 3MG;ETHINYLESTRADIOL 0.02MG	TABLETS	RECIEPT	- Oral contraception. - Treatment of moderate acne vulgaris in women who seek oral contraception. - Treatment of symptoms of premenstrual dysphoric disorder (PMDD ) in women who have chosen oral contraceptives as their method of birth control. The
5880	YAZ	YAZ PLUS	LEVOMEFOLATE CALCIUM	LEVOMEFOLATE CALCIUM 0.451MG Hormonal + Levomefolate tablet;ETHINYLESTRADIOL AS BETADEX CLATHRATE 0.02MG Hormonal + Levomefolate tablet;DROSPIRENONE 3MG Hormonal + Levomefolate tablet;LEVOMEFOLATE CALCIUM 0.451MG Levomefolate tablet	TABLETS	RECIEPT	- Oral contraception. - Treatment of symptoms of premenstrual dysphoric disorder (PMDD ) in women who choose to use an oral contraceptive as their method of birth control. - Treatment of moderate acne vulgaris in women at least 14 years of age, who ha
5881	YENTREVE	YENTREVE 20 MG	DULOXETINE AS HYDROCHLORIDE	DULOXETINE AS HYDROCHLORIDE 20MG	CAPSULES	RECIEPT	Yentreve is indicated for women for the treatment of moderate to severe Stress Urinary Incontinence (SUI).
5883	YENTREVE	YENTREVE 40 MG	DULOXETINE AS HYDROCHLORIDE	DULOXETINE AS HYDROCHLORIDE 40MG	CAPSULES	RECIEPT	Yentreve is indicated for women for the treatment of moderate to severe Stress Urinary Incontinence (SUI).
5885	YERVOY	YERVOY 5 MG/ML	IPILIMUMAB	IPILIMUMAB 5MG/ML	CONCENTRATE	RECIEPT	Yervoy (ipilimumab) is indicated for the treatment of advanced (unresectable or metastatic) melanoma. Yervoy in combination with Opdivo (nivolumab) is indicated for the treatment of patient with advanced (unresectable or metastatic) melanoma .
5886	YESCARTA	YESCARTA	AXICABTAGENE CILOLEUCEL	AXICABTAGENE CILOLEUCEL 0.4 – 2 x 10^8 cells	SOLUTION	RECIEPT	YESCARTA is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Limitation of Use :YESCARTA is not indicated for the treatment of patients with primary or secondary central nervous system lymphoma.
5887	YONDELIS	YONDELIS 1 MG	TRABECTEDIN	TRABECTEDIN 1MG/VIAL	POWDER	RECIEPT	Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
5888	YTRACIS	YTRACIS	YTTRIUM (90Y) CHLORIDE	YTTRIUM (90Y) CHLORIDE 1850MBQ	SOLUTION	RECIEPT	Ytracis is indicated to be used only for the radiolabelling of carrier molecules which have been specifically developed and authorized for radiolabelling with this radionuclide. Radiopharmaceutical precursor - Not intended for direct application to patients.
5890	ZALDIAR	ZALDIAR	PARACETAMOL	PARACETAMOL 325MG;TRAMADOL HYDROCHLORIDE 37.5MG	TABLETS	RECIEPT	Symptomatic treatment of moderate to severe pain. The use of Zaldiar should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol.
5892	ZANTAC	ZANTAC SYRUP	RANITIDINE AS HYDROCHLORIDE	RANITIDINE AS HYDROCHLORIDE 150MG/10ML	SYRUP	RECIEPT	Adults: Zantac syrup is indicated for the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. Zantac syrup is also indicated for the treatment of post-operative ulcer, Zollinger-Ellison Syndrome and oesophageal reflux disease including long term management of healed oesophagitis. Zantac syrup is indicated for the following conditions where reduction of gastric secretion and acid output is desirable; the prophylaxis of gastro-intestinal haemorrhage from stress ulceration in seriously ill patients and before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's Syndrome), particularly obstetric patients during labour. Children (3 to 18 years): Short term treatment of peptic ulcer. Treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.
5891	ZANTAC	ZANTAC INJECTION 25 MG/ML	RANITIDINE AS HYDROCHLORIDE	RANITIDINE AS HYDROCHLORIDE 25MG/ML	SOLUTION	RECIEPT	Adults: Zantac Injection is indicated for the treatment of duodenal ulcer, benign gastric ulcer, post - operative ulcer, reflux oesophagitis, Zollinger - Ellison Syndrome and the following conditions where reduction of gastric secretion and acid output is desirable. The prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients and before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson’s Syndrome), particularly obstetric patients during labour. Children (6 months to 18 years): Zantac Injection is indicated for the short term treatment of peptic ulcer and the treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.
5893	ZAPPA	ZAPPA 10	OLANZAPINE	OLANZAPINE 10MG	TABLETS	RECIEPT	Acute and maintenance treatment of Schizophrenia. Zappa is indicated for the management of the manifestations of psychotic disorders. Zappa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to Olanzapine treatment Zappa is indicated for the prevention of reccurence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zappa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5899	ZAPPA	ZAPPA ODT 10	OLANZAPINE	OLANZAPINE 10MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Zappa ODT is indicated for the management of the manifestations of psychotic disorders. Zappa ODT is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Zappa ODT is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zappa ODT with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5895	ZAPPA	ZAPPA 5	OLANZAPINE	OLANZAPINE 5MG	TABLETS	RECIEPT	Acute and maintenance treatment of Schizophrenia. Zappa is indicated for the management of the manifestations of psychotic disorders. Zappa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to Olanzapine treatment Zappa is indicated for the prevention of reccurence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zappa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5901	ZAPPA	ZAPPA ODT 5	OLANZAPINE	OLANZAPINE 5MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Zappa ODT is indicated for the management of the manifestations of psychotic disorders. Zappa ODT is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Zappa ODT is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zappa ODT with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5897	ZAPPA	ZAPPA 7.5	OLANZAPINE	OLANZAPINE 7.5MG	TABLETS	RECIEPT	Acute and maintenance treatment of Schizophrenia. Zappa is indicated for the management of the manifestations of psychotic disorders. Zappa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to Olanzapine treatment Zappa is indicated for the prevention of reccurence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zappa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5903	ZARIDEX	ZARIDEX 150	RANITIDINE AS HYDROCHLORIDE	RANITIDINE AS HYDROCHLORIDE 150MG	TABLETS	RECIEPT	Adults: ZARIDEX is indicated for the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. Zaridex is also indicated for the treatment of post-operative ulcer, Zollinger-Ellison Syndrome and oesophageal reflux disease including long term management of healed oesophagitis. ZARIDEX is indicated for the following conditions where reduction of gastric secretion and acid output is desirable; the prophylaxis of gastro-intestinal haemorrhage from stress ulceration in seriously ill patients and before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's Syndrome), particularly obstetric patients during labour. Children (6 to 18 years): Short term treatment of peptic ulcer. Treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.
5904	ZARIDEX	ZARIDEX 300	RANITIDINE AS HYDROCHLORIDE	RANITIDINE AS HYDROCHLORIDE 300MG	TABLETS	RECIEPT	Adults: Zaridex is indicated for the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. Zaridex is also indicated for the treatment of post-operative ulcer, Zollinger-Ellison Syndrome and oesophageal reflux disease including long term management of healed oesophagitis. Zaridex is indicated for the following conditions where reduction of gastric secretion and acid output is desirable; the prophylaxis of gastro-intestinal haemorrhage from stress ulceration in seriously ill patients and before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's Syndrome), particularly obstetric patients during labour. Children (6 to 18 years): Short term treatment of peptic ulcer. Treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.
5905	ZAVEDOS	ZAVEDOS 10 MG	IDARUBICIN HYDROCHLORIDE	IDARUBICIN HYDROCHLORIDE 10MG/VIAL	POWDER	RECIEPT	Antimitotic and cytotoxic agent. Acute non-limphocytic Leukemia (ANLL) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. Acute limphocytic leukemia (ALL) as second line treatment in adults and children.
5906	ZAVESCA	ZAVESCA	MIGLUSTAT	MIGLUSTAT 100MG	CAPSULES	RECIEPT	Zavesca is indicated for the oral treatment of mild to moderate type I Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.
5907	ZAVICEFTA	ZAVICEFTA	CEFTAZIDIME AS PENTAHYDRATE	CEFTAZIDIME AS PENTAHYDRATE 2G;AVIBACTAM AS SODIUM 0.5G	POWDER	RECIEPT	Zavicefta is indicated for the treatment of the following infections in adults: - Complicated intra-abdominal infection (cIAI) used in combination with metronidazole - Complicated urinary tract infection (cUTI), including pyelonephritis - Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) Zavicefta is also indicated for the treatment of infections due to aerobic gram negative organisms in adult patients with limited treatment options.
5909	ZEFFIX	ZEFFIX TABLETS	LAMIVUDINE	LAMIVUDINE 100MG	TABLETS	RECIEPT	Zeffix is indicated for the treatment of chronic hepatitis B associated with the evidence of hepatitis B viral (HBV) replication and active liver inflammation in adults and also in children and adolescents aged 2 to 17 years old.
5908	ZEFFIX	ZEFFIX ORAL SOLUTION	LAMIVUDINE	LAMIVUDINE 5MG/ML	SOLUTION	RECIEPT	Zeffix is indicated for the treatment of chronic hepatitis B associated with the evidence of hepatitis B viral (HBV) replication and active liver inflammation in adults and also in children and adolescents aged 2 to 17 years old.
5911	ZEJULA	ZEJULA 100 MG	NIRAPARIB AS TOSYLATE MONOHYDRATE	NIRAPARIB AS TOSYLATE MONOHYDRATE 100MG	CAPSULES	RECIEPT	Zejula is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy
5913	ZELBORAF	ZELBORAF	VEMURAFENIB	VEMURAFENIB 240MG	TABLETS	RECIEPT	ZELBORAF is indicated for the treatment of BRAFV600 mutation-positive unresectable or metastatic melanoma.
5914	ZEMPLAR	ZEMPLAR 1 MICROGRAM	PARICALCITOL	PARICALCITOL 1MCG	CAPSULES	RECIEPT	Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.
5915	ZENALB	ZENALB 20	ALBUMIN HUMAN	ALBUMIN HUMAN 20%	SOLUTION	RECIEPT	For restoration and maintenance of circulation blood volume where volume deficiency has been demonstrated and use of a colloid, is appropriate. The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.
5916	ZENALB	ZENALB 4.5	ALBUMIN HUMAN	ALBUMIN HUMAN 4.5%	SOLUTION	RECIEPT	For restoration and maintenance of circulation blood volume where volume deficiency has been demonstrated and use of a colloid, is appropriate. The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.
5917	ZEPATIER	ZEPATIER	ELBASVIR	ELBASVIR 50MG;GRAZOPREVIR 100MG	TABLETS	RECIEPT	ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) genotypes 1 or 4 infection in adults
5919	ZERBAXA	ZERBAXA 1 G/0.5 G	TAZOBACTAM AS SODIUM	TAZOBACTAM AS SODIUM 0.5G;CEFTOLOZANE AS SULFATE 1G	POWDER	RECIEPT	Zerbaxa is indicated for the treatment of the following infections in adults: -Complicated intra abdominal infections; -Acute pyelonephritis caused by pathogens resistant to other treatments as confirmed by urine culture -Complicated urinary tract infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
5921	ZETO	ZETO 250	AZITHROMYCIN AS DIHYDRATE	AZITHROMYCIN AS DIHYDRATE 250MG	TABLETS	RECIEPT	Zeto is indicated for infections caused by susceptible organisms, in low respiratory tract infections including bronchitis and pneumonia, skin and soft tissue infections, otitis media and in upper respiratory tract infections including sinusitis and pharyngitis/tonsilitis.It is also used for the treatment of uncomplicated genital infections due to chlamydia trachomatis.
5923	ZIAGEN	ZIAGEN ORAL SOLUTION	ABACAVIR AS SULFATE	ABACAVIR AS SULFATE 20MG/ML	SOLUTION	RECIEPT	Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected . 28/10/2018 בקשה לשינוי משטר מינון
5924	ZIAGEN	ZIAGEN TABLETS	ABACAVIR AS SULFATE	ABACAVIR AS SULFATE 300MG	TABLETS	RECIEPT	Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected . 28/10/2018 בקשה לשינוי משטר מינון
5926	ZIDOVAL	ZIDOVAL 7.5 MG/G VAGINAL GEL	METRONIDAZOLE	METRONIDAZOLE 7.5MG/G	GEL	RECIEPT	Zidoval vaginal gel is indicated for the treatment of bacterial vaginosis (formally called non-specific vaginitis gardnella vaginalis vaginitis or haemophilus vaginitis).
5927	ZIDOVAL	ZIDOVAL GEL	METRONIDAZOLE	METRONIDAZOLE 7.5MG/G	GEL	RECIEPT	Zidoval vaginal gel is indicated for the treatment of bacterial vaginosis (formally called non-specific vaginitis gardnella vaginalis vaginitis or haemophilus vaginitis).
5928	ZINACEF	ZINACEF 750 MG	CEFUROXIME AS SODIUM	CEFUROXIME AS SODIUM 750MG/VIAL	POWDER	RECIEPT	Therapeutic indications Zinacef is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth) • Community acquired pneumonia • Acute exacerbations of chronic bronchitis • Complicated urinary tract infections, including pyelonephritis • Soft-tissue infections: cellulitis, erysipelas and wound infections • Intra-abdominal infections • Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section) • nose infections for example, sinusitis • septic arthritis
5930	ZINC	ZINC LOTION VITAMED	ZINC AS OXIDE	ZINC AS OXIDE 20G/100ML	LOTION		Relief of minor skin irritations.
5929	ZINC	ZINC LOTION 100ML	ZINC OXIDE	ZINC OXIDE 20%	LOTION		Relief of minor skin irritations.
5931	ZINCOL COATING TABLETS	ZINCOL ENTERIC COATING TABLETS	ZINC AS SULFATE	ZINC AS SULFATE 50MG	TABLETS	RECIEPT	Zinc supplement.
5932	ZINDACLIN	ZINDACLIN 1 % GEL	CLINDAMYCIN PHOSPHATE	CLINDAMYCIN PHOSPHATE 1%	GEL	RECIEPT	Zindaclin is indicated for the treatment of acne vulgaris.
5933	ZINFORO	ZINFORO	CEFTAROLINE FOSAMIL	CEFTAROLINE FOSAMIL 600MG	POWDER	RECIEPT	Zinforo is indicated in adults and children from age of 2 months for the treatment of the following infections : • Complicated skin and soft tissue infections (cSSTI) • Community-acquired pneumonia (CAP) Consideration should be given to official guidance on the appropriate use of antibacterial agents. .
5936	ZINNAT	ZINNAT TABLETS 125 MG	CEFUROXIME AS AXETIL	CEFUROXIME AS AXETIL 125MG	TABLETS	RECIEPT	Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months . • Acute streptococcal tonsillitis and pharyngitis. • Acute bacterial sinusitis. • Acute otitis media. • Acute exacerbations of chronic bronchitis. • Cystitis. • Pyelonephritis. • Uncomplicated skin and soft tissue infections. •Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
5934	ZINNAT	ZINNAT SUSPENSION 125 MG/5 ML	CEFUROXIME AS AXETIL	CEFUROXIME AS AXETIL 125MG/5ML	GRANULES	RECIEPT	Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months. • Acute streptococcal tonsillitis and pharyngitis. • Acute bacterial sinusitis. • Acute otitis media. • Acute exacerbations of chronic bronchitis. • Cystitis. • Pyelonephritis. • Uncomplicated skin and soft tissue infections. • Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
5937	ZINNAT	ZINNAT TABLETS 250 MG	CEFUROXIME AS AXETIL	CEFUROXIME AS AXETIL 250MG	TABLETS	RECIEPT	Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months . • Acute streptococcal tonsillitis and pharyngitis. • Acute bacterial sinusitis. • Acute otitis media. • Acute exacerbations of chronic bronchitis. • Cystitis. • Pyelonephritis. • Uncomplicated skin and soft tissue infections. •Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
5935	ZINNAT	ZINNAT SUSPENSION 250 MG/5 ML	CEFUROXIME AS AXETIL	CEFUROXIME AS AXETIL 250MG/5ML	GRANULES	RECIEPT	Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months. • Acute streptococcal tonsillitis and pharyngitis. • Acute bacterial sinusitis. • Acute otitis media. • Acute exacerbations of chronic bronchitis. • Cystitis. • Pyelonephritis. • Uncomplicated skin and soft tissue infections. • Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
5938	ZINNAT	ZINNAT TABLETS 500 MG	CEFUROXIME AS AXETIL	CEFUROXIME AS AXETIL 500MG	TABLETS	RECIEPT	Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months . • Acute streptococcal tonsillitis and pharyngitis. • Acute bacterial sinusitis. • Acute otitis media. • Acute exacerbations of chronic bronchitis. • Cystitis. • Pyelonephritis. • Uncomplicated skin and soft tissue infections. •Treatment of early Lyme disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
5939	ZINPLAVA	ZINPLAVA 25 MG/ML	BEZLOTOXUMAB	BEZLOTOXUMAB 25MG/1ML	CONCENTRATE	RECIEPT	ZINPLAVA is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment of CDI and are at high risk for recurrence of CDI
5940	ZITHROMAX I.V.	ZITHROMAX I.V.	AZITHROMYCIN AS DIHYDRATE	AZITHROMYCIN AS DIHYDRATE 500MG/VIAL	POWDER	RECIEPT	Treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.
5942	ZMAX	ZMAX	AZITHROMYCIN	AZITHROMYCIN 2.096G DIHYDRATE	POWDER	RECIEPT	Zmax is indicated for the treatment of patients 18 years of age and above with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Adults: Acute bacterial sinusitis due to Haemophilus influenzae Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy.
5951	ZO DEX	ZOLADEX LA	GOSERELIN AS ACETATE	GOSERELIN AS ACETATE 10.8MG/VIAL	IMPLANT	RECIEPT	Prostate cancer suitable for hormonal manipulation.
5943	ZODORM	ZODORM 10	ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE 10MG	TABLETS	RECIEPT	Treatment of insomnia (Not more than 4 weeks).
5945	ZODORM	ZODORM 5	ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE 5MG	TABLETS	RECIEPT	Treatment of insomnia.
5946	ZOELY	ZOELY	NOMEGESTROL ACETATE	NOMEGESTROL ACETATE 2.5MG;ESTRADIOL AS HEMIHYDRATE 1.5MG	TABLETS	RECIEPT	Oral contraception
5947	ZOFRAN	ZOFRAN INJECTION 2MG/ML	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE 2MG/ML	SOLUTION	RECIEPT	Adults: Zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: Zofran is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥6 months, and for the prevention and treatment of PONV in children aged ≥ 1 month.
5948	ZOFRAN	ZOFRAN TABLETS 4 MG	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE 4MG	TABLETS	RECIEPT	Adults: Zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: Zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy.
5949	ZOFRAN	ZOFRAN TABLETS 8 MG	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE	ONDANSETRON AS HYDROCHLORIDE DIHYDRATE 8MG	TABLETS	RECIEPT	Adults: Zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (PONV). Paediatric Population: Zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy.
5950	ZOLADEX	ZOLADEX	GOSERELIN AS ACETATE	GOSERELIN AS ACETATE 3.6MG/DOSE	IMPLANT	RECIEPT	Treatment of prostate cancer suitable for hormonal manipulation. Breast cancer in pre-menopausal women suitable for hormone manipulation. Endometriosis. Assisted reproduction: pituitary down regulation in preparion for superovulation. Endometrial thinning: Zoladex is indicated for the prethinning of the utetine endometrium prior ro endometrial ablation or resection. Uterine Fibroids: For reduction of fibroid size prior to surgery.
5955	ZOLEDRONIC ACID	ZOLEDRONIC ACID HOSPIRA 4 MG/5 ML	ZOLEDRONIC ACID	ZOLEDRONIC ACID 4MG/5ML	CONCENTRATE	RECIEPT	Treatment of hypercalcaemia of malignancy. Treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
5956	ZOLEDRONIC ACID	ZOLEDRONIC ACID TARO 4 MG/ 5 ML	ZOLEDRONIC ACID	ZOLEDRONIC ACID 4MG/5ML	CONCENTRATE	RECIEPT	Treatment of hypercalcaemia of malignancy. Treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
5957	ZOLEDRONIC ACID	ZOLEDRONIC DEXCEL 4 MG / 5 ML	ZOLEDRONIC ACID	ZOLEDRONIC ACID 4MG/5ML	CONCENTRATE	RECIEPT	Treatment of hypercalcaemia of malignancy (HCM). Treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
5952	ZOLEDRONIC ACID	ZOLEDRONIC ACID FRESENIUS 4 MG/5 ML	ZOLEDRONIC ACID AS MONOHYDRATE	ZOLEDRONIC ACID AS MONOHYDRATE 4MG	CONCENTRATE	RECIEPT	Treatment of hypercalcaemia of malignancy. Treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
5954	ZOLEDRONIC ACID	ZOLEDRONIC ACID HOSPIRA 4 MG/100 ML	ZOLEDRONIC ACID AS MONOHYDRATE	ZOLEDRONIC ACID AS MONOHYDRATE 4MG/100ML	SOLUTION	RECIEPT	Treatment of hypercalcaemia of malignancy. Treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
5958	ZOMACTON	ZOMACTON 10 MG	SOMATROPIN	SOMATROPIN 10MG	POWDER	RECIEPT	Children : Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner's syndrome. Short stature in children with renal insufficiency.
5959	ZOMACTON	ZOMACTON 4 MG	SOMATROPIN	SOMATROPIN 4MG/VIAL	POWDER	RECIEPT	Children : Short stature due to inadequate or failed secretion of pituitary growth hormone or Turner's syndrome. Short stature in children with renal insufficiency.
5960	ZOMIG	ZOMIG 2.5 MG	ZOLMITRIPTAN	ZOLMITRIPTAN 2.5MG	TABLETS	RECIEPT	Acute treatment of migraine with or without aura.
5961	ZOMIG	ZOMIG RAPIMELT	ZOLMITRIPTAN	ZOLMITRIPTAN 2.5MG	TABLETS	RECIEPT	Acute treatment of migraine with or without aura.
5962	ZOSTAVAX	ZOSTAVAX (ZOSTER VACCINE LIVE)	LIVE ATTENUATED OKA/MERCK STRAIN OF VARICELLA-ZOSTER VIRUS	LIVE ATTENUATED OKA/MERCK STRAIN OF VARICELLA-ZOSTER VIRUS 19400PFU/0.65ML	POWDER	RECIEPT	ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.
5963	ZOSTRIX	ZOSTRIX	CAPSAICIN	CAPSAICIN 0.025%	CREAM		Treatment of arthritis
5964	ZOSTRIX	ZOSTRIX 30GR	CAPSAICIN	CAPSAICIN 0.025% W/V	CREAM		Local relief of pain in cases of herpetic neuralgias and diabetic neuropathy
5965	ZOSTRIX	ZOSTRIX H.P. 30GR	CAPSAICIN	CAPSAICIN 0.075% W/V	CREAM		Local relief of pain in cases of herpetic neuralgias and diabetic neuropathy
5966	ZOSTRIX	ZOSTRIX-HP	CAPSAICIN	CAPSAICIN 0.075%W/W	CREAM		Local relief of pain in cases of herpetic neuralgias and diabetic neuropathy
5973	ZOVIRAX	ZOVIRAX TABLETS 200 MG	ACYCLOVIR	ACICLOVIR 200MG	TABLETS	RECIEPT	•Zovirax Tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes (excluding neonatal HSV and severe HSV infections in immunocompromised children). •Zovirax Tablets are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immunocompetent patients. •Zovirax Tablets are indicated for the prophylaxis of herpes simplex infections in immunocompromised patients. •Zovirax Tablets are indicated for the treatment of varicella (chickenpox) and herpes zoster (shingles) infections
5972	ZOVIRAX	ZOVIRAX SUSPENSION	ACYCLOVIR	ACICLOVIR 200MG/5ML	SUSPENSION	RECIEPT	Zovirax suspenion is indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes (excluding neonatal HSV and severe HSV infections in immunocompromised children). Zovirax suspenion is indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. Zovirax suspenion is indicated for the prophylaxis of herpes simplex infections in immune-compromised patients. Zovirax suspenion is indicated for the treatment of varicella (chickenpox ) and herpes zoster (shingles) infections.
5970	ZOVIRAX	ZOVIRAX I.V.	ACYCLOVIR	ACICLOVIR 250MG/VIAL	POWDER	RECIEPT	Zovirax RECIEPT. is indicated for the treatment of Herpes simplex infections in immunocompromised patients and severe initial genital herpes in the non-immunocompromised. Zovirax I.V. is indicated for the prophylaxis of Herpes simplex infections in immunocompromised patients. Zovirax I.V. is indicated for the treatment of Varicella zoster infections. Zovirax I.V. is indicated for the treatment of herpes encephalitis. Zovirax I.V. is indicated for the treatment of Herpes simplex infections in the neonate and infant up to 3 months of age.
5971	ZOVIRAX	ZOVIRAX OPHTHALMIC OINTMENT	ACYCLOVIR	ACICLOVIR 3%W/W	OINTMENT	RECIEPT	Indicated for the treatment of herpes simplex keratitis.
5974	ZOVIRAX	ZOVIRAX TABLETS 400 MG	ACYCLOVIR	ACICLOVIR 400MG	TABLETS	RECIEPT	•Zovirax Tablets are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes (excluding neonatal HSV and severe HSV infections in immunocompromised children). •Zovirax Tablets are indicated for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immunocompetent patients. •Zovirax Tablets are indicated for the prophylaxis of herpes simplex infections in immunocompromised patients. •Zovirax Tablets are indicated for the treatment of varicella (chickenpox) and herpes zoster (shingles) infections
5968	ZOVIRAX	ZOVIRAX CREAM 5% 2G TUBES	ACYCLOVIR	ACICLOVIR 5% W/W	CREAM	RECIEPT	herpes
5967	ZOVIRAX	ZOVIRAX	ACYCLOVIR	ACICLOVIR 5%W/W	CREAM		For the treatment of cold sores (herpes labialis).
5975	ZOVIRAX	ZOVIRAX TABLETS DISPERSIBLE 800 MG	ACYCLOVIR	ACICLOVIR 800MG	TABLETS	RECIEPT	Zovirax tablets 800 mg are indicated for the treatment of varicella (chickenpox) and herpes zoster (shingles) infections (excluding neonatal HSV and severe HSV infections in immunocompromised children). Zovirax 800mg tablets is recommended in children over the age of 6.
5969	ZOVIRAX	ZOVIRAX CREAM 5% 2G PUMP	ACYCLOVIR	ACYCLOVIR 5%	CREAM		herpes
5978	ZUTECTRA	ZUTECTRA	HUMAN HEPATITIS B IMMUNOGLOBULIN	HUMAN HEPATITIS B IMMUNOGLOBULIN 500 IU	SOLUTION	RECIEPT	Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start. The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis.
5979	ZYBAN	ZYBAN	BUPROPION HYDROCHLORIDE	BUPROPION HYDROCHLORIDE 150MG	TABLETS	RECIEPT	Zyban is indicated as an aid to smoking cessation in combination with motivational support in nicotine-dependent patients.
5980	ZYKADIA	ZYKADIA 150 MG	CERITINIB	CERITINIB 150MG	CAPSULES	RECIEPT	ZYKADIA is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.
5981	ZYLET	ZYLET	TOBRAMYCIN	TOBRAMYCIN 3MG/ML;LOTEPREDNOL ETABONATE 5MG/ML	SUSPENSION	RECIEPT	Zylet is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.
5982	ZYLLERGY	ZYLLERGY	CETIRIZINE DIHYDROCHLORIDE	CETIRIZINE DIHYDROCHLORIDE 10MG	TABLETS		For the treatment of seasonal and perennial allergic rhinitis and of chronic idiopathic urticaria.
5983	ZYLLERGY	ZYLLERGY10MG 20TAB	CETIRIZINE DIHYDROCHLORIDE	CETIRIZINE DIHYDROCHLORIDE 10MG	TABLETS		For the treatment of seasonal and perennial allergic rhinitis and of chronic idiopathic urticaria.
5984	ZYPADHERA	ZYPADHERA 210 MG	OLANZAPINE	OLANZAPINE 210MG	POWDER	RECIEPT	Zypadhera is indicated for the treatment of schizophrenia. The use of Zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes . Zypadhera is NOT to be used in patients whose condition is adequately controlled with oral Zyprexa .
5985	ZYPADHERA	ZYPADHERA 300 MG	OLANZAPINE	OLANZAPINE 300MG	POWDER	RECIEPT	Zypadhera is indicated for the treatment of schizophrenia. The use of Zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes . Zypadhera is not to be used in patients whose condition is adequately controlled with oral Zyprexa .
5986	ZYPADHERA	ZYPADHERA 405 MG	OLANZAPINE AS PAMOATE MONOHYDRATE	OLANZAPINE AS PAMOATE MONOHYDRATE 405MG	POWDER	RECIEPT	Zypadhera is indicated for the treatment of schizophrenia. The use of Zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes . Zypadhera is not to be used in patients whose condition is adequately controlled with oral Zyprexa .
5987	ZYPREXA	ZYPREXA 10 MG	OLANZAPINE	OLANZAPINE 10MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Zyprexa is indicated for the management of the manifestations of psychotic disorders. Zyprexa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Zyprexa is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5994	ZYPREXA	ZYPREXA VELOTAB 10 MG	OLANZAPINE	OLANZAPINE 10MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Zyprexa is indicated for the management of the manifestations of psychotic disorders. Zyprexa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Zyprexa is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5989	ZYPREXA	ZYPREXA 5 MG	OLANZAPINE	OLANZAPINE 5MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Zyprexa is indicated for the management of the manifestations of psychotic disorders. Zyprexa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Zyprexa is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5995	ZYPREXA	ZYPREXA VELOTAB 5 MG	OLANZAPINE	OLANZAPINE 5MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Zyprexa is indicated for the management of the manifestations of psychotic disorders. Zyprexa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Zyprexa is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5991	ZYPREXA	ZYPREXA 7.5 MG	OLANZAPINE	OLANZAPINE 7.5MG	TABLETS	RECIEPT	Acute and maintenance treatment of schizophrenia. Zyprexa is indicated for the management of the manifestations of psychotic disorders. Zyprexa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Zyprexa is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
5993	ZYPREXA	ZYPREXA INTRAMUSCULAR	OLANZAPINE	OLANZAPINE 10MG/2ML	POWDER	RECIEPT	Treatment of agitation associated with schizophrenia and bipolar mania.
5996	ZYTIGA	ZYTIGA	ABIRATERONE ACETATE	ABIRATERONE ACETATE 250MG	TABLETS	RECIEPT	ZYTIGA is CYP 17 inbitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer
6000	ZYVOXID	ZYVOXID I.V. 2 MG/ML	LINEZOLID	LINEZOLID 2MG/ML	SOLUTION	RECIEPT	Therapy is indicated only when an organism resistant to all other antibiotics is suspected. Zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) Pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (MDRSP). 2) Skin and soft tissue infections including diabetic foot infections. 3) Enterococcal infections. Combination therapy may be indicated if a concomitant Gram negative pathogen is documented or suspected.
5997	ZYVOXID	ZYVOXID 600 MG	LINEZOLID	LINEZOLID 600MG	TABLETS	RECIEPT	Therapy is indicated only when an organism resistant to all other antibiotics is suspected. Zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) Pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (MDRSP). 2) Skin and soft tissue infections including diabetic foot infections. 3) Enterococcal infections. Combination therapy may be indicated if a concomitant Gram negative pathogen is documented or suspected.

//variables for language switch

Information provided by this site is FREE OF CHARGE FOR PERSONAL USE only and could be found in different forms at other sites free of charge too.

Information provided by this site do not replace the physician advise and you still need to CONSULT A DOCTOR before you take any new or discontinued medication.

Please don't rely on your personal experience and seek medical advice on the medications you choose.

This site is not the official govermental source of the information regarding medication database in Israel. We update this database less frequently than the Ministry of Health site do. Some new medications could be missed from the database.Some medication records could be updated, replaced or deleted from the official Ministry of Health database. Please search for them at Israel Ministry of Health official site.

Search results are based on the data provided by pharmaceutical companies.

The results of search by your keyword may be wider or lesser then you expected.

PRESCRIPTION service provided by Dr.Ilya Anisimov is a subject to FEE. Service fee rates depend on the prescription type, need for personal meeting with the doctor, type of delivery and more (See fee table).

Prescription service available in Israel only.

Doctor Ilya Anisimov does not advise patients by phone.

You may require to ATTEND Doctor Ilya Anisimov to allow your prescription to be done.

Prescription processing may require a day or more.

Dr. Ilya Anisimov is a licensed physician in Israel since 1997. License number: 31688

Visit of the Dr. Ilya Anisimov to a patient is a subject to fee (See fee table).

Safety and privacy. This site will never store at site database your personal data without your explicit permission.

This service is PRIVATE and is not owned, provided or financially supported by any other than 'Ilya Anisimov Ltd.' organization or department, including kupat-holim Clalit, Maccaby, Meuhedet and Leumit.

Names of drugs, dressings and other commercially sold medical substances and materials, medical instruments, names of companies and organizations, trademarks and other names cited on this site are the registered property items of their respective owners.

This medications database structure is subject to copiright. It is a the result of the years of hard work of structurising pharmacological records, based on official sources, including WHO and FDA, pharmaceutical advice and medical experience, done by our team.

By pressing 'Agree & Continue' button with checkbox 'I accept' checked you automatically confirm that you read, understand and agree with these Terms of service you will be alowed to continue on this site..

By pressing 'Decline' button at the site you automatically confirm that you disagree with these Terms of service and you will NOT be alowed to continue on this site.

Информация, представленная на этом сайте, БЕСПЛАТНА ТОЛЬКО ДЛЯ ЛИЧНОГО ИСПОЛЬЗОВАНИЯ и может быть бесплатно найдена в различных формах на других сайтах.

Информация, представленная на этом сайте, не заменяет рекомендации врача, и вам все равно необходимо КОНСУЛЬТИРОВАТЬСЯ С ВРАЧОМ, прежде чем принимать какие-либо новые или прекращенные лекарства.

Пожалуйста, не полагайтесь на свой личный опыт и обращайтесь к врачу за медикаментами, которые вы выбираете.

Этот сайт не является официальным государственным источником информации о базе данных лекарств в Израиле. Мы обновляем эту базу реже, чем сайт Минздрава. Некоторые новые лекарства могут быть пропущены из базы данных. Некоторые записи о лекарствах могут быть обновлены, заменены или удалены из официальной базы данных Министерства здравоохранения. Поищите их на официальном сайте Министерства здравоохранения Израиля.

Результаты поиска основаны на данных, предоставленных фармацевтическими компаниями.

Результаты поиска по вашему ключевому слову могут быть шире или меньше, чем вы ожидали.

ПРЕДПИСАНИЕ, предоставляемое доктором Ильей Анисимовым, требует ПЛАТЕЖА . Стоимость услуги зависит от типа рецепта, необходимости личной встречи с врачом, типа доставки и т. Д. ( См. Таблицу сборов ).

Рецептная услуга доступна только в Израиле.

Врач Илья Анисимов не консультирует пациентов по телефону.

Вам может потребоваться ПОСЕТИТЬ доктора Илью Анисимова, чтобы он выписал вам рецепт.

Обработка рецепта может занять день или больше.

Доктор Илья Анисимов является лицензированным врачом в Израиле с 1997 года. Номер лицензии: 31688

Визит доктора Ильи Анисимова к пациенту является платным ( См. таблицу сборов ).

Безопасность и конфиденциальность. Этот сайт никогда не будет хранить в базе данных сайта ваши личные данные без вашего явного разрешения.

Эта услуга является ЧАСТНОЙ и не принадлежит, не предоставляется и не получает финансовой поддержки никому, кроме компании Ilya Anisimov Ltd. организация или отдел, включая купат-холим Клалит, Маккаби, Меухедет и Леумит.

Названия лекарств, перевязочных материалов и других продаваемых на коммерческой основе медицинских веществ и материалов, медицинских инструментов, названия компаний и организаций, товарные знаки и другие наименования, упомянутые на этом сайте, являются зарегистрированными объектами собственности их соответствующих владельцев.

Эта структура базы данных лекарств подлежит повторному праву. Это результат многолетней упорной работы нашей команды по структурированию фармакологической документации, основанной на официальных источниках, включая ВОЗ и FDA, фармацевтических рекомендациях и медицинском опыте.

Нажимая кнопку «Принять и продолжить» с установленным флажком «Я принимаю», вы автоматически подтверждаете, что прочитали, поняли и согласны с настоящими Условиями обслуживания, и вам будет разрешено продолжить работу на этом сайте.

Нажимая кнопку "Отклонить" на сайте, вы автоматически подтверждаете, что не согласны с настоящими Условиями обслуживания, и вам НЕ будет разрешено продолжить работу на этом сайте.

המידע המסופק על ידי אתר זה הינו ללא תשלום לשימוש אישי בלבד וניתן למצוא אותו בצורות שונות באתרים אחרים ללא תשלום גם כן.

מידע המסופק על ידי אתר זה אינו מחליף את ייעוץ הרופא ואתה עדיין צריך להתייעץ עם רופא לפני שאתה נוטל תרופה חדשה או שהופסקה.

אנא אל תסתמך על הניסיון האישי שלך ופנה לייעוץ רפואי לגבי התרופות שאתה בוחר.

אתר זה אינו המקור הממשלתי הרשמי למידע בנוגע למאגר התרופות בישראל. אנו מעדכנים את המאגר הזה בתדירות נמוכה יותר מאתר משרד הבריאות. כמה תרופות חדשות עלולות להחמיץ מהמאגר. רישומי תרופות מסוימים עשויים להתעדכן, להחליף או למחוק ממאגר המידע הרשמי של משרד הבריאות. אנא חפש אותם באתר הרשמי של משרד הבריאות.

תוצאות החיפוש מבוססות על הנתונים שסופקו על ידי חברות תרופות.

תוצאות החיפוש לפי מילת המפתח שלך עשויות להיות רחבות יותר או פחות ממה שציפית.

שירות מרשם הניתן על ידי ד"ר איליה אניסימוב כפוף לעמלה. תעריפי עמלת שירות תלויים בסוג המרשם, הצורך בפגישה אישית עם הרופא, סוג הלידה ועוד (ראה טבלת אגרות ).

שירות מרשם זמין בישראל בלבד.

דוקטור איליה אניסימוב אינו מייעץ למטופלים בטלפון.

ייתכן שתצטרך להגיע לדוקטור איליה אניסימוב כדי לאפשר את ההרשמה שלך.

עיבוד מרשם עשוי לדרוש יום או יותר.

ד"ר. איליה אניסימובהוא רופא מורשה בישראל משנת 1997. מספר רישיון: 31688

ביקור של ד"ר איליה אניסימוב למטופל כרוך בתשלום (ראה טבלת שכר טרחה).

בטיחות ופרטיות. אתר זה לעולם לא יאחסן במסד הנתונים של האתר את הנתונים האישיים שלך ללא רשותך המפורשת.

שירות זה הינו פרטי ואינו בבעלות, מסופק או נתמך כלכלית על ידי אף אחד אחר מלבד 'Ilya Anisimov Ltd.' ארגון או מחלקה, לרבות קופת חולים כללית, מכבי, מאוחדת ולאומית.

שמות של תרופות, חבישות וחומרים רפואיים אחרים הנמכרים מסחרית, מכשירים רפואיים, שמות של חברות וארגונים, סימנים מסחריים ושמות אחרים המצוטטים באתר זה הם פריטי הרכוש הרשומים של בעליהם בהתאמה.

מבנה מסד הנתונים של תרופות זה כפוף לזכויות יוצרים. זוהי תוצאה של שנים של עבודה קשה של בניית רשומות פרמקולוגיות, המבוססות על מקורות רשמיים, כולל WHO וה-FDA, ייעוץ תרופתי וניסיון רפואי, שנעשו על ידי הצוות שלנו.

על ידי לחיצה על כפתור 'הסכים והמשך' עם תיבת הסימון 'אני מסכים' מסומנת, אתה מאשר באופן אוטומטי שקראת, מבין ומסכים לתנאים והגבלות אלה, תורשה להמשיך באתר זה.

על ידי לחיצה על כפתור 'דחה' באתר אתה מאשר באופן אוטומטי שאינך מסכים לתנאים והגבלות אלה ולא תורשה להמשיך באתר זה.

Israeli Drug Index